{
"company_details": [
{
"company_id": "0001069530",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001069530.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001069530.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001069530.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001069530_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001069530_main_keyfigs.svg",
"name": "Filana Therapeutics INC",
"rank": 1,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001069530.svg",
"report_text": "The relative strengths and weaknesses of Filana Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Filana Therapeutics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 176% points.The greatest weakness of Filana Therapeutics INC is the variable Assets, Current, reducing the Economic Capital Ratio by 48% points.
The company's Economic Capital Ratio, given in the ranking table, is 543%, being 300% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001069530_2014_Filana_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.41",
"Assets": "77.8",
"Liabilities": "-80.3",
"Stockholders Equity": "19.1",
"ECR before LimitedLiability": "89.2",
"Intangible Assets": "-11.6",
"Property and Equipment": "-7.30",
"Assets, Current": "109",
"Other Liabilities": "-105",
"Liabilities, Non-Current": "9.34",
"Liabilities, Current": "9.09",
"Research and Development": "17.1",
"Expenses": "44.5",
"Revenues": "-9.95",
"Net Income": "35.2",
"Other Expenses": "8.02",
"Cost of Goods Sold": "2.82",
"Selling, General and Administrative Expense": "14.7",
"Other Revenues": "-9.95",
"Comprehensive Net Income": "34.9",
"Economic Capital Ratio": "13.6"
},
"2012": {
"Property and Equipment": "-11.4",
"Assets": "47.2",
"Liabilities": "-106",
"Stockholders Equity": "-35.6",
"ECR before LimitedLiability": "41.2",
"Assets, Current": "53.1",
"Intangible Assets": "-16.0",
"Other Assets": "-10.6",
"Liabilities, Current": "10.9",
"Other Liabilities": "-137",
"Liabilities, Non-Current": "11.8",
"Selling, General and Administrative Expense": "13.6",
"Expenses": "47.2",
"Revenues": "-5.18",
"Net Income": "45.9",
"Research and Development": "13.9",
"Other Expenses": "15.9",
"Cost of Goods Sold": "4.01",
"Other Revenues": "-5.18",
"Comprehensive Net Income": "46.0",
"Economic Capital Ratio": "-31.9"
},
"2013": {
"Other Assets": "4.76",
"Assets": "-17.2",
"Liabilities": "176",
"Stockholders Equity": "165",
"ECR before LimitedLiability": "328",
"Intangible Assets": "5.98",
"Property and Equipment": "3.57",
"Assets, Current": "-47.7",
"Liabilities, Non-Current": "31.2",
"Liabilities, Current": "111",
"Other Liabilities": "78.4",
"Selling, General and Administrative Expense": "21.6",
"Expenses": "64.3",
"Revenues": "97.8",
"Net Income": "155",
"Other Expenses": "18.9",
"Research and Development": "21.4",
"Cost of Goods Sold": "4.33",
"Other Revenues": "97.8",
"Comprehensive Net Income": "155",
"Economic Capital Ratio": "300"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001069530_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "98,489",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "13,272",
"Liabilities, Non-Current": "0",
"Other Assets": "352",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "41,298",
"Other Net Income": "0",
"Other Revenues": "12,385",
"Property and Equipment": "122",
"Research and Development": "8,300",
"Selling, General and Administrative Expense": "6,698"
},
"output_variables": {
"Assets": "98,963",
"Liabilities": "54,570",
"Expenses": "14,998",
"Revenues": "12,385",
"Stockholders Equity": "44,393",
"Net Income": "-2,613",
"Comprehensive Net Income": "-2,613",
"BaseVar": "90,458",
"ECR before LimitedLiability": "123%",
"Economic Capital Ratio": "248%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "56,507",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,999",
"Liabilities, Non-Current": "0",
"Other Assets": "352",
"Other Compr. Net Income": "-124",
"Other Expenses": "0",
"Other Liabilities": "33,724",
"Other Net Income": "0",
"Other Revenues": "11,341",
"Property and Equipment": "0",
"Research and Development": "7,605",
"Selling, General and Administrative Expense": "7,182"
},
"output_variables": {
"Assets": "56,859",
"Liabilities": "43,723",
"Expenses": "14,787",
"Revenues": "11,341",
"Stockholders Equity": "13,136",
"Net Income": "-3,446",
"Comprehensive Net Income": "-3,508",
"BaseVar": "63,417",
"ECR before LimitedLiability": "50%",
"Economic Capital Ratio": "188%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "50,103",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,801",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-3.0",
"Other Expenses": "-73",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "41,225",
"Property and Equipment": "0",
"Research and Development": "4,917",
"Selling, General and Administrative Expense": "4,837"
},
"output_variables": {
"Assets": "50,103",
"Liabilities": "1,801",
"Expenses": "9,681",
"Revenues": "41,225",
"Stockholders Equity": "48,302",
"Net Income": "31,544",
"Comprehensive Net Income": "31,542",
"BaseVar": "51,406",
"ECR before LimitedLiability": "527%",
"Economic Capital Ratio": "543%"
}
}
},
"top_rated": true,
"trend": 131.0,
"value": 5.42538800531459,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001069530.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001069530.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001069530.svg"
},
{
"company_id": "0000847464",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000847464.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000847464.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000847464_main_keyfigs.svg",
"name": "Spring Pharmaceutical Group INC",
"rank": 2,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000847464.svg",
"report_text": "The relative strengths and weaknesses of Spring Pharmaceutical Group INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Spring Pharmaceutical Group INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 170% points.The greatest weakness of Spring Pharmaceutical Group INC is the variable Other Expenses, reducing the Economic Capital Ratio by 40% points.
The company's Economic Capital Ratio, given in the ranking table, is 494%, being 251% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000847464_2014_Spring_Pharmaceutical_Group_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "-2.85",
"Stockholders Equity": "181",
"ECR before LimitedLiability": "314",
"Intangible Assets": "-4.80",
"Assets, Current": "0.698",
"Other Liabilities": "49.6",
"Liabilities": "126",
"Liabilities, Non-Current": "22.4",
"Liabilities, Current": "78.9",
"Research and Development": "37.7",
"Expenses": "38.9",
"Revenues": "35.2",
"Net Income": "74.3",
"Other Expenses": "-35.9",
"Cost of Goods Sold": "4.46",
"Selling, General and Administrative Expense": "31.0",
"Other Revenues": "35.2",
"Comprehensive Net Income": "75.3",
"Other Net Income": "2.77",
"Other Compr. Net Income": "1.08",
"Economic Capital Ratio": "238"
},
"2012": {
"Property and Equipment": "20.5",
"Assets": "76.4",
"Liabilities": "31.9",
"Stockholders Equity": "129",
"ECR before LimitedLiability": "150",
"Intangible Assets": "53.2",
"Other Assets": "-6.21",
"Liabilities, Current": "24.2",
"Other Liabilities": "-5.79",
"Liabilities, Non-Current": "13.8",
"Selling, General and Administrative Expense": "11.7",
"Expenses": "1.90",
"Revenues": "-21.9",
"Net Income": "-17.6",
"Research and Development": "23.3",
"Other Expenses": "-35.5",
"Cost of Goods Sold": "3.64",
"Other Revenues": "-21.9",
"Comprehensive Net Income": "-16.2",
"Other Net Income": "2.44",
"Economic Capital Ratio": "76.9"
},
"2013": {
"Assets": "-4.02",
"Liabilities": "170",
"Stockholders Equity": "153",
"ECR before LimitedLiability": "279",
"Intangible Assets": "-7.17",
"Property and Equipment": "-3.26",
"Assets, Current": "2.92",
"Liabilities, Non-Current": "29.5",
"Liabilities, Current": "111",
"Other Liabilities": "73.6",
"Selling, General and Administrative Expense": "29.4",
"Expenses": "28.5",
"Revenues": "53.7",
"Net Income": "102",
"Other Expenses": "-40.3",
"Research and Development": "33.0",
"Cost of Goods Sold": "4.39",
"Other Revenues": "53.7",
"Comprehensive Net Income": "102",
"Other Net Income": "24.8",
"Economic Capital Ratio": "251"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000847464_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "21,708",
"Cost of Goods Sold": "0",
"Intangible Assets": "40,560",
"Liabilities, Current": "1,914",
"Liabilities, Non-Current": "0",
"Other Assets": "211",
"Other Compr. Net Income": "1,330",
"Other Expenses": "22,241",
"Other Liabilities": "0",
"Other Net Income": "23",
"Other Revenues": "33,465",
"Property and Equipment": "9,630",
"Research and Development": "280",
"Selling, General and Administrative Expense": "752"
},
"output_variables": {
"Assets": "72,109",
"Liabilities": "1,914",
"Expenses": "23,273",
"Revenues": "33,465",
"Stockholders Equity": "70,196",
"Net Income": "10,215",
"Comprehensive Net Income": "10,880",
"BaseVar": "66,057",
"ECR before LimitedLiability": "443%",
"Economic Capital Ratio": "472%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "24,262",
"Cost of Goods Sold": "0",
"Intangible Assets": "18,864",
"Liabilities, Current": "5,785",
"Liabilities, Non-Current": "0",
"Other Assets": "220",
"Other Compr. Net Income": "1,300",
"Other Expenses": "23,884",
"Other Liabilities": "5,532",
"Other Net Income": "305",
"Other Revenues": "377",
"Property and Equipment": "9,663",
"Research and Development": "849",
"Selling, General and Administrative Expense": "5,754"
},
"output_variables": {
"Assets": "53,008",
"Liabilities": "11,317",
"Expenses": "30,486",
"Revenues": "377",
"Stockholders Equity": "41,691",
"Net Income": "-29,804",
"Comprehensive Net Income": "-29,154",
"BaseVar": "48,396",
"ECR before LimitedLiability": "192%",
"Economic Capital Ratio": "297%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "31,377",
"Cost of Goods Sold": "0",
"Intangible Assets": "17,657",
"Liabilities, Current": "1,254",
"Liabilities, Non-Current": "0",
"Other Assets": "221",
"Other Compr. Net Income": "454",
"Other Expenses": "21,373",
"Other Liabilities": "0",
"Other Net Income": "8,404",
"Other Revenues": "33,103",
"Property and Equipment": "9,410",
"Research and Development": "1,756",
"Selling, General and Administrative Expense": "3,116"
},
"output_variables": {
"Assets": "58,664",
"Liabilities": "1,254",
"Expenses": "26,245",
"Revenues": "33,103",
"Stockholders Equity": "57,411",
"Net Income": "15,261",
"Comprehensive Net Income": "15,488",
"BaseVar": "64,062",
"ECR before LimitedLiability": "469%",
"Economic Capital Ratio": "494%"
}
}
},
"top_rated": true,
"trend": 68.0,
"value": 4.936456697990321,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000847464.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000847464.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000847464.svg"
},
{
"company_id": "0001178879",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001178879.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001178879.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001178879.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001178879_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001178879_main_keyfigs.svg",
"name": "Amicus Therapeutics INC",
"rank": 3,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001178879.svg",
"report_text": "The relative strengths and weaknesses of Amicus Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Amicus Therapeutics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 160% points.The greatest weakness of Amicus Therapeutics INC is the variable Research and Development, reducing the Economic Capital Ratio by 7.7% points.
The company's Economic Capital Ratio, given in the ranking table, is 486%, being 244% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001178879_2014_Amicus_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-11.4",
"Assets": "19.1",
"Liabilities": "37.6",
"Stockholders Equity": "59.6",
"ECR before LimitedLiability": "108",
"Intangible Assets": "-16.5",
"Property and Equipment": "-5.66",
"Assets, Current": "80.2",
"Other Liabilities": "36.1",
"Liabilities, Non-Current": "15.6",
"Liabilities, Current": "-14.5",
"Research and Development": "-40.5",
"Expenses": "-15.5",
"Revenues": "-1.11",
"Net Income": "-13.6",
"Other Expenses": "20.8",
"Cost of Goods Sold": "4.55",
"Selling, General and Administrative Expense": "1.62",
"Other Revenues": "-1.11",
"Comprehensive Net Income": "-13.9",
"Other Net Income": "3.15",
"Economic Capital Ratio": "32.1"
},
"2012": {
"Assets": "46.6",
"Liabilities": "85.3",
"Stockholders Equity": "168",
"ECR before LimitedLiability": "213",
"Assets, Current": "78.1",
"Intangible Assets": "-6.35",
"Other Assets": "-4.29",
"Liabilities, Current": "40.6",
"Other Liabilities": "36.5",
"Liabilities, Non-Current": "17.4",
"Selling, General and Administrative Expense": "5.08",
"Expenses": "-0.958",
"Revenues": "-5.31",
"Net Income": "-3.87",
"Research and Development": "-28.8",
"Other Expenses": "18.1",
"Cost of Goods Sold": "4.07",
"Other Revenues": "-5.31",
"Comprehensive Net Income": "-3.70",
"Other Net Income": "2.39",
"Economic Capital Ratio": "140"
},
"2013": {
"Liabilities, Non-Current": "31.2",
"Liabilities": "160",
"Stockholders Equity": "108",
"ECR before LimitedLiability": "272",
"Liabilities, Current": "92.9",
"Other Liabilities": "77.2",
"Selling, General and Administrative Expense": "19.1",
"Expenses": "36.8",
"Net Income": "132",
"Other Expenses": "21.0",
"Research and Development": "-7.67",
"Cost of Goods Sold": "4.72",
"Other Revenues": "98.0",
"Revenues": "98.0",
"Intangible Assets": "-3.65",
"Property and Equipment": "0.489",
"Other Assets": "1.31",
"Assets, Current": "1.12",
"Comprehensive Net Income": "132",
"Other Net Income": "2.94",
"Economic Capital Ratio": "244"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001178879_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "66,648",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "19,256",
"Liabilities, Non-Current": "0",
"Other Assets": "709",
"Other Compr. Net Income": "0",
"Other Expenses": "-4,660",
"Other Liabilities": "0",
"Other Net Income": "230",
"Other Revenues": "21,434",
"Property and Equipment": "2,438",
"Research and Development": "50,856",
"Selling, General and Administrative Expense": "19,880"
},
"output_variables": {
"Assets": "69,795",
"Liabilities": "19,256",
"Expenses": "66,076",
"Revenues": "21,434",
"Stockholders Equity": "50,539",
"Net Income": "-44,412",
"Comprehensive Net Income": "-44,412",
"BaseVar": "88,396",
"ECR before LimitedLiability": "148%",
"Economic Capital Ratio": "266%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "104,617",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,243",
"Liabilities, Non-Current": "0",
"Other Assets": "442",
"Other Compr. Net Income": "0",
"Other Expenses": "-2,104",
"Other Liabilities": "0",
"Other Net Income": "337",
"Other Revenues": "18,411",
"Property and Equipment": "5,029",
"Research and Development": "50,273",
"Selling, General and Administrative Expense": "19,364"
},
"output_variables": {
"Assets": "110,088",
"Liabilities": "9,243",
"Expenses": "67,533",
"Revenues": "18,411",
"Stockholders Equity": "100,845",
"Net Income": "-48,785",
"Comprehensive Net Income": "-48,785",
"BaseVar": "102,806",
"ECR before LimitedLiability": "287%",
"Economic Capital Ratio": "360%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "88,278",
"Cost of Goods Sold": "0",
"Intangible Assets": "34,613",
"Liabilities, Current": "10,461",
"Liabilities, Non-Current": "0",
"Other Assets": "552",
"Other Compr. Net Income": "0",
"Other Expenses": "-667",
"Other Liabilities": "0",
"Other Net Income": "426",
"Other Revenues": "122,238",
"Property and Equipment": "4,120",
"Research and Development": "41,944",
"Selling, General and Administrative Expense": "18,893"
},
"output_variables": {
"Assets": "127,563",
"Liabilities": "10,461",
"Expenses": "60,170",
"Revenues": "122,238",
"Stockholders Equity": "117,102",
"Net Income": "62,494",
"Comprehensive Net Income": "62,494",
"BaseVar": "160,429",
"ECR before LimitedLiability": "460%",
"Economic Capital Ratio": "486%"
}
}
},
"top_rated": true,
"trend": 32.0,
"value": 4.863298103865618,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001178879.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001178879.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001178879.svg"
},
{
"company_id": "0000875622",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000875622.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000875622.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000875622_main_keyfigs.svg",
"name": "Biospecifics Technologies CORP",
"rank": 4,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000875622.svg",
"report_text": "The relative strengths and weaknesses of Biospecifics Technologies CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Biospecifics Technologies CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 153% points.The greatest weakness of Biospecifics Technologies CORP is the variable Assets, reducing the Economic Capital Ratio by 2.7% points.
The company's Economic Capital Ratio, given in the ranking table, is 479%, being 236% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000875622_2014_Biospecifics_Technologies_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.15",
"Assets": "-5.40",
"Liabilities": "124",
"Stockholders Equity": "152",
"ECR before LimitedLiability": "324",
"Intangible Assets": "1.28",
"Assets, Current": "-6.08",
"Other Liabilities": "55.1",
"Liabilities, Non-Current": "25.0",
"Liabilities, Current": "69.3",
"Research and Development": "33.8",
"Expenses": "52.1",
"Revenues": "63.1",
"Net Income": "113",
"Other Expenses": "25.8",
"Cost of Goods Sold": "4.92",
"Selling, General and Administrative Expense": "-11.7",
"Other Revenues": "63.1",
"Comprehensive Net Income": "113",
"Other Net Income": "3.67",
"Economic Capital Ratio": "249"
},
"2012": {
"Assets": "0.509",
"Stockholders Equity": "170",
"ECR before LimitedLiability": "318",
"Assets, Current": "0.399",
"Other Assets": "0.287",
"Liabilities, Current": "87.8",
"Liabilities": "142",
"Other Liabilities": "57.4",
"Liabilities, Non-Current": "28.2",
"Selling, General and Administrative Expense": "-2.42",
"Expenses": "34.1",
"Revenues": "53.3",
"Net Income": "87.1",
"Research and Development": "27.2",
"Other Expenses": "4.01",
"Cost of Goods Sold": "5.58",
"Other Revenues": "53.3",
"Comprehensive Net Income": "87.4",
"Other Net Income": "3.05",
"Other Compr. Net Income": "0.235",
"Economic Capital Ratio": "245"
},
"2013": {
"Other Assets": "-1.94",
"Assets": "-2.69",
"Liabilities": "152",
"Stockholders Equity": "153",
"ECR before LimitedLiability": "264",
"Intangible Assets": "0.848",
"Property and Equipment": "0.563",
"Assets, Current": "-2.43",
"Liabilities, Non-Current": "26.4",
"Liabilities, Current": "95.0",
"Other Liabilities": "66.3",
"Selling, General and Administrative Expense": "1.52",
"Expenses": "29.6",
"Revenues": "61.9",
"Net Income": "90.4",
"Research and Development": "24.7",
"Cost of Goods Sold": "3.99",
"Other Revenues": "61.9",
"Comprehensive Net Income": "90.1",
"Other Net Income": "2.24",
"Economic Capital Ratio": "236"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000875622_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "13,087",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,116",
"Liabilities, Non-Current": "0",
"Other Assets": "3,179",
"Other Compr. Net Income": "0",
"Other Expenses": "-1,338",
"Other Liabilities": "0",
"Other Net Income": "72",
"Other Revenues": "11,396",
"Property and Equipment": "0",
"Research and Development": "972",
"Selling, General and Administrative Expense": "5,232"
},
"output_variables": {
"Assets": "16,265",
"Liabilities": "1,116",
"Expenses": "4,866",
"Revenues": "11,396",
"Stockholders Equity": "15,149",
"Net Income": "6,602",
"Comprehensive Net Income": "6,602",
"BaseVar": "16,857",
"ECR before LimitedLiability": "456%",
"Economic Capital Ratio": "483%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "13,876",
"Cost of Goods Sold": "0",
"Intangible Assets": "280",
"Liabilities, Current": "725",
"Liabilities, Non-Current": "0",
"Other Assets": "4,234",
"Other Compr. Net Income": "0",
"Other Expenses": "2,174",
"Other Liabilities": "0",
"Other Net Income": "35",
"Other Revenues": "11,145",
"Property and Equipment": "0",
"Research and Development": "1,250",
"Selling, General and Administrative Expense": "4,775"
},
"output_variables": {
"Assets": "18,390",
"Liabilities": "725",
"Expenses": "8,199",
"Revenues": "11,145",
"Stockholders Equity": "17,666",
"Net Income": "2,981",
"Comprehensive Net Income": "2,981",
"BaseVar": "19,247",
"ECR before LimitedLiability": "434%",
"Economic Capital Ratio": "465%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "18,273",
"Cost of Goods Sold": "0",
"Intangible Assets": "216",
"Liabilities, Current": "782",
"Liabilities, Non-Current": "0",
"Other Assets": "4,763",
"Other Compr. Net Income": "0",
"Other Expenses": "2,685",
"Other Liabilities": "0",
"Other Net Income": "26",
"Other Revenues": "14,467",
"Property and Equipment": "0",
"Research and Development": "1,484",
"Selling, General and Administrative Expense": "5,038"
},
"output_variables": {
"Assets": "23,252",
"Liabilities": "782",
"Expenses": "9,208",
"Revenues": "14,467",
"Stockholders Equity": "22,471",
"Net Income": "5,286",
"Comprehensive Net Income": "5,286",
"BaseVar": "23,867",
"ECR before LimitedLiability": "452%",
"Economic Capital Ratio": "479%"
}
}
},
"top_rated": true,
"trend": -3.0,
"value": 4.792173041337679,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000875622.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000875622.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000875622.svg"
},
{
"company_id": "0001177648",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001177648.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001177648.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001177648.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001177648_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001177648_main_keyfigs.svg",
"name": "Enanta Pharmaceuticals INC",
"rank": 5,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001177648.svg",
"report_text": "The relative strengths and weaknesses of Enanta Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Enanta Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 172% points.The greatest weakness of Enanta Pharmaceuticals INC is the variable Intangible Assets, reducing the Economic Capital Ratio by 1.3% points.
The company's Economic Capital Ratio, given in the ranking table, is 443%, being 201% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001177648_2014_Enanta_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "1.04",
"Assets": "13.3",
"Liabilities": "99.2",
"Stockholders Equity": "172",
"ECR before LimitedLiability": "229",
"Intangible Assets": "-1.29",
"Assets, Current": "15.8",
"Liabilities, Non-Current": "15.8",
"Liabilities, Current": "60.2",
"Other Liabilities": "38.5",
"Selling, General and Administrative Expense": "16.4",
"Expenses": "33.9",
"Revenues": "17.4",
"Net Income": "52.3",
"Other Expenses": "11.9",
"Research and Development": "3.59",
"Cost of Goods Sold": "2.75",
"Other Revenues": "17.4",
"Comprehensive Net Income": "52.1",
"Other Net Income": "2.15",
"Economic Capital Ratio": "201"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001177648_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "104,713",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,526",
"Liabilities, Non-Current": "359",
"Other Assets": "11,139",
"Other Compr. Net Income": "-12",
"Other Expenses": "0",
"Other Liabilities": "1,620",
"Other Net Income": "598",
"Other Revenues": "32,053",
"Property and Equipment": "1,121",
"Research and Development": "16,841",
"Selling, General and Administrative Expense": "6,183"
},
"output_variables": {
"Assets": "116,973",
"Liabilities": "6,505",
"Expenses": "23,024",
"Revenues": "32,053",
"Stockholders Equity": "110,468",
"Net Income": "9,627",
"Comprehensive Net Income": "9,621",
"BaseVar": "89,582",
"ECR before LimitedLiability": "406%",
"Economic Capital Ratio": "443%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.434603619415095,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001177648.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001177648.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001177648.svg"
},
{
"company_id": "0001580149",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001580149.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001580149.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001580149_main_keyfigs.svg",
"name": "Biovie INC",
"rank": 6,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001580149.svg",
"report_text": "The relative strengths and weaknesses of Biovie INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Biovie INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 218% points.The greatest weakness of Biovie INC is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.
The company's Economic Capital Ratio, given in the ranking table, is 442%, being 200% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001580149_2014_Biovie_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-0.773",
"Assets": "29.7",
"Liabilities": "78.9",
"Stockholders Equity": "218",
"ECR before LimitedLiability": "228",
"Intangible Assets": "-0.980",
"Assets, Current": "44.8",
"Liabilities, Non-Current": "12.6",
"Liabilities, Current": "43.2",
"Other Liabilities": "33.1",
"Selling, General and Administrative Expense": "12.0",
"Expenses": "38.5",
"Revenues": "-15.5",
"Net Income": "25.0",
"Other Expenses": "8.46",
"Research and Development": "16.9",
"Cost of Goods Sold": "1.96",
"Other Revenues": "-15.5",
"Comprehensive Net Income": "24.8",
"Other Net Income": "1.01",
"Economic Capital Ratio": "200"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001580149_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "506",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "15",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "18"
},
"output_variables": {
"Assets": "506",
"Liabilities": "15",
"Expenses": "18",
"Revenues": "0",
"Stockholders Equity": "491",
"Net Income": "-18",
"Comprehensive Net Income": "-18",
"BaseVar": "269",
"ECR before LimitedLiability": "404%",
"Economic Capital Ratio": "442%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.423349867248549,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001580149.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001580149.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001580149.svg"
},
{
"company_id": "0001354071",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001354071.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001354071.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001354071_main_keyfigs.svg",
"name": "China Pediatric Pharmaceuticals INC",
"rank": 7,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001354071.svg",
"report_text": "The relative strengths and weaknesses of China Pediatric Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of China Pediatric Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 161% points.The greatest weakness of China Pediatric Pharmaceuticals INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 27% points.
The company's Economic Capital Ratio, given in the ranking table, is 432%, being 189% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001354071_2014_China_Pediatric_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-9.50",
"Assets": "-27.1",
"Liabilities": "199",
"Stockholders Equity": "15.6",
"ECR before LimitedLiability": "225",
"Intangible Assets": "-7.83",
"Assets, Current": "-12.7",
"Other Liabilities": "78.7",
"Liabilities, Non-Current": "36.7",
"Liabilities, Current": "121",
"Research and Development": "66.2",
"Expenses": "-53.4",
"Revenues": "84.7",
"Net Income": "72.1",
"Other Expenses": "-51.3",
"Cost of Goods Sold": "-83.0",
"Selling, General and Administrative Expense": "7.73",
"Other Revenues": "84.7",
"Comprehensive Net Income": "73.9",
"Other Net Income": "37.5",
"Economic Capital Ratio": "150"
},
"2012": {
"Property and Equipment": "-5.29",
"Assets": "-35.7",
"Liabilities": "200",
"Stockholders Equity": "59.4",
"ECR before LimitedLiability": "194",
"Assets, Current": "-21.9",
"Intangible Assets": "-4.82",
"Other Assets": "-11.9",
"Liabilities, Current": "130",
"Other Liabilities": "75.7",
"Liabilities, Non-Current": "37.0",
"Selling, General and Administrative Expense": "22.1",
"Expenses": "-75.8",
"Revenues": "92.7",
"Net Income": "20.1",
"Research and Development": "64.7",
"Other Expenses": "-78.0",
"Cost of Goods Sold": "-87.1",
"Other Revenues": "92.7",
"Comprehensive Net Income": "21.3",
"Economic Capital Ratio": "121"
},
"2013": {
"Other Assets": "-1.76",
"Assets": "13.1",
"Liabilities": "116",
"Stockholders Equity": "161",
"ECR before LimitedLiability": "217",
"Intangible Assets": "0.997",
"Assets, Current": "13.6",
"Liabilities, Non-Current": "19.6",
"Liabilities, Current": "67.1",
"Other Liabilities": "50.1",
"Selling, General and Administrative Expense": "9.64",
"Expenses": "19.9",
"Revenues": "20.0",
"Net Income": "38.9",
"Other Expenses": "8.93",
"Research and Development": "27.1",
"Cost of Goods Sold": "-26.9",
"Other Revenues": "20.0",
"Comprehensive Net Income": "40.7",
"Other Compr. Net Income": "1.91",
"Economic Capital Ratio": "189"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001354071_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "19,620",
"Cost of Goods Sold": "15,082",
"Intangible Assets": "1,710",
"Liabilities, Current": "1,609",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "883",
"Other Expenses": "12,964",
"Other Liabilities": "0",
"Other Net Income": "5,737",
"Other Revenues": "27,415",
"Property and Equipment": "877",
"Research and Development": "1,856",
"Selling, General and Administrative Expense": "10,216"
},
"output_variables": {
"Assets": "22,207",
"Liabilities": "1,609",
"Expenses": "40,119",
"Revenues": "27,415",
"Stockholders Equity": "20,598",
"Net Income": "-6,967",
"Comprehensive Net Income": "-6,525",
"BaseVar": "48,985",
"ECR before LimitedLiability": "322%",
"Economic Capital Ratio": "384%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "9,881",
"Cost of Goods Sold": "8,895",
"Intangible Assets": "1,447",
"Liabilities, Current": "500",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "159",
"Other Expenses": "10,695",
"Other Liabilities": "0",
"Other Net Income": "-0.16",
"Other Revenues": "14,168",
"Property and Equipment": "791",
"Research and Development": "0",
"Selling, General and Administrative Expense": "3,730"
},
"output_variables": {
"Assets": "12,120",
"Liabilities": "500",
"Expenses": "23,320",
"Revenues": "14,168",
"Stockholders Equity": "11,619",
"Net Income": "-9,152",
"Comprehensive Net Income": "-9,073",
"BaseVar": "25,133",
"ECR before LimitedLiability": "258%",
"Economic Capital Ratio": "341%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "9,803",
"Cost of Goods Sold": "2,435",
"Intangible Assets": "1,208",
"Liabilities, Current": "509",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "363",
"Other Expenses": "395",
"Other Liabilities": "0",
"Other Net Income": "-161",
"Other Revenues": "3,726",
"Property and Equipment": "724",
"Research and Development": "0",
"Selling, General and Administrative Expense": "1,492"
},
"output_variables": {
"Assets": "11,736",
"Liabilities": "509",
"Expenses": "4,322",
"Revenues": "3,726",
"Stockholders Equity": "11,227",
"Net Income": "-756",
"Comprehensive Net Income": "-575",
"BaseVar": "10,408",
"ECR before LimitedLiability": "390%",
"Economic Capital Ratio": "432%"
}
}
},
"top_rated": true,
"trend": 34.0,
"value": 4.320393430606559,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001354071.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001354071.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001354071.svg"
},
{
"company_id": "0001232524",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001232524.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001232524.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001232524.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001232524_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001232524_main_keyfigs.svg",
"name": "Jazz Pharmaceuticals plc",
"rank": 8,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001232524.svg",
"report_text": "The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 140% points.The greatest weakness of Jazz Pharmaceuticals plc is the variable Assets, Current, reducing the Economic Capital Ratio by 4.8% points.
The company's Economic Capital Ratio, given in the ranking table, is 425%, being 182% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001232524_2014_Jazz_Pharmaceuticals_plc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Liabilities": "53.3",
"Liabilities": "89.3",
"Stockholders Equity": "56.2",
"ECR before LimitedLiability": "257",
"Liabilities, Non-Current": "24.3",
"Liabilities, Current": "24.4",
"Research and Development": "39.7",
"Expenses": "38.7",
"Net Income": "120",
"Other Expenses": "4.36",
"Cost of Goods Sold": "5.36",
"Selling, General and Administrative Expense": "-11.0",
"Other Revenues": "80.4",
"Revenues": "80.4",
"Other Assets": "-3.65",
"Property and Equipment": "-2.86",
"Assets, Current": "3.40",
"Intangible Assets": "3.53",
"Comprehensive Net Income": "119",
"Other Net Income": "2.73",
"Economic Capital Ratio": "181"
},
"2013": {
"Other Assets": "-0.512",
"Assets": "14.7",
"Liabilities": "94.3",
"Stockholders Equity": "140",
"ECR before LimitedLiability": "210",
"Intangible Assets": "32.1",
"Property and Equipment": "-1.28",
"Assets, Current": "-4.82",
"Liabilities, Non-Current": "18.4",
"Liabilities, Current": "43.5",
"Other Liabilities": "47.2",
"Selling, General and Administrative Expense": "7.95",
"Expenses": "30.2",
"Revenues": "28.2",
"Net Income": "56.9",
"Other Expenses": "-3.43",
"Research and Development": "23.0",
"Cost of Goods Sold": "2.98",
"Other Revenues": "28.2",
"Comprehensive Net Income": "56.6",
"Economic Capital Ratio": "182"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001232524_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "199,131",
"Cost of Goods Sold": "0",
"Intangible Assets": "52,798",
"Liabilities, Current": "52,870",
"Liabilities, Non-Current": "0",
"Other Assets": "87",
"Other Compr. Net Income": "0",
"Other Expenses": "23,065",
"Other Liabilities": "0",
"Other Net Income": "-1,172",
"Other Revenues": "272,277",
"Property and Equipment": "1,557",
"Research and Development": "14,120",
"Selling, General and Administrative Expense": "108,936"
},
"output_variables": {
"Assets": "253,573",
"Liabilities": "52,870",
"Expenses": "146,121",
"Revenues": "272,277",
"Stockholders Equity": "200,703",
"Net Income": "124,984",
"Comprehensive Net Income": "124,984",
"BaseVar": "363,006",
"ECR before LimitedLiability": "367%",
"Economic Capital Ratio": "415%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "864,617",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,262,852",
"Liabilities, Current": "204,028",
"Liabilities, Non-Current": "0",
"Other Assets": "96,506",
"Other Compr. Net Income": "0",
"Other Expenses": "274,523",
"Other Liabilities": "0",
"Other Net Income": "-30,665",
"Other Revenues": "872,423",
"Property and Equipment": "14,246",
"Research and Development": "46,620",
"Selling, General and Administrative Expense": "304,303"
},
"output_variables": {
"Assets": "2,238,221",
"Liabilities": "204,028",
"Expenses": "625,446",
"Revenues": "872,423",
"Stockholders Equity": "2,034,193",
"Net Income": "216,312",
"Comprehensive Net Income": "216,312",
"BaseVar": "1,985,392",
"ECR before LimitedLiability": "381%",
"Economic Capital Ratio": "425%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.250618574169674,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001232524.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001232524.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001232524.svg"
},
{
"company_id": "0001503802",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001503802.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001503802.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001503802.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001503802_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001503802_main_keyfigs.svg",
"name": "Karyopharm Therapeutics Inc",
"rank": 9,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001503802.svg",
"report_text": "The relative strengths and weaknesses of Karyopharm Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Karyopharm Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 212% points.The greatest weakness of Karyopharm Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.
The company's Economic Capital Ratio, given in the ranking table, is 422%, being 179% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001503802_2014_Karyopharm_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-1.63",
"Assets": "41.3",
"Liabilities": "90.0",
"Stockholders Equity": "212",
"ECR before LimitedLiability": "207",
"Intangible Assets": "-2.07",
"Property and Equipment": "-1.16",
"Assets, Current": "65.2",
"Liabilities, Non-Current": "13.7",
"Liabilities, Current": "52.8",
"Other Liabilities": "35.9",
"Selling, General and Administrative Expense": "14.0",
"Expenses": "19.6",
"Revenues": "-17.2",
"Net Income": "4.11",
"Other Expenses": "9.58",
"Research and Development": "-6.13",
"Cost of Goods Sold": "2.22",
"Other Revenues": "-17.2",
"Comprehensive Net Income": "3.92",
"Economic Capital Ratio": "179"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001503802_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "157,956",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,292",
"Liabilities, Non-Current": "0",
"Other Assets": "30",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "387",
"Property and Equipment": "240",
"Research and Development": "28,452",
"Selling, General and Administrative Expense": "5,885"
},
"output_variables": {
"Assets": "158,226",
"Liabilities": "3,292",
"Expenses": "34,337",
"Revenues": "387",
"Stockholders Equity": "154,934",
"Net Income": "-33,950",
"Comprehensive Net Income": "-33,950",
"BaseVar": "98,121",
"ECR before LimitedLiability": "376%",
"Economic Capital Ratio": "422%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.216540387840597,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001503802.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001503802.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001503802.svg"
},
{
"company_id": "0001023024",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001023024.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001023024.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001023024.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001023024_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001023024_main_keyfigs.svg",
"name": "ANI Pharmaceuticals INC",
"rank": 10,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001023024.svg",
"report_text": "The relative strengths and weaknesses of ANI Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of ANI Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 134% points.The greatest weakness of ANI Pharmaceuticals INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 27% points.
The company's Economic Capital Ratio, given in the ranking table, is 419%, being 177% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001023024_2014_ANI_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.16",
"Assets": "59.4",
"Liabilities": "-14.2",
"Stockholders Equity": "46.5",
"ECR before LimitedLiability": "47.9",
"Intangible Assets": "-20.0",
"Property and Equipment": "-10.3",
"Assets, Current": "70.0",
"Other Liabilities": "-57.7",
"Liabilities, Non-Current": "12.9",
"Liabilities, Current": "26.8",
"Research and Development": "-45.1",
"Expenses": "-14.5",
"Revenues": "-31.7",
"Net Income": "-42.7",
"Other Expenses": "10.6",
"Cost of Goods Sold": "4.32",
"Selling, General and Administrative Expense": "19.0",
"Other Revenues": "-31.7",
"Comprehensive Net Income": "-43.0",
"Economic Capital Ratio": "-27.7"
},
"2012": {
"Property and Equipment": "-8.83",
"Assets": "62.7",
"Liabilities": "26.7",
"Stockholders Equity": "99.8",
"ECR before LimitedLiability": "111",
"Assets, Current": "105",
"Intangible Assets": "-13.3",
"Other Assets": "5.12",
"Liabilities, Current": "-21.9",
"Other Liabilities": "32.4",
"Liabilities, Non-Current": "15.1",
"Other Revenues": "-20.1",
"Revenues": "-20.1",
"Net Income": "-28.0",
"Other Net Income": "-10.6",
"Comprehensive Net Income": "-27.8",
"Research and Development": "-20.4",
"Selling, General and Administrative Expense": "3.82",
"Other Expenses": "15.4",
"Cost of Goods Sold": "4.35",
"Economic Capital Ratio": "38.0"
},
"2013": {
"Other Assets": "-3.08",
"Assets": "1.51",
"Liabilities": "134",
"Stockholders Equity": "105",
"ECR before LimitedLiability": "205",
"Intangible Assets": "8.77",
"Property and Equipment": "1.95",
"Assets, Current": "-4.12",
"Liabilities, Non-Current": "24.5",
"Liabilities, Current": "74.2",
"Other Liabilities": "61.4",
"Selling, General and Administrative Expense": "-13.7",
"Expenses": "4.84",
"Revenues": "56.1",
"Net Income": "61.7",
"Other Expenses": "13.4",
"Research and Development": "30.0",
"Cost of Goods Sold": "-26.6",
"Other Revenues": "56.1",
"Comprehensive Net Income": "61.3",
"Economic Capital Ratio": "177"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001023024_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "58,026",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,228",
"Liabilities, Non-Current": "0",
"Other Assets": "3,492",
"Other Compr. Net Income": "0",
"Other Expenses": "880",
"Other Liabilities": "17,337",
"Other Net Income": "-15",
"Other Revenues": "450",
"Property and Equipment": "861",
"Research and Development": "44,182",
"Selling, General and Administrative Expense": "6,981"
},
"output_variables": {
"Assets": "62,380",
"Liabilities": "24,564",
"Expenses": "52,044",
"Revenues": "450",
"Stockholders Equity": "37,815",
"Net Income": "-51,609",
"Comprehensive Net Income": "-51,609",
"BaseVar": "69,727",
"ECR before LimitedLiability": "71%",
"Economic Capital Ratio": "206%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "35,173",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "10,594",
"Liabilities, Non-Current": "0",
"Other Assets": "3,430",
"Other Compr. Net Income": "0",
"Other Expenses": "580",
"Other Liabilities": "0",
"Other Net Income": "-4,320",
"Other Revenues": "2,301",
"Property and Equipment": "166",
"Research and Development": "16,889",
"Selling, General and Administrative Expense": "8,230"
},
"output_variables": {
"Assets": "38,769",
"Liabilities": "10,594",
"Expenses": "25,699",
"Revenues": "2,301",
"Stockholders Equity": "28,176",
"Net Income": "-27,718",
"Comprehensive Net Income": "-27,718",
"BaseVar": "40,841",
"ECR before LimitedLiability": "137%",
"Economic Capital Ratio": "258%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "27,716",
"Cost of Goods Sold": "9,974",
"Intangible Assets": "12,247",
"Liabilities, Current": "3,538",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,402",
"Other Liabilities": "0",
"Other Net Income": "-305",
"Other Revenues": "30,082",
"Property and Equipment": "4,537",
"Research and Development": "1,712",
"Selling, General and Administrative Expense": "16,388"
},
"output_variables": {
"Assets": "44,500",
"Liabilities": "3,538",
"Expenses": "29,476",
"Revenues": "30,082",
"Stockholders Equity": "40,962",
"Net Income": "301",
"Comprehensive Net Income": "301",
"BaseVar": "53,950",
"ECR before LimitedLiability": "373%",
"Economic Capital Ratio": "419%"
}
}
},
"top_rated": true,
"trend": 81.0,
"value": 4.193646660498878,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001023024.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001023024.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001023024.svg"
},
{
"company_id": "0001535955",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001535955.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001535955.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001535955.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001535955_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001535955_main_keyfigs.svg",
"name": "Lipocine Inc",
"rank": 11,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001535955.svg",
"report_text": "The relative strengths and weaknesses of Lipocine Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Lipocine Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 207% points.The greatest weakness of Lipocine Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.
The company's Economic Capital Ratio, given in the ranking table, is 416%, being 173% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001535955_2014_Lipocine_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-1.82",
"Assets": "44.6",
"Liabilities": "86.7",
"Stockholders Equity": "207",
"ECR before LimitedLiability": "201",
"Intangible Assets": "-2.36",
"Property and Equipment": "-1.36",
"Assets, Current": "70.7",
"Liabilities, Non-Current": "13.6",
"Liabilities, Current": "49.3",
"Other Liabilities": "35.5",
"Selling, General and Administrative Expense": "8.34",
"Expenses": "18.2",
"Revenues": "-17.6",
"Net Income": "2.46",
"Other Expenses": "3.95",
"Research and Development": "3.90",
"Cost of Goods Sold": "2.21",
"Other Revenues": "-17.6",
"Comprehensive Net Income": "2.26",
"Economic Capital Ratio": "173"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001535955_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "46,034",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,284",
"Liabilities, Non-Current": "0",
"Other Assets": "45",
"Other Compr. Net Income": "0",
"Other Expenses": "1,870",
"Other Liabilities": "0",
"Other Net Income": "38",
"Other Revenues": "0",
"Property and Equipment": "29",
"Research and Development": "5,123",
"Selling, General and Administrative Expense": "3,636"
},
"output_variables": {
"Assets": "46,108",
"Liabilities": "1,284",
"Expenses": "10,629",
"Revenues": "0",
"Stockholders Equity": "44,824",
"Net Income": "-10,590",
"Comprehensive Net Income": "-10,590",
"BaseVar": "29,029",
"ECR before LimitedLiability": "368%",
"Economic Capital Ratio": "416%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.155114111084423,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001535955.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001535955.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001535955.svg"
},
{
"company_id": "0001070494",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001070494.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001070494.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001070494.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001070494_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001070494_main_keyfigs.svg",
"name": "Acadia Pharmaceuticals INC",
"rank": 12,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001070494.svg",
"report_text": "The relative strengths and weaknesses of Acadia Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Acadia Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 202% points.The greatest weakness of Acadia Pharmaceuticals INC is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.
The company's Economic Capital Ratio, given in the ranking table, is 414%, being 172% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001070494_2014_Acadia_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-11.3",
"Assets": "58.6",
"Liabilities": "18.5",
"Stockholders Equity": "87.4",
"ECR before LimitedLiability": "100",
"Intangible Assets": "-14.8",
"Property and Equipment": "-8.88",
"Assets, Current": "120",
"Other Liabilities": "4.81",
"Liabilities, Non-Current": "13.1",
"Research and Development": "-27.1",
"Expenses": "-11.6",
"Revenues": "-22.5",
"Net Income": "-31.0",
"Other Expenses": "11.0",
"Cost of Goods Sold": "3.87",
"Selling, General and Administrative Expense": "1.49",
"Other Revenues": "-22.5",
"Comprehensive Net Income": "-31.3",
"Other Net Income": "2.67",
"Economic Capital Ratio": "24.9"
},
"2012": {
"Property and Equipment": "-1.94",
"Assets": "56.7",
"Liabilities": "74.5",
"Stockholders Equity": "206",
"ECR before LimitedLiability": "259",
"Assets, Current": "91.8",
"Intangible Assets": "-2.76",
"Other Assets": "-2.01",
"Liabilities, Current": "37.2",
"Other Liabilities": "31.4",
"Liabilities, Non-Current": "15.0",
"Selling, General and Administrative Expense": "12.1",
"Expenses": "25.8",
"Revenues": "-14.3",
"Net Income": "13.6",
"Other Expenses": "12.3",
"Cost of Goods Sold": "3.18",
"Other Revenues": "-14.3",
"Comprehensive Net Income": "13.8",
"Other Net Income": "1.62",
"Economic Capital Ratio": "186"
},
"2013": {
"Other Assets": "-1.84",
"Assets": "45.1",
"Liabilities": "82.2",
"Stockholders Equity": "202",
"ECR before LimitedLiability": "200",
"Intangible Assets": "-2.38",
"Property and Equipment": "-1.26",
"Assets, Current": "70.3",
"Liabilities, Non-Current": "13.3",
"Liabilities, Current": "44.6",
"Other Liabilities": "34.9",
"Selling, General and Administrative Expense": "9.75",
"Expenses": "20.8",
"Revenues": "-16.4",
"Net Income": "6.27",
"Other Expenses": "9.42",
"Cost of Goods Sold": "2.18",
"Other Revenues": "-16.4",
"Comprehensive Net Income": "6.09",
"Other Net Income": "1.38",
"Economic Capital Ratio": "172"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001070494_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "31,949",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,165",
"Liabilities, Non-Current": "0",
"Other Assets": "14",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "2,587",
"Other Net Income": "87",
"Other Revenues": "2,067",
"Property and Equipment": "151",
"Research and Development": "17,309",
"Selling, General and Administrative Expense": "7,610"
},
"output_variables": {
"Assets": "32,114",
"Liabilities": "8,752",
"Expenses": "24,919",
"Revenues": "2,067",
"Stockholders Equity": "23,362",
"Net Income": "-22,765",
"Comprehensive Net Income": "-22,765",
"BaseVar": "33,970",
"ECR before LimitedLiability": "138%",
"Economic Capital Ratio": "259%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "108,548",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "5,948",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-5.0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "37",
"Other Revenues": "4,907",
"Property and Equipment": "42",
"Research and Development": "18,794",
"Selling, General and Administrative Expense": "6,999"
},
"output_variables": {
"Assets": "108,590",
"Liabilities": "5,948",
"Expenses": "25,793",
"Revenues": "4,907",
"Stockholders Equity": "102,642",
"Net Income": "-20,849",
"Comprehensive Net Income": "-20,852",
"BaseVar": "72,640",
"ECR before LimitedLiability": "354%",
"Economic Capital Ratio": "406%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "188,360",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,979",
"Liabilities, Non-Current": "8.0",
"Other Assets": "179",
"Other Compr. Net Income": "44",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "349",
"Other Revenues": "1,145",
"Property and Equipment": "579",
"Research and Development": "26,722",
"Selling, General and Administrative Expense": "12,720"
},
"output_variables": {
"Assets": "189,118",
"Liabilities": "6,987",
"Expenses": "39,442",
"Revenues": "1,145",
"Stockholders Equity": "182,131",
"Net Income": "-37,948",
"Comprehensive Net Income": "-37,926",
"BaseVar": "118,542",
"ECR before LimitedLiability": "366%",
"Economic Capital Ratio": "414%"
}
}
},
"top_rated": true,
"trend": -2.0,
"value": 4.144817898902302,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001070494.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001070494.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001070494.svg"
},
{
"company_id": "0001362718",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001362718.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001362718.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001362718_main_keyfigs.svg",
"name": "Tianyin Pharmaceutical CO INC",
"rank": 13,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001362718.svg",
"report_text": "The relative strengths and weaknesses of Tianyin Pharmaceutical CO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tianyin Pharmaceutical CO INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 114% points.The greatest weakness of Tianyin Pharmaceutical CO INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 47% points.
The company's Economic Capital Ratio, given in the ranking table, is 413%, being 170% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001362718_2014_Tianyin_Pharmaceutical_CO_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.82",
"Assets": "-2.66",
"Liabilities": "147",
"Stockholders Equity": "79.3",
"ECR before LimitedLiability": "275",
"Property and Equipment": "7.93",
"Assets, Current": "-5.89",
"Other Liabilities": "65.7",
"Liabilities, Non-Current": "30.5",
"Liabilities, Current": "83.4",
"Research and Development": "54.5",
"Expenses": "12.0",
"Revenues": "84.1",
"Net Income": "101",
"Other Expenses": "-14.1",
"Cost of Goods Sold": "-76.9",
"Selling, General and Administrative Expense": "39.7",
"Other Revenues": "84.1",
"Comprehensive Net Income": "102",
"Other Net Income": "6.47",
"Economic Capital Ratio": "199"
},
"2012": {
"Property and Equipment": "12.9",
"Assets": "9.92",
"Liabilities": "99.3",
"Stockholders Equity": "107",
"ECR before LimitedLiability": "249",
"Assets, Current": "-4.04",
"Intangible Assets": "6.70",
"Other Assets": "-3.82",
"Liabilities, Current": "42.0",
"Other Liabilities": "48.8",
"Liabilities, Non-Current": "23.8",
"Selling, General and Administrative Expense": "29.0",
"Expenses": "21.9",
"Revenues": "46.4",
"Net Income": "70.0",
"Research and Development": "34.1",
"Other Expenses": "5.32",
"Cost of Goods Sold": "-49.6",
"Other Revenues": "46.4",
"Comprehensive Net Income": "71.4",
"Economic Capital Ratio": "176"
},
"2013": {
"Other Assets": "-3.25",
"Assets": "4.41",
"Liabilities": "114",
"Stockholders Equity": "102",
"ECR before LimitedLiability": "198",
"Intangible Assets": "5.27",
"Property and Equipment": "20.2",
"Assets, Current": "-9.80",
"Liabilities, Non-Current": "22.1",
"Liabilities, Current": "55.6",
"Other Liabilities": "56.1",
"Selling, General and Administrative Expense": "27.0",
"Expenses": "14.1",
"Revenues": "48.2",
"Net Income": "62.9",
"Research and Development": "30.9",
"Cost of Goods Sold": "-46.8",
"Other Revenues": "48.2",
"Comprehensive Net Income": "63.7",
"Other Net Income": "1.60",
"Economic Capital Ratio": "170"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001362718_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "47,396",
"Cost of Goods Sold": "52,698",
"Intangible Assets": "15,339",
"Liabilities, Current": "8,922",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "3,272",
"Other Expenses": "21,803",
"Other Liabilities": "0",
"Other Net Income": "1,641",
"Other Revenues": "95,201",
"Property and Equipment": "27,466",
"Research and Development": "1,073",
"Selling, General and Administrative Expense": "5,645"
},
"output_variables": {
"Assets": "90,201",
"Liabilities": "8,922",
"Expenses": "81,219",
"Revenues": "95,201",
"Stockholders Equity": "81,280",
"Net Income": "15,623",
"Comprehensive Net Income": "17,259",
"BaseVar": "140,228",
"ECR before LimitedLiability": "392%",
"Economic Capital Ratio": "434%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "56,901",
"Cost of Goods Sold": "45,274",
"Intangible Assets": "20,958",
"Liabilities, Current": "14,798",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "2,140",
"Other Expenses": "13,041",
"Other Liabilities": "0",
"Other Net Income": "67",
"Other Revenues": "69,606",
"Property and Equipment": "26,458",
"Research and Development": "860",
"Selling, General and Administrative Expense": "4,256"
},
"output_variables": {
"Assets": "104,318",
"Liabilities": "14,798",
"Expenses": "63,431",
"Revenues": "69,606",
"Stockholders Equity": "89,519",
"Net Income": "6,242",
"Comprehensive Net Income": "7,312",
"BaseVar": "127,180",
"ECR before LimitedLiability": "340%",
"Economic Capital Ratio": "396%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "47,825",
"Cost of Goods Sold": "41,497",
"Intangible Assets": "21,716",
"Liabilities, Current": "11,896",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "2,135",
"Other Expenses": "13,867",
"Other Liabilities": "0",
"Other Net Income": "-275",
"Other Revenues": "67,500",
"Property and Equipment": "40,603",
"Research and Development": "895",
"Selling, General and Administrative Expense": "4,352"
},
"output_variables": {
"Assets": "110,144",
"Liabilities": "11,896",
"Expenses": "60,610",
"Revenues": "67,500",
"Stockholders Equity": "98,248",
"Net Income": "6,615",
"Comprehensive Net Income": "7,683",
"BaseVar": "126,280",
"ECR before LimitedLiability": "364%",
"Economic Capital Ratio": "413%"
}
}
},
"top_rated": true,
"trend": 2.0,
"value": 4.125746343630511,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001362718.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001362718.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001362718.svg"
},
{
"company_id": "0000850693",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000850693.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000850693.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000850693_main_keyfigs.svg",
"name": "Allergan INC",
"rank": 14,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000850693.svg",
"report_text": "The relative strengths and weaknesses of Allergan INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Allergan INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 106% points.The greatest weakness of Allergan INC is the variable Assets, Current, reducing the Economic Capital Ratio by 6.9% points.
The company's Economic Capital Ratio, given in the ranking table, is 411%, being 168% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000850693_2014_Allergan_INC.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "0.767",
"Assets": "1.24",
"Liabilities": "80.4",
"Stockholders Equity": "59.0",
"ECR before LimitedLiability": "76.7",
"Other Assets": "-1.59",
"Intangible Assets": "4.20",
"Property and Equipment": "-1.73",
"Liabilities, Current": "30.3",
"Other Liabilities": "26.0",
"Liabilities, Non-Current": "35.5",
"Expenses": "-11.0",
"Revenues": "10.3",
"Net Income": "-2.12",
"Selling, General and Administrative Expense": "-11.2",
"Other Expenses": "1.40",
"Research and Development": "-1.89",
"Other Revenues": "10.3",
"Comprehensive Net Income": "-2.15",
"Other Net Income": "-1.62",
"Economic Capital Ratio": "77.5"
},
"2010": {
"Liabilities, Current": "0.718",
"Liabilities": "72.9",
"Stockholders Equity": "50.8",
"ECR before LimitedLiability": "88.0",
"Other Liabilities": "42.8",
"Liabilities, Non-Current": "35.0",
"Selling, General and Administrative Expense": "-3.03",
"Expenses": "-6.10",
"Net Income": "10.4",
"Research and Development": "4.71",
"Cost of Goods Sold": "5.80",
"Other Expenses": "-13.7",
"Other Revenues": "16.9",
"Revenues": "16.9",
"Other Assets": "-4.34",
"Assets, Current": "-2.40",
"Property and Equipment": "-2.92",
"Intangible Assets": "11.3",
"Comprehensive Net Income": "10.4",
"Other Net Income": "-0.506",
"Economic Capital Ratio": "81.6"
},
"2011": {
"Other Assets": "-1.27",
"Assets": "10.4",
"Liabilities": "97.2",
"Stockholders Equity": "116",
"ECR before LimitedLiability": "257",
"Intangible Assets": "16.3",
"Property and Equipment": "1.41",
"Assets, Current": "-3.54",
"Other Liabilities": "46.9",
"Liabilities, Non-Current": "21.2",
"Liabilities, Current": "44.6",
"Research and Development": "26.8",
"Expenses": "26.0",
"Revenues": "43.9",
"Net Income": "70.2",
"Other Expenses": "-6.14",
"Cost of Goods Sold": "4.64",
"Other Revenues": "43.9",
"Comprehensive Net Income": "69.9",
"Other Net Income": "1.85",
"Economic Capital Ratio": "182"
},
"2012": {
"Property and Equipment": "1.43",
"Assets": "11.7",
"Liabilities": "103",
"Stockholders Equity": "124",
"ECR before LimitedLiability": "266",
"Assets, Current": "-3.78",
"Intangible Assets": "17.5",
"Liabilities, Current": "47.3",
"Other Liabilities": "49.0",
"Liabilities, Non-Current": "23.9",
"Selling, General and Administrative Expense": "2.10",
"Expenses": "28.8",
"Revenues": "46.5",
"Net Income": "75.1",
"Research and Development": "20.9",
"Other Expenses": "1.03",
"Cost of Goods Sold": "5.13",
"Other Revenues": "46.5",
"Comprehensive Net Income": "75.3",
"Other Net Income": "1.43",
"Economic Capital Ratio": "193"
},
"2013": {
"Other Assets": "-1.81",
"Assets": "6.25",
"Liabilities": "106",
"Stockholders Equity": "103",
"ECR before LimitedLiability": "196",
"Intangible Assets": "18.1",
"Property and Equipment": "1.71",
"Assets, Current": "-6.88",
"Liabilities, Non-Current": "21.1",
"Liabilities, Current": "48.1",
"Other Liabilities": "53.7",
"Expenses": "21.4",
"Revenues": "46.5",
"Net Income": "64.4",
"Other Expenses": "-1.26",
"Research and Development": "18.4",
"Cost of Goods Sold": "3.55",
"Other Revenues": "46.5",
"Comprehensive Net Income": "64.2",
"Other Net Income": "-2.54",
"Economic Capital Ratio": "168"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000850693_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "3,106,300",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,355,500",
"Liabilities, Current": "811,600",
"Liabilities, Non-Current": "0",
"Other Assets": "266,700",
"Other Compr. Net Income": "0",
"Other Expenses": "1,172,800",
"Other Liabilities": "0",
"Other Net Income": "-79,500",
"Other Revenues": "4,503,600",
"Property and Equipment": "808,100",
"Research and Development": "706,000",
"Selling, General and Administrative Expense": "1,921,500"
},
"output_variables": {
"Assets": "7,536,600",
"Liabilities": "811,600",
"Expenses": "3,800,300",
"Revenues": "4,503,600",
"Stockholders Equity": "6,725,000",
"Net Income": "623,800",
"Comprehensive Net Income": "623,800",
"BaseVar": "8,365,800",
"ECR before LimitedLiability": "366%",
"Economic Capital Ratio": "414%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "3,993,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,034,600",
"Liabilities, Current": "1,528,400",
"Liabilities, Non-Current": "0",
"Other Assets": "479,200",
"Other Compr. Net Income": "0",
"Other Expenses": "2,004,500",
"Other Liabilities": "0",
"Other Net Income": "-87,800",
"Other Revenues": "4,919,400",
"Property and Equipment": "800,600",
"Research and Development": "804,600",
"Selling, General and Administrative Expense": "2,017,600"
},
"output_variables": {
"Assets": "8,308,100",
"Liabilities": "1,528,400",
"Expenses": "4,826,700",
"Revenues": "4,919,400",
"Stockholders Equity": "6,779,700",
"Net Income": "4,900",
"Comprehensive Net Income": "4,900",
"BaseVar": "9,835,200",
"ECR before LimitedLiability": "301%",
"Economic Capital Ratio": "369%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "4,048,300",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,253,600",
"Liabilities, Current": "955,000",
"Liabilities, Non-Current": "0",
"Other Assets": "399,700",
"Other Compr. Net Income": "0",
"Other Expenses": "1,266,200",
"Other Liabilities": "0",
"Other Net Income": "-65,400",
"Other Revenues": "5,419,100",
"Property and Equipment": "807,000",
"Research and Development": "902,800",
"Selling, General and Administrative Expense": "2,246,600"
},
"output_variables": {
"Assets": "8,508,600",
"Liabilities": "955,000",
"Expenses": "4,415,600",
"Revenues": "5,419,100",
"Stockholders Equity": "7,553,600",
"Net Income": "938,100",
"Comprehensive Net Income": "938,100",
"BaseVar": "9,681,850",
"ECR before LimitedLiability": "368%",
"Economic Capital Ratio": "416%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "4,458,800",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,468,600",
"Liabilities, Current": "1,095,200",
"Liabilities, Non-Current": "0",
"Other Assets": "399,000",
"Other Compr. Net Income": "-6,900",
"Other Expenses": "1,377,916",
"Other Liabilities": "0",
"Other Net Income": "-80,318",
"Other Revenues": "5,853,844",
"Property and Equipment": "852,900",
"Research and Development": "1,007,326",
"Selling, General and Administrative Expense": "2,269,703"
},
"output_variables": {
"Assets": "9,179,300",
"Liabilities": "1,095,200",
"Expenses": "4,654,944",
"Revenues": "5,853,844",
"Stockholders Equity": "8,084,100",
"Net Income": "1,118,581",
"Comprehensive Net Income": "1,115,131",
"BaseVar": "10,435,253",
"ECR before LimitedLiability": "365%",
"Economic Capital Ratio": "413%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "5,319,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,989,400",
"Liabilities, Current": "1,244,300",
"Liabilities, Non-Current": "0",
"Other Assets": "342,000",
"Other Compr. Net Income": "-6,889",
"Other Expenses": "1,390,450",
"Other Liabilities": "0",
"Other Net Income": "-754,222",
"Other Revenues": "6,366,660",
"Property and Equipment": "923,200",
"Research and Development": "1,053,545",
"Selling, General and Administrative Expense": "2,534,809"
},
"output_variables": {
"Assets": "10,574,300",
"Liabilities": "1,244,300",
"Expenses": "4,978,804",
"Revenues": "6,366,660",
"Stockholders Equity": "9,330,000",
"Net Income": "633,634",
"Comprehensive Net Income": "630,190",
"BaseVar": "11,962,587",
"ECR before LimitedLiability": "355%",
"Economic Capital Ratio": "406%"
}
}
},
"top_rated": true,
"trend": -6.0,
"value": 4.1073899294794005,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000850693.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000850693.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000850693.svg"
},
{
"company_id": "0001087294",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001087294.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001087294.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001087294.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001087294_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001087294_main_keyfigs.svg",
"name": "Cumberland Pharmaceuticals INC",
"rank": 15,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001087294.svg",
"report_text": "The relative strengths and weaknesses of Cumberland Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cumberland Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 133% points.The greatest weakness of Cumberland Pharmaceuticals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 16% points.
The company's Economic Capital Ratio, given in the ranking table, is 407%, being 164% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001087294_2014_Cumberland_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.82",
"Assets": "17.1",
"Liabilities": "79.1",
"Stockholders Equity": "114",
"ECR before LimitedLiability": "240",
"Property and Equipment": "-2.64",
"Assets, Current": "32.0",
"Other Liabilities": "15.3",
"Liabilities, Non-Current": "18.7",
"Liabilities, Current": "53.5",
"Research and Development": "30.0",
"Expenses": "24.9",
"Revenues": "32.1",
"Net Income": "58.9",
"Other Expenses": "-29.6",
"Cost of Goods Sold": "4.18",
"Selling, General and Administrative Expense": "19.2",
"Other Revenues": "32.1",
"Comprehensive Net Income": "58.6",
"Other Net Income": "2.83",
"Economic Capital Ratio": "165"
},
"2012": {
"Property and Equipment": "-2.45",
"Assets": "20.4",
"Liabilities": "84.4",
"Stockholders Equity": "129",
"ECR before LimitedLiability": "252",
"Assets, Current": "29.1",
"Other Assets": "-2.79",
"Liabilities, Current": "51.8",
"Other Liabilities": "25.0",
"Liabilities, Non-Current": "18.1",
"Selling, General and Administrative Expense": "18.1",
"Expenses": "28.0",
"Revenues": "31.6",
"Net Income": "61.2",
"Research and Development": "24.1",
"Other Expenses": "-19.1",
"Cost of Goods Sold": "4.53",
"Other Revenues": "31.6",
"Comprehensive Net Income": "61.4",
"Other Net Income": "2.62",
"Economic Capital Ratio": "179"
},
"2013": {
"Assets": "17.5",
"Liabilities": "93.3",
"Stockholders Equity": "133",
"ECR before LimitedLiability": "192",
"Intangible Assets": "5.71",
"Property and Equipment": "-1.71",
"Assets, Current": "14.5",
"Liabilities, Non-Current": "13.8",
"Liabilities, Current": "46.4",
"Other Liabilities": "46.3",
"Selling, General and Administrative Expense": "12.4",
"Expenses": "18.1",
"Revenues": "23.3",
"Net Income": "42.6",
"Other Expenses": "-15.6",
"Research and Development": "18.0",
"Cost of Goods Sold": "3.01",
"Other Revenues": "23.3",
"Comprehensive Net Income": "42.3",
"Other Net Income": "1.90",
"Economic Capital Ratio": "164"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001087294_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "87,308",
"Cost of Goods Sold": "0",
"Intangible Assets": "7,023",
"Liabilities, Current": "6,600",
"Liabilities, Non-Current": "0",
"Other Assets": "68",
"Other Compr. Net Income": "0",
"Other Expenses": "31,501",
"Other Liabilities": "6,083",
"Other Net Income": "211",
"Other Revenues": "51,143",
"Property and Equipment": "1,119",
"Research and Development": "5,028",
"Selling, General and Administrative Expense": "9,198"
},
"output_variables": {
"Assets": "95,518",
"Liabilities": "12,683",
"Expenses": "45,727",
"Revenues": "51,143",
"Stockholders Equity": "82,835",
"Net Income": "5,627",
"Comprehensive Net Income": "5,627",
"BaseVar": "102,641",
"ECR before LimitedLiability": "344%",
"Economic Capital Ratio": "399%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "87,232",
"Cost of Goods Sold": "0",
"Intangible Assets": "9,477",
"Liabilities, Current": "8,055",
"Liabilities, Non-Current": "612",
"Other Assets": "696",
"Other Compr. Net Income": "0",
"Other Expenses": "29,159",
"Other Liabilities": "4,360",
"Other Net Income": "305",
"Other Revenues": "48,851",
"Property and Equipment": "1,189",
"Research and Development": "5,095",
"Selling, General and Administrative Expense": "9,096"
},
"output_variables": {
"Assets": "98,594",
"Liabilities": "13,027",
"Expenses": "43,350",
"Revenues": "48,851",
"Stockholders Equity": "85,566",
"Net Income": "5,806",
"Comprehensive Net Income": "5,806",
"BaseVar": "102,063",
"ECR before LimitedLiability": "345%",
"Economic Capital Ratio": "399%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "68,680",
"Cost of Goods Sold": "0",
"Intangible Assets": "15,499",
"Liabilities, Current": "7,546",
"Liabilities, Non-Current": "776",
"Other Assets": "2,555",
"Other Compr. Net Income": "0",
"Other Expenses": "19,304",
"Other Liabilities": "0",
"Other Net Income": "230",
"Other Revenues": "32,027",
"Property and Equipment": "881",
"Research and Development": "5,616",
"Selling, General and Administrative Expense": "9,490"
},
"output_variables": {
"Assets": "87,614",
"Liabilities": "8,322",
"Expenses": "34,409",
"Revenues": "32,027",
"Stockholders Equity": "79,292",
"Net Income": "-2,151",
"Comprehensive Net Income": "-2,151",
"BaseVar": "81,301",
"ECR before LimitedLiability": "356%",
"Economic Capital Ratio": "407%"
}
}
},
"top_rated": true,
"trend": -1.0,
"value": 4.070832477089254,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001087294.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001087294.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001087294.svg"
},
{
"company_id": "0001559053",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001559053.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001559053.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001559053.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001559053_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001559053_main_keyfigs.svg",
"name": "Prothena CORP Public LTD CO",
"rank": 16,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001559053.svg",
"report_text": "The relative strengths and weaknesses of Prothena CORP Public LTD CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Prothena CORP Public LTD CO compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 194% points.The greatest weakness of Prothena CORP Public LTD CO is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.
The company's Economic Capital Ratio, given in the ranking table, is 404%, being 161% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001559053_2014_Prothena_CORP_Public_LTD_CO.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-2.02",
"Assets": "50.1",
"Liabilities": "76.2",
"Stockholders Equity": "194",
"ECR before LimitedLiability": "189",
"Intangible Assets": "-2.85",
"Property and Equipment": "-0.670",
"Assets, Current": "73.2",
"Liabilities, Non-Current": "13.0",
"Liabilities, Current": "42.4",
"Other Liabilities": "29.8",
"Selling, General and Administrative Expense": "7.87",
"Expenses": "18.8",
"Revenues": "-16.6",
"Net Income": "3.62",
"Other Expenses": "9.05",
"Cost of Goods Sold": "2.16",
"Other Revenues": "-16.6",
"Comprehensive Net Income": "3.43",
"Other Net Income": "1.00",
"Economic Capital Ratio": "161"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001559053_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "178,222",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,406",
"Liabilities, Non-Current": "0",
"Other Assets": "816",
"Other Compr. Net Income": "0",
"Other Expenses": "415",
"Other Liabilities": "1,734",
"Other Net Income": "-154",
"Other Revenues": "676",
"Property and Equipment": "3,372",
"Research and Development": "26,052",
"Selling, General and Administrative Expense": "15,051"
},
"output_variables": {
"Assets": "182,410",
"Liabilities": "9,140",
"Expenses": "41,518",
"Revenues": "676",
"Stockholders Equity": "173,270",
"Net Income": "-40,996",
"Comprehensive Net Income": "-40,996",
"BaseVar": "116,949",
"ECR before LimitedLiability": "352%",
"Economic Capital Ratio": "404%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.040543326618774,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001559053.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001559053.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001559053.svg"
},
{
"company_id": "0001516479",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001516479.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001516479.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001516479_main_keyfigs.svg",
"name": "Insys Therapeutics Inc",
"rank": 17,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001516479.svg",
"report_text": "The relative strengths and weaknesses of Insys Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Insys Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 105% points.The greatest weakness of Insys Therapeutics Inc is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 11% points.
The company's Economic Capital Ratio, given in the ranking table, is 404%, being 161% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001516479_2014_Insys_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Assets": "-4.91",
"Liabilities": "99.7",
"Stockholders Equity": "42.8",
"ECR before LimitedLiability": "189",
"Intangible Assets": "-5.19",
"Property and Equipment": "1.76",
"Assets, Current": "-1.00",
"Liabilities, Non-Current": "23.8",
"Liabilities, Current": "31.0",
"Other Liabilities": "59.9",
"Selling, General and Administrative Expense": "16.6",
"Expenses": "25.8",
"Revenues": "79.3",
"Net Income": "105",
"Other Expenses": "-5.91",
"Research and Development": "25.5",
"Cost of Goods Sold": "-10.7",
"Other Revenues": "79.3",
"Comprehensive Net Income": "105",
"Other Net Income": "0.966",
"Economic Capital Ratio": "161"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001516479_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "82,150",
"Cost of Goods Sold": "12,665",
"Intangible Assets": "0",
"Liabilities, Current": "21,081",
"Liabilities, Non-Current": "0",
"Other Assets": "8,281",
"Other Compr. Net Income": "0",
"Other Expenses": "20,394",
"Other Liabilities": "0",
"Other Net Income": "-982",
"Other Revenues": "99,289",
"Property and Equipment": "10,127",
"Research and Development": "8,499",
"Selling, General and Administrative Expense": "16,372"
},
"output_variables": {
"Assets": "100,558",
"Liabilities": "21,081",
"Expenses": "57,930",
"Revenues": "99,289",
"Stockholders Equity": "79,477",
"Net Income": "40,377",
"Comprehensive Net Income": "40,377",
"BaseVar": "139,920",
"ECR before LimitedLiability": "351%",
"Economic Capital Ratio": "404%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.038264255247482,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001516479.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001516479.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001516479.svg"
},
{
"company_id": "0001340652",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001340652.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001340652.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001340652.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001340652_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001340652_main_keyfigs.svg",
"name": "Chemocentryx Inc",
"rank": 18,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001340652.svg",
"report_text": "The relative strengths and weaknesses of Chemocentryx Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Chemocentryx Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 188% points.The greatest weakness of Chemocentryx Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.
The company's Economic Capital Ratio, given in the ranking table, is 402%, being 159% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001340652_2014_Chemocentryx_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-2.48",
"Assets": "67.7",
"Liabilities": "61.7",
"Stockholders Equity": "180",
"ECR before LimitedLiability": "221",
"Assets, Current": "67.5",
"Intangible Assets": "-4.78",
"Other Assets": "8.29",
"Liabilities, Current": "24.5",
"Other Liabilities": "29.3",
"Liabilities, Non-Current": "13.4",
"Selling, General and Administrative Expense": "11.1",
"Expenses": "14.4",
"Revenues": "-15.7",
"Comprehensive Net Income": "1.28",
"Research and Development": "-12.1",
"Other Expenses": "12.0",
"Cost of Goods Sold": "3.30",
"Other Revenues": "-15.7",
"Other Net Income": "2.16",
"Economic Capital Ratio": "148"
},
"2013": {
"Other Assets": "4.05",
"Assets": "44.5",
"Liabilities": "83.7",
"Stockholders Equity": "188",
"ECR before LimitedLiability": "187",
"Intangible Assets": "-3.18",
"Assets, Current": "47.3",
"Liabilities, Non-Current": "13.2",
"Liabilities, Current": "44.8",
"Other Liabilities": "36.4",
"Selling, General and Administrative Expense": "10.2",
"Expenses": "13.7",
"Revenues": "-13.1",
"Net Income": "2.47",
"Other Expenses": "10.1",
"Research and Development": "-9.05",
"Cost of Goods Sold": "2.34",
"Other Revenues": "-13.1",
"Comprehensive Net Income": "2.28",
"Other Net Income": "1.59",
"Economic Capital Ratio": "159"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001340652_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "104,480",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "11,300",
"Liabilities, Non-Current": "298",
"Other Assets": "16,422",
"Other Compr. Net Income": "33",
"Other Expenses": "794",
"Other Liabilities": "379",
"Other Net Income": "533",
"Other Revenues": "5,419",
"Property and Equipment": "1,421",
"Research and Development": "34,569",
"Selling, General and Administrative Expense": "10,480"
},
"output_variables": {
"Assets": "122,323",
"Liabilities": "11,977",
"Expenses": "45,843",
"Revenues": "5,419",
"Stockholders Equity": "110,346",
"Net Income": "-39,891",
"Comprehensive Net Income": "-39,874",
"BaseVar": "93,064",
"ECR before LimitedLiability": "299%",
"Economic Capital Ratio": "368%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "134,302",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,872",
"Liabilities, Non-Current": "226",
"Other Assets": "16,721",
"Other Compr. Net Income": "38",
"Other Expenses": "0",
"Other Liabilities": "16",
"Other Net Income": "442",
"Other Revenues": "6,060",
"Property and Equipment": "1,399",
"Research and Development": "33,541",
"Selling, General and Administrative Expense": "11,634"
},
"output_variables": {
"Assets": "152,422",
"Liabilities": "7,114",
"Expenses": "45,175",
"Revenues": "6,060",
"Stockholders Equity": "145,308",
"Net Income": "-38,673",
"Comprehensive Net Income": "-38,654",
"BaseVar": "105,626",
"ECR before LimitedLiability": "349%",
"Economic Capital Ratio": "402%"
}
}
},
"top_rated": true,
"trend": 10.0,
"value": 4.019931481941928,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001340652.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001340652.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001340652.svg"
},
{
"company_id": "0001309057",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001309057.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001309057.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001309057.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001309057_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001309057_main_keyfigs.svg",
"name": "China Health Industries Holdings Inc",
"rank": 19,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001309057.svg",
"report_text": "The relative strengths and weaknesses of China Health Industries Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of China Health Industries Holdings Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 142% points.The greatest weakness of China Health Industries Holdings Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 13% points.
The company's Economic Capital Ratio, given in the ranking table, is 401%, being 158% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001309057_2014_China_Health_Industries_Holdings_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "3.93",
"Assets": "29.3",
"Liabilities": "71.2",
"Stockholders Equity": "142",
"ECR before LimitedLiability": "186",
"Intangible Assets": "5.18",
"Property and Equipment": "-2.08",
"Assets, Current": "17.6",
"Liabilities, Non-Current": "15.2",
"Liabilities, Current": "24.6",
"Other Liabilities": "39.4",
"Selling, General and Administrative Expense": "16.5",
"Expenses": "26.6",
"Revenues": "7.24",
"Net Income": "35.2",
"Other Expenses": "-13.4",
"Research and Development": "20.8",
"Cost of Goods Sold": "2.55",
"Other Revenues": "7.24",
"Comprehensive Net Income": "36.8",
"Economic Capital Ratio": "158"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001309057_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "30,480",
"Cost of Goods Sold": "0",
"Intangible Assets": "6,317",
"Liabilities, Current": "4,600",
"Liabilities, Non-Current": "0",
"Other Assets": "4,906",
"Other Compr. Net Income": "1,295",
"Other Expenses": "8,036",
"Other Liabilities": "0",
"Other Net Income": "126",
"Other Revenues": "8,996",
"Property and Equipment": "0",
"Research and Development": "445",
"Selling, General and Administrative Expense": "1,888"
},
"output_variables": {
"Assets": "41,703",
"Liabilities": "4,600",
"Expenses": "10,368",
"Revenues": "8,996",
"Stockholders Equity": "37,103",
"Net Income": "-1,247",
"Comprehensive Net Income": "-599",
"BaseVar": "33,544",
"ECR before LimitedLiability": "347%",
"Economic Capital Ratio": "401%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.006770263242231,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001309057.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001309057.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001309057.svg"
},
{
"company_id": "0001178711",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001178711.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001178711.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001178711.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001178711_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001178711_main_keyfigs.svg",
"name": "Paratek Pharmaceuticals Inc",
"rank": 20,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001178711.svg",
"report_text": "The relative strengths and weaknesses of Paratek Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Paratek Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 201% points.The greatest weakness of Paratek Pharmaceuticals Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 29% points.
The company's Economic Capital Ratio, given in the ranking table, is 397%, being 154% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001178711_2014_Paratek_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-1.91",
"Assets": "23.6",
"Liabilities": "94.3",
"Stockholders Equity": "177",
"ECR before LimitedLiability": "269",
"Property and Equipment": "-1.47",
"Assets, Current": "38.6",
"Other Liabilities": "39.0",
"Liabilities, Non-Current": "17.0",
"Liabilities, Current": "52.7",
"Research and Development": "9.90",
"Expenses": "26.5",
"Revenues": "10.4",
"Net Income": "38.4",
"Other Expenses": "10.3",
"Cost of Goods Sold": "3.70",
"Selling, General and Administrative Expense": "3.01",
"Other Revenues": "10.4",
"Comprehensive Net Income": "38.2",
"Other Net Income": "2.04",
"Economic Capital Ratio": "194"
},
"2012": {
"Property and Equipment": "-1.17",
"Assets": "35.8",
"Liabilities": "92.7",
"Stockholders Equity": "218",
"ECR before LimitedLiability": "284",
"Assets, Current": "52.0",
"Other Assets": "-1.24",
"Liabilities, Current": "54.4",
"Other Liabilities": "35.1",
"Liabilities, Non-Current": "16.8",
"Selling, General and Administrative Expense": "7.42",
"Expenses": "30.5",
"Revenues": "-7.78",
"Net Income": "24.5",
"Research and Development": "6.93",
"Other Expenses": "13.2",
"Cost of Goods Sold": "3.43",
"Other Revenues": "-7.78",
"Comprehensive Net Income": "24.6",
"Other Net Income": "1.46",
"Economic Capital Ratio": "211"
},
"2013": {
"Other Assets": "-2.79",
"Assets": "48.6",
"Liabilities": "92.0",
"Stockholders Equity": "201",
"ECR before LimitedLiability": "182",
"Intangible Assets": "-3.52",
"Property and Equipment": "-2.04",
"Assets, Current": "81.9",
"Liabilities, Non-Current": "14.1",
"Liabilities, Current": "53.2",
"Other Liabilities": "36.9",
"Selling, General and Administrative Expense": "-1.96",
"Expenses": "13.5",
"Revenues": "-28.7",
"Net Income": "-13.4",
"Other Expenses": "4.92",
"Research and Development": "8.20",
"Cost of Goods Sold": "2.39",
"Other Revenues": "-28.7",
"Comprehensive Net Income": "-13.6",
"Economic Capital Ratio": "154"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001178711_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "65,837",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,962",
"Liabilities, Current": "3,339",
"Liabilities, Non-Current": "60",
"Other Assets": "38",
"Other Compr. Net Income": "0",
"Other Expenses": "9.0",
"Other Liabilities": "0",
"Other Net Income": "-107",
"Other Revenues": "19,694",
"Property and Equipment": "314",
"Research and Development": "11,273",
"Selling, General and Administrative Expense": "12,185"
},
"output_variables": {
"Assets": "69,151",
"Liabilities": "3,399",
"Expenses": "23,467",
"Revenues": "19,694",
"Stockholders Equity": "65,752",
"Net Income": "-3,880",
"Comprehensive Net Income": "-3,880",
"BaseVar": "57,909",
"ECR before LimitedLiability": "384%",
"Economic Capital Ratio": "428%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "94,966",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,962",
"Liabilities, Current": "2,663",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-22",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-159",
"Other Revenues": "9,597",
"Property and Equipment": "128",
"Research and Development": "11,191",
"Selling, General and Administrative Expense": "10,263"
},
"output_variables": {
"Assets": "98,056",
"Liabilities": "2,663",
"Expenses": "21,454",
"Revenues": "9,597",
"Stockholders Equity": "95,393",
"Net Income": "-12,016",
"Comprehensive Net Income": "-12,027",
"BaseVar": "65,976",
"ECR before LimitedLiability": "389%",
"Economic Capital Ratio": "431%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "73,627",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,928",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "15",
"Other Expenses": "2,962",
"Other Liabilities": "0",
"Other Net Income": "-75",
"Other Revenues": "-5,074",
"Property and Equipment": "43",
"Research and Development": "6,904",
"Selling, General and Administrative Expense": "12,431"
},
"output_variables": {
"Assets": "73,670",
"Liabilities": "1,928",
"Expenses": "22,297",
"Revenues": "-5,074",
"Stockholders Equity": "71,742",
"Net Income": "-27,446",
"Comprehensive Net Income": "-27,438",
"BaseVar": "51,530",
"ECR before LimitedLiability": "341%",
"Economic Capital Ratio": "397%"
}
}
},
"top_rated": true,
"trend": -17.0,
"value": 3.967557705016267,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001178711.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001178711.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001178711.svg"
},
{
"company_id": "0001262104",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001262104.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001262104.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001262104.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001262104_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001262104_main_keyfigs.svg",
"name": "Lite Strategy Inc",
"rank": 21,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001262104.svg",
"report_text": "The relative strengths and weaknesses of Lite Strategy Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Lite Strategy Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 193% points.The greatest weakness of Lite Strategy Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.
The company's Economic Capital Ratio, given in the ranking table, is 395%, being 153% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001262104_2014_Lite_Strategy_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.15",
"Assets": "-5.85",
"Liabilities": "-2.83",
"Stockholders Equity": "-7.27",
"ECR before LimitedLiability": "-25.9",
"Intangible Assets": "-6.24",
"Property and Equipment": "-4.12",
"Assets, Current": "19.1",
"Other Liabilities": "6.20",
"Liabilities, Non-Current": "2.57",
"Liabilities, Current": "-8.22",
"Research and Development": "-1.37",
"Expenses": "-7.96",
"Revenues": "-6.91",
"Net Income": "-43.8",
"Other Expenses": "3.68",
"Cost of Goods Sold": "1.24",
"Selling, General and Administrative Expense": "-8.41",
"Other Revenues": "-6.91",
"Comprehensive Net Income": "-44.2",
"Economic Capital Ratio": "-101"
},
"2012": {
"Liabilities, Current": "1.56",
"Liabilities": "57.3",
"Stockholders Equity": "57.3",
"ECR before LimitedLiability": "51.3",
"Other Liabilities": "44.4",
"Liabilities, Non-Current": "20.8",
"Selling, General and Administrative Expense": "-27.7",
"Expenses": "-56.7",
"Net Income": "-67.7",
"Research and Development": "-53.4",
"Other Expenses": "18.6",
"Cost of Goods Sold": "6.95",
"Other Revenues": "-41.2",
"Revenues": "-41.2",
"Assets, Current": "59.0",
"Intangible Assets": "-25.4",
"Other Assets": "-18.8",
"Property and Equipment": "-17.5",
"Comprehensive Net Income": "-67.5",
"Other Net Income": "31.9",
"Economic Capital Ratio": "-21.8"
},
"2013": {
"Other Assets": "-2.70",
"Assets": "51.3",
"Liabilities": "80.8",
"Stockholders Equity": "193",
"ECR before LimitedLiability": "181",
"Intangible Assets": "-2.65",
"Property and Equipment": "-1.93",
"Assets, Current": "79.9",
"Liabilities, Non-Current": "13.4",
"Liabilities, Current": "42.3",
"Other Liabilities": "35.0",
"Expenses": "10.9",
"Revenues": "-17.9",
"Net Income": "-5.36",
"Other Expenses": "9.78",
"Research and Development": "-2.25",
"Cost of Goods Sold": "2.26",
"Other Revenues": "-17.9",
"Comprehensive Net Income": "-5.57",
"Other Net Income": "1.30",
"Economic Capital Ratio": "153"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001262104_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,130",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,374",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1.0",
"Other Liabilities": "0",
"Other Net Income": "-329",
"Other Revenues": "0",
"Property and Equipment": "38",
"Research and Development": "2,115",
"Selling, General and Administrative Expense": "4,336"
},
"output_variables": {
"Assets": "4,168",
"Liabilities": "2,374",
"Expenses": "6,452",
"Revenues": "0",
"Stockholders Equity": "1,794",
"Net Income": "-6,781",
"Comprehensive Net Income": "-6,781",
"BaseVar": "6,662",
"ECR before LimitedLiability": "-88%",
"Economic Capital Ratio": "133%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "6,348",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,774",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "407",
"Other Liabilities": "0",
"Other Net Income": "1,278",
"Other Revenues": "0",
"Property and Equipment": "25",
"Research and Development": "4,915",
"Selling, General and Administrative Expense": "3,479"
},
"output_variables": {
"Assets": "6,373",
"Liabilities": "1,774",
"Expenses": "8,801",
"Revenues": "0",
"Stockholders Equity": "4,599",
"Net Income": "-7,523",
"Comprehensive Net Income": "-7,523",
"BaseVar": "9,113",
"ECR before LimitedLiability": "61%",
"Economic Capital Ratio": "198%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "36,029",
"Cost of Goods Sold": "0",
"Intangible Assets": "470",
"Liabilities, Current": "1,675",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1.0",
"Other Liabilities": "0",
"Other Net Income": "37",
"Other Revenues": "0",
"Property and Equipment": "48",
"Research and Development": "6,084",
"Selling, General and Administrative Expense": "5,138"
},
"output_variables": {
"Assets": "36,547",
"Liabilities": "1,675",
"Expenses": "11,223",
"Revenues": "0",
"Stockholders Equity": "34,872",
"Net Income": "-11,186",
"Comprehensive Net Income": "-11,186",
"BaseVar": "24,741",
"ECR before LimitedLiability": "339%",
"Economic Capital Ratio": "395%"
}
}
},
"top_rated": true,
"trend": 104.0,
"value": 3.954226097510712,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001262104.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001262104.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001262104.svg"
},
{
"company_id": "0000822411",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000822411.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000822411.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000822411_main_keyfigs.svg",
"name": "EOM Pharmaceutical Holdings Inc",
"rank": 22,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000822411.svg",
"report_text": "The relative strengths and weaknesses of EOM Pharmaceutical Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of EOM Pharmaceutical Holdings Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 186% points.The greatest weakness of EOM Pharmaceutical Holdings Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.
The company's Economic Capital Ratio, given in the ranking table, is 394%, being 151% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000822411_2014_EOM_Pharmaceutical_Holdings_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-24.3",
"Assets": "-82.6",
"Liabilities": "9.74",
"Stockholders Equity": "-34.4",
"ECR before LimitedLiability": "-100",
"Intangible Assets": "-40.9",
"Property and Equipment": "-25.3",
"Assets, Current": "-57.7",
"Other Liabilities": "5.04",
"Liabilities, Current": "5.08",
"Research and Development": "-39.2",
"Expenses": "-103",
"Revenues": "-33.3",
"Net Income": "-164",
"Other Expenses": "-49.2",
"Cost of Goods Sold": "4.11",
"Selling, General and Administrative Expense": "-33.6",
"Other Revenues": "-33.3",
"Comprehensive Net Income": "-165",
"Other Net Income": "8.83",
"Economic Capital Ratio": "-176"
},
"2012": {
"Property and Equipment": "-15.3",
"Assets": "27.3",
"Liabilities": "98.7",
"Stockholders Equity": "107",
"ECR before LimitedLiability": "90.8",
"Assets, Current": "99.5",
"Intangible Assets": "-21.9",
"Other Assets": "-16.2",
"Liabilities, Current": "80.8",
"Other Liabilities": "48.3",
"Liabilities, Non-Current": "22.6",
"Selling, General and Administrative Expense": "-24.3",
"Expenses": "-87.0",
"Revenues": "-39.6",
"Net Income": "-126",
"Research and Development": "-50.8",
"Other Expenses": "-22.9",
"Cost of Goods Sold": "6.91",
"Other Revenues": "-39.6",
"Comprehensive Net Income": "-126",
"Economic Capital Ratio": "17.8"
},
"2013": {
"Assets": "47.0",
"Liabilities": "83.6",
"Stockholders Equity": "186",
"ECR before LimitedLiability": "179",
"Intangible Assets": "-3.64",
"Property and Equipment": "-2.00",
"Assets, Current": "73.9",
"Liabilities, Non-Current": "13.9",
"Liabilities, Current": "43.8",
"Other Liabilities": "36.4",
"Selling, General and Administrative Expense": "5.21",
"Expenses": "9.09",
"Revenues": "-17.4",
"Net Income": "-3.73",
"Other Expenses": "5.15",
"Research and Development": "-3.63",
"Cost of Goods Sold": "2.36",
"Other Revenues": "-17.4",
"Comprehensive Net Income": "-3.94",
"Other Net Income": "4.22",
"Economic Capital Ratio": "151"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000822411_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,744",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,761",
"Liabilities, Non-Current": "0",
"Other Assets": "330",
"Other Compr. Net Income": "0",
"Other Expenses": "8,294",
"Other Liabilities": "0",
"Other Net Income": "953",
"Other Revenues": "300",
"Property and Equipment": "76",
"Research and Development": "10,549",
"Selling, General and Administrative Expense": "8,991"
},
"output_variables": {
"Assets": "7,151",
"Liabilities": "1,761",
"Expenses": "27,834",
"Revenues": "300",
"Stockholders Equity": "5,389",
"Net Income": "-26,581",
"Comprehensive Net Income": "-26,581",
"BaseVar": "19,000",
"ECR before LimitedLiability": "-333%",
"Economic Capital Ratio": "58%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "26,931",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,098",
"Liabilities, Non-Current": "0",
"Other Assets": "12",
"Other Compr. Net Income": "0",
"Other Expenses": "9,113",
"Other Liabilities": "0",
"Other Net Income": "-1,318",
"Other Revenues": "300",
"Property and Equipment": "76",
"Research and Development": "18,260",
"Selling, General and Administrative Expense": "12,685"
},
"output_variables": {
"Assets": "27,019",
"Liabilities": "1,098",
"Expenses": "40,058",
"Revenues": "300",
"Stockholders Equity": "25,921",
"Net Income": "-41,076",
"Comprehensive Net Income": "-41,076",
"BaseVar": "34,897",
"ECR before LimitedLiability": "110%",
"Economic Capital Ratio": "238%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "28,410",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,402",
"Liabilities, Non-Current": "0",
"Other Assets": "465",
"Other Compr. Net Income": "0",
"Other Expenses": "1,122",
"Other Liabilities": "0",
"Other Net Income": "660",
"Other Revenues": "300",
"Property and Equipment": "66",
"Research and Development": "5,340",
"Selling, General and Administrative Expense": "3,396"
},
"output_variables": {
"Assets": "28,941",
"Liabilities": "1,402",
"Expenses": "9,858",
"Revenues": "300",
"Stockholders Equity": "27,538",
"Net Income": "-8,898",
"Comprehensive Net Income": "-8,898",
"BaseVar": "20,580",
"ECR before LimitedLiability": "337%",
"Economic Capital Ratio": "394%"
}
}
},
"top_rated": true,
"trend": 88.0,
"value": 3.9389379692656683,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000822411.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000822411.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000822411.svg"
},
{
"company_id": "0001386858",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001386858.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001386858.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001386858_main_keyfigs.svg",
"name": "Hyperion Therapeutics INC",
"rank": 23,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001386858.svg",
"report_text": "The relative strengths and weaknesses of Hyperion Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Hyperion Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 95% points.The greatest weakness of Hyperion Therapeutics INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 2.6% points.
The company's Economic Capital Ratio, given in the ranking table, is 393%, being 150% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001386858_2014_Hyperion_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-14.5",
"Assets": "-33.6",
"Liabilities": "18.0",
"Stockholders Equity": "-7.16",
"ECR before LimitedLiability": "-40.8",
"Assets, Current": "-6.95",
"Intangible Assets": "-19.5",
"Other Assets": "-14.6",
"Liabilities, Current": "12.1",
"Other Liabilities": "2.74",
"Liabilities, Non-Current": "5.14",
"Expenses": "-59.2",
"Revenues": "-19.7",
"Net Income": "-111",
"Research and Development": "-34.8",
"Other Expenses": "-11.1",
"Cost of Goods Sold": "3.56",
"Other Revenues": "-19.7",
"Comprehensive Net Income": "-110",
"Other Net Income": "3.38",
"Economic Capital Ratio": "-114"
},
"2013": {
"Other Assets": "3.05",
"Assets": "12.0",
"Liabilities": "78.0",
"Stockholders Equity": "95.1",
"ECR before LimitedLiability": "178",
"Property and Equipment": "-2.48",
"Assets, Current": "10.8",
"Liabilities, Non-Current": "18.1",
"Liabilities, Current": "29.9",
"Other Liabilities": "39.7",
"Selling, General and Administrative Expense": "-2.63",
"Expenses": "23.2",
"Revenues": "10.9",
"Net Income": "60.6",
"Other Expenses": "9.63",
"Research and Development": "18.8",
"Cost of Goods Sold": "-2.53",
"Other Revenues": "10.9",
"Comprehensive Net Income": "60.3",
"Other Net Income": "27.6",
"Economic Capital Ratio": "150"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001386858_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "51,008",
"Cost of Goods Sold": "10",
"Intangible Assets": "0",
"Liabilities, Current": "9,065",
"Liabilities, Non-Current": "0",
"Other Assets": "147",
"Other Compr. Net Income": "0",
"Other Expenses": "27,037",
"Other Liabilities": "7,750",
"Other Net Income": "1,702",
"Other Revenues": "286",
"Property and Equipment": "49",
"Research and Development": "87,281",
"Selling, General and Administrative Expense": "26,657"
},
"output_variables": {
"Assets": "51,204",
"Liabilities": "16,815",
"Expenses": "140,985",
"Revenues": "286",
"Stockholders Equity": "34,389",
"Net Income": "-138,997",
"Comprehensive Net Income": "-138,997",
"BaseVar": "105,496",
"ECR before LimitedLiability": "-188%",
"Economic Capital Ratio": "106%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "111,612",
"Cost of Goods Sold": "6,740",
"Intangible Assets": "13,442",
"Liabilities, Current": "20,131",
"Liabilities, Non-Current": "0",
"Other Assets": "16,529",
"Other Compr. Net Income": "-55",
"Other Expenses": "4,646",
"Other Liabilities": "2,702",
"Other Net Income": "31,632",
"Other Revenues": "42,204",
"Property and Equipment": "936",
"Research and Development": "9,984",
"Selling, General and Administrative Expense": "35,839"
},
"output_variables": {
"Assets": "142,519",
"Liabilities": "22,833",
"Expenses": "57,209",
"Revenues": "42,204",
"Stockholders Equity": "119,686",
"Net Income": "16,627",
"Comprehensive Net Income": "16,600",
"BaseVar": "148,226",
"ECR before LimitedLiability": "336%",
"Economic Capital Ratio": "393%"
}
}
},
"top_rated": true,
"trend": 151.0,
"value": 3.9293268980181444,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001386858.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001386858.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001386858.svg"
},
{
"company_id": "0001434868",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001434868.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001434868.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001434868.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001434868_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001434868_main_keyfigs.svg",
"name": "Esperion Therapeutics Inc",
"rank": 24,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001434868.svg",
"report_text": "The relative strengths and weaknesses of Esperion Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Esperion Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 187% points.The greatest weakness of Esperion Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.
The company's Economic Capital Ratio, given in the ranking table, is 388%, being 146% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001434868_2014_Esperion_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "15.0",
"Assets": "52.2",
"Liabilities": "78.7",
"Stockholders Equity": "187",
"ECR before LimitedLiability": "173",
"Intangible Assets": "-3.82",
"Property and Equipment": "-2.18",
"Assets, Current": "36.5",
"Liabilities, Non-Current": "13.3",
"Liabilities, Current": "39.7",
"Other Liabilities": "35.0",
"Selling, General and Administrative Expense": "8.79",
"Expenses": "8.60",
"Revenues": "-18.1",
"Net Income": "-7.37",
"Other Expenses": "4.22",
"Research and Development": "-6.76",
"Cost of Goods Sold": "2.29",
"Other Revenues": "-18.1",
"Comprehensive Net Income": "-7.57",
"Economic Capital Ratio": "146"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001434868_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "60,620",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,202",
"Liabilities, Non-Current": "0",
"Other Assets": "17,593",
"Other Compr. Net Income": "-3.0",
"Other Expenses": "3,438",
"Other Liabilities": "0",
"Other Net Income": "438",
"Other Revenues": "0",
"Property and Equipment": "81",
"Research and Development": "16,100",
"Selling, General and Administrative Expense": "6,744"
},
"output_variables": {
"Assets": "78,294",
"Liabilities": "4,202",
"Expenses": "26,282",
"Revenues": "0",
"Stockholders Equity": "74,091",
"Net Income": "-25,844",
"Comprehensive Net Income": "-25,845",
"BaseVar": "54,610",
"ECR before LimitedLiability": "329%",
"Economic Capital Ratio": "388%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.8827898470821944,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001434868.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001434868.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001434868.svg"
},
{
"company_id": "0001596783",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001596783.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001596783.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001596783.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001596783_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001596783_main_keyfigs.svg",
"name": "Catalent Inc",
"rank": 25,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001596783.svg",
"report_text": "The relative strengths and weaknesses of Catalent Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Catalent Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 101% points.The greatest weakness of Catalent Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 38% points.
The company's Economic Capital Ratio, given in the ranking table, is 386%, being 144% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001596783_2014_Catalent_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Assets": "3.59",
"Liabilities": "101",
"Stockholders Equity": "85.0",
"ECR before LimitedLiability": "172",
"Intangible Assets": "36.2",
"Property and Equipment": "17.8",
"Assets, Current": "-22.9",
"Liabilities, Non-Current": "20.5",
"Liabilities, Current": "42.3",
"Other Liabilities": "52.5",
"Selling, General and Administrative Expense": "17.5",
"Expenses": "16.2",
"Revenues": "44.2",
"Net Income": "52.8",
"Other Expenses": "-37.8",
"Research and Development": "31.1",
"Cost of Goods Sold": "3.60",
"Other Revenues": "44.2",
"Comprehensive Net Income": "52.2",
"Other Net Income": "-7.45",
"Economic Capital Ratio": "144"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001596783_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "679,100",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,395,600",
"Liabilities, Current": "410,300",
"Liabilities, Non-Current": "0",
"Other Assets": "60,300",
"Other Compr. Net Income": "-13,800",
"Other Expenses": "1,282,300",
"Other Liabilities": "0",
"Other Net Income": "-227,100",
"Other Revenues": "1,800,300",
"Property and Equipment": "814,500",
"Research and Development": "0",
"Selling, General and Administrative Expense": "340,600"
},
"output_variables": {
"Assets": "2,949,500",
"Liabilities": "410,300",
"Expenses": "1,622,900",
"Revenues": "1,800,300",
"Stockholders Equity": "2,539,200",
"Net Income": "-49,700",
"Comprehensive Net Income": "-56,600",
"BaseVar": "3,511,950",
"ECR before LimitedLiability": "326%",
"Economic Capital Ratio": "386%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.8637044795233617,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001596783.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001596783.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001596783.svg"
},
{
"company_id": "0001070336",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001070336.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001070336.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001070336_main_keyfigs.svg",
"name": "Achillion Pharmaceuticals INC",
"rank": 26,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001070336.svg",
"report_text": "The relative strengths and weaknesses of Achillion Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Achillion Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 183% points.The greatest weakness of Achillion Pharmaceuticals INC is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.
The company's Economic Capital Ratio, given in the ranking table, is 382%, being 139% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001070336_2014_Achillion_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "40.9",
"Assets": "76.7",
"Liabilities": "43.5",
"Stockholders Equity": "152",
"ECR before LimitedLiability": "167",
"Intangible Assets": "-8.20",
"Property and Equipment": "-3.97",
"Assets, Current": "37.9",
"Other Liabilities": "17.1",
"Liabilities, Non-Current": "11.1",
"Liabilities, Current": "17.4",
"Other Revenues": "-24.0",
"Revenues": "-24.0",
"Net Income": "-22.2",
"Research and Development": "-22.3",
"Comprehensive Net Income": "-22.5",
"Cost of Goods Sold": "3.09",
"Selling, General and Administrative Expense": "10.2",
"Other Expenses": "8.65",
"Other Net Income": "2.14",
"Economic Capital Ratio": "91.2"
},
"2012": {
"Property and Equipment": "-3.71",
"Assets": "69.6",
"Liabilities": "64.7",
"Stockholders Equity": "169",
"ECR before LimitedLiability": "183",
"Assets, Current": "69.9",
"Intangible Assets": "-7.52",
"Other Assets": "12.9",
"Liabilities, Current": "23.8",
"Other Liabilities": "31.9",
"Liabilities, Non-Current": "13.4",
"Selling, General and Administrative Expense": "8.46",
"Expenses": "-4.80",
"Revenues": "-19.7",
"Net Income": "-22.3",
"Research and Development": "-31.3",
"Other Expenses": "14.4",
"Cost of Goods Sold": "3.70",
"Other Revenues": "-19.7",
"Comprehensive Net Income": "-22.1",
"Economic Capital Ratio": "110"
},
"2013": {
"Other Assets": "15.9",
"Assets": "53.3",
"Liabilities": "77.8",
"Stockholders Equity": "183",
"ECR before LimitedLiability": "167",
"Intangible Assets": "-4.19",
"Property and Equipment": "-1.92",
"Assets, Current": "36.6",
"Liabilities, Non-Current": "13.2",
"Liabilities, Current": "38.4",
"Other Liabilities": "34.9",
"Selling, General and Administrative Expense": "10.1",
"Expenses": "5.78",
"Revenues": "-18.3",
"Net Income": "-10.7",
"Other Expenses": "9.96",
"Research and Development": "-16.9",
"Cost of Goods Sold": "2.31",
"Other Revenues": "-18.3",
"Comprehensive Net Income": "-10.9",
"Economic Capital Ratio": "139"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001070336_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "55,092",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,944",
"Liabilities, Non-Current": "229",
"Other Assets": "26,544",
"Other Compr. Net Income": "0",
"Other Expenses": "45",
"Other Liabilities": "2,489",
"Other Net Income": "186",
"Other Revenues": "247",
"Property and Equipment": "994",
"Research and Development": "35,441",
"Selling, General and Administrative Expense": "9,153"
},
"output_variables": {
"Assets": "82,630",
"Liabilities": "11,662",
"Expenses": "44,639",
"Revenues": "247",
"Stockholders Equity": "70,968",
"Net Income": "-44,206",
"Comprehensive Net Income": "-44,206",
"BaseVar": "69,682",
"ECR before LimitedLiability": "234%",
"Economic Capital Ratio": "325%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "67,867",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,136",
"Liabilities, Non-Current": "347",
"Other Assets": "12,416",
"Other Compr. Net Income": "39",
"Other Expenses": "68",
"Other Liabilities": "0",
"Other Net Income": "234",
"Other Revenues": "2,607",
"Property and Equipment": "1,247",
"Research and Development": "38,999",
"Selling, General and Administrative Expense": "10,901"
},
"output_variables": {
"Assets": "81,530",
"Liabilities": "9,483",
"Expenses": "49,968",
"Revenues": "2,607",
"Stockholders Equity": "72,047",
"Net Income": "-47,127",
"Comprehensive Net Income": "-47,108",
"BaseVar": "71,930",
"ECR before LimitedLiability": "242%",
"Economic Capital Ratio": "330%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "124,782",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,403",
"Liabilities, Non-Current": "56",
"Other Assets": "36,370",
"Other Compr. Net Income": "-13",
"Other Expenses": "52",
"Other Liabilities": "0",
"Other Net Income": "582",
"Other Revenues": "0",
"Property and Equipment": "1,265",
"Research and Development": "46,736",
"Selling, General and Administrative Expense": "12,741"
},
"output_variables": {
"Assets": "162,417",
"Liabilities": "9,459",
"Expenses": "59,529",
"Revenues": "0",
"Stockholders Equity": "152,958",
"Net Income": "-58,947",
"Comprehensive Net Income": "-58,954",
"BaseVar": "116,000",
"ECR before LimitedLiability": "319%",
"Economic Capital Ratio": "382%"
}
}
},
"top_rated": true,
"trend": 21.0,
"value": 3.8176966969489885,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001070336.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001070336.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001070336.svg"
},
{
"company_id": "0000310158",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000310158.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000310158.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000310158.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000310158_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000310158_main_keyfigs.svg",
"name": "Merck Co Inc",
"rank": 27,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000310158.svg",
"report_text": "The relative strengths and weaknesses of Merck Co Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Merck Co Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 98% points.The greatest weakness of Merck Co Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 15% points.
The company's Economic Capital Ratio, given in the ranking table, is 382%, being 139% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000310158_2014_Merck_Co_Inc.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "-0.847",
"Assets": "25.1",
"Liabilities": "28.6",
"Stockholders Equity": "102",
"ECR before LimitedLiability": "64.5",
"Intangible Assets": "20.2",
"Property and Equipment": "3.56",
"Liabilities, Current": "-12.0",
"Other Liabilities": "16.9",
"Liabilities, Non-Current": "23.3",
"Cost of Goods Sold": "0.485",
"Expenses": "19.2",
"Revenues": "-13.5",
"Net Income": "5.96",
"Selling, General and Administrative Expense": "4.80",
"Other Expenses": "13.8",
"Research and Development": "0.222",
"Other Revenues": "-13.5",
"Comprehensive Net Income": "5.94",
"Other Net Income": "-0.165",
"Economic Capital Ratio": "65.3"
},
"2010": {
"Other Assets": "-1.65",
"Assets": "11.6",
"Liabilities": "70.0",
"Stockholders Equity": "85.2",
"ECR before LimitedLiability": "105",
"Assets, Current": "-9.35",
"Property and Equipment": "3.19",
"Intangible Assets": "25.5",
"Liabilities, Current": "4.33",
"Other Liabilities": "39.7",
"Liabilities, Non-Current": "32.4",
"Selling, General and Administrative Expense": "6.91",
"Expenses": "2.59",
"Revenues": "7.15",
"Net Income": "10.3",
"Research and Development": "1.62",
"Cost of Goods Sold": "5.18",
"Other Expenses": "-11.2",
"Other Revenues": "7.15",
"Comprehensive Net Income": "10.3",
"Economic Capital Ratio": "98.4"
},
"2011": {
"Assets": "24.2",
"Liabilities": "61.6",
"Stockholders Equity": "114",
"ECR before LimitedLiability": "230",
"Intangible Assets": "31.5",
"Property and Equipment": "6.81",
"Assets, Current": "-9.95",
"Other Liabilities": "37.4",
"Liabilities, Non-Current": "16.6",
"Liabilities, Current": "13.2",
"Research and Development": "23.5",
"Expenses": "28.5",
"Revenues": "24.1",
"Net Income": "54.2",
"Other Expenses": "-11.5",
"Cost of Goods Sold": "3.78",
"Selling, General and Administrative Expense": "12.6",
"Other Revenues": "24.1",
"Comprehensive Net Income": "53.9",
"Other Net Income": "2.31",
"Economic Capital Ratio": "155"
},
"2012": {
"Property and Equipment": "7.16",
"Assets": "26.9",
"Liabilities": "62.8",
"Stockholders Equity": "116",
"ECR before LimitedLiability": "233",
"Assets, Current": "-11.1",
"Intangible Assets": "28.6",
"Other Assets": "5.54",
"Liabilities, Current": "11.4",
"Other Liabilities": "38.4",
"Liabilities, Non-Current": "18.4",
"Selling, General and Administrative Expense": "13.2",
"Expenses": "30.7",
"Revenues": "24.9",
"Net Income": "57.1",
"Research and Development": "19.1",
"Other Expenses": "-5.67",
"Cost of Goods Sold": "4.15",
"Other Revenues": "24.9",
"Comprehensive Net Income": "56.4",
"Economic Capital Ratio": "160"
},
"2013": {
"Other Assets": "8.63",
"Assets": "17.3",
"Liabilities": "67.2",
"Stockholders Equity": "97.6",
"ECR before LimitedLiability": "167",
"Intangible Assets": "22.5",
"Property and Equipment": "6.98",
"Assets, Current": "-14.6",
"Liabilities, Non-Current": "16.6",
"Liabilities, Current": "13.8",
"Other Liabilities": "43.0",
"Selling, General and Administrative Expense": "12.3",
"Expenses": "22.7",
"Revenues": "25.5",
"Net Income": "49.2",
"Other Expenses": "-9.59",
"Research and Development": "17.1",
"Cost of Goods Sold": "2.90",
"Other Revenues": "25.5",
"Comprehensive Net Income": "50.2",
"Economic Capital Ratio": "139"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000310158_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "28,428,600",
"Cost of Goods Sold": "0",
"Intangible Assets": "59,578,900",
"Liabilities, Current": "15,750,700",
"Liabilities, Non-Current": "0",
"Other Assets": "5,808,700",
"Other Compr. Net Income": "0",
"Other Expenses": "15,900",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "27,428,300",
"Property and Equipment": "18,273,500",
"Research and Development": "5,845,000",
"Selling, General and Administrative Expense": "8,543,200"
},
"output_variables": {
"Assets": "112,089,700",
"Liabilities": "15,750,700",
"Expenses": "14,404,100",
"Revenues": "27,428,300",
"Stockholders Equity": "96,339,000",
"Net Income": "13,024,200",
"Comprehensive Net Income": "13,024,200",
"BaseVar": "84,836,400",
"ECR before LimitedLiability": "349%",
"Economic Capital Ratio": "402%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "29,064,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "51,834,000",
"Liabilities, Current": "15,641,000",
"Liabilities, Non-Current": "0",
"Other Assets": "7,801,000",
"Other Compr. Net Income": "0",
"Other Expenses": "20,769,000",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "45,987,000",
"Property and Equipment": "17,082,000",
"Research and Development": "10,991,000",
"Selling, General and Administrative Expense": "13,245,000"
},
"output_variables": {
"Assets": "105,781,000",
"Liabilities": "15,641,000",
"Expenses": "45,005,000",
"Revenues": "45,987,000",
"Stockholders Equity": "90,140,000",
"Net Income": "982,000",
"Comprehensive Net Income": "982,000",
"BaseVar": "106,207,000",
"ECR before LimitedLiability": "325%",
"Economic Capital Ratio": "386%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "33,181,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "46,457,000",
"Liabilities, Current": "16,245,000",
"Liabilities, Non-Current": "0",
"Other Assets": "9,193,000",
"Other Compr. Net Income": "0",
"Other Expenses": "19,455,000",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "48,047,000",
"Property and Equipment": "16,297,000",
"Research and Development": "8,467,000",
"Selling, General and Administrative Expense": "13,733,000"
},
"output_variables": {
"Assets": "105,128,000",
"Liabilities": "16,245,000",
"Expenses": "41,655,000",
"Revenues": "48,047,000",
"Stockholders Equity": "88,883,000",
"Net Income": "6,392,000",
"Comprehensive Net Income": "6,392,000",
"BaseVar": "105,537,500",
"ECR before LimitedLiability": "330%",
"Economic Capital Ratio": "389%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "34,857,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "41,217,000",
"Liabilities, Current": "18,348,000",
"Liabilities, Non-Current": "0",
"Other Assets": "14,028,000",
"Other Compr. Net Income": "-1,681,000",
"Other Expenses": "19,989,762",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "46,523,484",
"Property and Equipment": "16,030,000",
"Research and Development": "8,059,634",
"Selling, General and Administrative Expense": "12,034,957"
},
"output_variables": {
"Assets": "106,132,000",
"Liabilities": "18,348,000",
"Expenses": "40,084,354",
"Revenues": "46,523,484",
"Stockholders Equity": "87,784,000",
"Net Income": "6,439,131",
"Comprehensive Net Income": "5,598,631",
"BaseVar": "106,384,419",
"ECR before LimitedLiability": "316%",
"Economic Capital Ratio": "380%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "35,685,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "36,102,000",
"Liabilities, Current": "17,868,000",
"Liabilities, Non-Current": "0",
"Other Assets": "18,885,000",
"Other Compr. Net Income": "-1,678,469",
"Other Expenses": "20,097,317",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "40,927,271",
"Property and Equipment": "14,973,000",
"Research and Development": "7,258,773",
"Selling, General and Administrative Expense": "11,229,706"
},
"output_variables": {
"Assets": "105,645,000",
"Liabilities": "17,868,000",
"Expenses": "38,585,796",
"Revenues": "40,927,271",
"Stockholders Equity": "87,777,000",
"Net Income": "2,341,475",
"Comprehensive Net Income": "1,502,240",
"BaseVar": "102,352,268",
"ECR before LimitedLiability": "312%",
"Economic Capital Ratio": "377%"
}
}
},
"top_rated": true,
"trend": -5.0,
"value": 3.8154922943309346,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000310158.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000310158.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000310158.svg"
},
{
"company_id": "0001476963",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001476963.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001476963.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001476963.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001476963_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001476963_main_keyfigs.svg",
"name": "Scorpius Holdings Inc",
"rank": 28,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001476963.svg",
"report_text": "The relative strengths and weaknesses of Scorpius Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Scorpius Holdings Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 180% points.The greatest weakness of Scorpius Holdings Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.
The company's Economic Capital Ratio, given in the ranking table, is 380%, being 137% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001476963_2014_Scorpius_Holdings_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-3.49",
"Assets": "49.6",
"Liabilities": "81.8",
"Stockholders Equity": "180",
"ECR before LimitedLiability": "165",
"Intangible Assets": "-4.44",
"Property and Equipment": "-2.45",
"Assets, Current": "85.6",
"Liabilities, Non-Current": "11.4",
"Liabilities, Current": "43.4",
"Other Liabilities": "36.2",
"Selling, General and Administrative Expense": "7.52",
"Expenses": "16.3",
"Revenues": "-15.7",
"Net Income": "-11.5",
"Research and Development": "5.84",
"Cost of Goods Sold": "2.41",
"Other Revenues": "-15.7",
"Comprehensive Net Income": "-11.7",
"Other Net Income": "-12.5",
"Economic Capital Ratio": "137"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001476963_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "22,956",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,180",
"Liabilities, Non-Current": "123",
"Other Assets": "11",
"Other Compr. Net Income": "0",
"Other Expenses": "1,759",
"Other Liabilities": "0",
"Other Net Income": "-2,435",
"Other Revenues": "586",
"Property and Equipment": "54",
"Research and Development": "2,738",
"Selling, General and Administrative Expense": "2,430"
},
"output_variables": {
"Assets": "23,020",
"Liabilities": "1,303",
"Expenses": "6,926",
"Revenues": "586",
"Stockholders Equity": "21,717",
"Net Income": "-8,776",
"Comprehensive Net Income": "-8,776",
"BaseVar": "17,135",
"ECR before LimitedLiability": "317%",
"Economic Capital Ratio": "380%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.80214712541795,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001476963.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001476963.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001476963.svg"
},
{
"company_id": "0001513856",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001513856.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001513856.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001513856_main_keyfigs.svg",
"name": "Neurotrope Inc",
"rank": 29,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001513856.svg",
"report_text": "The relative strengths and weaknesses of Neurotrope Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Neurotrope Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 195% points.The greatest weakness of Neurotrope Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 39% points.
The company's Economic Capital Ratio, given in the ranking table, is 380%, being 137% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001513856_2014_Neurotrope_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-10.9",
"Assets": "86.1",
"Liabilities": "-47.3",
"Stockholders Equity": "43.9",
"ECR before LimitedLiability": "74.3",
"Intangible Assets": "-14.1",
"Property and Equipment": "-9.14",
"Assets, Current": "100",
"Other Liabilities": "-125",
"Liabilities, Non-Current": "10.4",
"Liabilities, Current": "48.7",
"Research and Development": "30.1",
"Expenses": "17.2",
"Revenues": "-24.9",
"Net Income": "-6.90",
"Other Expenses": "-36.4",
"Cost of Goods Sold": "3.27",
"Selling, General and Administrative Expense": "23.7",
"Other Revenues": "-24.9",
"Comprehensive Net Income": "-7.15",
"Other Net Income": "2.00",
"Economic Capital Ratio": "-1.26"
},
"2013": {
"Other Assets": "-3.71",
"Assets": "49.3",
"Liabilities": "95.9",
"Stockholders Equity": "195",
"ECR before LimitedLiability": "165",
"Intangible Assets": "-4.68",
"Property and Equipment": "-2.76",
"Assets, Current": "88.7",
"Liabilities, Non-Current": "14.5",
"Liabilities, Current": "55.5",
"Other Liabilities": "37.9",
"Selling, General and Administrative Expense": "5.60",
"Expenses": "-7.63",
"Revenues": "-20.1",
"Net Income": "-26.6",
"Other Expenses": "-39.2",
"Research and Development": "22.0",
"Cost of Goods Sold": "2.53",
"Other Revenues": "-20.1",
"Comprehensive Net Income": "-26.8",
"Economic Capital Ratio": "137"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001513856_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "8.0",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "3.5",
"Other Liabilities": "3.6",
"Other Net Income": "0",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0.10"
},
"output_variables": {
"Assets": "8.0",
"Liabilities": "3.6",
"Expenses": "3.6",
"Revenues": "0",
"Stockholders Equity": "4.4",
"Net Income": "-3.6",
"Comprehensive Net Income": "-3.6",
"BaseVar": "7.6",
"ECR before LimitedLiability": "103%",
"Economic Capital Ratio": "233%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "15,299",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "408",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "5,669",
"Other Liabilities": "0",
"Other Net Income": "1.4",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "1,921"
},
"output_variables": {
"Assets": "15,299",
"Liabilities": "408",
"Expenses": "7,591",
"Revenues": "0",
"Stockholders Equity": "14,890",
"Net Income": "-7,589",
"Comprehensive Net Income": "-7,589",
"BaseVar": "11,650",
"ECR before LimitedLiability": "317%",
"Economic Capital Ratio": "380%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.799189023136345,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001513856.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001513856.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001513856.svg"
},
{
"company_id": "0000949699",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000949699.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000949699.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000949699_main_keyfigs.svg",
"name": "Pharmacyclics INC",
"rank": 30,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000949699.svg",
"report_text": "The relative strengths and weaknesses of Pharmacyclics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Pharmacyclics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 105% points.The greatest weakness of Pharmacyclics INC is the variable Other Expenses, reducing the Economic Capital Ratio by 5.0% points.
The company's Economic Capital Ratio, given in the ranking table, is 379%, being 136% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000949699_2014_Pharmacyclics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.28",
"Assets": "65.5",
"Liabilities": "45.4",
"Stockholders Equity": "156",
"ECR before LimitedLiability": "200",
"Intangible Assets": "-5.90",
"Property and Equipment": "-2.85",
"Assets, Current": "117",
"Other Liabilities": "26.8",
"Liabilities, Non-Current": "12.3",
"Liabilities, Current": "9.08",
"Research and Development": "-9.02",
"Expenses": "14.8",
"Revenues": "-15.0",
"Net Income": "1.99",
"Other Expenses": "8.26",
"Cost of Goods Sold": "2.93",
"Selling, General and Administrative Expense": "12.6",
"Other Revenues": "-15.0",
"Other Net Income": "1.96",
"Economic Capital Ratio": "124"
},
"2012": {
"Property and Equipment": "-2.56",
"Assets": "56.2",
"Liabilities": "8.92",
"Stockholders Equity": "104",
"ECR before LimitedLiability": "196",
"Assets, Current": "91.9",
"Intangible Assets": "-5.80",
"Other Assets": "-3.68",
"Liabilities, Current": "29.0",
"Other Liabilities": "-38.8",
"Liabilities, Non-Current": "13.1",
"Selling, General and Administrative Expense": "15.9",
"Expenses": "36.7",
"Revenues": "4.23",
"Net Income": "42.7",
"Research and Development": "5.29",
"Other Expenses": "12.2",
"Cost of Goods Sold": "3.14",
"Other Revenues": "4.23",
"Comprehensive Net Income": "42.8",
"Economic Capital Ratio": "123"
},
"2013": {
"Other Assets": "-3.57",
"Assets": "26.6",
"Liabilities": "49.3",
"Stockholders Equity": "105",
"ECR before LimitedLiability": "164",
"Intangible Assets": "-4.77",
"Assets, Current": "45.7",
"Liabilities, Non-Current": "13.8",
"Liabilities, Current": "26.7",
"Other Liabilities": "12.5",
"Selling, General and Administrative Expense": "22.2",
"Expenses": "29.3",
"Revenues": "18.7",
"Net Income": "48.9",
"Other Expenses": "-5.03",
"Research and Development": "9.72",
"Cost of Goods Sold": "2.56",
"Other Revenues": "18.7",
"Comprehensive Net Income": "48.7",
"Other Net Income": "1.30",
"Economic Capital Ratio": "136"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000949699_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "114,696",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "14,268",
"Liabilities, Non-Current": "0",
"Other Assets": "344",
"Other Compr. Net Income": "-15",
"Other Expenses": "0",
"Other Liabilities": "410",
"Other Net Income": "171",
"Other Revenues": "8,233",
"Property and Equipment": "1,312",
"Research and Development": "34,482",
"Selling, General and Administrative Expense": "9,125"
},
"output_variables": {
"Assets": "116,352",
"Liabilities": "14,678",
"Expenses": "43,607",
"Revenues": "8,233",
"Stockholders Equity": "101,674",
"Net Income": "-35,203",
"Comprehensive Net Income": "-35,210",
"BaseVar": "91,528",
"ECR before LimitedLiability": "285%",
"Economic Capital Ratio": "358%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "346,492",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "29,257",
"Liabilities, Non-Current": "0",
"Other Assets": "2,234",
"Other Compr. Net Income": "12",
"Other Expenses": "39",
"Other Liabilities": "63,346",
"Other Net Income": "147",
"Other Revenues": "81,990",
"Property and Equipment": "6,403",
"Research and Development": "54,537",
"Selling, General and Administrative Expense": "15,575"
},
"output_variables": {
"Assets": "355,129",
"Liabilities": "92,603",
"Expenses": "70,151",
"Revenues": "81,990",
"Stockholders Equity": "262,526",
"Net Income": "11,986",
"Comprehensive Net Income": "11,992",
"BaseVar": "300,016",
"ECR before LimitedLiability": "261%",
"Economic Capital Ratio": "343%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "740,801",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "87,631",
"Liabilities, Non-Current": "1,472",
"Other Assets": "2,479",
"Other Compr. Net Income": "-4.0",
"Other Expenses": "108,238",
"Other Liabilities": "52,025",
"Other Net Income": "-129",
"Other Revenues": "260,510",
"Property and Equipment": "25,471",
"Research and Development": "85,133",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "768,751",
"Liabilities": "141,128",
"Expenses": "193,371",
"Revenues": "260,510",
"Stockholders Equity": "627,623",
"Net Income": "67,010",
"Comprehensive Net Income": "67,008",
"BaseVar": "681,946",
"ECR before LimitedLiability": "315%",
"Economic Capital Ratio": "379%"
}
}
},
"top_rated": true,
"trend": 10.0,
"value": 3.790940951031202,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000949699.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000949699.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000949699.svg"
},
{
"company_id": "0001003642",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001003642.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001003642.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001003642_main_keyfigs.svg",
"name": "Impax Laboratories LLC",
"rank": 31,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001003642.svg",
"report_text": "The relative strengths and weaknesses of Impax Laboratories LLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Impax Laboratories LLC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 102% points.The greatest weakness of Impax Laboratories LLC is the variable Other Revenues, reducing the Economic Capital Ratio by 20% points.
The company's Economic Capital Ratio, given in the ranking table, is 379%, being 136% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001003642_2014_Impax_Laboratories_LLC.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "12.5",
"Liabilities": "48.5",
"Stockholders Equity": "64.4",
"ECR before LimitedLiability": "197",
"Intangible Assets": "-5.86",
"Property and Equipment": "7.12",
"Assets, Current": "14.2",
"Other Liabilities": "31.5",
"Liabilities, Non-Current": "9.45",
"Liabilities, Current": "10.3",
"Research and Development": "25.4",
"Expenses": "23.3",
"Revenues": "36.1",
"Net Income": "62.1",
"Other Expenses": "6.25",
"Cost of Goods Sold": "-30.6",
"Selling, General and Administrative Expense": "21.6",
"Other Revenues": "36.1",
"Comprehensive Net Income": "61.7",
"Other Net Income": "2.33",
"Economic Capital Ratio": "121"
},
"2012": {
"Property and Equipment": "11.9",
"Assets": "11.0",
"Stockholders Equity": "85.2",
"ECR before LimitedLiability": "223",
"Intangible Assets": "-0.814",
"Liabilities, Current": "29.9",
"Liabilities": "76.1",
"Other Liabilities": "41.8",
"Liabilities, Non-Current": "12.1",
"Selling, General and Administrative Expense": "18.2",
"Expenses": "21.8",
"Revenues": "43.3",
"Net Income": "67.7",
"Research and Development": "22.9",
"Other Expenses": "14.3",
"Cost of Goods Sold": "-34.6",
"Other Revenues": "43.3",
"Comprehensive Net Income": "68.1",
"Other Net Income": "2.57",
"Other Compr. Net Income": "0.435",
"Economic Capital Ratio": "150"
},
"2013": {
"Other Assets": "2.42",
"Assets": "25.4",
"Liabilities": "49.3",
"Stockholders Equity": "102",
"ECR before LimitedLiability": "164",
"Property and Equipment": "11.4",
"Assets, Current": "9.22",
"Liabilities, Non-Current": "3.00",
"Liabilities, Current": "11.8",
"Other Liabilities": "37.0",
"Selling, General and Administrative Expense": "8.84",
"Expenses": "29.9",
"Revenues": "-20.5",
"Net Income": "50.9",
"Other Expenses": "4.06",
"Research and Development": "14.7",
"Cost of Goods Sold": "2.58",
"Other Revenues": "-20.5",
"Comprehensive Net Income": "50.4",
"Other Net Income": "41.0",
"Economic Capital Ratio": "136"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001003642_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "599,935",
"Cost of Goods Sold": "254,624",
"Intangible Assets": "27,574",
"Liabilities, Current": "156,861",
"Liabilities, Non-Current": "16,861",
"Other Assets": "48,192",
"Other Compr. Net Income": "-990",
"Other Expenses": "40,279",
"Other Liabilities": "17,131",
"Other Net Income": "-1,440",
"Other Revenues": "512,919",
"Property and Equipment": "118,158",
"Research and Development": "82,701",
"Selling, General and Administrative Expense": "68,477"
},
"output_variables": {
"Assets": "793,859",
"Liabilities": "190,853",
"Expenses": "446,081",
"Revenues": "512,919",
"Stockholders Equity": "603,006",
"Net Income": "65,398",
"Comprehensive Net Income": "64,903",
"BaseVar": "973,071",
"ECR before LimitedLiability": "280%",
"Economic Capital Ratio": "355%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "545,543",
"Cost of Goods Sold": "299,138",
"Intangible Assets": "75,524",
"Liabilities, Current": "145,295",
"Liabilities, Non-Current": "21,210",
"Other Assets": "62,145",
"Other Compr. Net Income": "3,520",
"Other Expenses": "37,842",
"Other Liabilities": "6,362",
"Other Net Income": "951",
"Other Revenues": "581,692",
"Property and Equipment": "180,758",
"Research and Development": "81,320",
"Selling, General and Administrative Expense": "108,470"
},
"output_variables": {
"Assets": "863,970",
"Liabilities": "172,867",
"Expenses": "526,770",
"Revenues": "581,692",
"Stockholders Equity": "691,103",
"Net Income": "55,873",
"Comprehensive Net Income": "57,633",
"BaseVar": "1,074,885",
"ECR before LimitedLiability": "302%",
"Economic Capital Ratio": "370%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "659,742",
"Cost of Goods Sold": "0",
"Intangible Assets": "57,244",
"Liabilities, Current": "153,890",
"Liabilities, Non-Current": "28,563",
"Other Assets": "91,746",
"Other Compr. Net Income": "-4,104",
"Other Expenses": "62,645",
"Other Liabilities": "4,267",
"Other Net Income": "353,046",
"Other Revenues": "0",
"Property and Equipment": "188,191",
"Research and Development": "68,854",
"Selling, General and Administrative Expense": "120,288"
},
"output_variables": {
"Assets": "996,923",
"Liabilities": "186,720",
"Expenses": "251,787",
"Revenues": "0",
"Stockholders Equity": "810,203",
"Net Income": "101,259",
"Comprehensive Net Income": "99,207",
"BaseVar": "896,290",
"ECR before LimitedLiability": "315%",
"Economic Capital Ratio": "379%"
}
}
},
"top_rated": true,
"trend": -5.0,
"value": 3.7890979816090553,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001003642.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001003642.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001003642.svg"
},
{
"company_id": "0001124105",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001124105.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001124105.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001124105.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001124105_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001124105_main_keyfigs.svg",
"name": "GYRE Therapeutics INC",
"rank": 32,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001124105.svg",
"report_text": "The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 172% points.The greatest weakness of GYRE Therapeutics INC is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.
The company's Economic Capital Ratio, given in the ranking table, is 378%, being 135% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001124105_2014_GYRE_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "19.9",
"Assets": "34.5",
"Stockholders Equity": "58.5",
"Other Liabilities": "26.0",
"ECR before LimitedLiability": "155",
"Intangible Assets": "-9.59",
"Property and Equipment": "-6.22",
"Assets, Current": "33.7",
"Research and Development": "-7.16",
"Expenses": "26.5",
"Revenues": "11.3",
"Net Income": "41.0",
"Other Expenses": "9.54",
"Cost of Goods Sold": "3.37",
"Selling, General and Administrative Expense": "20.7",
"Other Revenues": "11.3",
"Liabilities, Non-Current": "10.5",
"Liabilities, Current": "-38.8",
"Comprehensive Net Income": "40.8",
"Other Net Income": "2.53",
"Economic Capital Ratio": "79.8"
},
"2012": {
"Assets": "27.0",
"Liabilities": "93.3",
"Stockholders Equity": "172",
"ECR before LimitedLiability": "271",
"Assets, Current": "13.1",
"Intangible Assets": "-2.81",
"Other Assets": "15.5",
"Liabilities, Current": "52.5",
"Other Liabilities": "37.9",
"Liabilities, Non-Current": "16.7",
"Selling, General and Administrative Expense": "17.5",
"Expenses": "28.1",
"Revenues": "14.6",
"Net Income": "44.7",
"Research and Development": "-6.73",
"Other Expenses": "13.4",
"Cost of Goods Sold": "4.13",
"Other Revenues": "14.6",
"Comprehensive Net Income": "44.9",
"Other Net Income": "2.78",
"Economic Capital Ratio": "198"
},
"2013": {
"Other Assets": "32.3",
"Assets": "51.9",
"Liabilities": "71.2",
"Stockholders Equity": "172",
"ECR before LimitedLiability": "163",
"Intangible Assets": "-4.32",
"Property and Equipment": "-2.24",
"Assets, Current": "19.1",
"Liabilities, Non-Current": "12.3",
"Liabilities, Current": "31.6",
"Other Liabilities": "34.6",
"Selling, General and Administrative Expense": "9.79",
"Expenses": "8.84",
"Revenues": "-15.0",
"Net Income": "-4.35",
"Other Expenses": "9.96",
"Research and Development": "-13.4",
"Cost of Goods Sold": "2.30",
"Other Revenues": "-15.0",
"Comprehensive Net Income": "-4.60",
"Economic Capital Ratio": "135"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001124105_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "198,693",
"Cost of Goods Sold": "0",
"Intangible Assets": "132",
"Liabilities, Current": "78,611",
"Liabilities, Non-Current": "1,986",
"Other Assets": "59,301",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "3,241",
"Other Net Income": "1,216",
"Other Revenues": "97,637",
"Property and Equipment": "0",
"Research and Development": "95,215",
"Selling, General and Administrative Expense": "12,167"
},
"output_variables": {
"Assets": "258,126",
"Liabilities": "83,838",
"Expenses": "107,382",
"Revenues": "97,637",
"Stockholders Equity": "174,288",
"Net Income": "-8,529",
"Comprehensive Net Income": "-8,529",
"BaseVar": "274,100",
"ECR before LimitedLiability": "217%",
"Economic Capital Ratio": "314%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "127,743",
"Cost of Goods Sold": "0",
"Intangible Assets": "115",
"Liabilities, Current": "11,349",
"Liabilities, Non-Current": "1,136",
"Other Assets": "60,082",
"Other Compr. Net Income": "165",
"Other Expenses": "3,617",
"Other Liabilities": "1,179",
"Other Net Income": "1,039",
"Other Revenues": "57,860",
"Property and Equipment": "1,639",
"Research and Development": "49,087",
"Selling, General and Administrative Expense": "13,193"
},
"output_variables": {
"Assets": "189,579",
"Liabilities": "13,664",
"Expenses": "65,897",
"Revenues": "57,860",
"Stockholders Equity": "175,915",
"Net Income": "-6,998",
"Comprehensive Net Income": "-6,916",
"BaseVar": "164,102",
"ECR before LimitedLiability": "371%",
"Economic Capital Ratio": "418%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "93,606",
"Cost of Goods Sold": "0",
"Intangible Assets": "97",
"Liabilities, Current": "10,979",
"Liabilities, Non-Current": "283",
"Other Assets": "51,488",
"Other Compr. Net Income": "-114",
"Other Expenses": "7.0",
"Other Liabilities": "0",
"Other Net Income": "518",
"Other Revenues": "3,629",
"Property and Equipment": "682",
"Research and Development": "38,840",
"Selling, General and Administrative Expense": "12,005"
},
"output_variables": {
"Assets": "145,873",
"Liabilities": "11,262",
"Expenses": "50,852",
"Revenues": "3,629",
"Stockholders Equity": "134,611",
"Net Income": "-46,705",
"Comprehensive Net Income": "-46,762",
"BaseVar": "106,124",
"ECR before LimitedLiability": "314%",
"Economic Capital Ratio": "378%"
}
}
},
"top_rated": true,
"trend": -26.0,
"value": 3.780822104444045,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001124105.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001124105.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001124105.svg"
},
{
"company_id": "0000887151",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000887151.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000887151.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000887151_main_keyfigs.svg",
"name": "Capstone Holding Corp",
"rank": 33,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000887151.svg",
"report_text": "The relative strengths and weaknesses of Capstone Holding Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Capstone Holding Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 195% points.The greatest weakness of Capstone Holding Corp is the variable Research and Development, reducing the Economic Capital Ratio by 34% points.
The company's Economic Capital Ratio, given in the ranking table, is 378%, being 135% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000887151_2014_Capstone_Holding_Corp.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-4.08",
"Assets": "44.0",
"Liabilities": "106",
"Stockholders Equity": "195",
"ECR before LimitedLiability": "163",
"Intangible Assets": "3.93",
"Property and Equipment": "-3.01",
"Assets, Current": "53.0",
"Liabilities, Non-Current": "15.5",
"Liabilities, Current": "64.4",
"Other Liabilities": "40.3",
"Selling, General and Administrative Expense": "2.52",
"Expenses": "-15.9",
"Revenues": "-18.6",
"Net Income": "-33.5",
"Other Expenses": "12.1",
"Research and Development": "-34.0",
"Cost of Goods Sold": "2.72",
"Other Revenues": "-18.6",
"Comprehensive Net Income": "-33.7",
"Economic Capital Ratio": "135"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000887151_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "6,491",
"Cost of Goods Sold": "0",
"Intangible Assets": "823",
"Liabilities, Current": "100",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-21",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "158",
"Property and Equipment": "3.0",
"Research and Development": "3,124",
"Selling, General and Administrative Expense": "1,169"
},
"output_variables": {
"Assets": "7,317",
"Liabilities": "100",
"Expenses": "4,272",
"Revenues": "158",
"Stockholders Equity": "7,217",
"Net Income": "-4,114",
"Comprehensive Net Income": "-4,114",
"BaseVar": "5,924",
"ECR before LimitedLiability": "313%",
"Economic Capital Ratio": "378%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.776241055997608,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000887151.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000887151.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000887151.svg"
},
{
"company_id": "0001092662",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001092662.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001092662.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001092662.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001092662_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001092662_main_keyfigs.svg",
"name": "Chembio Diagnostics INC",
"rank": 34,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001092662.svg",
"report_text": "The relative strengths and weaknesses of Chembio Diagnostics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Chembio Diagnostics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 143% points.The greatest weakness of Chembio Diagnostics INC is the variable Other Expenses, reducing the Economic Capital Ratio by 64% points.
The company's Economic Capital Ratio, given in the ranking table, is 375%, being 132% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001092662_2014_Chembio_Diagnostics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "13.1",
"Assets": "-6.42",
"Liabilities": "114",
"Stockholders Equity": "39.5",
"ECR before LimitedLiability": "253",
"Intangible Assets": "-5.81",
"Assets, Current": "-8.71",
"Other Liabilities": "57.2",
"Liabilities, Non-Current": "27.7",
"Liabilities, Current": "49.4",
"Research and Development": "17.3",
"Expenses": "23.4",
"Revenues": "94.8",
"Net Income": "121",
"Other Expenses": "-20.3",
"Cost of Goods Sold": "6.21",
"Selling, General and Administrative Expense": "19.8",
"Other Revenues": "94.8",
"Comprehensive Net Income": "120",
"Other Net Income": "3.70",
"Economic Capital Ratio": "177"
},
"2012": {
"Assets": "-24.5",
"Liabilities": "150",
"Stockholders Equity": "15.0",
"ECR before LimitedLiability": "222",
"Assets, Current": "-23.4",
"Intangible Assets": "-10.9",
"Other Assets": "14.6",
"Liabilities, Current": "73.0",
"Other Liabilities": "67.5",
"Liabilities, Non-Current": "34.0",
"Selling, General and Administrative Expense": "21.8",
"Expenses": "-10.5",
"Revenues": "115",
"Net Income": "108",
"Research and Development": "26.2",
"Other Expenses": "-70.6",
"Cost of Goods Sold": "8.12",
"Other Revenues": "115",
"Comprehensive Net Income": "108",
"Other Net Income": "4.01",
"Economic Capital Ratio": "149"
},
"2013": {
"Other Assets": "3.59",
"Assets": "-22.9",
"Liabilities": "143",
"Stockholders Equity": "8.36",
"ECR before LimitedLiability": "160",
"Intangible Assets": "-9.57",
"Assets, Current": "-18.4",
"Liabilities, Non-Current": "28.2",
"Liabilities, Current": "67.7",
"Other Liabilities": "70.8",
"Selling, General and Administrative Expense": "19.4",
"Expenses": "-18.3",
"Revenues": "97.4",
"Net Income": "81.7",
"Other Expenses": "-63.7",
"Research and Development": "17.7",
"Cost of Goods Sold": "5.14",
"Other Revenues": "97.4",
"Comprehensive Net Income": "81.2",
"Other Net Income": "2.72",
"Economic Capital Ratio": "132"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001092662_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "8,992",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,858",
"Liabilities, Non-Current": "0",
"Other Assets": "5,432",
"Other Compr. Net Income": "0",
"Other Expenses": "4,865",
"Other Liabilities": "133",
"Other Net Income": "-12",
"Other Revenues": "19,388",
"Property and Equipment": "1,062",
"Research and Development": "4,878",
"Selling, General and Administrative Expense": "3,424"
},
"output_variables": {
"Assets": "15,486",
"Liabilities": "2,991",
"Expenses": "13,167",
"Revenues": "19,388",
"Stockholders Equity": "12,495",
"Net Income": "6,209",
"Comprehensive Net Income": "6,209",
"BaseVar": "25,522",
"ECR before LimitedLiability": "362%",
"Economic Capital Ratio": "411%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "11,009",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,378",
"Liabilities, Non-Current": "0",
"Other Assets": "4,899",
"Other Compr. Net Income": "0",
"Other Expenses": "15,330",
"Other Liabilities": "82",
"Other Net Income": "-1.6",
"Other Revenues": "25,611",
"Property and Equipment": "1,428",
"Research and Development": "4,486",
"Selling, General and Administrative Expense": "4,852"
},
"output_variables": {
"Assets": "17,335",
"Liabilities": "3,461",
"Expenses": "24,668",
"Revenues": "25,611",
"Stockholders Equity": "13,875",
"Net Income": "941",
"Comprehensive Net Income": "941",
"BaseVar": "35,538",
"ECR before LimitedLiability": "300%",
"Economic Capital Ratio": "369%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "18,531",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,309",
"Liabilities, Non-Current": "0",
"Other Assets": "3,978",
"Other Compr. Net Income": "0",
"Other Expenses": "17,736",
"Other Liabilities": "0",
"Other Net Income": "13",
"Other Revenues": "29,550",
"Property and Equipment": "1,978",
"Research and Development": "5,834",
"Selling, General and Administrative Expense": "5,461"
},
"output_variables": {
"Assets": "24,487",
"Liabilities": "4,309",
"Expenses": "29,032",
"Revenues": "29,550",
"Stockholders Equity": "20,177",
"Net Income": "531",
"Comprehensive Net Income": "531",
"BaseVar": "43,695",
"ECR before LimitedLiability": "309%",
"Economic Capital Ratio": "375%"
}
}
},
"top_rated": true,
"trend": -7.0,
"value": 3.7483619000992277,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001092662.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001092662.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001092662.svg"
},
{
"company_id": "0001226616",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001226616.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001226616.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001226616.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001226616_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001226616_main_keyfigs.svg",
"name": "Medicinova INC",
"rank": 35,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001226616.svg",
"report_text": "The relative strengths and weaknesses of Medicinova INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Medicinova INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 127% points.The greatest weakness of Medicinova INC is the variable Other Revenues, reducing the Economic Capital Ratio by 20% points.
The company's Economic Capital Ratio, given in the ranking table, is 372%, being 129% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001226616_2014_Medicinova_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-69.5",
"Assets": "-323",
"Liabilities": "-1.19",
"Stockholders Equity": "-555",
"ECR before LimitedLiability": "-129",
"Intangible Assets": "-77.7",
"Property and Equipment": "-78.2",
"Assets, Current": "-294",
"Liabilities, Current": "-0.978",
"Research and Development": "-112",
"Expenses": "-147",
"Revenues": "-80.2",
"Net Income": "-328",
"Other Expenses": "17.2",
"Cost of Goods Sold": "7.59",
"Selling, General and Administrative Expense": "-58.8",
"Other Revenues": "-80.2",
"Comprehensive Net Income": "-28.5",
"Other Net Income": "3.89",
"Other Compr. Net Income": "29.0",
"Economic Capital Ratio": "-205"
},
"2012": {
"Property and Equipment": "-30.8",
"Assets": "-78.2",
"Liabilities": "15.1",
"Stockholders Equity": "4.42",
"Assets, Current": "-133",
"Intangible Assets": "30.1",
"Other Assets": "8.57",
"Liabilities, Current": "11.8",
"ECR before LimitedLiability": "-2.27",
"Other Liabilities": "-1.88",
"Liabilities, Non-Current": "4.32",
"Selling, General and Administrative Expense": "3.83",
"Expenses": "8.53",
"Revenues": "-56.8",
"Comprehensive Net Income": "-111",
"Research and Development": "4.59",
"Other Expenses": "4.08",
"Other Revenues": "-56.8",
"Other Net Income": "-8.81",
"Other Compr. Net Income": "-110",
"Economic Capital Ratio": "-75.3"
},
"2013": {
"Other Assets": "11.4",
"Assets": "35.3",
"Liabilities": "59.7",
"Stockholders Equity": "127",
"ECR before LimitedLiability": "157",
"Intangible Assets": "25.1",
"Property and Equipment": "-2.79",
"Liabilities, Non-Current": "14.1",
"Liabilities, Current": "59.0",
"Other Liabilities": "-14.1",
"Selling, General and Administrative Expense": "-4.68",
"Expenses": "17.0",
"Revenues": "-19.7",
"Net Income": "22.7",
"Other Expenses": "-2.69",
"Research and Development": "21.7",
"Cost of Goods Sold": "2.50",
"Other Revenues": "-19.7",
"Comprehensive Net Income": "22.5",
"Other Net Income": "25.0",
"Economic Capital Ratio": "129"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001226616_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "15,708",
"Cost of Goods Sold": "1,258",
"Intangible Assets": "9,600",
"Liabilities, Current": "3,697",
"Liabilities, Non-Current": "0",
"Other Assets": "5,450",
"Other Compr. Net Income": "236,174",
"Other Expenses": "4,030",
"Other Liabilities": "3,592",
"Other Net Income": "-1,735",
"Other Revenues": "20,679",
"Property and Equipment": "29",
"Research and Development": "162,042",
"Selling, General and Administrative Expense": "105,523"
},
"output_variables": {
"Assets": "30,787",
"Liabilities": "7,290",
"Expenses": "272,853",
"Revenues": "20,679",
"Stockholders Equity": "23,498",
"Net Income": "-253,909",
"Comprehensive Net Income": "-135,822",
"BaseVar": "284,759",
"ECR before LimitedLiability": "-444%",
"Economic Capital Ratio": "29%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "4,422",
"Cost of Goods Sold": "1,258",
"Intangible Assets": "9,600",
"Liabilities, Current": "1,038",
"Liabilities, Non-Current": "0",
"Other Assets": "5,467",
"Other Compr. Net Income": "-31,374",
"Other Expenses": "2,388",
"Other Liabilities": "3,650",
"Other Net Income": "-1,735",
"Other Revenues": "827",
"Property and Equipment": "78",
"Research and Development": "5,013",
"Selling, General and Administrative Expense": "6,735"
},
"output_variables": {
"Assets": "19,568",
"Liabilities": "4,688",
"Expenses": "15,395",
"Revenues": "827",
"Stockholders Equity": "14,880",
"Net Income": "-16,302",
"Comprehensive Net Income": "-31,989",
"BaseVar": "36,794",
"ECR before LimitedLiability": "3.7%",
"Economic Capital Ratio": "145%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "14,383",
"Cost of Goods Sold": "0",
"Intangible Assets": "9,600",
"Liabilities, Current": "460",
"Liabilities, Non-Current": "0",
"Other Assets": "5,481",
"Other Compr. Net Income": "-13",
"Other Expenses": "3,394",
"Other Liabilities": "3,660",
"Other Net Income": "6,003",
"Other Revenues": "21",
"Property and Equipment": "82",
"Research and Development": "0",
"Selling, General and Administrative Expense": "6,658"
},
"output_variables": {
"Assets": "29,546",
"Liabilities": "4,120",
"Expenses": "10,052",
"Revenues": "21",
"Stockholders Equity": "25,426",
"Net Income": "-4,029",
"Comprehensive Net Income": "-4,035",
"BaseVar": "24,878",
"ECR before LimitedLiability": "305%",
"Economic Capital Ratio": "372%"
}
}
},
"top_rated": true,
"trend": 109.0,
"value": 3.722192756775897,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001226616.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001226616.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001226616.svg"
},
{
"company_id": "0001029142",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001029142.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001029142.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001029142.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001029142_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001029142_main_keyfigs.svg",
"name": "Dynavax Technologies CORP",
"rank": 36,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001029142.svg",
"report_text": "The relative strengths and weaknesses of Dynavax Technologies CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Dynavax Technologies CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 161% points.The greatest weakness of Dynavax Technologies CORP is the variable Other Revenues, reducing the Economic Capital Ratio by 12% points.
The company's Economic Capital Ratio, given in the ranking table, is 372%, being 129% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001029142_2014_Dynavax_Technologies_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-6.12",
"Assets": "53.1",
"Liabilities": "32.1",
"Stockholders Equity": "111",
"ECR before LimitedLiability": "163",
"Intangible Assets": "-7.26",
"Assets, Current": "90.9",
"Other Liabilities": "29.6",
"Liabilities, Non-Current": "12.8",
"Liabilities, Current": "-10.6",
"Research and Development": "-12.8",
"Expenses": "8.27",
"Revenues": "-8.42",
"Net Income": "2.60",
"Other Expenses": "7.49",
"Cost of Goods Sold": "3.31",
"Selling, General and Administrative Expense": "10.3",
"Other Revenues": "-8.42",
"Comprehensive Net Income": "2.35",
"Other Net Income": "2.79",
"Economic Capital Ratio": "87.4"
},
"2012": {
"Assets": "67.8",
"Liabilities": "44.4",
"Stockholders Equity": "139",
"ECR before LimitedLiability": "168",
"Assets, Current": "98.9",
"Intangible Assets": "-6.31",
"Other Assets": "-5.11",
"Liabilities, Current": "15.8",
"Other Liabilities": "17.8",
"Liabilities, Non-Current": "12.8",
"Selling, General and Administrative Expense": "1.17",
"Expenses": "2.30",
"Revenues": "-15.2",
"Net Income": "-11.1",
"Research and Development": "-14.7",
"Other Expenses": "12.4",
"Cost of Goods Sold": "3.65",
"Other Revenues": "-15.2",
"Comprehensive Net Income": "-10.8",
"Other Net Income": "1.80",
"Economic Capital Ratio": "95.2"
},
"2013": {
"Other Assets": "-3.48",
"Assets": "48.8",
"Liabilities": "69.7",
"Stockholders Equity": "161",
"ECR before LimitedLiability": "157",
"Intangible Assets": "-3.91",
"Assets, Current": "68.6",
"Liabilities, Non-Current": "11.4",
"Liabilities, Current": "32.1",
"Other Liabilities": "33.0",
"Selling, General and Administrative Expense": "5.15",
"Expenses": "7.42",
"Revenues": "-11.8",
"Net Income": "-3.22",
"Other Expenses": "9.72",
"Research and Development": "-9.92",
"Cost of Goods Sold": "2.37",
"Other Revenues": "-11.8",
"Comprehensive Net Income": "-3.30",
"Other Net Income": "1.08",
"Economic Capital Ratio": "129"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001029142_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "124,618",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,312",
"Liabilities, Current": "27,219",
"Liabilities, Non-Current": "0",
"Other Assets": "1,009",
"Other Compr. Net Income": "0",
"Other Expenses": "2,256",
"Other Liabilities": "0",
"Other Net Income": "937",
"Other Revenues": "21,614",
"Property and Equipment": "6,163",
"Research and Development": "51,322",
"Selling, General and Administrative Expense": "17,570"
},
"output_variables": {
"Assets": "134,102",
"Liabilities": "27,219",
"Expenses": "71,148",
"Revenues": "21,614",
"Stockholders Equity": "106,883",
"Net Income": "-48,597",
"Comprehensive Net Income": "-48,597",
"BaseVar": "127,510",
"ECR before LimitedLiability": "229%",
"Economic Capital Ratio": "321%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "128,187",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,475",
"Liabilities, Current": "19,014",
"Liabilities, Non-Current": "629",
"Other Assets": "1,125",
"Other Compr. Net Income": "414",
"Other Expenses": "2,351",
"Other Liabilities": "5,283",
"Other Net Income": "-2.0",
"Other Revenues": "9,714",
"Property and Equipment": "7,965",
"Research and Development": "49,146",
"Selling, General and Administrative Expense": "28,164"
},
"output_variables": {
"Assets": "139,752",
"Liabilities": "24,926",
"Expenses": "79,661",
"Revenues": "9,714",
"Stockholders Equity": "114,826",
"Net Income": "-69,949",
"Comprehensive Net Income": "-69,742",
"BaseVar": "127,234",
"ECR before LimitedLiability": "219%",
"Economic Capital Ratio": "315%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "192,378",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,579",
"Liabilities, Current": "16,192",
"Liabilities, Non-Current": "963",
"Other Assets": "959",
"Other Compr. Net Income": "447",
"Other Expenses": "926",
"Other Liabilities": "1,173",
"Other Net Income": "-232",
"Other Revenues": "11,251",
"Property and Equipment": "8,706",
"Research and Development": "50,870",
"Selling, General and Administrative Expense": "25,943"
},
"output_variables": {
"Assets": "204,622",
"Liabilities": "18,328",
"Expenses": "77,739",
"Revenues": "11,251",
"Stockholders Equity": "186,294",
"Net Income": "-66,720",
"Comprehensive Net Income": "-66,496",
"BaseVar": "156,310",
"ECR before LimitedLiability": "305%",
"Economic Capital Ratio": "372%"
}
}
},
"top_rated": true,
"trend": 21.0,
"value": 3.71787673020246,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001029142.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001029142.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001029142.svg"
},
{
"company_id": "0000821995",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000821995.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000821995.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000821995_main_keyfigs.svg",
"name": "Juniper Pharmaceuticals INC",
"rank": 37,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000821995.svg",
"report_text": "The relative strengths and weaknesses of Juniper Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Juniper Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 78% points.The greatest weakness of Juniper Pharmaceuticals INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 22% points.
The company's Economic Capital Ratio, given in the ranking table, is 371%, being 129% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000821995_2014_Juniper_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Assets": "2.91",
"Liabilities": "119",
"Stockholders Equity": "101",
"ECR before LimitedLiability": "277",
"Assets, Current": "14.8",
"Intangible Assets": "-3.53",
"Other Assets": "-2.55",
"Liabilities, Current": "69.1",
"Other Liabilities": "44.2",
"Liabilities, Non-Current": "28.3",
"Selling, General and Administrative Expense": "9.73",
"Expenses": "29.6",
"Revenues": "49.3",
"Net Income": "102",
"Research and Development": "37.2",
"Other Expenses": "20.1",
"Cost of Goods Sold": "-39.7",
"Other Revenues": "49.3",
"Comprehensive Net Income": "102",
"Other Net Income": "27.1",
"Economic Capital Ratio": "204"
},
"2013": {
"Other Assets": "-3.96",
"Assets": "14.1",
"Liabilities": "56.7",
"Stockholders Equity": "78.0",
"ECR before LimitedLiability": "157",
"Intangible Assets": "12.1",
"Property and Equipment": "14.4",
"Assets, Current": "-6.37",
"Liabilities, Non-Current": "16.4",
"Liabilities, Current": "40.1",
"Other Liabilities": "3.78",
"Selling, General and Administrative Expense": "10.7",
"Expenses": "24.9",
"Revenues": "30.8",
"Net Income": "57.1",
"Other Expenses": "10.3",
"Research and Development": "25.4",
"Cost of Goods Sold": "-21.9",
"Other Revenues": "30.8",
"Comprehensive Net Income": "57.8",
"Economic Capital Ratio": "129"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000821995_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "35,972",
"Cost of Goods Sold": "12,788",
"Intangible Assets": "0",
"Liabilities, Current": "3,815",
"Liabilities, Non-Current": "0",
"Other Assets": "39",
"Other Compr. Net Income": "0",
"Other Expenses": "893",
"Other Liabilities": "1,207",
"Other Net Income": "7,110",
"Other Revenues": "25,828",
"Property and Equipment": "927",
"Research and Development": "771",
"Selling, General and Administrative Expense": "8,570"
},
"output_variables": {
"Assets": "36,938",
"Liabilities": "5,022",
"Expenses": "23,022",
"Revenues": "25,828",
"Stockholders Equity": "31,915",
"Net Income": "9,917",
"Comprehensive Net Income": "9,917",
"BaseVar": "48,960",
"ECR before LimitedLiability": "379%",
"Economic Capital Ratio": "424%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "32,227",
"Cost of Goods Sold": "13,251",
"Intangible Assets": "13,980",
"Liabilities, Current": "6,297",
"Liabilities, Non-Current": "0",
"Other Assets": "659",
"Other Compr. Net Income": "1,087",
"Other Expenses": "1,291",
"Other Liabilities": "6,367",
"Other Net Income": "57",
"Other Revenues": "29,226",
"Property and Equipment": "13,226",
"Research and Development": "0",
"Selling, General and Administrative Expense": "8,038"
},
"output_variables": {
"Assets": "60,092",
"Liabilities": "12,665",
"Expenses": "22,580",
"Revenues": "29,226",
"Stockholders Equity": "47,428",
"Net Income": "6,704",
"Comprehensive Net Income": "7,247",
"BaseVar": "62,854",
"ECR before LimitedLiability": "304%",
"Economic Capital Ratio": "371%"
}
}
},
"top_rated": true,
"trend": -32.0,
"value": 3.714300553859056,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000821995.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000821995.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000821995.svg"
},
{
"company_id": "0001274057",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001274057.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001274057.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001274057_main_keyfigs.svg",
"name": "Hospira INC",
"rank": 38,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001274057.svg",
"report_text": "The relative strengths and weaknesses of Hospira INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Hospira INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 86% points.The greatest weakness of Hospira INC is the variable Other Expenses, reducing the Economic Capital Ratio by 39% points.
The company's Economic Capital Ratio, given in the ranking table, is 366%, being 123% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001274057_2014_Hospira_INC.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "0.926",
"Assets": "-5.61",
"Liabilities": "67.3",
"Stockholders Equity": "20.9",
"ECR before LimitedLiability": "50.0",
"Other Assets": "-2.95",
"Intangible Assets": "-6.13",
"Property and Equipment": "2.87",
"Liabilities, Current": "14.0",
"Other Liabilities": "25.5",
"Liabilities, Non-Current": "34.9",
"Cost of Goods Sold": "0.769",
"Expenses": "-18.8",
"Revenues": "14.4",
"Net Income": "-4.52",
"Selling, General and Administrative Expense": "9.16",
"Other Expenses": "-34.8",
"Research and Development": "5.34",
"Other Revenues": "14.4",
"Comprehensive Net Income": "-4.55",
"Economic Capital Ratio": "50.9"
},
"2010": {
"Other Assets": "-4.19",
"Assets": "-0.537",
"Liabilities": "88.2",
"Stockholders Equity": "58.7",
"ECR before LimitedLiability": "108",
"Assets, Current": "-6.29",
"Property and Equipment": "5.03",
"Intangible Assets": "6.52",
"Liabilities, Current": "14.7",
"Other Liabilities": "46.6",
"Liabilities, Non-Current": "38.2",
"Selling, General and Administrative Expense": "12.6",
"Expenses": "-6.22",
"Revenues": "23.7",
"Net Income": "17.9",
"Research and Development": "10.7",
"Cost of Goods Sold": "6.15",
"Other Expenses": "-36.9",
"Other Revenues": "23.7",
"Comprehensive Net Income": "17.9",
"Economic Capital Ratio": "101"
},
"2011": {
"Assets": "6.07",
"Liabilities": "92.7",
"Stockholders Equity": "86.3",
"ECR before LimitedLiability": "225",
"Intangible Assets": "10.2",
"Property and Equipment": "12.7",
"Assets, Current": "-11.5",
"Other Liabilities": "46.7",
"Liabilities, Non-Current": "21.0",
"Liabilities, Current": "37.5",
"Research and Development": "37.2",
"Expenses": "13.4",
"Revenues": "43.9",
"Net Income": "60.9",
"Other Expenses": "-55.0",
"Cost of Goods Sold": "4.88",
"Selling, General and Administrative Expense": "23.0",
"Other Revenues": "43.9",
"Comprehensive Net Income": "59.1",
"Other Net Income": "4.11",
"Economic Capital Ratio": "149"
},
"2012": {
"Property and Equipment": "14.0",
"Assets": "9.74",
"Liabilities": "89.6",
"Stockholders Equity": "94.1",
"ECR before LimitedLiability": "229",
"Assets, Current": "-11.6",
"Intangible Assets": "9.74",
"Liabilities, Current": "31.8",
"Other Liabilities": "46.6",
"Liabilities, Non-Current": "22.6",
"Selling, General and Administrative Expense": "20.6",
"Expenses": "16.9",
"Revenues": "44.1",
"Net Income": "63.7",
"Research and Development": "29.0",
"Other Expenses": "-39.5",
"Cost of Goods Sold": "5.16",
"Other Revenues": "44.1",
"Comprehensive Net Income": "64.0",
"Other Net Income": "2.95",
"Economic Capital Ratio": "156"
},
"2013": {
"Liabilities, Non-Current": "19.5",
"Liabilities": "86.0",
"Stockholders Equity": "62.3",
"ECR before LimitedLiability": "151",
"Liabilities, Current": "25.5",
"Other Liabilities": "50.3",
"Selling, General and Administrative Expense": "17.4",
"Expenses": "8.80",
"Net Income": "54.6",
"Other Expenses": "-38.9",
"Research and Development": "25.4",
"Cost of Goods Sold": "3.54",
"Other Revenues": "44.7",
"Revenues": "44.7",
"Intangible Assets": "8.20",
"Property and Equipment": "18.3",
"Assets, Current": "-18.8",
"Comprehensive Net Income": "53.2",
"Other Net Income": "1.15",
"Other Compr. Net Income": "-1.39",
"Economic Capital Ratio": "123"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001274057_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "2,526,200",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,649,900",
"Liabilities, Current": "881,900",
"Liabilities, Non-Current": "0",
"Other Assets": "179,000",
"Other Compr. Net Income": "0",
"Other Expenses": "2,604,300",
"Other Liabilities": "0",
"Other Net Income": "-11,800",
"Other Revenues": "3,879,300",
"Property and Equipment": "1,147,800",
"Research and Development": "240,500",
"Selling, General and Administrative Expense": "618,800"
},
"output_variables": {
"Assets": "5,502,900",
"Liabilities": "881,900",
"Expenses": "3,463,600",
"Revenues": "3,879,300",
"Stockholders Equity": "4,621,000",
"Net Income": "403,900",
"Comprehensive Net Income": "403,900",
"BaseVar": "6,869,750",
"ECR before LimitedLiability": "328%",
"Economic Capital Ratio": "388%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "2,477,500",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,998,900",
"Liabilities, Current": "931,600",
"Liabilities, Non-Current": "0",
"Other Assets": "290,700",
"Other Compr. Net Income": "0",
"Other Expenses": "2,557,900",
"Other Liabilities": "0",
"Other Net Income": "-26,600",
"Other Revenues": "3,917,200",
"Property and Equipment": "1,279,200",
"Research and Development": "300,500",
"Selling, General and Administrative Expense": "675,000"
},
"output_variables": {
"Assets": "6,046,300",
"Liabilities": "931,600",
"Expenses": "3,533,400",
"Revenues": "3,917,200",
"Stockholders Equity": "5,114,700",
"Net Income": "357,200",
"Comprehensive Net Income": "357,200",
"BaseVar": "7,227,550",
"ECR before LimitedLiability": "330%",
"Economic Capital Ratio": "389%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "2,570,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,438,700",
"Liabilities, Current": "847,800",
"Liabilities, Non-Current": "0",
"Other Assets": "414,700",
"Other Compr. Net Income": "-140,600",
"Other Expenses": "3,225,200",
"Other Liabilities": "0",
"Other Net Income": "54,800",
"Other Revenues": "4,057,100",
"Property and Equipment": "1,355,000",
"Research and Development": "258,800",
"Selling, General and Administrative Expense": "637,300"
},
"output_variables": {
"Assets": "5,779,100",
"Liabilities": "847,800",
"Expenses": "4,121,300",
"Revenues": "4,057,100",
"Stockholders Equity": "4,931,300",
"Net Income": "-9,400",
"Comprehensive Net Income": "-79,700",
"BaseVar": "7,500,350",
"ECR before LimitedLiability": "322%",
"Economic Capital Ratio": "384%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "2,760,400",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,345,900",
"Liabilities, Current": "1,029,200",
"Liabilities, Non-Current": "0",
"Other Assets": "537,200",
"Other Compr. Net Income": "-139,873",
"Other Expenses": "3,082,252",
"Other Liabilities": "0",
"Other Net Income": "33,305",
"Other Revenues": "4,092,469",
"Property and Equipment": "1,445,100",
"Research and Development": "312,084",
"Selling, General and Administrative Expense": "692,046"
},
"output_variables": {
"Assets": "6,088,600",
"Liabilities": "1,029,200",
"Expenses": "4,086,382",
"Revenues": "4,092,469",
"Stockholders Equity": "5,059,400",
"Net Income": "39,393",
"Comprehensive Net Income": "-30,543",
"BaseVar": "7,734,915",
"ECR before LimitedLiability": "309%",
"Economic Capital Ratio": "375%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,838,500",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,229,900",
"Liabilities, Current": "1,165,100",
"Liabilities, Non-Current": "0",
"Other Assets": "536,300",
"Other Compr. Net Income": "4,145",
"Other Expenses": "2,934,308",
"Other Liabilities": "0",
"Other Net Income": "-26,372",
"Other Revenues": "4,001,877",
"Property and Equipment": "1,574,200",
"Research and Development": "301,357",
"Selling, General and Administrative Expense": "747,763"
},
"output_variables": {
"Assets": "6,178,900",
"Liabilities": "1,165,100",
"Expenses": "3,983,428",
"Revenues": "4,001,877",
"Stockholders Equity": "5,013,800",
"Net Income": "-7,923",
"Comprehensive Net Income": "-5,850",
"BaseVar": "7,679,911",
"ECR before LimitedLiability": "298%",
"Economic Capital Ratio": "367%"
}
}
},
"top_rated": true,
"trend": -15.0,
"value": 3.6585445522675073,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001274057.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001274057.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001274057.svg"
},
{
"company_id": "0001551152",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001551152.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001551152.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001551152.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001551152_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001551152_main_keyfigs.svg",
"name": "Abbvie Inc",
"rank": 39,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001551152.svg",
"report_text": "The relative strengths and weaknesses of Abbvie Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Abbvie Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 66% points.The greatest weakness of Abbvie Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 7.9% points.
The company's Economic Capital Ratio, given in the ranking table, is 365%, being 122% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001551152_2014_Abbvie_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-3.48",
"Assets": "3.51",
"Liabilities": "64.0",
"Stockholders Equity": "54.3",
"ECR before LimitedLiability": "150",
"Intangible Assets": "16.1",
"Property and Equipment": "1.69",
"Assets, Current": "-7.86",
"Liabilities, Non-Current": "18.0",
"Liabilities, Current": "3.33",
"Other Liabilities": "46.6",
"Selling, General and Administrative Expense": "8.79",
"Expenses": "21.5",
"Revenues": "43.6",
"Net Income": "65.7",
"Other Expenses": "-7.24",
"Research and Development": "16.7",
"Cost of Goods Sold": "3.26",
"Other Revenues": "43.6",
"Comprehensive Net Income": "66.5",
"Economic Capital Ratio": "122"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001551152_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "17,848,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "8,167,000",
"Liabilities, Current": "6,879,000",
"Liabilities, Non-Current": "0",
"Other Assets": "885,000",
"Other Compr. Net Income": "570,000",
"Other Expenses": "5,785,000",
"Other Liabilities": "0",
"Other Net Income": "-332,000",
"Other Revenues": "18,790,000",
"Property and Equipment": "2,298,000",
"Research and Development": "3,193,000",
"Selling, General and Administrative Expense": "5,352,000"
},
"output_variables": {
"Assets": "29,198,000",
"Liabilities": "6,879,000",
"Expenses": "14,330,000",
"Revenues": "18,790,000",
"Stockholders Equity": "22,319,000",
"Net Income": "4,128,000",
"Comprehensive Net Income": "4,413,000",
"BaseVar": "35,049,500",
"ECR before LimitedLiability": "294%",
"Economic Capital Ratio": "365%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.647712207926139,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001551152.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001551152.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001551152.svg"
},
{
"company_id": "0000001800",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000001800.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000001800.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000001800.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000001800_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000001800_main_keyfigs.svg",
"name": "Abbott Laboratories",
"rank": 40,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000001800.svg",
"report_text": "The relative strengths and weaknesses of Abbott Laboratories are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Abbott Laboratories compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 69% points.The greatest weakness of Abbott Laboratories is the variable Other Expenses, reducing the Economic Capital Ratio by 15% points.
The company's Economic Capital Ratio, given in the ranking table, is 361%, being 118% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000001800_2014_Abbott_Laboratories.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "1.92",
"Assets": "-3.13",
"Liabilities": "25.3",
"Stockholders Equity": "7.40",
"ECR before LimitedLiability": "17.4",
"Other Assets": "-3.10",
"Intangible Assets": "-0.953",
"Property and Equipment": "-0.937",
"Liabilities, Current": "-27.0",
"Other Liabilities": "20.7",
"Liabilities, Non-Current": "28.4",
"Cost of Goods Sold": "0.654",
"Expenses": "-6.03",
"Revenues": "3.65",
"Net Income": "0.406",
"Selling, General and Administrative Expense": "2.14",
"Other Expenses": "-12.3",
"Research and Development": "3.40",
"Other Revenues": "3.65",
"Other Net Income": "2.77",
"Economic Capital Ratio": "18.3"
},
"2010": {
"Other Assets": "-8.74",
"Assets": "-1.21",
"Liabilities": "34.8",
"Stockholders Equity": "20.9",
"ECR before LimitedLiability": "55.7",
"Assets, Current": "-12.2",
"Intangible Assets": "27.2",
"Liabilities, Current": "-39.2",
"Other Liabilities": "37.6",
"Liabilities, Non-Current": "30.6",
"Selling, General and Administrative Expense": "4.56",
"Expenses": "1.86",
"Revenues": "14.6",
"Net Income": "17.5",
"Research and Development": "7.94",
"Cost of Goods Sold": "5.31",
"Other Expenses": "-16.0",
"Other Revenues": "14.6",
"Comprehensive Net Income": "17.5",
"Other Net Income": "0.937",
"Economic Capital Ratio": "49.3"
},
"2011": {
"Other Assets": "-2.98",
"Assets": "11.8",
"Liabilities": "43.9",
"Stockholders Equity": "58.2",
"ECR before LimitedLiability": "189",
"Intangible Assets": "37.0",
"Property and Equipment": "5.62",
"Assets, Current": "-16.5",
"Other Liabilities": "38.0",
"Liabilities, Non-Current": "16.8",
"Liabilities, Current": "-10.8",
"Research and Development": "28.1",
"Expenses": "23.8",
"Revenues": "35.0",
"Net Income": "61.9",
"Other Expenses": "-17.2",
"Cost of Goods Sold": "4.13",
"Selling, General and Administrative Expense": "8.61",
"Other Revenues": "35.0",
"Comprehensive Net Income": "60.4",
"Economic Capital Ratio": "114"
},
"2012": {
"Property and Equipment": "4.31",
"Assets": "16.8",
"Liabilities": "68.3",
"Stockholders Equity": "94.1",
"ECR before LimitedLiability": "226",
"Assets, Current": "-8.04",
"Intangible Assets": "25.4",
"Other Assets": "-0.982",
"Liabilities, Current": "12.5",
"Other Liabilities": "41.8",
"Liabilities, Non-Current": "20.1",
"Selling, General and Administrative Expense": "10.0",
"Expenses": "29.2",
"Revenues": "36.9",
"Net Income": "66.1",
"Research and Development": "23.4",
"Other Expenses": "-8.84",
"Cost of Goods Sold": "4.61",
"Other Revenues": "36.9",
"Comprehensive Net Income": "65.5",
"Economic Capital Ratio": "152"
},
"2013": {
"Other Assets": "-1.38",
"Assets": "11.1",
"Liabilities": "57.6",
"Stockholders Equity": "69.1",
"ECR before LimitedLiability": "146",
"Intangible Assets": "27.8",
"Property and Equipment": "7.36",
"Assets, Current": "-14.8",
"Liabilities, Non-Current": "16.5",
"Other Liabilities": "43.1",
"Selling, General and Administrative Expense": "8.81",
"Expenses": "19.4",
"Revenues": "31.6",
"Net Income": "52.7",
"Other Expenses": "-15.2",
"Research and Development": "22.6",
"Cost of Goods Sold": "3.01",
"Other Revenues": "31.6",
"Comprehensive Net Income": "53.2",
"Other Net Income": "1.68",
"Economic Capital Ratio": "118"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000001800_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "23,313,891",
"Cost of Goods Sold": "0",
"Intangible Assets": "19,492,163",
"Liabilities, Current": "13,049,489",
"Liabilities, Non-Current": "0",
"Other Assets": "1,991,080",
"Other Compr. Net Income": "0",
"Other Expenses": "15,346,921",
"Other Liabilities": "0",
"Other Net Income": "1,477,689",
"Other Revenues": "30,764,707",
"Property and Equipment": "7,619,489",
"Research and Development": "2,743,733",
"Selling, General and Administrative Expense": "8,405,904"
},
"output_variables": {
"Assets": "52,416,623",
"Liabilities": "13,049,489",
"Expenses": "26,496,558",
"Revenues": "30,764,707",
"Stockholders Equity": "39,367,134",
"Net Income": "5,745,838",
"Comprehensive Net Income": "5,745,838",
"BaseVar": "62,102,533",
"ECR before LimitedLiability": "280%",
"Economic Capital Ratio": "355%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "22,317,529",
"Cost of Goods Sold": "0",
"Intangible Assets": "28,081,705",
"Liabilities, Current": "17,262,434",
"Liabilities, Non-Current": "0",
"Other Assets": "1,092,076",
"Other Compr. Net Income": "0",
"Other Expenses": "16,618,189",
"Other Liabilities": "0",
"Other Net Income": "178,388",
"Other Revenues": "35,166,721",
"Property and Equipment": "7,970,956",
"Research and Development": "3,724,424",
"Selling, General and Administrative Expense": "10,376,324"
},
"output_variables": {
"Assets": "59,462,266",
"Liabilities": "17,262,434",
"Expenses": "30,718,937",
"Revenues": "35,166,721",
"Stockholders Equity": "42,199,832",
"Net Income": "4,626,172",
"Comprehensive Net Income": "4,626,172",
"BaseVar": "71,394,373",
"ECR before LimitedLiability": "252%",
"Economic Capital Ratio": "337%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "23,768,774",
"Cost of Goods Sold": "0",
"Intangible Assets": "25,695,016",
"Liabilities, Current": "15,480,228",
"Liabilities, Non-Current": "0",
"Other Assets": "2,939,148",
"Other Compr. Net Income": "-1,230,339",
"Other Expenses": "16,540,914",
"Other Liabilities": "0",
"Other Net Income": "-23,165",
"Other Revenues": "38,851,259",
"Property and Equipment": "7,873,955",
"Research and Development": "4,801,914",
"Selling, General and Administrative Expense": "12,756,817"
},
"output_variables": {
"Assets": "60,276,893",
"Liabilities": "15,480,228",
"Expenses": "34,099,645",
"Revenues": "38,851,259",
"Stockholders Equity": "44,796,665",
"Net Income": "4,728,449",
"Comprehensive Net Income": "4,113,280",
"BaseVar": "74,980,764",
"ECR before LimitedLiability": "269%",
"Economic Capital Ratio": "348%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "31,322,583",
"Cost of Goods Sold": "0",
"Intangible Assets": "24,362,412",
"Liabilities, Current": "13,280,176",
"Liabilities, Non-Current": "0",
"Other Assets": "3,486,902",
"Other Compr. Net Income": "-1,033,850",
"Other Expenses": "15,964,534",
"Other Liabilities": "0",
"Other Net Income": "-907,114",
"Other Revenues": "40,066,777",
"Property and Equipment": "8,063,047",
"Research and Development": "4,499,806",
"Selling, General and Administrative Expense": "11,834,275"
},
"output_variables": {
"Assets": "67,234,944",
"Liabilities": "13,280,176",
"Expenses": "32,298,615",
"Revenues": "40,066,777",
"Stockholders Equity": "53,954,768",
"Net Income": "6,861,048",
"Comprehensive Net Income": "6,344,123",
"BaseVar": "77,410,738",
"ECR before LimitedLiability": "308%",
"Economic Capital Ratio": "374%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "19,247,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "15,507,000",
"Liabilities, Current": "9,507,000",
"Liabilities, Non-Current": "0",
"Other Assets": "2,294,000",
"Other Compr. Net Income": "655,278",
"Other Expenses": "10,626,084",
"Other Liabilities": "0",
"Other Net Income": "-428,213",
"Other Revenues": "18,920,717",
"Property and Equipment": "5,905,000",
"Research and Development": "-877,299",
"Selling, General and Administrative Expense": "4,876,751"
},
"output_variables": {
"Assets": "42,953,000",
"Liabilities": "9,507,000",
"Expenses": "14,625,537",
"Revenues": "18,920,717",
"Stockholders Equity": "33,446,000",
"Net Income": "3,866,968",
"Comprehensive Net Income": "4,194,607",
"BaseVar": "43,544,872",
"ECR before LimitedLiability": "294%",
"Economic Capital Ratio": "365%"
}
}
},
"top_rated": true,
"trend": -15.0,
"value": 3.6074066605611717,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000001800.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000001800.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000001800.svg"
},
{
"company_id": "0001367644",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001367644.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001367644.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001367644.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001367644_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001367644_main_keyfigs.svg",
"name": "Emergent Biosolutions Inc",
"rank": 41,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001367644.svg",
"report_text": "The relative strengths and weaknesses of Emergent Biosolutions Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Emergent Biosolutions Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 71% points.The greatest weakness of Emergent Biosolutions Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 25% points.
The company's Economic Capital Ratio, given in the ranking table, is 360%, being 117% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001367644_2014_Emergent_Biosolutions_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "6.28",
"Assets": "23.2",
"Liabilities": "36.9",
"Stockholders Equity": "77.1",
"ECR before LimitedLiability": "192",
"Intangible Assets": "-7.18",
"Property and Equipment": "37.5",
"Assets, Current": "-6.57",
"Other Liabilities": "32.9",
"Liabilities, Non-Current": "-24.4",
"Liabilities, Current": "26.0",
"Research and Development": "8.61",
"Expenses": "24.8",
"Revenues": "23.8",
"Net Income": "51.1",
"Cost of Goods Sold": "3.73",
"Selling, General and Administrative Expense": "13.3",
"Other Revenues": "23.8",
"Comprehensive Net Income": "50.8",
"Other Net Income": "2.25",
"Economic Capital Ratio": "117"
},
"2012": {
"Property and Equipment": "42.7",
"Assets": "23.2",
"Liabilities": "54.2",
"Stockholders Equity": "93.6",
"ECR before LimitedLiability": "213",
"Assets, Current": "-6.94",
"Intangible Assets": "-5.93",
"Other Assets": "2.74",
"Liabilities, Current": "38.8",
"Other Liabilities": "38.2",
"Liabilities, Non-Current": "-24.5",
"Selling, General and Administrative Expense": "13.2",
"Expenses": "26.3",
"Revenues": "27.3",
"Net Income": "56.2",
"Research and Development": "5.75",
"Other Expenses": "3.16",
"Cost of Goods Sold": "4.27",
"Other Revenues": "27.3",
"Comprehensive Net Income": "56.8",
"Economic Capital Ratio": "140"
},
"2013": {
"Other Assets": "0.168",
"Assets": "12.2",
"Liabilities": "56.9",
"Stockholders Equity": "71.1",
"ECR before LimitedLiability": "145",
"Intangible Assets": "-1.53",
"Property and Equipment": "42.8",
"Assets, Current": "-15.1",
"Liabilities, Non-Current": "-24.9",
"Liabilities, Current": "46.2",
"Other Liabilities": "33.8",
"Selling, General and Administrative Expense": "10.8",
"Expenses": "18.9",
"Revenues": "30.9",
"Net Income": "51.5",
"Research and Development": "5.30",
"Cost of Goods Sold": "2.98",
"Other Revenues": "30.9",
"Comprehensive Net Income": "51.4",
"Other Net Income": "1.64",
"Economic Capital Ratio": "117"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001367644_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "254,418",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,502",
"Liabilities, Current": "71,054",
"Liabilities, Non-Current": "56,078",
"Other Assets": "77,971",
"Other Compr. Net Income": "0",
"Other Expenses": "58,001",
"Other Liabilities": "3,005",
"Other Net Income": "-156",
"Other Revenues": "273,384",
"Property and Equipment": "208,973",
"Research and Development": "124,832",
"Selling, General and Administrative Expense": "74,282"
},
"output_variables": {
"Assets": "546,864",
"Liabilities": "130,137",
"Expenses": "257,115",
"Revenues": "273,384",
"Stockholders Equity": "416,727",
"Net Income": "16,113",
"Comprehensive Net Income": "16,113",
"BaseVar": "603,828",
"ECR before LimitedLiability": "273%",
"Economic Capital Ratio": "351%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "263,347",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,502",
"Liabilities, Current": "61,907",
"Liabilities, Non-Current": "60,195",
"Other Assets": "53,617",
"Other Compr. Net Income": "4,565",
"Other Expenses": "69,599",
"Other Liabilities": "0",
"Other Net Income": "2,098",
"Other Revenues": "281,888",
"Property and Equipment": "241,764",
"Research and Development": "120,226",
"Selling, General and Administrative Expense": "76,018"
},
"output_variables": {
"Assets": "564,230",
"Liabilities": "122,102",
"Expenses": "265,843",
"Revenues": "281,888",
"Stockholders Equity": "442,128",
"Net Income": "18,143",
"Comprehensive Net Income": "20,426",
"BaseVar": "620,363",
"ECR before LimitedLiability": "287%",
"Economic Capital Ratio": "360%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "273,115",
"Cost of Goods Sold": "0",
"Intangible Assets": "44,102",
"Liabilities, Current": "56,651",
"Liabilities, Non-Current": "64,117",
"Other Assets": "45,173",
"Other Compr. Net Income": "1,540",
"Other Expenses": "75,235",
"Other Liabilities": "16,697",
"Other Net Income": "565",
"Other Revenues": "312,745",
"Property and Equipment": "264,240",
"Research and Development": "119,933",
"Selling, General and Administrative Expense": "87,883"
},
"output_variables": {
"Assets": "626,630",
"Liabilities": "137,465",
"Expenses": "283,051",
"Revenues": "312,745",
"Stockholders Equity": "489,165",
"Net Income": "30,259",
"Comprehensive Net Income": "31,029",
"BaseVar": "680,998",
"ECR before LimitedLiability": "287%",
"Economic Capital Ratio": "360%"
}
}
},
"top_rated": true,
"trend": -7.0,
"value": 3.601392499386015,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001367644.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001367644.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001367644.svg"
},
{
"company_id": "0000057725",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000057725.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000057725.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000057725.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000057725_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000057725_main_keyfigs.svg",
"name": "Lannett CO INC",
"rank": 42,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000057725.svg",
"report_text": "The relative strengths and weaknesses of Lannett CO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Lannett CO INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 93% points.The greatest weakness of Lannett CO INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 58% points.
The company's Economic Capital Ratio, given in the ranking table, is 358%, being 116% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000057725_2014_Lannett_CO_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "2.86",
"Assets": "3.32",
"Liabilities": "45.3",
"Stockholders Equity": "39.6",
"ECR before LimitedLiability": "172",
"Intangible Assets": "-7.63",
"Property and Equipment": "13.9",
"Assets, Current": "-3.80",
"Other Liabilities": "39.6",
"Liabilities, Current": "5.35",
"Research and Development": "33.7",
"Expenses": "14.8",
"Revenues": "39.5",
"Net Income": "58.4",
"Other Expenses": "11.7",
"Cost of Goods Sold": "-53.0",
"Selling, General and Administrative Expense": "22.2",
"Other Revenues": "39.5",
"Comprehensive Net Income": "58.0",
"Other Net Income": "3.04",
"Economic Capital Ratio": "96.6"
},
"2012": {
"Property and Equipment": "17.4",
"Assets": "-1.52",
"Liabilities": "88.8",
"Stockholders Equity": "60.5",
"ECR before LimitedLiability": "211",
"Assets, Current": "-7.91",
"Intangible Assets": "-6.55",
"Liabilities, Current": "40.9",
"Other Liabilities": "49.1",
"Liabilities, Non-Current": "7.10",
"Selling, General and Administrative Expense": "21.4",
"Expenses": "12.3",
"Revenues": "58.0",
"Net Income": "73.3",
"Research and Development": "29.1",
"Other Expenses": "19.9",
"Cost of Goods Sold": "-60.7",
"Other Revenues": "58.0",
"Comprehensive Net Income": "73.5",
"Other Net Income": "2.56",
"Economic Capital Ratio": "138"
},
"2013": {
"Other Assets": "-3.37",
"Assets": "-13.2",
"Liabilities": "93.5",
"Stockholders Equity": "25.4",
"ECR before LimitedLiability": "144",
"Intangible Assets": "-8.08",
"Property and Equipment": "15.9",
"Assets, Current": "-14.3",
"Liabilities, Non-Current": "9.20",
"Liabilities, Current": "37.4",
"Other Liabilities": "56.0",
"Other Revenues": "65.5",
"Revenues": "65.5",
"Net Income": "71.8",
"Selling, General and Administrative Expense": "20.9",
"Comprehensive Net Income": "71.4",
"Other Expenses": "12.8",
"Cost of Goods Sold": "-58.2",
"Other Net Income": "3.32",
"Research and Development": "24.8",
"Economic Capital Ratio": "116"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000057725_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "94,142",
"Cost of Goods Sold": "81,899",
"Intangible Assets": "5,910",
"Liabilities, Current": "34,860",
"Liabilities, Non-Current": "7,193",
"Other Assets": "17,763",
"Other Compr. Net Income": "0",
"Other Expenses": "1,155",
"Other Liabilities": "2.0",
"Other Net Income": "478",
"Other Revenues": "106,835",
"Property and Equipment": "29,929",
"Research and Development": "8,587",
"Selling, General and Administrative Expense": "15,912"
},
"output_variables": {
"Assets": "147,744",
"Liabilities": "42,055",
"Expenses": "107,553",
"Revenues": "106,835",
"Stockholders Equity": "105,689",
"Net Income": "-240",
"Comprehensive Net Income": "-240",
"BaseVar": "202,332",
"ECR before LimitedLiability": "243%",
"Economic Capital Ratio": "331%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "90,855",
"Cost of Goods Sold": "84,043",
"Intangible Assets": "4,429",
"Liabilities, Current": "24,766",
"Liabilities, Non-Current": "6,513",
"Other Assets": "10,240",
"Other Compr. Net Income": "-157",
"Other Expenses": "2,600",
"Other Liabilities": "0",
"Other Net Income": "-292",
"Other Revenues": "122,990",
"Property and Equipment": "37,068",
"Research and Development": "11,844",
"Selling, General and Administrative Expense": "20,193"
},
"output_variables": {
"Assets": "142,592",
"Liabilities": "31,279",
"Expenses": "118,680",
"Revenues": "122,990",
"Stockholders Equity": "111,313",
"Net Income": "4,018",
"Comprehensive Net Income": "3,940",
"BaseVar": "207,995",
"ECR before LimitedLiability": "284%",
"Economic Capital Ratio": "358%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "116,129",
"Cost of Goods Sold": "93,634",
"Intangible Assets": "2,547",
"Liabilities, Current": "33,099",
"Liabilities, Non-Current": "5,844",
"Other Assets": "8,935",
"Other Compr. Net Income": "-49",
"Other Expenses": "7,303",
"Other Liabilities": "0",
"Other Net Income": "1,928",
"Other Revenues": "151,054",
"Property and Equipment": "40,141",
"Research and Development": "16,253",
"Selling, General and Administrative Expense": "22,410"
},
"output_variables": {
"Assets": "167,752",
"Liabilities": "38,943",
"Expenses": "139,600",
"Revenues": "151,054",
"Stockholders Equity": "128,809",
"Net Income": "13,382",
"Comprehensive Net Income": "13,358",
"BaseVar": "249,663",
"ECR before LimitedLiability": "285%",
"Economic Capital Ratio": "358%"
}
}
},
"top_rated": true,
"trend": -6.0,
"value": 3.5840421991891454,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000057725.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000057725.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000057725.svg"
},
{
"company_id": "0001369786",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001369786.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001369786.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001369786_main_keyfigs.svg",
"name": "Sagent Pharmaceuticals Inc",
"rank": 43,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001369786.svg",
"report_text": "The relative strengths and weaknesses of Sagent Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Sagent Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 81% points.The greatest weakness of Sagent Pharmaceuticals Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 42% points.
The company's Economic Capital Ratio, given in the ranking table, is 357%, being 114% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001369786_2014_Sagent_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Liabilities": "37.0",
"Liabilities": "16.5",
"Stockholders Equity": "12.4",
"ECR before LimitedLiability": "128",
"Liabilities, Non-Current": "10.0",
"Liabilities, Current": "-33.9",
"Research and Development": "35.2",
"Expenses": "12.5",
"Net Income": "48.2",
"Other Expenses": "-46.9",
"Cost of Goods Sold": "4.47",
"Selling, General and Administrative Expense": "22.9",
"Other Revenues": "31.6",
"Revenues": "31.6",
"Other Assets": "0.808",
"Property and Equipment": "-9.13",
"Assets, Current": "26.1",
"Intangible Assets": "-12.1",
"Comprehensive Net Income": "48.1",
"Other Net Income": "2.85",
"Economic Capital Ratio": "52.8"
},
"2012": {
"Property and Equipment": "-8.22",
"Assets": "-17.5",
"Liabilities": "107",
"Stockholders Equity": "32.9",
"ECR before LimitedLiability": "192",
"Assets, Current": "-2.41",
"Intangible Assets": "-9.96",
"Liabilities, Current": "36.9",
"Other Liabilities": "55.1",
"Liabilities, Non-Current": "26.5",
"Selling, General and Administrative Expense": "24.5",
"Expenses": "-4.25",
"Revenues": "74.2",
"Net Income": "73.2",
"Research and Development": "34.3",
"Other Expenses": "-71.4",
"Cost of Goods Sold": "6.57",
"Other Revenues": "74.2",
"Comprehensive Net Income": "73.6",
"Other Net Income": "3.40",
"Economic Capital Ratio": "118"
},
"2013": {
"Other Assets": "-6.33",
"Assets": "-8.08",
"Liabilities": "81.2",
"Stockholders Equity": "33.7",
"ECR before LimitedLiability": "142",
"Intangible Assets": "-5.31",
"Property and Equipment": "10.9",
"Assets, Current": "-5.93",
"Liabilities, Non-Current": "17.6",
"Liabilities, Current": "28.0",
"Other Liabilities": "43.8",
"Selling, General and Administrative Expense": "20.2",
"Expenses": "8.71",
"Revenues": "55.1",
"Net Income": "68.8",
"Other Expenses": "-42.2",
"Research and Development": "25.7",
"Other Revenues": "55.1",
"Comprehensive Net Income": "68.1",
"Other Net Income": "4.66",
"Economic Capital Ratio": "114"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001369786_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "200,846",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,426",
"Liabilities, Current": "84,142",
"Liabilities, Non-Current": "4,697",
"Other Assets": "23,352",
"Other Compr. Net Income": "877",
"Other Expenses": "141,200",
"Other Liabilities": "0",
"Other Net Income": "284",
"Other Revenues": "152,405",
"Property and Equipment": "884",
"Research and Development": "12,763",
"Selling, General and Administrative Expense": "25,148"
},
"output_variables": {
"Assets": "230,508",
"Liabilities": "88,839",
"Expenses": "179,111",
"Revenues": "152,405",
"Stockholders Equity": "141,669",
"Net Income": "-26,422",
"Comprehensive Net Income": "-25,984",
"BaseVar": "326,012",
"ECR before LimitedLiability": "177%",
"Economic Capital Ratio": "287%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "147,268",
"Cost of Goods Sold": "0",
"Intangible Assets": "4,277",
"Liabilities, Current": "40,454",
"Liabilities, Non-Current": "6.0",
"Other Assets": "19,990",
"Other Compr. Net Income": "338",
"Other Expenses": "153,446",
"Other Liabilities": "0",
"Other Net Income": "243",
"Other Revenues": "183,615",
"Property and Equipment": "780",
"Research and Development": "17,136",
"Selling, General and Administrative Expense": "30,093"
},
"output_variables": {
"Assets": "172,315",
"Liabilities": "40,460",
"Expenses": "200,675",
"Revenues": "183,615",
"Stockholders Equity": "131,855",
"Net Income": "-16,817",
"Comprehensive Net Income": "-16,648",
"BaseVar": "298,823",
"ECR before LimitedLiability": "255%",
"Economic Capital Ratio": "339%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "235,791",
"Cost of Goods Sold": "0",
"Intangible Assets": "14,364",
"Liabilities, Current": "63,524",
"Liabilities, Non-Current": "2,329",
"Other Assets": "2,369",
"Other Compr. Net Income": "-2,013",
"Other Expenses": "166,658",
"Other Liabilities": "8,329",
"Other Net Income": "7,936",
"Other Revenues": "244,789",
"Property and Equipment": "57,684",
"Research and Development": "20,275",
"Selling, General and Administrative Expense": "36,198"
},
"output_variables": {
"Assets": "310,208",
"Liabilities": "74,182",
"Expenses": "223,131",
"Revenues": "244,789",
"Stockholders Equity": "236,026",
"Net Income": "29,594",
"Comprehensive Net Income": "28,588",
"BaseVar": "431,130",
"ECR before LimitedLiability": "283%",
"Economic Capital Ratio": "357%"
}
}
},
"top_rated": true,
"trend": 0.0,
"value": 3.570484042676285,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001369786.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001369786.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001369786.svg"
},
{
"company_id": "0001436304",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001436304.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001436304.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001436304_main_keyfigs.svg",
"name": "Kythera Biopharmaceuticals INC",
"rank": 44,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001436304.svg",
"report_text": "The relative strengths and weaknesses of Kythera Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Kythera Biopharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 149% points.The greatest weakness of Kythera Biopharmaceuticals INC is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.
The company's Economic Capital Ratio, given in the ranking table, is 355%, being 112% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001436304_2014_Kythera_Biopharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-6.78",
"Assets": "54.7",
"Liabilities": "18.4",
"Stockholders Equity": "91.0",
"ECR before LimitedLiability": "144",
"Assets, Current": "85.6",
"Intangible Assets": "-10.0",
"Other Assets": "4.10",
"Liabilities, Current": "10.1",
"Other Liabilities": "-6.02",
"Liabilities, Non-Current": "14.3",
"Selling, General and Administrative Expense": "13.5",
"Expenses": "10.3",
"Revenues": "-23.8",
"Net Income": "6.66",
"Research and Development": "-21.5",
"Other Expenses": "15.1",
"Other Revenues": "-23.8",
"Comprehensive Net Income": "6.82",
"Other Net Income": "21.0",
"Economic Capital Ratio": "71.2"
},
"2013": {
"Other Assets": "-4.06",
"Assets": "63.1",
"Liabilities": "44.4",
"Stockholders Equity": "149",
"ECR before LimitedLiability": "140",
"Intangible Assets": "-5.16",
"Property and Equipment": "-2.99",
"Assets, Current": "107",
"Liabilities, Non-Current": "11.6",
"Liabilities, Current": "17.9",
"Other Liabilities": "17.8",
"Selling, General and Administrative Expense": "7.65",
"Expenses": "13.2",
"Revenues": "-16.6",
"Net Income": "-2.01",
"Other Expenses": "7.82",
"Research and Development": "-4.34",
"Cost of Goods Sold": "2.11",
"Other Revenues": "-16.6",
"Comprehensive Net Income": "-2.19",
"Economic Capital Ratio": "112"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001436304_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "87,589",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "16,222",
"Liabilities, Non-Current": "0",
"Other Assets": "8,358",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "11,094",
"Other Net Income": "16,890",
"Other Revenues": "0",
"Property and Equipment": "275",
"Research and Development": "43,184",
"Selling, General and Administrative Expense": "10,505"
},
"output_variables": {
"Assets": "96,222",
"Liabilities": "27,316",
"Expenses": "53,689",
"Revenues": "0",
"Stockholders Equity": "68,906",
"Net Income": "-36,799",
"Comprehensive Net Income": "-36,799",
"BaseVar": "97,058",
"ECR before LimitedLiability": "184%",
"Economic Capital Ratio": "291%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "173,276",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "17,581",
"Liabilities, Non-Current": "0",
"Other Assets": "37",
"Other Compr. Net Income": "4.0",
"Other Expenses": "1,980",
"Other Liabilities": "5,987",
"Other Net Income": "135",
"Other Revenues": "0",
"Property and Equipment": "94",
"Research and Development": "33,974",
"Selling, General and Administrative Expense": "16,092"
},
"output_variables": {
"Assets": "173,407",
"Liabilities": "23,568",
"Expenses": "52,046",
"Revenues": "0",
"Stockholders Equity": "149,839",
"Net Income": "-51,911",
"Comprehensive Net Income": "-51,909",
"BaseVar": "124,580",
"ECR before LimitedLiability": "279%",
"Economic Capital Ratio": "355%"
}
}
},
"top_rated": true,
"trend": 29.0,
"value": 3.5464198962727655,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001436304.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001436304.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001436304.svg"
},
{
"company_id": "0001117480",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001117480.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001117480.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001117480.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001117480_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001117480_main_keyfigs.svg",
"name": "Chimerix INC",
"rank": 45,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001117480.svg",
"report_text": "The relative strengths and weaknesses of Chimerix INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Chimerix INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 145% points.The greatest weakness of Chimerix INC is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.
The company's Economic Capital Ratio, given in the ranking table, is 354%, being 111% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001117480_2014_Chimerix_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-4.34",
"Assets": "55.2",
"Liabilities": "51.8",
"Stockholders Equity": "145",
"ECR before LimitedLiability": "139",
"Intangible Assets": "-5.52",
"Property and Equipment": "-2.99",
"Assets, Current": "96.6",
"Liabilities, Non-Current": "11.1",
"Liabilities, Current": "25.8",
"Other Liabilities": "18.5",
"Selling, General and Administrative Expense": "11.1",
"Expenses": "9.43",
"Revenues": "-13.1",
"Net Income": "-2.47",
"Other Expenses": "1.73",
"Research and Development": "-5.70",
"Cost of Goods Sold": "2.25",
"Other Revenues": "-13.1",
"Comprehensive Net Income": "-2.67",
"Economic Capital Ratio": "111"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001117480_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "113,009",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "10,207",
"Liabilities, Non-Current": "347",
"Other Assets": "40",
"Other Compr. Net Income": "0",
"Other Expenses": "7,822",
"Other Liabilities": "4,294",
"Other Net Income": "-4.0",
"Other Revenues": "4,370",
"Property and Equipment": "338",
"Research and Development": "24,662",
"Selling, General and Administrative Expense": "8,327"
},
"output_variables": {
"Assets": "113,387",
"Liabilities": "14,848",
"Expenses": "40,811",
"Revenues": "4,370",
"Stockholders Equity": "98,539",
"Net Income": "-36,445",
"Comprehensive Net Income": "-36,445",
"BaseVar": "86,710",
"ECR before LimitedLiability": "278%",
"Economic Capital Ratio": "354%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.541342557382003,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001117480.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001117480.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001117480.svg"
},
{
"company_id": "0001274644",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001274644.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001274644.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001274644_main_keyfigs.svg",
"name": "Ocera Therapeutics Inc",
"rank": 46,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001274644.svg",
"report_text": "The relative strengths and weaknesses of Ocera Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ocera Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 151% points.The greatest weakness of Ocera Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.
The company's Economic Capital Ratio, given in the ranking table, is 353%, being 110% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001274644_2014_Ocera_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-14.1",
"Assets": "32.5",
"Liabilities": "-23.0",
"Stockholders Equity": "17.7",
"ECR before LimitedLiability": "68.5",
"Intangible Assets": "-18.2",
"Property and Equipment": "-7.43",
"Assets, Current": "86.6",
"Other Liabilities": "-41.3",
"Liabilities, Non-Current": "13.2",
"Liabilities, Current": "3.66",
"Research and Development": "-23.4",
"Expenses": "4.49",
"Revenues": "-8.06",
"Comprehensive Net Income": "-1.15",
"Other Expenses": "8.01",
"Cost of Goods Sold": "4.22",
"Selling, General and Administrative Expense": "16.9",
"Other Revenues": "-8.06",
"Other Net Income": "2.88",
"Economic Capital Ratio": "-7.07"
},
"2012": {
"Property and Equipment": "-9.86",
"Assets": "-41.3",
"Liabilities": "75.5",
"Stockholders Equity": "63.9",
"ECR before LimitedLiability": "66.8",
"Assets, Current": "19.0",
"Intangible Assets": "-29.3",
"Other Assets": "-21.8",
"Liabilities, Current": "56.0",
"Other Liabilities": "54.3",
"Liabilities, Non-Current": "26.7",
"Expenses": "-74.2",
"Revenues": "13.2",
"Net Income": "-69.0",
"Research and Development": "-96.2",
"Other Expenses": "14.8",
"Cost of Goods Sold": "8.70",
"Other Revenues": "13.2",
"Comprehensive Net Income": "-68.6",
"Other Net Income": "-6.65",
"Economic Capital Ratio": "-6.32"
},
"2013": {
"Other Assets": "-1.63",
"Assets": "61.5",
"Liabilities": "48.8",
"Stockholders Equity": "151",
"ECR before LimitedLiability": "138",
"Intangible Assets": "-3.84",
"Property and Equipment": "-3.07",
"Assets, Current": "88.3",
"Liabilities, Non-Current": "11.8",
"Liabilities, Current": "8.37",
"Other Liabilities": "31.4",
"Expenses": "14.7",
"Revenues": "-16.8",
"Net Income": "-5.78",
"Other Expenses": "1.82",
"Research and Development": "11.0",
"Cost of Goods Sold": "2.17",
"Other Revenues": "-16.8",
"Comprehensive Net Income": "-5.97",
"Other Net Income": "-3.83",
"Economic Capital Ratio": "110"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001274644_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "43,540",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,332",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,589",
"Other Liabilities": "10,897",
"Other Net Income": "126",
"Other Revenues": "10,167",
"Property and Equipment": "1,171",
"Research and Development": "24,884",
"Selling, General and Administrative Expense": "6,028"
},
"output_variables": {
"Assets": "44,711",
"Liabilities": "20,229",
"Expenses": "32,501",
"Revenues": "10,167",
"Stockholders Equity": "24,482",
"Net Income": "-22,208",
"Comprehensive Net Income": "-22,208",
"BaseVar": "53,867",
"ECR before LimitedLiability": "96%",
"Economic Capital Ratio": "227%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "16,586",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,117",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "18",
"Other Expenses": "2,377",
"Other Liabilities": "137",
"Other Net Income": "-1,373",
"Other Revenues": "8,447",
"Property and Equipment": "942",
"Research and Development": "20,980",
"Selling, General and Administrative Expense": "6,561"
},
"output_variables": {
"Assets": "17,528",
"Liabilities": "3,254",
"Expenses": "29,918",
"Revenues": "8,447",
"Stockholders Equity": "14,274",
"Net Income": "-22,844",
"Comprehensive Net Income": "-22,835",
"BaseVar": "30,269",
"ECR before LimitedLiability": "80%",
"Economic Capital Ratio": "214%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "49,292",
"Cost of Goods Sold": "0",
"Intangible Assets": "930",
"Liabilities, Current": "6,687",
"Liabilities, Non-Current": "0",
"Other Assets": "1,539",
"Other Compr. Net Income": "3.0",
"Other Expenses": "3,365",
"Other Liabilities": "1.0",
"Other Net Income": "-2,185",
"Other Revenues": "85",
"Property and Equipment": "59",
"Research and Development": "3,549",
"Selling, General and Administrative Expense": "8,500"
},
"output_variables": {
"Assets": "51,820",
"Liabilities": "6,688",
"Expenses": "15,414",
"Revenues": "85",
"Stockholders Equity": "45,132",
"Net Income": "-17,514",
"Comprehensive Net Income": "-17,512",
"BaseVar": "38,098",
"ECR before LimitedLiability": "276%",
"Economic Capital Ratio": "353%"
}
}
},
"top_rated": true,
"trend": 72.0,
"value": 3.5298707714366593,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001274644.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001274644.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001274644.svg"
},
{
"company_id": "0001080709",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001080709.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001080709.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001080709_main_keyfigs.svg",
"name": "Arena Pharmaceuticals INC",
"rank": 47,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001080709.svg",
"report_text": "The relative strengths and weaknesses of Arena Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Arena Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 98% points.The greatest weakness of Arena Pharmaceuticals INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 11% points.
The company's Economic Capital Ratio, given in the ranking table, is 353%, being 110% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001080709_2014_Arena_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.83",
"Assets": "54.4",
"Liabilities": "75.6",
"Stockholders Equity": "160",
"ECR before LimitedLiability": "168",
"Intangible Assets": "-1.97",
"Property and Equipment": "108",
"Assets, Current": "-10.9",
"Other Liabilities": "33.4",
"Liabilities, Non-Current": "14.6",
"Liabilities, Current": "33.3",
"Research and Development": "-12.2",
"Expenses": "1.53",
"Revenues": "-19.6",
"Net Income": "-36.2",
"Cost of Goods Sold": "3.73",
"Selling, General and Administrative Expense": "9.17",
"Other Revenues": "-19.6",
"Comprehensive Net Income": "-36.5",
"Other Net Income": "-18.0",
"Economic Capital Ratio": "92.0"
},
"2012": {
"Property and Equipment": "27.3",
"Assets": "59.7",
"Liabilities": "62.0",
"Stockholders Equity": "165",
"ECR before LimitedLiability": "214",
"Assets, Current": "26.1",
"Intangible Assets": "-2.15",
"Other Assets": "-2.71",
"Liabilities, Current": "20.3",
"Other Liabilities": "31.9",
"Liabilities, Non-Current": "15.2",
"Selling, General and Administrative Expense": "11.0",
"Expenses": "25.2",
"Revenues": "-9.71",
"Net Income": "4.49",
"Other Expenses": "11.6",
"Cost of Goods Sold": "3.51",
"Other Revenues": "-9.71",
"Comprehensive Net Income": "4.81",
"Other Net Income": "-11.3",
"Economic Capital Ratio": "141"
},
"2013": {
"Other Assets": "-3.94",
"Assets": "34.3",
"Liabilities": "37.1",
"Stockholders Equity": "98.4",
"ECR before LimitedLiability": "138",
"Intangible Assets": "-3.61",
"Property and Equipment": "19.1",
"Assets, Current": "21.0",
"Liabilities, Non-Current": "13.2",
"Liabilities, Current": "-11.5",
"Other Liabilities": "35.0",
"Selling, General and Administrative Expense": "11.1",
"Expenses": "22.0",
"Revenues": "7.22",
"Net Income": "31.6",
"Other Expenses": "8.57",
"Cost of Goods Sold": "2.43",
"Other Revenues": "7.22",
"Comprehensive Net Income": "31.4",
"Other Net Income": "2.38",
"Economic Capital Ratio": "110"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001080709_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "60,260",
"Cost of Goods Sold": "0",
"Intangible Assets": "11,032",
"Liabilities, Current": "14,360",
"Liabilities, Non-Current": "0",
"Other Assets": "3,771",
"Other Compr. Net Income": "0",
"Other Expenses": "12,564",
"Other Liabilities": "0",
"Other Net Income": "-26,425",
"Other Revenues": "12,719",
"Property and Equipment": "82,066",
"Research and Development": "58,706",
"Selling, General and Administrative Expense": "24,248"
},
"output_variables": {
"Assets": "157,129",
"Liabilities": "14,360",
"Expenses": "95,518",
"Revenues": "12,719",
"Stockholders Equity": "142,769",
"Net Income": "-109,224",
"Comprehensive Net Income": "-109,224",
"BaseVar": "153,076",
"ECR before LimitedLiability": "236%",
"Economic Capital Ratio": "326%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "171,159",
"Cost of Goods Sold": "0",
"Intangible Assets": "10,611",
"Liabilities, Current": "29,914",
"Liabilities, Non-Current": "0",
"Other Assets": "4,019",
"Other Compr. Net Income": "746",
"Other Expenses": "4,362",
"Other Liabilities": "0",
"Other Net Income": "-28,364",
"Other Revenues": "27,587",
"Property and Equipment": "75,417",
"Research and Development": "54,112",
"Selling, General and Administrative Expense": "26,226"
},
"output_variables": {
"Assets": "261,206",
"Liabilities": "29,914",
"Expenses": "84,700",
"Revenues": "27,587",
"Stockholders Equity": "231,292",
"Net Income": "-85,477",
"Comprehensive Net Income": "-85,104",
"BaseVar": "216,258",
"ECR before LimitedLiability": "288%",
"Economic Capital Ratio": "361%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "248,810",
"Cost of Goods Sold": "0",
"Intangible Assets": "10,182",
"Liabilities, Current": "70,744",
"Liabilities, Non-Current": "0",
"Other Assets": "3,427",
"Other Compr. Net Income": "239",
"Other Expenses": "6,180",
"Other Liabilities": "0",
"Other Net Income": "3,500",
"Other Revenues": "81,394",
"Property and Equipment": "77,388",
"Research and Development": "66,468",
"Selling, General and Administrative Expense": "31,681"
},
"output_variables": {
"Assets": "339,807",
"Liabilities": "70,744",
"Expenses": "104,329",
"Revenues": "81,394",
"Stockholders Equity": "269,063",
"Net Income": "-19,435",
"Comprehensive Net Income": "-19,316",
"BaseVar": "300,006",
"ECR before LimitedLiability": "276%",
"Economic Capital Ratio": "353%"
}
}
},
"top_rated": true,
"trend": -16.0,
"value": 3.529031788807642,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001080709.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001080709.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001080709.svg"
},
{
"company_id": "0001466301",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001466301.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001466301.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001466301.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001466301_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001466301_main_keyfigs.svg",
"name": "Clovis Oncology Inc",
"rank": 48,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001466301.svg",
"report_text": "The relative strengths and weaknesses of Clovis Oncology Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Clovis Oncology Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 121% points.The greatest weakness of Clovis Oncology Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 58% points.
The company's Economic Capital Ratio, given in the ranking table, is 349%, being 107% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001466301_2014_Clovis_Oncology_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-3.33",
"Assets": "76.8",
"Liabilities": "-5.42",
"Stockholders Equity": "121",
"ECR before LimitedLiability": "135",
"Intangible Assets": "60.9",
"Property and Equipment": "-2.42",
"Assets, Current": "13.0",
"Liabilities, Non-Current": "9.08",
"Liabilities, Current": "33.0",
"Other Liabilities": "-58.0",
"Selling, General and Administrative Expense": "7.98",
"Expenses": "38.3",
"Revenues": "-13.1",
"Net Income": "25.9",
"Other Expenses": "51.5",
"Research and Development": "-22.9",
"Cost of Goods Sold": "1.67",
"Other Revenues": "-13.1",
"Comprehensive Net Income": "26.1",
"Economic Capital Ratio": "107"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001466301_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "328,596",
"Cost of Goods Sold": "0",
"Intangible Assets": "319,329",
"Liabilities, Current": "20,952",
"Liabilities, Non-Current": "88",
"Other Assets": "755",
"Other Compr. Net Income": "4,696",
"Other Expenses": "-267,359",
"Other Liabilities": "130,709",
"Other Net Income": "-1,146",
"Other Revenues": "0",
"Property and Equipment": "955",
"Research and Development": "226,835",
"Selling, General and Administrative Expense": "40,576"
},
"output_variables": {
"Assets": "649,635",
"Liabilities": "151,749",
"Expenses": "52",
"Revenues": "0",
"Stockholders Equity": "497,886",
"Net Income": "-1,198",
"Comprehensive Net Income": "1,150",
"BaseVar": "403,639",
"ECR before LimitedLiability": "271%",
"Economic Capital Ratio": "349%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.4948968955252675,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001466301.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001466301.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001466301.svg"
},
{
"company_id": "0001447028",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001447028.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001447028.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001447028.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001447028_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001447028_main_keyfigs.svg",
"name": "Arbutus Biopharma Corp",
"rank": 49,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001447028.svg",
"report_text": "The relative strengths and weaknesses of Arbutus Biopharma Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Arbutus Biopharma Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 107% points.The greatest weakness of Arbutus Biopharma Corp is the variable Research and Development, reducing the Economic Capital Ratio by 11% points.
The company's Economic Capital Ratio, given in the ranking table, is 348%, being 105% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001447028_2014_Arbutus_Biopharma_Corp.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-5.31",
"Assets": "32.1",
"Liabilities": "53.4",
"Stockholders Equity": "107",
"ECR before LimitedLiability": "133",
"Intangible Assets": "-6.70",
"Assets, Current": "63.1",
"Liabilities, Non-Current": "14.0",
"Liabilities, Current": "5.11",
"Other Liabilities": "37.1",
"Selling, General and Administrative Expense": "14.2",
"Expenses": "16.4",
"Revenues": "3.85",
"Net Income": "18.6",
"Other Expenses": "10.4",
"Research and Development": "-10.7",
"Cost of Goods Sold": "2.61",
"Other Revenues": "3.85",
"Comprehensive Net Income": "16.0",
"Other Compr. Net Income": "-2.69",
"Economic Capital Ratio": "105"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001447028_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "70,343",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "12,522",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-3,135",
"Other Expenses": "613",
"Other Liabilities": "0",
"Other Net Income": "-1,911",
"Other Revenues": "15,464",
"Property and Equipment": "1,373",
"Research and Development": "21,458",
"Selling, General and Administrative Expense": "5,546"
},
"output_variables": {
"Assets": "71,716",
"Liabilities": "12,522",
"Expenses": "27,617",
"Revenues": "15,464",
"Stockholders Equity": "59,193",
"Net Income": "-14,064",
"Comprehensive Net Income": "-15,632",
"BaseVar": "66,183",
"ECR before LimitedLiability": "269%",
"Economic Capital Ratio": "348%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.4823132411033506,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001447028.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001447028.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001447028.svg"
},
{
"company_id": "0001439222",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001439222.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001439222.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001439222.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001439222_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001439222_main_keyfigs.svg",
"name": "Agios Pharmaceuticals INC",
"rank": 50,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001439222.svg",
"report_text": "The relative strengths and weaknesses of Agios Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Agios Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 117% points.The greatest weakness of Agios Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 10% points.
The company's Economic Capital Ratio, given in the ranking table, is 347%, being 104% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001439222_2014_Agios_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "8.58",
"Assets": "46.7",
"Liabilities": "37.9",
"Stockholders Equity": "117",
"ECR before LimitedLiability": "132",
"Intangible Assets": "-5.98",
"Property and Equipment": "-1.86",
"Assets, Current": "47.1",
"Liabilities, Non-Current": "12.4",
"Liabilities, Current": "-6.94",
"Other Liabilities": "32.8",
"Selling, General and Administrative Expense": "14.6",
"Expenses": "16.4",
"Revenues": "-3.74",
"Net Income": "13.9",
"Other Expenses": "9.63",
"Research and Development": "-10.1",
"Cost of Goods Sold": "2.29",
"Other Revenues": "-3.74",
"Comprehensive Net Income": "13.7",
"Economic Capital Ratio": "104"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001439222_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "169,747",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "36,930",
"Liabilities, Non-Current": "0",
"Other Assets": "27,700",
"Other Compr. Net Income": "16",
"Other Expenses": "579",
"Other Liabilities": "0",
"Other Net Income": "55",
"Other Revenues": "25,548",
"Property and Equipment": "3,758",
"Research and Development": "54,502",
"Selling, General and Administrative Expense": "9,929"
},
"output_variables": {
"Assets": "201,205",
"Liabilities": "36,930",
"Expenses": "65,010",
"Revenues": "25,548",
"Stockholders Equity": "164,275",
"Net Income": "-39,407",
"Comprehensive Net Income": "-39,399",
"BaseVar": "164,382",
"ECR before LimitedLiability": "268%",
"Economic Capital Ratio": "347%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.4718974611500326,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001439222.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001439222.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001439222.svg"
},
{
"company_id": "0000038074",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000038074.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000038074.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000038074_main_keyfigs.svg",
"name": "Forest Laboratories LLC",
"rank": 51,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000038074.svg",
"report_text": "The relative strengths and weaknesses of Forest Laboratories LLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Forest Laboratories LLC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 69% points.The greatest weakness of Forest Laboratories LLC is the variable Assets, Current, reducing the Economic Capital Ratio by 18% points.
The company's Economic Capital Ratio, given in the ranking table, is 344%, being 101% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000038074_2014_Forest_Laboratories_LLC.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "20.4",
"Assets": "-5.80",
"Liabilities": "71.7",
"Stockholders Equity": "19.0",
"ECR before LimitedLiability": "59.3",
"Other Assets": "1.41",
"Intangible Assets": "-14.1",
"Property and Equipment": "-5.31",
"Liabilities, Current": "16.9",
"Other Liabilities": "26.7",
"Liabilities, Non-Current": "36.4",
"Cost of Goods Sold": "0.794",
"Expenses": "-15.5",
"Revenues": "19.4",
"Net Income": "4.15",
"Selling, General and Administrative Expense": "-11.0",
"Research and Development": "-4.46",
"Other Revenues": "19.4",
"Comprehensive Net Income": "3.18",
"Other Compr. Net Income": "-0.977",
"Economic Capital Ratio": "60.2"
},
"2010": {
"Other Assets": "0.970",
"Assets": "-0.813",
"Liabilities": "88.6",
"Stockholders Equity": "57.1",
"ECR before LimitedLiability": "113",
"Assets, Current": "15.5",
"Property and Equipment": "-4.75",
"Intangible Assets": "-8.36",
"Liabilities, Current": "13.9",
"Other Liabilities": "47.4",
"Liabilities, Non-Current": "38.9",
"Selling, General and Administrative Expense": "1.95",
"Expenses": "-3.46",
"Revenues": "26.5",
"Net Income": "23.9",
"Research and Development": "-3.45",
"Cost of Goods Sold": "6.21",
"Other Expenses": "-8.26",
"Other Revenues": "26.5",
"Comprehensive Net Income": "24.4",
"Economic Capital Ratio": "106"
},
"2011": {
"Other Assets": "0.606",
"Assets": "14.2",
"Liabilities": "57.4",
"Stockholders Equity": "80.3",
"ECR before LimitedLiability": "219",
"Property and Equipment": "-1.31",
"Assets, Current": "14.9",
"Other Liabilities": "-47.9",
"Liabilities, Non-Current": "17.8",
"Liabilities, Current": "74.9",
"Research and Development": "24.7",
"Expenses": "28.3",
"Revenues": "38.2",
"Net Income": "68.7",
"Other Expenses": "-8.72",
"Cost of Goods Sold": "4.13",
"Selling, General and Administrative Expense": "8.14",
"Other Revenues": "38.2",
"Comprehensive Net Income": "68.4",
"Other Net Income": "2.53",
"Economic Capital Ratio": "143"
},
"2012": {
"Property and Equipment": "-1.30",
"Assets": "17.1",
"Liabilities": "52.4",
"Stockholders Equity": "78.9",
"ECR before LimitedLiability": "213",
"Assets, Current": "-8.39",
"Intangible Assets": "29.1",
"Other Assets": "2.54",
"Liabilities, Current": "39.2",
"Other Liabilities": "-3.72",
"Liabilities, Non-Current": "19.0",
"Selling, General and Administrative Expense": "6.90",
"Expenses": "29.4",
"Revenues": "37.0",
"Net Income": "69.1",
"Research and Development": "18.7",
"Cost of Goods Sold": "4.44",
"Other Revenues": "37.0",
"Comprehensive Net Income": "69.2",
"Other Net Income": "2.20",
"Economic Capital Ratio": "140"
},
"2013": {
"Other Assets": "12.7",
"Assets": "18.6",
"Liabilities": "40.3",
"Stockholders Equity": "69.1",
"ECR before LimitedLiability": "129",
"Intangible Assets": "34.2",
"Assets, Current": "-18.3",
"Liabilities, Non-Current": "13.0",
"Liabilities, Current": "27.7",
"Other Liabilities": "0.988",
"Selling, General and Administrative Expense": "2.58",
"Expenses": "19.3",
"Revenues": "21.3",
"Net Income": "42.8",
"Other Expenses": "3.17",
"Research and Development": "10.8",
"Cost of Goods Sold": "2.75",
"Other Revenues": "21.3",
"Comprehensive Net Income": "42.6",
"Other Net Income": "1.87",
"Economic Capital Ratio": "101"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000038074_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "3,785,954",
"Cost of Goods Sold": "0",
"Intangible Assets": "512,862",
"Liabilities, Current": "817,828",
"Liabilities, Non-Current": "0",
"Other Assets": "552,057",
"Other Compr. Net Income": "-81,737",
"Other Expenses": "1,019,471",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "3,922,782",
"Property and Equipment": "345,935",
"Research and Development": "661,294",
"Selling, General and Administrative Expense": "1,474,274"
},
"output_variables": {
"Assets": "5,196,808",
"Liabilities": "817,828",
"Expenses": "3,155,039",
"Revenues": "3,922,782",
"Stockholders Equity": "4,378,980",
"Net Income": "767,743",
"Comprehensive Net Income": "726,874",
"BaseVar": "6,587,097",
"ECR before LimitedLiability": "342%",
"Economic Capital Ratio": "397%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "4,579,191",
"Cost of Goods Sold": "0",
"Intangible Assets": "481,707",
"Liabilities, Current": "979,646",
"Liabilities, Non-Current": "0",
"Other Assets": "839,349",
"Other Compr. Net Income": "50,840",
"Other Expenses": "1,192,649",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "4,192,862",
"Property and Equipment": "323,284",
"Research and Development": "1,053,561",
"Selling, General and Administrative Expense": "1,264,269"
},
"output_variables": {
"Assets": "6,223,531",
"Liabilities": "979,646",
"Expenses": "3,510,479",
"Revenues": "4,192,862",
"Stockholders Equity": "5,243,885",
"Net Income": "682,383",
"Comprehensive Net Income": "707,803",
"BaseVar": "7,478,679",
"ECR before LimitedLiability": "337%",
"Economic Capital Ratio": "394%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "5,259,673",
"Cost of Goods Sold": "0",
"Intangible Assets": "740,459",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "602,556",
"Other Compr. Net Income": "4,301",
"Other Expenses": "1,254,947",
"Other Liabilities": "1,423,574",
"Other Net Income": "0",
"Other Revenues": "4,419,700",
"Property and Equipment": "319,766",
"Research and Development": "715,872",
"Selling, General and Administrative Expense": "1,402,111"
},
"output_variables": {
"Assets": "6,922,454",
"Liabilities": "1,423,574",
"Expenses": "3,372,930",
"Revenues": "4,419,700",
"Stockholders Equity": "5,498,880",
"Net Income": "1,046,770",
"Comprehensive Net Income": "1,048,920",
"BaseVar": "8,071,480",
"ECR before LimitedLiability": "312%",
"Economic Capital Ratio": "377%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "3,586,195",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,817,139",
"Liabilities, Current": "899,786",
"Liabilities, Non-Current": "0",
"Other Assets": "728,401",
"Other Compr. Net Income": "-4,601",
"Other Expenses": "1,257,092",
"Other Liabilities": "915,152",
"Other Net Income": "0",
"Other Revenues": "4,599,470",
"Property and Equipment": "360,020",
"Research and Development": "810,258",
"Selling, General and Administrative Expense": "1,534,527"
},
"output_variables": {
"Assets": "7,491,755",
"Liabilities": "1,814,938",
"Expenses": "3,601,876",
"Revenues": "4,599,470",
"Stockholders Equity": "5,676,817",
"Net Income": "997,594",
"Comprehensive Net Income": "995,293",
"BaseVar": "8,756,320",
"ECR before LimitedLiability": "287%",
"Economic Capital Ratio": "360%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,947,786",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,840,730",
"Liabilities, Current": "997,691",
"Liabilities, Non-Current": "36,080",
"Other Assets": "1,464,106",
"Other Compr. Net Income": "2,945",
"Other Expenses": "505,983",
"Other Liabilities": "850,556",
"Other Net Income": "32,123",
"Other Revenues": "3,001,160",
"Property and Equipment": "376,960",
"Research and Development": "995,068",
"Selling, General and Administrative Expense": "1,557,695"
},
"output_variables": {
"Assets": "7,629,582",
"Liabilities": "1,884,327",
"Expenses": "3,058,745",
"Revenues": "3,001,160",
"Stockholders Equity": "5,745,255",
"Net Income": "-25,462",
"Comprehensive Net Income": "-23,990",
"BaseVar": "7,804,441",
"ECR before LimitedLiability": "263%",
"Economic Capital Ratio": "344%"
}
}
},
"top_rated": true,
"trend": -18.0,
"value": 3.439427667898363,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000038074.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000038074.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000038074.svg"
},
{
"company_id": "0000025743",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000025743.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000025743.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000025743.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000025743_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000025743_main_keyfigs.svg",
"name": "Therapeuticsmd Inc",
"rank": 52,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000025743.svg",
"report_text": "The relative strengths and weaknesses of Therapeuticsmd Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Therapeuticsmd Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 131% points.The greatest weakness of Therapeuticsmd Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 12% points.
The company's Economic Capital Ratio, given in the ranking table, is 343%, being 101% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000025743_2014_Therapeuticsmd_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-16.3",
"Assets": "-100",
"Liabilities": "-2.43",
"Stockholders Equity": "-130",
"ECR before LimitedLiability": "-119",
"Intangible Assets": "-29.9",
"Property and Equipment": "-15.4",
"Assets, Current": "-85.6",
"Other Liabilities": "1.12",
"Liabilities, Current": "-6.55",
"Research and Development": "17.3",
"Expenses": "-39.8",
"Revenues": "3.33",
"Net Income": "-33.1",
"Other Expenses": "-4.17",
"Cost of Goods Sold": "2.42",
"Selling, General and Administrative Expense": "-65.3",
"Other Revenues": "3.33",
"Comprehensive Net Income": "-33.4",
"Other Net Income": "1.49",
"Economic Capital Ratio": "-195"
},
"2012": {
"Property and Equipment": "-16.8",
"Assets": "-69.0",
"Liabilities": "-3.99",
"Stockholders Equity": "-70.0",
"ECR before LimitedLiability": "-76.7",
"Assets, Current": "-60.3",
"Intangible Assets": "-24.9",
"Other Assets": "3.39",
"Liabilities, Current": "0.478",
"Other Liabilities": "5.53",
"Liabilities, Non-Current": "-13.8",
"Selling, General and Administrative Expense": "-48.8",
"Expenses": "-40.9",
"Revenues": "-1.70",
"Net Income": "-41.0",
"Other Expenses": "5.75",
"Cost of Goods Sold": "3.31",
"Other Revenues": "-1.70",
"Comprehensive Net Income": "-40.8",
"Other Net Income": "1.64",
"Economic Capital Ratio": "-150"
},
"2013": {
"Other Assets": "-2.95",
"Assets": "34.8",
"Liabilities": "74.6",
"Stockholders Equity": "131",
"ECR before LimitedLiability": "129",
"Intangible Assets": "-6.38",
"Property and Equipment": "-4.26",
"Assets, Current": "64.5",
"Liabilities, Non-Current": "14.7",
"Liabilities, Current": "27.5",
"Other Liabilities": "38.7",
"Selling, General and Administrative Expense": "-12.0",
"Expenses": "-2.59",
"Revenues": "-4.85",
"Net Income": "-11.0",
"Other Expenses": "8.15",
"Cost of Goods Sold": "2.75",
"Other Revenues": "-4.85",
"Comprehensive Net Income": "-11.2",
"Other Net Income": "-3.54",
"Economic Capital Ratio": "101"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000025743_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,237",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,151",
"Liabilities, Non-Current": "0",
"Other Assets": "131",
"Other Compr. Net Income": "0",
"Other Expenses": "1,002",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "2,088",
"Property and Equipment": "70",
"Research and Development": "107",
"Selling, General and Administrative Expense": "6,406"
},
"output_variables": {
"Assets": "1,439",
"Liabilities": "3,151",
"Expenses": "7,515",
"Revenues": "2,088",
"Stockholders Equity": "-1,712",
"Net Income": "-5,427",
"Comprehensive Net Income": "-5,427",
"BaseVar": "7,096",
"ECR before LimitedLiability": "-399%",
"Economic Capital Ratio": "39%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "4,527",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,512",
"Liabilities, Non-Current": "3,739",
"Other Assets": "1,225",
"Other Compr. Net Income": "0",
"Other Expenses": "1,404",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "3,818",
"Property and Equipment": "66",
"Research and Development": "4,492",
"Selling, General and Administrative Expense": "14,070"
},
"output_variables": {
"Assets": "5,818",
"Liabilities": "7,251",
"Expenses": "19,966",
"Revenues": "3,818",
"Stockholders Equity": "-1,433",
"Net Income": "-16,148",
"Comprehensive Net Income": "-16,148",
"BaseVar": "18,427",
"ECR before LimitedLiability": "-295%",
"Economic Capital Ratio": "70%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "59,403",
"Cost of Goods Sold": "0",
"Intangible Assets": "666",
"Liabilities, Current": "7,318",
"Liabilities, Non-Current": "0",
"Other Assets": "1,886",
"Other Compr. Net Income": "0",
"Other Expenses": "2,018",
"Other Liabilities": "0",
"Other Net Income": "-2,611",
"Other Revenues": "8,776",
"Property and Equipment": "61",
"Research and Development": "13,551",
"Selling, General and Administrative Expense": "19,015"
},
"output_variables": {
"Assets": "62,016",
"Liabilities": "7,318",
"Expenses": "34,584",
"Revenues": "8,776",
"Stockholders Equity": "54,698",
"Net Income": "-28,419",
"Comprehensive Net Income": "-28,419",
"BaseVar": "57,652",
"ECR before LimitedLiability": "262%",
"Economic Capital Ratio": "343%"
}
}
},
"top_rated": true,
"trend": 131.0,
"value": 3.4343714466241493,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000025743.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000025743.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000025743.svg"
},
{
"company_id": "0000899866",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000899866.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000899866.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000899866_main_keyfigs.svg",
"name": "Alexion Pharmaceuticals INC",
"rank": 53,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000899866.svg",
"report_text": "The relative strengths and weaknesses of Alexion Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Alexion Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 55% points.The greatest weakness of Alexion Pharmaceuticals INC is the variable Other Assets, reducing the Economic Capital Ratio by 4.4% points.
The company's Economic Capital Ratio, given in the ranking table, is 339%, being 96% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000899866_2014_Alexion_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "3.22",
"Assets": "6.70",
"Liabilities": "76.8",
"Stockholders Equity": "77.1",
"ECR before LimitedLiability": "114",
"Assets, Current": "12.3",
"Property and Equipment": "2.35",
"Intangible Assets": "-8.58",
"Liabilities, Current": "13.4",
"Other Liabilities": "41.1",
"Liabilities, Non-Current": "31.4",
"Selling, General and Administrative Expense": "-3.74",
"Expenses": "4.24",
"Revenues": "16.5",
"Net Income": "21.2",
"Research and Development": "3.25",
"Cost of Goods Sold": "5.53",
"Other Expenses": "-0.833",
"Other Revenues": "16.5",
"Comprehensive Net Income": "21.2",
"Economic Capital Ratio": "108"
},
"2012": {
"Assets": "30.0",
"Liabilities": "35.8",
"Stockholders Equity": "90.6",
"ECR before LimitedLiability": "208",
"Assets, Current": "4.32",
"Intangible Assets": "27.6",
"Other Assets": "-3.10",
"Liabilities, Current": "23.7",
"Other Liabilities": "14.1",
"Liabilities, Non-Current": "-0.806",
"Selling, General and Administrative Expense": "9.80",
"Expenses": "32.8",
"Revenues": "21.4",
"Net Income": "58.6",
"Research and Development": "17.3",
"Other Expenses": "1.90",
"Cost of Goods Sold": "3.89",
"Other Revenues": "21.4",
"Comprehensive Net Income": "58.9",
"Other Net Income": "4.11",
"Economic Capital Ratio": "135"
},
"2013": {
"Other Assets": "-4.41",
"Assets": "15.1",
"Liabilities": "32.4",
"Stockholders Equity": "55.0",
"ECR before LimitedLiability": "124",
"Intangible Assets": "18.4",
"Assets, Current": "1.13",
"Liabilities, Non-Current": "3.04",
"Liabilities, Current": "14.8",
"Other Liabilities": "15.8",
"Selling, General and Administrative Expense": "9.20",
"Expenses": "23.7",
"Revenues": "26.4",
"Net Income": "51.9",
"Other Expenses": "-2.92",
"Research and Development": "14.6",
"Cost of Goods Sold": "2.78",
"Other Revenues": "26.4",
"Comprehensive Net Income": "51.1",
"Other Net Income": "1.22",
"Economic Capital Ratio": "96.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000899866_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "646,556",
"Cost of Goods Sold": "0",
"Intangible Assets": "44,100",
"Liabilities, Current": "138,515",
"Liabilities, Non-Current": "9,324",
"Other Assets": "159,141",
"Other Compr. Net Income": "0",
"Other Expenses": "117,122",
"Other Liabilities": "4,462",
"Other Net Income": "-923",
"Other Revenues": "540,957",
"Property and Equipment": "162,240",
"Research and Development": "98,394",
"Selling, General and Administrative Expense": "227,488"
},
"output_variables": {
"Assets": "1,012,037",
"Liabilities": "152,301",
"Expenses": "443,004",
"Revenues": "540,957",
"Stockholders Equity": "859,736",
"Net Income": "97,030",
"Comprehensive Net Income": "97,030",
"BaseVar": "1,074,611",
"ECR before LimitedLiability": "339%",
"Economic Capital Ratio": "395%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,495,600",
"Cost of Goods Sold": "0",
"Intangible Assets": "900,323",
"Liabilities, Current": "360,089",
"Liabilities, Non-Current": "123,792",
"Other Assets": "52,008",
"Other Compr. Net Income": "2,456",
"Other Expenses": "325,889",
"Other Liabilities": "158,829",
"Other Net Income": "54,007",
"Other Revenues": "1,134,114",
"Property and Equipment": "165,629",
"Research and Development": "222,732",
"Selling, General and Administrative Expense": "384,678"
},
"output_variables": {
"Assets": "2,613,560",
"Liabilities": "642,710",
"Expenses": "933,299",
"Revenues": "1,134,114",
"Stockholders Equity": "1,970,850",
"Net Income": "254,822",
"Comprehensive Net Income": "256,050",
"BaseVar": "2,690,073",
"ECR before LimitedLiability": "280%",
"Economic Capital Ratio": "355%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,186,857",
"Cost of Goods Sold": "0",
"Intangible Assets": "863,792",
"Liabilities, Current": "582,429",
"Liabilities, Non-Current": "112,973",
"Other Assets": "65,938",
"Other Compr. Net Income": "-29,492",
"Other Expenses": "484,828",
"Other Liabilities": "240,215",
"Other Net Income": "-6,810",
"Other Revenues": "1,551,346",
"Property and Equipment": "201,109",
"Research and Development": "317,093",
"Selling, General and Administrative Expense": "489,720"
},
"output_variables": {
"Assets": "3,317,696",
"Liabilities": "935,617",
"Expenses": "1,291,641",
"Revenues": "1,551,346",
"Stockholders Equity": "2,382,079",
"Net Income": "252,895",
"Comprehensive Net Income": "238,149",
"BaseVar": "3,566,301",
"ECR before LimitedLiability": "255%",
"Economic Capital Ratio": "339%"
}
}
},
"top_rated": true,
"trend": -15.0,
"value": 3.3908962575467823,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000899866.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000899866.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000899866.svg"
},
{
"company_id": "0001098880",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001098880.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001098880.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001098880.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001098880_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001098880_main_keyfigs.svg",
"name": "Intelgenx Technologies Corp",
"rank": 54,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001098880.svg",
"report_text": "The relative strengths and weaknesses of Intelgenx Technologies Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Intelgenx Technologies Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 105% points.The greatest weakness of Intelgenx Technologies Corp is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 13% points.
The company's Economic Capital Ratio, given in the ranking table, is 334%, being 92% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001098880_2014_Intelgenx_Technologies_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-7.03",
"Assets": "57.2",
"Liabilities": "51.9",
"Stockholders Equity": "137",
"ECR before LimitedLiability": "165",
"Intangible Assets": "-6.32",
"Property and Equipment": "-2.32",
"Assets, Current": "103",
"Other Liabilities": "-24.7",
"Liabilities, Non-Current": "13.4",
"Liabilities, Current": "60.0",
"Research and Development": "-8.00",
"Expenses": "-3.71",
"Revenues": "-16.1",
"Net Income": "-17.7",
"Other Expenses": "-16.4",
"Cost of Goods Sold": "3.44",
"Selling, General and Administrative Expense": "17.4",
"Other Revenues": "-16.1",
"Comprehensive Net Income": "-17.3",
"Economic Capital Ratio": "89.9"
},
"2012": {
"Property and Equipment": "4.15",
"Assets": "18.1",
"Liabilities": "-9.58",
"Stockholders Equity": "12.8",
"ECR before LimitedLiability": "69.5",
"Assets, Current": "52.8",
"Intangible Assets": "-13.9",
"Other Assets": "-13.6",
"Liabilities, Current": "-20.3",
"Other Liabilities": "-6.26",
"Liabilities, Non-Current": "16.4",
"Selling, General and Administrative Expense": "25.6",
"Expenses": "2.11",
"Net Income": "4.14",
"Other Net Income": "2.58",
"Research and Development": "-16.2",
"Other Expenses": "-11.1",
"Cost of Goods Sold": "5.24",
"Comprehensive Net Income": "5.72",
"Other Compr. Net Income": "1.56",
"Economic Capital Ratio": "-3.60"
},
"2013": {
"Other Assets": "-5.67",
"Assets": "40.1",
"Liabilities": "41.7",
"Stockholders Equity": "105",
"ECR before LimitedLiability": "120",
"Intangible Assets": "-5.97",
"Property and Equipment": "5.65",
"Assets, Current": "53.5",
"Liabilities, Non-Current": "13.0",
"Liabilities, Current": "13.3",
"Other Liabilities": "17.7",
"Selling, General and Administrative Expense": "-13.0",
"Expenses": "10.8",
"Revenues": "-2.50",
"Net Income": "9.54",
"Other Expenses": "9.48",
"Research and Development": "11.8",
"Cost of Goods Sold": "2.47",
"Other Revenues": "-2.50",
"Comprehensive Net Income": "8.22",
"Economic Capital Ratio": "91.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001098880_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,296",
"Cost of Goods Sold": "0",
"Intangible Assets": "125",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "49",
"Other Expenses": "1,035",
"Other Liabilities": "666",
"Other Net Income": "0",
"Other Revenues": "440",
"Property and Equipment": "149",
"Research and Development": "1,524",
"Selling, General and Administrative Expense": "333"
},
"output_variables": {
"Assets": "4,570",
"Liabilities": "666",
"Expenses": "2,892",
"Revenues": "440",
"Stockholders Equity": "3,904",
"Net Income": "-2,452",
"Comprehensive Net Income": "-2,428",
"BaseVar": "4,308",
"ECR before LimitedLiability": "232%",
"Economic Capital Ratio": "324%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "3,656",
"Cost of Goods Sold": "0",
"Intangible Assets": "116",
"Liabilities, Current": "1,366",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "100",
"Other Expenses": "1,176",
"Other Liabilities": "615",
"Other Net Income": "0",
"Other Revenues": "1,208",
"Property and Equipment": "387",
"Research and Development": "1,935",
"Selling, General and Administrative Expense": "347"
},
"output_variables": {
"Assets": "4,159",
"Liabilities": "1,981",
"Expenses": "3,458",
"Revenues": "1,208",
"Stockholders Equity": "2,178",
"Net Income": "-2,250",
"Comprehensive Net Income": "-2,200",
"BaseVar": "5,453",
"ECR before LimitedLiability": "83%",
"Economic Capital Ratio": "216%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "5,550",
"Cost of Goods Sold": "0",
"Intangible Assets": "79",
"Liabilities, Current": "901",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-124",
"Other Expenses": "72",
"Other Liabilities": "308",
"Other Net Income": "0",
"Other Revenues": "948",
"Property and Equipment": "588",
"Research and Development": "561",
"Selling, General and Administrative Expense": "1,954"
},
"output_variables": {
"Assets": "6,217",
"Liabilities": "1,209",
"Expenses": "2,587",
"Revenues": "948",
"Stockholders Equity": "5,008",
"Net Income": "-1,639",
"Comprehensive Net Income": "-1,701",
"BaseVar": "5,542",
"ECR before LimitedLiability": "248%",
"Economic Capital Ratio": "334%"
}
}
},
"top_rated": true,
"trend": 63.0,
"value": 3.343792290086085,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001098880.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001098880.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001098880.svg"
},
{
"company_id": "0001087432",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001087432.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001087432.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001087432_main_keyfigs.svg",
"name": "Intermune INC",
"rank": 55,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001087432.svg",
"report_text": "The relative strengths and weaknesses of Intermune INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Intermune INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 121% points.The greatest weakness of Intermune INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 12% points.
The company's Economic Capital Ratio, given in the ranking table, is 334%, being 91% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001087432_2014_Intermune_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "61.4",
"Liabilities": "65.8",
"Stockholders Equity": "183",
"ECR before LimitedLiability": "221",
"Intangible Assets": "-4.81",
"Property and Equipment": "-2.74",
"Assets, Current": "88.9",
"Other Liabilities": "29.9",
"Liabilities, Non-Current": "13.2",
"Liabilities, Current": "29.3",
"Research and Development": "6.62",
"Expenses": "12.4",
"Revenues": "-17.3",
"Net Income": "-2.70",
"Other Expenses": "4.46",
"Cost of Goods Sold": "3.02",
"Selling, General and Administrative Expense": "-1.62",
"Other Revenues": "-17.3",
"Comprehensive Net Income": "-2.94",
"Other Net Income": "1.82",
"Economic Capital Ratio": "146"
},
"2012": {
"Property and Equipment": "-4.23",
"Assets": "51.7",
"Liabilities": "57.9",
"Stockholders Equity": "138",
"ECR before LimitedLiability": "186",
"Assets, Current": "76.4",
"Intangible Assets": "-7.62",
"Other Assets": "2.37",
"Liabilities, Current": "12.4",
"Other Liabilities": "33.3",
"Liabilities, Non-Current": "15.7",
"Selling, General and Administrative Expense": "-7.73",
"Expenses": "4.25",
"Revenues": "-16.3",
"Comprehensive Net Income": "0.890",
"Research and Development": "-7.16",
"Other Expenses": "15.3",
"Cost of Goods Sold": "3.86",
"Other Revenues": "-16.3",
"Other Net Income": "12.8",
"Economic Capital Ratio": "113"
},
"2013": {
"Other Assets": "-3.88",
"Assets": "32.9",
"Liabilities": "70.2",
"Stockholders Equity": "121",
"ECR before LimitedLiability": "119",
"Intangible Assets": "-4.37",
"Property and Equipment": "-3.73",
"Assets, Current": "56.6",
"Liabilities, Non-Current": "14.6",
"Liabilities, Current": "22.1",
"Other Liabilities": "38.6",
"Selling, General and Administrative Expense": "-11.8",
"Expenses": "-7.29",
"Revenues": "-4.18",
"Net Income": "-11.4",
"Other Expenses": "5.66",
"Research and Development": "-3.91",
"Cost of Goods Sold": "2.79",
"Other Revenues": "-4.18",
"Comprehensive Net Income": "-11.6",
"Economic Capital Ratio": "91.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001087432_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "443,138",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "34,091",
"Liabilities, Non-Current": "0",
"Other Assets": "27,144",
"Other Compr. Net Income": "0",
"Other Expenses": "15,137",
"Other Liabilities": "0",
"Other Net Income": "-102",
"Other Revenues": "25,630",
"Property and Equipment": "2,341",
"Research and Development": "74,973",
"Selling, General and Administrative Expense": "90,192"
},
"output_variables": {
"Assets": "472,623",
"Liabilities": "34,091",
"Expenses": "180,302",
"Revenues": "25,630",
"Stockholders Equity": "438,532",
"Net Income": "-154,774",
"Comprehensive Net Income": "-154,774",
"BaseVar": "356,374",
"ECR before LimitedLiability": "316%",
"Economic Capital Ratio": "380%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "331,651",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "56,671",
"Liabilities, Non-Current": "0",
"Other Assets": "27,483",
"Other Compr. Net Income": "-524",
"Other Expenses": "-790",
"Other Liabilities": "0",
"Other Net Income": "34,821",
"Other Revenues": "26,174",
"Property and Equipment": "4,332",
"Research and Development": "106,571",
"Selling, General and Administrative Expense": "105,295"
},
"output_variables": {
"Assets": "363,466",
"Liabilities": "56,671",
"Expenses": "211,076",
"Revenues": "26,174",
"Stockholders Equity": "306,795",
"Net Income": "-150,081",
"Comprehensive Net Income": "-150,343",
"BaseVar": "346,366",
"ECR before LimitedLiability": "247%",
"Economic Capital Ratio": "333%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "429,168",
"Cost of Goods Sold": "0",
"Intangible Assets": "17,250",
"Liabilities, Current": "63,048",
"Liabilities, Non-Current": "0",
"Other Assets": "11,509",
"Other Compr. Net Income": "273",
"Other Expenses": "25,898",
"Other Liabilities": "0",
"Other Net Income": "-5,452",
"Other Revenues": "70,339",
"Property and Equipment": "4,706",
"Research and Development": "113,506",
"Selling, General and Administrative Expense": "145,051"
},
"output_variables": {
"Assets": "462,633",
"Liabilities": "63,048",
"Expenses": "284,455",
"Revenues": "70,339",
"Stockholders Equity": "399,585",
"Net Income": "-219,568",
"Comprehensive Net Income": "-219,432",
"BaseVar": "443,100",
"ECR before LimitedLiability": "248%",
"Economic Capital Ratio": "334%"
}
}
},
"top_rated": true,
"trend": -10.0,
"value": 3.34188742306953,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001087432.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001087432.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001087432.svg"
},
{
"company_id": "0000886744",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000886744.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000886744.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000886744.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000886744_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000886744_main_keyfigs.svg",
"name": "Geron CORP",
"rank": 56,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000886744.svg",
"report_text": "The relative strengths and weaknesses of Geron CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Geron CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 145% points.The greatest weakness of Geron CORP is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 27% points.
The company's Economic Capital Ratio, given in the ranking table, is 332%, being 90% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000886744_2014_Geron_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "18.8",
"Assets": "67.3",
"Liabilities": "68.4",
"Stockholders Equity": "174",
"ECR before LimitedLiability": "182",
"Intangible Assets": "-7.84",
"Property and Equipment": "-4.27",
"Assets, Current": "58.9",
"Other Liabilities": "30.7",
"Liabilities, Non-Current": "13.4",
"Liabilities, Current": "29.6",
"Research and Development": "-23.3",
"Expenses": "-7.96",
"Revenues": "-23.8",
"Net Income": "-31.0",
"Other Expenses": "5.07",
"Cost of Goods Sold": "3.33",
"Selling, General and Administrative Expense": "6.79",
"Other Revenues": "-23.8",
"Comprehensive Net Income": "-31.3",
"Economic Capital Ratio": "106"
},
"2012": {
"Property and Equipment": "-5.67",
"Assets": "62.8",
"Liabilities": "64.4",
"Stockholders Equity": "153",
"ECR before LimitedLiability": "160",
"Assets, Current": "133",
"Intangible Assets": "-9.63",
"Other Assets": "-6.54",
"Liabilities, Current": "18.7",
"Other Liabilities": "33.5",
"Liabilities, Non-Current": "15.7",
"Selling, General and Administrative Expense": "2.64",
"Expenses": "-13.5",
"Revenues": "-18.8",
"Net Income": "-30.2",
"Research and Development": "-32.3",
"Other Expenses": "12.5",
"Cost of Goods Sold": "4.07",
"Other Revenues": "-18.8",
"Comprehensive Net Income": "-29.9",
"Economic Capital Ratio": "87.0"
},
"2013": {
"Other Assets": "-5.76",
"Assets": "47.9",
"Liabilities": "69.6",
"Stockholders Equity": "145",
"ECR before LimitedLiability": "118",
"Intangible Assets": "-7.63",
"Property and Equipment": "-4.37",
"Assets, Current": "97.4",
"Liabilities, Non-Current": "13.6",
"Liabilities, Current": "25.0",
"Other Liabilities": "36.1",
"Selling, General and Administrative Expense": "-4.60",
"Expenses": "-11.1",
"Revenues": "-16.4",
"Net Income": "-26.8",
"Other Expenses": "8.67",
"Research and Development": "-17.8",
"Cost of Goods Sold": "2.60",
"Other Revenues": "-16.4",
"Comprehensive Net Income": "-27.1",
"Economic Capital Ratio": "89.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000886744_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "125,625",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "13,444",
"Liabilities, Non-Current": "0",
"Other Assets": "33,181",
"Other Compr. Net Income": "0",
"Other Expenses": "5,686",
"Other Liabilities": "0",
"Other Net Income": "-1,524",
"Other Revenues": "3,462",
"Property and Equipment": "1,241",
"Research and Development": "69,316",
"Selling, General and Administrative Expense": "23,789"
},
"output_variables": {
"Assets": "160,047",
"Liabilities": "13,444",
"Expenses": "98,791",
"Revenues": "3,462",
"Stockholders Equity": "146,603",
"Net Income": "-96,853",
"Comprehensive Net Income": "-96,853",
"BaseVar": "138,634",
"ECR before LimitedLiability": "257%",
"Economic Capital Ratio": "340%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "98,417",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "14,148",
"Liabilities, Non-Current": "0",
"Other Assets": "410",
"Other Compr. Net Income": "131",
"Other Expenses": "2,935",
"Other Liabilities": "0",
"Other Net Income": "13",
"Other Revenues": "5,806",
"Property and Equipment": "974",
"Research and Development": "51,368",
"Selling, General and Administrative Expense": "20,397"
},
"output_variables": {
"Assets": "99,801",
"Liabilities": "14,148",
"Expenses": "74,700",
"Revenues": "5,806",
"Stockholders Equity": "85,653",
"Net Income": "-68,881",
"Comprehensive Net Income": "-68,816",
"BaseVar": "97,300",
"ECR before LimitedLiability": "207%",
"Economic Capital Ratio": "307%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "67,057",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,587",
"Liabilities, Non-Current": "0",
"Other Assets": "195",
"Other Compr. Net Income": "-54",
"Other Expenses": "1,518",
"Other Liabilities": "0",
"Other Net Income": "-316",
"Other Revenues": "2,234",
"Property and Equipment": "92",
"Research and Development": "23,155",
"Selling, General and Administrative Expense": "15,624"
},
"output_variables": {
"Assets": "67,344",
"Liabilities": "7,587",
"Expenses": "40,297",
"Revenues": "2,234",
"Stockholders Equity": "59,757",
"Net Income": "-38,379",
"Comprehensive Net Income": "-38,406",
"BaseVar": "58,916",
"ECR before LimitedLiability": "245%",
"Economic Capital Ratio": "332%"
}
}
},
"top_rated": true,
"trend": 7.0,
"value": 3.323899065475074,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000886744.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000886744.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000886744.svg"
},
{
"company_id": "0001104506",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001104506.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001104506.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001104506_main_keyfigs.svg",
"name": "Insmed Inc",
"rank": 57,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001104506.svg",
"report_text": "The relative strengths and weaknesses of Insmed Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Insmed Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 118% points.The greatest weakness of Insmed Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 24% points.
The company's Economic Capital Ratio, given in the ranking table, is 332%, being 89% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001104506_2014_Insmed_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "39.1",
"Assets": "53.4",
"Liabilities": "35.5",
"Stockholders Equity": "118",
"ECR before LimitedLiability": "117",
"Intangible Assets": "-6.76",
"Property and Equipment": "-2.96",
"Assets, Current": "20.5",
"Liabilities, Non-Current": "-23.9",
"Liabilities, Current": "26.2",
"Other Liabilities": "31.2",
"Selling, General and Administrative Expense": "6.06",
"Expenses": "9.78",
"Revenues": "-10.6",
"Net Income": "0.429",
"Other Expenses": "9.19",
"Research and Development": "-7.75",
"Cost of Goods Sold": "2.28",
"Other Revenues": "-10.6",
"Other Net Income": "1.26",
"Economic Capital Ratio": "89.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001104506_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "116,163",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "16,456",
"Liabilities, Non-Current": "16,338",
"Other Assets": "58,523",
"Other Compr. Net Income": "0",
"Other Expenses": "1,191",
"Other Liabilities": "380",
"Other Net Income": "133",
"Other Revenues": "11,500",
"Property and Equipment": "1,812",
"Research and Development": "44,279",
"Selling, General and Administrative Expense": "22,236"
},
"output_variables": {
"Assets": "176,498",
"Liabilities": "33,174",
"Expenses": "67,706",
"Revenues": "11,500",
"Stockholders Equity": "143,324",
"Net Income": "-56,073",
"Comprehensive Net Income": "-56,073",
"BaseVar": "144,506",
"ECR before LimitedLiability": "245%",
"Economic Capital Ratio": "332%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.319622967780839,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001104506.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001104506.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001104506.svg"
},
{
"company_id": "0001005201",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001005201.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001005201.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001005201_main_keyfigs.svg",
"name": "Assertio Therapeutics Inc",
"rank": 58,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001005201.svg",
"report_text": "The relative strengths and weaknesses of Assertio Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Assertio Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 69% points.The greatest weakness of Assertio Therapeutics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 50% points.
The company's Economic Capital Ratio, given in the ranking table, is 331%, being 88% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001005201_2014_Assertio_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "17.0",
"Assets": "8.80",
"Liabilities": "51.4",
"Stockholders Equity": "65.0",
"ECR before LimitedLiability": "234",
"Intangible Assets": "-5.63",
"Property and Equipment": "-3.31",
"Assets, Current": "3.81",
"Other Liabilities": "42.1",
"Liabilities, Non-Current": "18.9",
"Liabilities, Current": "-8.23",
"Research and Development": "27.2",
"Expenses": "42.8",
"Revenues": "54.4",
"Net Income": "99.4",
"Other Expenses": "34.4",
"Cost of Goods Sold": "4.28",
"Selling, General and Administrative Expense": "-23.7",
"Other Revenues": "54.4",
"Comprehensive Net Income": "99.1",
"Economic Capital Ratio": "158"
},
"2012": {
"Property and Equipment": "-1.98",
"Assets": "4.25",
"Liabilities": "64.8",
"Stockholders Equity": "58.4",
"ECR before LimitedLiability": "171",
"Assets, Current": "-3.00",
"Intangible Assets": "8.07",
"Liabilities, Current": "4.82",
"Other Liabilities": "42.8",
"Liabilities, Non-Current": "20.2",
"Selling, General and Administrative Expense": "-38.6",
"Expenses": "4.19",
"Revenues": "35.4",
"Net Income": "42.9",
"Research and Development": "23.9",
"Other Expenses": "14.3",
"Cost of Goods Sold": "5.17",
"Other Revenues": "35.4",
"Comprehensive Net Income": "43.2",
"Other Net Income": "2.91",
"Economic Capital Ratio": "97.8"
},
"2013": {
"Other Assets": "10.8",
"Assets": "38.7",
"Liabilities": "0.295",
"Stockholders Equity": "69.1",
"ECR before LimitedLiability": "116",
"Intangible Assets": "9.39",
"Property and Equipment": "-2.39",
"Assets, Current": "14.7",
"Liabilities, Non-Current": "11.6",
"Liabilities, Current": "-50.0",
"Other Liabilities": "31.0",
"Selling, General and Administrative Expense": "-1.36",
"Expenses": "34.1",
"Revenues": "9.25",
"Net Income": "43.9",
"Other Expenses": "15.0",
"Research and Development": "17.9",
"Cost of Goods Sold": "2.22",
"Other Revenues": "9.25",
"Comprehensive Net Income": "43.7",
"Economic Capital Ratio": "88.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001005201_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "109,489",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "39,840",
"Liabilities, Non-Current": "0",
"Other Assets": "53,813",
"Other Compr. Net Income": "0",
"Other Expenses": "-34,060",
"Other Liabilities": "0",
"Other Net Income": "424",
"Other Revenues": "132,973",
"Property and Equipment": "1,070",
"Research and Development": "15,187",
"Selling, General and Administrative Expense": "81,544"
},
"output_variables": {
"Assets": "164,372",
"Liabilities": "39,840",
"Expenses": "62,671",
"Revenues": "132,973",
"Stockholders Equity": "124,532",
"Net Income": "70,726",
"Comprehensive Net Income": "70,726",
"BaseVar": "200,140",
"ECR before LimitedLiability": "335%",
"Economic Capital Ratio": "393%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "95,267",
"Cost of Goods Sold": "0",
"Intangible Assets": "25,078",
"Liabilities, Current": "36,681",
"Liabilities, Non-Current": "0",
"Other Assets": "13,071",
"Other Compr. Net Income": "44",
"Other Expenses": "7,970",
"Other Liabilities": "0",
"Other Net Income": "481",
"Other Revenues": "90,816",
"Property and Equipment": "8,237",
"Research and Development": "15,462",
"Selling, General and Administrative Expense": "97,646"
},
"output_variables": {
"Assets": "141,653",
"Liabilities": "36,681",
"Expenses": "121,078",
"Revenues": "90,816",
"Stockholders Equity": "104,972",
"Net Income": "-29,781",
"Comprehensive Net Income": "-29,759",
"BaseVar": "195,376",
"ECR before LimitedLiability": "223%",
"Economic Capital Ratio": "318%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "337,045",
"Cost of Goods Sold": "0",
"Intangible Assets": "82,521",
"Liabilities, Current": "156,857",
"Liabilities, Non-Current": "0",
"Other Assets": "80,747",
"Other Compr. Net Income": "-38",
"Other Expenses": "-27,094",
"Other Liabilities": "0",
"Other Net Income": "-4,737",
"Other Revenues": "134,205",
"Property and Equipment": "8,340",
"Research and Development": "8,073",
"Selling, General and Administrative Expense": "105,176"
},
"output_variables": {
"Assets": "508,653",
"Liabilities": "156,857",
"Expenses": "86,155",
"Revenues": "134,205",
"Stockholders Equity": "351,796",
"Net Income": "43,313",
"Comprehensive Net Income": "43,294",
"BaseVar": "445,322",
"ECR before LimitedLiability": "243%",
"Economic Capital Ratio": "331%"
}
}
},
"top_rated": true,
"trend": -4.0,
"value": 3.312636358784109,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001005201.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001005201.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001005201.svg"
},
{
"company_id": "0001505512",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001505512.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001505512.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001505512.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001505512_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001505512_main_keyfigs.svg",
"name": "Regulus Therapeutics Inc",
"rank": 59,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001505512.svg",
"report_text": "The relative strengths and weaknesses of Regulus Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Regulus Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 93% points.The greatest weakness of Regulus Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 19% points.
The company's Economic Capital Ratio, given in the ranking table, is 331%, being 88% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001505512_2014_Regulus_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-2.45",
"Assets": "74.6",
"Liabilities": "-29.2",
"Stockholders Equity": "64.7",
"ECR before LimitedLiability": "130",
"Assets, Current": "123",
"Intangible Assets": "-7.91",
"Other Assets": "-6.60",
"Liabilities, Current": "16.6",
"Other Liabilities": "-60.1",
"Liabilities, Non-Current": "9.65",
"Selling, General and Administrative Expense": "16.7",
"Expenses": "35.9",
"Revenues": "-8.05",
"Net Income": "23.9",
"Other Expenses": "12.6",
"Cost of Goods Sold": "3.25",
"Other Revenues": "-8.05",
"Comprehensive Net Income": "24.1",
"Other Net Income": "-2.95",
"Economic Capital Ratio": "56.8"
},
"2013": {
"Other Assets": "-4.67",
"Assets": "44.5",
"Liabilities": "21.5",
"Stockholders Equity": "93.3",
"ECR before LimitedLiability": "116",
"Intangible Assets": "-6.01",
"Property and Equipment": "-1.03",
"Assets, Current": "71.8",
"Liabilities, Non-Current": "7.85",
"Liabilities, Current": "30.5",
"Other Liabilities": "-18.7",
"Selling, General and Administrative Expense": "13.7",
"Expenses": "20.3",
"Revenues": "-0.756",
"Net Income": "19.7",
"Other Expenses": "9.97",
"Research and Development": "-5.71",
"Cost of Goods Sold": "2.29",
"Other Revenues": "-0.756",
"Comprehensive Net Income": "19.5",
"Economic Capital Ratio": "87.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001505512_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "98,929",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,154",
"Liabilities, Current": "12,768",
"Liabilities, Non-Current": "767",
"Other Assets": "125",
"Other Compr. Net Income": "15",
"Other Expenses": "237",
"Other Liabilities": "27,890",
"Other Net Income": "-4,707",
"Other Revenues": "12,810",
"Property and Equipment": "3,310",
"Research and Development": "20,342",
"Selling, General and Administrative Expense": "4,932"
},
"output_variables": {
"Assets": "103,518",
"Liabilities": "41,425",
"Expenses": "25,511",
"Revenues": "12,810",
"Stockholders Equity": "62,093",
"Net Income": "-17,408",
"Comprehensive Net Income": "-17,400",
"BaseVar": "93,993",
"ECR before LimitedLiability": "163%",
"Economic Capital Ratio": "277%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "117,182",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,128",
"Liabilities, Current": "10,370",
"Liabilities, Non-Current": "1,459",
"Other Assets": "987",
"Other Compr. Net Income": "36",
"Other Expenses": "13",
"Other Liabilities": "17,779",
"Other Net Income": "-1,145",
"Other Revenues": "19,861",
"Property and Equipment": "3,768",
"Research and Development": "29,942",
"Selling, General and Administrative Expense": "7,429"
},
"output_variables": {
"Assets": "123,065",
"Liabilities": "29,608",
"Expenses": "37,384",
"Revenues": "19,861",
"Stockholders Equity": "93,457",
"Net Income": "-18,668",
"Comprehensive Net Income": "-18,650",
"BaseVar": "105,550",
"ECR before LimitedLiability": "242%",
"Economic Capital Ratio": "331%"
}
}
},
"top_rated": false,
"trend": 23.0,
"value": 3.3058963125782874,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001505512.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001505512.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001505512.svg"
},
{
"company_id": "0001563855",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001563855.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001563855.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001563855_main_keyfigs.svg",
"name": "Sophiris BIO INC",
"rank": 60,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001563855.svg",
"report_text": "The relative strengths and weaknesses of Sophiris BIO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Sophiris BIO INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 107% points.The greatest weakness of Sophiris BIO INC is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.
The company's Economic Capital Ratio, given in the ranking table, is 330%, being 87% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001563855_2014_Sophiris_BIO_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-5.14",
"Assets": "55.3",
"Liabilities": "20.6",
"Stockholders Equity": "107",
"ECR before LimitedLiability": "115",
"Intangible Assets": "-6.53",
"Property and Equipment": "-3.70",
"Assets, Current": "100.0",
"Liabilities, Non-Current": "11.3",
"Liabilities, Current": "-15.1",
"Other Liabilities": "23.4",
"Selling, General and Administrative Expense": "9.67",
"Expenses": "18.0",
"Revenues": "-16.9",
"Net Income": "10.7",
"Other Expenses": "8.40",
"Research and Development": "-2.28",
"Other Revenues": "-16.9",
"Comprehensive Net Income": "10.7",
"Other Net Income": "9.72",
"Economic Capital Ratio": "87.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001563855_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "51,795",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "10,528",
"Liabilities, Non-Current": "0",
"Other Assets": "19",
"Other Compr. Net Income": "144",
"Other Expenses": "500",
"Other Liabilities": "1,085",
"Other Net Income": "4,141",
"Other Revenues": "0",
"Property and Equipment": "78",
"Research and Development": "10,279",
"Selling, General and Administrative Expense": "4,511"
},
"output_variables": {
"Assets": "51,892",
"Liabilities": "11,613",
"Expenses": "15,290",
"Revenues": "0",
"Stockholders Equity": "40,279",
"Net Income": "-11,149",
"Comprehensive Net Income": "-11,077",
"BaseVar": "41,540",
"ECR before LimitedLiability": "242%",
"Economic Capital Ratio": "330%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.300585570115033,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001563855.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001563855.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001563855.svg"
},
{
"company_id": "0001410939",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001410939.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001410939.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001410939.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001410939_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001410939_main_keyfigs.svg",
"name": "Iveric bio Inc",
"rank": 61,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001410939.svg",
"report_text": "The relative strengths and weaknesses of Iveric bio Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Iveric bio Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 120% points.The greatest weakness of Iveric bio Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 45% points.
The company's Economic Capital Ratio, given in the ranking table, is 330%, being 87% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001410939_2014_Iveric_bio_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-4.59",
"Assets": "70.9",
"Liabilities": "12.5",
"Stockholders Equity": "118",
"ECR before LimitedLiability": "115",
"Intangible Assets": "-5.95",
"Property and Equipment": "-3.49",
"Assets, Current": "120",
"Liabilities, Non-Current": "10.3",
"Liabilities, Current": "39.9",
"Other Liabilities": "-45.3",
"Selling, General and Administrative Expense": "10.2",
"Expenses": "22.0",
"Revenues": "-15.3",
"Net Income": "6.29",
"Other Expenses": "8.97",
"Research and Development": "0.772",
"Cost of Goods Sold": "1.96",
"Other Revenues": "-15.3",
"Comprehensive Net Income": "6.12",
"Economic Capital Ratio": "87.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001410939_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "217,400",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,295",
"Liabilities, Non-Current": "0",
"Other Assets": "255",
"Other Compr. Net Income": "0",
"Other Expenses": "-835",
"Other Liabilities": "41,667",
"Other Net Income": "-2,545",
"Other Revenues": "0",
"Property and Equipment": "27",
"Research and Development": "33,215",
"Selling, General and Administrative Expense": "14,210"
},
"output_variables": {
"Assets": "217,682",
"Liabilities": "47,962",
"Expenses": "46,590",
"Revenues": "0",
"Stockholders Equity": "169,720",
"Net Income": "-49,135",
"Comprehensive Net Income": "-49,135",
"BaseVar": "157,390",
"ECR before LimitedLiability": "242%",
"Economic Capital Ratio": "330%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.300014621134127,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001410939.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001410939.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001410939.svg"
},
{
"company_id": "0001113148",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001113148.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001113148.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001113148.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001113148_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001113148_main_keyfigs.svg",
"name": "Infinity Pharmaceuticals INC",
"rank": 62,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001113148.svg",
"report_text": "The relative strengths and weaknesses of Infinity Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Infinity Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 143% points.The greatest weakness of Infinity Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 29% points.
The company's Economic Capital Ratio, given in the ranking table, is 329%, being 86% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001113148_2014_Infinity_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-18.1",
"Assets": "-51.1",
"Liabilities": "-71.5",
"Stockholders Equity": "-115",
"Intangible Assets": "-28.9",
"Property and Equipment": "-9.40",
"Assets, Current": "0.245",
"Other Liabilities": "-120",
"Liabilities, Non-Current": "0.427",
"Liabilities, Current": "0.849",
"Research and Development": "-31.7",
"Expenses": "0.309",
"Revenues": "-41.3",
"Net Income": "2.81",
"Other Expenses": "0.557",
"Selling, General and Administrative Expense": "1.13",
"Other Revenues": "-41.3",
"ECR before LimitedLiability": "-17.5",
"Comprehensive Net Income": "2.76",
"Other Net Income": "8.33",
"Economic Capital Ratio": "-93.1"
},
"2012": {
"Assets": "33.4",
"Liabilities": "90.8",
"Stockholders Equity": "169",
"ECR before LimitedLiability": "252",
"Assets, Current": "59.4",
"Intangible Assets": "-3.95",
"Other Assets": "-2.58",
"Liabilities, Current": "53.4",
"Other Liabilities": "31.5",
"Liabilities, Non-Current": "18.2",
"Selling, General and Administrative Expense": "16.1",
"Expenses": "18.4",
"Revenues": "-26.8",
"Net Income": "29.7",
"Research and Development": "-18.1",
"Other Expenses": "15.9",
"Cost of Goods Sold": "4.12",
"Other Revenues": "-26.8",
"Comprehensive Net Income": "29.9",
"Other Net Income": "36.9",
"Economic Capital Ratio": "179"
},
"2013": {
"Other Assets": "-5.13",
"Assets": "54.7",
"Liabilities": "60.1",
"Stockholders Equity": "143",
"ECR before LimitedLiability": "114",
"Intangible Assets": "-7.48",
"Property and Equipment": "-2.54",
"Assets, Current": "98.1",
"Liabilities, Non-Current": "11.6",
"Liabilities, Current": "28.0",
"Other Liabilities": "24.4",
"Selling, General and Administrative Expense": "7.59",
"Expenses": "-7.93",
"Revenues": "-19.3",
"Net Income": "-25.6",
"Other Expenses": "10.8",
"Research and Development": "-28.8",
"Cost of Goods Sold": "2.48",
"Other Revenues": "-19.3",
"Comprehensive Net Income": "-25.8",
"Economic Capital Ratio": "86.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001113148_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "117,980",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "28,986",
"Liabilities, Non-Current": "371",
"Other Assets": "1,928",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "79,700",
"Other Net Income": "91,259",
"Other Revenues": "0",
"Property and Equipment": "4,582",
"Research and Development": "108,582",
"Selling, General and Administrative Expense": "22,719"
},
"output_variables": {
"Assets": "124,490",
"Liabilities": "109,057",
"Expenses": "131,301",
"Revenues": "0",
"Stockholders Equity": "15,433",
"Net Income": "-40,042",
"Comprehensive Net Income": "-40,042",
"BaseVar": "228,053",
"ECR before LimitedLiability": "-5.5%",
"Economic Capital Ratio": "141%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "329,749",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "18,663",
"Liabilities, Non-Current": "540",
"Other Assets": "1,832",
"Other Compr. Net Income": "112",
"Other Expenses": "0",
"Other Liabilities": "6,252",
"Other Net Income": "92,513",
"Other Revenues": "0",
"Property and Equipment": "4,079",
"Research and Development": "118,595",
"Selling, General and Administrative Expense": "27,882"
},
"output_variables": {
"Assets": "335,660",
"Liabilities": "25,455",
"Expenses": "146,477",
"Revenues": "0",
"Stockholders Equity": "310,205",
"Net Income": "-53,964",
"Comprehensive Net Income": "-53,908",
"BaseVar": "300,108",
"ECR before LimitedLiability": "345%",
"Economic Capital Ratio": "399%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "224,941",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "22,206",
"Liabilities, Non-Current": "773",
"Other Assets": "1,759",
"Other Compr. Net Income": "22",
"Other Expenses": "0",
"Other Liabilities": "6,456",
"Other Net Income": "896",
"Other Revenues": "0",
"Property and Equipment": "4,010",
"Research and Development": "99,760",
"Selling, General and Administrative Expense": "27,916"
},
"output_variables": {
"Assets": "230,710",
"Liabilities": "29,435",
"Expenses": "127,676",
"Revenues": "0",
"Stockholders Equity": "201,275",
"Net Income": "-126,780",
"Comprehensive Net Income": "-126,769",
"BaseVar": "194,370",
"ECR before LimitedLiability": "240%",
"Economic Capital Ratio": "329%"
}
}
},
"top_rated": false,
"trend": -49.0,
"value": 3.288869543180045,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001113148.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001113148.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001113148.svg"
},
{
"company_id": "0001369568",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001369568.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001369568.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001369568.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001369568_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001369568_main_keyfigs.svg",
"name": "Catalyst Pharmaceuticals INC",
"rank": 63,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001369568.svg",
"report_text": "The relative strengths and weaknesses of Catalyst Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Catalyst Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 132% points.The greatest weakness of Catalyst Pharmaceuticals INC is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.
The company's Economic Capital Ratio, given in the ranking table, is 328%, being 85% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001369568_2014_Catalyst_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-15.1",
"Assets": "-135",
"Liabilities": "-5.35",
"Stockholders Equity": "-41.5",
"ECR before LimitedLiability": "-155",
"Intangible Assets": "-23.3",
"Property and Equipment": "-11.5",
"Assets, Current": "-92.0",
"Other Liabilities": "-2.36",
"Liabilities, Non-Current": "0.705",
"Liabilities, Current": "-3.89",
"Research and Development": "-79.4",
"Expenses": "-117",
"Revenues": "-10.3",
"Net Income": "-135",
"Other Expenses": "1.47",
"Selling, General and Administrative Expense": "-16.2",
"Other Revenues": "-10.3",
"Comprehensive Net Income": "-136",
"Other Net Income": "1.41",
"Economic Capital Ratio": "-231"
},
"2012": {
"Property and Equipment": "-8.48",
"Assets": "-42.2",
"Liabilities": "30.9",
"Stockholders Equity": "16.0",
"ECR before LimitedLiability": "-18.7",
"Intangible Assets": "-10.7",
"Other Assets": "-8.78",
"Liabilities, Current": "18.4",
"Other Liabilities": "12.2",
"Liabilities, Non-Current": "3.75",
"Selling, General and Administrative Expense": "-12.5",
"Expenses": "-130",
"Revenues": "-11.8",
"Net Income": "-161",
"Research and Development": "-106",
"Other Expenses": "12.6",
"Cost of Goods Sold": "2.92",
"Other Revenues": "-11.8",
"Comprehensive Net Income": "-161",
"Other Net Income": "8.93",
"Economic Capital Ratio": "-91.8"
},
"2013": {
"Other Assets": "-5.71",
"Assets": "55.7",
"Liabilities": "47.8",
"Stockholders Equity": "132",
"ECR before LimitedLiability": "113",
"Intangible Assets": "-7.25",
"Property and Equipment": "-4.12",
"Assets, Current": "107",
"Liabilities, Non-Current": "12.3",
"Liabilities, Current": "30.5",
"Other Liabilities": "7.15",
"Other Revenues": "-18.5",
"Revenues": "-18.5",
"Net Income": "-15.2",
"Selling, General and Administrative Expense": "10.9",
"Comprehensive Net Income": "-15.5",
"Other Expenses": "1.86",
"Cost of Goods Sold": "2.38",
"Other Net Income": "3.64",
"Research and Development": "-15.5",
"Economic Capital Ratio": "85.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001369568_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,228",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "834",
"Liabilities, Non-Current": "1,645",
"Other Assets": "8.9",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "9.5",
"Other Net Income": "1,647",
"Other Revenues": "0",
"Property and Equipment": "12",
"Research and Development": "25,644",
"Selling, General and Administrative Expense": "14,106"
},
"output_variables": {
"Assets": "6,249",
"Liabilities": "2,489",
"Expenses": "39,749",
"Revenues": "0",
"Stockholders Equity": "3,761",
"Net Income": "-38,103",
"Comprehensive Net Income": "-38,103",
"BaseVar": "25,067",
"ECR before LimitedLiability": "-684%",
"Economic Capital Ratio": "3.3%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "16,727",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,647",
"Liabilities, Non-Current": "499",
"Other Assets": "8.9",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "22",
"Other Net Income": "2,792",
"Other Revenues": "0",
"Property and Equipment": "54",
"Research and Development": "28,303",
"Selling, General and Administrative Expense": "16,667"
},
"output_variables": {
"Assets": "16,789",
"Liabilities": "2,167",
"Expenses": "44,971",
"Revenues": "0",
"Stockholders Equity": "14,622",
"Net Income": "-42,179",
"Comprehensive Net Income": "-42,179",
"BaseVar": "33,359",
"ECR before LimitedLiability": "-109%",
"Economic Capital Ratio": "128%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "25,320",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,140",
"Liabilities, Non-Current": "0",
"Other Assets": "8.9",
"Other Compr. Net Income": "0",
"Other Expenses": "1,890",
"Other Liabilities": "1,839",
"Other Net Income": "536",
"Other Revenues": "0",
"Property and Equipment": "41",
"Research and Development": "8,097",
"Selling, General and Administrative Expense": "2,215"
},
"output_variables": {
"Assets": "25,370",
"Liabilities": "3,978",
"Expenses": "12,202",
"Revenues": "0",
"Stockholders Equity": "21,391",
"Net Income": "-11,666",
"Comprehensive Net Income": "-11,666",
"BaseVar": "21,043",
"ECR before LimitedLiability": "238%",
"Economic Capital Ratio": "328%"
}
}
},
"top_rated": false,
"trend": 104.0,
"value": 3.2784728607760627,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001369568.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001369568.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001369568.svg"
},
{
"company_id": "0001557421",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001557421.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001557421.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001557421_main_keyfigs.svg",
"name": "Ignyta Inc",
"rank": 64,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001557421.svg",
"report_text": "The relative strengths and weaknesses of Ignyta Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ignyta Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 118% points.The greatest weakness of Ignyta Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 34% points.
The company's Economic Capital Ratio, given in the ranking table, is 327%, being 84% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001557421_2014_Ignyta_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-4.92",
"Assets": "69.4",
"Liabilities": "16.1",
"Stockholders Equity": "118",
"ECR before LimitedLiability": "112",
"Intangible Assets": "-6.26",
"Property and Equipment": "-2.08",
"Assets, Current": "114",
"Liabilities, Non-Current": "3.52",
"Liabilities, Current": "41.2",
"Other Liabilities": "-33.9",
"Selling, General and Administrative Expense": "10.2",
"Expenses": "18.1",
"Revenues": "-15.8",
"Net Income": "2.67",
"Other Expenses": "8.81",
"Research and Development": "-2.92",
"Cost of Goods Sold": "2.02",
"Other Revenues": "-15.8",
"Comprehensive Net Income": "2.49",
"Economic Capital Ratio": "84.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001557421_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "52,475",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,531",
"Liabilities, Non-Current": "1,050",
"Other Assets": "13",
"Other Compr. Net Income": "0",
"Other Expenses": "2.1",
"Other Liabilities": "8,950",
"Other Net Income": "-310",
"Other Revenues": "0",
"Property and Equipment": "831",
"Research and Development": "10,171",
"Selling, General and Administrative Expense": "3,731"
},
"output_variables": {
"Assets": "53,319",
"Liabilities": "11,531",
"Expenses": "13,904",
"Revenues": "0",
"Stockholders Equity": "41,788",
"Net Income": "-14,214",
"Comprehensive Net Income": "-14,214",
"BaseVar": "39,532",
"ECR before LimitedLiability": "237%",
"Economic Capital Ratio": "327%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.2706721775331684,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001557421.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001557421.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001557421.svg"
},
{
"company_id": "0000872589",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000872589.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000872589.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000872589.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000872589_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000872589_main_keyfigs.svg",
"name": "Regeneron Pharmaceuticals INC",
"rank": 65,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000872589.svg",
"report_text": "The relative strengths and weaknesses of Regeneron Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Regeneron Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 67% points.The greatest weakness of Regeneron Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 32% points.
The company's Economic Capital Ratio, given in the ranking table, is 327%, being 84% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000872589_2014_Regeneron_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "44.3",
"Assets": "-5.23",
"Liabilities": "-31.6",
"Stockholders Equity": "-30.1",
"ECR before LimitedLiability": "-30.3",
"Assets, Current": "-26.5",
"Property and Equipment": "32.3",
"Intangible Assets": "-30.7",
"Liabilities, Current": "25.0",
"Other Liabilities": "-91.4",
"Liabilities, Non-Current": "23.9",
"Selling, General and Administrative Expense": "16.6",
"Expenses": "3.55",
"Revenues": "-3.58",
"Net Income": "-0.0762",
"Research and Development": "-29.1",
"Cost of Goods Sold": "5.29",
"Other Expenses": "12.4",
"Other Revenues": "-3.58",
"Comprehensive Net Income": "-0.0618",
"Economic Capital Ratio": "-36.7"
},
"2011": {
"Other Assets": "30.5",
"Assets": "25.9",
"Liabilities": "-69.5",
"Stockholders Equity": "-26.0",
"ECR before LimitedLiability": "53.4",
"Intangible Assets": "-18.4",
"Property and Equipment": "46.6",
"Assets, Current": "-19.6",
"Other Liabilities": "-121",
"Liabilities, Non-Current": "10.9",
"Liabilities, Current": "29.4",
"Research and Development": "-5.45",
"Expenses": "31.7",
"Revenues": "2.79",
"Net Income": "35.9",
"Other Expenses": "11.2",
"Cost of Goods Sold": "4.02",
"Selling, General and Administrative Expense": "21.4",
"Other Revenues": "2.79",
"Comprehensive Net Income": "35.5",
"Economic Capital Ratio": "-22.2"
},
"2012": {
"Property and Equipment": "12.0",
"Assets": "18.6",
"Liabilities": "-0.382",
"Stockholders Equity": "35.9",
"ECR before LimitedLiability": "180",
"Assets, Current": "-1.90",
"Intangible Assets": "-8.16",
"Other Assets": "18.2",
"Liabilities, Current": "45.3",
"Other Liabilities": "-77.8",
"Liabilities, Non-Current": "14.9",
"Selling, General and Administrative Expense": "16.4",
"Expenses": "46.7",
"Revenues": "37.8",
"Net Income": "88.0",
"Research and Development": "-1.38",
"Other Expenses": "27.0",
"Cost of Goods Sold": "3.96",
"Other Revenues": "37.8",
"Comprehensive Net Income": "88.2",
"Economic Capital Ratio": "107"
},
"2013": {
"Other Assets": "13.9",
"Assets": "-4.12",
"Liabilities": "38.3",
"Stockholders Equity": "17.5",
"ECR before LimitedLiability": "112",
"Intangible Assets": "-9.77",
"Property and Equipment": "12.5",
"Assets, Current": "-15.5",
"Liabilities, Non-Current": "15.5",
"Liabilities, Current": "49.9",
"Other Liabilities": "-31.6",
"Selling, General and Administrative Expense": "17.6",
"Expenses": "20.0",
"Revenues": "45.8",
"Net Income": "67.4",
"Other Expenses": "-0.697",
"Cost of Goods Sold": "3.25",
"Other Revenues": "45.8",
"Comprehensive Net Income": "67.1",
"Other Compr. Net Income": "-0.286",
"Economic Capital Ratio": "84.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000872589_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "357,622",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "109,056",
"Liabilities, Non-Current": "7,350",
"Other Assets": "384,360",
"Other Compr. Net Income": "0",
"Other Expenses": "2,093",
"Other Liabilities": "445,211",
"Other Net Income": "-6,996",
"Other Revenues": "459,074",
"Property and Equipment": "347,450",
"Research and Development": "489,252",
"Selling, General and Administrative Expense": "65,201"
},
"output_variables": {
"Assets": "1,089,432",
"Liabilities": "561,617",
"Expenses": "556,546",
"Revenues": "459,074",
"Stockholders Equity": "527,815",
"Net Income": "-104,468",
"Comprehensive Net Income": "-104,468",
"BaseVar": "1,336,832",
"ECR before LimitedLiability": "127%",
"Economic Capital Ratio": "251%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "652,875",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "148,271",
"Liabilities, Non-Current": "6,443",
"Other Assets": "302,753",
"Other Compr. Net Income": "0",
"Other Expenses": "3,084",
"Other Liabilities": "683,137",
"Other Net Income": "-17,733",
"Other Revenues": "445,824",
"Property and Equipment": "367,955",
"Research and Development": "529,506",
"Selling, General and Administrative Expense": "117,261"
},
"output_variables": {
"Assets": "1,323,583",
"Liabilities": "837,851",
"Expenses": "649,851",
"Revenues": "445,824",
"Stockholders Equity": "485,732",
"Net Income": "-221,760",
"Comprehensive Net Income": "-221,760",
"BaseVar": "1,637,421",
"ECR before LimitedLiability": "77%",
"Economic Capital Ratio": "212%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,206,012",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "163,550",
"Liabilities, Non-Current": "7,259",
"Other Assets": "494,538",
"Other Compr. Net Income": "696",
"Other Expenses": "-251,393",
"Other Liabilities": "664,296",
"Other Net Income": "-43,292",
"Other Revenues": "1,378,477",
"Property and Equipment": "379,940",
"Research and Development": "625,554",
"Selling, General and Administrative Expense": "210,755"
},
"output_variables": {
"Assets": "2,080,490",
"Liabilities": "835,105",
"Expenses": "584,916",
"Revenues": "1,378,477",
"Stockholders Equity": "1,245,385",
"Net Income": "750,269",
"Comprehensive Net Income": "750,617",
"BaseVar": "2,461,488",
"ECR before LimitedLiability": "238%",
"Economic Capital Ratio": "327%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "1,796,934",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "298,835",
"Liabilities, Non-Current": "11,330",
"Other Assets": "627,096",
"Other Compr. Net Income": "690",
"Other Expenses": "-250,973",
"Other Liabilities": "688,772",
"Other Net Income": "-50,357",
"Other Revenues": "3,143,605",
"Property and Equipment": "526,983",
"Research and Development": "912,838",
"Selling, General and Administrative Expense": "922,531"
},
"output_variables": {
"Assets": "2,951,013",
"Liabilities": "998,937",
"Expenses": "1,584,396",
"Revenues": "3,143,605",
"Stockholders Equity": "1,952,076",
"Net Income": "1,508,852",
"Comprehensive Net Income": "1,509,197",
"BaseVar": "4,364,499",
"ECR before LimitedLiability": "292%",
"Economic Capital Ratio": "363%"
}
}
},
"top_rated": false,
"trend": -17.0,
"value": 3.26966934612425,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000872589.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000872589.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000872589.svg"
},
{
"company_id": "0001130166",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001130166.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001130166.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001130166_main_keyfigs.svg",
"name": "Bio Green Med Solution Inc",
"rank": 66,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001130166.svg",
"report_text": "The relative strengths and weaknesses of Bio Green Med Solution Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Bio Green Med Solution Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 93% points.The greatest weakness of Bio Green Med Solution Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.
The company's Economic Capital Ratio, given in the ranking table, is 327%, being 84% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001130166_2014_Bio_Green_Med_Solution_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.11",
"Assets": "26.1",
"Liabilities": "34.8",
"Stockholders Equity": "73.1",
"ECR before LimitedLiability": "160",
"Intangible Assets": "-10.5",
"Property and Equipment": "-6.17",
"Assets, Current": "78.2",
"Other Liabilities": "33.8",
"Liabilities, Non-Current": "14.7",
"Liabilities, Current": "-14.5",
"Research and Development": "-998",
"Expenses": "9.76",
"Revenues": "9.57",
"Net Income": "24.2",
"Other Expenses": "318",
"Selling, General and Administrative Expense": "-415",
"Other Revenues": "9.57",
"Comprehensive Net Income": "23.9",
"Other Net Income": "4.71",
"Economic Capital Ratio": "84.1"
},
"2012": {
"Property and Equipment": "-11.4",
"Assets": "56.3",
"Liabilities": "-31.5",
"Stockholders Equity": "30.9",
"ECR before LimitedLiability": "50.3",
"Assets, Current": "63.9",
"Intangible Assets": "-17.8",
"Other Assets": "-9.46",
"Liabilities, Current": "-82.3",
"Other Liabilities": "30.3",
"Liabilities, Non-Current": "14.0",
"Other Revenues": "-27.9",
"Revenues": "-27.9",
"Net Income": "-21.6",
"Other Net Income": "5.76",
"Comprehensive Net Income": "-21.4",
"Research and Development": "-8.24",
"Selling, General and Administrative Expense": "-20.9",
"Other Expenses": "27.2",
"Cost of Goods Sold": "4.67",
"Economic Capital Ratio": "-22.7"
},
"2013": {
"Other Assets": "-6.12",
"Assets": "33.2",
"Liabilities": "42.3",
"Stockholders Equity": "93.0",
"ECR before LimitedLiability": "112",
"Intangible Assets": "-7.97",
"Property and Equipment": "-3.94",
"Assets, Current": "72.0",
"Liabilities, Non-Current": "13.5",
"Liabilities, Current": "-6.47",
"Other Liabilities": "35.9",
"Expenses": "6.44",
"Revenues": "-17.0",
"Net Income": "9.61",
"Other Expenses": "16.5",
"Research and Development": "-11.6",
"Cost of Goods Sold": "2.61",
"Other Revenues": "-17.0",
"Comprehensive Net Income": "9.38",
"Other Net Income": "20.3",
"Economic Capital Ratio": "84.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001130166_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "25,831",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,498",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-258,764",
"Other Liabilities": "0",
"Other Net Income": "580",
"Other Revenues": "9,769",
"Property and Equipment": "167",
"Research and Development": "185,799",
"Selling, General and Administrative Expense": "89,487"
},
"output_variables": {
"Assets": "25,998",
"Liabilities": "6,498",
"Expenses": "16,522",
"Revenues": "9,769",
"Stockholders Equity": "19,500",
"Net Income": "-6,173",
"Comprehensive Net Income": "-6,173",
"BaseVar": "29,684",
"ECR before LimitedLiability": "224%",
"Economic Capital Ratio": "318%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "18,872",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,335",
"Liabilities, Non-Current": "0",
"Other Assets": "353",
"Other Compr. Net Income": "0",
"Other Expenses": "-1,351",
"Other Liabilities": "0",
"Other Net Income": "566",
"Other Revenues": "69",
"Property and Equipment": "129",
"Research and Development": "6,592",
"Selling, General and Administrative Expense": "8,580"
},
"output_variables": {
"Assets": "19,354",
"Liabilities": "9,335",
"Expenses": "13,821",
"Revenues": "69",
"Stockholders Equity": "10,019",
"Net Income": "-13,186",
"Comprehensive Net Income": "-13,186",
"BaseVar": "21,572",
"ECR before LimitedLiability": "60%",
"Economic Capital Ratio": "197%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "35,173",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,497",
"Liabilities, Non-Current": "0",
"Other Assets": "72",
"Other Compr. Net Income": "0",
"Other Expenses": "-1,670",
"Other Liabilities": "0",
"Other Net Income": "6,151",
"Other Revenues": "1,084",
"Property and Equipment": "275",
"Research and Development": "11,277",
"Selling, General and Administrative Expense": "7,781"
},
"output_variables": {
"Assets": "35,520",
"Liabilities": "7,497",
"Expenses": "17,388",
"Revenues": "1,084",
"Stockholders Equity": "28,023",
"Net Income": "-10,153",
"Comprehensive Net Income": "-10,153",
"BaseVar": "33,820",
"ECR before LimitedLiability": "237%",
"Economic Capital Ratio": "327%"
}
}
},
"top_rated": false,
"trend": 60.0,
"value": 3.268776871268441,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001130166.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001130166.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001130166.svg"
},
{
"company_id": "0001544227",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001544227.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001544227.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001544227.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001544227_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001544227_main_keyfigs.svg",
"name": "Tempest Therapeutics Inc",
"rank": 67,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001544227.svg",
"report_text": "The relative strengths and weaknesses of Tempest Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tempest Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 144% points.The greatest weakness of Tempest Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 32% points.
The company's Economic Capital Ratio, given in the ranking table, is 324%, being 81% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001544227_2014_Tempest_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Assets": "71.9",
"Liabilities": "73.3",
"Stockholders Equity": "201",
"ECR before LimitedLiability": "226",
"Assets, Current": "113",
"Intangible Assets": "-4.56",
"Other Assets": "-3.10",
"Liabilities, Current": "35.5",
"Other Liabilities": "30.9",
"Liabilities, Non-Current": "14.6",
"Selling, General and Administrative Expense": "-11.7",
"Expenses": "8.40",
"Revenues": "-21.4",
"Net Income": "-11.0",
"Research and Development": "-6.34",
"Other Expenses": "22.8",
"Cost of Goods Sold": "3.32",
"Other Revenues": "-21.4",
"Comprehensive Net Income": "-10.9",
"Other Net Income": "1.71",
"Economic Capital Ratio": "153"
},
"2013": {
"Other Assets": "-2.65",
"Assets": "52.5",
"Liabilities": "64.6",
"Stockholders Equity": "144",
"ECR before LimitedLiability": "109",
"Intangible Assets": "-8.06",
"Property and Equipment": "-2.67",
"Assets, Current": "87.5",
"Liabilities, Non-Current": "12.6",
"Liabilities, Current": "20.8",
"Other Liabilities": "35.2",
"Selling, General and Administrative Expense": "-10.4",
"Expenses": "-13.1",
"Revenues": "-20.0",
"Net Income": "-31.6",
"Other Expenses": "11.2",
"Research and Development": "-16.5",
"Cost of Goods Sold": "2.57",
"Other Revenues": "-20.0",
"Comprehensive Net Income": "-31.8",
"Economic Capital Ratio": "80.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001544227_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "31,965",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,086",
"Liabilities, Non-Current": "7.0",
"Other Assets": "93",
"Other Compr. Net Income": "-6.0",
"Other Expenses": "-2,624",
"Other Liabilities": "0",
"Other Net Income": "19",
"Other Revenues": "0",
"Property and Equipment": "756",
"Research and Development": "7,493",
"Selling, General and Administrative Expense": "8,660"
},
"output_variables": {
"Assets": "32,814",
"Liabilities": "2,093",
"Expenses": "13,529",
"Revenues": "0",
"Stockholders Equity": "30,721",
"Net Income": "-13,510",
"Comprehensive Net Income": "-13,513",
"BaseVar": "24,230",
"ECR before LimitedLiability": "306%",
"Economic Capital Ratio": "373%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "45,077",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "5,774",
"Liabilities, Non-Current": "70",
"Other Assets": "1,588",
"Other Compr. Net Income": "16",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "90",
"Other Revenues": "0",
"Property and Equipment": "880",
"Research and Development": "15,802",
"Selling, General and Administrative Expense": "13,332"
},
"output_variables": {
"Assets": "47,545",
"Liabilities": "5,844",
"Expenses": "29,134",
"Revenues": "0",
"Stockholders Equity": "41,701",
"Net Income": "-29,044",
"Comprehensive Net Income": "-29,036",
"BaseVar": "41,314",
"ECR before LimitedLiability": "232%",
"Economic Capital Ratio": "324%"
}
}
},
"top_rated": false,
"trend": -43.0,
"value": 3.2355237123046283,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001544227.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001544227.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001544227.svg"
},
{
"company_id": "0001160308",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001160308.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001160308.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001160308.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001160308_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001160308_main_keyfigs.svg",
"name": "Savara Inc",
"rank": 68,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001160308.svg",
"report_text": "The relative strengths and weaknesses of Savara Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Savara Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 134% points.The greatest weakness of Savara Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 26% points.
The company's Economic Capital Ratio, given in the ranking table, is 323%, being 80% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001160308_2014_Savara_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.19",
"Assets": "-45.5",
"Liabilities": "31.6",
"Stockholders Equity": "13.5",
"ECR before LimitedLiability": "-38.7",
"Intangible Assets": "-14.3",
"Property and Equipment": "-12.2",
"Assets, Current": "-16.7",
"Other Liabilities": "9.95",
"Liabilities, Non-Current": "5.60",
"Liabilities, Current": "21.4",
"Research and Development": "-21.0",
"Expenses": "-148",
"Revenues": "-17.9",
"Net Income": "-194",
"Other Expenses": "-17.8",
"Selling, General and Administrative Expense": "-18.2",
"Other Revenues": "-17.9",
"Comprehensive Net Income": "-194",
"Other Net Income": "6.29",
"Economic Capital Ratio": "-114"
},
"2012": {
"Property and Equipment": "-28.0",
"Assets": "-92.5",
"Liabilities": "7.40",
"Stockholders Equity": "-4.95",
"ECR before LimitedLiability": "-99.4",
"Assets, Current": "-80.3",
"Intangible Assets": "-28.4",
"Liabilities, Current": "5.37",
"Other Liabilities": "2.78",
"Liabilities, Non-Current": "1.75",
"Selling, General and Administrative Expense": "-49.0",
"Expenses": "-119",
"Revenues": "-30.7",
"Net Income": "-216",
"Research and Development": "-69.8",
"Other Expenses": "-13.0",
"Cost of Goods Sold": "4.54",
"Other Revenues": "-30.7",
"Comprehensive Net Income": "-215",
"Other Net Income": "-5.70",
"Economic Capital Ratio": "-172"
},
"2013": {
"Other Assets": "7.84",
"Assets": "47.1",
"Liabilities": "63.2",
"Stockholders Equity": "134",
"ECR before LimitedLiability": "108",
"Intangible Assets": "-2.26",
"Property and Equipment": "-4.67",
"Assets, Current": "46.7",
"Liabilities, Non-Current": "13.4",
"Liabilities, Current": "34.4",
"Other Liabilities": "19.2",
"Selling, General and Administrative Expense": "5.05",
"Expenses": "-11.6",
"Revenues": "-16.0",
"Net Income": "-26.1",
"Other Expenses": "-15.1",
"Research and Development": "-4.16",
"Cost of Goods Sold": "2.62",
"Other Revenues": "-16.0",
"Comprehensive Net Income": "-26.4",
"Economic Capital Ratio": "80.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001160308_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "51,792",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,007",
"Liabilities, Current": "2,469",
"Liabilities, Non-Current": "0",
"Other Assets": "6,593",
"Other Compr. Net Income": "0",
"Other Expenses": "40,462",
"Other Liabilities": "2,609",
"Other Net Income": "4,893",
"Other Revenues": "2,094",
"Property and Equipment": "464",
"Research and Development": "77,969",
"Selling, General and Administrative Expense": "60,147"
},
"output_variables": {
"Assets": "61,856",
"Liabilities": "5,078",
"Expenses": "178,579",
"Revenues": "2,094",
"Stockholders Equity": "56,779",
"Net Income": "-171,592",
"Comprehensive Net Income": "-171,592",
"BaseVar": "126,250",
"ECR before LimitedLiability": "-143%",
"Economic Capital Ratio": "120%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "37,174",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,007",
"Liabilities, Current": "2,571",
"Liabilities, Non-Current": "0",
"Other Assets": "6,593",
"Other Compr. Net Income": "-28",
"Other Expenses": "28,243",
"Other Liabilities": "2,609",
"Other Net Income": "-7,278",
"Other Revenues": "2,094",
"Property and Equipment": "198",
"Research and Development": "86,057",
"Selling, General and Administrative Expense": "67,667"
},
"output_variables": {
"Assets": "46,972",
"Liabilities": "5,179",
"Expenses": "181,967",
"Revenues": "2,094",
"Stockholders Equity": "41,792",
"Net Income": "-187,151",
"Comprehensive Net Income": "-187,165",
"BaseVar": "121,759",
"ECR before LimitedLiability": "-368%",
"Economic Capital Ratio": "48%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "45,528",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,007",
"Liabilities, Current": "4,833",
"Liabilities, Non-Current": "0",
"Other Assets": "6,609",
"Other Compr. Net Income": "-47",
"Other Expenses": "12,602",
"Other Liabilities": "2,609",
"Other Net Income": "59",
"Other Revenues": "2,094",
"Property and Equipment": "106",
"Research and Development": "12,902",
"Selling, General and Administrative Expense": "8,518"
},
"output_variables": {
"Assets": "55,250",
"Liabilities": "7,442",
"Expenses": "34,022",
"Revenues": "2,094",
"Stockholders Equity": "47,808",
"Net Income": "-31,869",
"Comprehensive Net Income": "-31,893",
"BaseVar": "49,456",
"ECR before LimitedLiability": "231%",
"Economic Capital Ratio": "323%"
}
}
},
"top_rated": false,
"trend": 124.0,
"value": 3.2286844751880173,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001160308.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001160308.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001160308.svg"
},
{
"company_id": "0001385228",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001385228.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001385228.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001385228_main_keyfigs.svg",
"name": "DNIB Unwind INC",
"rank": 69,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001385228.svg",
"report_text": "The relative strengths and weaknesses of DNIB Unwind INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of DNIB Unwind INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 100% points.The greatest weakness of DNIB Unwind INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 17% points.
The company's Economic Capital Ratio, given in the ranking table, is 322%, being 79% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001385228_2014_DNIB_Unwind_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "18.0",
"Assets": "44.1",
"Liabilities": "33.4",
"Stockholders Equity": "100",
"ECR before LimitedLiability": "107",
"Intangible Assets": "-7.74",
"Property and Equipment": "3.04",
"Assets, Current": "26.7",
"Liabilities, Non-Current": "-16.5",
"Liabilities, Current": "15.6",
"Other Liabilities": "33.3",
"Selling, General and Administrative Expense": "4.88",
"Expenses": "9.34",
"Revenues": "-5.59",
"Net Income": "3.99",
"Other Expenses": "10.6",
"Research and Development": "-8.57",
"Cost of Goods Sold": "2.43",
"Other Revenues": "-5.59",
"Comprehensive Net Income": "3.53",
"Economic Capital Ratio": "79.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001385228_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "64,797",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "12,061",
"Liabilities, Non-Current": "7,033",
"Other Assets": "17,532",
"Other Compr. Net Income": "-399",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-800",
"Other Revenues": "10,901",
"Property and Equipment": "6,079",
"Research and Development": "24,370",
"Selling, General and Administrative Expense": "13,394"
},
"output_variables": {
"Assets": "88,408",
"Liabilities": "19,094",
"Expenses": "37,764",
"Revenues": "10,901",
"Stockholders Equity": "69,314",
"Net Income": "-27,663",
"Comprehensive Net Income": "-27,862",
"BaseVar": "78,683",
"ECR before LimitedLiability": "229%",
"Economic Capital Ratio": "322%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.219054861234965,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001385228.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001385228.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001385228.svg"
},
{
"company_id": "0000818033",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000818033.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000818033.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000818033.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000818033_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000818033_main_keyfigs.svg",
"name": "Heron Therapeutics INC DE",
"rank": 70,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000818033.svg",
"report_text": "The relative strengths and weaknesses of Heron Therapeutics INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Heron Therapeutics INC DE compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 154% points.The greatest weakness of Heron Therapeutics INC DE is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 45% points.
The company's Economic Capital Ratio, given in the ranking table, is 322%, being 79% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000818033_2014_Heron_Therapeutics_INC_DE.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-6.76",
"Assets": "47.3",
"Liabilities": "80.9",
"Stockholders Equity": "154",
"ECR before LimitedLiability": "107",
"Intangible Assets": "-8.75",
"Property and Equipment": "-0.655",
"Assets, Current": "88.8",
"Liabilities, Non-Current": "14.1",
"Liabilities, Current": "35.1",
"Other Liabilities": "37.7",
"Selling, General and Administrative Expense": "-10.2",
"Expenses": "-23.2",
"Revenues": "-21.6",
"Net Income": "-44.8",
"Other Expenses": "12.1",
"Research and Development": "-27.8",
"Cost of Goods Sold": "2.77",
"Other Revenues": "-21.6",
"Comprehensive Net Income": "-45.1",
"Economic Capital Ratio": "79.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000818033_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "72,925",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,992",
"Liabilities, Non-Current": "0",
"Other Assets": "130",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-826",
"Other Revenues": "0",
"Property and Equipment": "2,882",
"Research and Development": "32,780",
"Selling, General and Administrative Expense": "21,677"
},
"output_variables": {
"Assets": "75,937",
"Liabilities": "6,992",
"Expenses": "54,457",
"Revenues": "0",
"Stockholders Equity": "68,945",
"Net Income": "-55,283",
"Comprehensive Net Income": "-55,283",
"BaseVar": "69,106",
"ECR before LimitedLiability": "229%",
"Economic Capital Ratio": "322%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.218194429350633,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000818033.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000818033.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000818033.svg"
},
{
"company_id": "0001095858",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001095858.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001095858.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001095858_main_keyfigs.svg",
"name": "ERBA Diagnostics Inc",
"rank": 71,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001095858.svg",
"report_text": "The relative strengths and weaknesses of ERBA Diagnostics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of ERBA Diagnostics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 85% points.The greatest weakness of ERBA Diagnostics Inc is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 51% points.
The company's Economic Capital Ratio, given in the ranking table, is 321%, being 78% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001095858_2014_ERBA_Diagnostics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "2.82",
"Assets": "-27.1",
"Liabilities": "49.4",
"Stockholders Equity": "-15.3",
"ECR before LimitedLiability": "123",
"Intangible Assets": "-11.2",
"Property and Equipment": "-12.2",
"Assets, Current": "-9.43",
"Other Liabilities": "45.8",
"Liabilities, Non-Current": "-5.30",
"Liabilities, Current": "9.15",
"Research and Development": "43.3",
"Expenses": "-2.49",
"Revenues": "57.8",
"Net Income": "56.5",
"Other Expenses": "-12.0",
"Cost of Goods Sold": "-41.0",
"Selling, General and Administrative Expense": "10.8",
"Other Revenues": "57.8",
"Comprehensive Net Income": "56.0",
"Economic Capital Ratio": "47.6"
},
"2012": {
"Property and Equipment": "-8.79",
"Assets": "-4.26",
"Liabilities": "50.2",
"Stockholders Equity": "28.9",
"ECR before LimitedLiability": "161",
"Assets, Current": "-8.64",
"Intangible Assets": "12.3",
"Other Assets": "2.97",
"Liabilities, Current": "6.59",
"Other Liabilities": "43.2",
"Liabilities, Non-Current": "1.33",
"Selling, General and Administrative Expense": "16.2",
"Expenses": "12.4",
"Revenues": "47.1",
"Net Income": "62.7",
"Research and Development": "32.2",
"Cost of Goods Sold": "-36.1",
"Other Revenues": "47.1",
"Comprehensive Net Income": "62.9",
"Other Net Income": "1.69",
"Economic Capital Ratio": "87.6"
},
"2013": {
"Assets": "-31.3",
"Liabilities": "85.2",
"Stockholders Equity": "-21.1",
"ECR before LimitedLiability": "106",
"Intangible Assets": "5.22",
"Property and Equipment": "-8.09",
"Assets, Current": "-28.3",
"Liabilities, Non-Current": "2.44",
"Liabilities, Current": "29.6",
"Other Liabilities": "57.8",
"Selling, General and Administrative Expense": "17.2",
"Expenses": "-4.93",
"Revenues": "79.3",
"Net Income": "75.1",
"Other Expenses": "-1.84",
"Research and Development": "31.6",
"Cost of Goods Sold": "-51.5",
"Other Revenues": "79.3",
"Comprehensive Net Income": "75.5",
"Other Net Income": "1.33",
"Economic Capital Ratio": "78.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001095858_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "13,666",
"Cost of Goods Sold": "8,158",
"Intangible Assets": "1,153",
"Liabilities, Current": "5,035",
"Liabilities, Non-Current": "1,444",
"Other Assets": "2,388",
"Other Compr. Net Income": "0",
"Other Expenses": "4,762",
"Other Liabilities": "0",
"Other Net Income": "-361",
"Other Revenues": "16,760",
"Property and Equipment": "0",
"Research and Development": "1,452",
"Selling, General and Administrative Expense": "5,324"
},
"output_variables": {
"Assets": "17,207",
"Liabilities": "6,480",
"Expenses": "19,696",
"Revenues": "16,760",
"Stockholders Equity": "10,727",
"Net Income": "-3,297",
"Comprehensive Net Income": "-3,297",
"BaseVar": "30,252",
"ECR before LimitedLiability": "170%",
"Economic Capital Ratio": "282%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "16,553",
"Cost of Goods Sold": "10,257",
"Intangible Assets": "5,307",
"Liabilities, Current": "6,719",
"Liabilities, Non-Current": "1,503",
"Other Assets": "2,694",
"Other Compr. Net Income": "0",
"Other Expenses": "4,739",
"Other Liabilities": "0",
"Other Net Income": "-228",
"Other Revenues": "19,349",
"Property and Equipment": "0",
"Research and Development": "1,123",
"Selling, General and Administrative Expense": "4,556"
},
"output_variables": {
"Assets": "24,554",
"Liabilities": "8,222",
"Expenses": "20,674",
"Revenues": "19,349",
"Stockholders Equity": "16,332",
"Net Income": "-1,553",
"Comprehensive Net Income": "-1,553",
"BaseVar": "36,514",
"ECR before LimitedLiability": "208%",
"Economic Capital Ratio": "308%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "18,302",
"Cost of Goods Sold": "14,443",
"Intangible Assets": "4,975",
"Liabilities, Current": "6,753",
"Liabilities, Non-Current": "1,604",
"Other Assets": "2,598",
"Other Compr. Net Income": "376",
"Other Expenses": "5,428",
"Other Liabilities": "0",
"Other Net Income": "-242",
"Other Revenues": "28,255",
"Property and Equipment": "0",
"Research and Development": "1,920",
"Selling, General and Administrative Expense": "5,547"
},
"output_variables": {
"Assets": "25,874",
"Liabilities": "8,357",
"Expenses": "27,338",
"Revenues": "28,255",
"Stockholders Equity": "17,518",
"Net Income": "676",
"Comprehensive Net Income": "864",
"BaseVar": "45,221",
"ECR before LimitedLiability": "228%",
"Economic Capital Ratio": "321%"
}
}
},
"top_rated": false,
"trend": -9.0,
"value": 3.2116875991703098,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001095858.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001095858.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001095858.svg"
},
{
"company_id": "0000936402",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000936402.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000936402.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000936402_main_keyfigs.svg",
"name": "Shire plc",
"rank": 72,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000936402.svg",
"report_text": "The relative strengths and weaknesses of Shire plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Shire plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 58% points.The greatest weakness of Shire plc is the variable Assets, Current, reducing the Economic Capital Ratio by 20% points.
The company's Economic Capital Ratio, given in the ranking table, is 315%, being 73% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000936402_2014_Shire_plc.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "-20.3",
"Assets": "-27.8",
"Liabilities": "-59.5",
"Stockholders Equity": "-82.2",
"ECR before LimitedLiability": "-86.0",
"Other Assets": "-6.71",
"Intangible Assets": "2.70",
"Property and Equipment": "-5.41",
"Liabilities, Current": "-1.45",
"Other Liabilities": "-67.9",
"Liabilities, Non-Current": "8.33",
"Cost of Goods Sold": "0.686",
"Expenses": "-1.61",
"Revenues": "-0.0897",
"Net Income": "-1.74",
"Selling, General and Administrative Expense": "-7.24",
"Other Expenses": "8.73",
"Research and Development": "-3.61",
"Other Revenues": "-0.0897",
"Comprehensive Net Income": "-1.23",
"Other Compr. Net Income": "0.508",
"Economic Capital Ratio": "-85.2"
},
"2010": {
"Other Assets": "-11.0",
"Assets": "-19.0",
"Liabilities": "-26.0",
"Stockholders Equity": "-48.2",
"ECR before LimitedLiability": "-19.2",
"Assets, Current": "-28.2",
"Intangible Assets": "27.9",
"Liabilities, Current": "-6.98",
"Other Liabilities": "-39.8",
"Liabilities, Non-Current": "19.2",
"Selling, General and Administrative Expense": "-3.14",
"Expenses": "7.47",
"Revenues": "12.8",
"Net Income": "20.8",
"Research and Development": "3.53",
"Cost of Goods Sold": "5.62",
"Other Expenses": "1.46",
"Other Revenues": "12.8",
"Comprehensive Net Income": "20.2",
"Other Compr. Net Income": "-0.539",
"Economic Capital Ratio": "-25.6"
},
"2011": {
"Other Assets": "-8.11",
"Assets": "5.89",
"Liabilities": "-22.9",
"Stockholders Equity": "-7.06",
"ECR before LimitedLiability": "118",
"Intangible Assets": "66.6",
"Property and Equipment": "9.54",
"Assets, Current": "-32.9",
"Other Liabilities": "5.06",
"Liabilities, Non-Current": "14.1",
"Liabilities, Current": "-44.6",
"Research and Development": "24.9",
"Expenses": "32.3",
"Revenues": "32.1",
"Net Income": "70.0",
"Cost of Goods Sold": "4.03",
"Selling, General and Administrative Expense": "4.24",
"Other Revenues": "32.1",
"Comprehensive Net Income": "69.4",
"Other Net Income": "2.21",
"Economic Capital Ratio": "42.8"
},
"2012": {
"Property and Equipment": "7.60",
"Assets": "9.54",
"Liabilities": "-8.48",
"Stockholders Equity": "8.62",
"ECR before LimitedLiability": "133",
"Assets, Current": "-25.2",
"Intangible Assets": "52.8",
"Other Assets": "-7.19",
"Liabilities, Current": "10.8",
"Other Liabilities": "-27.7",
"Liabilities, Non-Current": "7.18",
"Selling, General and Administrative Expense": "1.96",
"Expenses": "32.3",
"Revenues": "33.3",
"Net Income": "70.8",
"Research and Development": "18.3",
"Other Expenses": "6.87",
"Cost of Goods Sold": "4.49",
"Other Revenues": "33.3",
"Comprehensive Net Income": "71.2",
"Economic Capital Ratio": "60.1"
},
"2013": {
"Liabilities, Non-Current": "-7.09",
"Liabilities": "24.5",
"Stockholders Equity": "21.4",
"ECR before LimitedLiability": "101",
"Liabilities, Current": "10.5",
"Other Liabilities": "21.1",
"Selling, General and Administrative Expense": "7.21",
"Expenses": "29.1",
"Net Income": "57.6",
"Other Expenses": "2.69",
"Research and Development": "15.8",
"Cost of Goods Sold": "3.04",
"Other Revenues": "35.1",
"Revenues": "35.1",
"Intangible Assets": "33.4",
"Property and Equipment": "5.36",
"Other Assets": "-5.56",
"Assets, Current": "-20.4",
"Comprehensive Net Income": "57.4",
"Other Net Income": "-7.71",
"Economic Capital Ratio": "72.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000936402_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "1,570,200",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,175,400",
"Liabilities, Current": "1,020,000",
"Liabilities, Non-Current": "290,700",
"Other Assets": "195,100",
"Other Compr. Net Income": "52,300",
"Other Expenses": "545,100",
"Other Liabilities": "1,394,300",
"Other Net Income": "9,700",
"Other Revenues": "3,007,700",
"Property and Equipment": "676,800",
"Research and Development": "638,300",
"Selling, General and Administrative Expense": "1,342,600"
},
"output_variables": {
"Assets": "4,617,500",
"Liabilities": "2,705,000",
"Expenses": "2,526,000",
"Revenues": "3,007,700",
"Stockholders Equity": "1,912,500",
"Net Income": "491,400",
"Comprehensive Net Income": "517,550",
"BaseVar": "6,459,100",
"ECR before LimitedLiability": "128%",
"Economic Capital Ratio": "252%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "1,880,300",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,381,400",
"Liabilities, Current": "1,293,300",
"Liabilities, Non-Current": "182,900",
"Other Assets": "272,500",
"Other Compr. Net Income": "-63,400",
"Other Expenses": "671,900",
"Other Liabilities": "1,460,000",
"Other Net Income": "-23,400",
"Other Revenues": "3,471,100",
"Property and Equipment": "853,400",
"Research and Development": "661,500",
"Selling, General and Administrative Expense": "1,526,300"
},
"output_variables": {
"Assets": "5,387,600",
"Liabilities": "2,936,200",
"Expenses": "2,859,700",
"Revenues": "3,471,100",
"Stockholders Equity": "2,451,400",
"Net Income": "588,000",
"Comprehensive Net Income": "556,300",
"BaseVar": "7,370,700",
"ECR before LimitedLiability": "142%",
"Economic Capital Ratio": "262%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "2,208,200",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,085,600",
"Liabilities, Current": "2,534,300",
"Liabilities, Non-Current": "0",
"Other Assets": "154,300",
"Other Compr. Net Income": "-25,400",
"Other Expenses": "859,700",
"Other Liabilities": "660,900",
"Other Net Income": "-16,600",
"Other Revenues": "4,263,400",
"Property and Equipment": "932,100",
"Research and Development": "770,700",
"Selling, General and Administrative Expense": "1,751,400"
},
"output_variables": {
"Assets": "6,380,200",
"Liabilities": "3,195,200",
"Expenses": "3,381,800",
"Revenues": "4,263,400",
"Stockholders Equity": "3,185,000",
"Net Income": "865,000",
"Comprehensive Net Income": "852,300",
"BaseVar": "8,631,300",
"ECR before LimitedLiability": "163%",
"Economic Capital Ratio": "277%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "3,212,100",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,032,600",
"Liabilities, Current": "1,645,600",
"Liabilities, Non-Current": "241,600",
"Other Assets": "116,700",
"Other Compr. Net Income": "9,240",
"Other Expenses": "806,465",
"Other Liabilities": "1,620,800",
"Other Net Income": "-29,235",
"Other Revenues": "4,793,255",
"Property and Equipment": "955,800",
"Research and Development": "985,230",
"Selling, General and Administrative Expense": "2,202,298"
},
"output_variables": {
"Assets": "7,317,200",
"Liabilities": "3,508,000",
"Expenses": "3,993,993",
"Revenues": "4,793,255",
"Stockholders Equity": "3,809,200",
"Net Income": "770,027",
"Comprehensive Net Income": "774,647",
"BaseVar": "9,825,461",
"ECR before LimitedLiability": "168%",
"Economic Capital Ratio": "280%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "4,288,300",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,937,200",
"Liabilities, Current": "1,807,900",
"Liabilities, Non-Current": "588,500",
"Other Assets": "205,700",
"Other Compr. Net Income": "24,300",
"Other Expenses": "916,911",
"Other Liabilities": "560,600",
"Other Net Income": "-4,527,190",
"Other Revenues": "5,004,984",
"Property and Equipment": "891,800",
"Research and Development": "930,958",
"Selling, General and Administrative Expense": "1,599,891"
},
"output_variables": {
"Assets": "8,323,000",
"Liabilities": "2,957,000",
"Expenses": "3,447,760",
"Revenues": "5,004,984",
"Stockholders Equity": "5,366,000",
"Net Income": "-2,969,966",
"Comprehensive Net Income": "-2,957,816",
"BaseVar": "12,142,117",
"ECR before LimitedLiability": "155%",
"Economic Capital Ratio": "271%"
}
}
},
"top_rated": false,
"trend": 8.0,
"value": 3.153725943472183,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000936402.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000936402.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000936402.svg"
},
{
"company_id": "0000891288",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000891288.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000891288.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000891288_main_keyfigs.svg",
"name": "Questcor Pharmaceuticals INC",
"rank": 73,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000891288.svg",
"report_text": "The relative strengths and weaknesses of Questcor Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Questcor Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 104% points.The greatest weakness of Questcor Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 34% points.
The company's Economic Capital Ratio, given in the ranking table, is 313%, being 71% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000891288_2014_Questcor_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.50",
"Assets": "7.34",
"Liabilities": "69.4",
"Stockholders Equity": "73.4",
"ECR before LimitedLiability": "235",
"Intangible Assets": "-5.36",
"Property and Equipment": "-3.42",
"Assets, Current": "27.1",
"Other Liabilities": "44.5",
"Liabilities, Non-Current": "19.7",
"Liabilities, Current": "11.9",
"Research and Development": "32.6",
"Expenses": "32.9",
"Revenues": "53.6",
"Net Income": "88.3",
"Other Expenses": "-31.7",
"Cost of Goods Sold": "4.55",
"Selling, General and Administrative Expense": "26.1",
"Other Revenues": "53.6",
"Comprehensive Net Income": "88.0",
"Economic Capital Ratio": "160"
},
"2012": {
"Property and Equipment": "-6.36",
"Assets": "-24.8",
"Liabilities": "121",
"Stockholders Equity": "-43.0",
"ECR before LimitedLiability": "236",
"Assets, Current": "-11.5",
"Intangible Assets": "-9.08",
"Other Assets": "-4.63",
"Liabilities, Current": "34.3",
"Other Liabilities": "70.7",
"Liabilities, Non-Current": "34.9",
"Selling, General and Administrative Expense": "39.7",
"Expenses": "25.7",
"Revenues": "152",
"Net Income": "189",
"Research and Development": "41.5",
"Other Expenses": "-68.8",
"Cost of Goods Sold": "8.20",
"Other Revenues": "152",
"Comprehensive Net Income": "190",
"Economic Capital Ratio": "163"
},
"2013": {
"Other Assets": "30.0",
"Assets": "-23.9",
"Liabilities": "32.0",
"Stockholders Equity": "-34.4",
"ECR before LimitedLiability": "98.6",
"Intangible Assets": "-6.16",
"Property and Equipment": "-3.29",
"Assets, Current": "-33.3",
"Liabilities, Non-Current": "12.0",
"Liabilities, Current": "31.0",
"Other Liabilities": "-11.4",
"Selling, General and Administrative Expense": "26.0",
"Expenses": "22.6",
"Revenues": "74.5",
"Net Income": "104",
"Other Expenses": "-31.9",
"Research and Development": "25.6",
"Cost of Goods Sold": "3.72",
"Other Revenues": "74.5",
"Comprehensive Net Income": "103",
"Economic Capital Ratio": "70.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000891288_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "265,600",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,778",
"Liabilities, Current": "55,721",
"Liabilities, Non-Current": "261",
"Other Assets": "5,460",
"Other Compr. Net Income": "0",
"Other Expenses": "104,684",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "218,796",
"Property and Equipment": "1,970",
"Research and Development": "16,778",
"Selling, General and Administrative Expense": "17,743"
},
"output_variables": {
"Assets": "275,808",
"Liabilities": "55,982",
"Expenses": "139,205",
"Revenues": "218,796",
"Stockholders Equity": "219,826",
"Net Income": "79,591",
"Comprehensive Net Income": "79,591",
"BaseVar": "344,896",
"ECR before LimitedLiability": "337%",
"Economic Capital Ratio": "394%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "237,276",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,493",
"Liabilities, Current": "90,399",
"Liabilities, Non-Current": "203",
"Other Assets": "11,589",
"Other Compr. Net Income": "76",
"Other Expenses": "244,455",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "509,995",
"Property and Equipment": "2,073",
"Research and Development": "34,269",
"Selling, General and Administrative Expense": "33,596"
},
"output_variables": {
"Assets": "252,431",
"Liabilities": "90,602",
"Expenses": "312,320",
"Revenues": "509,995",
"Stockholders Equity": "161,829",
"Net Income": "197,675",
"Comprehensive Net Income": "197,713",
"BaseVar": "582,712",
"ECR before LimitedLiability": "321%",
"Economic Capital Ratio": "383%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "396,776",
"Cost of Goods Sold": "0",
"Intangible Assets": "50,595",
"Liabilities, Current": "161,172",
"Liabilities, Non-Current": "16,959",
"Other Assets": "257,250",
"Other Compr. Net Income": "-3,293",
"Other Expenses": "389,884",
"Other Liabilities": "158,859",
"Other Net Income": "-548",
"Other Revenues": "799,179",
"Property and Equipment": "31,733",
"Research and Development": "59,730",
"Selling, General and Administrative Expense": "56,408"
},
"output_variables": {
"Assets": "736,354",
"Liabilities": "336,990",
"Expenses": "506,022",
"Revenues": "799,179",
"Stockholders Equity": "399,364",
"Net Income": "292,609",
"Comprehensive Net Income": "290,962",
"BaseVar": "1,191,193",
"ECR before LimitedLiability": "216%",
"Economic Capital Ratio": "313%"
}
}
},
"top_rated": false,
"trend": -52.0,
"value": 3.134030325551671,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000891288.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000891288.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000891288.svg"
},
{
"company_id": "0001082038",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001082038.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001082038.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001082038.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001082038_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001082038_main_keyfigs.svg",
"name": "Durect CORP",
"rank": 74,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001082038.svg",
"report_text": "The relative strengths and weaknesses of Durect CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Durect CORP compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 84% points.The greatest weakness of Durect CORP is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.
The company's Economic Capital Ratio, given in the ranking table, is 313%, being 70% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001082038_2014_Durect_CORP.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-1.07",
"Assets": "-2.76",
"Liabilities": "137",
"Stockholders Equity": "75.4",
"ECR before LimitedLiability": "280",
"Intangible Assets": "0.581",
"Other Assets": "-2.33",
"Liabilities, Current": "68.4",
"Other Liabilities": "65.6",
"Liabilities, Non-Current": "32.8",
"Selling, General and Administrative Expense": "12.5",
"Expenses": "25.5",
"Revenues": "95.5",
"Net Income": "123",
"Research and Development": "-8.30",
"Other Expenses": "14.4",
"Cost of Goods Sold": "7.01",
"Other Revenues": "95.5",
"Comprehensive Net Income": "123",
"Other Net Income": "3.87",
"Economic Capital Ratio": "207"
},
"2013": {
"Other Assets": "2.68",
"Assets": "3.00",
"Liabilities": "83.7",
"Stockholders Equity": "73.6",
"ECR before LimitedLiability": "98.4",
"Intangible Assets": "7.37",
"Property and Equipment": "-1.18",
"Assets, Current": "-5.28",
"Liabilities, Non-Current": "17.4",
"Liabilities, Current": "25.8",
"Other Liabilities": "46.2",
"Selling, General and Administrative Expense": "-4.58",
"Expenses": "-21.0",
"Revenues": "15.3",
"Net Income": "-4.95",
"Other Expenses": "1.78",
"Research and Development": "-21.7",
"Cost of Goods Sold": "3.49",
"Other Revenues": "15.3",
"Comprehensive Net Income": "-5.26",
"Economic Capital Ratio": "70.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001082038_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "36,355",
"Cost of Goods Sold": "0",
"Intangible Assets": "6,435",
"Liabilities, Current": "6,927",
"Liabilities, Non-Current": "0",
"Other Assets": "688",
"Other Compr. Net Income": "1.0",
"Other Expenses": "4,654",
"Other Liabilities": "0",
"Other Net Income": "144",
"Other Revenues": "53,070",
"Property and Equipment": "2,457",
"Research and Development": "20,265",
"Selling, General and Administrative Expense": "12,095"
},
"output_variables": {
"Assets": "45,935",
"Liabilities": "6,927",
"Expenses": "37,014",
"Revenues": "53,070",
"Stockholders Equity": "39,008",
"Net Income": "16,200",
"Comprehensive Net Income": "16,200",
"BaseVar": "71,546",
"ECR before LimitedLiability": "383%",
"Economic Capital Ratio": "427%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "28,328",
"Cost of Goods Sold": "0",
"Intangible Assets": "6,417",
"Liabilities, Current": "7,185",
"Liabilities, Non-Current": "0",
"Other Assets": "4,090",
"Other Compr. Net Income": "-5.0",
"Other Expenses": "4,837",
"Other Liabilities": "0",
"Other Net Income": "-290",
"Other Revenues": "15,326",
"Property and Equipment": "1,985",
"Research and Development": "18,945",
"Selling, General and Administrative Expense": "12,706"
},
"output_variables": {
"Assets": "40,820",
"Liabilities": "7,185",
"Expenses": "36,488",
"Revenues": "15,326",
"Stockholders Equity": "33,635",
"Net Income": "-21,452",
"Comprehensive Net Income": "-21,454",
"BaseVar": "50,057",
"ECR before LimitedLiability": "216%",
"Economic Capital Ratio": "313%"
}
}
},
"top_rated": false,
"trend": -70.0,
"value": 3.1317788828200634,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001082038.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001082038.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001082038.svg"
},
{
"company_id": "0001338042",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001338042.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001338042.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001338042_main_keyfigs.svg",
"name": "Aegerion Pharmaceuticals Inc",
"rank": 75,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001338042.svg",
"report_text": "The relative strengths and weaknesses of Aegerion Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Aegerion Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 71% points.The greatest weakness of Aegerion Pharmaceuticals Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 30% points.
The company's Economic Capital Ratio, given in the ranking table, is 311%, being 69% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001338042_2014_Aegerion_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-25.5",
"Assets": "-9.07",
"Liabilities": "15.6",
"Stockholders Equity": "15.5",
"Intangible Assets": "-37.1",
"Property and Equipment": "-22.6",
"Assets, Current": "23.3",
"Other Liabilities": "4.31",
"ECR before LimitedLiability": "-4.91",
"Liabilities, Non-Current": "12.6",
"Liabilities, Current": "13.8",
"Research and Development": "-79.6",
"Expenses": "-95.2",
"Revenues": "-53.2",
"Net Income": "-129",
"Cost of Goods Sold": "7.26",
"Selling, General and Administrative Expense": "-26.6",
"Other Revenues": "-53.2",
"Comprehensive Net Income": "-129",
"Other Net Income": "12.2",
"Economic Capital Ratio": "-80.5"
},
"2012": {
"Property and Equipment": "-7.30",
"Assets": "75.7",
"Liabilities": "16.7",
"Stockholders Equity": "100.0",
"ECR before LimitedLiability": "104",
"Assets, Current": "113",
"Intangible Assets": "-13.3",
"Other Assets": "-9.35",
"Other Liabilities": "2.03",
"Liabilities, Non-Current": "14.3",
"Selling, General and Administrative Expense": "-18.7",
"Expenses": "-7.75",
"Revenues": "-25.6",
"Net Income": "-31.9",
"Research and Development": "-5.91",
"Other Expenses": "13.4",
"Cost of Goods Sold": "4.20",
"Other Revenues": "-25.6",
"Comprehensive Net Income": "-31.7",
"Other Net Income": "1.08",
"Economic Capital Ratio": "30.5"
},
"2013": {
"Other Assets": "-8.54",
"Assets": "9.30",
"Liabilities": "66.8",
"Stockholders Equity": "70.9",
"ECR before LimitedLiability": "96.5",
"Intangible Assets": "-10.9",
"Property and Equipment": "-5.18",
"Assets, Current": "47.5",
"Liabilities, Non-Current": "6.42",
"Liabilities, Current": "21.7",
"Other Liabilities": "42.0",
"Selling, General and Administrative Expense": "-30.3",
"Expenses": "-12.5",
"Revenues": "12.4",
"Net Income": "1.46",
"Other Expenses": "9.43",
"Research and Development": "5.37",
"Cost of Goods Sold": "3.25",
"Other Revenues": "12.4",
"Other Net Income": "1.72",
"Economic Capital Ratio": "68.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001338042_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "74,077",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,400",
"Liabilities, Non-Current": "0",
"Other Assets": "965",
"Other Compr. Net Income": "0",
"Other Expenses": "9,596",
"Other Liabilities": "8,966",
"Other Net Income": "3,686",
"Other Revenues": "0",
"Property and Equipment": "526",
"Research and Development": "73,558",
"Selling, General and Administrative Expense": "39,254"
},
"output_variables": {
"Assets": "75,568",
"Liabilities": "18,367",
"Expenses": "122,408",
"Revenues": "0",
"Stockholders Equity": "57,201",
"Net Income": "-118,722",
"Comprehensive Net Income": "-118,722",
"BaseVar": "110,014",
"ECR before LimitedLiability": "13%",
"Economic Capital Ratio": "154%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "83,748",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "16,926",
"Liabilities, Non-Current": "0",
"Other Assets": "198",
"Other Compr. Net Income": "65",
"Other Expenses": "2,303",
"Other Liabilities": "7,762",
"Other Net Income": "-721",
"Other Revenues": "0",
"Property and Equipment": "1,143",
"Research and Development": "25,164",
"Selling, General and Administrative Expense": "34,077"
},
"output_variables": {
"Assets": "85,089",
"Liabilities": "24,688",
"Expenses": "61,544",
"Revenues": "0",
"Stockholders Equity": "60,401",
"Net Income": "-62,265",
"Comprehensive Net Income": "-62,232",
"BaseVar": "86,054",
"ECR before LimitedLiability": "127%",
"Economic Capital Ratio": "251%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "140,514",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "24,844",
"Liabilities, Non-Current": "4,011",
"Other Assets": "164",
"Other Compr. Net Income": "11",
"Other Expenses": "6,092",
"Other Liabilities": "445",
"Other Net Income": "58",
"Other Revenues": "48,546",
"Property and Equipment": "1,654",
"Research and Development": "29,788",
"Selling, General and Administrative Expense": "76,082"
},
"output_variables": {
"Assets": "142,332",
"Liabilities": "29,300",
"Expenses": "111,962",
"Revenues": "48,546",
"Stockholders Equity": "113,032",
"Net Income": "-63,358",
"Comprehensive Net Income": "-63,352",
"BaseVar": "166,104",
"ECR before LimitedLiability": "213%",
"Economic Capital Ratio": "311%"
}
}
},
"top_rated": false,
"trend": 22.0,
"value": 3.1132413003299786,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001338042.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001338042.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001338042.svg"
},
{
"company_id": "0000849146",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000849146.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000849146.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000849146.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000849146_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000849146_main_keyfigs.svg",
"name": "Lifevantage Corp",
"rank": 76,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000849146.svg",
"report_text": "The relative strengths and weaknesses of Lifevantage Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Lifevantage Corp compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 209% points.The greatest weakness of Lifevantage Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 324% points.
The company's Economic Capital Ratio, given in the ranking table, is 310%, being 68% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000849146_2014_Lifevantage_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-26.7",
"Assets": "-129",
"Liabilities": "-0.578",
"Stockholders Equity": "-200",
"ECR before LimitedLiability": "-124",
"Intangible Assets": "-26.6",
"Property and Equipment": "-21.2",
"Assets, Current": "-102",
"Other Liabilities": "-1.35",
"Liabilities, Non-Current": "0.250",
"Research and Development": "18.8",
"Expenses": "16.6",
"Revenues": "14.5",
"Net Income": "-17.7",
"Other Expenses": "-15.4",
"Cost of Goods Sold": "-3.28",
"Selling, General and Administrative Expense": "11.6",
"Other Revenues": "14.5",
"Comprehensive Net Income": "-18.0",
"Other Net Income": "-71.3",
"Economic Capital Ratio": "-200"
},
"2012": {
"Property and Equipment": "-11.9",
"Assets": "-64.2",
"Liabilities": "191",
"Stockholders Equity": "-130",
"ECR before LimitedLiability": "185",
"Assets, Current": "-48.7",
"Intangible Assets": "-17.9",
"Other Assets": "-12.5",
"Liabilities, Current": "86.9",
"Other Liabilities": "91.2",
"Liabilities, Non-Current": "43.3",
"Selling, General and Administrative Expense": "40.8",
"Expenses": "-20.4",
"Revenues": "195",
"Net Income": "191",
"Research and Development": "79.2",
"Other Expenses": "-115",
"Cost of Goods Sold": "-27.6",
"Other Revenues": "195",
"Comprehensive Net Income": "191",
"Economic Capital Ratio": "112"
},
"2013": {
"Other Assets": "-22.2",
"Assets": "-96.6",
"Liabilities": "177",
"Stockholders Equity": "-324",
"ECR before LimitedLiability": "95.5",
"Intangible Assets": "-28.4",
"Property and Equipment": "-10.5",
"Assets, Current": "-84.7",
"Liabilities, Non-Current": "45.2",
"Liabilities, Current": "135",
"Other Liabilities": "127",
"Selling, General and Administrative Expense": "-7.10",
"Expenses": "-105",
"Revenues": "209",
"Net Income": "173",
"Other Expenses": "-151",
"Research and Development": "103",
"Cost of Goods Sold": "-44.1",
"Other Revenues": "209",
"Comprehensive Net Income": "173",
"Economic Capital Ratio": "67.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000849146_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "10,275",
"Cost of Goods Sold": "5,917",
"Intangible Assets": "1,963",
"Liabilities, Current": "13,380",
"Liabilities, Non-Current": "0",
"Other Assets": "32",
"Other Compr. Net Income": "-28",
"Other Expenses": "21,367",
"Other Liabilities": "19,926",
"Other Net Income": "-54,402",
"Other Revenues": "38,919",
"Property and Equipment": "228",
"Research and Development": "509",
"Selling, General and Administrative Expense": "7,516"
},
"output_variables": {
"Assets": "12,499",
"Liabilities": "33,307",
"Expenses": "35,309",
"Revenues": "38,919",
"Stockholders Equity": "-20,808",
"Net Income": "-50,792",
"Comprehensive Net Income": "-50,806",
"BaseVar": "87,232",
"ECR before LimitedLiability": "-420%",
"Economic Capital Ratio": "34%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "38,828",
"Cost of Goods Sold": "18,052",
"Intangible Assets": "1,882",
"Liabilities, Current": "16,028",
"Liabilities, Non-Current": "217",
"Other Assets": "1,821",
"Other Compr. Net Income": "38",
"Other Expenses": "71,121",
"Other Liabilities": "0",
"Other Net Income": "-6,785",
"Other Revenues": "126,183",
"Property and Equipment": "1,997",
"Research and Development": "1,359",
"Selling, General and Administrative Expense": "16,397"
},
"output_variables": {
"Assets": "44,528",
"Liabilities": "16,245",
"Expenses": "106,929",
"Revenues": "126,183",
"Stockholders Equity": "28,283",
"Net Income": "12,469",
"Comprehensive Net Income": "12,488",
"BaseVar": "150,354",
"ECR before LimitedLiability": "244%",
"Economic Capital Ratio": "332%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "45,941",
"Cost of Goods Sold": "31,845",
"Intangible Assets": "1,747",
"Liabilities, Current": "20,566",
"Liabilities, Non-Current": "973",
"Other Assets": "2,104",
"Other Compr. Net Income": "-92",
"Other Expenses": "110,080",
"Other Liabilities": "0",
"Other Net Income": "-915",
"Other Revenues": "208,178",
"Property and Equipment": "5,692",
"Research and Development": "0",
"Selling, General and Administrative Expense": "57,730"
},
"output_variables": {
"Assets": "55,484",
"Liabilities": "21,539",
"Expenses": "199,655",
"Revenues": "208,178",
"Stockholders Equity": "33,945",
"Net Income": "7,608",
"Comprehensive Net Income": "7,562",
"BaseVar": "242,932",
"ECR before LimitedLiability": "212%",
"Economic Capital Ratio": "310%"
}
}
},
"top_rated": false,
"trend": -30.0,
"value": 3.103072104922098,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000849146.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000849146.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000849146.svg"
},
{
"company_id": "0001082554",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001082554.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001082554.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001082554.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001082554_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001082554_main_keyfigs.svg",
"name": "United Therapeutics Corp",
"rank": 77,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001082554.svg",
"report_text": "The relative strengths and weaknesses of United Therapeutics Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of United Therapeutics Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 56% points.The greatest weakness of United Therapeutics Corp is the variable Liabilities, Current, reducing the Economic Capital Ratio by 30% points.
The company's Economic Capital Ratio, given in the ranking table, is 309%, being 67% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001082554_2014_United_Therapeutics_Corp.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "18.3",
"Assets": "11.4",
"Liabilities": "-6.47",
"Stockholders Equity": "16.0",
"ECR before LimitedLiability": "27.3",
"Assets, Current": "8.10",
"Property and Equipment": "10.8",
"Intangible Assets": "-20.0",
"Liabilities, Current": "-44.9",
"Other Liabilities": "16.8",
"Liabilities, Non-Current": "16.9",
"Selling, General and Administrative Expense": "5.49",
"Expenses": "13.8",
"Revenues": "2.11",
"Net Income": "15.4",
"Research and Development": "0.872",
"Cost of Goods Sold": "4.52",
"Other Expenses": "2.85",
"Other Revenues": "2.11",
"Comprehensive Net Income": "15.4",
"Economic Capital Ratio": "21.0"
},
"2011": {
"Other Assets": "43.4",
"Assets": "27.8",
"Liabilities": "-7.97",
"Stockholders Equity": "42.7",
"ECR before LimitedLiability": "159",
"Intangible Assets": "-9.44",
"Property and Equipment": "21.6",
"Assets, Current": "-15.9",
"Other Liabilities": "-25.4",
"Liabilities, Non-Current": "-3.59",
"Liabilities, Current": "19.2",
"Research and Development": "18.5",
"Expenses": "36.4",
"Revenues": "20.9",
"Net Income": "59.7",
"Other Expenses": "-1.37",
"Cost of Goods Sold": "3.38",
"Selling, General and Administrative Expense": "15.3",
"Other Revenues": "20.9",
"Comprehensive Net Income": "59.4",
"Economic Capital Ratio": "83.2"
},
"2012": {
"Property and Equipment": "23.9",
"Assets": "21.8",
"Liabilities": "19.8",
"Stockholders Equity": "57.5",
"ECR before LimitedLiability": "188",
"Assets, Current": "-14.0",
"Intangible Assets": "-7.86",
"Other Assets": "28.0",
"Liabilities, Current": "37.2",
"Other Liabilities": "-20.9",
"Liabilities, Non-Current": "0.415",
"Selling, General and Administrative Expense": "14.2",
"Expenses": "35.6",
"Revenues": "30.4",
"Net Income": "70.9",
"Research and Development": "16.9",
"Cost of Goods Sold": "4.04",
"Other Revenues": "30.4",
"Comprehensive Net Income": "71.0",
"Other Net Income": "3.16",
"Economic Capital Ratio": "115"
},
"2013": {
"Other Assets": "37.0",
"Assets": "6.83",
"Liabilities": "12.9",
"Stockholders Equity": "21.8",
"ECR before LimitedLiability": "94.5",
"Intangible Assets": "-9.89",
"Property and Equipment": "21.0",
"Assets, Current": "-24.9",
"Liabilities, Non-Current": "0.902",
"Liabilities, Current": "-29.6",
"Other Liabilities": "37.8",
"Selling, General and Administrative Expense": "7.00",
"Expenses": "23.2",
"Revenues": "30.0",
"Net Income": "55.6",
"Other Expenses": "1.61",
"Research and Development": "11.5",
"Cost of Goods Sold": "2.89",
"Other Revenues": "30.0",
"Comprehensive Net Income": "55.4",
"Economic Capital Ratio": "66.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001082554_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "764,487",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "428,686",
"Liabilities, Non-Current": "39,252",
"Other Assets": "361,104",
"Other Compr. Net Income": "0",
"Other Expenses": "115,388",
"Other Liabilities": "68,929",
"Other Net Income": "-16,166",
"Other Revenues": "603,831",
"Property and Equipment": "306,044",
"Research and Development": "166,761",
"Selling, General and Administrative Expense": "199,600"
},
"output_variables": {
"Assets": "1,431,635",
"Liabilities": "536,867",
"Expenses": "481,749",
"Revenues": "603,831",
"Stockholders Equity": "894,768",
"Net Income": "105,916",
"Comprehensive Net Income": "105,916",
"BaseVar": "1,535,124",
"ECR before LimitedLiability": "209%",
"Economic Capital Ratio": "308%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "562,455",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "212,577",
"Liabilities, Non-Current": "80,500",
"Other Assets": "589,578",
"Other Compr. Net Income": "0",
"Other Expenses": "170,778",
"Other Liabilities": "265,632",
"Other Net Income": "-18,665",
"Other Revenues": "743,183",
"Property and Equipment": "366,046",
"Research and Development": "180,015",
"Selling, General and Administrative Expense": "156,482"
},
"output_variables": {
"Assets": "1,518,079",
"Liabilities": "558,709",
"Expenses": "507,275",
"Revenues": "743,183",
"Stockholders Equity": "959,370",
"Net Income": "217,243",
"Comprehensive Net Income": "217,243",
"BaseVar": "1,672,956",
"ECR before LimitedLiability": "222%",
"Economic Capital Ratio": "317%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "668,470",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "176,755",
"Liabilities, Non-Current": "79,967",
"Other Assets": "504,440",
"Other Compr. Net Income": "-4,072",
"Other Expenses": "255,526",
"Other Liabilities": "275,010",
"Other Net Income": "19,025",
"Other Revenues": "916,076",
"Property and Equipment": "453,685",
"Research and Development": "173,387",
"Selling, General and Administrative Expense": "201,746"
},
"output_variables": {
"Assets": "1,626,595",
"Liabilities": "531,732",
"Expenses": "630,659",
"Revenues": "916,076",
"Stockholders Equity": "1,094,863",
"Net Income": "304,442",
"Comprehensive Net Income": "302,406",
"BaseVar": "1,864,080",
"ECR before LimitedLiability": "249%",
"Economic Capital Ratio": "335%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "909,013",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "687,674",
"Liabilities, Non-Current": "91,858",
"Other Assets": "713,604",
"Other Compr. Net Income": "-4,061",
"Other Expenses": "222,326",
"Other Liabilities": "3,724",
"Other Net Income": "4,068",
"Other Revenues": "1,222,479",
"Property and Equipment": "464,950",
"Research and Development": "305,414",
"Selling, General and Administrative Expense": "386,188"
},
"output_variables": {
"Assets": "2,087,567",
"Liabilities": "783,256",
"Expenses": "913,928",
"Revenues": "1,222,479",
"Stockholders Equity": "1,304,311",
"Net Income": "312,619",
"Comprehensive Net Income": "310,589",
"BaseVar": "2,507,680",
"ECR before LimitedLiability": "220%",
"Economic Capital Ratio": "316%"
}
}
},
"top_rated": false,
"trend": -33.0,
"value": 3.093246853672902,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001082554.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001082554.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001082554.svg"
},
{
"company_id": "0001069308",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001069308.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001069308.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001069308.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001069308_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001069308_main_keyfigs.svg",
"name": "Acer Therapeutics Inc",
"rank": 78,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001069308.svg",
"report_text": "The relative strengths and weaknesses of Acer Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Acer Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 112% points.The greatest weakness of Acer Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 48% points.
The company's Economic Capital Ratio, given in the ranking table, is 308%, being 65% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001069308_2014_Acer_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "0",
"Assets": "-132",
"Stockholders Equity": "0",
"ECR before LimitedLiability": "-159",
"Intangible Assets": "-0.0228",
"Property and Equipment": "0",
"Assets, Current": "-74.1",
"Other Liabilities": "0",
"Liabilities": "-0.111",
"Liabilities, Non-Current": "0",
"Liabilities, Current": "0",
"Research and Development": "0",
"Expenses": "0",
"Net Income": "-120",
"Other Expenses": "0",
"Selling, General and Administrative Expense": "0",
"Other Revenues": "0",
"Revenues": "0",
"Comprehensive Net Income": "-121",
"Other Net Income": "-245",
"Economic Capital Ratio": "-234"
},
"2013": {
"Other Assets": "-5.63",
"Assets": "62.1",
"Liabilities": "26.3",
"Stockholders Equity": "112",
"ECR before LimitedLiability": "92.8",
"Intangible Assets": "-8.09",
"Property and Equipment": "1.25",
"Assets, Current": "96.4",
"Liabilities, Non-Current": "11.4",
"Liabilities, Current": "55.0",
"Other Liabilities": "-48.4",
"Selling, General and Administrative Expense": "20.4",
"Expenses": "44.7",
"Revenues": "-17.8",
"Net Income": "-13.1",
"Research and Development": "20.5",
"Cost of Goods Sold": "2.30",
"Other Revenues": "-17.8",
"Comprehensive Net Income": "-13.3",
"Other Net Income": "-37.9",
"Economic Capital Ratio": "64.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001069308_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "7,234",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,068",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "9,057",
"Other Liabilities": "0",
"Other Net Income": "-91,624",
"Other Revenues": "0",
"Property and Equipment": "1,029",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "8,263",
"Liabilities": "1,068",
"Expenses": "9,057",
"Revenues": "0",
"Stockholders Equity": "7,195",
"Net Income": "-100,681",
"Comprehensive Net Income": "-100,681",
"BaseVar": "55,006",
"ECR before LimitedLiability": "-1,822%",
"Economic Capital Ratio": "0.00000000042%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "24,767",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "178",
"Other Compr. Net Income": "0",
"Other Expenses": "2,267",
"Other Liabilities": "5,663",
"Other Net Income": "-9,447",
"Other Revenues": "0",
"Property and Equipment": "1,295",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "26,240",
"Liabilities": "5,663",
"Expenses": "2,267",
"Revenues": "0",
"Stockholders Equity": "20,577",
"Net Income": "-11,714",
"Comprehensive Net Income": "-11,714",
"BaseVar": "21,808",
"ECR before LimitedLiability": "208%",
"Economic Capital Ratio": "308%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.0763723841549764,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001069308.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001069308.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001069308.svg"
},
{
"company_id": "0001174940",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001174940.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001174940.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001174940.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001174940_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001174940_main_keyfigs.svg",
"name": "Oragenics INC",
"rank": 79,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001174940.svg",
"report_text": "The relative strengths and weaknesses of Oragenics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Oragenics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 150% points.The greatest weakness of Oragenics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 67% points.
The company's Economic Capital Ratio, given in the ranking table, is 307%, being 64% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001174940_2014_Oragenics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-11.6",
"Assets": "-97.6",
"Liabilities": "8.08",
"Stockholders Equity": "-145",
"ECR before LimitedLiability": "-136",
"Intangible Assets": "-15.7",
"Property and Equipment": "-7.06",
"Assets, Current": "-72.1",
"Other Liabilities": "-0.583",
"Liabilities, Current": "12.5",
"Research and Development": "1.68",
"Expenses": "-7.27",
"Revenues": "-4.24",
"Net Income": "-12.9",
"Other Expenses": "0.762",
"Cost of Goods Sold": "1.08",
"Selling, General and Administrative Expense": "-11.9",
"Other Revenues": "-4.24",
"Comprehensive Net Income": "-13.0",
"Other Net Income": "-0.418",
"Economic Capital Ratio": "-211"
},
"2012": {
"Property and Equipment": "-12.8",
"Assets": "20.1",
"Liabilities": "105",
"Stockholders Equity": "106",
"ECR before LimitedLiability": "98.5",
"Assets, Current": "105",
"Intangible Assets": "-19.8",
"Other Assets": "-14.6",
"Liabilities, Current": "50.1",
"Other Liabilities": "45.5",
"Liabilities, Non-Current": "21.3",
"Selling, General and Administrative Expense": "-22.9",
"Expenses": "-58.4",
"Revenues": "-22.2",
"Net Income": "-83.1",
"Research and Development": "-54.9",
"Other Expenses": "13.5",
"Cost of Goods Sold": "6.38",
"Other Revenues": "-22.2",
"Comprehensive Net Income": "-82.9",
"Economic Capital Ratio": "25.5"
},
"2013": {
"Other Assets": "-9.36",
"Assets": "24.3",
"Liabilities": "112",
"Stockholders Equity": "150",
"ECR before LimitedLiability": "92.4",
"Intangible Assets": "-11.7",
"Property and Equipment": "-6.81",
"Assets, Current": "81.8",
"Liabilities, Non-Current": "16.9",
"Liabilities, Current": "59.4",
"Other Liabilities": "44.9",
"Selling, General and Administrative Expense": "-26.3",
"Expenses": "-50.4",
"Revenues": "-18.8",
"Net Income": "-66.5",
"Other Expenses": "12.4",
"Research and Development": "-39.7",
"Cost of Goods Sold": "3.43",
"Other Revenues": "-18.8",
"Comprehensive Net Income": "-66.9",
"Economic Capital Ratio": "64.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001174940_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,118",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,446",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "714",
"Other Liabilities": "0",
"Other Net Income": "-333",
"Other Revenues": "1,444",
"Property and Equipment": "149",
"Research and Development": "2,449",
"Selling, General and Administrative Expense": "5,628"
},
"output_variables": {
"Assets": "1,267",
"Liabilities": "9,446",
"Expenses": "8,791",
"Revenues": "1,444",
"Stockholders Equity": "-8,179",
"Net Income": "-7,679",
"Comprehensive Net Income": "-7,679",
"BaseVar": "10,640",
"ECR before LimitedLiability": "-476%",
"Economic Capital Ratio": "23%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "10,404",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,256",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "878",
"Other Liabilities": "0",
"Other Net Income": "-658",
"Other Revenues": "1,332",
"Property and Equipment": "85",
"Research and Development": "7,861",
"Selling, General and Administrative Expense": "5,025"
},
"output_variables": {
"Assets": "10,488",
"Liabilities": "1,256",
"Expenses": "13,764",
"Revenues": "1,332",
"Stockholders Equity": "9,232",
"Net Income": "-13,090",
"Comprehensive Net Income": "-13,090",
"BaseVar": "13,749",
"ECR before LimitedLiability": "120%",
"Economic Capital Ratio": "246%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "16,805",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "993",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "343",
"Other Liabilities": "0",
"Other Net Income": "141",
"Other Revenues": "1,032",
"Property and Equipment": "27",
"Research and Development": "9,359",
"Selling, General and Administrative Expense": "7,540"
},
"output_variables": {
"Assets": "16,831",
"Liabilities": "993",
"Expenses": "17,242",
"Revenues": "1,032",
"Stockholders Equity": "15,839",
"Net Income": "-16,069",
"Comprehensive Net Income": "-16,069",
"BaseVar": "18,120",
"ECR before LimitedLiability": "207%",
"Economic Capital Ratio": "307%"
}
}
},
"top_rated": false,
"trend": 25.0,
"value": 3.0719811405611135,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001174940.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001174940.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001174940.svg"
},
{
"company_id": "0001322505",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001322505.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001322505.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001322505.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001322505_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001322505_main_keyfigs.svg",
"name": "Albireo Pharma INC",
"rank": 80,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001322505.svg",
"report_text": "The relative strengths and weaknesses of Albireo Pharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Albireo Pharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 111% points.The greatest weakness of Albireo Pharma INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 20% points.
The company's Economic Capital Ratio, given in the ranking table, is 306%, being 63% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001322505_2014_Albireo_Pharma_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.03",
"Assets": "34.1",
"Liabilities": "74.6",
"Stockholders Equity": "138",
"ECR before LimitedLiability": "212",
"Intangible Assets": "-6.48",
"Assets, Current": "62.8",
"Other Liabilities": "25.5",
"Liabilities, Non-Current": "16.0",
"Liabilities, Current": "40.8",
"Research and Development": "-7.40",
"Expenses": "7.46",
"Revenues": "-30.2",
"Net Income": "15.1",
"Other Expenses": "10.2",
"Cost of Goods Sold": "3.76",
"Selling, General and Administrative Expense": "0.826",
"Other Revenues": "-30.2",
"Comprehensive Net Income": "14.8",
"Other Net Income": "36.8",
"Economic Capital Ratio": "136"
},
"2012": {
"Assets": "85.7",
"Liabilities": "17.7",
"Stockholders Equity": "121",
"ECR before LimitedLiability": "142",
"Assets, Current": "146",
"Intangible Assets": "-9.13",
"Other Assets": "-6.76",
"Liabilities, Current": "34.9",
"Other Liabilities": "-33.3",
"Liabilities, Non-Current": "13.0",
"Selling, General and Administrative Expense": "4.48",
"Expenses": "11.5",
"Revenues": "-21.4",
"Net Income": "-14.3",
"Research and Development": "-10.0",
"Other Expenses": "13.7",
"Cost of Goods Sold": "3.48",
"Other Revenues": "-21.4",
"Comprehensive Net Income": "-14.1",
"Other Net Income": "-4.00",
"Economic Capital Ratio": "68.9"
},
"2013": {
"Other Assets": "-6.78",
"Assets": "56.8",
"Liabilities": "32.5",
"Stockholders Equity": "111",
"ECR before LimitedLiability": "90.9",
"Intangible Assets": "-8.44",
"Property and Equipment": "-2.01",
"Assets, Current": "104",
"Liabilities, Non-Current": "11.7",
"Liabilities, Current": "38.9",
"Other Liabilities": "-19.7",
"Other Revenues": "-18.5",
"Revenues": "-18.5",
"Net Income": "-16.2",
"Selling, General and Administrative Expense": "2.69",
"Comprehensive Net Income": "-16.5",
"Other Expenses": "11.8",
"Cost of Goods Sold": "2.41",
"Other Net Income": "2.84",
"Research and Development": "-17.2",
"Economic Capital Ratio": "62.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001322505_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "39,196",
"Cost of Goods Sold": "0",
"Intangible Assets": "49",
"Liabilities, Current": "3,289",
"Liabilities, Non-Current": "0",
"Other Assets": "7.0",
"Other Compr. Net Income": "0",
"Other Expenses": "119",
"Other Liabilities": "1,138",
"Other Net Income": "11,984",
"Other Revenues": "60",
"Property and Equipment": "2,253",
"Research and Development": "13,901",
"Selling, General and Administrative Expense": "9,321"
},
"output_variables": {
"Assets": "41,505",
"Liabilities": "4,427",
"Expenses": "23,341",
"Revenues": "60",
"Stockholders Equity": "37,078",
"Net Income": "-11,297",
"Comprehensive Net Income": "-11,297",
"BaseVar": "40,658",
"ECR before LimitedLiability": "303%",
"Economic Capital Ratio": "371%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "39,536",
"Cost of Goods Sold": "0",
"Intangible Assets": "46",
"Liabilities, Current": "2,780",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "8.0",
"Other Liabilities": "7,338",
"Other Net Income": "-2,137",
"Other Revenues": "80",
"Property and Equipment": "1,552",
"Research and Development": "12,571",
"Selling, General and Administrative Expense": "6,816"
},
"output_variables": {
"Assets": "41,134",
"Liabilities": "10,118",
"Expenses": "19,395",
"Revenues": "80",
"Stockholders Equity": "31,016",
"Net Income": "-21,452",
"Comprehensive Net Income": "-21,452",
"BaseVar": "36,432",
"ECR before LimitedLiability": "180%",
"Economic Capital Ratio": "289%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "40,077",
"Cost of Goods Sold": "0",
"Intangible Assets": "43",
"Liabilities, Current": "2,441",
"Liabilities, Non-Current": "26",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-453",
"Other Liabilities": "6,121",
"Other Net Income": "590",
"Other Revenues": "56",
"Property and Equipment": "1,031",
"Research and Development": "14,296",
"Selling, General and Administrative Expense": "6,843"
},
"output_variables": {
"Assets": "41,151",
"Liabilities": "8,588",
"Expenses": "20,686",
"Revenues": "56",
"Stockholders Equity": "32,563",
"Net Income": "-20,040",
"Comprehensive Net Income": "-20,040",
"BaseVar": "35,536",
"ECR before LimitedLiability": "205%",
"Economic Capital Ratio": "306%"
}
}
},
"top_rated": false,
"trend": -6.0,
"value": 3.0568098664201306,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001322505.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001322505.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001322505.svg"
},
{
"company_id": "0000832489",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000832489.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000832489.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000832489.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000832489_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000832489_main_keyfigs.svg",
"name": "Geovax Labs Inc",
"rank": 81,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000832489.svg",
"report_text": "The relative strengths and weaknesses of Geovax Labs Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Geovax Labs Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 164% points.The greatest weakness of Geovax Labs Inc is the variable Research and Development, reducing the Economic Capital Ratio by 75% points.
The company's Economic Capital Ratio, given in the ranking table, is 306%, being 63% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000832489_2014_Geovax_Labs_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-19.9",
"Assets": "-183",
"Liabilities": "31.3",
"Stockholders Equity": "-238",
"Intangible Assets": "-36.3",
"Property and Equipment": "-3.89",
"Assets, Current": "-144",
"Other Liabilities": "15.8",
"ECR before LimitedLiability": "-21.8",
"Liabilities, Non-Current": "6.30",
"Liabilities, Current": "9.56",
"Research and Development": "-100",
"Expenses": "-120",
"Revenues": "-77.1",
"Net Income": "9.25",
"Other Expenses": "9.47",
"Selling, General and Administrative Expense": "-35.6",
"Other Revenues": "-77.1",
"Comprehensive Net Income": "8.93",
"Other Net Income": "109",
"Economic Capital Ratio": "-97.4"
},
"2012": {
"Property and Equipment": "-27.0",
"Assets": "-146",
"Liabilities": "63.6",
"Stockholders Equity": "-98.8",
"ECR before LimitedLiability": "33.5",
"Assets, Current": "-110",
"Intangible Assets": "-53.5",
"Other Assets": "-41.4",
"Liabilities, Current": "45.9",
"Other Liabilities": "42.7",
"Liabilities, Non-Current": "39.6",
"Selling, General and Administrative Expense": "-62.3",
"Expenses": "-148",
"Revenues": "-92.3",
"Net Income": "-9.32",
"Research and Development": "-158",
"Other Expenses": "40.5",
"Cost of Goods Sold": "16.9",
"Other Revenues": "-92.3",
"Other Net Income": "99.3",
"Economic Capital Ratio": "-39.5"
},
"2013": {
"Other Assets": "-13.8",
"Assets": "-43.5",
"Liabilities": "164",
"Stockholders Equity": "23.6",
"ECR before LimitedLiability": "90.7",
"Intangible Assets": "-18.2",
"Property and Equipment": "-5.84",
"Assets, Current": "-17.2",
"Liabilities, Non-Current": "26.6",
"Liabilities, Current": "88.4",
"Other Liabilities": "69.8",
"Selling, General and Administrative Expense": "-27.6",
"Expenses": "-73.5",
"Revenues": "-42.3",
"Net Income": "-11.2",
"Other Expenses": "24.4",
"Research and Development": "-75.0",
"Other Revenues": "-42.3",
"Comprehensive Net Income": "-11.7",
"Other Net Income": "120",
"Economic Capital Ratio": "62.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000832489_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,418",
"Cost of Goods Sold": "0",
"Intangible Assets": "40",
"Liabilities, Current": "942",
"Liabilities, Non-Current": "0",
"Other Assets": "11",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "4,902",
"Other Revenues": "0",
"Property and Equipment": "176",
"Research and Development": "4,276",
"Selling, General and Administrative Expense": "2,973"
},
"output_variables": {
"Assets": "1,645",
"Liabilities": "942",
"Expenses": "7,249",
"Revenues": "0",
"Stockholders Equity": "704",
"Net Income": "-2,347",
"Comprehensive Net Income": "-2,347",
"BaseVar": "7,369",
"ECR before LimitedLiability": "-63%",
"Economic Capital Ratio": "137%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,344",
"Cost of Goods Sold": "0",
"Intangible Assets": "20",
"Liabilities, Current": "327",
"Liabilities, Non-Current": "0",
"Other Assets": "11",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "2,661",
"Other Revenues": "0",
"Property and Equipment": "102",
"Research and Development": "3,044",
"Selling, General and Administrative Expense": "1,753"
},
"output_variables": {
"Assets": "1,478",
"Liabilities": "327",
"Expenses": "4,796",
"Revenues": "0",
"Stockholders Equity": "1,151",
"Net Income": "-2,135",
"Comprehensive Net Income": "-2,135",
"BaseVar": "4,631",
"ECR before LimitedLiability": "41%",
"Economic Capital Ratio": "181%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,698",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "312",
"Liabilities, Non-Current": "0",
"Other Assets": "21",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "2,422",
"Other Revenues": "0",
"Property and Equipment": "120",
"Research and Development": "2,915",
"Selling, General and Administrative Expense": "1,792"
},
"output_variables": {
"Assets": "2,840",
"Liabilities": "312",
"Expenses": "4,707",
"Revenues": "0",
"Stockholders Equity": "2,527",
"Net Income": "-2,285",
"Comprehensive Net Income": "-2,285",
"BaseVar": "5,141",
"ECR before LimitedLiability": "205%",
"Economic Capital Ratio": "306%"
}
}
},
"top_rated": false,
"trend": 54.0,
"value": 3.05507431062801,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000832489.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000832489.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000832489.svg"
},
{
"company_id": "0000003116",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000003116.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000003116.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000003116_main_keyfigs.svg",
"name": "Akorn INC",
"rank": 82,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000003116.svg",
"report_text": "The relative strengths and weaknesses of Akorn INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Akorn INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 68% points.The greatest weakness of Akorn INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 71% points.
The company's Economic Capital Ratio, given in the ranking table, is 305%, being 63% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000003116_2014_Akorn_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "26.9",
"Liabilities": "-37.7",
"Stockholders Equity": "12.3",
"ECR before LimitedLiability": "124",
"Intangible Assets": "22.2",
"Property and Equipment": "10.6",
"Assets, Current": "-7.40",
"Other Liabilities": "28.4",
"Liabilities, Non-Current": "-126",
"Liabilities, Current": "32.7",
"Research and Development": "27.5",
"Expenses": "38.8",
"Revenues": "14.9",
"Net Income": "62.0",
"Other Expenses": "9.12",
"Cost of Goods Sold": "-13.8",
"Selling, General and Administrative Expense": "15.7",
"Other Revenues": "14.9",
"Comprehensive Net Income": "61.7",
"Other Net Income": "5.86",
"Economic Capital Ratio": "48.6"
},
"2012": {
"Property and Equipment": "19.9",
"Assets": "4.52",
"Liabilities": "3.26",
"Stockholders Equity": "9.76",
"ECR before LimitedLiability": "138",
"Assets, Current": "-27.7",
"Intangible Assets": "21.2",
"Other Assets": "1.85",
"Liabilities, Current": "42.9",
"Other Liabilities": "36.8",
"Liabilities, Non-Current": "-96.2",
"Selling, General and Administrative Expense": "18.5",
"Expenses": "30.3",
"Revenues": "37.8",
"Net Income": "72.9",
"Research and Development": "28.5",
"Other Expenses": "6.55",
"Cost of Goods Sold": "-22.5",
"Other Revenues": "37.8",
"Comprehensive Net Income": "72.2",
"Economic Capital Ratio": "65.3"
},
"2013": {
"Assets": "-10.3",
"Liabilities": "26.6",
"Stockholders Equity": "-1.95",
"ECR before LimitedLiability": "90.5",
"Intangible Assets": "30.3",
"Property and Equipment": "15.4",
"Assets, Current": "-36.7",
"Liabilities, Non-Current": "-71.3",
"Liabilities, Current": "40.1",
"Other Liabilities": "43.7",
"Selling, General and Administrative Expense": "17.6",
"Expenses": "18.7",
"Revenues": "46.3",
"Net Income": "67.8",
"Other Expenses": "5.34",
"Research and Development": "25.3",
"Cost of Goods Sold": "-28.7",
"Other Revenues": "46.3",
"Comprehensive Net Income": "66.7",
"Other Compr. Net Income": "-1.01",
"Economic Capital Ratio": "62.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000003116_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "155,949",
"Cost of Goods Sold": "57,231",
"Intangible Assets": "79,685",
"Liabilities, Current": "28,289",
"Liabilities, Non-Current": "120,648",
"Other Assets": "27,122",
"Other Compr. Net Income": "0",
"Other Expenses": "1,974",
"Other Liabilities": "0",
"Other Net Income": "12,267",
"Other Revenues": "136,920",
"Property and Equipment": "44,389",
"Research and Development": "11,555",
"Selling, General and Administrative Expense": "33,135"
},
"output_variables": {
"Assets": "307,145",
"Liabilities": "148,937",
"Expenses": "103,895",
"Revenues": "136,920",
"Stockholders Equity": "158,208",
"Net Income": "45,292",
"Comprehensive Net Income": "45,292",
"BaseVar": "354,582",
"ECR before LimitedLiability": "171%",
"Economic Capital Ratio": "283%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "158,707",
"Cost of Goods Sold": "107,466",
"Intangible Assets": "95,813",
"Liabilities, Current": "43,291",
"Liabilities, Non-Current": "125,193",
"Other Assets": "34,366",
"Other Compr. Net Income": "-5,904",
"Other Expenses": "45,365",
"Other Liabilities": "0",
"Other Net Income": "-4,038",
"Other Revenues": "256,158",
"Property and Equipment": "80,679",
"Research and Development": "15,858",
"Selling, General and Administrative Expense": "48,053"
},
"output_variables": {
"Assets": "369,565",
"Liabilities": "168,484",
"Expenses": "216,742",
"Revenues": "256,158",
"Stockholders Equity": "201,081",
"Net Income": "35,378",
"Comprehensive Net Income": "32,426",
"BaseVar": "510,446",
"ECR before LimitedLiability": "175%",
"Economic Capital Ratio": "285%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "168,856",
"Cost of Goods Sold": "145,807",
"Intangible Assets": "145,731",
"Liabilities, Current": "61,245",
"Liabilities, Non-Current": "110,380",
"Other Assets": "35,110",
"Other Compr. Net Income": "-6,463",
"Other Expenses": "41,314",
"Other Liabilities": "0",
"Other Net Income": "-4,862",
"Other Revenues": "317,711",
"Property and Equipment": "82,108",
"Research and Development": "19,858",
"Selling, General and Administrative Expense": "53,508"
},
"output_variables": {
"Assets": "431,805",
"Liabilities": "171,625",
"Expenses": "260,487",
"Revenues": "317,711",
"Stockholders Equity": "260,180",
"Net Income": "52,362",
"Comprehensive Net Income": "49,130",
"BaseVar": "596,476",
"ECR before LimitedLiability": "204%",
"Economic Capital Ratio": "305%"
}
}
},
"top_rated": false,
"trend": -5.0,
"value": 3.0528887321649982,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000003116.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000003116.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000003116.svg"
},
{
"company_id": "0000792977",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000792977.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000792977.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000792977_main_keyfigs.svg",
"name": "AMAG Pharmaceuticals INC",
"rank": 83,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000792977.svg",
"report_text": "The relative strengths and weaknesses of AMAG Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of AMAG Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 49% points.The greatest weakness of AMAG Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 39% points.
The company's Economic Capital Ratio, given in the ranking table, is 305%, being 63% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000792977_2014_AMAG_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Assets": "27.1",
"Liabilities": "15.3",
"Stockholders Equity": "57.2",
"ECR before LimitedLiability": "29.7",
"Assets, Current": "88.9",
"Property and Equipment": "-8.39",
"Intangible Assets": "-19.1",
"Liabilities, Current": "13.6",
"Other Liabilities": "-24.5",
"Liabilities, Non-Current": "24.2",
"Selling, General and Administrative Expense": "-8.15",
"Expenses": "-1.71",
"Revenues": "-16.7",
"Net Income": "-17.4",
"Research and Development": "-5.24",
"Cost of Goods Sold": "4.36",
"Other Expenses": "7.39",
"Other Revenues": "-16.7",
"Comprehensive Net Income": "-17.4",
"Other Net Income": "0.942",
"Economic Capital Ratio": "23.4"
},
"2011": {
"Other Assets": "-0.378",
"Assets": "46.2",
"Stockholders Equity": "64.3",
"Other Liabilities": "-28.2",
"ECR before LimitedLiability": "129",
"Intangible Assets": "-11.5",
"Property and Equipment": "-3.14",
"Assets, Current": "79.0",
"Research and Development": "7.80",
"Expenses": "14.4",
"Revenues": "-3.31",
"Net Income": "13.8",
"Other Expenses": "4.23",
"Cost of Goods Sold": "3.44",
"Selling, General and Administrative Expense": "-1.17",
"Other Revenues": "-3.31",
"Liabilities, Non-Current": "12.4",
"Liabilities, Current": "14.3",
"Comprehensive Net Income": "13.5",
"Other Net Income": "2.71",
"Economic Capital Ratio": "53.6"
},
"2012": {
"Property and Equipment": "-4.84",
"Assets": "41.8",
"Liabilities": "5.72",
"Stockholders Equity": "69.5",
"ECR before LimitedLiability": "162",
"Assets, Current": "87.8",
"Intangible Assets": "-8.70",
"Other Assets": "-6.16",
"Liabilities, Current": "23.7",
"Other Liabilities": "-36.0",
"Liabilities, Non-Current": "14.3",
"Selling, General and Administrative Expense": "3.44",
"Expenses": "27.6",
"Revenues": "9.95",
"Net Income": "39.9",
"Research and Development": "12.1",
"Other Expenses": "7.96",
"Cost of Goods Sold": "3.68",
"Other Revenues": "9.95",
"Comprehensive Net Income": "40.1",
"Economic Capital Ratio": "88.4"
},
"2013": {
"Other Assets": "-6.15",
"Assets": "27.4",
"Liabilities": "1.52",
"Stockholders Equity": "45.8",
"ECR before LimitedLiability": "90.5",
"Intangible Assets": "-2.19",
"Property and Equipment": "-4.54",
"Assets, Current": "49.3",
"Liabilities, Non-Current": "12.4",
"Liabilities, Current": "24.4",
"Other Liabilities": "-39.4",
"Expenses": "23.3",
"Revenues": "10.7",
"Net Income": "36.7",
"Other Expenses": "6.48",
"Research and Development": "14.5",
"Cost of Goods Sold": "2.51",
"Other Revenues": "10.7",
"Comprehensive Net Income": "36.4",
"Other Net Income": "2.05",
"Economic Capital Ratio": "62.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000792977_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "290,784",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "36,711",
"Liabilities, Non-Current": "0",
"Other Assets": "34,057",
"Other Compr. Net Income": "0",
"Other Expenses": "9,358",
"Other Liabilities": "54,079",
"Other Net Income": "1,361",
"Other Revenues": "66,245",
"Property and Equipment": "11,235",
"Research and Development": "54,462",
"Selling, General and Administrative Expense": "84,939"
},
"output_variables": {
"Assets": "336,076",
"Liabilities": "90,790",
"Expenses": "148,759",
"Revenues": "66,245",
"Stockholders Equity": "245,286",
"Net Income": "-81,153",
"Comprehensive Net Income": "-81,153",
"BaseVar": "321,616",
"ECR before LimitedLiability": "213%",
"Economic Capital Ratio": "311%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "240,031",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "38,994",
"Liabilities, Non-Current": "0",
"Other Assets": "17,987",
"Other Compr. Net Income": "0",
"Other Expenses": "14,039",
"Other Liabilities": "47,634",
"Other Net Income": "1,554",
"Other Revenues": "61,249",
"Property and Equipment": "9,206",
"Research and Development": "58,140",
"Selling, General and Administrative Expense": "68,863"
},
"output_variables": {
"Assets": "267,224",
"Liabilities": "86,628",
"Expenses": "141,042",
"Revenues": "61,249",
"Stockholders Equity": "180,596",
"Net Income": "-78,239",
"Comprehensive Net Income": "-78,239",
"BaseVar": "278,848",
"ECR before LimitedLiability": "178%",
"Economic Capital Ratio": "288%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "254,380",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "32,957",
"Liabilities, Non-Current": "0",
"Other Assets": "460",
"Other Compr. Net Income": "0",
"Other Expenses": "16,435",
"Other Liabilities": "52,383",
"Other Net Income": "-180",
"Other Revenues": "85,378",
"Property and Equipment": "3,297",
"Research and Development": "33,296",
"Selling, General and Administrative Expense": "53,071"
},
"output_variables": {
"Assets": "258,137",
"Liabilities": "85,340",
"Expenses": "102,802",
"Revenues": "85,378",
"Stockholders Equity": "172,797",
"Net Income": "-17,604",
"Comprehensive Net Income": "-17,604",
"BaseVar": "265,918",
"ECR before LimitedLiability": "209%",
"Economic Capital Ratio": "309%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "244,405",
"Cost of Goods Sold": "0",
"Intangible Assets": "16,844",
"Liabilities, Current": "33,121",
"Liabilities, Non-Current": "0",
"Other Assets": "2,364",
"Other Compr. Net Income": "-244",
"Other Expenses": "9,188",
"Other Liabilities": "59,930",
"Other Net Income": "742",
"Other Revenues": "81,312",
"Property and Equipment": "1,846",
"Research and Development": "18,857",
"Selling, General and Administrative Expense": "59,010"
},
"output_variables": {
"Assets": "265,459",
"Liabilities": "93,051",
"Expenses": "87,056",
"Revenues": "81,312",
"Stockholders Equity": "172,408",
"Net Income": "-5,001",
"Comprehensive Net Income": "-5,123",
"BaseVar": "263,932",
"ECR before LimitedLiability": "207%",
"Economic Capital Ratio": "307%"
}
}
},
"top_rated": false,
"trend": -24.0,
"value": 3.0527224669784543,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000792977.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000792977.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000792977.svg"
},
{
"company_id": "0001125345",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001125345.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001125345.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001125345.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001125345_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001125345_main_keyfigs.svg",
"name": "Macrogenics INC",
"rank": 84,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001125345.svg",
"report_text": "The relative strengths and weaknesses of Macrogenics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Macrogenics INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 46% points.The greatest weakness of Macrogenics INC is the variable Research and Development, reducing the Economic Capital Ratio by 11% points.
The company's Economic Capital Ratio, given in the ranking table, is 302%, being 59% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001125345_2014_Macrogenics_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-7.05",
"Assets": "10.7",
"Liabilities": "10.1",
"Stockholders Equity": "25.9",
"ECR before LimitedLiability": "86.9",
"Intangible Assets": "-10.2",
"Property and Equipment": "-1.67",
"Assets, Current": "38.2",
"Liabilities, Non-Current": "13.9",
"Liabilities, Current": "1.38",
"Other Liabilities": "-5.31",
"Selling, General and Administrative Expense": "16.4",
"Expenses": "20.3",
"Revenues": "23.5",
"Net Income": "45.9",
"Other Expenses": "12.4",
"Research and Development": "-11.3",
"Cost of Goods Sold": "2.84",
"Other Revenues": "23.5",
"Comprehensive Net Income": "45.6",
"Economic Capital Ratio": "59.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001125345_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "119,457",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "28,822",
"Liabilities, Non-Current": "0",
"Other Assets": "1,290",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "18,046",
"Other Net Income": "-627",
"Other Revenues": "58,035",
"Property and Equipment": "5,035",
"Research and Development": "46,582",
"Selling, General and Administrative Expense": "11,087"
},
"output_variables": {
"Assets": "125,782",
"Liabilities": "46,868",
"Expenses": "57,669",
"Revenues": "58,035",
"Stockholders Equity": "78,914",
"Net Income": "-261",
"Comprehensive Net Income": "-261",
"BaseVar": "144,490",
"ECR before LimitedLiability": "199%",
"Economic Capital Ratio": "302%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.0173770719190607,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001125345.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001125345.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001125345.svg"
},
{
"company_id": "0001488039",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001488039.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001488039.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001488039.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001488039_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001488039_main_keyfigs.svg",
"name": "Atossa Therapeutics INC",
"rank": 85,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001488039.svg",
"report_text": "The relative strengths and weaknesses of Atossa Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Atossa Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 123% points.The greatest weakness of Atossa Therapeutics INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 56% points.
The company's Economic Capital Ratio, given in the ranking table, is 296%, being 54% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001488039_2014_Atossa_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-9.28",
"Assets": "24.3",
"Liabilities": "89.9",
"Stockholders Equity": "123",
"ECR before LimitedLiability": "81.5",
"Intangible Assets": "58.2",
"Property and Equipment": "-5.41",
"Assets, Current": "-4.75",
"Liabilities, Non-Current": "15.9",
"Liabilities, Current": "37.0",
"Other Liabilities": "42.7",
"Selling, General and Administrative Expense": "-56.3",
"Expenses": "-39.0",
"Revenues": "-14.3",
"Net Income": "-51.4",
"Research and Development": "18.1",
"Other Revenues": "-14.3",
"Comprehensive Net Income": "-51.7",
"Other Net Income": "1.71",
"Other Compr. Net Income": "-0.291",
"Economic Capital Ratio": "53.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001488039_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "7,414",
"Cost of Goods Sold": "346",
"Intangible Assets": "4,396",
"Liabilities, Current": "1,407",
"Liabilities, Non-Current": "0",
"Other Assets": "36",
"Other Compr. Net Income": "0",
"Other Expenses": "1,408",
"Other Liabilities": "0",
"Other Net Income": "0.29",
"Other Revenues": "1,116",
"Property and Equipment": "163",
"Research and Development": "1,105",
"Selling, General and Administrative Expense": "8,559"
},
"output_variables": {
"Assets": "12,009",
"Liabilities": "1,407",
"Expenses": "11,418",
"Revenues": "1,116",
"Stockholders Equity": "10,602",
"Net Income": "-10,301",
"Comprehensive Net Income": "-10,301",
"BaseVar": "12,975",
"ECR before LimitedLiability": "191%",
"Economic Capital Ratio": "296%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.963208027321556,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001488039.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001488039.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001488039.svg"
},
{
"company_id": "0000944809",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000944809.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000944809.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000944809.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000944809_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000944809_main_keyfigs.svg",
"name": "OPKO Health INC",
"rank": 86,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000944809.svg",
"report_text": "The relative strengths and weaknesses of OPKO Health INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of OPKO Health INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 136% points.The greatest weakness of OPKO Health INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 104% points.
The company's Economic Capital Ratio, given in the ranking table, is 294%, being 51% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000944809_2014_OPKO_Health_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "63.9",
"Liabilities": "14.0",
"Stockholders Equity": "131",
"ECR before LimitedLiability": "206",
"Intangible Assets": "55.3",
"Property and Equipment": "-1.38",
"Assets, Current": "6.08",
"Other Liabilities": "25.3",
"Liabilities, Non-Current": "-37.4",
"Liabilities, Current": "20.5",
"Research and Development": "17.3",
"Expenses": "36.3",
"Revenues": "-6.89",
"Net Income": "32.3",
"Other Expenses": "15.0",
"Cost of Goods Sold": "-5.84",
"Selling, General and Administrative Expense": "9.97",
"Other Revenues": "-6.89",
"Comprehensive Net Income": "32.1",
"Other Net Income": "2.82",
"Economic Capital Ratio": "131"
},
"2012": {
"Property and Equipment": "0.991",
"Assets": "64.7",
"Liabilities": "-1.38",
"Stockholders Equity": "93.6",
"ECR before LimitedLiability": "169",
"Assets, Current": "-16.5",
"Intangible Assets": "112",
"Other Assets": "1.58",
"Liabilities, Current": "-2.83",
"Other Liabilities": "26.8",
"Liabilities, Non-Current": "-28.3",
"Selling, General and Administrative Expense": "10.9",
"Expenses": "31.9",
"Revenues": "-3.45",
"Net Income": "29.2",
"Research and Development": "14.7",
"Other Expenses": "12.6",
"Cost of Goods Sold": "-6.64",
"Other Revenues": "-3.45",
"Comprehensive Net Income": "30.2",
"Economic Capital Ratio": "96.4"
},
"2013": {
"Other Assets": "136",
"Assets": "65.8",
"Liabilities": "-29.4",
"Stockholders Equity": "63.4",
"ECR before LimitedLiability": "78.8",
"Intangible Assets": "21.3",
"Property and Equipment": "-4.54",
"Assets, Current": "-30.4",
"Liabilities, Non-Current": "-104",
"Liabilities, Current": "28.6",
"Other Liabilities": "26.2",
"Selling, General and Administrative Expense": "13.7",
"Expenses": "34.1",
"Revenues": "-8.62",
"Net Income": "23.2",
"Other Expenses": "7.31",
"Research and Development": "13.8",
"Other Revenues": "-8.62",
"Comprehensive Net Income": "23.0",
"Other Net Income": "-1.54",
"Economic Capital Ratio": "50.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000944809_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "99,582",
"Cost of Goods Sold": "17,243",
"Intangible Assets": "116,545",
"Liabilities, Current": "18,778",
"Liabilities, Non-Current": "25,443",
"Other Assets": "8,004",
"Other Compr. Net Income": "0",
"Other Expenses": "-15,954",
"Other Liabilities": "0",
"Other Net Income": "2,548",
"Other Revenues": "27,979",
"Property and Equipment": "5,358",
"Research and Development": "11,352",
"Selling, General and Administrative Expense": "19,169"
},
"output_variables": {
"Assets": "229,489",
"Liabilities": "44,221",
"Expenses": "31,810",
"Revenues": "27,979",
"Stockholders Equity": "185,268",
"Net Income": "-1,283",
"Comprehensive Net Income": "-1,283",
"BaseVar": "168,024",
"ECR before LimitedLiability": "294%",
"Economic Capital Ratio": "365%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "78,657",
"Cost of Goods Sold": "27,878",
"Intangible Assets": "176,234",
"Liabilities, Current": "52,382",
"Liabilities, Non-Current": "34,168",
"Other Assets": "18,413",
"Other Compr. Net Income": "4,701",
"Other Expenses": "-506",
"Other Liabilities": "0",
"Other Net Income": "-1,897",
"Other Revenues": "47,044",
"Property and Equipment": "16,526",
"Research and Development": "19,520",
"Selling, General and Administrative Expense": "27,795"
},
"output_variables": {
"Assets": "289,830",
"Liabilities": "86,550",
"Expenses": "74,687",
"Revenues": "47,044",
"Stockholders Equity": "203,280",
"Net Income": "-29,540",
"Comprehensive Net Income": "-27,190",
"BaseVar": "252,354",
"ECR before LimitedLiability": "221%",
"Economic Capital Ratio": "316%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "242,728",
"Cost of Goods Sold": "48,860",
"Intangible Assets": "300,906",
"Liabilities, Current": "91,850",
"Liabilities, Non-Current": "426,687",
"Other Assets": "847,882",
"Other Compr. Net Income": "-1,419",
"Other Expenses": "19,752",
"Other Liabilities": "0",
"Other Net Income": "-36,042",
"Other Revenues": "96,530",
"Property and Equipment": "0",
"Research and Development": "53,902",
"Selling, General and Administrative Expense": "55,320"
},
"output_variables": {
"Assets": "1,391,516",
"Liabilities": "518,537",
"Expenses": "177,834",
"Revenues": "96,530",
"Stockholders Equity": "872,979",
"Net Income": "-117,346",
"Comprehensive Net Income": "-118,056",
"BaseVar": "1,110,939",
"ECR before LimitedLiability": "187%",
"Economic Capital Ratio": "294%"
}
}
},
"top_rated": false,
"trend": -30.0,
"value": 2.935663851752927,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000944809.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000944809.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000944809.svg"
},
{
"company_id": "0001293310",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001293310.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001293310.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001293310.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001293310_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001293310_main_keyfigs.svg",
"name": "Humanigen INC",
"rank": 87,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001293310.svg",
"report_text": "The relative strengths and weaknesses of Humanigen INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Humanigen INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 115% points.The greatest weakness of Humanigen INC is the variable Research and Development, reducing the Economic Capital Ratio by 24% points.
The company's Economic Capital Ratio, given in the ranking table, is 293%, being 50% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001293310_2014_Humanigen_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-1.30",
"Assets": "-1.52",
"Liabilities": "-8.81",
"Stockholders Equity": "-33.6",
"ECR before LimitedLiability": "-7.62",
"Assets, Current": "1.92",
"Intangible Assets": "-1.61",
"Other Assets": "0.893",
"Other Liabilities": "-30.4",
"Liabilities, Non-Current": "1.23",
"Selling, General and Administrative Expense": "2.01",
"Expenses": "-1.31",
"Revenues": "-4.86",
"Net Income": "-1.59",
"Research and Development": "-34.0",
"Other Expenses": "2.90",
"Cost of Goods Sold": "0.611",
"Other Revenues": "-4.86",
"Comprehensive Net Income": "-1.58",
"Other Net Income": "3.86",
"Economic Capital Ratio": "-80.7"
},
"2013": {
"Other Assets": "-6.36",
"Assets": "57.7",
"Liabilities": "26.9",
"Stockholders Equity": "103",
"ECR before LimitedLiability": "78.0",
"Intangible Assets": "-9.44",
"Property and Equipment": "-5.14",
"Assets, Current": "115",
"Liabilities, Non-Current": "11.9",
"Liabilities, Current": "11.8",
"Other Liabilities": "3.79",
"Selling, General and Administrative Expense": "9.98",
"Expenses": "-2.79",
"Revenues": "-19.0",
"Net Income": "-20.3",
"Other Expenses": "9.26",
"Research and Development": "-23.9",
"Cost of Goods Sold": "2.47",
"Other Revenues": "-19.0",
"Comprehensive Net Income": "-20.5",
"Economic Capital Ratio": "50.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001293310_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "21,256",
"Cost of Goods Sold": "0",
"Intangible Assets": "45",
"Liabilities, Current": "7,217",
"Liabilities, Non-Current": "355",
"Other Assets": "3,008",
"Other Compr. Net Income": "5.0",
"Other Expenses": "0",
"Other Liabilities": "9,888",
"Other Net Income": "6,071",
"Other Revenues": "0",
"Property and Equipment": "230",
"Research and Development": "24,519",
"Selling, General and Administrative Expense": "5,061"
},
"output_variables": {
"Assets": "24,539",
"Liabilities": "17,460",
"Expenses": "29,580",
"Revenues": "0",
"Stockholders Equity": "7,079",
"Net Income": "-23,509",
"Comprehensive Net Income": "-23,506",
"BaseVar": "38,828",
"ECR before LimitedLiability": "-38%",
"Economic Capital Ratio": "139%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "77,722",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "11,382",
"Liabilities, Non-Current": "0",
"Other Assets": "706",
"Other Compr. Net Income": "-1.0",
"Other Expenses": "1,086",
"Other Liabilities": "6,786",
"Other Net Income": "91",
"Other Revenues": "0",
"Property and Equipment": "276",
"Research and Development": "32,640",
"Selling, General and Administrative Expense": "8,313"
},
"output_variables": {
"Assets": "78,704",
"Liabilities": "18,168",
"Expenses": "42,039",
"Revenues": "0",
"Stockholders Equity": "60,536",
"Net Income": "-41,948",
"Comprehensive Net Income": "-41,948",
"BaseVar": "69,502",
"ECR before LimitedLiability": "186%",
"Economic Capital Ratio": "293%"
}
}
},
"top_rated": false,
"trend": 67.0,
"value": 2.9284651024560553,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001293310.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001293310.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001293310.svg"
},
{
"company_id": "0001567514",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001567514.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001567514.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001567514.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001567514_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001567514_main_keyfigs.svg",
"name": "Intra Cellular Therapies Inc",
"rank": 88,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001567514.svg",
"report_text": "The relative strengths and weaknesses of Intra Cellular Therapies Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Intra Cellular Therapies Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 107% points.The greatest weakness of Intra Cellular Therapies Inc is the variable Research and Development, reducing the Economic Capital Ratio by 42% points.
The company's Economic Capital Ratio, given in the ranking table, is 293%, being 50% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001567514_2014_Intra_Cellular_Therapies_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-8.44",
"Assets": "35.2",
"Liabilities": "59.7",
"Stockholders Equity": "107",
"ECR before LimitedLiability": "78.0",
"Intangible Assets": "-11.2",
"Property and Equipment": "-6.41",
"Assets, Current": "92.8",
"Liabilities, Non-Current": "14.1",
"Liabilities, Current": "9.82",
"Other Liabilities": "38.0",
"Selling, General and Administrative Expense": "7.87",
"Expenses": "-21.5",
"Revenues": "-14.6",
"Net Income": "-34.2",
"Other Expenses": "11.0",
"Research and Development": "-42.5",
"Cost of Goods Sold": "2.95",
"Other Revenues": "-14.6",
"Comprehensive Net Income": "-34.5",
"Economic Capital Ratio": "50.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001567514_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "38,249",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,834",
"Liabilities, Non-Current": "0",
"Other Assets": "132",
"Other Compr. Net Income": "0",
"Other Expenses": "631",
"Other Liabilities": "0",
"Other Net Income": "30",
"Other Revenues": "2,737",
"Property and Equipment": "68",
"Research and Development": "23,028",
"Selling, General and Administrative Expense": "5,976"
},
"output_variables": {
"Assets": "38,449",
"Liabilities": "6,834",
"Expenses": "29,635",
"Revenues": "2,737",
"Stockholders Equity": "31,615",
"Net Income": "-26,868",
"Comprehensive Net Income": "-26,868",
"BaseVar": "38,842",
"ECR before LimitedLiability": "186%",
"Economic Capital Ratio": "293%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.927644940288307,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001567514.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001567514.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001567514.svg"
},
{
"company_id": "0001427925",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001427925.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001427925.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001427925.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001427925_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001427925_main_keyfigs.svg",
"name": "Talphera INC",
"rank": 89,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001427925.svg",
"report_text": "The relative strengths and weaknesses of Talphera INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Talphera INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points.The greatest weakness of Talphera INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 30% points.
The company's Economic Capital Ratio, given in the ranking table, is 292%, being 50% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001427925_2014_Talphera_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-11.3",
"Assets": "-23.5",
"Liabilities": "1.92",
"Stockholders Equity": "-21.1",
"ECR before LimitedLiability": "-42.9",
"Intangible Assets": "-14.9",
"Property and Equipment": "-5.43",
"Assets, Current": "-3.46",
"Other Liabilities": "8.30",
"Liabilities, Non-Current": "-16.2",
"Liabilities, Current": "8.17",
"Research and Development": "-25.1",
"Expenses": "-24.5",
"Revenues": "-15.5",
"Net Income": "-42.6",
"Other Expenses": "1.55",
"Cost of Goods Sold": "2.33",
"Other Revenues": "-15.5",
"Comprehensive Net Income": "-43.2",
"Other Net Income": "4.70",
"Economic Capital Ratio": "-118"
},
"2012": {
"Property and Equipment": "-3.92",
"Assets": "-10.1",
"Liabilities": "5.71",
"Stockholders Equity": "-5.74",
"ECR before LimitedLiability": "-17.1",
"Assets, Current": "5.98",
"Intangible Assets": "-7.73",
"Other Assets": "-5.89",
"Liabilities, Current": "6.07",
"Other Liabilities": "2.31",
"Liabilities, Non-Current": "-2.59",
"Expenses": "-21.4",
"Revenues": "-8.57",
"Net Income": "-58.6",
"Research and Development": "-44.9",
"Other Expenses": "3.75",
"Cost of Goods Sold": "1.84",
"Other Revenues": "-8.57",
"Comprehensive Net Income": "-58.3",
"Other Net Income": "3.04",
"Economic Capital Ratio": "-90.2"
},
"2013": {
"Other Assets": "-7.84",
"Assets": "25.6",
"Liabilities": "10.3",
"Stockholders Equity": "47.6",
"ECR before LimitedLiability": "77.6",
"Intangible Assets": "-10.2",
"Assets, Current": "58.1",
"Liabilities, Non-Current": "-29.8",
"Liabilities, Current": "44.7",
"Other Liabilities": "-8.80",
"Selling, General and Administrative Expense": "14.5",
"Expenses": "27.1",
"Revenues": "6.51",
"Net Income": "20.5",
"Other Expenses": "10.3",
"Research and Development": "-0.890",
"Cost of Goods Sold": "2.69",
"Other Revenues": "6.51",
"Comprehensive Net Income": "20.2",
"Other Net Income": "-12.7",
"Economic Capital Ratio": "49.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001427925_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "38,146",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,845",
"Liabilities, Non-Current": "15,275",
"Other Assets": "383",
"Other Compr. Net Income": "0",
"Other Expenses": "5,439",
"Other Liabilities": "247",
"Other Net Income": "3,490",
"Other Revenues": "0",
"Property and Equipment": "2,306",
"Research and Development": "67,421",
"Selling, General and Administrative Expense": "19,294"
},
"output_variables": {
"Assets": "40,835",
"Liabilities": "23,367",
"Expenses": "92,154",
"Revenues": "0",
"Stockholders Equity": "17,468",
"Net Income": "-88,664",
"Comprehensive Net Income": "-88,664",
"BaseVar": "79,923",
"ECR before LimitedLiability": "-158%",
"Economic Capital Ratio": "116%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "61,766",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "14,331",
"Liabilities, Non-Current": "8,530",
"Other Assets": "269",
"Other Compr. Net Income": "1.0",
"Other Expenses": "7,722",
"Other Liabilities": "7,812",
"Other Net Income": "4,517",
"Other Revenues": "0",
"Property and Equipment": "2,485",
"Research and Development": "92,329",
"Selling, General and Administrative Expense": "26,493"
},
"output_variables": {
"Assets": "64,520",
"Liabilities": "30,673",
"Expenses": "126,544",
"Revenues": "0",
"Stockholders Equity": "33,847",
"Net Income": "-122,027",
"Comprehensive Net Income": "-122,026",
"BaseVar": "113,128",
"ECR before LimitedLiability": "-101%",
"Economic Capital Ratio": "130%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "104,560",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,868",
"Liabilities, Non-Current": "14,364",
"Other Assets": "292",
"Other Compr. Net Income": "0",
"Other Expenses": "1,518",
"Other Liabilities": "15,640",
"Other Net Income": "-15,241",
"Other Revenues": "29,502",
"Property and Equipment": "5,179",
"Research and Development": "26,292",
"Selling, General and Administrative Expense": "9,877"
},
"output_variables": {
"Assets": "110,031",
"Liabilities": "36,872",
"Expenses": "37,687",
"Revenues": "29,502",
"Stockholders Equity": "73,159",
"Net Income": "-23,426",
"Comprehensive Net Income": "-23,426",
"BaseVar": "114,666",
"ECR before LimitedLiability": "185%",
"Economic Capital Ratio": "292%"
}
}
},
"top_rated": false,
"trend": 76.0,
"value": 2.9242721515108,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001427925.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001427925.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001427925.svg"
},
{
"company_id": "0000200406",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000200406.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000200406.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000200406.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000200406_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000200406_main_keyfigs.svg",
"name": "Johnson Johnson",
"rank": 90,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000200406.svg",
"report_text": "The relative strengths and weaknesses of Johnson Johnson are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Johnson Johnson compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 60% points.The greatest weakness of Johnson Johnson is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 35% points.
The company's Economic Capital Ratio, given in the ranking table, is 292%, being 49% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000200406_2014_Johnson_Johnson.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-4.05",
"Assets": "-13.5",
"Liabilities": "-7.71",
"Stockholders Equity": "-29.5",
"ECR before LimitedLiability": "5.42",
"Assets, Current": "-17.1",
"Intangible Assets": "8.71",
"Liabilities, Current": "-6.15",
"Other Liabilities": "11.8",
"Liabilities, Non-Current": "-13.8",
"Selling, General and Administrative Expense": "3.15",
"Expenses": "5.77",
"Revenues": "15.1",
"Net Income": "22.4",
"Research and Development": "7.74",
"Cost of Goods Sold": "5.44",
"Other Expenses": "-10.4",
"Other Revenues": "15.1",
"Comprehensive Net Income": "22.4",
"Other Net Income": "1.26",
"Economic Capital Ratio": "-0.917"
},
"2011": {
"Assets": "13.6",
"Liabilities": "-16.6",
"Stockholders Equity": "10.3",
"ECR before LimitedLiability": "133",
"Intangible Assets": "28.1",
"Property and Equipment": "8.90",
"Assets, Current": "-17.6",
"Other Liabilities": "11.7",
"Liabilities, Non-Current": "-32.2",
"Liabilities, Current": "2.49",
"Research and Development": "27.9",
"Expenses": "32.1",
"Revenues": "27.3",
"Net Income": "65.3",
"Other Expenses": "-10.2",
"Cost of Goods Sold": "3.80",
"Selling, General and Administrative Expense": "10.5",
"Other Revenues": "27.3",
"Comprehensive Net Income": "65.0",
"Other Net Income": "3.12",
"Economic Capital Ratio": "56.9"
},
"2012": {
"Property and Equipment": "8.48",
"Assets": "18.5",
"Liabilities": "-13.2",
"Stockholders Equity": "18.2",
"ECR before LimitedLiability": "135",
"Assets, Current": "-26.4",
"Intangible Assets": "55.7",
"Liabilities, Current": "13.1",
"Other Liabilities": "5.49",
"Liabilities, Non-Current": "-33.4",
"Selling, General and Administrative Expense": "11.3",
"Expenses": "34.7",
"Revenues": "26.7",
"Net Income": "65.1",
"Research and Development": "23.1",
"Other Expenses": "-4.44",
"Cost of Goods Sold": "4.21",
"Other Revenues": "26.7",
"Comprehensive Net Income": "65.3",
"Other Net Income": "0.853",
"Economic Capital Ratio": "62.4"
},
"2013": {
"Other Assets": "-1.41",
"Assets": "3.75",
"Liabilities": "-3.51",
"Stockholders Equity": "3.91",
"ECR before LimitedLiability": "77.3",
"Intangible Assets": "43.7",
"Property and Equipment": "8.57",
"Assets, Current": "-29.6",
"Liabilities, Non-Current": "-34.7",
"Liabilities, Current": "15.5",
"Other Liabilities": "13.1",
"Selling, General and Administrative Expense": "9.95",
"Expenses": "27.9",
"Revenues": "29.1",
"Net Income": "58.8",
"Other Expenses": "-5.23",
"Research and Development": "20.0",
"Cost of Goods Sold": "2.91",
"Other Revenues": "29.1",
"Comprehensive Net Income": "59.7",
"Economic Capital Ratio": "49.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000200406_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "39,541,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "31,185,000",
"Liabilities, Current": "21,731,000",
"Liabilities, Non-Current": "14,170,000",
"Other Assets": "9,197,000",
"Other Compr. Net Income": "0",
"Other Expenses": "23,460,000",
"Other Liabilities": "8,193,000",
"Other Net Income": "616,000",
"Other Revenues": "61,897,000",
"Property and Equipment": "14,759,000",
"Research and Development": "6,986,000",
"Selling, General and Administrative Expense": "19,801,000"
},
"output_variables": {
"Assets": "94,682,000",
"Liabilities": "44,094,000",
"Expenses": "50,247,000",
"Revenues": "61,897,000",
"Stockholders Equity": "50,588,000",
"Net Income": "12,266,000",
"Comprehensive Net Income": "12,266,000",
"BaseVar": "125,768,000",
"ECR before LimitedLiability": "177%",
"Economic Capital Ratio": "287%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "47,307,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "32,010,000",
"Liabilities, Current": "23,072,000",
"Liabilities, Non-Current": "15,723,000",
"Other Assets": "9,038,000",
"Other Compr. Net Income": "0",
"Other Expenses": "22,860,000",
"Other Liabilities": "7,534,000",
"Other Net Income": "875,000",
"Other Revenues": "61,587,000",
"Property and Equipment": "14,553,000",
"Research and Development": "6,844,000",
"Selling, General and Administrative Expense": "19,424,000"
},
"output_variables": {
"Assets": "102,908,000",
"Liabilities": "46,329,000",
"Expenses": "49,128,000",
"Revenues": "61,587,000",
"Stockholders Equity": "56,579,000",
"Net Income": "13,334,000",
"Comprehensive Net Income": "13,334,000",
"BaseVar": "130,413,500",
"ECR before LimitedLiability": "183%",
"Economic Capital Ratio": "291%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "46,116,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "51,176,000",
"Liabilities, Current": "24,262,000",
"Liabilities, Non-Current": "20,041,000",
"Other Assets": "7,958,000",
"Other Compr. Net Income": "161,000",
"Other Expenses": "26,614,000",
"Other Liabilities": "12,218,000",
"Other Net Income": "-1,562,000",
"Other Revenues": "67,224,000",
"Property and Equipment": "16,097,000",
"Research and Development": "7,665,000",
"Selling, General and Administrative Expense": "20,869,000"
},
"output_variables": {
"Assets": "121,347,000",
"Liabilities": "56,521,000",
"Expenses": "55,148,000",
"Revenues": "67,224,000",
"Stockholders Equity": "64,826,000",
"Net Income": "10,514,000",
"Comprehensive Net Income": "10,594,500",
"BaseVar": "150,981,500",
"ECR before LimitedLiability": "171%",
"Economic Capital Ratio": "283%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "56,407,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "50,745,000",
"Liabilities, Current": "25,675,000",
"Liabilities, Non-Current": "21,182,000",
"Other Assets": "8,821,000",
"Other Compr. Net Income": "16,892,889",
"Other Expenses": "25,103,424",
"Other Liabilities": "11,773,000",
"Other Net Income": "-2,718,917",
"Other Revenues": "71,314,253",
"Property and Equipment": "16,710,000",
"Research and Development": "8,175,949",
"Selling, General and Administrative Expense": "21,814,134"
},
"output_variables": {
"Assets": "132,683,000",
"Liabilities": "58,630,000",
"Expenses": "55,093,507",
"Revenues": "71,314,253",
"Stockholders Equity": "74,053,000",
"Net Income": "13,501,828",
"Comprehensive Net Income": "21,948,273",
"BaseVar": "168,666,283",
"ECR before LimitedLiability": "192%",
"Economic Capital Ratio": "297%"
}
}
},
"top_rated": false,
"trend": -11.0,
"value": 2.9210519169963973,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000200406.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000200406.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000200406.svg"
},
{
"company_id": "0000768710",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000768710.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000768710.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000768710.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000768710_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000768710_main_keyfigs.svg",
"name": "Reliv International INC",
"rank": 91,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000768710.svg",
"report_text": "The relative strengths and weaknesses of Reliv International INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Reliv International INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 157% points.The greatest weakness of Reliv International INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 175% points.
The company's Economic Capital Ratio, given in the ranking table, is 292%, being 49% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000768710_2014_Reliv_International_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-17.2",
"Assets": "-86.1",
"Liabilities": "158",
"Stockholders Equity": "-190",
"ECR before LimitedLiability": "140",
"Intangible Assets": "-25.5",
"Property and Equipment": "12.3",
"Assets, Current": "-76.6",
"Other Liabilities": "89.8",
"Liabilities, Current": "113",
"Research and Development": "113",
"Expenses": "-56.9",
"Revenues": "169",
"Net Income": "158",
"Other Expenses": "-204",
"Cost of Goods Sold": "-47.3",
"Selling, General and Administrative Expense": "93.0",
"Other Revenues": "169",
"Comprehensive Net Income": "158",
"Other Net Income": "7.16",
"Economic Capital Ratio": "64.0"
},
"2012": {
"Property and Equipment": "11.4",
"Assets": "-77.4",
"Liabilities": "164",
"Stockholders Equity": "-131",
"ECR before LimitedLiability": "157",
"Assets, Current": "-73.1",
"Intangible Assets": "-20.6",
"Liabilities, Current": "111",
"Other Liabilities": "90.1",
"Liabilities, Non-Current": "8.74",
"Selling, General and Administrative Expense": "83.7",
"Expenses": "-45.6",
"Revenues": "170",
"Net Income": "164",
"Research and Development": "87.3",
"Other Expenses": "-169",
"Cost of Goods Sold": "-40.2",
"Other Revenues": "170",
"Comprehensive Net Income": "164",
"Other Net Income": "7.91",
"Economic Capital Ratio": "84.1"
},
"2013": {
"Other Assets": "-4.77",
"Assets": "-86.8",
"Liabilities": "151",
"Stockholders Equity": "-175",
"ECR before LimitedLiability": "76.8",
"Intangible Assets": "-15.8",
"Property and Equipment": "12.3",
"Assets, Current": "-84.2",
"Liabilities, Non-Current": "-15.0",
"Liabilities, Current": "106",
"Other Liabilities": "93.3",
"Selling, General and Administrative Expense": "73.2",
"Expenses": "-58.1",
"Revenues": "157",
"Net Income": "146",
"Other Expenses": "-154",
"Research and Development": "73.3",
"Cost of Goods Sold": "-40.4",
"Other Revenues": "157",
"Comprehensive Net Income": "145",
"Economic Capital Ratio": "48.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000768710_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "13,412",
"Cost of Goods Sold": "15,105",
"Intangible Assets": "1,598",
"Liabilities, Current": "6,110",
"Liabilities, Non-Current": "3,823",
"Other Assets": "1,987",
"Other Compr. Net Income": "0",
"Other Expenses": "57,168",
"Other Liabilities": "0",
"Other Net Income": "65",
"Other Revenues": "73,880",
"Property and Equipment": "7,422",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "24,419",
"Liabilities": "9,933",
"Expenses": "72,274",
"Revenues": "73,880",
"Stockholders Equity": "14,486",
"Net Income": "1,671",
"Comprehensive Net Income": "1,671",
"BaseVar": "90,286",
"ECR before LimitedLiability": "194%",
"Economic Capital Ratio": "298%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "12,491",
"Cost of Goods Sold": "13,686",
"Intangible Assets": "1,444",
"Liabilities, Current": "6,615",
"Liabilities, Non-Current": "3,062",
"Other Assets": "4,212",
"Other Compr. Net Income": "123",
"Other Expenses": "54,201",
"Other Liabilities": "0",
"Other Net Income": "536",
"Other Revenues": "68,710",
"Property and Equipment": "7,112",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "25,259",
"Liabilities": "9,677",
"Expenses": "67,887",
"Revenues": "68,710",
"Stockholders Equity": "15,582",
"Net Income": "1,359",
"Comprehensive Net Income": "1,420",
"BaseVar": "86,095",
"ECR before LimitedLiability": "203%",
"Economic Capital Ratio": "304%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "13,156",
"Cost of Goods Sold": "14,023",
"Intangible Assets": "3,196",
"Liabilities, Current": "6,649",
"Liabilities, Non-Current": "4,819",
"Other Assets": "4,511",
"Other Compr. Net Income": "7.2",
"Other Expenses": "53,419",
"Other Liabilities": "0",
"Other Net Income": "12",
"Other Revenues": "68,207",
"Property and Equipment": "6,735",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "27,599",
"Liabilities": "11,468",
"Expenses": "67,442",
"Revenues": "68,207",
"Stockholders Equity": "16,130",
"Net Income": "777",
"Comprehensive Net Income": "780",
"BaseVar": "87,367",
"ECR before LimitedLiability": "184%",
"Economic Capital Ratio": "292%"
}
}
},
"top_rated": false,
"trend": -25.0,
"value": 2.9159167054241726,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000768710.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000768710.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000768710.svg"
},
{
"company_id": "0001368148",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001368148.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001368148.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001368148.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001368148_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001368148_main_keyfigs.svg",
"name": "Athersys INC NEW",
"rank": 92,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001368148.svg",
"report_text": "The relative strengths and weaknesses of Athersys INC NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Athersys INC NEW compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 121% points.The greatest weakness of Athersys INC NEW is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 56% points.
The company's Economic Capital Ratio, given in the ranking table, is 287%, being 45% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001368148_2014_Athersys_INC_NEW.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-26.9",
"Assets": "-56.6",
"Liabilities": "28.4",
"Stockholders Equity": "-49.9",
"ECR before LimitedLiability": "18.2",
"Intangible Assets": "-34.8",
"Property and Equipment": "-5.35",
"Other Liabilities": "35.8",
"Liabilities, Non-Current": "20.1",
"Liabilities, Current": "-41.6",
"Research and Development": "-77.4",
"Expenses": "-43.2",
"Revenues": "25.7",
"Net Income": "-15.9",
"Other Expenses": "18.6",
"Cost of Goods Sold": "7.30",
"Selling, General and Administrative Expense": "15.3",
"Other Revenues": "25.7",
"Comprehensive Net Income": "-16.4",
"Other Net Income": "4.71",
"Economic Capital Ratio": "-57.3"
},
"2012": {
"Property and Equipment": "-2.38",
"Assets": "22.0",
"Liabilities": "81.7",
"Stockholders Equity": "110",
"ECR before LimitedLiability": "170",
"Assets, Current": "60.9",
"Intangible Assets": "-10.7",
"Other Assets": "-7.86",
"Liabilities, Current": "27.6",
"Other Liabilities": "40.8",
"Liabilities, Non-Current": "19.3",
"Selling, General and Administrative Expense": "12.5",
"Expenses": "-12.5",
"Research and Development": "-47.6",
"Other Expenses": "17.9",
"Cost of Goods Sold": "4.91",
"Other Revenues": "4.89",
"Revenues": "4.89",
"Economic Capital Ratio": "97.2",
"Other Net Income": "7.67",
"Other Compr. Net Income": "0.148"
},
"2013": {
"Other Assets": "-10.3",
"Assets": "25.1",
"Liabilities": "86.4",
"Stockholders Equity": "121",
"ECR before LimitedLiability": "72.5",
"Intangible Assets": "-12.9",
"Assets, Current": "72.7",
"Liabilities, Non-Current": "15.8",
"Liabilities, Current": "33.3",
"Other Liabilities": "42.4",
"Selling, General and Administrative Expense": "7.62",
"Expenses": "-19.4",
"Revenues": "-17.1",
"Net Income": "-55.9",
"Other Expenses": "13.4",
"Research and Development": "-42.7",
"Cost of Goods Sold": "3.34",
"Other Revenues": "-17.1",
"Comprehensive Net Income": "-56.2",
"Other Net Income": "-20.4",
"Economic Capital Ratio": "44.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001368148_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "14,406",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,420",
"Liabilities, Non-Current": "0",
"Other Assets": "28",
"Other Compr. Net Income": "0",
"Other Expenses": "278",
"Other Liabilities": "0",
"Other Net Income": "34",
"Other Revenues": "10,344",
"Property and Equipment": "1,267",
"Research and Development": "18,930",
"Selling, General and Administrative Expense": "4,916"
},
"output_variables": {
"Assets": "15,701",
"Liabilities": "7,420",
"Expenses": "24,124",
"Revenues": "10,344",
"Stockholders Equity": "8,281",
"Net Income": "-13,746",
"Comprehensive Net Income": "-13,746",
"BaseVar": "28,812",
"ECR before LimitedLiability": "37%",
"Economic Capital Ratio": "177%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "26,309",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,478",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-28",
"Other Expenses": "320",
"Other Liabilities": "0",
"Other Net Income": "1,266",
"Other Revenues": "8,708",
"Property and Equipment": "1,294",
"Research and Development": "19,636",
"Selling, General and Administrative Expense": "4,753"
},
"output_variables": {
"Assets": "27,603",
"Liabilities": "4,478",
"Expenses": "24,709",
"Revenues": "8,708",
"Stockholders Equity": "23,125",
"Net Income": "-14,735",
"Comprehensive Net Income": "-14,749",
"BaseVar": "33,396",
"ECR before LimitedLiability": "222%",
"Economic Capital Ratio": "317%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "32,855",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,368",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "346",
"Other Liabilities": "0",
"Other Net Income": "-6,286",
"Other Revenues": "2,438",
"Property and Equipment": "1,333",
"Research and Development": "20,484",
"Selling, General and Administrative Expense": "6,065"
},
"output_variables": {
"Assets": "34,188",
"Liabilities": "4,368",
"Expenses": "26,895",
"Revenues": "2,438",
"Stockholders Equity": "29,820",
"Net Income": "-30,743",
"Comprehensive Net Income": "-30,743",
"BaseVar": "37,088",
"ECR before LimitedLiability": "178%",
"Economic Capital Ratio": "287%"
}
}
},
"top_rated": false,
"trend": -37.0,
"value": 2.8728770247614355,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001368148.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001368148.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001368148.svg"
},
{
"company_id": "0001178670",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001178670.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001178670.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001178670.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001178670_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001178670_main_keyfigs.svg",
"name": "Alnylam Pharmaceuticals INC",
"rank": 93,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001178670.svg",
"report_text": "The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 57% points.The greatest weakness of Alnylam Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 43% points.
The company's Economic Capital Ratio, given in the ranking table, is 286%, being 43% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001178670_2014_Alnylam_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "40.2",
"Assets": "11.2",
"Liabilities": "-65.6",
"Stockholders Equity": "-34.9",
"ECR before LimitedLiability": "-54.1",
"Assets, Current": "32.7",
"Property and Equipment": "-12.8",
"Intangible Assets": "-31.2",
"Liabilities, Current": "-23.2",
"Other Liabilities": "-65.8",
"Liabilities, Non-Current": "22.3",
"Selling, General and Administrative Expense": "10.9",
"Expenses": "13.0",
"Revenues": "-15.7",
"Net Income": "-2.44",
"Research and Development": "-13.8",
"Cost of Goods Sold": "4.85",
"Other Expenses": "11.4",
"Other Revenues": "-15.7",
"Comprehensive Net Income": "-2.43",
"Economic Capital Ratio": "-60.4"
},
"2011": {
"Other Assets": "80.6",
"Assets": "35.0",
"Liabilities": "-61.5",
"Stockholders Equity": "-10.2",
"ECR before LimitedLiability": "63.2",
"Intangible Assets": "-16.9",
"Property and Equipment": "-2.46",
"Assets, Current": "-7.33",
"Other Liabilities": "-52.7",
"Liabilities, Non-Current": "11.2",
"Liabilities, Current": "-19.5",
"Expenses": "28.0",
"Revenues": "-29.0",
"Net Income": "29.2",
"Other Expenses": "10.9",
"Cost of Goods Sold": "3.84",
"Selling, General and Administrative Expense": "14.9",
"Other Revenues": "-29.0",
"Comprehensive Net Income": "28.8",
"Other Net Income": "32.9",
"Economic Capital Ratio": "-12.4"
},
"2012": {
"Assets": "25.6",
"Liabilities": "-31.2",
"Stockholders Equity": "3.28",
"ECR before LimitedLiability": "73.6",
"Assets, Current": "-31.4",
"Intangible Assets": "-16.8",
"Other Assets": "81.8",
"Liabilities, Current": "21.9",
"Other Liabilities": "-73.3",
"Liabilities, Non-Current": "15.1",
"Selling, General and Administrative Expense": "14.8",
"Expenses": "18.4",
"Net Income": "20.1",
"Other Expenses": "-1.63",
"Cost of Goods Sold": "4.77",
"Other Revenues": "-28.8",
"Revenues": "-28.8",
"Comprehensive Net Income": "23.5",
"Other Compr. Net Income": "3.13",
"Other Net Income": "33.2",
"Economic Capital Ratio": "0.529"
},
"2013": {
"Other Assets": "53.8",
"Assets": "49.3",
"Liabilities": "-12.0",
"Stockholders Equity": "57.4",
"ECR before LimitedLiability": "71.3",
"Intangible Assets": "-9.25",
"Assets, Current": "8.35",
"Liabilities, Non-Current": "11.0",
"Liabilities, Current": "17.0",
"Other Liabilities": "-43.2",
"Selling, General and Administrative Expense": "13.9",
"Expenses": "20.2",
"Revenues": "-17.8",
"Net Income": "14.7",
"Other Expenses": "10.8",
"Research and Development": "-6.96",
"Cost of Goods Sold": "2.32",
"Other Revenues": "-17.8",
"Comprehensive Net Income": "15.0",
"Other Net Income": "13.0",
"Economic Capital Ratio": "43.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001178670_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "254,139",
"Cost of Goods Sold": "0",
"Intangible Assets": "448",
"Liabilities, Current": "102,046",
"Liabilities, Non-Current": "143",
"Other Assets": "120,389",
"Other Compr. Net Income": "-2.0",
"Other Expenses": "514",
"Other Liabilities": "132,843",
"Other Net Income": "1,069",
"Other Revenues": "100,041",
"Property and Equipment": "18,289",
"Research and Development": "106,384",
"Selling, General and Administrative Expense": "37,727"
},
"output_variables": {
"Assets": "393,265",
"Liabilities": "235,032",
"Expenses": "144,625",
"Revenues": "100,041",
"Stockholders Equity": "158,233",
"Net Income": "-43,515",
"Comprehensive Net Income": "-43,516",
"BaseVar": "437,017",
"ECR before LimitedLiability": "96%",
"Economic Capital Ratio": "227%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "152,028",
"Cost of Goods Sold": "0",
"Intangible Assets": "275",
"Liabilities, Current": "80,990",
"Liabilities, Non-Current": "716",
"Other Assets": "114,971",
"Other Compr. Net Income": "-879",
"Other Expenses": "0",
"Other Liabilities": "82,214",
"Other Net Income": "79,926",
"Other Revenues": "0",
"Property and Equipment": "14,643",
"Research and Development": "99,295",
"Selling, General and Administrative Expense": "38,280"
},
"output_variables": {
"Assets": "281,917",
"Liabilities": "163,920",
"Expenses": "137,575",
"Revenues": "0",
"Stockholders Equity": "117,997",
"Net Income": "-57,649",
"Comprehensive Net Income": "-58,088",
"BaseVar": "332,108",
"ECR before LimitedLiability": "89%",
"Economic Capital Ratio": "222%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "125,456",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "48,345",
"Liabilities, Non-Current": "0",
"Other Assets": "142,265",
"Other Compr. Net Income": "15,827",
"Other Expenses": "54,428",
"Other Liabilities": "105,122",
"Other Net Income": "79,595",
"Other Revenues": "0",
"Property and Equipment": "19,799",
"Research and Development": "86,569",
"Selling, General and Administrative Expense": "44,612"
},
"output_variables": {
"Assets": "287,520",
"Liabilities": "153,467",
"Expenses": "185,609",
"Revenues": "0",
"Stockholders Equity": "134,053",
"Net Income": "-106,014",
"Comprehensive Net Income": "-98,100",
"BaseVar": "361,009",
"ECR before LimitedLiability": "88%",
"Economic Capital Ratio": "221%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "254,028",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "53,864",
"Liabilities, Non-Current": "0",
"Other Assets": "150,054",
"Other Compr. Net Income": "10,363",
"Other Expenses": "54,076",
"Other Liabilities": "96,319",
"Other Net Income": "47,839",
"Other Revenues": "0",
"Property and Equipment": "16,448",
"Research and Development": "110,852",
"Selling, General and Administrative Expense": "28,123"
},
"output_variables": {
"Assets": "420,530",
"Liabilities": "150,183",
"Expenses": "193,051",
"Revenues": "0",
"Stockholders Equity": "270,347",
"Net Income": "-145,212",
"Comprehensive Net Income": "-140,031",
"BaseVar": "410,983",
"ECR before LimitedLiability": "157%",
"Economic Capital Ratio": "273%"
}
}
},
"top_rated": false,
"trend": 22.0,
"value": 2.8607231422334563,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001178670.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001178670.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001178670.svg"
},
{
"company_id": "0001130598",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001130598.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001130598.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001130598.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001130598_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001130598_main_keyfigs.svg",
"name": "Traws Pharma Inc",
"rank": 94,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001130598.svg",
"report_text": "The relative strengths and weaknesses of Traws Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Traws Pharma Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 104% points.The greatest weakness of Traws Pharma Inc is the variable Research and Development, reducing the Economic Capital Ratio by 29% points.
The company's Economic Capital Ratio, given in the ranking table, is 286%, being 43% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001130598_2014_Traws_Pharma_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-8.34",
"Assets": "45.0",
"Liabilities": "35.4",
"Stockholders Equity": "94.4",
"ECR before LimitedLiability": "71.2",
"Intangible Assets": "-10.7",
"Property and Equipment": "-5.56",
"Assets, Current": "104",
"Liabilities, Non-Current": "12.8",
"Liabilities, Current": "31.8",
"Other Liabilities": "-9.27",
"Selling, General and Administrative Expense": "5.85",
"Expenses": "-9.82",
"Revenues": "-15.8",
"Net Income": "-24.0",
"Other Expenses": "11.5",
"Research and Development": "-29.1",
"Cost of Goods Sold": "2.71",
"Other Revenues": "-15.8",
"Comprehensive Net Income": "-24.3",
"Economic Capital Ratio": "43.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001130598_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "104,390",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "10,338",
"Liabilities, Non-Current": "6.0",
"Other Assets": "137",
"Other Compr. Net Income": "1.0",
"Other Expenses": "397",
"Other Liabilities": "13,909",
"Other Net Income": "63",
"Other Revenues": "4,753",
"Property and Equipment": "626",
"Research and Development": "50,182",
"Selling, General and Administrative Expense": "16,793"
},
"output_variables": {
"Assets": "105,153",
"Liabilities": "24,253",
"Expenses": "67,372",
"Revenues": "4,753",
"Stockholders Equity": "80,900",
"Net Income": "-62,556",
"Comprehensive Net Income": "-62,556",
"BaseVar": "100,798",
"ECR before LimitedLiability": "176%",
"Economic Capital Ratio": "286%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.8601338811244945,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001130598.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001130598.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001130598.svg"
},
{
"company_id": "0000748592",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000748592.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000748592.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000748592.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000748592_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000748592_main_keyfigs.svg",
"name": "Ernexa Therapeutics Inc",
"rank": 95,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000748592.svg",
"report_text": "The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 125% points.The greatest weakness of Ernexa Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 86% points.
The company's Economic Capital Ratio, given in the ranking table, is 285%, being 42% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000748592_2014_Ernexa_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "-91.0",
"Liabilities": "108",
"Stockholders Equity": "-125",
"ECR before LimitedLiability": "90.0",
"Intangible Assets": "-12.4",
"Property and Equipment": "39.9",
"Assets, Current": "-97.1",
"Other Liabilities": "46.6",
"Liabilities, Non-Current": "23.6",
"Liabilities, Current": "56.4",
"Research and Development": "96.6",
"Expenses": "-45.6",
"Revenues": "111",
"Net Income": "107",
"Other Expenses": "-31.2",
"Cost of Goods Sold": "9.72",
"Selling, General and Administrative Expense": "-100",
"Other Revenues": "111",
"Comprehensive Net Income": "106",
"Other Net Income": "6.08",
"Economic Capital Ratio": "14.4"
},
"2012": {
"Property and Equipment": "21.8",
"Assets": "-62.6",
"Liabilities": "135",
"Stockholders Equity": "-68.0",
"ECR before LimitedLiability": "146",
"Assets, Current": "-69.7",
"Intangible Assets": "-7.32",
"Other Assets": "9.50",
"Liabilities, Current": "71.2",
"Other Liabilities": "45.9",
"Liabilities, Non-Current": "30.2",
"Selling, General and Administrative Expense": "-80.1",
"Expenses": "-26.5",
"Revenues": "152",
"Net Income": "124",
"Research and Development": "67.8",
"Other Expenses": "-16.9",
"Cost of Goods Sold": "9.34",
"Other Revenues": "152",
"Comprehensive Net Income": "125",
"Economic Capital Ratio": "73.2"
},
"2013": {
"Other Assets": "5.95",
"Assets": "-64.2",
"Liabilities": "107",
"Stockholders Equity": "-86.2",
"ECR before LimitedLiability": "70.2",
"Intangible Assets": "-12.0",
"Property and Equipment": "14.2",
"Assets, Current": "-66.3",
"Liabilities, Non-Current": "26.3",
"Liabilities, Current": "64.3",
"Other Liabilities": "23.4",
"Selling, General and Administrative Expense": "-53.3",
"Expenses": "-28.4",
"Revenues": "125",
"Net Income": "91.1",
"Other Expenses": "-28.6",
"Research and Development": "52.8",
"Cost of Goods Sold": "5.69",
"Other Revenues": "125",
"Comprehensive Net Income": "89.9",
"Economic Capital Ratio": "42.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000748592_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,798",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,081",
"Liabilities, Current": "3,868",
"Liabilities, Non-Current": "323",
"Other Assets": "2,513",
"Other Compr. Net Income": "-223",
"Other Expenses": "6,698",
"Other Liabilities": "1,106",
"Other Net Income": "20",
"Other Revenues": "23,870",
"Property and Equipment": "4,255",
"Research and Development": "0",
"Selling, General and Administrative Expense": "20,448"
},
"output_variables": {
"Assets": "11,647",
"Liabilities": "5,297",
"Expenses": "27,146",
"Revenues": "23,870",
"Stockholders Equity": "6,350",
"Net Income": "-3,256",
"Comprehensive Net Income": "-3,368",
"BaseVar": "34,102",
"ECR before LimitedLiability": "124%",
"Economic Capital Ratio": "248%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "4,229",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,844",
"Liabilities, Current": "3,388",
"Liabilities, Non-Current": "170",
"Other Assets": "2,800",
"Other Compr. Net Income": "46",
"Other Expenses": "6,795",
"Other Liabilities": "1,204",
"Other Net Income": "-16",
"Other Revenues": "24,064",
"Property and Equipment": "3,783",
"Research and Development": "0",
"Selling, General and Administrative Expense": "18,248"
},
"output_variables": {
"Assets": "12,656",
"Liabilities": "4,762",
"Expenses": "25,043",
"Revenues": "24,064",
"Stockholders Equity": "7,894",
"Net Income": "-995",
"Comprehensive Net Income": "-972",
"BaseVar": "33,294",
"ECR before LimitedLiability": "186%",
"Economic Capital Ratio": "293%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "7,918",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,339",
"Liabilities, Current": "3,608",
"Liabilities, Non-Current": "0",
"Other Assets": "2,963",
"Other Compr. Net Income": "-137",
"Other Expenses": "8,465",
"Other Liabilities": "2,647",
"Other Net Income": "112",
"Other Revenues": "23,749",
"Property and Equipment": "3,237",
"Research and Development": "0",
"Selling, General and Administrative Expense": "16,449"
},
"output_variables": {
"Assets": "15,457",
"Liabilities": "6,255",
"Expenses": "24,914",
"Revenues": "23,749",
"Stockholders Equity": "9,202",
"Net Income": "-1,053",
"Comprehensive Net Income": "-1,122",
"BaseVar": "35,312",
"ECR before LimitedLiability": "174%",
"Economic Capital Ratio": "285%"
}
}
},
"top_rated": false,
"trend": -23.0,
"value": 2.850219312491493,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000748592.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000748592.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000748592.svg"
},
{
"company_id": "0001048477",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001048477.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001048477.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001048477.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001048477_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001048477_main_keyfigs.svg",
"name": "Biomarin Pharmaceutical INC",
"rank": 96,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001048477.svg",
"report_text": "The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 35% points.The greatest weakness of Biomarin Pharmaceutical INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 66% points.
The company's Economic Capital Ratio, given in the ranking table, is 285%, being 42% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001048477_2014_Biomarin_Pharmaceutical_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "28.3",
"Assets": "28.9",
"Liabilities": "-39.4",
"Stockholders Equity": "18.5",
"ECR before LimitedLiability": "18.5",
"Property and Equipment": "8.23",
"Intangible Assets": "-6.47",
"Liabilities, Current": "23.0",
"Other Liabilities": "-71.6",
"Liabilities, Non-Current": "1.71",
"Selling, General and Administrative Expense": "4.77",
"Expenses": "27.0",
"Revenues": "-4.74",
"Net Income": "22.6",
"Research and Development": "-0.696",
"Cost of Goods Sold": "-1.43",
"Other Expenses": "24.2",
"Other Revenues": "-4.74",
"Comprehensive Net Income": "22.6",
"Other Net Income": "0.605",
"Economic Capital Ratio": "12.1"
},
"2011": {
"Other Assets": "27.5",
"Assets": "39.9",
"Liabilities": "-23.6",
"Stockholders Equity": "38.5",
"ECR before LimitedLiability": "129",
"Intangible Assets": "11.3",
"Property and Equipment": "21.1",
"Assets, Current": "-18.4",
"Other Liabilities": "-56.8",
"Liabilities, Non-Current": "-8.30",
"Liabilities, Current": "35.3",
"Research and Development": "13.2",
"Expenses": "30.0",
"Revenues": "7.14",
"Net Income": "39.9",
"Other Expenses": "7.70",
"Cost of Goods Sold": "-3.01",
"Selling, General and Administrative Expense": "11.5",
"Other Revenues": "7.14",
"Comprehensive Net Income": "39.6",
"Economic Capital Ratio": "53.3"
},
"2012": {
"Property and Equipment": "16.3",
"Assets": "44.3",
"Liabilities": "-5.17",
"Stockholders Equity": "60.4",
"ECR before LimitedLiability": "150",
"Assets, Current": "-6.92",
"Intangible Assets": "6.62",
"Other Assets": "23.3",
"Liabilities, Current": "29.2",
"Other Liabilities": "-48.8",
"Liabilities, Non-Current": "8.83",
"Selling, General and Administrative Expense": "11.7",
"Expenses": "29.1",
"Revenues": "7.98",
"Net Income": "39.5",
"Research and Development": "6.08",
"Other Expenses": "12.9",
"Cost of Goods Sold": "-2.04",
"Other Revenues": "7.98",
"Comprehensive Net Income": "39.5",
"Economic Capital Ratio": "76.8"
},
"2013": {
"Other Assets": "29.6",
"Assets": "33.8",
"Liabilities": "-17.0",
"Stockholders Equity": "35.5",
"ECR before LimitedLiability": "70.0",
"Intangible Assets": "2.01",
"Property and Equipment": "13.3",
"Assets, Current": "-10.7",
"Liabilities, Non-Current": "6.57",
"Liabilities, Current": "34.3",
"Other Liabilities": "-66.1",
"Selling, General and Administrative Expense": "11.3",
"Expenses": "24.8",
"Revenues": "4.94",
"Net Income": "31.5",
"Other Expenses": "8.90",
"Research and Development": "5.99",
"Cost of Goods Sold": "-1.74",
"Other Revenues": "4.94",
"Comprehensive Net Income": "31.4",
"Economic Capital Ratio": "42.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001048477_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "504,260",
"Cost of Goods Sold": "70,285",
"Intangible Assets": "157,012",
"Liabilities, Current": "83,844",
"Liabilities, Non-Current": "84,001",
"Other Assets": "379,485",
"Other Compr. Net Income": "0",
"Other Expenses": "-196,846",
"Other Liabilities": "377,521",
"Other Net Income": "2,023",
"Other Revenues": "376,267",
"Property and Equipment": "221,866",
"Research and Development": "147,309",
"Selling, General and Administrative Expense": "151,723"
},
"output_variables": {
"Assets": "1,262,623",
"Liabilities": "545,366",
"Expenses": "172,471",
"Revenues": "376,267",
"Stockholders Equity": "717,257",
"Net Income": "205,819",
"Comprehensive Net Income": "205,819",
"BaseVar": "1,179,375",
"ECR before LimitedLiability": "196%",
"Economic Capital Ratio": "300%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "469,802",
"Cost of Goods Sold": "84,023",
"Intangible Assets": "231,820",
"Liabilities, Current": "94,125",
"Liabilities, Non-Current": "88,179",
"Other Assets": "333,088",
"Other Compr. Net Income": "0",
"Other Expenses": "21,882",
"Other Liabilities": "348,329",
"Other Net Income": "508",
"Other Revenues": "441,358",
"Property and Equipment": "268,971",
"Research and Development": "214,374",
"Selling, General and Administrative Expense": "175,423"
},
"output_variables": {
"Assets": "1,303,681",
"Liabilities": "530,633",
"Expenses": "495,702",
"Revenues": "441,358",
"Stockholders Equity": "773,048",
"Net Income": "-53,836",
"Comprehensive Net Income": "-53,836",
"BaseVar": "1,385,941",
"ECR before LimitedLiability": "178%",
"Economic Capital Ratio": "287%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "743,462",
"Cost of Goods Sold": "91,830",
"Intangible Assets": "214,523",
"Liabilities, Current": "170,433",
"Liabilities, Non-Current": "26,674",
"Other Assets": "359,185",
"Other Compr. Net Income": "-5,089",
"Other Expenses": "22,425",
"Other Liabilities": "388,773",
"Other Net Income": "-424",
"Other Revenues": "500,723",
"Property and Equipment": "284,473",
"Research and Development": "302,218",
"Selling, General and Administrative Expense": "198,173"
},
"output_variables": {
"Assets": "1,601,643",
"Liabilities": "585,880",
"Expenses": "614,646",
"Revenues": "500,723",
"Stockholders Equity": "1,015,763",
"Net Income": "-114,347",
"Comprehensive Net Income": "-116,892",
"BaseVar": "1,654,202",
"ECR before LimitedLiability": "192%",
"Economic Capital Ratio": "297%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "1,137,418",
"Cost of Goods Sold": "96,798",
"Intangible Assets": "217,405",
"Liabilities, Current": "183,271",
"Liabilities, Non-Current": "38,549",
"Other Assets": "575,078",
"Other Compr. Net Income": "-5,079",
"Other Expenses": "35,236",
"Other Liabilities": "686,356",
"Other Net Income": "1,430",
"Other Revenues": "561,090",
"Property and Equipment": "319,316",
"Research and Development": "427,784",
"Selling, General and Administrative Expense": "245,040"
},
"output_variables": {
"Assets": "2,249,217",
"Liabilities": "908,176",
"Expenses": "804,858",
"Revenues": "561,090",
"Stockholders Equity": "1,341,041",
"Net Income": "-242,338",
"Comprehensive Net Income": "-244,878",
"BaseVar": "2,264,925",
"ECR before LimitedLiability": "170%",
"Economic Capital Ratio": "282%"
}
}
},
"top_rated": false,
"trend": -25.0,
"value": 2.8482954054924363,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001048477.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001048477.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001048477.svg"
},
{
"company_id": "0000357097",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000357097.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000357097.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000357097_main_keyfigs.svg",
"name": "Fibrocell Science Inc",
"rank": 97,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000357097.svg",
"report_text": "The relative strengths and weaknesses of Fibrocell Science Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Fibrocell Science Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 87% points.The greatest weakness of Fibrocell Science Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 44% points.
The company's Economic Capital Ratio, given in the ranking table, is 284%, being 42% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000357097_2014_Fibrocell_Science_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-1.03",
"Assets": "50.1",
"Liabilities": "95.9",
"Stockholders Equity": "186",
"ECR before LimitedLiability": "209",
"Assets, Current": "49.0",
"Intangible Assets": "-6.70",
"Other Assets": "9.47",
"Liabilities, Current": "57.9",
"Other Liabilities": "33.6",
"Liabilities, Non-Current": "14.2",
"Selling, General and Administrative Expense": "-10.4",
"Expenses": "-10.8",
"Revenues": "-26.3",
"Net Income": "-20.2",
"Other Expenses": "-5.02",
"Cost of Goods Sold": "4.17",
"Other Revenues": "-26.3",
"Comprehensive Net Income": "-20.0",
"Other Net Income": "16.6",
"Economic Capital Ratio": "136"
},
"2013": {
"Other Assets": "-7.18",
"Assets": "61.2",
"Liabilities": "8.97",
"Stockholders Equity": "87.4",
"ECR before LimitedLiability": "69.7",
"Intangible Assets": "0.589",
"Property and Equipment": "-2.34",
"Assets, Current": "81.9",
"Liabilities, Non-Current": "8.72",
"Liabilities, Current": "39.3",
"Other Liabilities": "-44.0",
"Selling, General and Administrative Expense": "5.04",
"Expenses": "6.25",
"Revenues": "-17.9",
"Net Income": "-12.3",
"Other Expenses": "-2.29",
"Research and Development": "1.12",
"Cost of Goods Sold": "2.38",
"Other Revenues": "-17.9",
"Comprehensive Net Income": "-12.5",
"Economic Capital Ratio": "41.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000357097_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "33,156",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,554",
"Liabilities, Non-Current": "344",
"Other Assets": "5,789",
"Other Compr. Net Income": "0",
"Other Expenses": "6,871",
"Other Liabilities": "374",
"Other Net Income": "4,737",
"Other Revenues": "153",
"Property and Equipment": "1,658",
"Research and Development": "9,021",
"Selling, General and Administrative Expense": "12,167"
},
"output_variables": {
"Assets": "40,603",
"Liabilities": "2,272",
"Expenses": "28,059",
"Revenues": "153",
"Stockholders Equity": "38,331",
"Net Income": "-23,169",
"Comprehensive Net Income": "-23,169",
"BaseVar": "37,912",
"ECR before LimitedLiability": "282%",
"Economic Capital Ratio": "356%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "61,860",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,238",
"Liabilities, Current": "3,593",
"Liabilities, Non-Current": "539",
"Other Assets": "215",
"Other Compr. Net Income": "0",
"Other Expenses": "8,050",
"Other Liabilities": "15,216",
"Other Net Income": "-1,053",
"Other Revenues": "200",
"Property and Equipment": "1,701",
"Research and Development": "12,578",
"Selling, General and Administrative Expense": "10,073"
},
"output_variables": {
"Assets": "69,014",
"Liabilities": "19,348",
"Expenses": "30,701",
"Revenues": "200",
"Stockholders Equity": "49,666",
"Net Income": "-31,554",
"Comprehensive Net Income": "-31,554",
"BaseVar": "60,158",
"ECR before LimitedLiability": "174%",
"Economic Capital Ratio": "284%"
}
}
},
"top_rated": false,
"trend": -60.0,
"value": 2.844611157526786,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000357097.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000357097.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000357097.svg"
},
{
"company_id": "0001516551",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001516551.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001516551.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001516551_main_keyfigs.svg",
"name": "Skye Bioscience Inc",
"rank": 98,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001516551.svg",
"report_text": "The relative strengths and weaknesses of Skye Bioscience Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Skye Bioscience Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 169% points.The greatest weakness of Skye Bioscience Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 180% points.
The company's Economic Capital Ratio, given in the ranking table, is 283%, being 40% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001516551_2014_Skye_Bioscience_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-22.0",
"Assets": "-89.2",
"Liabilities": "142",
"Stockholders Equity": "-167",
"ECR before LimitedLiability": "67.9",
"Intangible Assets": "-27.1",
"Property and Equipment": "18.0",
"Assets, Current": "-77.9",
"Liabilities, Non-Current": "34.6",
"Liabilities, Current": "55.1",
"Other Liabilities": "90.6",
"Selling, General and Administrative Expense": "50.0",
"Expenses": "-56.8",
"Revenues": "-56.8",
"Net Income": "137",
"Other Expenses": "-180",
"Research and Development": "72.3",
"Other Revenues": "-56.8",
"Comprehensive Net Income": "136",
"Other Net Income": "169",
"Economic Capital Ratio": "39.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001516551_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "106",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "62",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "319",
"Other Liabilities": "0",
"Other Net Income": "343",
"Other Revenues": "0",
"Property and Equipment": "40",
"Research and Development": "0",
"Selling, General and Administrative Expense": "28"
},
"output_variables": {
"Assets": "146",
"Liabilities": "62",
"Expenses": "347",
"Revenues": "0",
"Stockholders Equity": "83",
"Net Income": "-3.8",
"Comprehensive Net Income": "-3.8",
"BaseVar": "449",
"ECR before LimitedLiability": "171%",
"Economic Capital Ratio": "283%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.827146754077508,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001516551.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001516551.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001516551.svg"
},
{
"company_id": "0001088856",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001088856.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001088856.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001088856.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001088856_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001088856_main_keyfigs.svg",
"name": "Corcept Therapeutics INC",
"rank": 99,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001088856.svg",
"report_text": "The relative strengths and weaknesses of Corcept Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Corcept Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 83% points.The greatest weakness of Corcept Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 33% points.
The company's Economic Capital Ratio, given in the ranking table, is 281%, being 38% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001088856_2014_Corcept_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-25.9",
"Assets": "-132",
"Liabilities": "-7.45",
"Stockholders Equity": "-27.3",
"ECR before LimitedLiability": "-150",
"Intangible Assets": "-37.2",
"Property and Equipment": "-20.5",
"Assets, Current": "-91.2",
"Other Liabilities": "-3.05",
"Liabilities, Non-Current": "-1.37",
"Liabilities, Current": "-4.62",
"Research and Development": "-127",
"Expenses": "-132",
"Revenues": "-14.4",
"Net Income": "-217",
"Other Expenses": "3.13",
"Cost of Goods Sold": "1.43",
"Selling, General and Administrative Expense": "-16.8",
"Other Revenues": "-14.4",
"Comprehensive Net Income": "-219",
"Economic Capital Ratio": "-225"
},
"2012": {
"Property and Equipment": "-3.37",
"Assets": "68.7",
"Liabilities": "67.6",
"Stockholders Equity": "187",
"ECR before LimitedLiability": "220",
"Assets, Current": "103",
"Intangible Assets": "-4.93",
"Liabilities, Current": "28.5",
"Other Liabilities": "31.0",
"Liabilities, Non-Current": "14.7",
"Selling, General and Administrative Expense": "-9.64",
"Expenses": "9.91",
"Revenues": "-17.4",
"Net Income": "-5.63",
"Research and Development": "5.36",
"Other Expenses": "10.9",
"Cost of Goods Sold": "3.25",
"Other Revenues": "-17.4",
"Comprehensive Net Income": "-5.49",
"Other Net Income": "1.66",
"Economic Capital Ratio": "147"
},
"2013": {
"Assets": "17.4",
"Liabilities": "64.1",
"Stockholders Equity": "83.4",
"ECR before LimitedLiability": "65.8",
"Intangible Assets": "-13.3",
"Property and Equipment": "-7.47",
"Assets, Current": "50.6",
"Liabilities, Non-Current": "15.4",
"Liabilities, Current": "9.63",
"Other Liabilities": "41.5",
"Selling, General and Administrative Expense": "-27.9",
"Expenses": "-27.5",
"Revenues": "-6.66",
"Net Income": "-32.3",
"Other Expenses": "6.09",
"Research and Development": "-8.62",
"Cost of Goods Sold": "3.05",
"Other Revenues": "-6.66",
"Comprehensive Net Income": "-32.5",
"Other Net Income": "1.71",
"Economic Capital Ratio": "37.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001088856_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "39,775",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "5,026",
"Liabilities, Non-Current": "0",
"Other Assets": "32",
"Other Compr. Net Income": "0",
"Other Expenses": "1,655",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "7,839",
"Property and Equipment": "26",
"Research and Development": "154,161",
"Selling, General and Administrative Expense": "60,581"
},
"output_variables": {
"Assets": "39,833",
"Liabilities": "5,026",
"Expenses": "216,397",
"Revenues": "7,839",
"Stockholders Equity": "34,807",
"Net Income": "-208,558",
"Comprehensive Net Income": "-208,558",
"BaseVar": "134,548",
"ECR before LimitedLiability": "-592%",
"Economic Capital Ratio": "8.6%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "95,062",
"Cost of Goods Sold": "91",
"Intangible Assets": "0",
"Liabilities, Current": "8,359",
"Liabilities, Non-Current": "0",
"Other Assets": "3,954",
"Other Compr. Net Income": "0",
"Other Expenses": "1,776",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "3,307",
"Property and Equipment": "150",
"Research and Development": "14,074",
"Selling, General and Administrative Expense": "25,414"
},
"output_variables": {
"Assets": "99,166",
"Liabilities": "8,359",
"Expenses": "41,355",
"Revenues": "3,307",
"Stockholders Equity": "90,807",
"Net Income": "-38,048",
"Comprehensive Net Income": "-38,048",
"BaseVar": "76,094",
"ECR before LimitedLiability": "297%",
"Economic Capital Ratio": "367%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "58,311",
"Cost of Goods Sold": "143",
"Intangible Assets": "0",
"Liabilities, Current": "12,738",
"Liabilities, Non-Current": "0",
"Other Assets": "4,563",
"Other Compr. Net Income": "0",
"Other Expenses": "4,515",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "10,357",
"Property and Equipment": "203",
"Research and Development": "20,470",
"Selling, General and Administrative Expense": "31,240"
},
"output_variables": {
"Assets": "63,077",
"Liabilities": "12,738",
"Expenses": "56,368",
"Revenues": "10,357",
"Stockholders Equity": "50,339",
"Net Income": "-46,011",
"Comprehensive Net Income": "-46,011",
"BaseVar": "71,270",
"ECR before LimitedLiability": "168%",
"Economic Capital Ratio": "281%"
}
}
},
"top_rated": false,
"trend": -70.0,
"value": 2.8061935252372168,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001088856.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001088856.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001088856.svg"
},
{
"company_id": "0001461993",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001461993.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001461993.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001461993_main_keyfigs.svg",
"name": "Melinta Therapeutics INC NEW",
"rank": 100,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001461993.svg",
"report_text": "The relative strengths and weaknesses of Melinta Therapeutics INC NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Melinta Therapeutics INC NEW compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 103% points.The greatest weakness of Melinta Therapeutics INC NEW is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 30% points.
The company's Economic Capital Ratio, given in the ranking table, is 280%, being 38% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001461993_2014_Melinta_Therapeutics_INC_NEW.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-19.5",
"Assets": "21.3",
"Liabilities": "48.4",
"Stockholders Equity": "52.7",
"ECR before LimitedLiability": "40.7",
"Assets, Current": "55.9",
"Intangible Assets": "-27.2",
"Other Assets": "-19.0",
"Liabilities, Current": "47.0",
"Other Liabilities": "7.60",
"Liabilities, Non-Current": "21.0",
"Expenses": "-83.3",
"Revenues": "-42.7",
"Net Income": "-116",
"Research and Development": "-111",
"Other Expenses": "28.9",
"Cost of Goods Sold": "7.22",
"Other Revenues": "-42.7",
"Comprehensive Net Income": "-115",
"Other Net Income": "3.55",
"Economic Capital Ratio": "-32.4"
},
"2013": {
"Other Assets": "-7.97",
"Assets": "45.2",
"Liabilities": "13.9",
"Stockholders Equity": "73.2",
"ECR before LimitedLiability": "65.7",
"Intangible Assets": "-10.6",
"Property and Equipment": "-6.10",
"Assets, Current": "103",
"Liabilities, Non-Current": "-30.3",
"Liabilities, Current": "26.5",
"Other Liabilities": "15.4",
"Selling, General and Administrative Expense": "12.6",
"Expenses": "3.98",
"Revenues": "-11.6",
"Net Income": "-8.62",
"Other Expenses": "11.4",
"Research and Development": "-21.9",
"Cost of Goods Sold": "2.59",
"Other Revenues": "-11.6",
"Comprehensive Net Income": "-8.84",
"Economic Capital Ratio": "37.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001461993_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "70,374",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "5,345",
"Liabilities, Non-Current": "0",
"Other Assets": "321",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "7,623",
"Other Net Income": "0",
"Other Revenues": "0",
"Property and Equipment": "43",
"Research and Development": "83,728",
"Selling, General and Administrative Expense": "21,562"
},
"output_variables": {
"Assets": "70,738",
"Liabilities": "12,968",
"Expenses": "105,290",
"Revenues": "0",
"Stockholders Equity": "57,770",
"Net Income": "-105,290",
"Comprehensive Net Income": "-105,290",
"BaseVar": "94,498",
"ECR before LimitedLiability": "49%",
"Economic Capital Ratio": "188%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "98,537",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "10,862",
"Liabilities, Non-Current": "12,538",
"Other Assets": "333",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "5,633",
"Other Net Income": "-2,115",
"Other Revenues": "7,813",
"Property and Equipment": "138",
"Research and Development": "41,300",
"Selling, General and Administrative Expense": "9,433"
},
"output_variables": {
"Assets": "99,008",
"Liabilities": "29,032",
"Expenses": "50,733",
"Revenues": "7,813",
"Stockholders Equity": "69,975",
"Net Income": "-45,035",
"Comprehensive Net Income": "-45,035",
"BaseVar": "94,350",
"ECR before LimitedLiability": "168%",
"Economic Capital Ratio": "280%"
}
}
},
"top_rated": false,
"trend": 33.0,
"value": 2.804935288968962,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001461993.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001461993.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001461993.svg"
},
{
"company_id": "0000275053",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000275053.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000275053.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000275053.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000275053_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000275053_main_keyfigs.svg",
"name": "Natures Sunshine Products INC",
"rank": 101,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000275053.svg",
"report_text": "The relative strengths and weaknesses of Natures Sunshine Products INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Natures Sunshine Products INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 139% points.The greatest weakness of Natures Sunshine Products INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 125% points.
The company's Economic Capital Ratio, given in the ranking table, is 280%, being 37% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000275053_2014_Natures_Sunshine_Products_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-6.34",
"Assets": "-74.4",
"Liabilities": "94.5",
"Stockholders Equity": "-119",
"ECR before LimitedLiability": "114",
"Intangible Assets": "-26.9",
"Assets, Current": "-58.7",
"Other Liabilities": "65.9",
"Liabilities, Non-Current": "-2.90",
"Liabilities, Current": "35.1",
"Research and Development": "82.6",
"Expenses": "-19.6",
"Revenues": "132",
"Net Income": "132",
"Other Expenses": "-55.8",
"Cost of Goods Sold": "-28.1",
"Selling, General and Administrative Expense": "-6.87",
"Other Revenues": "132",
"Comprehensive Net Income": "132",
"Other Net Income": "6.16",
"Economic Capital Ratio": "38.5"
},
"2012": {
"Assets": "-54.6",
"Liabilities": "119",
"Stockholders Equity": "-65.5",
"ECR before LimitedLiability": "158",
"Assets, Current": "-42.6",
"Intangible Assets": "-18.9",
"Other Assets": "-4.58",
"Liabilities, Current": "52.6",
"Other Liabilities": "67.9",
"Liabilities, Non-Current": "7.41",
"Selling, General and Administrative Expense": "3.85",
"Expenses": "-11.8",
"Revenues": "149",
"Net Income": "139",
"Research and Development": "62.1",
"Other Expenses": "-36.5",
"Cost of Goods Sold": "-36.8",
"Other Revenues": "149",
"Comprehensive Net Income": "139",
"Other Net Income": "5.01",
"Economic Capital Ratio": "84.8"
},
"2013": {
"Other Assets": "-9.23",
"Assets": "-75.7",
"Liabilities": "113",
"Stockholders Equity": "-125",
"ECR before LimitedLiability": "65.0",
"Intangible Assets": "-23.0",
"Property and Equipment": "4.84",
"Assets, Current": "-64.5",
"Liabilities, Non-Current": "-7.47",
"Liabilities, Current": "50.1",
"Other Liabilities": "75.3",
"Expenses": "-29.0",
"Revenues": "139",
"Net Income": "123",
"Other Expenses": "-41.2",
"Research and Development": "58.5",
"Cost of Goods Sold": "-37.7",
"Other Revenues": "139",
"Comprehensive Net Income": "121",
"Other Net Income": "3.98",
"Economic Capital Ratio": "37.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000275053_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "125,103",
"Cost of Goods Sold": "69,410",
"Intangible Assets": "1,151",
"Liabilities, Current": "67,798",
"Liabilities, Non-Current": "20,575",
"Other Assets": "24,420",
"Other Compr. Net Income": "-2,421",
"Other Expenses": "153,044",
"Other Liabilities": "0",
"Other Net Income": "1,847",
"Other Revenues": "367,813",
"Property and Equipment": "25,137",
"Research and Development": "0",
"Selling, General and Administrative Expense": "129,605"
},
"output_variables": {
"Assets": "175,811",
"Liabilities": "88,373",
"Expenses": "352,059",
"Revenues": "367,813",
"Stockholders Equity": "87,438",
"Net Income": "17,601",
"Comprehensive Net Income": "16,390",
"BaseVar": "494,162",
"ECR before LimitedLiability": "157%",
"Economic Capital Ratio": "273%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "145,333",
"Cost of Goods Sold": "93,324",
"Intangible Assets": "1,002",
"Liabilities, Current": "61,390",
"Liabilities, Non-Current": "16,893",
"Other Assets": "19,634",
"Other Compr. Net Income": "-497",
"Other Expenses": "143,383",
"Other Liabilities": "0",
"Other Net Income": "1,480",
"Other Revenues": "367,468",
"Property and Equipment": "27,950",
"Research and Development": "0",
"Selling, General and Administrative Expense": "106,861"
},
"output_variables": {
"Assets": "193,919",
"Liabilities": "78,283",
"Expenses": "343,568",
"Revenues": "367,468",
"Stockholders Equity": "115,636",
"Net Income": "25,380",
"Comprehensive Net Income": "25,132",
"BaseVar": "492,608",
"ECR before LimitedLiability": "204%",
"Economic Capital Ratio": "305%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "148,594",
"Cost of Goods Sold": "94,814",
"Intangible Assets": "853",
"Liabilities, Current": "68,569",
"Liabilities, Non-Current": "25,784",
"Other Assets": "18,143",
"Other Compr. Net Income": "-3,397",
"Other Expenses": "146,526",
"Other Liabilities": "0",
"Other Net Income": "1,596",
"Other Revenues": "378,096",
"Property and Equipment": "32,022",
"Research and Development": "0",
"Selling, General and Administrative Expense": "120,743"
},
"output_variables": {
"Assets": "199,612",
"Liabilities": "94,353",
"Expenses": "362,083",
"Revenues": "378,096",
"Stockholders Equity": "105,259",
"Net Income": "17,609",
"Comprehensive Net Income": "15,910",
"BaseVar": "519,568",
"ECR before LimitedLiability": "167%",
"Economic Capital Ratio": "280%"
}
}
},
"top_rated": false,
"trend": -36.0,
"value": 2.7980077043823357,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000275053.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000275053.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000275053.svg"
},
{
"company_id": "0000059478",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000059478.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000059478.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000059478.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000059478_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000059478_main_keyfigs.svg",
"name": "ELI Lilly Co",
"rank": 102,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000059478.svg",
"report_text": "The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of ELI Lilly Co compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 70% points.The greatest weakness of ELI Lilly Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 59% points.
The company's Economic Capital Ratio, given in the ranking table, is 280%, being 37% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000059478_2014_ELI_Lilly_Co.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "-13.7",
"Assets": "-42.3",
"Liabilities": "-64.7",
"Stockholders Equity": "-108",
"ECR before LimitedLiability": "-98.7",
"Other Assets": "25.3",
"Intangible Assets": "-54.5",
"Property and Equipment": "15.4",
"Other Liabilities": "18.8",
"Liabilities, Non-Current": "-88.1",
"Cost of Goods Sold": "0.754",
"Expenses": "-4.73",
"Revenues": "6.89",
"Net Income": "1.81",
"Selling, General and Administrative Expense": "-1.40",
"Other Expenses": "0.299",
"Research and Development": "-4.38",
"Other Revenues": "6.89",
"Comprehensive Net Income": "2.32",
"Other Compr. Net Income": "0.508",
"Economic Capital Ratio": "-97.9"
},
"2010": {
"Other Assets": "19.1",
"Assets": "-28.4",
"Liabilities": "-31.4",
"Stockholders Equity": "-66.5",
"ECR before LimitedLiability": "-28.5",
"Assets, Current": "-19.8",
"Property and Equipment": "13.6",
"Intangible Assets": "-33.6",
"Other Liabilities": "35.9",
"Liabilities, Non-Current": "-74.7",
"Selling, General and Administrative Expense": "3.75",
"Expenses": "6.77",
"Revenues": "18.9",
"Net Income": "26.8",
"Research and Development": "1.30",
"Cost of Goods Sold": "5.96",
"Other Expenses": "-4.22",
"Other Revenues": "18.9",
"Comprehensive Net Income": "26.5",
"Other Net Income": "0.704",
"Economic Capital Ratio": "-34.8"
},
"2011": {
"Other Assets": "45.8",
"Assets": "-5.82",
"Liabilities": "-38.2",
"Stockholders Equity": "-35.3",
"ECR before LimitedLiability": "90.0",
"Intangible Assets": "-17.4",
"Property and Equipment": "24.8",
"Assets, Current": "-36.0",
"Other Liabilities": "33.8",
"Liabilities, Non-Current": "-81.0",
"Research and Development": "25.7",
"Expenses": "34.2",
"Revenues": "34.9",
"Net Income": "76.0",
"Other Expenses": "-7.24",
"Cost of Goods Sold": "4.42",
"Selling, General and Administrative Expense": "10.9",
"Other Revenues": "34.9",
"Comprehensive Net Income": "73.5",
"Other Net Income": "2.69",
"Economic Capital Ratio": "14.4"
},
"2012": {
"Property and Equipment": "24.1",
"Assets": "4.89",
"Liabilities": "-28.4",
"Stockholders Equity": "-13.8",
"ECR before LimitedLiability": "110",
"Assets, Current": "-36.4",
"Intangible Assets": "-14.2",
"Other Assets": "61.0",
"Liabilities, Current": "7.96",
"Other Liabilities": "34.5",
"Liabilities, Non-Current": "-79.5",
"Selling, General and Administrative Expense": "9.86",
"Expenses": "35.4",
"Revenues": "33.9",
"Net Income": "75.8",
"Research and Development": "17.4",
"Other Expenses": "2.38",
"Cost of Goods Sold": "4.65",
"Other Revenues": "33.9",
"Comprehensive Net Income": "76.1",
"Economic Capital Ratio": "36.4"
},
"2013": {
"Other Assets": "53.1",
"Assets": "-10.2",
"Liabilities": "-4.97",
"Stockholders Equity": "-20.7",
"ECR before LimitedLiability": "64.8",
"Intangible Assets": "-13.0",
"Property and Equipment": "23.3",
"Assets, Current": "-42.0",
"Liabilities, Non-Current": "-59.5",
"Liabilities, Current": "6.82",
"Other Liabilities": "40.2",
"Selling, General and Administrative Expense": "9.32",
"Expenses": "25.3",
"Revenues": "37.7",
"Net Income": "67.7",
"Research and Development": "13.7",
"Cost of Goods Sold": "3.21",
"Other Revenues": "37.7",
"Comprehensive Net Income": "70.2",
"Other Compr. Net Income": "2.09",
"Economic Capital Ratio": "36.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000059478_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "12,486,500",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,568,100",
"Liabilities, Non-Current": "11,367,500",
"Other Assets": "6,777,000",
"Other Compr. Net Income": "314,900",
"Other Expenses": "6,288,200",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "21,836,000",
"Property and Equipment": "8,197,400",
"Research and Development": "4,326,500",
"Selling, General and Administrative Expense": "6,892,500"
},
"output_variables": {
"Assets": "27,460,900",
"Liabilities": "17,935,600",
"Expenses": "17,507,200",
"Revenues": "21,836,000",
"Stockholders Equity": "9,525,300",
"Net Income": "4,328,800",
"Comprehensive Net Income": "4,486,250",
"BaseVar": "42,527,300",
"ECR before LimitedLiability": "111%",
"Economic Capital Ratio": "239%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "14,840,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,101,400",
"Liabilities, Non-Current": "11,487,200",
"Other Assets": "8,220,700",
"Other Compr. Net Income": "-198,200",
"Other Expenses": "6,068,900",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "23,076,000",
"Property and Equipment": "7,940,700",
"Research and Development": "4,884,200",
"Selling, General and Administrative Expense": "7,053,400"
},
"output_variables": {
"Assets": "31,001,400",
"Liabilities": "18,588,600",
"Expenses": "18,006,500",
"Revenues": "23,076,000",
"Stockholders Equity": "12,412,800",
"Net Income": "5,069,500",
"Comprehensive Net Income": "4,970,400",
"BaseVar": "45,435,350",
"ECR before LimitedLiability": "129%",
"Economic Capital Ratio": "253%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "14,248,200",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,930,900",
"Liabilities, Non-Current": "11,193,300",
"Other Assets": "11,651,300",
"Other Compr. Net Income": "-1,188,500",
"Other Expenses": "7,038,100",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "24,286,500",
"Property and Equipment": "7,760,300",
"Research and Development": "5,020,800",
"Selling, General and Administrative Expense": "7,879,900"
},
"output_variables": {
"Assets": "33,659,800",
"Liabilities": "20,124,200",
"Expenses": "19,938,800",
"Revenues": "24,286,500",
"Stockholders Equity": "13,535,600",
"Net Income": "4,347,700",
"Comprehensive Net Income": "3,753,450",
"BaseVar": "49,598,900",
"ECR before LimitedLiability": "124%",
"Economic Capital Ratio": "248%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "13,038,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,389,500",
"Liabilities, Non-Current": "11,235,500",
"Other Assets": "13,600,000",
"Other Compr. Net Income": "-501,354",
"Other Expenses": "5,810,035",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "22,504,841",
"Property and Equipment": "7,760,200",
"Research and Development": "5,317,405",
"Selling, General and Administrative Expense": "7,506,219"
},
"output_variables": {
"Assets": "34,398,900",
"Liabilities": "19,625,000",
"Expenses": "18,633,660",
"Revenues": "22,504,841",
"Stockholders Equity": "14,773,900",
"Net Income": "3,871,181",
"Comprehensive Net Income": "3,620,505",
"BaseVar": "47,831,877",
"ECR before LimitedLiability": "133%",
"Economic Capital Ratio": "255%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "13,104,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,916,600",
"Liabilities, Non-Current": "8,691,400",
"Other Assets": "14,168,500",
"Other Compr. Net Income": "3,127,090",
"Other Expenses": "5,768,275",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "23,141,749",
"Property and Equipment": "7,975,500",
"Research and Development": "5,570,974",
"Selling, General and Administrative Expense": "7,116,725"
},
"output_variables": {
"Assets": "35,248,700",
"Liabilities": "17,608,000",
"Expenses": "18,455,974",
"Revenues": "23,141,749",
"Stockholders Equity": "17,640,700",
"Net Income": "4,685,775",
"Comprehensive Net Income": "6,249,319",
"BaseVar": "48,790,757",
"ECR before LimitedLiability": "169%",
"Economic Capital Ratio": "281%"
}
}
},
"top_rated": false,
"trend": -9.0,
"value": 2.795860523542757,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000059478.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000059478.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000059478.svg"
},
{
"company_id": "0001325879",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001325879.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001325879.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001325879.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001325879_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001325879_main_keyfigs.svg",
"name": "AVEO Pharmaceuticals INC",
"rank": 103,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001325879.svg",
"report_text": "The relative strengths and weaknesses of AVEO Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of AVEO Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 101% points.The greatest weakness of AVEO Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 39% points.
The company's Economic Capital Ratio, given in the ranking table, is 276%, being 33% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001325879_2014_AVEO_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "5.97",
"Assets": "14.6",
"Liabilities": "87.0",
"Stockholders Equity": "121",
"ECR before LimitedLiability": "254",
"Intangible Assets": "-4.09",
"Property and Equipment": "-1.85",
"Assets, Current": "16.2",
"Other Liabilities": "43.6",
"Liabilities, Non-Current": "19.6",
"Liabilities, Current": "36.4",
"Research and Development": "-5.99",
"Expenses": "29.3",
"Revenues": "36.3",
"Net Income": "65.4",
"Other Expenses": "12.0",
"Cost of Goods Sold": "4.30",
"Selling, General and Administrative Expense": "19.2",
"Other Revenues": "36.3",
"Comprehensive Net Income": "65.1",
"Economic Capital Ratio": "178"
},
"2012": {
"Property and Equipment": "1.16",
"Assets": "62.2",
"Liabilities": "46.2",
"Stockholders Equity": "131",
"ECR before LimitedLiability": "159",
"Assets, Current": "96.9",
"Intangible Assets": "-9.27",
"Other Assets": "-4.50",
"Liabilities, Current": "0.739",
"Other Liabilities": "31.9",
"Liabilities, Non-Current": "14.9",
"Selling, General and Administrative Expense": "5.22",
"Expenses": "-0.710",
"Revenues": "-13.9",
"Net Income": "-14.2",
"Research and Development": "-23.1",
"Other Expenses": "13.7",
"Cost of Goods Sold": "3.87",
"Other Revenues": "-13.9",
"Comprehensive Net Income": "-14.0",
"Economic Capital Ratio": "85.6"
},
"2013": {
"Other Assets": "-6.24",
"Assets": "44.7",
"Liabilities": "43.5",
"Stockholders Equity": "101",
"ECR before LimitedLiability": "61.2",
"Intangible Assets": "-11.9",
"Property and Equipment": "8.37",
"Assets, Current": "65.8",
"Liabilities, Non-Current": "13.3",
"Liabilities, Current": "-5.21",
"Other Liabilities": "35.9",
"Selling, General and Administrative Expense": "2.38",
"Expenses": "-17.4",
"Revenues": "-20.9",
"Net Income": "-38.7",
"Other Expenses": "6.15",
"Research and Development": "-28.3",
"Cost of Goods Sold": "2.87",
"Other Revenues": "-20.9",
"Comprehensive Net Income": "-39.0",
"Economic Capital Ratio": "33.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001325879_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "234,395",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "34,609",
"Liabilities, Non-Current": "0",
"Other Assets": "55,184",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-3,299",
"Other Revenues": "164,849",
"Property and Equipment": "5,471",
"Research and Development": "101,735",
"Selling, General and Administrative Expense": "29,167"
},
"output_variables": {
"Assets": "295,050",
"Liabilities": "34,609",
"Expenses": "130,902",
"Revenues": "164,849",
"Stockholders Equity": "260,441",
"Net Income": "30,648",
"Comprehensive Net Income": "30,648",
"BaseVar": "314,354",
"ECR before LimitedLiability": "363%",
"Economic Capital Ratio": "412%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "190,681",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "39,130",
"Liabilities, Non-Current": "0",
"Other Assets": "3,921",
"Other Compr. Net Income": "148",
"Other Expenses": "2,633",
"Other Liabilities": "0",
"Other Net Income": "-2,757",
"Other Revenues": "19,286",
"Property and Equipment": "12,867",
"Research and Development": "91,358",
"Selling, General and Administrative Expense": "36,932"
},
"output_variables": {
"Assets": "207,469",
"Liabilities": "39,130",
"Expenses": "130,923",
"Revenues": "19,286",
"Stockholders Equity": "168,339",
"Net Income": "-114,394",
"Comprehensive Net Income": "-114,320",
"BaseVar": "199,856",
"ECR before LimitedLiability": "205%",
"Economic Capital Ratio": "306%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "128,919",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "31,408",
"Liabilities, Non-Current": "0",
"Other Assets": "3,287",
"Other Compr. Net Income": "17",
"Other Expenses": "8,017",
"Other Liabilities": "0",
"Other Net Income": "-3,125",
"Other Revenues": "1,293",
"Property and Equipment": "14,140",
"Research and Development": "68,468",
"Selling, General and Administrative Expense": "28,712"
},
"output_variables": {
"Assets": "146,346",
"Liabilities": "31,408",
"Expenses": "105,197",
"Revenues": "1,293",
"Stockholders Equity": "114,938",
"Net Income": "-107,029",
"Comprehensive Net Income": "-107,020",
"BaseVar": "143,693",
"ECR before LimitedLiability": "162%",
"Economic Capital Ratio": "276%"
}
}
},
"top_rated": false,
"trend": -39.0,
"value": 2.7599065844215804,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001325879.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001325879.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001325879.svg"
},
{
"company_id": "0001375850",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001375850.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001375850.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001375850_main_keyfigs.svg",
"name": "Hubei Minkang Pharmaceutical Ltd",
"rank": 104,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001375850.svg",
"report_text": "The relative strengths and weaknesses of Hubei Minkang Pharmaceutical Ltd are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Hubei Minkang Pharmaceutical Ltd compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 59% points.The greatest weakness of Hubei Minkang Pharmaceutical Ltd is the variable Liabilities, Current, reducing the Economic Capital Ratio by 57% points.
The company's Economic Capital Ratio, given in the ranking table, is 274%, being 31% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001375850_2014_Hubei_Minkang_Pharmaceutical_Ltd.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "23.8",
"Assets": "3.86",
"Other Liabilities": "36.8",
"Stockholders Equity": "7.11",
"ECR before LimitedLiability": "132",
"Assets, Current": "-7.55",
"Intangible Assets": "-13.0",
"Other Assets": "5.42",
"Selling, General and Administrative Expense": "16.3",
"Expenses": "26.8",
"Revenues": "36.5",
"Net Income": "68.5",
"Research and Development": "33.1",
"Other Expenses": "6.83",
"Cost of Goods Sold": "-28.0",
"Other Revenues": "36.5",
"Liabilities, Current": "-60.2",
"Liabilities, Non-Current": "17.2",
"Comprehensive Net Income": "69.0",
"Other Net Income": "2.01",
"Economic Capital Ratio": "58.8"
},
"2013": {
"Other Assets": "1.82",
"Assets": "-16.1",
"Liabilities": "8.98",
"Stockholders Equity": "-21.0",
"ECR before LimitedLiability": "59.1",
"Intangible Assets": "-14.3",
"Property and Equipment": "23.2",
"Assets, Current": "-21.1",
"Liabilities, Non-Current": "15.8",
"Liabilities, Current": "-56.6",
"Other Liabilities": "42.7",
"Selling, General and Administrative Expense": "16.2",
"Expenses": "14.0",
"Revenues": "40.6",
"Net Income": "58.5",
"Research and Development": "31.0",
"Cost of Goods Sold": "-32.5",
"Other Revenues": "40.6",
"Comprehensive Net Income": "59.0",
"Other Net Income": "1.92",
"Economic Capital Ratio": "31.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001375850_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "13,199",
"Cost of Goods Sold": "7,163",
"Intangible Assets": "0",
"Liabilities, Current": "9,538",
"Liabilities, Non-Current": "0",
"Other Assets": "2,445",
"Other Compr. Net Income": "68",
"Other Expenses": "2,491",
"Other Liabilities": "0",
"Other Net Income": "-70",
"Other Revenues": "13,919",
"Property and Equipment": "4,848",
"Research and Development": "44",
"Selling, General and Administrative Expense": "3,191"
},
"output_variables": {
"Assets": "20,491",
"Liabilities": "9,538",
"Expenses": "12,888",
"Revenues": "13,919",
"Stockholders Equity": "10,953",
"Net Income": "961",
"Comprehensive Net Income": "995",
"BaseVar": "28,487",
"ECR before LimitedLiability": "166%",
"Economic Capital Ratio": "279%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "14,599",
"Cost of Goods Sold": "8,314",
"Intangible Assets": "0",
"Liabilities, Current": "10,188",
"Liabilities, Non-Current": "0",
"Other Assets": "2,276",
"Other Compr. Net Income": "347",
"Other Expenses": "3,031",
"Other Liabilities": "0",
"Other Net Income": "32",
"Other Revenues": "14,743",
"Property and Equipment": "4,740",
"Research and Development": "82",
"Selling, General and Administrative Expense": "3,220"
},
"output_variables": {
"Assets": "21,615",
"Liabilities": "10,188",
"Expenses": "14,647",
"Revenues": "14,743",
"Stockholders Equity": "11,427",
"Net Income": "127",
"Comprehensive Net Income": "301",
"BaseVar": "30,786",
"ECR before LimitedLiability": "159%",
"Economic Capital Ratio": "274%"
}
}
},
"top_rated": false,
"trend": -23.0,
"value": 2.7390513081545373,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001375850.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001375850.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001375850.svg"
},
{
"company_id": "0001019695",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001019695.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001019695.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001019695_main_keyfigs.svg",
"name": "Arqule INC",
"rank": 105,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001019695.svg",
"report_text": "The relative strengths and weaknesses of Arqule INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Arqule INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 43% points.The greatest weakness of Arqule INC is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.
The company's Economic Capital Ratio, given in the ranking table, is 274%, being 31% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001019695_2014_Arqule_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "50.1",
"Assets": "13.0",
"Liabilities": "-89.7",
"Stockholders Equity": "-55.0",
"ECR before LimitedLiability": "32.3",
"Intangible Assets": "-20.8",
"Property and Equipment": "-9.15",
"Assets, Current": "-7.23",
"Other Liabilities": "-54.4",
"Liabilities, Non-Current": "12.3",
"Liabilities, Current": "-44.9",
"Expenses": "36.7",
"Revenues": "-32.1",
"Net Income": "48.0",
"Other Expenses": "12.1",
"Cost of Goods Sold": "4.27",
"Selling, General and Administrative Expense": "20.7",
"Other Revenues": "-32.1",
"Comprehensive Net Income": "47.7",
"Other Net Income": "46.5",
"Economic Capital Ratio": "-43.3"
},
"2012": {
"Property and Equipment": "-5.08",
"Assets": "49.8",
"Liabilities": "-16.4",
"Stockholders Equity": "54.6",
"ECR before LimitedLiability": "140",
"Assets, Current": "10.7",
"Intangible Assets": "-9.61",
"Other Assets": "60.2",
"Other Liabilities": "-31.8",
"Liabilities, Non-Current": "13.2",
"Selling, General and Administrative Expense": "13.3",
"Expenses": "30.7",
"Revenues": "-22.2",
"Net Income": "37.6",
"Research and Development": "-0.779",
"Other Expenses": "14.0",
"Cost of Goods Sold": "3.57",
"Other Revenues": "-22.2",
"Comprehensive Net Income": "37.8",
"Other Net Income": "29.9",
"Economic Capital Ratio": "66.7"
},
"2013": {
"Other Assets": "25.5",
"Assets": "38.1",
"Liabilities": "-10.7",
"Stockholders Equity": "42.6",
"ECR before LimitedLiability": "59.0",
"Intangible Assets": "-10.7",
"Property and Equipment": "-4.86",
"Assets, Current": "30.0",
"Liabilities, Non-Current": "11.7",
"Liabilities, Current": "-6.56",
"Other Liabilities": "-16.3",
"Selling, General and Administrative Expense": "8.95",
"Expenses": "15.5",
"Revenues": "-19.4",
"Net Income": "14.2",
"Other Expenses": "10.4",
"Research and Development": "-6.42",
"Other Revenues": "-19.4",
"Comprehensive Net Income": "13.9",
"Other Net Income": "18.8",
"Economic Capital Ratio": "31.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001019695_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "72,188",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "48,889",
"Liabilities, Non-Current": "0",
"Other Assets": "41,924",
"Other Compr. Net Income": "0",
"Other Expenses": "25",
"Other Liabilities": "38,433",
"Other Net Income": "47,647",
"Other Revenues": "0",
"Property and Equipment": "2,939",
"Research and Development": "45,011",
"Selling, General and Administrative Expense": "13,373"
},
"output_variables": {
"Assets": "117,051",
"Liabilities": "87,322",
"Expenses": "58,409",
"Revenues": "0",
"Stockholders Equity": "29,729",
"Net Income": "-10,762",
"Comprehensive Net Income": "-10,762",
"BaseVar": "155,214",
"ECR before LimitedLiability": "53%",
"Economic Capital Ratio": "191%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "79,615",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "26,647",
"Liabilities, Non-Current": "0",
"Other Assets": "52,586",
"Other Compr. Net Income": "108",
"Other Expenses": "26",
"Other Liabilities": "26,517",
"Other Net Income": "36,972",
"Other Revenues": "0",
"Property and Equipment": "1,992",
"Research and Development": "33,966",
"Selling, General and Administrative Expense": "13,852"
},
"output_variables": {
"Assets": "134,193",
"Liabilities": "53,164",
"Expenses": "47,844",
"Revenues": "0",
"Stockholders Equity": "81,029",
"Net Income": "-10,872",
"Comprehensive Net Income": "-10,818",
"BaseVar": "136,140",
"ECR before LimitedLiability": "177%",
"Economic Capital Ratio": "287%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "75,636",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "21,753",
"Liabilities, Non-Current": "0",
"Other Assets": "21,415",
"Other Compr. Net Income": "-35",
"Other Expenses": "682",
"Other Liabilities": "15,800",
"Other Net Income": "16,416",
"Other Revenues": "57",
"Property and Equipment": "1,128",
"Research and Development": "27,555",
"Selling, General and Administrative Expense": "12,836"
},
"output_variables": {
"Assets": "98,179",
"Liabilities": "37,553",
"Expenses": "41,073",
"Revenues": "57",
"Stockholders Equity": "60,626",
"Net Income": "-24,600",
"Comprehensive Net Income": "-24,618",
"BaseVar": "96,656",
"ECR before LimitedLiability": "158%",
"Economic Capital Ratio": "274%"
}
}
},
"top_rated": false,
"trend": -29.0,
"value": 2.7384566002128,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001019695.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001019695.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001019695.svg"
},
{
"company_id": "0001107332",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001107332.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001107332.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001107332_main_keyfigs.svg",
"name": "Dendreon CORP",
"rank": 106,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001107332.svg",
"report_text": "The relative strengths and weaknesses of Dendreon CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Dendreon CORP compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 101% points.The greatest weakness of Dendreon CORP is the variable Expenses, reducing the Economic Capital Ratio by 45% points.
The company's Economic Capital Ratio, given in the ranking table, is 273%, being 30% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001107332_2014_Dendreon_CORP.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-6.20",
"Assets": "24.7",
"Liabilities": "86.0",
"Stockholders Equity": "121",
"ECR before LimitedLiability": "44.5",
"Assets, Current": "16.7",
"Property and Equipment": "51.2",
"Intangible Assets": "-20.1",
"Liabilities, Current": "27.7",
"Other Liabilities": "36.2",
"Liabilities, Non-Current": "29.4",
"Selling, General and Administrative Expense": "-25.6",
"Expenses": "-44.3",
"Revenues": "-35.1",
"Net Income": "-81.0",
"Research and Development": "-1.28",
"Cost of Goods Sold": "-0.553",
"Other Expenses": "-16.7",
"Other Revenues": "-35.1",
"Comprehensive Net Income": "-81.0",
"Economic Capital Ratio": "38.1"
},
"2011": {
"Other Assets": "1.44",
"Assets": "26.4",
"Liabilities": "93.7",
"Stockholders Equity": "142",
"ECR before LimitedLiability": "217",
"Intangible Assets": "-6.80",
"Property and Equipment": "17.2",
"Assets, Current": "13.6",
"Other Liabilities": "40.0",
"Liabilities, Non-Current": "17.8",
"Liabilities, Current": "47.8",
"Research and Development": "27.2",
"Expenses": "-1.39",
"Revenues": "9.76",
"Net Income": "11.1",
"Cost of Goods Sold": "-15.9",
"Selling, General and Administrative Expense": "-14.3",
"Other Revenues": "9.76",
"Comprehensive Net Income": "10.8",
"Other Net Income": "2.74",
"Economic Capital Ratio": "142"
},
"2012": {
"Property and Equipment": "18.6",
"Assets": "12.1",
"Liabilities": "97.4",
"Stockholders Equity": "107",
"ECR before LimitedLiability": "176",
"Intangible Assets": "-11.1",
"Other Assets": "5.15",
"Liabilities, Current": "40.3",
"Other Liabilities": "44.4",
"Liabilities, Non-Current": "21.1",
"Selling, General and Administrative Expense": "-15.8",
"Expenses": "-18.1",
"Revenues": "18.4",
"Net Income": "3.06",
"Research and Development": "24.5",
"Other Expenses": "4.61",
"Cost of Goods Sold": "-31.1",
"Other Revenues": "18.4",
"Comprehensive Net Income": "3.30",
"Other Net Income": "2.86",
"Economic Capital Ratio": "103"
},
"2013": {
"Other Assets": "-6.93",
"Assets": "-35.8",
"Liabilities": "101",
"Stockholders Equity": "11.5",
"ECR before LimitedLiability": "58.4",
"Intangible Assets": "-18.8",
"Property and Equipment": "42.8",
"Assets, Current": "-39.0",
"Liabilities, Non-Current": "21.2",
"Liabilities, Current": "29.4",
"Other Liabilities": "56.7",
"Selling, General and Administrative Expense": "-20.1",
"Expenses": "-44.7",
"Revenues": "40.4",
"Net Income": "-5.53",
"Other Expenses": "-8.94",
"Research and Development": "22.8",
"Cost of Goods Sold": "-37.8",
"Other Revenues": "40.4",
"Comprehensive Net Income": "-5.95",
"Economic Capital Ratio": "30.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001107332_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "330,394",
"Cost of Goods Sold": "28,520",
"Intangible Assets": "0",
"Liabilities, Current": "50,079",
"Liabilities, Non-Current": "0",
"Other Assets": "26,670",
"Other Compr. Net Income": "0",
"Other Expenses": "143,744",
"Other Liabilities": "0",
"Other Net Income": "-3,572",
"Other Revenues": "48,057",
"Property and Equipment": "246,889",
"Research and Development": "75,941",
"Selling, General and Administrative Expense": "235,760"
},
"output_variables": {
"Assets": "603,953",
"Liabilities": "50,079",
"Expenses": "483,965",
"Revenues": "48,057",
"Stockholders Equity": "553,874",
"Net Income": "-439,480",
"Comprehensive Net Income": "-439,480",
"BaseVar": "594,813",
"ECR before LimitedLiability": "235%",
"Economic Capital Ratio": "326%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "670,222",
"Cost of Goods Sold": "159,090",
"Intangible Assets": "0",
"Liabilities, Current": "77,716",
"Liabilities, Non-Current": "0",
"Other Assets": "88,764",
"Other Compr. Net Income": "0",
"Other Expenses": "86,292",
"Other Liabilities": "0",
"Other Net Income": "1,595",
"Other Revenues": "341,613",
"Property and Equipment": "242,505",
"Research and Development": "74,290",
"Selling, General and Administrative Expense": "361,342"
},
"output_variables": {
"Assets": "1,001,491",
"Liabilities": "77,716",
"Expenses": "681,014",
"Revenues": "341,613",
"Stockholders Equity": "923,775",
"Net Income": "-337,806",
"Comprehensive Net Income": "-337,806",
"BaseVar": "1,051,714",
"ECR before LimitedLiability": "311%",
"Economic Capital Ratio": "376%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "487,290",
"Cost of Goods Sold": "227,892",
"Intangible Assets": "0",
"Liabilities, Current": "103,942",
"Liabilities, Non-Current": "0",
"Other Assets": "83,225",
"Other Compr. Net Income": "182",
"Other Expenses": "100,919",
"Other Liabilities": "0",
"Other Net Income": "1,445",
"Other Revenues": "325,530",
"Property and Equipment": "150,604",
"Research and Development": "74,643",
"Selling, General and Administrative Expense": "317,131"
},
"output_variables": {
"Assets": "721,119",
"Liabilities": "103,942",
"Expenses": "720,585",
"Revenues": "325,530",
"Stockholders Equity": "617,177",
"Net Income": "-393,610",
"Comprehensive Net Income": "-393,519",
"BaseVar": "936,402",
"ECR before LimitedLiability": "231%",
"Economic Capital Ratio": "323%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "283,748",
"Cost of Goods Sold": "129,674",
"Intangible Assets": "0",
"Liabilities, Current": "103,761",
"Liabilities, Non-Current": "0",
"Other Assets": "25,485",
"Other Compr. Net Income": "182",
"Other Expenses": "108,348",
"Other Liabilities": "0",
"Other Net Income": "871",
"Other Revenues": "278,405",
"Property and Equipment": "125,168",
"Research and Development": "70,915",
"Selling, General and Administrative Expense": "181,816"
},
"output_variables": {
"Assets": "434,401",
"Liabilities": "103,761",
"Expenses": "490,753",
"Revenues": "278,405",
"Stockholders Equity": "330,640",
"Net Income": "-211,478",
"Comprehensive Net Income": "-211,387",
"BaseVar": "654,186",
"ECR before LimitedLiability": "189%",
"Economic Capital Ratio": "295%"
}
}
},
"top_rated": false,
"trend": -54.0,
"value": 2.731996869415926,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001107332.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001107332.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001107332.svg"
},
{
"company_id": "0001510964",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001510964.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001510964.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001510964.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001510964_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001510964_main_keyfigs.svg",
"name": "CV Sciences Inc",
"rank": 107,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001510964.svg",
"report_text": "The relative strengths and weaknesses of CV Sciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of CV Sciences Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 54% points.The greatest weakness of CV Sciences Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 99% points.
The company's Economic Capital Ratio, given in the ranking table, is 273%, being 30% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001510964_2014_CV_Sciences_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-1.10",
"Assets": "45.2",
"Liabilities": "-25.9",
"Stockholders Equity": "38.2",
"ECR before LimitedLiability": "57.9",
"Intangible Assets": "54.3",
"Property and Equipment": "-4.04",
"Liabilities, Non-Current": "10.9",
"Liabilities, Current": "45.5",
"Other Liabilities": "-99.3",
"Selling, General and Administrative Expense": "4.15",
"Expenses": "23.6",
"Revenues": "-3.33",
"Net Income": "21.3",
"Other Expenses": "5.54",
"Research and Development": "17.5",
"Cost of Goods Sold": "-3.81",
"Other Revenues": "-3.33",
"Comprehensive Net Income": "21.1",
"Other Net Income": "1.22",
"Economic Capital Ratio": "29.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001510964_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "8,056",
"Cost of Goods Sold": "880",
"Intangible Assets": "5,212",
"Liabilities, Current": "423",
"Liabilities, Non-Current": "0",
"Other Assets": "750",
"Other Compr. Net Income": "0",
"Other Expenses": "683",
"Other Liabilities": "5,503",
"Other Net Income": "0",
"Other Revenues": "2,154",
"Property and Equipment": "214",
"Research and Development": "524",
"Selling, General and Administrative Expense": "2,366"
},
"output_variables": {
"Assets": "14,232",
"Liabilities": "5,925",
"Expenses": "4,454",
"Revenues": "2,154",
"Stockholders Equity": "8,307",
"Net Income": "-2,300",
"Comprehensive Net Income": "-2,300",
"BaseVar": "13,383",
"ECR before LimitedLiability": "157%",
"Economic Capital Ratio": "273%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.7270046422759897,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001510964.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001510964.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001510964.svg"
},
{
"company_id": "0000831547",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000831547.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000831547.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000831547.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000831547_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000831547_main_keyfigs.svg",
"name": "Spectrum Pharmaceuticals INC",
"rank": 108,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000831547.svg",
"report_text": "The relative strengths and weaknesses of Spectrum Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Spectrum Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 90% points.The greatest weakness of Spectrum Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 42% points.
The company's Economic Capital Ratio, given in the ranking table, is 271%, being 28% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000831547_2014_Spectrum_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.30",
"Assets": "10.8",
"Liabilities": "20.6",
"Stockholders Equity": "36.9",
"ECR before LimitedLiability": "174",
"Intangible Assets": "3.45",
"Property and Equipment": "-5.53",
"Assets, Current": "19.5",
"Other Liabilities": "20.3",
"Liabilities, Non-Current": "15.7",
"Liabilities, Current": "-16.5",
"Research and Development": "25.4",
"Expenses": "31.5",
"Revenues": "37.0",
"Net Income": "70.4",
"Other Expenses": "-2.05",
"Cost of Goods Sold": "3.96",
"Selling, General and Administrative Expense": "4.02",
"Other Revenues": "37.0",
"Comprehensive Net Income": "70.0",
"Economic Capital Ratio": "98.3"
},
"2013": {
"Other Assets": "-6.13",
"Assets": "19.9",
"Liabilities": "-14.5",
"Stockholders Equity": "17.3",
"ECR before LimitedLiability": "55.9",
"Intangible Assets": "90.4",
"Property and Equipment": "-6.58",
"Assets, Current": "-22.8",
"Liabilities, Non-Current": "12.6",
"Liabilities, Current": "12.3",
"Other Liabilities": "-41.8",
"Selling, General and Administrative Expense": "4.29",
"Expenses": "19.4",
"Revenues": "9.71",
"Net Income": "31.6",
"Other Expenses": "-2.82",
"Research and Development": "15.0",
"Cost of Goods Sold": "2.75",
"Other Revenues": "9.71",
"Comprehensive Net Income": "31.3",
"Economic Capital Ratio": "27.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000831547_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "225,801",
"Cost of Goods Sold": "0",
"Intangible Assets": "41,654",
"Liabilities, Current": "78,537",
"Liabilities, Non-Current": "0",
"Other Assets": "10,644",
"Other Compr. Net Income": "0",
"Other Expenses": "37,558",
"Other Liabilities": "14,336",
"Other Net Income": "-6,615",
"Other Revenues": "192,963",
"Property and Equipment": "2,681",
"Research and Development": "27,720",
"Selling, General and Administrative Expense": "72,553"
},
"output_variables": {
"Assets": "280,780",
"Liabilities": "92,873",
"Expenses": "137,831",
"Revenues": "192,963",
"Stockholders Equity": "187,907",
"Net Income": "48,517",
"Comprehensive Net Income": "48,517",
"BaseVar": "355,531",
"ECR before LimitedLiability": "245%",
"Economic Capital Ratio": "332%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "235,190",
"Cost of Goods Sold": "0",
"Intangible Assets": "249,853",
"Liabilities, Current": "89,984",
"Liabilities, Non-Current": "0",
"Other Assets": "12,577",
"Other Compr. Net Income": "0",
"Other Expenses": "74,152",
"Other Liabilities": "127,565",
"Other Net Income": "2,149",
"Other Revenues": "155,854",
"Property and Equipment": "1,535",
"Research and Development": "46,670",
"Selling, General and Administrative Expense": "99,315"
},
"output_variables": {
"Assets": "499,155",
"Liabilities": "217,549",
"Expenses": "220,137",
"Revenues": "155,854",
"Stockholders Equity": "281,606",
"Net Income": "-62,134",
"Comprehensive Net Income": "-62,134",
"BaseVar": "547,422",
"ECR before LimitedLiability": "154%",
"Economic Capital Ratio": "271%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.7065327337770726,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000831547.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000831547.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000831547.svg"
},
{
"company_id": "0001061983",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001061983.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001061983.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001061983.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001061983_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001061983_main_keyfigs.svg",
"name": "Cytokinetics INC",
"rank": 109,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001061983.svg",
"report_text": "The relative strengths and weaknesses of Cytokinetics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cytokinetics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 38% points.The greatest weakness of Cytokinetics INC is the variable Research and Development, reducing the Economic Capital Ratio by 33% points.
The company's Economic Capital Ratio, given in the ranking table, is 269%, being 26% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001061983_2014_Cytokinetics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-10.9",
"Assets": "-271",
"Stockholders Equity": "-118",
"ECR before LimitedLiability": "-158",
"Intangible Assets": "-25.1",
"Property and Equipment": "-5.43",
"Assets, Current": "-178",
"Other Liabilities": "-0.729",
"Liabilities": "-5.94",
"Liabilities, Non-Current": "-0.140",
"Liabilities, Current": "-2.51",
"Research and Development": "-234",
"Expenses": "-223",
"Net Income": "-90.8",
"Other Expenses": "0.0161",
"Selling, General and Administrative Expense": "-0.181",
"Other Revenues": "0.0179",
"Revenues": "0.0179",
"Comprehensive Net Income": "-92.0",
"Other Net Income": "0.0153",
"Economic Capital Ratio": "-234"
},
"2012": {
"Property and Equipment": "-26.8",
"Assets": "-263",
"Liabilities": "-12.0",
"Stockholders Equity": "-101",
"ECR before LimitedLiability": "-144",
"Assets, Current": "-179",
"Intangible Assets": "-48.8",
"Other Assets": "-29.4",
"Liabilities, Current": "-7.95",
"Other Liabilities": "-4.50",
"Liabilities, Non-Current": "-2.10",
"Selling, General and Administrative Expense": "-6.31",
"Expenses": "-240",
"Revenues": "2.57",
"Net Income": "-122",
"Research and Development": "-291",
"Other Expenses": "2.41",
"Other Revenues": "2.57",
"Comprehensive Net Income": "-121",
"Other Net Income": "1.63",
"Economic Capital Ratio": "-217"
},
"2013": {
"Liabilities, Non-Current": "15.2",
"Liabilities": "28.6",
"Stockholders Equity": "24.5",
"ECR before LimitedLiability": "54.3",
"Liabilities, Current": "-21.7",
"Other Liabilities": "33.9",
"Selling, General and Administrative Expense": "10.1",
"Expenses": "-6.10",
"Net Income": "9.03",
"Other Expenses": "14.8",
"Research and Development": "-32.8",
"Cost of Goods Sold": "3.35",
"Other Revenues": "13.3",
"Revenues": "13.3",
"Intangible Assets": "-14.2",
"Property and Equipment": "-6.46",
"Other Assets": "-7.04",
"Assets, Current": "38.0",
"Comprehensive Net Income": "8.73",
"Other Net Income": "1.95",
"Economic Capital Ratio": "26.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001061983_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "51,140",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,592",
"Liabilities, Non-Current": "0",
"Other Assets": "323",
"Other Compr. Net Income": "0",
"Other Expenses": "3,616",
"Other Liabilities": "3.0",
"Other Net Income": "21,454",
"Other Revenues": "170,076",
"Property and Equipment": "1,310",
"Research and Development": "452,472",
"Selling, General and Administrative Expense": "143,952"
},
"output_variables": {
"Assets": "52,773",
"Liabilities": "4,595",
"Expenses": "600,040",
"Revenues": "170,076",
"Stockholders Equity": "48,178",
"Net Income": "-408,510",
"Comprehensive Net Income": "-408,510",
"BaseVar": "424,469",
"ECR before LimitedLiability": "-1,058%",
"Economic Capital Ratio": "0.018%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "76,427",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,105",
"Liabilities, Non-Current": "0",
"Other Assets": "127",
"Other Compr. Net Income": "18",
"Other Expenses": "3,560",
"Other Liabilities": "361",
"Other Net Income": "21,541",
"Other Revenues": "177,635",
"Property and Equipment": "997",
"Research and Development": "488,115",
"Selling, General and Administrative Expense": "156,381"
},
"output_variables": {
"Assets": "77,551",
"Liabilities": "7,466",
"Expenses": "648,056",
"Revenues": "177,635",
"Stockholders Equity": "70,085",
"Net Income": "-448,880",
"Comprehensive Net Income": "-448,871",
"BaseVar": "466,134",
"ECR before LimitedLiability": "-697%",
"Economic Capital Ratio": "2.9%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "79,338",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "26,704",
"Liabilities, Non-Current": "0",
"Other Assets": "2,629",
"Other Compr. Net Income": "-11",
"Other Expenses": "0",
"Other Liabilities": "2,042",
"Other Net Income": "177",
"Other Revenues": "30,648",
"Property and Equipment": "1,221",
"Research and Development": "49,450",
"Selling, General and Administrative Expense": "15,092"
},
"output_variables": {
"Assets": "83,188",
"Liabilities": "28,746",
"Expenses": "64,542",
"Revenues": "30,648",
"Stockholders Equity": "54,442",
"Net Income": "-33,717",
"Comprehensive Net Income": "-33,722",
"BaseVar": "103,656",
"ECR before LimitedLiability": "152%",
"Economic Capital Ratio": "269%"
}
}
},
"top_rated": false,
"trend": 102.0,
"value": 2.6910582450572322,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001061983.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001061983.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001061983.svg"
},
{
"company_id": "0001235007",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001235007.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001235007.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001235007_main_keyfigs.svg",
"name": "Endocyte INC",
"rank": 110,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001235007.svg",
"report_text": "The relative strengths and weaknesses of Endocyte INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Endocyte INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 37% points.The greatest weakness of Endocyte INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 67% points.
The company's Economic Capital Ratio, given in the ranking table, is 266%, being 23% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001235007_2014_Endocyte_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.83",
"Assets": "80.7",
"Liabilities": "33.3",
"Stockholders Equity": "159",
"ECR before LimitedLiability": "194",
"Intangible Assets": "-5.71",
"Property and Equipment": "-2.92",
"Assets, Current": "139",
"Other Liabilities": "-13.7",
"Liabilities, Non-Current": "11.1",
"Liabilities, Current": "34.9",
"Research and Development": "-1.84",
"Expenses": "17.6",
"Revenues": "-21.1",
"Comprehensive Net Income": "-1.74",
"Other Expenses": "5.76",
"Cost of Goods Sold": "2.66",
"Selling, General and Administrative Expense": "11.1",
"Other Revenues": "-21.1",
"Other Net Income": "1.74",
"Economic Capital Ratio": "118"
},
"2013": {
"Other Assets": "12.5",
"Assets": "8.53",
"Liabilities": "-11.6",
"Stockholders Equity": "3.67",
"ECR before LimitedLiability": "50.7",
"Intangible Assets": "-12.9",
"Property and Equipment": "-4.55",
"Assets, Current": "16.6",
"Liabilities, Non-Current": "13.3",
"Liabilities, Current": "-67.1",
"Other Liabilities": "34.6",
"Selling, General and Administrative Expense": "10.6",
"Expenses": "17.4",
"Revenues": "16.7",
"Net Income": "36.8",
"Other Expenses": "13.0",
"Research and Development": "-9.18",
"Cost of Goods Sold": "2.96",
"Other Revenues": "16.7",
"Comprehensive Net Income": "36.5",
"Economic Capital Ratio": "22.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001235007_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "129,756",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "5,470",
"Liabilities, Non-Current": "0",
"Other Assets": "811",
"Other Compr. Net Income": "0",
"Other Expenses": "1,988",
"Other Liabilities": "12,833",
"Other Net Income": "129",
"Other Revenues": "155",
"Property and Equipment": "1,108",
"Research and Development": "28,828",
"Selling, General and Administrative Expense": "10,000"
},
"output_variables": {
"Assets": "131,675",
"Liabilities": "18,303",
"Expenses": "40,816",
"Revenues": "155",
"Stockholders Equity": "113,372",
"Net Income": "-40,532",
"Comprehensive Net Income": "-40,532",
"BaseVar": "95,539",
"ECR before LimitedLiability": "276%",
"Economic Capital Ratio": "352%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "133,332",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "73,663",
"Liabilities, Non-Current": "33",
"Other Assets": "25,687",
"Other Compr. Net Income": "-16",
"Other Expenses": "2.5",
"Other Liabilities": "932",
"Other Net Income": "312",
"Other Revenues": "64,871",
"Property and Equipment": "3,839",
"Research and Development": "57,899",
"Selling, General and Administrative Expense": "25,314"
},
"output_variables": {
"Assets": "162,858",
"Liabilities": "74,629",
"Expenses": "83,215",
"Revenues": "64,871",
"Stockholders Equity": "88,229",
"Net Income": "-18,032",
"Comprehensive Net Income": "-18,040",
"BaseVar": "192,950",
"ECR before LimitedLiability": "147%",
"Economic Capital Ratio": "266%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.6550098632554437,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001235007.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001235007.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001235007.svg"
},
{
"company_id": "0001383701",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001383701.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001383701.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001383701.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001383701_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001383701_main_keyfigs.svg",
"name": "Histogen Inc",
"rank": 111,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001383701.svg",
"report_text": "The relative strengths and weaknesses of Histogen Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Histogen Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 125% points.The greatest weakness of Histogen Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 109% points.
The company's Economic Capital Ratio, given in the ranking table, is 265%, being 22% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001383701_2014_Histogen_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-13.9",
"Assets": "13.3",
"Liabilities": "124",
"Stockholders Equity": "125",
"ECR before LimitedLiability": "50.0",
"Intangible Assets": "-17.4",
"Property and Equipment": "-10.4",
"Assets, Current": "90.1",
"Liabilities, Non-Current": "18.3",
"Liabilities, Current": "70.8",
"Other Liabilities": "49.3",
"Selling, General and Administrative Expense": "-18.8",
"Expenses": "-72.4",
"Revenues": "-30.8",
"Net Income": "-108",
"Other Expenses": "18.2",
"Research and Development": "-74.8",
"Other Revenues": "-30.8",
"Comprehensive Net Income": "-109",
"Other Net Income": "-7.22",
"Economic Capital Ratio": "22.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001383701_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "56,898",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,817",
"Liabilities, Non-Current": "0",
"Other Assets": "14",
"Other Compr. Net Income": "11",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-3,884",
"Other Revenues": "0",
"Property and Equipment": "23",
"Research and Development": "47,773",
"Selling, General and Administrative Expense": "22,767"
},
"output_variables": {
"Assets": "56,936",
"Liabilities": "2,817",
"Expenses": "70,540",
"Revenues": "0",
"Stockholders Equity": "54,119",
"Net Income": "-74,424",
"Comprehensive Net Income": "-74,418",
"BaseVar": "67,094",
"ECR before LimitedLiability": "146%",
"Economic Capital Ratio": "265%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.647922383681418,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001383701.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001383701.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001383701.svg"
},
{
"company_id": "0000875320",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000875320.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000875320.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000875320.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000875320_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000875320_main_keyfigs.svg",
"name": "Vertex Pharmaceuticals INC MA",
"rank": 112,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000875320.svg",
"report_text": "The relative strengths and weaknesses of Vertex Pharmaceuticals INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Vertex Pharmaceuticals INC MA compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 44% points.The greatest weakness of Vertex Pharmaceuticals INC MA is the variable Other Liabilities, reducing the Economic Capital Ratio by 25% points.
The company's Economic Capital Ratio, given in the ranking table, is 265%, being 22% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000875320_2014_Vertex_Pharmaceuticals_INC_MA.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "24.2",
"Assets": "5.83",
"Liabilities": "-90.6",
"Stockholders Equity": "-66.5",
"ECR before LimitedLiability": "-117",
"Assets, Current": "22.8",
"Property and Equipment": "-19.2",
"Intangible Assets": "-41.0",
"Liabilities, Current": "-24.5",
"Other Liabilities": "-89.3",
"Liabilities, Non-Current": "22.2",
"Selling, General and Administrative Expense": "11.5",
"Expenses": "1.90",
"Revenues": "-36.8",
"Net Income": "-36.8",
"Research and Development": "-25.2",
"Cost of Goods Sold": "5.60",
"Other Expenses": "11.1",
"Other Revenues": "-36.8",
"Comprehensive Net Income": "-36.8",
"Economic Capital Ratio": "-124"
},
"2011": {
"Other Liabilities": "-75.4",
"Liabilities": "-34.2",
"Stockholders Equity": "-24.2",
"ECR before LimitedLiability": "90.7",
"Liabilities, Non-Current": "13.4",
"Liabilities, Current": "21.5",
"Research and Development": "7.20",
"Expenses": "28.5",
"Net Income": "62.0",
"Other Expenses": "1.38",
"Cost of Goods Sold": "4.32",
"Selling, General and Administrative Expense": "14.9",
"Other Revenues": "28.7",
"Revenues": "28.7",
"Other Assets": "42.1",
"Property and Equipment": "-2.75",
"Assets, Current": "-13.0",
"Intangible Assets": "-15.3",
"Comprehensive Net Income": "61.6",
"Other Net Income": "1.98",
"Economic Capital Ratio": "15.1"
},
"2012": {
"Property and Equipment": "13.6",
"Assets": "9.23",
"Liabilities": "-26.9",
"Stockholders Equity": "-8.12",
"ECR before LimitedLiability": "100",
"Assets, Current": "-15.2",
"Intangible Assets": "-13.5",
"Other Assets": "32.3",
"Liabilities, Current": "29.1",
"Other Liabilities": "-78.2",
"Liabilities, Non-Current": "14.5",
"Selling, General and Administrative Expense": "15.5",
"Expenses": "30.7",
"Revenues": "25.1",
"Net Income": "61.0",
"Research and Development": "3.33",
"Other Expenses": "6.36",
"Cost of Goods Sold": "4.70",
"Other Revenues": "25.1",
"Comprehensive Net Income": "60.0",
"Economic Capital Ratio": "27.1"
},
"2013": {
"Other Assets": "-12.5",
"Assets": "-18.4",
"Liabilities": "26.0",
"Stockholders Equity": "-10.7",
"ECR before LimitedLiability": "49.9",
"Intangible Assets": "-14.2",
"Property and Equipment": "43.6",
"Assets, Current": "-22.6",
"Liabilities, Non-Current": "15.1",
"Liabilities, Current": "34.2",
"Other Liabilities": "-24.8",
"Selling, General and Administrative Expense": "16.6",
"Expenses": "3.77",
"Revenues": "25.5",
"Net Income": "28.1",
"Other Expenses": "-7.96",
"Research and Development": "-8.10",
"Other Revenues": "25.5",
"Comprehensive Net Income": "33.5",
"Other Compr. Net Income": "5.05",
"Economic Capital Ratio": "22.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000875320_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,057,039",
"Cost of Goods Sold": "0",
"Intangible Assets": "26,102",
"Liabilities, Current": "474,783",
"Liabilities, Non-Current": "0",
"Other Assets": "569,972",
"Other Compr. Net Income": "0",
"Other Expenses": "33,506",
"Other Liabilities": "746,690",
"Other Net Income": "-39,274",
"Other Revenues": "143,370",
"Property and Equipment": "72,333",
"Research and Development": "637,416",
"Selling, General and Administrative Expense": "187,800"
},
"output_variables": {
"Assets": "1,725,446",
"Liabilities": "1,221,473",
"Expenses": "858,722",
"Revenues": "143,370",
"Stockholders Equity": "503,973",
"Net Income": "-754,626",
"Comprehensive Net Income": "-754,626",
"BaseVar": "1,994,142",
"ECR before LimitedLiability": "23%",
"Economic Capital Ratio": "164%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,331,254",
"Cost of Goods Sold": "0",
"Intangible Assets": "30,992",
"Liabilities, Current": "392,348",
"Liabilities, Non-Current": "7,287",
"Other Assets": "708,858",
"Other Compr. Net Income": "0",
"Other Expenses": "246,097",
"Other Liabilities": "839,133",
"Other Net Income": "-14,923",
"Other Revenues": "1,410,626",
"Property and Equipment": "133,176",
"Research and Development": "707,706",
"Selling, General and Administrative Expense": "400,721"
},
"output_variables": {
"Assets": "2,204,280",
"Liabilities": "1,238,768",
"Expenses": "1,354,524",
"Revenues": "1,410,626",
"Stockholders Equity": "965,512",
"Net Income": "41,179",
"Comprehensive Net Income": "41,179",
"BaseVar": "3,111,560",
"ECR before LimitedLiability": "125%",
"Economic Capital Ratio": "249%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,589,585",
"Cost of Goods Sold": "0",
"Intangible Assets": "30,992",
"Liabilities, Current": "432,624",
"Liabilities, Non-Current": "13,902",
"Other Assets": "705,102",
"Other Compr. Net Income": "-55,394",
"Other Expenses": "337,136",
"Other Liabilities": "1,078,380",
"Other Net Income": "1,940",
"Other Revenues": "1,527,042",
"Property and Equipment": "433,609",
"Research and Development": "806,185",
"Selling, General and Administrative Expense": "436,796"
},
"output_variables": {
"Assets": "2,759,288",
"Liabilities": "1,524,906",
"Expenses": "1,580,117",
"Revenues": "1,527,042",
"Stockholders Equity": "1,234,382",
"Net Income": "-51,135",
"Comprehensive Net Income": "-78,832",
"BaseVar": "3,724,344",
"ECR before LimitedLiability": "122%",
"Economic Capital Ratio": "247%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "1,588,576",
"Cost of Goods Sold": "0",
"Intangible Assets": "30,992",
"Liabilities, Current": "397,829",
"Liabilities, Non-Current": "11,590",
"Other Assets": "2,562",
"Other Compr. Net Income": "-55,286",
"Other Expenses": "1,168,246",
"Other Liabilities": "553,217",
"Other Net Income": "-33,470",
"Other Revenues": "1,143,588",
"Property and Equipment": "696,911",
"Research and Development": "938,532",
"Selling, General and Administrative Expense": "276,170"
},
"output_variables": {
"Assets": "2,319,041",
"Liabilities": "962,636",
"Expenses": "2,382,948",
"Revenues": "1,143,588",
"Stockholders Equity": "1,356,405",
"Net Income": "-1,272,829",
"Comprehensive Net Income": "-1,300,472",
"BaseVar": "3,448,485",
"ECR before LimitedLiability": "101%",
"Economic Capital Ratio": "231%"
}
}
},
"top_rated": false,
"trend": -12.0,
"value": 2.647213524414255,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000875320.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000875320.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000875320.svg"
},
{
"company_id": "0001534525",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001534525.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001534525.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001534525.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001534525_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001534525_main_keyfigs.svg",
"name": "Xenetic Biosciences Inc",
"rank": 113,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001534525.svg",
"report_text": "The relative strengths and weaknesses of Xenetic Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Xenetic Biosciences Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 122% points.The greatest weakness of Xenetic Biosciences Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 37% points.
The company's Economic Capital Ratio, given in the ranking table, is 263%, being 21% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001534525_2014_Xenetic_Biosciences_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "122",
"Assets": "49.7",
"Liabilities": "-5.10",
"Stockholders Equity": "57.4",
"ECR before LimitedLiability": "48.5",
"Intangible Assets": "19.2",
"Property and Equipment": "-5.64",
"Assets, Current": "-36.8",
"Liabilities, Non-Current": "11.6",
"Liabilities, Current": "2.70",
"Other Liabilities": "-20.0",
"Selling, General and Administrative Expense": "-13.4",
"Expenses": "5.78",
"Revenues": "-14.3",
"Net Income": "-7.20",
"Other Expenses": "11.3",
"Research and Development": "5.68",
"Cost of Goods Sold": "2.57",
"Other Revenues": "-14.3",
"Comprehensive Net Income": "-7.46",
"Economic Capital Ratio": "20.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001534525_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "5,330",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,665",
"Liabilities, Current": "3,590",
"Liabilities, Non-Current": "0",
"Other Assets": "10,318",
"Other Compr. Net Income": "-15",
"Other Expenses": "0",
"Other Liabilities": "3,258",
"Other Net Income": "34",
"Other Revenues": "1,000",
"Property and Equipment": "153",
"Research and Development": "3,060",
"Selling, General and Administrative Expense": "6,553"
},
"output_variables": {
"Assets": "19,466",
"Liabilities": "6,848",
"Expenses": "9,613",
"Revenues": "1,000",
"Stockholders Equity": "12,618",
"Net Income": "-8,579",
"Comprehensive Net Income": "-8,587",
"BaseVar": "18,488",
"ECR before LimitedLiability": "144%",
"Economic Capital Ratio": "263%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.6334326747386987,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001534525.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001534525.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001534525.svg"
},
{
"company_id": "0001130591",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001130591.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001130591.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001130591_main_keyfigs.svg",
"name": "Xenoport INC",
"rank": 114,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001130591.svg",
"report_text": "The relative strengths and weaknesses of Xenoport INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Xenoport INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 108% points.The greatest weakness of Xenoport INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 75% points.
The company's Economic Capital Ratio, given in the ranking table, is 263%, being 20% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001130591_2014_Xenoport_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-7.28",
"Assets": "34.6",
"Liabilities": "74.3",
"Stockholders Equity": "127",
"ECR before LimitedLiability": "45.4",
"Assets, Current": "131",
"Property and Equipment": "-5.27",
"Intangible Assets": "-18.6",
"Liabilities, Current": "19.2",
"Other Liabilities": "33.6",
"Liabilities, Non-Current": "27.3",
"Selling, General and Administrative Expense": "-7.94",
"Expenses": "-36.4",
"Revenues": "-37.7",
"Net Income": "-74.7",
"Research and Development": "-39.4",
"Cost of Goods Sold": "4.79",
"Other Expenses": "6.09",
"Other Revenues": "-37.7",
"Comprehensive Net Income": "-74.7",
"Economic Capital Ratio": "39.1"
},
"2011": {
"Other Assets": "-4.54",
"Assets": "21.0",
"Liabilities": "80.2",
"Stockholders Equity": "111",
"ECR before LimitedLiability": "196",
"Intangible Assets": "-8.65",
"Property and Equipment": "-2.38",
"Assets, Current": "50.7",
"Other Liabilities": "39.4",
"Liabilities, Non-Current": "17.5",
"Liabilities, Current": "31.3",
"Other Revenues": "15.6",
"Revenues": "15.6",
"Net Income": "16.9",
"Research and Development": "-11.8",
"Comprehensive Net Income": "16.5",
"Cost of Goods Sold": "4.24",
"Selling, General and Administrative Expense": "-2.55",
"Other Expenses": "8.67",
"Other Net Income": "2.59",
"Economic Capital Ratio": "120"
},
"2012": {
"Property and Equipment": "-2.16",
"Assets": "51.0",
"Liabilities": "71.4",
"Stockholders Equity": "178",
"ECR before LimitedLiability": "243",
"Assets, Current": "80.3",
"Intangible Assets": "-3.89",
"Other Assets": "-1.87",
"Liabilities, Current": "30.2",
"Other Liabilities": "33.4",
"Liabilities, Non-Current": "15.9",
"Expenses": "21.6",
"Revenues": "-4.80",
"Net Income": "18.7",
"Research and Development": "-10.5",
"Other Expenses": "29.4",
"Cost of Goods Sold": "3.50",
"Other Revenues": "-4.80",
"Comprehensive Net Income": "18.8",
"Other Net Income": "1.73",
"Economic Capital Ratio": "170"
},
"2013": {
"Other Assets": "16.2",
"Assets": "6.40",
"Liabilities": "101",
"Stockholders Equity": "108",
"ECR before LimitedLiability": "48.0",
"Intangible Assets": "-17.0",
"Property and Equipment": "-4.62",
"Assets, Current": "16.5",
"Liabilities, Non-Current": "17.6",
"Liabilities, Current": "42.3",
"Other Liabilities": "47.4",
"Selling, General and Administrative Expense": "-58.8",
"Expenses": "-60.4",
"Revenues": "-17.3",
"Net Income": "-74.3",
"Other Expenses": "14.7",
"Research and Development": "-19.6",
"Cost of Goods Sold": "3.95",
"Other Revenues": "-17.3",
"Comprehensive Net Income": "-74.6",
"Economic Capital Ratio": "20.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001130591_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "110,801",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "11,487",
"Liabilities, Non-Current": "0",
"Other Assets": "3,219",
"Other Compr. Net Income": "0",
"Other Expenses": "5,275",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "3,675",
"Property and Equipment": "7,209",
"Research and Development": "52,546",
"Selling, General and Administrative Expense": "28,323"
},
"output_variables": {
"Assets": "121,229",
"Liabilities": "11,487",
"Expenses": "86,144",
"Revenues": "3,675",
"Stockholders Equity": "109,742",
"Net Income": "-82,469",
"Comprehensive Net Income": "-82,469",
"BaseVar": "111,268",
"ECR before LimitedLiability": "236%",
"Economic Capital Ratio": "326%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "97,452",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "13,530",
"Liabilities, Non-Current": "0",
"Other Assets": "2,663",
"Other Compr. Net Income": "-10",
"Other Expenses": "2,923",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "43,758",
"Property and Equipment": "3,921",
"Research and Development": "43,788",
"Selling, General and Administrative Expense": "30,427"
},
"output_variables": {
"Assets": "104,036",
"Liabilities": "13,530",
"Expenses": "77,138",
"Revenues": "43,758",
"Stockholders Equity": "90,506",
"Net Income": "-33,380",
"Comprehensive Net Income": "-33,385",
"BaseVar": "119,236",
"ECR before LimitedLiability": "279%",
"Economic Capital Ratio": "355%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "155,088",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "13,771",
"Liabilities, Non-Current": "0",
"Other Assets": "2,432",
"Other Compr. Net Income": "38",
"Other Expenses": "-20,499",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "21,878",
"Property and Equipment": "1,528",
"Research and Development": "42,947",
"Selling, General and Administrative Expense": "30,244"
},
"output_variables": {
"Assets": "159,048",
"Liabilities": "13,771",
"Expenses": "52,692",
"Revenues": "21,878",
"Stockholders Equity": "145,277",
"Net Income": "-30,814",
"Comprehensive Net Income": "-30,795",
"BaseVar": "123,714",
"ECR before LimitedLiability": "331%",
"Economic Capital Ratio": "390%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "63,685",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "10,069",
"Liabilities, Non-Current": "0",
"Other Assets": "12,304",
"Other Compr. Net Income": "38",
"Other Expenses": "-11,959",
"Other Liabilities": "0",
"Other Net Income": "213",
"Other Revenues": "10,297",
"Property and Equipment": "2,552",
"Research and Development": "34,628",
"Selling, General and Administrative Expense": "61,151"
},
"output_variables": {
"Assets": "78,541",
"Liabilities": "10,069",
"Expenses": "83,820",
"Revenues": "10,297",
"Stockholders Equity": "68,472",
"Net Income": "-73,310",
"Comprehensive Net Income": "-73,291",
"BaseVar": "91,489",
"ECR before LimitedLiability": "171%",
"Economic Capital Ratio": "283%"
}
}
},
"top_rated": false,
"trend": -95.0,
"value": 2.627925258272933,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001130591.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001130591.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001130591.svg"
},
{
"company_id": "0001311596",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001311596.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001311596.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001311596_main_keyfigs.svg",
"name": "Tobira Therapeutics Inc",
"rank": 115,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001311596.svg",
"report_text": "The relative strengths and weaknesses of Tobira Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tobira Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 85% points.The greatest weakness of Tobira Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 40% points.
The company's Economic Capital Ratio, given in the ranking table, is 263%, being 20% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001311596_2014_Tobira_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "14.2",
"Assets": "41.3",
"Liabilities": "33.9",
"Stockholders Equity": "84.6",
"ECR before LimitedLiability": "47.9",
"Intangible Assets": "-13.1",
"Property and Equipment": "-7.42",
"Assets, Current": "56.1",
"Liabilities, Non-Current": "-4.53",
"Liabilities, Current": "2.29",
"Other Liabilities": "36.0",
"Selling, General and Administrative Expense": "7.46",
"Expenses": "-17.8",
"Revenues": "-20.4",
"Net Income": "-37.5",
"Other Expenses": "13.1",
"Research and Development": "-39.6",
"Cost of Goods Sold": "2.96",
"Other Revenues": "-20.4",
"Comprehensive Net Income": "-37.8",
"Economic Capital Ratio": "19.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001311596_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "39,128",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,100",
"Liabilities, Non-Current": "2,452",
"Other Assets": "6,517",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-600",
"Other Revenues": "832",
"Property and Equipment": "108",
"Research and Development": "26,542",
"Selling, General and Administrative Expense": "7,297"
},
"output_variables": {
"Assets": "45,753",
"Liabilities": "11,552",
"Expenses": "33,839",
"Revenues": "832",
"Stockholders Equity": "34,201",
"Net Income": "-33,607",
"Comprehensive Net Income": "-33,607",
"BaseVar": "46,288",
"ECR before LimitedLiability": "143%",
"Economic Capital Ratio": "263%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.62706224362531,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001311596.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001311596.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001311596.svg"
},
{
"company_id": "0000078003",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000078003.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000078003.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000078003.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000078003_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000078003_main_keyfigs.svg",
"name": "Pfizer INC",
"rank": 116,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000078003.svg",
"report_text": "The relative strengths and weaknesses of Pfizer INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Pfizer INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 78% points.The greatest weakness of Pfizer INC is the variable Liabilities, reducing the Economic Capital Ratio by 49% points.
The company's Economic Capital Ratio, given in the ranking table, is 262%, being 19% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000078003_2014_Pfizer_INC.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "-9.58",
"Assets": "20.3",
"Liabilities": "-92.2",
"Stockholders Equity": "-36.6",
"ECR before LimitedLiability": "-90.0",
"Other Assets": "3.10",
"Intangible Assets": "34.8",
"Property and Equipment": "-3.77",
"Liabilities, Current": "-5.50",
"Other Liabilities": "-34.2",
"Liabilities, Non-Current": "-45.5",
"Cost of Goods Sold": "-3.48",
"Expenses": "18.2",
"Revenues": "-21.7",
"Net Income": "-4.66",
"Selling, General and Administrative Expense": "8.03",
"Other Expenses": "10.1",
"Research and Development": "3.33",
"Other Revenues": "-21.7",
"Comprehensive Net Income": "-4.67",
"Economic Capital Ratio": "-89.1"
},
"2010": {
"Other Assets": "-5.24",
"Assets": "11.1",
"Liabilities": "-53.4",
"Stockholders Equity": "-22.7",
"ECR before LimitedLiability": "-25.6",
"Assets, Current": "-21.2",
"Property and Equipment": "-3.96",
"Intangible Assets": "59.2",
"Liabilities, Current": "6.98",
"Other Liabilities": "-19.2",
"Liabilities, Non-Current": "-40.1",
"Selling, General and Administrative Expense": "9.71",
"Expenses": "18.1",
"Revenues": "-5.95",
"Net Income": "12.4",
"Research and Development": "7.77",
"Cost of Goods Sold": "-3.41",
"Other Expenses": "3.83",
"Other Revenues": "-5.95",
"Comprehensive Net Income": "12.4",
"Economic Capital Ratio": "-32.0"
},
"2011": {
"Other Assets": "0.297",
"Assets": "38.2",
"Liabilities": "-62.5",
"ECR before LimitedLiability": "94.4",
"Intangible Assets": "97.9",
"Property and Equipment": "4.16",
"Assets, Current": "-29.6",
"Other Liabilities": "-25.7",
"Liabilities, Non-Current": "-50.7",
"Liabilities, Current": "14.6",
"Research and Development": "26.0",
"Expenses": "41.3",
"Net Income": "51.7",
"Other Expenses": "3.12",
"Cost of Goods Sold": "-4.27",
"Selling, General and Administrative Expense": "15.5",
"Other Revenues": "7.74",
"Revenues": "7.74",
"Comprehensive Net Income": "51.4",
"Other Net Income": "1.46",
"Economic Capital Ratio": "18.9"
},
"2012": {
"Property and Equipment": "2.76",
"Assets": "46.4",
"Liabilities": "-57.7",
"Stockholders Equity": "11.5",
"ECR before LimitedLiability": "108",
"Assets, Current": "-26.1",
"Intangible Assets": "88.3",
"Other Assets": "6.43",
"Liabilities, Current": "15.3",
"Other Liabilities": "-30.7",
"Liabilities, Non-Current": "-41.6",
"Selling, General and Administrative Expense": "15.4",
"Expenses": "45.3",
"Revenues": "7.34",
"Net Income": "56.3",
"Research and Development": "21.1",
"Other Expenses": "9.25",
"Other Revenues": "7.34",
"Comprehensive Net Income": "55.9",
"Other Net Income": "2.33",
"Economic Capital Ratio": "34.8"
},
"2013": {
"Other Assets": "7.95",
"Assets": "21.0",
"Liabilities": "-49.5",
"Stockholders Equity": "-7.21",
"ECR before LimitedLiability": "47.5",
"Intangible Assets": "78.4",
"Property and Equipment": "2.86",
"Assets, Current": "-35.6",
"Liabilities, Non-Current": "-46.5",
"Liabilities, Current": "22.4",
"Other Liabilities": "-26.5",
"Selling, General and Administrative Expense": "14.9",
"Expenses": "38.2",
"Revenues": "8.17",
"Net Income": "55.8",
"Other Expenses": "5.67",
"Research and Development": "19.3",
"Other Revenues": "8.17",
"Comprehensive Net Income": "56.4",
"Other Net Income": "7.47",
"Economic Capital Ratio": "19.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000078003_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "61,670,000",
"Cost of Goods Sold": "8,888,000",
"Intangible Assets": "110,391,000",
"Liabilities, Current": "37,225,000",
"Liabilities, Non-Current": "48,804,000",
"Other Assets": "18,108,000",
"Other Compr. Net Income": "0",
"Other Expenses": "9,771,000",
"Other Liabilities": "36,474,000",
"Other Net Income": "14,000",
"Other Revenues": "50,009,000",
"Property and Equipment": "22,780,000",
"Research and Development": "7,845,000",
"Selling, General and Administrative Expense": "14,875,000"
},
"output_variables": {
"Assets": "212,949,000",
"Liabilities": "122,503,000",
"Expenses": "41,379,000",
"Revenues": "50,009,000",
"Stockholders Equity": "90,446,000",
"Net Income": "8,644,000",
"Comprehensive Net Income": "8,644,000",
"BaseVar": "213,427,000",
"ECR before LimitedLiability": "123%",
"Economic Capital Ratio": "248%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "60,468,000",
"Cost of Goods Sold": "16,279,000",
"Intangible Assets": "101,505,000",
"Liabilities, Current": "28,609,000",
"Liabilities, Non-Current": "44,011,000",
"Other Assets": "13,918,000",
"Other Compr. Net Income": "0",
"Other Expenses": "14,205,000",
"Other Liabilities": "34,129,000",
"Other Net Income": "-9,000",
"Other Revenues": "67,809,000",
"Property and Equipment": "19,123,000",
"Research and Development": "9,413,000",
"Selling, General and Administrative Expense": "19,614,000"
},
"output_variables": {
"Assets": "195,014,000",
"Liabilities": "106,749,000",
"Expenses": "59,511,000",
"Revenues": "67,809,000",
"Stockholders Equity": "88,265,000",
"Net Income": "8,289,000",
"Comprehensive Net Income": "8,289,000",
"BaseVar": "214,546,000",
"ECR before LimitedLiability": "133%",
"Economic Capital Ratio": "255%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "57,728,000",
"Cost of Goods Sold": "15,085,000",
"Intangible Assets": "98,900,000",
"Liabilities, Current": "28,069,000",
"Liabilities, Non-Current": "41,130,000",
"Other Assets": "14,436,000",
"Other Compr. Net Income": "0",
"Other Expenses": "12,542,000",
"Other Liabilities": "36,182,000",
"Other Net Income": "-1,167,000",
"Other Revenues": "67,425,000",
"Property and Equipment": "16,938,000",
"Research and Development": "9,112,000",
"Selling, General and Administrative Expense": "19,468,000"
},
"output_variables": {
"Assets": "188,002,000",
"Liabilities": "105,381,000",
"Expenses": "56,207,000",
"Revenues": "67,425,000",
"Stockholders Equity": "82,621,000",
"Net Income": "10,051,000",
"Comprehensive Net Income": "10,051,000",
"BaseVar": "209,091,000",
"ECR before LimitedLiability": "130%",
"Economic Capital Ratio": "253%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "61,415,000",
"Cost of Goods Sold": "8,272,318",
"Intangible Assets": "90,685,000",
"Liabilities, Current": "28,619,000",
"Liabilities, Non-Current": "35,975,000",
"Other Assets": "19,237,000",
"Other Compr. Net Income": "-1,852,000",
"Other Expenses": "8,075,901",
"Other Liabilities": "39,526,000",
"Other Net Income": "-1,164,741",
"Other Revenues": "55,123,972",
"Property and Equipment": "14,461,000",
"Research and Development": "7,577,990",
"Selling, General and Administrative Expense": "15,464,218"
},
"output_variables": {
"Assets": "185,798,000",
"Liabilities": "104,120,000",
"Expenses": "39,390,428",
"Revenues": "55,123,972",
"Stockholders Equity": "81,678,000",
"Net Income": "14,568,803",
"Comprehensive Net Income": "13,642,803",
"BaseVar": "193,724,570",
"ECR before LimitedLiability": "132%",
"Economic Capital Ratio": "255%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "56,244,000",
"Cost of Goods Sold": "8,153,168",
"Intangible Assets": "81,904,000",
"Liabilities, Current": "23,366,000",
"Liabilities, Non-Current": "35,229,000",
"Other Assets": "21,556,000",
"Other Compr. Net Income": "-1,849,224",
"Other Expenses": "10,299,412",
"Other Liabilities": "36,886,000",
"Other Net Income": "61,821,205",
"Other Revenues": "47,976,923",
"Property and Equipment": "12,397,000",
"Research and Development": "6,364,165",
"Selling, General and Administrative Expense": "13,368,251"
},
"output_variables": {
"Assets": "172,101,000",
"Liabilities": "95,481,000",
"Expenses": "38,184,995",
"Revenues": "47,976,923",
"Stockholders Equity": "76,620,000",
"Net Income": "71,613,133",
"Comprehensive Net Income": "70,688,521",
"BaseVar": "208,707,174",
"ECR before LimitedLiability": "178%",
"Economic Capital Ratio": "287%"
}
}
},
"top_rated": false,
"trend": -21.0,
"value": 2.6225972197482426,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000078003.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000078003.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000078003.svg"
},
{
"company_id": "0001062822",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001062822.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001062822.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001062822.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001062822_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001062822_main_keyfigs.svg",
"name": "Lexicon Pharmaceuticals INC",
"rank": 117,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001062822.svg",
"report_text": "The relative strengths and weaknesses of Lexicon Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Lexicon Pharmaceuticals INC compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 63% points.The greatest weakness of Lexicon Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 51% points.
The company's Economic Capital Ratio, given in the ranking table, is 261%, being 19% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001062822_2014_Lexicon_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "9.77",
"Assets": "94.1",
"Liabilities": "-20.5",
"Stockholders Equity": "95.1",
"ECR before LimitedLiability": "136",
"Intangible Assets": "4.32",
"Property and Equipment": "8.60",
"Assets, Current": "45.9",
"Other Liabilities": "-1.64",
"Liabilities, Non-Current": "-54.6",
"Liabilities, Current": "29.9",
"Expenses": "24.5",
"Revenues": "-19.9",
"Net Income": "5.50",
"Other Expenses": "5.14",
"Cost of Goods Sold": "2.62",
"Selling, General and Administrative Expense": "15.5",
"Other Revenues": "-19.9",
"Comprehensive Net Income": "5.29",
"Other Net Income": "1.69",
"Economic Capital Ratio": "60.9"
},
"2012": {
"Property and Equipment": "9.46",
"Assets": "94.7",
"Liabilities": "-4.81",
"Stockholders Equity": "112",
"ECR before LimitedLiability": "154",
"Assets, Current": "34.0",
"Intangible Assets": "7.52",
"Other Assets": "13.6",
"Liabilities, Current": "34.1",
"Other Liabilities": "-3.81",
"Liabilities, Non-Current": "-39.7",
"Selling, General and Administrative Expense": "14.7",
"Expenses": "22.9",
"Revenues": "-18.3",
"Net Income": "5.62",
"Research and Development": "-3.18",
"Other Expenses": "8.20",
"Cost of Goods Sold": "2.97",
"Other Revenues": "-18.3",
"Comprehensive Net Income": "5.74",
"Economic Capital Ratio": "80.7"
},
"2013": {
"Other Assets": "24.8",
"Assets": "62.9",
"Liabilities": "-20.5",
"Stockholders Equity": "56.3",
"ECR before LimitedLiability": "46.6",
"Intangible Assets": "15.2",
"Property and Equipment": "18.8",
"Assets, Current": "-6.59",
"Liabilities, Non-Current": "-51.0",
"Liabilities, Current": "32.5",
"Other Liabilities": "-5.95",
"Selling, General and Administrative Expense": "14.4",
"Expenses": "13.2",
"Revenues": "-17.2",
"Net Income": "-3.24",
"Other Expenses": "10.5",
"Research and Development": "-13.6",
"Cost of Goods Sold": "2.37",
"Other Revenues": "-17.2",
"Comprehensive Net Income": "-3.45",
"Economic Capital Ratio": "18.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001062822_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "285,790",
"Cost of Goods Sold": "0",
"Intangible Assets": "44,543",
"Liabilities, Current": "21,390",
"Liabilities, Non-Current": "78,597",
"Other Assets": "53,762",
"Other Compr. Net Income": "0",
"Other Expenses": "9,294",
"Other Liabilities": "32,957",
"Other Net Income": "408",
"Other Revenues": "1,849",
"Property and Equipment": "46,417",
"Research and Development": "91,828",
"Selling, General and Administrative Expense": "17,350"
},
"output_variables": {
"Assets": "430,512",
"Liabilities": "132,944",
"Expenses": "118,472",
"Revenues": "1,849",
"Stockholders Equity": "297,568",
"Net Income": "-116,215",
"Comprehensive Net Income": "-116,215",
"BaseVar": "342,092",
"ECR before LimitedLiability": "189%",
"Economic Capital Ratio": "295%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "230,935",
"Cost of Goods Sold": "0",
"Intangible Assets": "44,543",
"Liabilities, Current": "18,285",
"Liabilities, Non-Current": "54,160",
"Other Assets": "53,666",
"Other Compr. Net Income": "2.0",
"Other Expenses": "12,001",
"Other Liabilities": "32,655",
"Other Net Income": "318",
"Other Revenues": "1,089",
"Property and Equipment": "42,634",
"Research and Development": "82,574",
"Selling, General and Administrative Expense": "17,043"
},
"output_variables": {
"Assets": "371,778",
"Liabilities": "105,100",
"Expenses": "111,618",
"Revenues": "1,089",
"Stockholders Equity": "266,678",
"Net Income": "-110,211",
"Comprehensive Net Income": "-110,210",
"BaseVar": "294,952",
"ECR before LimitedLiability": "198%",
"Economic Capital Ratio": "301%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "134,554",
"Cost of Goods Sold": "0",
"Intangible Assets": "44,543",
"Liabilities, Current": "19,294",
"Liabilities, Non-Current": "52,553",
"Other Assets": "53,701",
"Other Compr. Net Income": "-21",
"Other Expenses": "-239",
"Other Liabilities": "32,150",
"Other Net Income": "216",
"Other Revenues": "2,222",
"Property and Equipment": "41,362",
"Research and Development": "89,682",
"Selling, General and Administrative Expense": "17,121"
},
"output_variables": {
"Assets": "274,160",
"Liabilities": "103,997",
"Expenses": "106,564",
"Revenues": "2,222",
"Stockholders Equity": "170,163",
"Net Income": "-104,126",
"Comprehensive Net Income": "-104,136",
"BaseVar": "243,590",
"ECR before LimitedLiability": "141%",
"Economic Capital Ratio": "261%"
}
}
},
"top_rated": false,
"trend": -50.0,
"value": 2.61391194443165,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001062822.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001062822.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001062822.svg"
},
{
"company_id": "0001373707",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001373707.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001373707.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001373707_main_keyfigs.svg",
"name": "Tetraphase Pharmaceuticals INC",
"rank": 118,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001373707.svg",
"report_text": "The relative strengths and weaknesses of Tetraphase Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tetraphase Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 112% points.The greatest weakness of Tetraphase Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 87% points.
The company's Economic Capital Ratio, given in the ranking table, is 259%, being 17% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001373707_2014_Tetraphase_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-14.5",
"Assets": "-6.56",
"Liabilities": "112",
"Stockholders Equity": "96.7",
"ECR before LimitedLiability": "44.5",
"Intangible Assets": "-18.5",
"Property and Equipment": "-10.8",
"Assets, Current": "54.8",
"Liabilities, Non-Current": "18.9",
"Liabilities, Current": "49.7",
"Other Liabilities": "50.8",
"Selling, General and Administrative Expense": "7.34",
"Expenses": "-59.9",
"Revenues": "-10.7",
"Net Income": "-75.3",
"Other Expenses": "19.0",
"Research and Development": "-86.9",
"Other Revenues": "-10.7",
"Comprehensive Net Income": "-75.6",
"Other Net Income": "-6.25",
"Economic Capital Ratio": "16.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001373707_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "105,420",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "13,191",
"Liabilities, Non-Current": "0",
"Other Assets": "231",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-6,906",
"Other Revenues": "18,271",
"Property and Equipment": "235",
"Research and Development": "106,615",
"Selling, General and Administrative Expense": "24,471"
},
"output_variables": {
"Assets": "105,886",
"Liabilities": "13,191",
"Expenses": "131,086",
"Revenues": "18,271",
"Stockholders Equity": "92,695",
"Net Income": "-119,721",
"Comprehensive Net Income": "-119,721",
"BaseVar": "137,670",
"ECR before LimitedLiability": "138%",
"Economic Capital Ratio": "259%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.593503251608671,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001373707.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001373707.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001373707.svg"
},
{
"company_id": "0001024126",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001024126.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001024126.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001024126_main_keyfigs.svg",
"name": "Pernix Therapeutics Holdings INC",
"rank": 119,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001024126.svg",
"report_text": "The relative strengths and weaknesses of Pernix Therapeutics Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Pernix Therapeutics Holdings INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 68% points.The greatest weakness of Pernix Therapeutics Holdings INC is the variable Assets, Current, reducing the Economic Capital Ratio by 44% points.
The company's Economic Capital Ratio, given in the ranking table, is 259%, being 16% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001024126_2014_Pernix_Therapeutics_Holdings_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Liabilities, Non-Current": "-5.33",
"Liabilities": "-10.4",
"Stockholders Equity": "-6.09",
"ECR before LimitedLiability": "43.8",
"Liabilities, Current": "-22.0",
"Other Liabilities": "16.2",
"Selling, General and Administrative Expense": "-2.07",
"Expenses": "15.9",
"Net Income": "38.5",
"Other Expenses": "-10.5",
"Research and Development": "26.0",
"Cost of Goods Sold": "3.13",
"Other Revenues": "15.9",
"Revenues": "15.9",
"Intangible Assets": "16.0",
"Property and Equipment": "-3.87",
"Other Assets": "67.6",
"Assets, Current": "-43.5",
"Comprehensive Net Income": "37.4",
"Other Net Income": "5.53",
"Economic Capital Ratio": "15.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001024126_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "76,385",
"Cost of Goods Sold": "0",
"Intangible Assets": "42,497",
"Liabilities, Current": "69,468",
"Liabilities, Non-Current": "14,388",
"Other Assets": "85,632",
"Other Compr. Net Income": "-2,975",
"Other Expenses": "51,428",
"Other Liabilities": "16,809",
"Other Net Income": "8,269",
"Other Revenues": "84,872",
"Property and Equipment": "6,872",
"Research and Development": "4,798",
"Selling, General and Administrative Expense": "62,551"
},
"output_variables": {
"Assets": "211,386",
"Liabilities": "100,664",
"Expenses": "118,777",
"Revenues": "84,872",
"Stockholders Equity": "110,722",
"Net Income": "-25,635",
"Comprehensive Net Income": "-27,123",
"BaseVar": "263,472",
"ECR before LimitedLiability": "137%",
"Economic Capital Ratio": "259%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.5861576080535507,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001024126.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001024126.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001024126.svg"
},
{
"company_id": "0001114220",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001114220.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001114220.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001114220_main_keyfigs.svg",
"name": "Keryx Biopharmaceuticals INC",
"rank": 120,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001114220.svg",
"report_text": "The relative strengths and weaknesses of Keryx Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Keryx Biopharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 69% points.The greatest weakness of Keryx Biopharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 37% points.
The company's Economic Capital Ratio, given in the ranking table, is 259%, being 16% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001114220_2014_Keryx_Biopharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-10.8",
"Assets": "48.7",
"Liabilities": "17.8",
"Stockholders Equity": "76.9",
"ECR before LimitedLiability": "103",
"Property and Equipment": "-9.42",
"Assets, Current": "102",
"Other Liabilities": "12.2",
"Liabilities, Non-Current": "13.1",
"Liabilities, Current": "-7.70",
"Research and Development": "-34.3",
"Expenses": "-8.74",
"Revenues": "-17.7",
"Net Income": "-22.3",
"Other Expenses": "11.2",
"Cost of Goods Sold": "3.94",
"Selling, General and Administrative Expense": "11.9",
"Other Revenues": "-17.7",
"Comprehensive Net Income": "-22.5",
"Other Net Income": "4.05",
"Economic Capital Ratio": "27.6"
},
"2013": {
"Other Assets": "-11.2",
"Assets": "19.2",
"Liabilities": "47.0",
"Stockholders Equity": "68.8",
"ECR before LimitedLiability": "43.8",
"Intangible Assets": "-6.79",
"Property and Equipment": "-8.01",
"Assets, Current": "60.9",
"Liabilities, Non-Current": "14.6",
"Liabilities, Current": "-7.47",
"Other Liabilities": "40.2",
"Selling, General and Administrative Expense": "-7.96",
"Expenses": "-27.0",
"Revenues": "-12.4",
"Net Income": "-36.5",
"Other Expenses": "14.8",
"Research and Development": "-36.1",
"Cost of Goods Sold": "3.35",
"Other Revenues": "-12.4",
"Comprehensive Net Income": "-36.7",
"Economic Capital Ratio": "15.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001114220_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "40,004",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,208",
"Liabilities, Current": "9,767",
"Liabilities, Non-Current": "35",
"Other Assets": "209",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "2,639",
"Other Net Income": "626",
"Other Revenues": "5,000",
"Property and Equipment": "67",
"Research and Development": "27,012",
"Selling, General and Administrative Expense": "6,737"
},
"output_variables": {
"Assets": "43,488",
"Liabilities": "12,441",
"Expenses": "33,749",
"Revenues": "5,000",
"Stockholders Equity": "31,047",
"Net Income": "-28,123",
"Comprehensive Net Income": "-28,123",
"BaseVar": "47,652",
"ECR before LimitedLiability": "141%",
"Economic Capital Ratio": "262%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "56,928",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,208",
"Liabilities, Current": "15,328",
"Liabilities, Non-Current": "38",
"Other Assets": "281",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "351",
"Other Revenues": "7,000",
"Property and Equipment": "349",
"Research and Development": "34,734",
"Selling, General and Administrative Expense": "19,349"
},
"output_variables": {
"Assets": "60,766",
"Liabilities": "15,366",
"Expenses": "54,083",
"Revenues": "7,000",
"Stockholders Equity": "45,400",
"Net Income": "-46,732",
"Comprehensive Net Income": "-46,732",
"BaseVar": "68,783",
"ECR before LimitedLiability": "137%",
"Economic Capital Ratio": "259%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.585548440310221,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001114220.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001114220.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001114220.svg"
},
{
"company_id": "0001106838",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001106838.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001106838.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001106838.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001106838_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001106838_main_keyfigs.svg",
"name": "Sonnet Biotherapeutics Holdings Inc",
"rank": 121,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001106838.svg",
"report_text": "The relative strengths and weaknesses of Sonnet Biotherapeutics Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Sonnet Biotherapeutics Holdings Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 94% points.The greatest weakness of Sonnet Biotherapeutics Holdings Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 67% points.
The company's Economic Capital Ratio, given in the ranking table, is 256%, being 13% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001106838_2014_Sonnet_Biotherapeutics_Holdings_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "35.6",
"Assets": "-26.6",
"Liabilities": "94.5",
"Stockholders Equity": "21.4",
"ECR before LimitedLiability": "140",
"Assets, Current": "-56.9",
"Other Assets": "35.8",
"Liabilities, Current": "36.8",
"Other Liabilities": "46.4",
"Liabilities, Non-Current": "17.2",
"Selling, General and Administrative Expense": "7.33",
"Expenses": "-14.5",
"Revenues": "58.0",
"Net Income": "37.3",
"Research and Development": "48.5",
"Other Expenses": "-72.1",
"Cost of Goods Sold": "6.80",
"Other Revenues": "58.0",
"Comprehensive Net Income": "37.6",
"Other Net Income": "-3.78",
"Economic Capital Ratio": "66.9"
},
"2013": {
"Other Assets": "9.72",
"Assets": "-1.70",
"Liabilities": "2.34",
"ECR before LimitedLiability": "40.7",
"Intangible Assets": "94.0",
"Property and Equipment": "42.6",
"Assets, Current": "-67.0",
"Liabilities, Non-Current": "8.84",
"Liabilities, Current": "-5.04",
"Other Liabilities": "-1.56",
"Selling, General and Administrative Expense": "7.20",
"Expenses": "9.34",
"Net Income": "24.6",
"Other Expenses": "-29.0",
"Research and Development": "30.0",
"Cost of Goods Sold": "3.29",
"Other Revenues": "16.9",
"Revenues": "16.9",
"Comprehensive Net Income": "25.0",
"Other Net Income": "-1.91",
"Economic Capital Ratio": "12.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001106838_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "2,030",
"Cost of Goods Sold": "0",
"Intangible Assets": "956",
"Liabilities, Current": "1,773",
"Liabilities, Non-Current": "186",
"Other Assets": "2,344",
"Other Compr. Net Income": "-4.4",
"Other Expenses": "7,154",
"Other Liabilities": "159",
"Other Net Income": "-505",
"Other Revenues": "6,883",
"Property and Equipment": "2,316",
"Research and Development": "0",
"Selling, General and Administrative Expense": "2,618"
},
"output_variables": {
"Assets": "7,646",
"Liabilities": "2,118",
"Expenses": "9,772",
"Revenues": "6,883",
"Stockholders Equity": "5,529",
"Net Income": "-3,395",
"Comprehensive Net Income": "-3,397",
"BaseVar": "13,465",
"ECR before LimitedLiability": "177%",
"Economic Capital Ratio": "287%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "1,713",
"Cost of Goods Sold": "0",
"Intangible Assets": "9,921",
"Liabilities, Current": "5,532",
"Liabilities, Non-Current": "399",
"Other Assets": "2,833",
"Other Compr. Net Income": "233",
"Other Expenses": "8,661",
"Other Liabilities": "2,918",
"Other Net Income": "-706",
"Other Revenues": "8,247",
"Property and Equipment": "5,620",
"Research and Development": "0",
"Selling, General and Administrative Expense": "4,234"
},
"output_variables": {
"Assets": "20,088",
"Liabilities": "8,849",
"Expenses": "12,895",
"Revenues": "8,247",
"Stockholders Equity": "11,239",
"Net Income": "-5,353",
"Comprehensive Net Income": "-5,236",
"BaseVar": "25,509",
"ECR before LimitedLiability": "133%",
"Economic Capital Ratio": "256%"
}
}
},
"top_rated": false,
"trend": -46.0,
"value": 2.555474913463713,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001106838.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001106838.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001106838.svg"
},
{
"company_id": "0000919745",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000919745.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000919745.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000919745_main_keyfigs.svg",
"name": "Midatech Pharma US Inc",
"rank": 122,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000919745.svg",
"report_text": "The relative strengths and weaknesses of Midatech Pharma US Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Midatech Pharma US Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 114% points.The greatest weakness of Midatech Pharma US Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 75% points.
The company's Economic Capital Ratio, given in the ranking table, is 255%, being 13% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000919745_2014_Midatech_Pharma_US_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-9.33",
"Assets": "67.1",
"Liabilities": "41.3",
"Stockholders Equity": "114",
"ECR before LimitedLiability": "108",
"Assets, Current": "13.3",
"Intangible Assets": "82.5",
"Other Assets": "-9.34",
"Liabilities, Current": "11.6",
"Other Liabilities": "15.2",
"Liabilities, Non-Current": "15.6",
"Selling, General and Administrative Expense": "-18.1",
"Expenses": "-4.04",
"Revenues": "-27.1",
"Net Income": "-45.7",
"Other Expenses": "7.43",
"Cost of Goods Sold": "4.54",
"Other Revenues": "-27.1",
"Comprehensive Net Income": "-45.3",
"Other Net Income": "-15.8",
"Economic Capital Ratio": "34.8"
},
"2013": {
"Other Assets": "-19.6",
"Assets": "-66.5",
"Liabilities": "114",
"Stockholders Equity": "-46.4",
"ECR before LimitedLiability": "40.5",
"Intangible Assets": "89.3",
"Property and Equipment": "-14.3",
"Assets, Current": "-74.6",
"Liabilities, Non-Current": "25.2",
"Liabilities, Current": "60.9",
"Other Liabilities": "39.8",
"Selling, General and Administrative Expense": "-9.94",
"Expenses": "-22.8",
"Revenues": "-37.4",
"Net Income": "-54.0",
"Other Expenses": "-40.0",
"Research and Development": "23.6",
"Other Revenues": "-37.4",
"Comprehensive Net Income": "15.8",
"Other Compr. Net Income": "81.2",
"Economic Capital Ratio": "12.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000919745_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "7,045",
"Cost of Goods Sold": "0",
"Intangible Assets": "4,530",
"Liabilities, Current": "2,039",
"Liabilities, Non-Current": "0",
"Other Assets": "67",
"Other Compr. Net Income": "45",
"Other Expenses": "993",
"Other Liabilities": "660",
"Other Net Income": "-1,778",
"Other Revenues": "54",
"Property and Equipment": "50",
"Research and Development": "2,735",
"Selling, General and Administrative Expense": "4,663"
},
"output_variables": {
"Assets": "11,692",
"Liabilities": "2,699",
"Expenses": "8,391",
"Revenues": "54",
"Stockholders Equity": "8,993",
"Net Income": "-10,115",
"Comprehensive Net Income": "-10,092",
"BaseVar": "12,329",
"ECR before LimitedLiability": "132%",
"Economic Capital Ratio": "255%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "3,889",
"Cost of Goods Sold": "0",
"Intangible Assets": "4,046",
"Liabilities, Current": "1,675",
"Liabilities, Non-Current": "0",
"Other Assets": "13",
"Other Compr. Net Income": "10,322",
"Other Expenses": "4,718",
"Other Liabilities": "751",
"Other Net Income": "150",
"Other Revenues": "419",
"Property and Equipment": "41",
"Research and Development": "1,953",
"Selling, General and Administrative Expense": "4,266"
},
"output_variables": {
"Assets": "7,988",
"Liabilities": "2,426",
"Expenses": "10,937",
"Revenues": "419",
"Stockholders Equity": "5,562",
"Net Income": "-10,368",
"Comprehensive Net Income": "-5,207",
"BaseVar": "16,122",
"ECR before LimitedLiability": "133%",
"Economic Capital Ratio": "255%"
}
}
},
"top_rated": false,
"trend": -26.0,
"value": 2.5533810506983645,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000919745.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000919745.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000919745.svg"
},
{
"company_id": "0001585364",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001585364.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001585364.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001585364.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001585364_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001585364_main_keyfigs.svg",
"name": "Perrigo Co plc",
"rank": 123,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001585364.svg",
"report_text": "The relative strengths and weaknesses of Perrigo Co plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Perrigo Co plc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 66% points.The greatest weakness of Perrigo Co plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 119% points.
The company's Economic Capital Ratio, given in the ranking table, is 255%, being 12% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001585364_2014_Perrigo_Co_plc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "24.2",
"Assets": "-15.6",
"Liabilities": "-18.5",
"Stockholders Equity": "-36.9",
"ECR before LimitedLiability": "40.3",
"Intangible Assets": "15.8",
"Property and Equipment": "9.16",
"Assets, Current": "-45.8",
"Liabilities, Non-Current": "-119",
"Liabilities, Current": "37.7",
"Other Liabilities": "40.0",
"Selling, General and Administrative Expense": "26.0",
"Expenses": "22.6",
"Revenues": "38.4",
"Net Income": "65.6",
"Other Expenses": "6.26",
"Research and Development": "28.2",
"Cost of Goods Sold": "-35.1",
"Other Revenues": "38.4",
"Comprehensive Net Income": "65.7",
"Economic Capital Ratio": "12.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001585364_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "2,236,900",
"Cost of Goods Sold": "2,259,800",
"Intangible Assets": "1,157,600",
"Liabilities, Current": "749,400",
"Liabilities, Non-Current": "2,268,800",
"Other Assets": "1,274,900",
"Other Compr. Net Income": "37,700",
"Other Expenses": "472,800",
"Other Liabilities": "0",
"Other Net Income": "-900",
"Other Revenues": "3,539,800",
"Property and Equipment": "681,400",
"Research and Development": "124,200",
"Selling, General and Administrative Expense": "240,200"
},
"output_variables": {
"Assets": "5,350,800",
"Liabilities": "3,018,200",
"Expenses": "3,097,000",
"Revenues": "3,539,800",
"Stockholders Equity": "2,332,600",
"Net Income": "441,900",
"Comprehensive Net Income": "460,750",
"BaseVar": "7,522,200",
"ECR before LimitedLiability": "133%",
"Economic Capital Ratio": "255%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.550895238480111,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001585364.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001585364.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001585364.svg"
},
{
"company_id": "0001042074",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001042074.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001042074.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001042074.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001042074_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001042074_main_keyfigs.svg",
"name": "Cymabay Therapeutics Inc",
"rank": 124,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001042074.svg",
"report_text": "The relative strengths and weaknesses of Cymabay Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cymabay Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 113% points.The greatest weakness of Cymabay Therapeutics Inc is the variable Liabilities, reducing the Economic Capital Ratio by 37% points.
The company's Economic Capital Ratio, given in the ranking table, is 254%, being 11% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001042074_2014_Cymabay_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-7.33",
"Assets": "67.1",
"Liabilities": "-36.7",
"Stockholders Equity": "44.6",
"ECR before LimitedLiability": "39.4",
"Intangible Assets": "-10.7",
"Property and Equipment": "-6.32",
"Assets, Current": "113",
"Liabilities, Non-Current": "10.0",
"Liabilities, Current": "-35.1",
"Other Liabilities": "-11.8",
"Selling, General and Administrative Expense": "4.48",
"Expenses": "20.2",
"Revenues": "-17.4",
"Net Income": "3.45",
"Other Expenses": "7.38",
"Research and Development": "5.62",
"Cost of Goods Sold": "2.29",
"Other Revenues": "-17.4",
"Comprehensive Net Income": "3.25",
"Economic Capital Ratio": "11.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001042074_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "32,239",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,488",
"Liabilities, Non-Current": "9.0",
"Other Assets": "258",
"Other Compr. Net Income": "2.0",
"Other Expenses": "822",
"Other Liabilities": "4,407",
"Other Net Income": "145",
"Other Revenues": "0",
"Property and Equipment": "3.0",
"Research and Development": "4,525",
"Selling, General and Administrative Expense": "4,871"
},
"output_variables": {
"Assets": "32,500",
"Liabilities": "13,904",
"Expenses": "10,218",
"Revenues": "0",
"Stockholders Equity": "18,596",
"Net Income": "-10,073",
"Comprehensive Net Income": "-10,072",
"BaseVar": "28,384",
"ECR before LimitedLiability": "131%",
"Economic Capital Ratio": "254%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.5418610119829763,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001042074.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001042074.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001042074.svg"
},
{
"company_id": "0000816284",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000816284.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000816284.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000816284_main_keyfigs.svg",
"name": "Celgene CORP DE",
"rank": 125,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000816284.svg",
"report_text": "The relative strengths and weaknesses of Celgene CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Celgene CORP DE compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 61% points.The greatest weakness of Celgene CORP DE is the variable Other Liabilities, reducing the Economic Capital Ratio by 76% points.
The company's Economic Capital Ratio, given in the ranking table, is 253%, being 10% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000816284_2014_Celgene_CORP_DE.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.10",
"Assets": "26.9",
"Liabilities": "-28.3",
"Stockholders Equity": "20.8",
"ECR before LimitedLiability": "133",
"Intangible Assets": "63.6",
"Assets, Current": "-14.1",
"Other Liabilities": "-52.9",
"Liabilities, Non-Current": "4.68",
"Liabilities, Current": "16.1",
"Research and Development": "15.3",
"Expenses": "36.7",
"Revenues": "19.0",
"Net Income": "60.1",
"Other Expenses": "2.88",
"Cost of Goods Sold": "3.43",
"Selling, General and Administrative Expense": "14.1",
"Other Revenues": "19.0",
"Comprehensive Net Income": "59.7",
"Other Net Income": "2.27",
"Economic Capital Ratio": "57.5"
},
"2012": {
"Property and Equipment": "-1.95",
"Assets": "28.9",
"Liabilities": "-35.2",
"Stockholders Equity": "13.6",
"ECR before LimitedLiability": "125",
"Assets, Current": "-14.3",
"Intangible Assets": "63.8",
"Other Assets": "-3.24",
"Liabilities, Current": "23.4",
"Other Liabilities": "-70.7",
"Liabilities, Non-Current": "5.77",
"Selling, General and Administrative Expense": "14.7",
"Expenses": "40.5",
"Revenues": "19.8",
"Net Income": "64.9",
"Research and Development": "12.8",
"Other Expenses": "7.60",
"Cost of Goods Sold": "3.90",
"Other Revenues": "19.8",
"Comprehensive Net Income": "65.2",
"Economic Capital Ratio": "52.1"
},
"2013": {
"Other Assets": "-7.28",
"Assets": "3.31",
"Liabilities": "-41.5",
"Stockholders Equity": "-25.1",
"ECR before LimitedLiability": "38.1",
"Intangible Assets": "48.8",
"Property and Equipment": "-1.99",
"Assets, Current": "-22.1",
"Liabilities, Non-Current": "1.37",
"Liabilities, Current": "27.0",
"Other Liabilities": "-75.9",
"Selling, General and Administrative Expense": "13.9",
"Expenses": "32.9",
"Revenues": "23.7",
"Net Income": "60.3",
"Other Expenses": "5.08",
"Research and Development": "10.00",
"Cost of Goods Sold": "2.92",
"Other Revenues": "23.7",
"Comprehensive Net Income": "60.6",
"Economic Capital Ratio": "10.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000816284_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,353,225",
"Cost of Goods Sold": "0",
"Intangible Assets": "4,731,918",
"Liabilities, Current": "1,539,972",
"Liabilities, Non-Current": "273,516",
"Other Assets": "414,725",
"Other Compr. Net Income": "0",
"Other Expenses": "717,542",
"Other Liabilities": "2,679,695",
"Other Net Income": "19,506",
"Other Revenues": "4,842,070",
"Property and Equipment": "506,042",
"Research and Development": "1,600,264",
"Selling, General and Administrative Expense": "1,226,314"
},
"output_variables": {
"Assets": "10,005,910",
"Liabilities": "4,493,183",
"Expenses": "3,544,120",
"Revenues": "4,842,070",
"Stockholders Equity": "5,512,727",
"Net Income": "1,317,456",
"Comprehensive Net Income": "1,317,456",
"BaseVar": "11,452,394",
"ECR before LimitedLiability": "184%",
"Economic Capital Ratio": "292%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "5,533,665",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,143,196",
"Liabilities, Current": "1,690,235",
"Liabilities, Non-Current": "355,546",
"Other Assets": "479,083",
"Other Compr. Net Income": "12,590",
"Other Expenses": "951,090",
"Other Liabilities": "3,994,058",
"Other Net Income": "-1,746",
"Other Revenues": "5,506,713",
"Property and Equipment": "578,362",
"Research and Development": "1,724,156",
"Selling, General and Administrative Expense": "1,373,541"
},
"output_variables": {
"Assets": "11,734,306",
"Liabilities": "6,039,839",
"Expenses": "4,048,787",
"Revenues": "5,506,713",
"Stockholders Equity": "5,694,467",
"Net Income": "1,456,180",
"Comprehensive Net Income": "1,462,475",
"BaseVar": "13,671,990",
"ECR before LimitedLiability": "156%",
"Economic Capital Ratio": "272%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "7,550,500",
"Cost of Goods Sold": "0",
"Intangible Assets": "4,880,900",
"Liabilities, Current": "1,945,500",
"Liabilities, Non-Current": "582,700",
"Other Assets": "353,400",
"Other Compr. Net Income": "143,700",
"Other Expenses": "1,081,400",
"Other Liabilities": "5,260,100",
"Other Net Income": "-51,900",
"Other Revenues": "6,493,900",
"Property and Equipment": "593,400",
"Research and Development": "2,226,200",
"Selling, General and Administrative Expense": "1,684,500"
},
"output_variables": {
"Assets": "13,378,200",
"Liabilities": "7,788,300",
"Expenses": "4,992,100",
"Revenues": "6,493,900",
"Stockholders Equity": "5,589,900",
"Net Income": "1,449,900",
"Comprehensive Net Income": "1,521,750",
"BaseVar": "16,424,050",
"ECR before LimitedLiability": "130%",
"Economic Capital Ratio": "253%"
}
}
},
"top_rated": false,
"trend": -40.0,
"value": 2.528557137372597,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000816284.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000816284.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000816284.svg"
},
{
"company_id": "0000786947",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000786947.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000786947.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000786947.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000786947_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000786947_main_keyfigs.svg",
"name": "Acura Pharmaceuticals INC",
"rank": 126,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000786947.svg",
"report_text": "The relative strengths and weaknesses of Acura Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Acura Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 106% points.The greatest weakness of Acura Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 79% points.
The company's Economic Capital Ratio, given in the ranking table, is 252%, being 9.0% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000786947_2014_Acura_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "2.03",
"Assets": "-19.0",
"Liabilities": "142",
"Stockholders Equity": "192",
"ECR before LimitedLiability": "343",
"Intangible Assets": "2.64",
"Assets, Current": "-38.0",
"Other Liabilities": "54.7",
"Liabilities, Non-Current": "24.7",
"Liabilities, Current": "92.8",
"Research and Development": "23.8",
"Expenses": "49.3",
"Revenues": "50.4",
"Net Income": "98.3",
"Other Expenses": "12.6",
"Cost of Goods Sold": "4.72",
"Selling, General and Administrative Expense": "9.44",
"Other Revenues": "50.4",
"Comprehensive Net Income": "97.9",
"Other Net Income": "2.88",
"Economic Capital Ratio": "267"
},
"2012": {
"Assets": "67.1",
"Liabilities": "77.0",
"Stockholders Equity": "211",
"ECR before LimitedLiability": "243",
"Assets, Current": "97.1",
"Intangible Assets": "-3.58",
"Other Assets": "-2.58",
"Liabilities, Current": "40.2",
"Other Liabilities": "31.1",
"Liabilities, Non-Current": "14.8",
"Selling, General and Administrative Expense": "-5.99",
"Expenses": "14.9",
"Revenues": "-20.9",
"Net Income": "-3.53",
"Research and Development": "5.18",
"Other Expenses": "12.5",
"Cost of Goods Sold": "3.24",
"Other Revenues": "-20.9",
"Comprehensive Net Income": "-3.48",
"Other Net Income": "1.96",
"Economic Capital Ratio": "170"
},
"2013": {
"Other Assets": "-8.36",
"Assets": "55.1",
"Liabilities": "-12.9",
"Stockholders Equity": "53.2",
"ECR before LimitedLiability": "37.0",
"Intangible Assets": "-12.1",
"Assets, Current": "106",
"Liabilities, Non-Current": "11.3",
"Liabilities, Current": "44.8",
"Other Liabilities": "-78.8",
"Selling, General and Administrative Expense": "-11.1",
"Expenses": "5.06",
"Revenues": "-19.2",
"Net Income": "-12.4",
"Other Expenses": "9.95",
"Research and Development": "3.94",
"Cost of Goods Sold": "2.58",
"Other Revenues": "-19.2",
"Comprehensive Net Income": "-12.5",
"Other Net Income": "2.05",
"Economic Capital Ratio": "9.05"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000786947_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "36,129",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "530",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "147",
"Other Liabilities": "0",
"Other Net Income": "-2.0",
"Other Revenues": "20,466",
"Property and Equipment": "1,044",
"Research and Development": "4,037",
"Selling, General and Administrative Expense": "5,895"
},
"output_variables": {
"Assets": "37,173",
"Liabilities": "530",
"Expenses": "10,079",
"Revenues": "20,466",
"Stockholders Equity": "36,643",
"Net Income": "10,385",
"Comprehensive Net Income": "10,385",
"BaseVar": "34,125",
"ECR before LimitedLiability": "479%",
"Economic Capital Ratio": "501%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "27,991",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,419",
"Liabilities, Non-Current": "0",
"Other Assets": "11",
"Other Compr. Net Income": "-40",
"Other Expenses": "8.0",
"Other Liabilities": "0",
"Other Net Income": "79",
"Other Revenues": "0",
"Property and Equipment": "1,052",
"Research and Development": "3,726",
"Selling, General and Administrative Expense": "6,013"
},
"output_variables": {
"Assets": "29,054",
"Liabilities": "1,419",
"Expenses": "9,747",
"Revenues": "0",
"Stockholders Equity": "27,635",
"Net Income": "-9,668",
"Comprehensive Net Income": "-9,688",
"BaseVar": "20,170",
"ECR before LimitedLiability": "332%",
"Economic Capital Ratio": "390%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "27,453",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,107",
"Liabilities, Non-Current": "0",
"Other Assets": "236",
"Other Compr. Net Income": "59",
"Other Expenses": "364",
"Other Liabilities": "9,600",
"Other Net Income": "189",
"Other Revenues": "123",
"Property and Equipment": "941",
"Research and Development": "4,923",
"Selling, General and Administrative Expense": "8,926"
},
"output_variables": {
"Assets": "28,630",
"Liabilities": "10,707",
"Expenses": "14,213",
"Revenues": "123",
"Stockholders Equity": "17,923",
"Net Income": "-13,901",
"Comprehensive Net Income": "-13,872",
"BaseVar": "26,960",
"ECR before LimitedLiability": "128%",
"Economic Capital Ratio": "252%"
}
}
},
"top_rated": false,
"trend": -108.0,
"value": 2.5181511147859963,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000786947.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000786947.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000786947.svg"
},
{
"company_id": "0000855654",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000855654.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000855654.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000855654.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000855654_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000855654_main_keyfigs.svg",
"name": "Immunogen Inc",
"rank": 127,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000855654.svg",
"report_text": "The relative strengths and weaknesses of Immunogen Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Immunogen Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points.The greatest weakness of Immunogen Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 66% points.
The company's Economic Capital Ratio, given in the ranking table, is 250%, being 7.6% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000855654_2014_Immunogen_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-6.46",
"Assets": "73.4",
"Liabilities": "-23.6",
"Stockholders Equity": "69.3",
"ECR before LimitedLiability": "121",
"Intangible Assets": "-10.5",
"Assets, Current": "118",
"Other Liabilities": "-65.6",
"Liabilities, Non-Current": "5.01",
"Liabilities, Current": "30.0",
"Research and Development": "-3.78",
"Expenses": "22.6",
"Revenues": "-14.1",
"Net Income": "10.6",
"Other Expenses": "8.43",
"Cost of Goods Sold": "2.97",
"Selling, General and Administrative Expense": "14.8",
"Other Revenues": "-14.1",
"Comprehensive Net Income": "10.3",
"Other Net Income": "2.72",
"Economic Capital Ratio": "45.9"
},
"2012": {
"Assets": "65.5",
"Liabilities": "-51.5",
"Stockholders Equity": "20.1",
"ECR before LimitedLiability": "66.3",
"Assets, Current": "74.1",
"Intangible Assets": "-15.0",
"Other Assets": "-8.65",
"Liabilities, Current": "32.4",
"Other Liabilities": "-99.5",
"Liabilities, Non-Current": "7.09",
"Selling, General and Administrative Expense": "14.8",
"Expenses": "21.3",
"Revenues": "-15.7",
"Net Income": "6.72",
"Research and Development": "-13.5",
"Other Expenses": "16.3",
"Cost of Goods Sold": "4.11",
"Other Revenues": "-15.7",
"Comprehensive Net Income": "6.88",
"Other Net Income": "2.02",
"Economic Capital Ratio": "-6.73"
},
"2013": {
"Other Assets": "-8.92",
"Assets": "30.9",
"Liabilities": "-17.4",
"Stockholders Equity": "24.6",
"ECR before LimitedLiability": "35.6",
"Intangible Assets": "-13.0",
"Assets, Current": "69.5",
"Liabilities, Non-Current": "7.33",
"Liabilities, Current": "35.3",
"Other Liabilities": "-66.4",
"Selling, General and Administrative Expense": "14.1",
"Expenses": "10.5",
"Revenues": "-4.21",
"Net Income": "7.58",
"Other Expenses": "12.3",
"Research and Development": "-17.9",
"Cost of Goods Sold": "2.79",
"Other Revenues": "-4.21",
"Comprehensive Net Income": "7.38",
"Other Net Income": "1.44",
"Economic Capital Ratio": "7.63"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000855654_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "201,525",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "14,566",
"Liabilities, Non-Current": "3,978",
"Other Assets": "2,707",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "59,128",
"Other Net Income": "1,914",
"Other Revenues": "19,305",
"Property and Equipment": "13,409",
"Research and Development": "63,453",
"Selling, General and Administrative Expense": "16,040"
},
"output_variables": {
"Assets": "217,641",
"Liabilities": "77,672",
"Expenses": "79,493",
"Revenues": "19,305",
"Stockholders Equity": "139,969",
"Net Income": "-58,274",
"Comprehensive Net Income": "-58,274",
"BaseVar": "198,012",
"ECR before LimitedLiability": "167%",
"Economic Capital Ratio": "280%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "166,270",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "16,254",
"Liabilities, Non-Current": "3,798",
"Other Assets": "2,405",
"Other Compr. Net Income": "-62",
"Other Expenses": "0",
"Other Liabilities": "76,366",
"Other Net Income": "0",
"Other Revenues": "16,357",
"Property and Equipment": "11,633",
"Research and Development": "69,192",
"Selling, General and Administrative Expense": "20,422"
},
"output_variables": {
"Assets": "180,308",
"Liabilities": "96,418",
"Expenses": "89,614",
"Revenues": "16,357",
"Stockholders Equity": "83,890",
"Net Income": "-73,257",
"Comprehensive Net Income": "-73,288",
"BaseVar": "191,380",
"ECR before LimitedLiability": "79%",
"Economic Capital Ratio": "213%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "200,684",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "19,173",
"Liabilities, Non-Current": "3,566",
"Other Assets": "2,129",
"Other Compr. Net Income": "198",
"Other Expenses": "0",
"Other Liabilities": "69,010",
"Other Net Income": "0",
"Other Revenues": "35,535",
"Property and Equipment": "10,783",
"Research and Development": "87,073",
"Selling, General and Administrative Expense": "21,471"
},
"output_variables": {
"Assets": "213,596",
"Liabilities": "91,749",
"Expenses": "108,544",
"Revenues": "35,535",
"Stockholders Equity": "121,847",
"Net Income": "-73,009",
"Comprehensive Net Income": "-72,910",
"BaseVar": "224,811",
"ECR before LimitedLiability": "126%",
"Economic Capital Ratio": "250%"
}
}
},
"top_rated": false,
"trend": -8.0,
"value": 2.503955582074568,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000855654.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000855654.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000855654.svg"
},
{
"company_id": "0000912183",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000912183.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000912183.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000912183_main_keyfigs.svg",
"name": "Cubist Pharmaceuticals INC",
"rank": 128,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000912183.svg",
"report_text": "The relative strengths and weaknesses of Cubist Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cubist Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 50% points.The greatest weakness of Cubist Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 101% points.
The company's Economic Capital Ratio, given in the ranking table, is 248%, being 5.4% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000912183_2014_Cubist_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Liabilities, Current": "21.2",
"Liabilities": "-40.6",
"Stockholders Equity": "-27.6",
"ECR before LimitedLiability": "-18.9",
"Other Liabilities": "-97.6",
"Liabilities, Non-Current": "23.3",
"Selling, General and Administrative Expense": "17.0",
"Expenses": "16.3",
"Net Income": "15.3",
"Research and Development": "2.55",
"Cost of Goods Sold": "-4.56",
"Other Expenses": "1.42",
"Other Revenues": "0.833",
"Revenues": "0.833",
"Other Assets": "7.83",
"Assets, Current": "34.7",
"Property and Equipment": "-10.1",
"Intangible Assets": "-21.9",
"Comprehensive Net Income": "15.3",
"Other Net Income": "-1.79",
"Economic Capital Ratio": "-25.3"
},
"2011": {
"Other Assets": "20.6",
"Assets": "29.7",
"Liabilities": "-60.0",
"Stockholders Equity": "-8.63",
"ECR before LimitedLiability": "86.8",
"Intangible Assets": "8.37",
"Property and Equipment": "3.62",
"Assets, Current": "-4.42",
"Other Liabilities": "-97.6",
"Liabilities, Non-Current": "7.66",
"Liabilities, Current": "21.7",
"Research and Development": "23.1",
"Expenses": "39.0",
"Revenues": "10.2",
"Net Income": "51.3",
"Other Expenses": "1.33",
"Cost of Goods Sold": "-5.20",
"Selling, General and Administrative Expense": "19.0",
"Other Revenues": "10.2",
"Comprehensive Net Income": "51.0",
"Economic Capital Ratio": "11.2"
},
"2012": {
"Property and Equipment": "2.76",
"Assets": "26.4",
"Liabilities": "-25.5",
"Stockholders Equity": "18.3",
"ECR before LimitedLiability": "129",
"Assets, Current": "-0.218",
"Intangible Assets": "6.03",
"Other Assets": "15.7",
"Liabilities, Current": "27.5",
"Other Liabilities": "-71.4",
"Liabilities, Non-Current": "10.5",
"Selling, General and Administrative Expense": "18.0",
"Expenses": "38.4",
"Revenues": "20.6",
"Net Income": "61.5",
"Research and Development": "13.7",
"Other Expenses": "13.0",
"Cost of Goods Sold": "-7.24",
"Other Revenues": "20.6",
"Comprehensive Net Income": "61.7",
"Economic Capital Ratio": "55.6"
},
"2013": {
"Other Assets": "46.7",
"Assets": "18.5",
"Liabilities": "-46.4",
"Stockholders Equity": "-10.7",
"ECR before LimitedLiability": "33.4",
"Intangible Assets": "50.4",
"Assets, Current": "-45.2",
"Liabilities, Non-Current": "9.18",
"Liabilities, Current": "33.6",
"Other Liabilities": "-101",
"Selling, General and Administrative Expense": "16.3",
"Expenses": "32.9",
"Revenues": "11.4",
"Net Income": "44.5",
"Other Expenses": "11.8",
"Research and Development": "9.30",
"Cost of Goods Sold": "-5.25",
"Other Revenues": "11.4",
"Comprehensive Net Income": "44.2",
"Other Net Income": "-0.751",
"Economic Capital Ratio": "5.44"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000912183_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,016,243",
"Cost of Goods Sold": "140,765",
"Intangible Assets": "75,304",
"Liabilities, Current": "150,644",
"Liabilities, Non-Current": "6,370",
"Other Assets": "241,176",
"Other Compr. Net Income": "0",
"Other Expenses": "150,383",
"Other Liabilities": "594,720",
"Other Net Income": "-35,290",
"Other Revenues": "636,458",
"Property and Equipment": "82,434",
"Research and Development": "157,854",
"Selling, General and Administrative Expense": "57,841"
},
"output_variables": {
"Assets": "1,415,157",
"Liabilities": "751,734",
"Expenses": "506,843",
"Revenues": "636,458",
"Stockholders Equity": "663,423",
"Net Income": "94,325",
"Comprehensive Net Income": "94,325",
"BaseVar": "1,672,741",
"ECR before LimitedLiability": "142%",
"Economic Capital Ratio": "262%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,043,274",
"Cost of Goods Sold": "172,864",
"Intangible Assets": "297,113",
"Liabilities, Current": "252,385",
"Liabilities, Non-Current": "30,039",
"Other Assets": "378,643",
"Other Compr. Net Income": "0",
"Other Expenses": "172,582",
"Other Liabilities": "805,174",
"Other Net Income": "-27,742",
"Other Revenues": "753,972",
"Property and Equipment": "168,425",
"Research and Development": "184,533",
"Selling, General and Administrative Expense": "163,228"
},
"output_variables": {
"Assets": "1,887,455",
"Liabilities": "1,087,598",
"Expenses": "693,207",
"Revenues": "753,972",
"Stockholders Equity": "799,857",
"Net Income": "33,023",
"Comprehensive Net Income": "33,023",
"BaseVar": "2,224,987",
"ECR before LimitedLiability": "119%",
"Economic Capital Ratio": "245%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,157,050",
"Cost of Goods Sold": "230,057",
"Intangible Assets": "266,960",
"Liabilities, Current": "258,518",
"Liabilities, Non-Current": "27,921",
"Other Assets": "341,910",
"Other Compr. Net Income": "126",
"Other Expenses": "55,200",
"Other Liabilities": "655,198",
"Other Net Income": "-37,510",
"Other Revenues": "926,359",
"Property and Equipment": "166,465",
"Research and Development": "277,729",
"Selling, General and Administrative Expense": "171,788"
},
"output_variables": {
"Assets": "1,932,385",
"Liabilities": "941,637",
"Expenses": "734,774",
"Revenues": "926,359",
"Stockholders Equity": "990,748",
"Net Income": "154,075",
"Comprehensive Net Income": "154,138",
"BaseVar": "2,286,396",
"ECR before LimitedLiability": "161%",
"Economic Capital Ratio": "276%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "869,769",
"Cost of Goods Sold": "275,502",
"Intangible Assets": "1,104,084",
"Liabilities, Current": "310,828",
"Liabilities, Non-Current": "31,726",
"Other Assets": "994,424",
"Other Compr. Net Income": "1,012",
"Other Expenses": "-3,144",
"Other Liabilities": "1,409,536",
"Other Net Income": "-69,545",
"Other Revenues": "1,099,648",
"Property and Equipment": "177,544",
"Research and Development": "918,359",
"Selling, General and Administrative Expense": "351,883"
},
"output_variables": {
"Assets": "3,145,821",
"Liabilities": "1,752,090",
"Expenses": "1,542,599",
"Revenues": "1,099,648",
"Stockholders Equity": "1,393,731",
"Net Income": "-512,497",
"Comprehensive Net Income": "-511,991",
"BaseVar": "3,805,358",
"ECR before LimitedLiability": "103%",
"Economic Capital Ratio": "233%"
}
}
},
"top_rated": false,
"trend": -44.0,
"value": 2.4820531790879166,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000912183.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000912183.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000912183.svg"
},
{
"company_id": "0000891293",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000891293.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000891293.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000891293.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000891293_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000891293_main_keyfigs.svg",
"name": "CTI Biopharma CORP",
"rank": 129,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000891293.svg",
"report_text": "The relative strengths and weaknesses of CTI Biopharma CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of CTI Biopharma CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 37% points.The greatest weakness of CTI Biopharma CORP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 37% points.
The company's Economic Capital Ratio, given in the ranking table, is 246%, being 3.6% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000891293_2014_CTI_Biopharma_CORP.pdf",
"shrinked_graph_json": {
"2013": {
"Assets": "-6.53",
"Liabilities": "18.1",
"Stockholders Equity": "5.08",
"ECR before LimitedLiability": "31.6",
"Intangible Assets": "-16.6",
"Property and Equipment": "-0.606",
"Assets, Current": "13.4",
"Liabilities, Non-Current": "-36.7",
"Liabilities, Current": "15.3",
"Other Liabilities": "36.8",
"Selling, General and Administrative Expense": "-17.2",
"Expenses": "-6.49",
"Revenues": "12.5",
"Net Income": "5.26",
"Other Expenses": "15.4",
"Research and Development": "-7.52",
"Cost of Goods Sold": "3.57",
"Other Revenues": "12.5",
"Comprehensive Net Income": "5.32",
"Other Net Income": "-0.502",
"Economic Capital Ratio": "3.62"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000891293_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "80,515",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "20,069",
"Liabilities, Non-Current": "15,809",
"Other Assets": "7,730",
"Other Compr. Net Income": "651",
"Other Expenses": "292",
"Other Liabilities": "1,626",
"Other Net Income": "-2,024",
"Other Revenues": "34,678",
"Property and Equipment": "5,478",
"Research and Development": "33,624",
"Selling, General and Administrative Expense": "42,288"
},
"output_variables": {
"Assets": "93,723",
"Liabilities": "37,504",
"Expenses": "76,204",
"Revenues": "34,678",
"Stockholders Equity": "56,219",
"Net Income": "-43,550",
"Comprehensive Net Income": "-43,224",
"BaseVar": "122,392",
"ECR before LimitedLiability": "121%",
"Economic Capital Ratio": "246%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.463890500517684,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000891293.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000891293.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000891293.svg"
},
{
"company_id": "0000874015",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000874015.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000874015.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000874015.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000874015_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000874015_main_keyfigs.svg",
"name": "Ionis Pharmaceuticals INC",
"rank": 130,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000874015.svg",
"report_text": "The relative strengths and weaknesses of Ionis Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ionis Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points.The greatest weakness of Ionis Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 103% points.
The company's Economic Capital Ratio, given in the ranking table, is 244%, being 1.0% points above the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000874015_2014_Ionis_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-6.94",
"Assets": "23.7",
"Liabilities": "-62.7",
"Stockholders Equity": "-18.0",
"ECR before LimitedLiability": "-42.9",
"Assets, Current": "97.4",
"Property and Equipment": "-8.26",
"Intangible Assets": "-28.1",
"Liabilities, Current": "-8.38",
"Other Liabilities": "-78.8",
"Liabilities, Non-Current": "21.3",
"Selling, General and Administrative Expense": "17.0",
"Expenses": "15.3",
"Revenues": "-18.2",
"Net Income": "-3.10",
"Research and Development": "-14.0",
"Cost of Goods Sold": "4.48",
"Other Expenses": "8.21",
"Other Revenues": "-18.2",
"Comprehensive Net Income": "-3.09",
"Economic Capital Ratio": "-49.2"
},
"2011": {
"Other Assets": "-3.18",
"Assets": "47.2",
"Liabilities": "-84.1",
"Stockholders Equity": "-19.4",
"ECR before LimitedLiability": "49.1",
"Intangible Assets": "-17.1",
"Property and Equipment": "28.8",
"Assets, Current": "42.0",
"Other Liabilities": "-114",
"Liabilities, Non-Current": "11.0",
"Liabilities, Current": "12.6",
"Expenses": "35.3",
"Revenues": "-7.73",
"Net Income": "29.9",
"Other Expenses": "6.78",
"Cost of Goods Sold": "3.65",
"Selling, General and Administrative Expense": "25.3",
"Other Revenues": "-7.73",
"Comprehensive Net Income": "29.6",
"Other Net Income": "2.87",
"Economic Capital Ratio": "-26.4"
},
"2012": {
"Property and Equipment": "21.3",
"Assets": "53.1",
"Liabilities": "-82.0",
"Stockholders Equity": "-13.0",
"ECR before LimitedLiability": "62.3",
"Assets, Current": "49.0",
"Intangible Assets": "-14.7",
"Liabilities, Current": "20.5",
"Other Liabilities": "-125",
"Liabilities, Non-Current": "12.3",
"Selling, General and Administrative Expense": "24.2",
"Expenses": "42.6",
"Revenues": "-6.04",
"Net Income": "38.0",
"Research and Development": "-2.51",
"Other Expenses": "15.7",
"Cost of Goods Sold": "3.96",
"Other Revenues": "-6.04",
"Comprehensive Net Income": "39.9",
"Other Net Income": "1.95",
"Economic Capital Ratio": "-10.8"
},
"2013": {
"Other Assets": "-5.05",
"Assets": "42.2",
"Liabilities": "-60.3",
"Stockholders Equity": "2.58",
"ECR before LimitedLiability": "29.0",
"Intangible Assets": "-11.8",
"Property and Equipment": "9.05",
"Assets, Current": "57.1",
"Liabilities, Non-Current": "10.5",
"Liabilities, Current": "22.3",
"Other Liabilities": "-103",
"Selling, General and Administrative Expense": "20.1",
"Expenses": "34.0",
"Revenues": "-1.85",
"Net Income": "33.3",
"Other Expenses": "-10.6",
"Research and Development": "21.9",
"Cost of Goods Sold": "2.43",
"Other Revenues": "-1.85",
"Comprehensive Net Income": "33.1",
"Other Net Income": "1.25",
"Economic Capital Ratio": "1.02"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000874015_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "483,137",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "105,890",
"Liabilities, Non-Current": "0",
"Other Assets": "31,637",
"Other Compr. Net Income": "0",
"Other Expenses": "13,324",
"Other Liabilities": "200,045",
"Other Net Income": "429",
"Other Revenues": "108,473",
"Property and Equipment": "35,703",
"Research and Development": "145,160",
"Selling, General and Administrative Expense": "11,669"
},
"output_variables": {
"Assets": "550,477",
"Liabilities": "305,935",
"Expenses": "170,153",
"Revenues": "108,473",
"Stockholders Equity": "244,542",
"Net Income": "-61,251",
"Comprehensive Net Income": "-61,251",
"BaseVar": "567,734",
"ECR before LimitedLiability": "110%",
"Economic Capital Ratio": "238%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "360,139",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "76,112",
"Liabilities, Non-Current": "0",
"Other Assets": "28,140",
"Other Compr. Net Income": "0",
"Other Expenses": "16,743",
"Other Liabilities": "237,348",
"Other Net Income": "3,042",
"Other Revenues": "99,086",
"Property and Equipment": "96,615",
"Research and Development": "157,397",
"Selling, General and Administrative Expense": "12,789"
},
"output_variables": {
"Assets": "484,894",
"Liabilities": "313,460",
"Expenses": "186,929",
"Revenues": "99,086",
"Stockholders Equity": "171,434",
"Net Income": "-84,801",
"Comprehensive Net Income": "-84,801",
"BaseVar": "543,706",
"ECR before LimitedLiability": "72%",
"Economic Capital Ratio": "208%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "423,438",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "74,322",
"Liabilities, Non-Current": "0",
"Other Assets": "31,164",
"Other Compr. Net Income": "16,696",
"Other Expenses": "0",
"Other Liabilities": "288,598",
"Other Net Income": "0",
"Other Revenues": "102,049",
"Property and Equipment": "91,084",
"Research and Development": "158,458",
"Selling, General and Administrative Expense": "12,515"
},
"output_variables": {
"Assets": "545,686",
"Liabilities": "362,920",
"Expenses": "170,973",
"Revenues": "102,049",
"Stockholders Equity": "182,766",
"Net Income": "-68,924",
"Comprehensive Net Income": "-60,576",
"BaseVar": "599,162",
"ECR before LimitedLiability": "74%",
"Economic Capital Ratio": "209%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "735,510",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "97,812",
"Liabilities, Non-Current": "0",
"Other Assets": "25,448",
"Other Compr. Net Income": "16,534",
"Other Expenses": "43",
"Other Liabilities": "370,954",
"Other Net Income": "0",
"Other Revenues": "144,056",
"Property and Equipment": "86,198",
"Research and Development": "-13,111",
"Selling, General and Administrative Expense": "15,150"
},
"output_variables": {
"Assets": "847,156",
"Liabilities": "468,766",
"Expenses": "2,082",
"Revenues": "144,056",
"Stockholders Equity": "378,390",
"Net Income": "141,974",
"Comprehensive Net Income": "150,241",
"BaseVar": "739,297",
"ECR before LimitedLiability": "148%",
"Economic Capital Ratio": "267%"
}
}
},
"top_rated": false,
"trend": -9.0,
"value": 2.437902308334108,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000874015.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000874015.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000874015.svg"
},
{
"company_id": "0000908259",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000908259.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000908259.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000908259.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000908259_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000908259_main_keyfigs.svg",
"name": "Oncotelic Therapeutics Inc",
"rank": 131,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000908259.svg",
"report_text": "The relative strengths and weaknesses of Oncotelic Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Oncotelic Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 101% points.The greatest weakness of Oncotelic Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 81% points.
The company's Economic Capital Ratio, given in the ranking table, is 242%, being 1.2% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000908259_2014_Oncotelic_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-12.4",
"Assets": "25.0",
"Liabilities": "59.8",
"Stockholders Equity": "90.6",
"ECR before LimitedLiability": "104",
"Intangible Assets": "-13.7",
"Property and Equipment": "-11.0",
"Assets, Current": "99.2",
"Other Liabilities": "37.3",
"Liabilities, Non-Current": "16.2",
"Liabilities, Current": "8.36",
"Research and Development": "-15.5",
"Expenses": "-33.1",
"Revenues": "-36.0",
"Net Income": "-42.5",
"Cost of Goods Sold": "4.76",
"Selling, General and Administrative Expense": "-22.7",
"Other Revenues": "-36.0",
"Comprehensive Net Income": "-42.9",
"Other Net Income": "28.3",
"Economic Capital Ratio": "28.7"
},
"2012": {
"Property and Equipment": "-18.8",
"Assets": "16.8",
"Liabilities": "55.9",
"Stockholders Equity": "59.8",
"ECR before LimitedLiability": "48.0",
"Assets, Current": "58.0",
"Intangible Assets": "-18.7",
"Other Assets": "-19.8",
"Liabilities, Current": "36.5",
"Other Liabilities": "46.0",
"Liabilities, Non-Current": "21.5",
"Selling, General and Administrative Expense": "-73.8",
"Expenses": "-84.3",
"Revenues": "-39.2",
"Net Income": "-114",
"Research and Development": "-45.0",
"Other Expenses": "28.7",
"Cost of Goods Sold": "7.28",
"Other Revenues": "-39.2",
"Comprehensive Net Income": "-114",
"Economic Capital Ratio": "-25.0"
},
"2013": {
"Other Assets": "-14.6",
"Assets": "16.3",
"Liabilities": "80.2",
"Stockholders Equity": "101",
"ECR before LimitedLiability": "26.8",
"Intangible Assets": "-16.0",
"Property and Equipment": "-10.0",
"Assets, Current": "87.1",
"Liabilities, Non-Current": "16.4",
"Liabilities, Current": "23.2",
"Other Liabilities": "44.4",
"Selling, General and Administrative Expense": "-48.3",
"Expenses": "-58.0",
"Revenues": "-27.3",
"Net Income": "-80.9",
"Other Expenses": "17.1",
"Research and Development": "-30.3",
"Cost of Goods Sold": "3.86",
"Other Revenues": "-27.3",
"Comprehensive Net Income": "-81.2",
"Other Net Income": "2.04",
"Economic Capital Ratio": "-1.18"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000908259_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "10,647",
"Cost of Goods Sold": "0",
"Intangible Assets": "289",
"Liabilities, Current": "2,253",
"Liabilities, Non-Current": "0",
"Other Assets": "86",
"Other Compr. Net Income": "0",
"Other Expenses": "1,226",
"Other Liabilities": "6.0",
"Other Net Income": "2,239",
"Other Revenues": "0",
"Property and Equipment": "34",
"Research and Development": "5,291",
"Selling, General and Administrative Expense": "5,375"
},
"output_variables": {
"Assets": "11,056",
"Liabilities": "2,259",
"Expenses": "11,892",
"Revenues": "0",
"Stockholders Equity": "8,797",
"Net Income": "-9,653",
"Comprehensive Net Income": "-9,653",
"BaseVar": "13,723",
"ECR before LimitedLiability": "143%",
"Economic Capital Ratio": "263%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "5,243",
"Cost of Goods Sold": "0",
"Intangible Assets": "191",
"Liabilities, Current": "901",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "15",
"Other Liabilities": "0",
"Other Net Income": "-7.0",
"Other Revenues": "156",
"Property and Equipment": "13",
"Research and Development": "3,523",
"Selling, General and Administrative Expense": "4,690"
},
"output_variables": {
"Assets": "5,447",
"Liabilities": "901",
"Expenses": "8,228",
"Revenues": "156",
"Stockholders Equity": "4,546",
"Net Income": "-8,079",
"Comprehensive Net Income": "-8,079",
"BaseVar": "7,370",
"ECR before LimitedLiability": "58%",
"Economic Capital Ratio": "195%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "7,165",
"Cost of Goods Sold": "0",
"Intangible Assets": "93",
"Liabilities, Current": "1,251",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "3.0",
"Other Revenues": "95",
"Property and Equipment": "36",
"Research and Development": "3,636",
"Selling, General and Administrative Expense": "4,739"
},
"output_variables": {
"Assets": "7,294",
"Liabilities": "1,251",
"Expenses": "8,375",
"Revenues": "95",
"Stockholders Equity": "6,043",
"Net Income": "-8,277",
"Comprehensive Net Income": "-8,277",
"BaseVar": "8,509",
"ECR before LimitedLiability": "115%",
"Economic Capital Ratio": "242%"
}
}
},
"top_rated": false,
"trend": -4.0,
"value": 2.41588309709433,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000908259.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000908259.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000908259.svg"
},
{
"company_id": "0001578845",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001578845.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001578845.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001578845_main_keyfigs.svg",
"name": "Allergan plc",
"rank": 132,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001578845.svg",
"report_text": "The relative strengths and weaknesses of Allergan plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Allergan plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 109% points.The greatest weakness of Allergan plc is the variable Other Liabilities, reducing the Economic Capital Ratio by 86% points.
The company's Economic Capital Ratio, given in the ranking table, is 239%, being 3.4% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001578845_2014_Allergan_plc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-9.90",
"Assets": "8.75",
"Liabilities": "-45.0",
"Stockholders Equity": "-22.2",
"ECR before LimitedLiability": "24.6",
"Intangible Assets": "109",
"Property and Equipment": "2.35",
"Assets, Current": "-57.7",
"Liabilities, Non-Current": "8.72",
"Liabilities, Current": "25.3",
"Other Liabilities": "-86.2",
"Selling, General and Administrative Expense": "21.9",
"Expenses": "28.5",
"Revenues": "14.8",
"Net Income": "45.1",
"Other Expenses": "-19.3",
"Research and Development": "23.8",
"Cost of Goods Sold": "2.94",
"Other Revenues": "14.8",
"Comprehensive Net Income": "45.0",
"Economic Capital Ratio": "-3.38"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001578845_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "4,434,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "16,432,100",
"Liabilities, Current": "3,294,900",
"Liabilities, Non-Current": "326,200",
"Other Assets": "242,300",
"Other Compr. Net Income": "54,400",
"Other Expenses": "7,569,100",
"Other Liabilities": "9,567,700",
"Other Net Income": "-215,200",
"Other Revenues": "8,677,600",
"Property and Equipment": "1,616,800",
"Research and Development": "616,900",
"Selling, General and Administrative Expense": "1,027,500"
},
"output_variables": {
"Assets": "22,725,900",
"Liabilities": "13,188,800",
"Expenses": "9,213,500",
"Revenues": "8,677,600",
"Stockholders Equity": "9,537,100",
"Net Income": "-751,100",
"Comprehensive Net Income": "-723,900",
"BaseVar": "27,037,700",
"ECR before LimitedLiability": "112%",
"Economic Capital Ratio": "239%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.3938560035575507,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001578845.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001578845.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001578845.svg"
},
{
"company_id": "0001444307",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001444307.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001444307.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001444307.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001444307_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001444307_main_keyfigs.svg",
"name": "Oncosec Medical Inc",
"rank": 133,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001444307.svg",
"report_text": "The relative strengths and weaknesses of Oncosec Medical Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Oncosec Medical Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 73% points.The greatest weakness of Oncosec Medical Inc is the variable Expenses, reducing the Economic Capital Ratio by 48% points.
The company's Economic Capital Ratio, given in the ranking table, is 238%, being 5.0% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001444307_2014_Oncosec_Medical_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-5.54",
"Assets": "97.6",
"Liabilities": "-35.3",
"Stockholders Equity": "71.2",
"ECR before LimitedLiability": "113",
"Assets, Current": "64.7",
"Intangible Assets": "33.7",
"Other Assets": "-7.20",
"Liabilities, Current": "-31.7",
"Other Liabilities": "-14.9",
"Liabilities, Non-Current": "11.2",
"Selling, General and Administrative Expense": "21.4",
"Expenses": "63.2",
"Revenues": "-19.7",
"Net Income": "6.43",
"Research and Development": "22.3",
"Other Expenses": "12.6",
"Other Revenues": "-19.7",
"Comprehensive Net Income": "6.56",
"Other Net Income": "-30.4",
"Economic Capital Ratio": "40.3"
},
"2013": {
"Other Assets": "-16.1",
"Assets": "-25.3",
"Liabilities": "73.4",
"Stockholders Equity": "24.7",
"ECR before LimitedLiability": "23.0",
"Intangible Assets": "12.7",
"Property and Equipment": "-8.56",
"Assets, Current": "-13.5",
"Liabilities, Non-Current": "18.7",
"Liabilities, Current": "6.92",
"Other Liabilities": "50.3",
"Selling, General and Administrative Expense": "-32.9",
"Expenses": "-48.0",
"Revenues": "-33.0",
"Net Income": "-37.5",
"Research and Development": "-19.8",
"Cost of Goods Sold": "4.45",
"Other Revenues": "-33.0",
"Comprehensive Net Income": "-37.9",
"Other Net Income": "49.4",
"Economic Capital Ratio": "-4.97"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001444307_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "5,493",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,859",
"Liabilities, Current": "2,023",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "2.4",
"Other Liabilities": "979",
"Other Net Income": "-2,362",
"Other Revenues": "0",
"Property and Equipment": "77",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "7,429",
"Liabilities": "3,002",
"Expenses": "2.4",
"Revenues": "0",
"Stockholders Equity": "4,426",
"Net Income": "-2,365",
"Comprehensive Net Income": "-2,365",
"BaseVar": "6,398",
"ECR before LimitedLiability": "140%",
"Economic Capital Ratio": "260%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "5,170",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,162",
"Liabilities, Current": "1,771",
"Liabilities, Non-Current": "0",
"Other Assets": "27",
"Other Compr. Net Income": "0",
"Other Expenses": "1,067",
"Other Liabilities": "0",
"Other Net Income": "2,342",
"Other Revenues": "0",
"Property and Equipment": "152",
"Research and Development": "3,159",
"Selling, General and Administrative Expense": "3,906"
},
"output_variables": {
"Assets": "6,510",
"Liabilities": "1,771",
"Expenses": "8,132",
"Revenues": "0",
"Stockholders Equity": "4,739",
"Net Income": "-5,790",
"Comprehensive Net Income": "-5,790",
"BaseVar": "9,377",
"ECR before LimitedLiability": "110%",
"Economic Capital Ratio": "238%"
}
}
},
"top_rated": false,
"trend": -43.0,
"value": 2.377994502251342,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001444307.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001444307.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001444307.svg"
},
{
"company_id": "0000879407",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000879407.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000879407.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000879407.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000879407_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000879407_main_keyfigs.svg",
"name": "Arrowhead Pharmaceuticals INC",
"rank": 134,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000879407.svg",
"report_text": "The relative strengths and weaknesses of Arrowhead Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Arrowhead Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 59% points.The greatest weakness of Arrowhead Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 48% points.
The company's Economic Capital Ratio, given in the ranking table, is 230%, being 13% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000879407_2014_Arrowhead_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "0",
"Assets": "-138",
"Stockholders Equity": "-4.39",
"ECR before LimitedLiability": "-158",
"Intangible Assets": "-3.66",
"Property and Equipment": "-0.832",
"Assets, Current": "-113",
"Other Liabilities": "-0.180",
"Liabilities": "-1.70",
"Liabilities, Non-Current": "-0.0251",
"Liabilities, Current": "-0.521",
"Research and Development": "-0.222",
"Expenses": "-10.6",
"Net Income": "-138",
"Other Expenses": "-0.800",
"Selling, General and Administrative Expense": "-0.0268",
"Other Revenues": "-0.153",
"Revenues": "-0.153",
"Comprehensive Net Income": "-138",
"Other Net Income": "-1.94",
"Economic Capital Ratio": "-234"
},
"2012": {
"Property and Equipment": "0",
"Assets": "-134",
"Stockholders Equity": "-4.11",
"ECR before LimitedLiability": "-147",
"Assets, Current": "-120",
"Intangible Assets": "-1.57",
"Liabilities, Current": "-0.310",
"Liabilities": "-1.14",
"Other Liabilities": "-0.138",
"Liabilities, Non-Current": "0",
"Selling, General and Administrative Expense": "-0.0220",
"Expenses": "-7.47",
"Net Income": "-109",
"Research and Development": "-0.107",
"Other Expenses": "-0.605",
"Cost of Goods Sold": "0",
"Other Revenues": "-0.0682",
"Revenues": "-0.0682",
"Comprehensive Net Income": "-108",
"Other Net Income": "-0.626",
"Economic Capital Ratio": "-220"
},
"2013": {
"Other Assets": "13.7",
"Assets": "31.7",
"Liabilities": "23.3",
"Stockholders Equity": "59.3",
"ECR before LimitedLiability": "15.2",
"Intangible Assets": "-16.6",
"Property and Equipment": "9.03",
"Assets, Current": "27.4",
"Liabilities, Non-Current": "-11.0",
"Liabilities, Current": "-4.08",
"Other Liabilities": "37.4",
"Selling, General and Administrative Expense": "18.2",
"Expenses": "-4.76",
"Revenues": "-24.1",
"Net Income": "-47.8",
"Other Expenses": "-25.8",
"Cost of Goods Sold": "3.32",
"Other Revenues": "-24.1",
"Comprehensive Net Income": "-48.1",
"Other Net Income": "-20.7",
"Economic Capital Ratio": "-12.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000879407_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "9,861",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,582",
"Liabilities, Non-Current": "742",
"Other Assets": "6,002",
"Other Compr. Net Income": "0",
"Other Expenses": "34,099",
"Other Liabilities": "0",
"Other Net Income": "-35,415",
"Other Revenues": "3,992",
"Property and Equipment": "25",
"Research and Development": "40,429",
"Selling, General and Administrative Expense": "25,591"
},
"output_variables": {
"Assets": "15,889",
"Liabilities": "3,324",
"Expenses": "100,119",
"Revenues": "3,992",
"Stockholders Equity": "12,564",
"Net Income": "-131,542",
"Comprehensive Net Income": "-131,542",
"BaseVar": "79,370",
"ECR before LimitedLiability": "-1,084%",
"Economic Capital Ratio": "0.012%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "6,567",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "5,328",
"Liabilities, Non-Current": "2,391",
"Other Assets": "5,065",
"Other Compr. Net Income": "0",
"Other Expenses": "47,383",
"Other Liabilities": "0",
"Other Net Income": "-36,437",
"Other Revenues": "4,139",
"Property and Equipment": "4,896",
"Research and Development": "42,619",
"Selling, General and Administrative Expense": "31,353"
},
"output_variables": {
"Assets": "16,528",
"Liabilities": "7,719",
"Expenses": "121,355",
"Revenues": "4,139",
"Stockholders Equity": "8,809",
"Net Income": "-153,653",
"Comprehensive Net Income": "-153,653",
"BaseVar": "93,089",
"ECR before LimitedLiability": "-1,109%",
"Economic Capital Ratio": "0.0075%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "28,844",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,725",
"Liabilities, Non-Current": "2,870",
"Other Assets": "4,973",
"Other Compr. Net Income": "0",
"Other Expenses": "12,685",
"Other Liabilities": "0",
"Other Net Income": "-7,114",
"Other Revenues": "290",
"Property and Equipment": "3,513",
"Research and Development": "8,706",
"Selling, General and Administrative Expense": "3,489"
},
"output_variables": {
"Assets": "37,330",
"Liabilities": "11,595",
"Expenses": "24,880",
"Revenues": "290",
"Stockholders Equity": "25,735",
"Net Income": "-31,703",
"Comprehensive Net Income": "-31,703",
"BaseVar": "40,604",
"ECR before LimitedLiability": "100%",
"Economic Capital Ratio": "230%"
}
}
},
"top_rated": false,
"trend": 81.0,
"value": 2.2999652487594426,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000879407.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000879407.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000879407.svg"
},
{
"company_id": "0001344413",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001344413.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001344413.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001344413_main_keyfigs.svg",
"name": "Alexza Pharmaceuticals Inc",
"rank": 135,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001344413.svg",
"report_text": "The relative strengths and weaknesses of Alexza Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Alexza Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 89% points.The greatest weakness of Alexza Pharmaceuticals Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 96% points.
The company's Economic Capital Ratio, given in the ranking table, is 229%, being 14% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001344413_2014_Alexza_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "63.7",
"Assets": "34.8",
"Liabilities": "-13.2",
"Stockholders Equity": "24.9",
"ECR before LimitedLiability": "55.4",
"Assets, Current": "-9.02",
"Intangible Assets": "-19.3",
"Other Assets": "-12.3",
"Liabilities, Current": "-68.3",
"Other Liabilities": "33.8",
"Liabilities, Non-Current": "15.7",
"Expenses": "-5.54",
"Revenues": "-20.2",
"Net Income": "-16.7",
"Research and Development": "-27.1",
"Other Expenses": "16.2",
"Cost of Goods Sold": "5.18",
"Other Revenues": "-20.2",
"Comprehensive Net Income": "-16.5",
"Other Net Income": "9.36",
"Economic Capital Ratio": "-17.7"
},
"2013": {
"Other Assets": "-20.1",
"Assets": "-81.6",
"Liabilities": "89.1",
"Stockholders Equity": "-59.6",
"ECR before LimitedLiability": "14.2",
"Intangible Assets": "-29.8",
"Property and Equipment": "57.9",
"Assets, Current": "-76.6",
"Liabilities, Non-Current": "26.2",
"Liabilities, Current": "34.2",
"Other Liabilities": "69.6",
"Selling, General and Administrative Expense": "15.7",
"Expenses": "-71.6",
"Revenues": "81.3",
"Comprehensive Net Income": "-2.77",
"Other Expenses": "-95.6",
"Research and Development": "7.03",
"Cost of Goods Sold": "6.42",
"Other Revenues": "81.3",
"Other Net Income": "3.37",
"Economic Capital Ratio": "-13.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001344413_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "23,618",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "18,718",
"Liabilities, Non-Current": "0",
"Other Assets": "402",
"Other Compr. Net Income": "0",
"Other Expenses": "1,426",
"Other Liabilities": "0",
"Other Net Income": "2,320",
"Other Revenues": "4,070",
"Property and Equipment": "16,531",
"Research and Development": "21,849",
"Selling, General and Administrative Expense": "11,093"
},
"output_variables": {
"Assets": "40,551",
"Liabilities": "18,718",
"Expenses": "34,368",
"Revenues": "4,070",
"Stockholders Equity": "21,833",
"Net Income": "-27,978",
"Comprehensive Net Income": "-27,978",
"BaseVar": "50,014",
"ECR before LimitedLiability": "66%",
"Economic Capital Ratio": "202%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "30,913",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "14,898",
"Liabilities, Non-Current": "0",
"Other Assets": "1,168",
"Other Compr. Net Income": "0",
"Other Expenses": "52,620",
"Other Liabilities": "0",
"Other Net Income": "26",
"Other Revenues": "47,839",
"Property and Equipment": "14,991",
"Research and Development": "19,082",
"Selling, General and Administrative Expense": "15,778"
},
"output_variables": {
"Assets": "47,072",
"Liabilities": "14,898",
"Expenses": "87,480",
"Revenues": "47,839",
"Stockholders Equity": "32,174",
"Net Income": "-39,615",
"Comprehensive Net Income": "-39,615",
"BaseVar": "98,658",
"ECR before LimitedLiability": "99%",
"Economic Capital Ratio": "229%"
}
}
},
"top_rated": false,
"trend": -12.0,
"value": 2.2902416786311917,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001344413.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001344413.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001344413.svg"
},
{
"company_id": "0001473579",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001473579.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001473579.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001473579_main_keyfigs.svg",
"name": "Nanomix Corp",
"rank": 136,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001473579.svg",
"report_text": "The relative strengths and weaknesses of Nanomix Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Nanomix Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 61% points.The greatest weakness of Nanomix Corp is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 65% points.
The company's Economic Capital Ratio, given in the ranking table, is 225%, being 17% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001473579_2014_Nanomix_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-18.8",
"Assets": "12.0",
"Liabilities": "-76.0",
"Stockholders Equity": "-24.3",
"ECR before LimitedLiability": "-7.06",
"Intangible Assets": "79.1",
"Property and Equipment": "-15.8",
"Assets, Current": "-68.8",
"Other Liabilities": "-32.7",
"Liabilities, Non-Current": "10.4",
"Liabilities, Current": "-53.6",
"Research and Development": "10.5",
"Expenses": "3.34",
"Revenues": "-33.5",
"Net Income": "-27.9",
"Other Expenses": "-11.1",
"Cost of Goods Sold": "4.49",
"Selling, General and Administrative Expense": "-9.11",
"Other Revenues": "-33.5",
"Comprehensive Net Income": "-28.2",
"Economic Capital Ratio": "-82.6"
},
"2012": {
"Property and Equipment": "-17.8",
"Assets": "3.78",
"Liabilities": "-21.7",
"Stockholders Equity": "3.13",
"ECR before LimitedLiability": "-2.83",
"Assets, Current": "-56.1",
"Intangible Assets": "40.1",
"Other Assets": "-19.2",
"Liabilities, Current": "-14.4",
"Other Liabilities": "-24.2",
"Liabilities, Non-Current": "3.32",
"Selling, General and Administrative Expense": "-51.5",
"Expenses": "-27.4",
"Revenues": "-33.3",
"Net Income": "-56.1",
"Research and Development": "3.68",
"Other Expenses": "-4.41",
"Cost of Goods Sold": "3.14",
"Other Revenues": "-33.3",
"Comprehensive Net Income": "-55.9",
"Economic Capital Ratio": "-75.9"
},
"2013": {
"Other Assets": "-15.5",
"Assets": "8.33",
"Liabilities": "52.8",
"Stockholders Equity": "60.7",
"ECR before LimitedLiability": "10.6",
"Intangible Assets": "16.3",
"Property and Equipment": "-11.1",
"Assets, Current": "24.1",
"Liabilities, Non-Current": "15.9",
"Liabilities, Current": "16.4",
"Other Liabilities": "22.3",
"Selling, General and Administrative Expense": "-65.4",
"Expenses": "-46.3",
"Revenues": "-20.6",
"Net Income": "-63.1",
"Research and Development": "19.3",
"Cost of Goods Sold": "3.89",
"Other Revenues": "-20.6",
"Comprehensive Net Income": "-63.3",
"Other Net Income": "1.96",
"Economic Capital Ratio": "-17.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001473579_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "255",
"Cost of Goods Sold": "0",
"Intangible Assets": "895",
"Liabilities, Current": "467",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "229",
"Other Liabilities": "258",
"Other Net Income": "0",
"Other Revenues": "4.1",
"Property and Equipment": "0",
"Research and Development": "194",
"Selling, General and Administrative Expense": "408"
},
"output_variables": {
"Assets": "1,150",
"Liabilities": "725",
"Expenses": "831",
"Revenues": "4.1",
"Stockholders Equity": "425",
"Net Income": "-827",
"Comprehensive Net Income": "-827",
"BaseVar": "1,355",
"ECR before LimitedLiability": "11%",
"Economic Capital Ratio": "151%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "596",
"Cost of Goods Sold": "0",
"Intangible Assets": "830",
"Liabilities, Current": "441",
"Liabilities, Non-Current": "0",
"Other Assets": "2.1",
"Other Compr. Net Income": "0",
"Other Expenses": "308",
"Other Liabilities": "298",
"Other Net Income": "-3.2",
"Other Revenues": "42",
"Property and Equipment": "7.1",
"Research and Development": "179",
"Selling, General and Administrative Expense": "1,037"
},
"output_variables": {
"Assets": "1,435",
"Liabilities": "739",
"Expenses": "1,523",
"Revenues": "42",
"Stockholders Equity": "696",
"Net Income": "-1,484",
"Comprehensive Net Income": "-1,484",
"BaseVar": "1,871",
"ECR before LimitedLiability": "3.1%",
"Economic Capital Ratio": "144%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "3,752",
"Cost of Goods Sold": "0",
"Intangible Assets": "766",
"Liabilities, Current": "892",
"Liabilities, Non-Current": "0",
"Other Assets": "2.1",
"Other Compr. Net Income": "0",
"Other Expenses": "627",
"Other Liabilities": "298",
"Other Net Income": "-1.6",
"Other Revenues": "323",
"Property and Equipment": "15",
"Research and Development": "542",
"Selling, General and Administrative Expense": "3,754"
},
"output_variables": {
"Assets": "4,535",
"Liabilities": "1,190",
"Expenses": "4,923",
"Revenues": "323",
"Stockholders Equity": "3,345",
"Net Income": "-4,602",
"Comprehensive Net Income": "-4,602",
"BaseVar": "5,487",
"ECR before LimitedLiability": "94%",
"Economic Capital Ratio": "225%"
}
}
},
"top_rated": false,
"trend": 10.0,
"value": 2.254361949466177,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001473579.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001473579.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001473579.svg"
},
{
"company_id": "0001133416",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001133416.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001133416.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001133416.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001133416_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001133416_main_keyfigs.svg",
"name": "Galectin Therapeutics INC",
"rank": 137,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001133416.svg",
"report_text": "The relative strengths and weaknesses of Galectin Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Galectin Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 80% points.The greatest weakness of Galectin Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 79% points.
The company's Economic Capital Ratio, given in the ranking table, is 221%, being 22% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001133416_2014_Galectin_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-1.02",
"Assets": "-0.862",
"Liabilities": "3.84",
"Stockholders Equity": "2.33",
"ECR before LimitedLiability": "-18.5",
"Intangible Assets": "-11.4",
"Property and Equipment": "-1.01",
"Assets, Current": "18.2",
"Other Liabilities": "3.99",
"Liabilities, Non-Current": "1.41",
"Liabilities, Current": "-0.890",
"Research and Development": "-0.851",
"Expenses": "-59.8",
"Revenues": "-26.1",
"Net Income": "-110",
"Other Expenses": "1.78",
"Cost of Goods Sold": "0.533",
"Selling, General and Administrative Expense": "-67.6",
"Other Revenues": "-26.1",
"Comprehensive Net Income": "-111",
"Economic Capital Ratio": "-94.0"
},
"2012": {
"Property and Equipment": "-10.8",
"Assets": "55.4",
"Liabilities": "68.8",
"Stockholders Equity": "117",
"ECR before LimitedLiability": "110",
"Assets, Current": "118",
"Intangible Assets": "-14.7",
"Other Assets": "-11.1",
"Liabilities, Current": "17.4",
"Other Liabilities": "37.1",
"Liabilities, Non-Current": "17.1",
"Selling, General and Administrative Expense": "-36.4",
"Expenses": "-37.5",
"Revenues": "-30.5",
"Net Income": "-61.3",
"Research and Development": "-24.9",
"Other Expenses": "19.9",
"Other Revenues": "-30.5",
"Comprehensive Net Income": "-61.1",
"Other Net Income": "5.44",
"Economic Capital Ratio": "37.1"
},
"2013": {
"Other Assets": "-16.1",
"Assets": "14.5",
"Liabilities": "60.5",
"Stockholders Equity": "77.9",
"ECR before LimitedLiability": "6.26",
"Intangible Assets": "-19.7",
"Property and Equipment": "-12.0",
"Assets, Current": "80.3",
"Liabilities, Non-Current": "16.0",
"Liabilities, Current": "2.84",
"Other Liabilities": "43.2",
"Selling, General and Administrative Expense": "-42.1",
"Expenses": "-54.9",
"Revenues": "-29.4",
"Net Income": "-79.0",
"Other Expenses": "17.5",
"Research and Development": "-33.9",
"Cost of Goods Sold": "3.94",
"Other Revenues": "-29.4",
"Comprehensive Net Income": "-79.2",
"Economic Capital Ratio": "-21.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001133416_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,501",
"Cost of Goods Sold": "0",
"Intangible Assets": "36",
"Liabilities, Current": "2,215",
"Liabilities, Non-Current": "0",
"Other Assets": "69",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-506",
"Other Revenues": "0",
"Property and Equipment": "6.0",
"Research and Development": "3,552",
"Selling, General and Administrative Expense": "6,857"
},
"output_variables": {
"Assets": "6,612",
"Liabilities": "2,215",
"Expenses": "10,409",
"Revenues": "0",
"Stockholders Equity": "4,397",
"Net Income": "-10,915",
"Comprehensive Net Income": "-10,915",
"BaseVar": "9,871",
"ECR before LimitedLiability": "-30%",
"Economic Capital Ratio": "140%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "9,517",
"Cost of Goods Sold": "0",
"Intangible Assets": "30",
"Liabilities, Current": "1,638",
"Liabilities, Non-Current": "6.0",
"Other Assets": "6.0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "224",
"Other Revenues": "0",
"Property and Equipment": "8.0",
"Research and Development": "4,527",
"Selling, General and Administrative Expense": "5,372"
},
"output_variables": {
"Assets": "9,561",
"Liabilities": "1,644",
"Expenses": "9,899",
"Revenues": "0",
"Stockholders Equity": "7,917",
"Net Income": "-9,675",
"Comprehensive Net Income": "-9,675",
"BaseVar": "10,664",
"ECR before LimitedLiability": "135%",
"Economic Capital Ratio": "257%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "10,687",
"Cost of Goods Sold": "0",
"Intangible Assets": "23",
"Liabilities, Current": "2,486",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "16",
"Other Revenues": "0",
"Property and Equipment": "3.0",
"Research and Development": "5,688",
"Selling, General and Administrative Expense": "6,416"
},
"output_variables": {
"Assets": "10,713",
"Liabilities": "2,486",
"Expenses": "12,104",
"Revenues": "0",
"Stockholders Equity": "8,227",
"Net Income": "-12,088",
"Comprehensive Net Income": "-12,088",
"BaseVar": "12,660",
"ECR before LimitedLiability": "89%",
"Economic Capital Ratio": "221%"
}
}
},
"top_rated": false,
"trend": -45.0,
"value": 2.2105840869831686,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001133416.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001133416.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001133416.svg"
},
{
"company_id": "0001302573",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001302573.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001302573.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001302573_main_keyfigs.svg",
"name": "Oncomed Pharmaceuticals Inc",
"rank": 138,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001302573.svg",
"report_text": "The relative strengths and weaknesses of Oncomed Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Oncomed Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 77% points.The greatest weakness of Oncomed Pharmaceuticals Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 102% points.
The company's Economic Capital Ratio, given in the ranking table, is 218%, being 25% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001302573_2014_Oncomed_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-5.46",
"Assets": "48.4",
"Liabilities": "-85.5",
"Stockholders Equity": "-16.6",
"ECR before LimitedLiability": "2.73",
"Intangible Assets": "-13.2",
"Property and Equipment": "-5.53",
"Assets, Current": "76.8",
"Liabilities, Non-Current": "9.94",
"Liabilities, Current": "3.22",
"Other Liabilities": "-102",
"Selling, General and Administrative Expense": "18.4",
"Expenses": "39.1",
"Revenues": "-7.73",
"Net Income": "31.8",
"Other Expenses": "10.2",
"Research and Development": "6.59",
"Cost of Goods Sold": "2.45",
"Other Revenues": "-7.73",
"Comprehensive Net Income": "31.5",
"Economic Capital Ratio": "-25.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001302573_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "318,744",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "62,017",
"Liabilities, Non-Current": "0",
"Other Assets": "10,300",
"Other Compr. Net Income": "-1.0",
"Other Expenses": "1,944",
"Other Liabilities": "153,546",
"Other Net Income": "-228",
"Other Revenues": "37,779",
"Property and Equipment": "4,641",
"Research and Development": "50,048",
"Selling, General and Administrative Expense": "11,630"
},
"output_variables": {
"Assets": "333,685",
"Liabilities": "215,563",
"Expenses": "63,622",
"Revenues": "37,779",
"Stockholders Equity": "118,122",
"Net Income": "-26,071",
"Comprehensive Net Income": "-26,072",
"BaseVar": "325,439",
"ECR before LimitedLiability": "84%",
"Economic Capital Ratio": "218%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.1753028842606907,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001302573.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001302573.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001302573.svg"
},
{
"company_id": "0001533040",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001533040.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001533040.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001533040.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001533040_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001533040_main_keyfigs.svg",
"name": "Phio Pharmaceuticals Corp",
"rank": 139,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001533040.svg",
"report_text": "The relative strengths and weaknesses of Phio Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Phio Pharmaceuticals Corp compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 77% points.The greatest weakness of Phio Pharmaceuticals Corp is the variable Research and Development, reducing the Economic Capital Ratio by 112% points.
The company's Economic Capital Ratio, given in the ranking table, is 217%, being 26% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001533040_2014_Phio_Pharmaceuticals_Corp.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "0",
"Assets": "-139",
"Stockholders Equity": "0",
"ECR before LimitedLiability": "-147",
"Assets, Current": "-99.9",
"Intangible Assets": "0",
"Other Assets": "0",
"Liabilities, Current": "0",
"Liabilities": "-0.0789",
"Other Liabilities": "0",
"Liabilities, Non-Current": "0",
"Selling, General and Administrative Expense": "0",
"Expenses": "-12.1",
"Net Income": "-31.1",
"Research and Development": "-0.0292",
"Other Expenses": "0",
"Other Revenues": "0",
"Revenues": "0",
"Comprehensive Net Income": "-30.6",
"Other Net Income": "0",
"Economic Capital Ratio": "-220"
},
"2013": {
"Other Assets": "-19.0",
"Assets": "-8.20",
"Liabilities": "77.0",
"Stockholders Equity": "76.7",
"Economic Capital Ratio": "-25.8",
"Intangible Assets": "-24.0",
"Property and Equipment": "-11.9",
"Assets, Current": "69.9",
"Liabilities, Non-Current": "19.0",
"Liabilities, Current": "44.9",
"Other Liabilities": "51.0",
"Selling, General and Administrative Expense": "5.67",
"Expenses": "-87.6",
"Revenues": "-31.5",
"Net Income": "-112",
"Other Expenses": "21.1",
"Research and Development": "-112",
"Cost of Goods Sold": "4.74",
"Other Revenues": "-31.5",
"Comprehensive Net Income": "-112",
"Other Net Income": "2.67"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001533040_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "5,392",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,679",
"Liabilities, Non-Current": "0",
"Other Assets": "2.0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "27",
"Other Net Income": "7,039",
"Other Revenues": "97",
"Property and Equipment": "198",
"Research and Development": "56,182",
"Selling, General and Administrative Expense": "39,837"
},
"output_variables": {
"Assets": "5,592",
"Liabilities": "1,706",
"Expenses": "96,019",
"Revenues": "97",
"Stockholders Equity": "3,886",
"Net Income": "-88,883",
"Comprehensive Net Income": "-88,883",
"BaseVar": "55,226",
"ECR before LimitedLiability": "-2,204%",
"Economic Capital Ratio": "0.0000000000000019%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "14,743",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,076",
"Liabilities, Non-Current": "0",
"Other Assets": "18",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "24",
"Other Revenues": "399",
"Property and Equipment": "177",
"Research and Development": "17,651",
"Selling, General and Administrative Expense": "3,697"
},
"output_variables": {
"Assets": "14,938",
"Liabilities": "2,076",
"Expenses": "21,348",
"Revenues": "399",
"Stockholders Equity": "12,862",
"Net Income": "-20,925",
"Comprehensive Net Income": "-20,925",
"BaseVar": "19,392",
"ECR before LimitedLiability": "84%",
"Economic Capital Ratio": "217%"
}
}
},
"top_rated": false,
"trend": 78.0,
"value": 2.1699990185918283,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001533040.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001533040.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001533040.svg"
},
{
"company_id": "0001059790",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001059790.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001059790.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001059790_main_keyfigs.svg",
"name": "Pozen INC NC",
"rank": 140,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001059790.svg",
"report_text": "The relative strengths and weaknesses of Pozen INC NC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Pozen INC NC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 56% points.The greatest weakness of Pozen INC NC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 73% points.
The company's Economic Capital Ratio, given in the ranking table, is 217%, being 26% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001059790_2014_Pozen_INC_NC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-1.85",
"Assets": "7.06",
"Liabilities": "91.4",
"Stockholders Equity": "114",
"ECR before LimitedLiability": "278",
"Intangible Assets": "-2.41",
"Assets, Current": "19.5",
"Other Liabilities": "48.1",
"Liabilities, Non-Current": "21.8",
"Liabilities, Current": "35.7",
"Research and Development": "15.7",
"Expenses": "42.8",
"Revenues": "55.0",
"Net Income": "97.4",
"Other Expenses": "12.9",
"Cost of Goods Sold": "4.60",
"Selling, General and Administrative Expense": "10.8",
"Other Revenues": "55.0",
"Comprehensive Net Income": "97.1",
"Other Net Income": "2.99",
"Economic Capital Ratio": "202"
},
"2012": {
"Property and Equipment": "-2.59",
"Assets": "58.8",
"Liabilities": "76.6",
"Stockholders Equity": "197",
"ECR before LimitedLiability": "244",
"Assets, Current": "99.7",
"Intangible Assets": "-3.72",
"Other Assets": "-2.71",
"Liabilities, Current": "37.9",
"Other Liabilities": "32.4",
"Liabilities, Non-Current": "15.5",
"Selling, General and Administrative Expense": "-5.40",
"Expenses": "16.9",
"Revenues": "-13.9",
"Net Income": "5.38",
"Research and Development": "5.84",
"Other Expenses": "13.1",
"Cost of Goods Sold": "3.39",
"Other Revenues": "-13.9",
"Comprehensive Net Income": "5.54",
"Economic Capital Ratio": "170"
},
"2013": {
"Other Assets": "-14.8",
"Assets": "-3.49",
"Liabilities": "-12.9",
"Stockholders Equity": "-14.8",
"ECR before LimitedLiability": "2.08",
"Intangible Assets": "-18.6",
"Property and Equipment": "-10.9",
"Assets, Current": "56.5",
"Liabilities, Non-Current": "14.3",
"Liabilities, Current": "-72.6",
"Other Liabilities": "38.7",
"Selling, General and Administrative Expense": "-21.7",
"Expenses": "-3.29",
"Revenues": "4.51",
"Net Income": "3.25",
"Other Expenses": "15.7",
"Cost of Goods Sold": "3.55",
"Other Revenues": "4.51",
"Comprehensive Net Income": "2.94",
"Other Net Income": "2.06",
"Economic Capital Ratio": "-25.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001059790_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "121,450",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "16,055",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "161",
"Other Revenues": "86,951",
"Property and Equipment": "103",
"Research and Development": "23,020",
"Selling, General and Administrative Expense": "21,752"
},
"output_variables": {
"Assets": "121,553",
"Liabilities": "16,055",
"Expenses": "44,772",
"Revenues": "86,951",
"Stockholders Equity": "105,498",
"Net Income": "42,340",
"Comprehensive Net Income": "42,340",
"BaseVar": "134,746",
"ECR before LimitedLiability": "396%",
"Economic Capital Ratio": "436%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "89,525",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "5,519",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "14",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "259",
"Other Revenues": "5,349",
"Property and Equipment": "72",
"Research and Development": "11,867",
"Selling, General and Administrative Expense": "19,024"
},
"output_variables": {
"Assets": "89,597",
"Liabilities": "5,519",
"Expenses": "30,891",
"Revenues": "5,349",
"Stockholders Equity": "84,077",
"Net Income": "-25,283",
"Comprehensive Net Income": "-25,276",
"BaseVar": "65,815",
"ECR before LimitedLiability": "332%",
"Economic Capital Ratio": "391%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "35,295",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "17,546",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "3.3",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "76",
"Other Revenues": "10,322",
"Property and Equipment": "39",
"Research and Development": "9,945",
"Selling, General and Administrative Expense": "17,161"
},
"output_variables": {
"Assets": "35,334",
"Liabilities": "17,546",
"Expenses": "27,106",
"Revenues": "10,322",
"Stockholders Equity": "17,789",
"Net Income": "-16,708",
"Comprehensive Net Income": "-16,707",
"BaseVar": "45,193",
"ECR before LimitedLiability": "83%",
"Economic Capital Ratio": "217%"
}
}
},
"top_rated": false,
"trend": -123.0,
"value": 2.168809490871481,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001059790.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001059790.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001059790.svg"
},
{
"company_id": "0001295947",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001295947.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001295947.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001295947_main_keyfigs.svg",
"name": "Prestige Consumer Healthcare Inc",
"rank": 141,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001295947.svg",
"report_text": "The relative strengths and weaknesses of Prestige Consumer Healthcare Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Prestige Consumer Healthcare Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 116% points.The greatest weakness of Prestige Consumer Healthcare Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 152% points.
The company's Economic Capital Ratio, given in the ranking table, is 209%, being 34% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001295947_2014_Prestige_Consumer_Healthcare_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-10.6",
"Assets": "7.82",
"Liabilities": "-81.0",
"Stockholders Equity": "-51.0",
"ECR before LimitedLiability": "-5.98",
"Intangible Assets": "116",
"Property and Equipment": "-8.70",
"Assets, Current": "-73.5",
"Liabilities, Non-Current": "-152",
"Liabilities, Current": "44.9",
"Other Liabilities": "5.14",
"Selling, General and Administrative Expense": "23.7",
"Expenses": "43.5",
"Revenues": "12.1",
"Net Income": "53.3",
"Other Expenses": "-10.6",
"Research and Development": "26.9",
"Other Revenues": "12.1",
"Comprehensive Net Income": "53.0",
"Other Net Income": "-3.27",
"Economic Capital Ratio": "-33.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001295947_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "164,173",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,540,786",
"Liabilities, Current": "96,668",
"Liabilities, Non-Current": "970,900",
"Other Assets": "24,944",
"Other Compr. Net Income": "-91",
"Other Expenses": "420,775",
"Other Liabilities": "194,288",
"Other Net Income": "-85,850",
"Other Revenues": "623,597",
"Property and Equipment": "9,896",
"Research and Development": "0",
"Selling, General and Administrative Expense": "51,467"
},
"output_variables": {
"Assets": "1,739,799",
"Liabilities": "1,261,856",
"Expenses": "472,242",
"Revenues": "623,597",
"Stockholders Equity": "477,943",
"Net Income": "65,505",
"Comprehensive Net Income": "65,460",
"BaseVar": "2,091,718",
"ECR before LimitedLiability": "74%",
"Economic Capital Ratio": "209%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.088205234198139,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001295947.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001295947.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001295947.svg"
},
{
"company_id": "0000704562",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000704562.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000704562.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000704562.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000704562_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000704562_main_keyfigs.svg",
"name": "Avid Bioservices Inc",
"rank": 142,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000704562.svg",
"report_text": "The relative strengths and weaknesses of Avid Bioservices Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Avid Bioservices Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 48% points.The greatest weakness of Avid Bioservices Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 43% points.
The company's Economic Capital Ratio, given in the ranking table, is 207%, being 35% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000704562_2014_Avid_Bioservices_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-15.9",
"Assets": "-40.8",
"Liabilities": "2.86",
"Stockholders Equity": "-44.0",
"Intangible Assets": "-35.3",
"Property and Equipment": "-7.87",
"Assets, Current": "11.7",
"Other Liabilities": "12.6",
"Liabilities, Non-Current": "11.7",
"Liabilities, Current": "-62.5",
"Research and Development": "-46.4",
"Expenses": "-41.7",
"Net Income": "-37.8",
"Other Net Income": "4.17",
"Other Expenses": "-9.72",
"Cost of Goods Sold": "6.85",
"Selling, General and Administrative Expense": "8.40",
"ECR before LimitedLiability": "-5.80",
"Comprehensive Net Income": "-38.2",
"Other Compr. Net Income": "-0.526",
"Economic Capital Ratio": "-81.4"
},
"2012": {
"Assets": "-39.1",
"Liabilities": "3.41",
"Stockholders Equity": "-26.3",
"ECR before LimitedLiability": "-13.5",
"Assets, Current": "-6.55",
"Intangible Assets": "-6.15",
"Other Assets": "-4.37",
"Liabilities, Current": "-6.45",
"Other Liabilities": "8.27",
"Liabilities, Non-Current": "3.69",
"Selling, General and Administrative Expense": "1.89",
"Expenses": "-7.50",
"Revenues": "1.54",
"Net Income": "-7.31",
"Research and Development": "-17.8",
"Other Expenses": "-1.49",
"Cost of Goods Sold": "1.70",
"Other Revenues": "1.54",
"Comprehensive Net Income": "-7.29",
"Other Net Income": "0.821",
"Economic Capital Ratio": "-86.5"
},
"2013": {
"Other Assets": "-17.3",
"Assets": "-39.9",
"Liabilities": "25.9",
"Stockholders Equity": "-34.1",
"ECR before LimitedLiability": "-7.48",
"Intangible Assets": "-23.9",
"Property and Equipment": "-2.92",
"Liabilities, Non-Current": "17.8",
"Liabilities, Current": "-43.5",
"Other Liabilities": "47.9",
"Selling, General and Administrative Expense": "5.83",
"Expenses": "-24.7",
"Revenues": "22.0",
"Net Income": "-6.13",
"Other Expenses": "-12.7",
"Research and Development": "-22.2",
"Cost of Goods Sold": "4.54",
"Other Revenues": "22.0",
"Comprehensive Net Income": "-6.52",
"Other Net Income": "-2.03",
"Economic Capital Ratio": "-35.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000704562_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "30,815",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "17,679",
"Liabilities, Non-Current": "0",
"Other Assets": "1,742",
"Other Compr. Net Income": "0",
"Other Expenses": "7,812",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "14,544",
"Property and Equipment": "2,209",
"Research and Development": "29,462",
"Selling, General and Administrative Expense": "11,421"
},
"output_variables": {
"Assets": "34,766",
"Liabilities": "17,679",
"Expenses": "48,695",
"Revenues": "14,544",
"Stockholders Equity": "17,087",
"Net Income": "-34,151",
"Comprehensive Net Income": "-34,151",
"BaseVar": "57,842",
"ECR before LimitedLiability": "12%",
"Economic Capital Ratio": "153%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "24,792",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "17,639",
"Liabilities, Non-Current": "0",
"Other Assets": "570",
"Other Compr. Net Income": "0",
"Other Expenses": "10,243",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "15,274",
"Property and Equipment": "2,900",
"Research and Development": "35,688",
"Selling, General and Administrative Expense": "11,462"
},
"output_variables": {
"Assets": "28,262",
"Liabilities": "17,639",
"Expenses": "57,393",
"Revenues": "15,274",
"Stockholders Equity": "10,623",
"Net Income": "-42,119",
"Comprehensive Net Income": "-42,119",
"BaseVar": "59,284",
"ECR before LimitedLiability": "-83%",
"Economic Capital Ratio": "134%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "41,914",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "20,561",
"Liabilities, Non-Current": "0",
"Other Assets": "466",
"Other Compr. Net Income": "0",
"Other Expenses": "12,649",
"Other Liabilities": "0",
"Other Net Income": "-1,696",
"Other Revenues": "22,005",
"Property and Equipment": "2,678",
"Research and Development": "24,306",
"Selling, General and Administrative Expense": "13,134"
},
"output_variables": {
"Assets": "45,058",
"Liabilities": "20,561",
"Expenses": "50,089",
"Revenues": "22,005",
"Stockholders Equity": "24,497",
"Net Income": "-29,780",
"Comprehensive Net Income": "-29,780",
"BaseVar": "69,704",
"ECR before LimitedLiability": "72%",
"Economic Capital Ratio": "207%"
}
}
},
"top_rated": false,
"trend": 19.0,
"value": 2.073191094493555,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000704562.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000704562.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000704562.svg"
},
{
"company_id": "0001036968",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001036968.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001036968.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001036968_main_keyfigs.svg",
"name": "Diadexus Inc",
"rank": 143,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001036968.svg",
"report_text": "The relative strengths and weaknesses of Diadexus Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Diadexus Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 66% points.The greatest weakness of Diadexus Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 104% points.
The company's Economic Capital Ratio, given in the ranking table, is 207%, being 36% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001036968_2014_Diadexus_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.78",
"Assets": "-21.3",
"Liabilities": "-12.2",
"Stockholders Equity": "-37.9",
"ECR before LimitedLiability": "63.2",
"Intangible Assets": "-23.0",
"Property and Equipment": "-6.04",
"Assets, Current": "15.4",
"Other Liabilities": "-58.7",
"Liabilities, Non-Current": "13.4",
"Liabilities, Current": "28.8",
"Research and Development": "25.8",
"Expenses": "3.87",
"Revenues": "29.8",
"Net Income": "38.0",
"Other Expenses": "-24.1",
"Cost of Goods Sold": "5.36",
"Other Revenues": "29.8",
"Comprehensive Net Income": "37.5",
"Other Net Income": "3.59",
"Economic Capital Ratio": "-12.3"
},
"2012": {
"Property and Equipment": "-6.77",
"Assets": "-40.3",
"Liabilities": "16.9",
"Stockholders Equity": "-49.2",
"ECR before LimitedLiability": "85.5",
"Assets, Current": "-13.0",
"Intangible Assets": "-21.9",
"Other Assets": "-4.96",
"Liabilities, Current": "49.9",
"Other Liabilities": "-56.1",
"Liabilities, Non-Current": "17.3",
"Selling, General and Administrative Expense": "8.34",
"Expenses": "6.06",
"Revenues": "65.1",
"Net Income": "76.4",
"Research and Development": "25.6",
"Other Expenses": "-32.2",
"Cost of Goods Sold": "6.73",
"Other Revenues": "65.1",
"Comprehensive Net Income": "76.8",
"Economic Capital Ratio": "12.4"
},
"2013": {
"Other Assets": "-10.9",
"Assets": "-69.4",
"Liabilities, Non-Current": "15.1",
"Stockholders Equity": "-104",
"ECR before LimitedLiability": "-7.86",
"Intangible Assets": "-25.9",
"Property and Equipment": "-9.09",
"Assets, Current": "-41.5",
"Selling, General and Administrative Expense": "11.7",
"Expenses": "-3.26",
"Revenues": "66.0",
"Net Income": "66.0",
"Other Expenses": "-40.7",
"Research and Development": "24.1",
"Cost of Goods Sold": "4.97",
"Other Revenues": "66.0",
"Liabilities, Current": "29.8",
"Other Liabilities": "-45.8",
"Comprehensive Net Income": "66.0",
"Other Net Income": "4.03",
"Economic Capital Ratio": "-35.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001036968_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "21,180",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,546",
"Liabilities, Non-Current": "284",
"Other Assets": "1,825",
"Other Compr. Net Income": "0",
"Other Expenses": "9,260",
"Other Liabilities": "8,385",
"Other Net Income": "75",
"Other Revenues": "16,384",
"Property and Equipment": "1,350",
"Research and Development": "5,138",
"Selling, General and Administrative Expense": "9,544"
},
"output_variables": {
"Assets": "24,355",
"Liabilities": "13,215",
"Expenses": "23,942",
"Revenues": "16,384",
"Stockholders Equity": "11,140",
"Net Income": "-7,483",
"Comprehensive Net Income": "-7,483",
"BaseVar": "38,986",
"ECR before LimitedLiability": "89%",
"Economic Capital Ratio": "222%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "17,692",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,599",
"Liabilities, Non-Current": "346",
"Other Assets": "1,542",
"Other Compr. Net Income": "5.0",
"Other Expenses": "12,158",
"Other Liabilities": "7,684",
"Other Net Income": "6.0",
"Other Revenues": "20,776",
"Property and Equipment": "1,250",
"Research and Development": "4,196",
"Selling, General and Administrative Expense": "7,217"
},
"output_variables": {
"Assets": "20,484",
"Liabilities": "11,629",
"Expenses": "23,571",
"Revenues": "20,776",
"Stockholders Equity": "8,855",
"Net Income": "-2,789",
"Comprehensive Net Income": "-2,786",
"BaseVar": "38,236",
"ECR before LimitedLiability": "103%",
"Economic Capital Ratio": "232%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "21,179",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,553",
"Liabilities, Non-Current": "414",
"Other Assets": "1,500",
"Other Compr. Net Income": "0",
"Other Expenses": "15,197",
"Other Liabilities": "9,160",
"Other Net Income": "344",
"Other Revenues": "24,884",
"Property and Equipment": "968",
"Research and Development": "4,709",
"Selling, General and Administrative Expense": "7,486"
},
"output_variables": {
"Assets": "23,647",
"Liabilities": "16,127",
"Expenses": "27,392",
"Revenues": "24,884",
"Stockholders Equity": "7,520",
"Net Income": "-2,164",
"Comprehensive Net Income": "-2,164",
"BaseVar": "46,197",
"ECR before LimitedLiability": "72%",
"Economic Capital Ratio": "207%"
}
}
},
"top_rated": false,
"trend": -32.0,
"value": 2.06939380230994,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001036968.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001036968.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001036968.svg"
},
{
"company_id": "0001420720",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001420720.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001420720.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001420720.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001420720_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001420720_main_keyfigs.svg",
"name": "iBio Inc",
"rank": 144,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001420720.svg",
"report_text": "The relative strengths and weaknesses of iBio Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of iBio Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 49% points.The greatest weakness of iBio Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 66% points.
The company's Economic Capital Ratio, given in the ranking table, is 207%, being 36% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001420720_2014_iBio_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-13.5",
"Assets": "-6.49",
"Liabilities": "39.9",
"Stockholders Equity": "24.4",
"ECR before LimitedLiability": "95.9",
"Assets, Current": "-8.10",
"Intangible Assets": "37.9",
"Other Assets": "-13.9",
"Liabilities, Current": "-23.5",
"Other Liabilities": "42.4",
"Liabilities, Non-Current": "19.8",
"Selling, General and Administrative Expense": "-24.9",
"Expenses": "-14.1",
"Revenues": "-22.1",
"Net Income": "8.33",
"Research and Development": "-16.5",
"Other Expenses": "23.0",
"Other Revenues": "-22.1",
"Comprehensive Net Income": "8.58",
"Other Net Income": "48.5",
"Economic Capital Ratio": "22.8"
},
"2013": {
"Other Assets": "-15.4",
"Assets": "6.56",
"Liabilities": "-8.27",
"ECR before LimitedLiability": "-8.23",
"Intangible Assets": "49.3",
"Property and Equipment": "-11.5",
"Assets, Current": "-4.95",
"Liabilities, Non-Current": "14.0",
"Liabilities, Current": "-66.0",
"Other Liabilities": "38.1",
"Selling, General and Administrative Expense": "-20.8",
"Expenses": "-13.5",
"Net Income": "-20.7",
"Other Expenses": "15.8",
"Research and Development": "-11.2",
"Cost of Goods Sold": "3.57",
"Other Revenues": "-15.0",
"Revenues": "-15.0",
"Comprehensive Net Income": "-21.0",
"Other Net Income": "7.73",
"Economic Capital Ratio": "-36.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001420720_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "6,900",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,862",
"Liabilities, Current": "3,596",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "63",
"Other Liabilities": "0",
"Other Net Income": "3,714",
"Other Revenues": "1,277",
"Property and Equipment": "3.0",
"Research and Development": "4,981",
"Selling, General and Administrative Expense": "5,623"
},
"output_variables": {
"Assets": "9,765",
"Liabilities": "3,596",
"Expenses": "10,667",
"Revenues": "1,277",
"Stockholders Equity": "6,169",
"Net Income": "-5,676",
"Comprehensive Net Income": "-5,676",
"BaseVar": "14,510",
"ECR before LimitedLiability": "116%",
"Economic Capital Ratio": "243%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "6,635",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,713",
"Liabilities, Current": "4,286",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "469",
"Other Revenues": "1,007",
"Property and Equipment": "6.0",
"Research and Development": "3,431",
"Selling, General and Administrative Expense": "4,243"
},
"output_variables": {
"Assets": "9,354",
"Liabilities": "4,286",
"Expenses": "7,674",
"Revenues": "1,007",
"Stockholders Equity": "5,068",
"Net Income": "-6,198",
"Comprehensive Net Income": "-6,198",
"BaseVar": "11,395",
"ECR before LimitedLiability": "71%",
"Economic Capital Ratio": "207%"
}
}
},
"top_rated": false,
"trend": -39.0,
"value": 2.065721382132411,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001420720.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001420720.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001420720.svg"
},
{
"company_id": "0001159019",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001159019.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001159019.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001159019_main_keyfigs.svg",
"name": "Tribute Pharmaceuticals Canada Inc",
"rank": 145,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001159019.svg",
"report_text": "The relative strengths and weaknesses of Tribute Pharmaceuticals Canada Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tribute Pharmaceuticals Canada Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 78% points.The greatest weakness of Tribute Pharmaceuticals Canada Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 85% points.
The company's Economic Capital Ratio, given in the ranking table, is 206%, being 36% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001159019_2014_Tribute_Pharmaceuticals_Canada_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.86",
"Assets": "60.1",
"Liabilities": "-11.5",
"Stockholders Equity": "83.1",
"ECR before LimitedLiability": "163",
"Intangible Assets": "154",
"Property and Equipment": "1.52",
"Assets, Current": "-19.0",
"Liabilities, Non-Current": "10.9",
"Liabilities, Current": "-23.0",
"Research and Development": "24.6",
"Expenses": "33.9",
"Revenues": "-1.50",
"Net Income": "33.5",
"Other Expenses": "6.33",
"Cost of Goods Sold": "-2.14",
"Selling, General and Administrative Expense": "4.77",
"Other Revenues": "-1.50",
"Comprehensive Net Income": "33.3",
"Other Net Income": "1.15",
"Economic Capital Ratio": "87.4"
},
"2012": {
"Liabilities, Current": "-11.6",
"Liabilities": "14.8",
"Stockholders Equity": "9.74",
"ECR before LimitedLiability": "117",
"Other Liabilities": "7.84",
"Liabilities, Non-Current": "18.2",
"Selling, General and Administrative Expense": "-8.98",
"Expenses": "13.4",
"Net Income": "45.3",
"Research and Development": "36.8",
"Other Expenses": "-12.0",
"Other Revenues": "27.9",
"Revenues": "27.9",
"Assets, Current": "-51.5",
"Intangible Assets": "126",
"Other Assets": "-9.31",
"Property and Equipment": "-3.44",
"Comprehensive Net Income": "48.4",
"Other Net Income": "2.56",
"Other Compr. Net Income": "2.82",
"Economic Capital Ratio": "44.1"
},
"2013": {
"Other Assets": "-16.5",
"Assets": "-46.1",
"Liabilities": "-7.32",
"Stockholders Equity": "-69.1",
"ECR before LimitedLiability": "-8.45",
"Intangible Assets": "78.1",
"Property and Equipment": "-4.41",
"Assets, Current": "-85.0",
"Liabilities, Non-Current": "17.1",
"Liabilities, Current": "2.37",
"Other Liabilities": "-27.7",
"Other Revenues": "38.8",
"Revenues": "38.8",
"Net Income": "43.6",
"Selling, General and Administrative Expense": "-13.4",
"Comprehensive Net Income": "38.7",
"Other Compr. Net Income": "-4.29",
"Other Expenses": "-18.2",
"Cost of Goods Sold": "-3.75",
"Research and Development": "40.3",
"Economic Capital Ratio": "-36.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001159019_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,182",
"Cost of Goods Sold": "933",
"Intangible Assets": "13,818",
"Liabilities, Current": "4,311",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "290",
"Other Liabilities": "1,524",
"Other Net Income": "-103",
"Other Revenues": "3,889",
"Property and Equipment": "1,207",
"Research and Development": "50",
"Selling, General and Administrative Expense": "3,035"
},
"output_variables": {
"Assets": "19,208",
"Liabilities": "5,836",
"Expenses": "4,307",
"Revenues": "3,889",
"Stockholders Equity": "13,373",
"Net Income": "-522",
"Comprehensive Net Income": "-522",
"BaseVar": "16,672",
"ECR before LimitedLiability": "229%",
"Economic Capital Ratio": "321%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "4,886",
"Cost of Goods Sold": "1,221",
"Intangible Assets": "14,482",
"Liabilities, Current": "6,762",
"Liabilities, Non-Current": "0",
"Other Assets": "301",
"Other Compr. Net Income": "1,072",
"Other Expenses": "6,672",
"Other Liabilities": "2,333",
"Other Net Income": "0",
"Other Revenues": "12,343",
"Property and Equipment": "1,159",
"Research and Development": "0",
"Selling, General and Administrative Expense": "8,871"
},
"output_variables": {
"Assets": "20,829",
"Liabilities": "9,094",
"Expenses": "16,763",
"Revenues": "12,343",
"Stockholders Equity": "11,734",
"Net Income": "-4,421",
"Comprehensive Net Income": "-3,885",
"BaseVar": "30,050",
"ECR before LimitedLiability": "145%",
"Economic Capital Ratio": "264%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "5,375",
"Cost of Goods Sold": "1,542",
"Intangible Assets": "13,316",
"Liabilities, Current": "6,494",
"Liabilities, Non-Current": "0",
"Other Assets": "254",
"Other Compr. Net Income": "-1,494",
"Other Expenses": "7,147",
"Other Liabilities": "5,640",
"Other Net Income": "0",
"Other Revenues": "13,440",
"Property and Equipment": "1,090",
"Research and Development": "0",
"Selling, General and Administrative Expense": "9,830"
},
"output_variables": {
"Assets": "20,035",
"Liabilities": "12,134",
"Expenses": "18,519",
"Revenues": "13,440",
"Stockholders Equity": "7,900",
"Net Income": "-5,079",
"Comprehensive Net Income": "-5,826",
"BaseVar": "32,811",
"ECR before LimitedLiability": "71%",
"Economic Capital Ratio": "206%"
}
}
},
"top_rated": false,
"trend": -57.0,
"value": 2.0634998093671175,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001159019.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001159019.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001159019.svg"
},
{
"company_id": "0001333248",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001333248.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001333248.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001333248_main_keyfigs.svg",
"name": "Cadence Pharmaceuticals INC",
"rank": 146,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001333248.svg",
"report_text": "The relative strengths and weaknesses of Cadence Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cadence Pharmaceuticals INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 66% points.The greatest weakness of Cadence Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 118% points.
The company's Economic Capital Ratio, given in the ranking table, is 206%, being 37% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001333248_2014_Cadence_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.69",
"Assets": "58.7",
"Liabilities": "14.6",
"Stockholders Equity": "87.4",
"ECR before LimitedLiability": "116",
"Intangible Assets": "-1.39",
"Property and Equipment": "1.11",
"Assets, Current": "66.8",
"Other Liabilities": "29.3",
"Liabilities, Non-Current": "-48.6",
"Liabilities, Current": "28.7",
"Research and Development": "26.5",
"Expenses": "0.944",
"Revenues": "-16.8",
"Net Income": "-16.6",
"Cost of Goods Sold": "3.60",
"Selling, General and Administrative Expense": "-27.6",
"Other Revenues": "-16.8",
"Comprehensive Net Income": "-16.8",
"Other Net Income": "-0.701",
"Economic Capital Ratio": "40.8"
},
"2012": {
"Property and Equipment": "-16.9",
"Assets": "-37.3",
"Liabilities": "16.7",
"Stockholders Equity": "-30.1",
"ECR before LimitedLiability": "24.4",
"Assets, Current": "-16.5",
"Intangible Assets": "-2.30",
"Other Assets": "-5.50",
"Liabilities, Current": "30.4",
"Other Liabilities": "30.6",
"Liabilities, Non-Current": "-68.0",
"Selling, General and Administrative Expense": "-56.6",
"Expenses": "-24.6",
"Revenues": "16.9",
"Net Income": "-10.6",
"Research and Development": "30.6",
"Other Expenses": "-13.3",
"Cost of Goods Sold": "7.44",
"Other Revenues": "16.9",
"Comprehensive Net Income": "-10.3",
"Economic Capital Ratio": "-48.6"
},
"2013": {
"Other Assets": "-24.1",
"Assets": "-88.2",
"Liabilities": "42.6",
"Stockholders Equity": "-118",
"ECR before LimitedLiability": "-8.73",
"Intangible Assets": "-11.6",
"Property and Equipment": "-14.7",
"Assets, Current": "-64.5",
"Liabilities, Non-Current": "-34.4",
"Liabilities, Current": "12.7",
"Other Liabilities": "61.0",
"Selling, General and Administrative Expense": "-53.6",
"Expenses": "-26.8",
"Revenues": "66.0",
"Net Income": "65.0",
"Other Expenses": "-18.9",
"Research and Development": "46.3",
"Other Revenues": "66.0",
"Comprehensive Net Income": "65.0",
"Other Net Income": "6.83",
"Economic Capital Ratio": "-36.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001333248_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "132,929",
"Cost of Goods Sold": "0",
"Intangible Assets": "13,433",
"Liabilities, Current": "16,037",
"Liabilities, Non-Current": "28,813",
"Other Assets": "7,229",
"Other Compr. Net Income": "0",
"Other Expenses": "15,049",
"Other Liabilities": "0",
"Other Net Income": "-4,279",
"Other Revenues": "16,696",
"Property and Equipment": "10,569",
"Research and Development": "8,885",
"Selling, General and Administrative Expense": "81,504"
},
"output_variables": {
"Assets": "164,160",
"Liabilities": "44,850",
"Expenses": "105,438",
"Revenues": "16,696",
"Stockholders Equity": "119,310",
"Net Income": "-93,021",
"Comprehensive Net Income": "-93,021",
"BaseVar": "167,712",
"ECR before LimitedLiability": "160%",
"Economic Capital Ratio": "275%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "76,516",
"Cost of Goods Sold": "0",
"Intangible Assets": "12,090",
"Liabilities, Current": "20,999",
"Liabilities, Non-Current": "28,869",
"Other Assets": "7,106",
"Other Compr. Net Income": "-2.0",
"Other Expenses": "33,496",
"Other Liabilities": "0",
"Other Net Income": "-4,299",
"Other Revenues": "50,184",
"Property and Equipment": "1,967",
"Research and Development": "6,519",
"Selling, General and Administrative Expense": "86,843"
},
"output_variables": {
"Assets": "97,679",
"Liabilities": "49,868",
"Expenses": "126,858",
"Revenues": "50,184",
"Stockholders Equity": "47,811",
"Net Income": "-80,973",
"Comprehensive Net Income": "-80,974",
"BaseVar": "164,445",
"ECR before LimitedLiability": "32%",
"Economic Capital Ratio": "171%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "77,888",
"Cost of Goods Sold": "0",
"Intangible Assets": "10,747",
"Liabilities, Current": "36,543",
"Liabilities, Non-Current": "19,382",
"Other Assets": "108",
"Other Compr. Net Income": "0",
"Other Expenses": "38,875",
"Other Liabilities": "0",
"Other Net Income": "3,250",
"Other Revenues": "112,556",
"Property and Equipment": "2,060",
"Research and Development": "6,743",
"Selling, General and Administrative Expense": "94,482"
},
"output_variables": {
"Assets": "90,803",
"Liabilities": "55,925",
"Expenses": "140,100",
"Revenues": "112,556",
"Stockholders Equity": "34,878",
"Net Income": "-24,294",
"Comprehensive Net Income": "-24,294",
"BaseVar": "201,317",
"ECR before LimitedLiability": "71%",
"Economic Capital Ratio": "206%"
}
}
},
"top_rated": false,
"trend": -9.0,
"value": 2.0607037334014664,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001333248.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001333248.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001333248.svg"
},
{
"company_id": "0001401667",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001401667.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001401667.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001401667.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001401667_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001401667_main_keyfigs.svg",
"name": "PUMA Biotechnology INC",
"rank": 147,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001401667.svg",
"report_text": "The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 65% points.The greatest weakness of PUMA Biotechnology INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 104% points.
The company's Economic Capital Ratio, given in the ranking table, is 206%, being 37% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001401667_2014_PUMA_Biotechnology_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-0.788",
"Assets": "47.6",
"Liabilities": "80.4",
"Stockholders Equity": "226",
"ECR before LimitedLiability": "269",
"Intangible Assets": "-1.91",
"Assets, Current": "69.9",
"Other Liabilities": "25.5",
"Liabilities, Non-Current": "13.0",
"Liabilities, Current": "51.5",
"Research and Development": "21.7",
"Expenses": "28.1",
"Revenues": "-22.1",
"Net Income": "8.52",
"Other Expenses": "7.65",
"Cost of Goods Sold": "2.74",
"Selling, General and Administrative Expense": "-3.78",
"Other Revenues": "-22.1",
"Comprehensive Net Income": "8.31",
"Other Net Income": "1.47",
"Economic Capital Ratio": "193"
},
"2012": {
"Property and Equipment": "-3.93",
"Assets": "81.7",
"Liabilities": "45.1",
"Stockholders Equity": "160",
"ECR before LimitedLiability": "180",
"Assets, Current": "144",
"Intangible Assets": "-7.00",
"Other Assets": "-4.22",
"Liabilities, Current": "7.37",
"Other Liabilities": "26.3",
"Liabilities, Non-Current": "13.5",
"Selling, General and Administrative Expense": "3.15",
"Expenses": "4.77",
"Revenues": "-21.2",
"Net Income": "-14.7",
"Research and Development": "-14.7",
"Other Expenses": "13.1",
"Cost of Goods Sold": "3.35",
"Other Revenues": "-21.2",
"Comprehensive Net Income": "-14.5",
"Economic Capital Ratio": "107"
},
"2013": {
"Liabilities, Non-Current": "17.7",
"Liabilities": "65.2",
"Stockholders Equity": "65.2",
"ECR before LimitedLiability": "-8.94",
"Liabilities, Current": "25.5",
"Other Liabilities": "44.3",
"Selling, General and Administrative Expense": "-19.5",
"Expenses": "-77.2",
"Net Income": "-103",
"Other Expenses": "20.2",
"Research and Development": "-80.6",
"Cost of Goods Sold": "4.55",
"Other Revenues": "-33.7",
"Revenues": "-33.7",
"Intangible Assets": "-24.0",
"Property and Equipment": "-10.8",
"Other Assets": "-5.39",
"Assets, Current": "51.7",
"Comprehensive Net Income": "-104",
"Other Net Income": "2.61",
"Economic Capital Ratio": "-36.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001401667_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "53,663",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "586",
"Liabilities, Non-Current": "0",
"Other Assets": "1,053",
"Other Compr. Net Income": "0",
"Other Expenses": "11",
"Other Liabilities": "439",
"Other Net Income": "-76",
"Other Revenues": "0",
"Property and Equipment": "682",
"Research and Development": "826",
"Selling, General and Administrative Expense": "9,320"
},
"output_variables": {
"Assets": "55,398",
"Liabilities": "1,026",
"Expenses": "10,157",
"Revenues": "0",
"Stockholders Equity": "54,373",
"Net Income": "-10,233",
"Comprehensive Net Income": "-10,233",
"BaseVar": "33,328",
"ECR before LimitedLiability": "384%",
"Economic Capital Ratio": "427%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "148,972",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "21,701",
"Liabilities, Non-Current": "0",
"Other Assets": "1,248",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "1,089",
"Other Net Income": "98",
"Other Revenues": "0",
"Property and Equipment": "1,479",
"Research and Development": "49,636",
"Selling, General and Administrative Expense": "24,814"
},
"output_variables": {
"Assets": "151,699",
"Liabilities": "22,790",
"Expenses": "74,450",
"Revenues": "0",
"Stockholders Equity": "128,909",
"Net Income": "-74,352",
"Comprehensive Net Income": "-74,352",
"BaseVar": "124,518",
"ECR before LimitedLiability": "237%",
"Economic Capital Ratio": "327%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "96,396",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "19,271",
"Liabilities, Non-Current": "0",
"Other Assets": "6,294",
"Other Compr. Net Income": "3.0",
"Other Expenses": "0",
"Other Liabilities": "1,116",
"Other Net Income": "196",
"Other Revenues": "0",
"Property and Equipment": "1,684",
"Research and Development": "95,508",
"Selling, General and Administrative Expense": "43,939"
},
"output_variables": {
"Assets": "104,374",
"Liabilities": "20,387",
"Expenses": "139,447",
"Revenues": "0",
"Stockholders Equity": "83,987",
"Net Income": "-139,251",
"Comprehensive Net Income": "-139,250",
"BaseVar": "132,204",
"ECR before LimitedLiability": "70%",
"Economic Capital Ratio": "206%"
}
}
},
"top_rated": false,
"trend": -97.0,
"value": 2.0586424989973082,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001401667.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001401667.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001401667.svg"
},
{
"company_id": "0001379006",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001379006.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001379006.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001379006_main_keyfigs.svg",
"name": "Nanoviricides INC",
"rank": 148,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001379006.svg",
"report_text": "The relative strengths and weaknesses of Nanoviricides INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Nanoviricides INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 64% points.The greatest weakness of Nanoviricides INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 131% points.
The company's Economic Capital Ratio, given in the ranking table, is 205%, being 38% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001379006_2014_Nanoviricides_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.29",
"Assets": "68.9",
"Liabilities": "77.2",
"Stockholders Equity": "192",
"ECR before LimitedLiability": "195",
"Intangible Assets": "-3.54",
"Property and Equipment": "2.89",
"Assets, Current": "89.6",
"Other Liabilities": "31.0",
"Liabilities, Non-Current": "13.6",
"Liabilities, Current": "39.8",
"Research and Development": "-19.5",
"Expenses": "-8.81",
"Revenues": "-26.3",
"Net Income": "-33.9",
"Other Expenses": "9.25",
"Cost of Goods Sold": "3.29",
"Selling, General and Administrative Expense": "-1.97",
"Other Revenues": "-26.3",
"Comprehensive Net Income": "-34.1",
"Economic Capital Ratio": "119"
},
"2012": {
"Assets": "79.3",
"Liabilities": "53.2",
"Stockholders Equity": "178",
"ECR before LimitedLiability": "205",
"Assets, Current": "107",
"Intangible Assets": "-3.01",
"Other Assets": "-3.93",
"Liabilities, Current": "14.6",
"Other Liabilities": "28.8",
"Liabilities, Non-Current": "13.6",
"Selling, General and Administrative Expense": "7.07",
"Expenses": "11.9",
"Revenues": "-20.4",
"Net Income": "-7.63",
"Research and Development": "-10.8",
"Other Expenses": "12.4",
"Cost of Goods Sold": "3.19",
"Other Revenues": "-20.4",
"Comprehensive Net Income": "-7.50",
"Other Net Income": "0.623",
"Economic Capital Ratio": "132"
},
"2013": {
"Assets": "45.5",
"Liabilities": "-44.2",
"Stockholders Equity": "8.31",
"ECR before LimitedLiability": "-9.84",
"Intangible Assets": "-11.5",
"Property and Equipment": "-4.08",
"Assets, Current": "64.0",
"Liabilities, Non-Current": "-131",
"Liabilities, Current": "37.5",
"Other Liabilities": "31.2",
"Selling, General and Administrative Expense": "9.85",
"Expenses": "22.0",
"Revenues": "-22.0",
"Net Income": "-15.2",
"Other Expenses": "12.9",
"Research and Development": "-3.90",
"Cost of Goods Sold": "2.91",
"Other Revenues": "-22.0",
"Comprehensive Net Income": "-15.4",
"Other Net Income": "-13.9",
"Economic Capital Ratio": "-37.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001379006_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "9,556",
"Cost of Goods Sold": "0",
"Intangible Assets": "399",
"Liabilities, Current": "587",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-48",
"Other Revenues": "0",
"Property and Equipment": "802",
"Research and Development": "4,156",
"Selling, General and Administrative Expense": "2,274"
},
"output_variables": {
"Assets": "10,758",
"Liabilities": "587",
"Expenses": "6,429",
"Revenues": "0",
"Stockholders Equity": "10,171",
"Net Income": "-6,477",
"Comprehensive Net Income": "-6,477",
"BaseVar": "8,911",
"ECR before LimitedLiability": "277%",
"Economic Capital Ratio": "353%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "14,589",
"Cost of Goods Sold": "0",
"Intangible Assets": "426",
"Liabilities, Current": "1,780",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-125",
"Other Revenues": "0",
"Property and Equipment": "615",
"Research and Development": "4,266",
"Selling, General and Administrative Expense": "1,816"
},
"output_variables": {
"Assets": "15,630",
"Liabilities": "1,780",
"Expenses": "6,082",
"Revenues": "0",
"Stockholders Equity": "13,850",
"Net Income": "-6,207",
"Comprehensive Net Income": "-6,207",
"BaseVar": "11,808",
"ECR before LimitedLiability": "276%",
"Economic Capital Ratio": "352%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "14,522",
"Cost of Goods Sold": "0",
"Intangible Assets": "417",
"Liabilities, Current": "1,178",
"Liabilities, Non-Current": "7,220",
"Other Assets": "1,000",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-2,285",
"Other Revenues": "0",
"Property and Equipment": "469",
"Research and Development": "4,293",
"Selling, General and Administrative Expense": "2,297"
},
"output_variables": {
"Assets": "16,408",
"Liabilities": "8,398",
"Expenses": "6,590",
"Revenues": "0",
"Stockholders Equity": "8,010",
"Net Income": "-8,876",
"Comprehensive Net Income": "-8,876",
"BaseVar": "16,841",
"ECR before LimitedLiability": "69%",
"Economic Capital Ratio": "205%"
}
}
},
"top_rated": false,
"trend": -109.0,
"value": 2.049645832217928,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001379006.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001379006.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001379006.svg"
},
{
"company_id": "0001347178",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001347178.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001347178.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001347178.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001347178_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001347178_main_keyfigs.svg",
"name": "Vanda Pharmaceuticals Inc",
"rank": 149,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001347178.svg",
"report_text": "The relative strengths and weaknesses of Vanda Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Vanda Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points.The greatest weakness of Vanda Pharmaceuticals Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 94% points.
The company's Economic Capital Ratio, given in the ranking table, is 199%, being 43% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001347178_2014_Vanda_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "7.36",
"Assets": "36.7",
"Liabilities": "-128",
"Stockholders Equity": "-52.0",
"ECR before LimitedLiability": "19.0",
"Intangible Assets": "-10.5",
"Property and Equipment": "-10.9",
"Assets, Current": "38.1",
"Other Liabilities": "-152",
"Liabilities, Non-Current": "9.95",
"Liabilities, Current": "7.24",
"Research and Development": "15.6",
"Expenses": "36.7",
"Revenues": "-10.6",
"Net Income": "36.5",
"Other Expenses": "9.51",
"Cost of Goods Sold": "3.55",
"Selling, General and Administrative Expense": "20.6",
"Other Revenues": "-10.6",
"Comprehensive Net Income": "36.5",
"Economic Capital Ratio": "-56.6"
},
"2012": {
"Property and Equipment": "-7.54",
"Assets": "0.668",
"Liabilities": "-119",
"Stockholders Equity": "-77.6",
"Assets, Current": "6.15",
"Intangible Assets": "-7.62",
"Other Assets": "-10.7",
"Liabilities, Current": "0.0748",
"Other Liabilities": "-143",
"Liabilities, Non-Current": "0.308",
"Selling, General and Administrative Expense": "0.719",
"Expenses": "2.37",
"Revenues": "-0.530",
"Net Income": "2.09",
"Other Expenses": "0.534",
"Cost of Goods Sold": "0.0773",
"Other Revenues": "-0.530",
"ECR before LimitedLiability": "-5.98",
"Comprehensive Net Income": "2.11",
"Other Net Income": "0.0316",
"Economic Capital Ratio": "-79.1"
},
"2013": {
"Other Assets": "-12.7",
"Assets": "16.6",
"Liabilities": "-78.0",
"Stockholders Equity": "-42.6",
"ECR before LimitedLiability": "-15.5",
"Intangible Assets": "-10.8",
"Property and Equipment": "-7.27",
"Assets, Current": "58.3",
"Liabilities, Non-Current": "11.5",
"Liabilities, Current": "1.40",
"Other Liabilities": "-93.7",
"Selling, General and Administrative Expense": "8.58",
"Expenses": "30.4",
"Revenues": "1.08",
"Net Income": "33.3",
"Other Expenses": "12.0",
"Research and Development": "6.00",
"Cost of Goods Sold": "2.97",
"Other Revenues": "1.08",
"Comprehensive Net Income": "33.0",
"Other Net Income": "1.53",
"Economic Capital Ratio": "-43.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001347178_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "153,501",
"Cost of Goods Sold": "0",
"Intangible Assets": "8,027",
"Liabilities, Current": "31,619",
"Liabilities, Non-Current": "0",
"Other Assets": "20,126",
"Other Compr. Net Income": "0",
"Other Expenses": "1,051",
"Other Liabilities": "117,525",
"Other Net Income": "461",
"Other Revenues": "31,270",
"Property and Equipment": "964",
"Research and Development": "28,996",
"Selling, General and Administrative Expense": "11,486"
},
"output_variables": {
"Assets": "182,618",
"Liabilities": "149,144",
"Expenses": "41,533",
"Revenues": "31,270",
"Stockholders Equity": "33,474",
"Net Income": "-9,802",
"Comprehensive Net Income": "-9,802",
"BaseVar": "202,513",
"ECR before LimitedLiability": "38%",
"Economic Capital Ratio": "178%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "125,968",
"Cost of Goods Sold": "0",
"Intangible Assets": "6,532",
"Liabilities, Current": "32,263",
"Liabilities, Non-Current": "0",
"Other Assets": "600",
"Other Compr. Net Income": "-11",
"Other Expenses": "1,624",
"Other Liabilities": "93,280",
"Other Net Income": "0",
"Other Revenues": "33,288",
"Property and Equipment": "2,348",
"Research and Development": "45,446",
"Selling, General and Administrative Expense": "13,882"
},
"output_variables": {
"Assets": "135,448",
"Liabilities": "125,543",
"Expenses": "60,952",
"Revenues": "33,288",
"Stockholders Equity": "9,905",
"Net Income": "-27,664",
"Comprehensive Net Income": "-27,670",
"BaseVar": "177,621",
"ECR before LimitedLiability": "-4.7%",
"Economic Capital Ratio": "141%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "135,614",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,037",
"Liabilities, Current": "32,851",
"Liabilities, Non-Current": "0",
"Other Assets": "500",
"Other Compr. Net Income": "11",
"Other Expenses": "1,495",
"Other Liabilities": "66,374",
"Other Net Income": "0",
"Other Revenues": "34,024",
"Property and Equipment": "2,198",
"Research and Development": "28,190",
"Selling, General and Administrative Expense": "24,594"
},
"output_variables": {
"Assets": "143,349",
"Liabilities": "99,225",
"Expenses": "54,279",
"Revenues": "34,024",
"Stockholders Equity": "44,124",
"Net Income": "-20,255",
"Comprehensive Net Income": "-20,250",
"BaseVar": "165,444",
"ECR before LimitedLiability": "63%",
"Economic Capital Ratio": "199%"
}
}
},
"top_rated": false,
"trend": -1.0,
"value": 1.993049290789459,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001347178.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001347178.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001347178.svg"
},
{
"company_id": "0001430306",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001430306.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001430306.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001430306_main_keyfigs.svg",
"name": "Tonix Pharmaceuticals Holding Corp",
"rank": 150,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001430306.svg",
"report_text": "The relative strengths and weaknesses of Tonix Pharmaceuticals Holding Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tonix Pharmaceuticals Holding Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 57% points.The greatest weakness of Tonix Pharmaceuticals Holding Corp is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 92% points.
The company's Economic Capital Ratio, given in the ranking table, is 197%, being 45% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001430306_2014_Tonix_Pharmaceuticals_Holding_Corp.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-17.6",
"Assets": "1.09",
"Liabilities": "56.4",
"Stockholders Equity": "56.4",
"ECR before LimitedLiability": "-17.4",
"Intangible Assets": "-23.9",
"Property and Equipment": "-13.3",
"Assets, Current": "57.1",
"Liabilities, Non-Current": "16.8",
"Other Liabilities": "44.7",
"Selling, General and Administrative Expense": "-56.0",
"Expenses": "-66.2",
"Revenues": "-32.5",
"Net Income": "-91.9",
"Other Expenses": "19.4",
"Research and Development": "-33.8",
"Cost of Goods Sold": "4.38",
"Other Revenues": "-32.5",
"Comprehensive Net Income": "-92.2",
"Other Net Income": "2.32",
"Economic Capital Ratio": "-45.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001430306_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "8,631",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,211",
"Liabilities, Non-Current": "0",
"Other Assets": "60",
"Other Compr. Net Income": "-1.0",
"Other Expenses": "0",
"Other Liabilities": "13",
"Other Net Income": "4.0",
"Other Revenues": "0",
"Property and Equipment": "45",
"Research and Development": "4,650",
"Selling, General and Administrative Expense": "6,238"
},
"output_variables": {
"Assets": "8,736",
"Liabilities": "2,224",
"Expenses": "10,888",
"Revenues": "0",
"Stockholders Equity": "6,512",
"Net Income": "-10,884",
"Comprehensive Net Income": "-10,884",
"BaseVar": "10,926",
"ECR before LimitedLiability": "60%",
"Economic Capital Ratio": "197%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.9741792594553749,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001430306.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001430306.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001430306.svg"
},
{
"company_id": "0001415684",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001415684.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001415684.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001415684.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001415684_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001415684_main_keyfigs.svg",
"name": "Musclepharm Corp",
"rank": 151,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001415684.svg",
"report_text": "The relative strengths and weaknesses of Musclepharm Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Musclepharm Corp compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 73% points.The greatest weakness of Musclepharm Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 191% points.
The company's Economic Capital Ratio, given in the ranking table, is 197%, being 46% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001415684_2014_Musclepharm_Corp.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-5.35",
"Assets": "-164",
"Liabilities": "-1.89",
"Stockholders Equity": "-136",
"ECR before LimitedLiability": "-276",
"Assets, Current": "-113",
"Property and Equipment": "-28.0",
"Intangible Assets": "-64.2",
"Liabilities, Current": "2.17",
"Other Liabilities": "-2.42",
"Selling, General and Administrative Expense": "-98.8",
"Expenses": "-82.2",
"Revenues": "-4.59",
"Net Income": "-115",
"Research and Development": "2.20",
"Cost of Goods Sold": "-3.65",
"Other Expenses": "1.99",
"Other Revenues": "-4.59",
"Comprehensive Net Income": "-115",
"Other Net Income": "-1.98",
"Economic Capital Ratio": "-283"
},
"2011": {
"Other Assets": "-24.3",
"Assets": "-133",
"Liabilities": "0.516",
"Stockholders Equity": "-222",
"ECR before LimitedLiability": "-130",
"Intangible Assets": "-34.0",
"Property and Equipment": "-12.9",
"Assets, Current": "-108",
"Other Liabilities": "-0.333",
"Liabilities, Current": "1.59",
"Research and Development": "16.4",
"Expenses": "-19.0",
"Revenues": "13.9",
"Net Income": "-10.7",
"Other Expenses": "6.37",
"Cost of Goods Sold": "-29.4",
"Selling, General and Administrative Expense": "-27.0",
"Other Revenues": "13.9",
"Comprehensive Net Income": "-10.9",
"Other Net Income": "-12.4",
"Economic Capital Ratio": "-206"
},
"2012": {
"Property and Equipment": "-33.6",
"Assets": "-250",
"Liabilities": "9.42",
"Stockholders Equity": "-409",
"ECR before LimitedLiability": "-92.7",
"Assets, Current": "-212",
"Intangible Assets": "-59.0",
"Other Assets": "-42.1",
"Other Liabilities": "7.02",
"Liabilities, Non-Current": "3.81",
"Selling, General and Administrative Expense": "-6.72",
"Expenses": "-52.7",
"Revenues": "52.7",
"Net Income": "37.6",
"Research and Development": "39.2",
"Other Expenses": "26.4",
"Cost of Goods Sold": "-160",
"Other Revenues": "52.7",
"Comprehensive Net Income": "37.7",
"Other Net Income": "-24.1",
"Economic Capital Ratio": "-166"
},
"2013": {
"Other Assets": "-19.2",
"Assets": "-131",
"Liabilities": "58.9",
"Stockholders Equity": "-191",
"ECR before LimitedLiability": "-17.9",
"Intangible Assets": "-42.0",
"Property and Equipment": "-18.1",
"Assets, Current": "-109",
"Liabilities, Non-Current": "31.7",
"Liabilities, Current": "2.95",
"Other Liabilities": "56.6",
"Selling, General and Administrative Expense": "-23.3",
"Expenses": "-60.2",
"Revenues": "72.9",
"Net Income": "58.5",
"Other Expenses": "40.6",
"Research and Development": "56.4",
"Cost of Goods Sold": "-128",
"Other Revenues": "72.9",
"Comprehensive Net Income": "58.4",
"Economic Capital Ratio": "-45.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001415684_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,406",
"Cost of Goods Sold": "2,804",
"Intangible Assets": "0",
"Liabilities, Current": "4,216",
"Liabilities, Non-Current": "250",
"Other Assets": "1,176",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-1,318",
"Other Revenues": "4,047",
"Property and Equipment": "139",
"Research and Development": "0",
"Selling, General and Administrative Expense": "19,495"
},
"output_variables": {
"Assets": "2,721",
"Liabilities": "4,466",
"Expenses": "22,299",
"Revenues": "4,047",
"Stockholders Equity": "-1,745",
"Net Income": "-19,569",
"Comprehensive Net Income": "-19,569",
"BaseVar": "17,425",
"ECR before LimitedLiability": "-650%",
"Economic Capital Ratio": "4.8%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "4,017",
"Cost of Goods Sold": "14,471",
"Intangible Assets": "0",
"Liabilities, Current": "17,710",
"Liabilities, Non-Current": "307",
"Other Assets": "122",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-7,061",
"Other Revenues": "20,838",
"Property and Equipment": "908",
"Research and Development": "0",
"Selling, General and Administrative Expense": "22,588"
},
"output_variables": {
"Assets": "5,046",
"Liabilities": "18,017",
"Expenses": "37,058",
"Revenues": "20,838",
"Stockholders Equity": "-12,971",
"Net Income": "-23,281",
"Comprehensive Net Income": "-23,281",
"BaseVar": "44,011",
"ECR before LimitedLiability": "-447%",
"Economic Capital Ratio": "29%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "4,950",
"Cost of Goods Sold": "52,727",
"Intangible Assets": "0",
"Liabilities, Current": "16,520",
"Liabilities, Non-Current": "4.5",
"Other Assets": "460",
"Other Compr. Net Income": "-7.9",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-10,217",
"Other Revenues": "67,055",
"Property and Equipment": "1,356",
"Research and Development": "0",
"Selling, General and Administrative Expense": "23,064"
},
"output_variables": {
"Assets": "6,767",
"Liabilities": "16,525",
"Expenses": "75,791",
"Revenues": "67,055",
"Stockholders Equity": "-9,758",
"Net Income": "-18,953",
"Comprehensive Net Income": "-18,957",
"BaseVar": "88,181",
"ECR before LimitedLiability": "-345%",
"Economic Capital Ratio": "54%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "44,526",
"Cost of Goods Sold": "167,381",
"Intangible Assets": "0",
"Liabilities, Current": "32,369",
"Liabilities, Non-Current": "0",
"Other Assets": "5,018",
"Other Compr. Net Income": "-6.5",
"Other Expenses": "-1,003",
"Other Liabilities": "55",
"Other Net Income": "-2,649",
"Other Revenues": "329,739",
"Property and Equipment": "2,614",
"Research and Development": "1,119",
"Selling, General and Administrative Expense": "53,153"
},
"output_variables": {
"Assets": "52,158",
"Liabilities": "32,423",
"Expenses": "220,650",
"Revenues": "329,739",
"Stockholders Equity": "19,735",
"Net Income": "106,441",
"Comprehensive Net Income": "106,438",
"BaseVar": "318,812",
"ECR before LimitedLiability": "353%",
"Economic Capital Ratio": "405%"
}
}
},
"top_rated": false,
"trend": 39.0,
"value": 1.9689123497139733,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001415684.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001415684.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001415684.svg"
},
{
"company_id": "0000069499",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000069499.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000069499.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000069499_main_keyfigs.svg",
"name": "Mylan INC",
"rank": 152,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000069499.svg",
"report_text": "The relative strengths and weaknesses of Mylan INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Mylan INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 50% points.The greatest weakness of Mylan INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 148% points.
The company's Economic Capital Ratio, given in the ranking table, is 189%, being 54% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000069499_2014_Mylan_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-11.4",
"Assets": "-15.4",
"Liabilities": "-69.6",
"Stockholders Equity": "-68.4",
"ECR before LimitedLiability": "-63.3",
"Assets, Current": "-36.0",
"Property and Equipment": "-7.28",
"Intangible Assets": "60.2",
"Liabilities, Current": "11.8",
"Other Liabilities": "20.8",
"Liabilities, Non-Current": "-111",
"Selling, General and Administrative Expense": "14.2",
"Expenses": "13.9",
"Revenues": "-1.25",
"Net Income": "12.9",
"Research and Development": "12.6",
"Cost of Goods Sold": "-21.1",
"Other Expenses": "9.13",
"Other Revenues": "-1.25",
"Comprehensive Net Income": "13.0",
"Economic Capital Ratio": "-69.7"
},
"2011": {
"Other Assets": "-6.75",
"Assets": "7.71",
"Liabilities": "-74.9",
"Stockholders Equity": "-46.0",
"ECR before LimitedLiability": "58.0",
"Intangible Assets": "76.5",
"Property and Equipment": "6.36",
"Assets, Current": "-47.7",
"Other Liabilities": "15.6",
"Liabilities, Non-Current": "-103",
"Liabilities, Current": "6.93",
"Research and Development": "36.0",
"Expenses": "39.0",
"Revenues": "18.9",
"Net Income": "62.9",
"Other Expenses": "7.61",
"Cost of Goods Sold": "-24.8",
"Selling, General and Administrative Expense": "21.5",
"Other Revenues": "18.9",
"Comprehensive Net Income": "62.5",
"Economic Capital Ratio": "-17.5"
},
"2012": {
"Property and Equipment": "7.13",
"Assets": "3.66",
"Liabilities": "-64.8",
"Stockholders Equity": "-44.4",
"ECR before LimitedLiability": "65.0",
"Assets, Current": "-50.8",
"Intangible Assets": "71.5",
"Liabilities, Current": "22.8",
"Other Liabilities": "27.2",
"Liabilities, Non-Current": "-130",
"Selling, General and Administrative Expense": "20.9",
"Expenses": "40.3",
"Revenues": "25.5",
"Net Income": "71.0",
"Research and Development": "30.9",
"Other Expenses": "15.4",
"Cost of Goods Sold": "-25.8",
"Other Revenues": "25.5",
"Comprehensive Net Income": "71.0",
"Other Net Income": "2.42",
"Economic Capital Ratio": "-8.06"
},
"2013": {
"Other Assets": "12.8",
"Assets": "-12.1",
"Liabilities": "-86.3",
"Stockholders Equity": "-76.9",
"ECR before LimitedLiability": "-25.8",
"Intangible Assets": "49.6",
"Property and Equipment": "8.94",
"Assets, Current": "-68.7",
"Liabilities, Non-Current": "-148",
"Liabilities, Current": "18.5",
"Other Liabilities": "27.2",
"Selling, General and Administrative Expense": "20.5",
"Expenses": "37.7",
"Revenues": "19.2",
"Net Income": "48.2",
"Other Expenses": "11.9",
"Research and Development": "26.8",
"Cost of Goods Sold": "-21.0",
"Other Revenues": "19.2",
"Comprehensive Net Income": "48.1",
"Economic Capital Ratio": "-53.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000069499_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "3,559,443",
"Cost of Goods Sold": "3,233,125",
"Intangible Assets": "6,100,484",
"Liabilities, Current": "1,809,612",
"Liabilities, Non-Current": "5,633,697",
"Other Assets": "667,535",
"Other Compr. Net Income": "0",
"Other Expenses": "468,922",
"Other Liabilities": "478,094",
"Other Net Income": "-34,178",
"Other Revenues": "5,450,522",
"Property and Equipment": "1,209,342",
"Research and Development": "282,146",
"Selling, General and Administrative Expense": "1,086,609"
},
"output_variables": {
"Assets": "11,536,804",
"Liabilities": "7,921,403",
"Expenses": "5,070,802",
"Revenues": "5,450,522",
"Stockholders Equity": "3,615,401",
"Net Income": "345,542",
"Comprehensive Net Income": "345,542",
"BaseVar": "15,006,854",
"ECR before LimitedLiability": "85%",
"Economic Capital Ratio": "218%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "3,568,844",
"Cost of Goods Sold": "3,566,461",
"Intangible Assets": "6,148,682",
"Liabilities, Current": "2,563,156",
"Liabilities, Non-Current": "4,845,180",
"Other Assets": "582,583",
"Other Compr. Net Income": "0",
"Other Expenses": "500,333",
"Other Liabilities": "685,025",
"Other Net Income": "-14,869",
"Other Revenues": "6,129,825",
"Property and Equipment": "1,298,034",
"Research and Development": "294,728",
"Selling, General and Administrative Expense": "1,214,631"
},
"output_variables": {
"Assets": "11,598,143",
"Liabilities": "8,093,361",
"Expenses": "5,576,153",
"Revenues": "6,129,825",
"Stockholders Equity": "3,504,782",
"Net Income": "538,803",
"Comprehensive Net Income": "538,803",
"BaseVar": "15,706,176",
"ECR before LimitedLiability": "83%",
"Economic Capital Ratio": "217%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "3,902,717",
"Cost of Goods Sold": "3,887,806",
"Intangible Assets": "5,740,112",
"Liabilities, Current": "2,193,503",
"Liabilities, Non-Current": "6,108,307",
"Other Assets": "891,852",
"Other Compr. Net Income": "-743",
"Other Expenses": "466,711",
"Other Liabilities": "274,259",
"Other Net Income": "3,429",
"Other Revenues": "6,796,110",
"Property and Equipment": "1,397,216",
"Research and Development": "401,341",
"Selling, General and Administrative Expense": "1,400,747"
},
"output_variables": {
"Assets": "11,931,897",
"Liabilities": "8,576,069",
"Expenses": "6,156,605",
"Revenues": "6,796,110",
"Stockholders Equity": "3,355,828",
"Net Income": "642,934",
"Comprehensive Net Income": "642,562",
"BaseVar": "16,732,426",
"ECR before LimitedLiability": "78%",
"Economic Capital Ratio": "212%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "4,471,260",
"Cost of Goods Sold": "3,866,439",
"Intangible Assets": "6,806,012",
"Liabilities, Current": "2,956,070",
"Liabilities, Non-Current": "8,851,834",
"Other Assets": "2,295,993",
"Other Compr. Net Income": "-935,009",
"Other Expenses": "416,020",
"Other Liabilities": "468,530",
"Other Net Income": "-11,493",
"Other Revenues": "6,927,267",
"Property and Equipment": "1,663,076",
"Research and Development": "530,916",
"Selling, General and Administrative Expense": "1,413,312"
},
"output_variables": {
"Assets": "15,236,341",
"Liabilities": "12,276,434",
"Expenses": "6,226,687",
"Revenues": "6,927,267",
"Stockholders Equity": "2,959,907",
"Net Income": "689,087",
"Comprehensive Net Income": "221,582",
"BaseVar": "20,806,616",
"ECR before LimitedLiability": "49%",
"Economic Capital Ratio": "187%"
}
}
},
"top_rated": false,
"trend": -32.0,
"value": 1.890469776158949,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000069499.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000069499.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000069499.svg"
},
{
"company_id": "0000896747",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000896747.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000896747.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000896747.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000896747_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000896747_main_keyfigs.svg",
"name": "American BIO Medica CORP",
"rank": 153,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000896747.svg",
"report_text": "The relative strengths and weaknesses of American BIO Medica CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of American BIO Medica CORP compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 56% points.The greatest weakness of American BIO Medica CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 182% points.
The company's Economic Capital Ratio, given in the ranking table, is 188%, being 55% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000896747_2014_American_BIO_Medica_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-22.2",
"Assets": "-74.5",
"Liabilities": "48.4",
"Stockholders Equity": "-106",
"ECR before LimitedLiability": "78.2",
"Intangible Assets": "-29.9",
"Property and Equipment": "16.3",
"Assets, Current": "-53.7",
"Other Liabilities": "51.0",
"Liabilities, Non-Current": "-10.7",
"Liabilities, Current": "7.68",
"Research and Development": "70.6",
"Expenses": "-13.2",
"Revenues": "96.2",
"Net Income": "95.8",
"Other Expenses": "-96.4",
"Cost of Goods Sold": "7.77",
"Selling, General and Administrative Expense": "22.8",
"Other Revenues": "96.2",
"Comprehensive Net Income": "95.8",
"Other Net Income": "4.88",
"Economic Capital Ratio": "2.66"
},
"2012": {
"Property and Equipment": "19.4",
"Assets": "-114",
"Liabilities": "43.7",
"Stockholders Equity": "-146",
"ECR before LimitedLiability": "37.2",
"Assets, Current": "-93.8",
"Intangible Assets": "-39.6",
"Other Assets": "-27.5",
"Liabilities, Current": "-20.1",
"Other Liabilities": "43.5",
"Liabilities, Non-Current": "24.3",
"Selling, General and Administrative Expense": "23.1",
"Expenses": "-29.1",
"Revenues": "55.2",
"Net Income": "49.9",
"Research and Development": "44.3",
"Other Expenses": "-114",
"Cost of Goods Sold": "11.1",
"Other Revenues": "55.2",
"Comprehensive Net Income": "50.0",
"Economic Capital Ratio": "-35.9"
},
"2013": {
"Other Assets": "-27.6",
"Assets": "-124",
"Liabilities": "47.2",
"Stockholders Equity": "-182",
"ECR before LimitedLiability": "-27.0",
"Intangible Assets": "-39.1",
"Property and Equipment": "17.8",
"Assets, Current": "-107",
"Liabilities, Non-Current": "20.6",
"Liabilities, Current": "-23.7",
"Other Liabilities": "47.3",
"Selling, General and Administrative Expense": "17.1",
"Expenses": "-41.7",
"Revenues": "56.1",
"Net Income": "51.1",
"Other Expenses": "-104",
"Research and Development": "46.9",
"Other Revenues": "56.1",
"Comprehensive Net Income": "51.0",
"Other Net Income": "17.8",
"Economic Capital Ratio": "-54.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000896747_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,276",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,391",
"Liabilities, Non-Current": "751",
"Other Assets": "56",
"Other Compr. Net Income": "0",
"Other Expenses": "7,381",
"Other Liabilities": "124",
"Other Net Income": "9.0",
"Other Revenues": "9,272",
"Property and Equipment": "1,304",
"Research and Development": "223",
"Selling, General and Administrative Expense": "2,022"
},
"output_variables": {
"Assets": "5,636",
"Liabilities": "3,266",
"Expenses": "9,626",
"Revenues": "9,272",
"Stockholders Equity": "2,370",
"Net Income": "-345",
"Comprehensive Net Income": "-345",
"BaseVar": "13,904",
"ECR before LimitedLiability": "108%",
"Economic Capital Ratio": "237%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "3,520",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,146",
"Liabilities, Non-Current": "145",
"Other Assets": "67",
"Other Compr. Net Income": "0",
"Other Expenses": "8,020",
"Other Liabilities": "124",
"Other Net Income": "10",
"Other Revenues": "9,343",
"Property and Equipment": "1,192",
"Research and Development": "207",
"Selling, General and Administrative Expense": "2,237"
},
"output_variables": {
"Assets": "4,779",
"Liabilities": "3,415",
"Expenses": "10,464",
"Revenues": "9,343",
"Stockholders Equity": "1,364",
"Net Income": "-1,111",
"Comprehensive Net Income": "-1,111",
"BaseVar": "14,006",
"ECR before LimitedLiability": "45%",
"Economic Capital Ratio": "184%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "3,739",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,357",
"Liabilities, Non-Current": "147",
"Other Assets": "137",
"Other Compr. Net Income": "0",
"Other Expenses": "7,356",
"Other Liabilities": "124",
"Other Net Income": "655",
"Other Revenues": "8,894",
"Property and Equipment": "1,090",
"Research and Development": "645",
"Selling, General and Administrative Expense": "2,336"
},
"output_variables": {
"Assets": "4,966",
"Liabilities": "3,628",
"Expenses": "10,337",
"Revenues": "8,894",
"Stockholders Equity": "1,338",
"Net Income": "-788",
"Comprehensive Net Income": "-788",
"BaseVar": "14,240",
"ECR before LimitedLiability": "50%",
"Economic Capital Ratio": "188%"
}
}
},
"top_rated": false,
"trend": -19.0,
"value": 1.8784732375141806,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000896747.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000896747.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000896747.svg"
},
{
"company_id": "0001411906",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001411906.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001411906.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001411906.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001411906_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001411906_main_keyfigs.svg",
"name": "Ampio Pharmaceuticals Inc",
"rank": 154,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001411906.svg",
"report_text": "The relative strengths and weaknesses of Ampio Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ampio Pharmaceuticals Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 52% points.The greatest weakness of Ampio Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 164% points.
The company's Economic Capital Ratio, given in the ranking table, is 184%, being 58% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001411906_2014_Ampio_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "91.4",
"Assets": "30.7",
"Liabilities": "90.8",
"Stockholders Equity": "95.1",
"ECR before LimitedLiability": "73.1",
"Intangible Assets": "-19.3",
"Property and Equipment": "-14.9",
"Assets, Current": "-8.70",
"Other Liabilities": "34.4",
"Liabilities, Non-Current": "18.3",
"Liabilities, Current": "60.8",
"Research and Development": "-18.7",
"Expenses": "-27.3",
"Revenues": "-43.2",
"Net Income": "-118",
"Other Expenses": "14.3",
"Cost of Goods Sold": "5.83",
"Selling, General and Administrative Expense": "-27.8",
"Other Revenues": "-43.2",
"Comprehensive Net Income": "-118",
"Other Net Income": "-55.3",
"Economic Capital Ratio": "-2.47"
},
"2012": {
"Property and Equipment": "-16.7",
"Assets": "26.5",
"Liabilities": "82.6",
"Stockholders Equity": "90.1",
"ECR before LimitedLiability": "74.6",
"Assets, Current": "7.86",
"Intangible Assets": "-20.4",
"Other Assets": "78.8",
"Liabilities, Current": "71.7",
"Other Liabilities": "42.1",
"Liabilities, Non-Current": "22.2",
"Selling, General and Administrative Expense": "48.8",
"Expenses": "-51.4",
"Revenues": "-41.7",
"Net Income": "-125",
"Research and Development": "50.8",
"Other Expenses": "-134",
"Cost of Goods Sold": "7.05",
"Other Revenues": "-41.7",
"Comprehensive Net Income": "-124",
"Other Net Income": "-41.8",
"Economic Capital Ratio": "1.49"
},
"2013": {
"Other Assets": "43.4",
"Assets": "-36.2",
"Liabilities": "52.3",
"Stockholders Equity": "49.2",
"ECR before LimitedLiability": "-30.3",
"Intangible Assets": "-27.8",
"Property and Equipment": "-9.80",
"Assets, Current": "-33.8",
"Liabilities, Non-Current": "22.1",
"Liabilities, Current": "44.9",
"Other Liabilities": "43.6",
"Selling, General and Administrative Expense": "-37.6",
"Expenses": "-104",
"Revenues": "-43.8",
"Net Income": "-164",
"Other Expenses": "26.4",
"Research and Development": "-97.7",
"Other Revenues": "-43.8",
"Comprehensive Net Income": "-164",
"Other Net Income": "-33.0",
"Economic Capital Ratio": "-58.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001411906_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "11,405",
"Cost of Goods Sold": "0",
"Intangible Assets": "466",
"Liabilities, Current": "1,292",
"Liabilities, Non-Current": "0",
"Other Assets": "7,535",
"Other Compr. Net Income": "0",
"Other Expenses": "313",
"Other Liabilities": "431",
"Other Net Income": "-8,473",
"Other Revenues": "0",
"Property and Equipment": "76",
"Research and Development": "9,460",
"Selling, General and Administrative Expense": "9,679"
},
"output_variables": {
"Assets": "19,483",
"Liabilities": "1,723",
"Expenses": "19,452",
"Revenues": "0",
"Stockholders Equity": "17,760",
"Net Income": "-27,926",
"Comprehensive Net Income": "-27,926",
"BaseVar": "24,565",
"ECR before LimitedLiability": "102%",
"Economic Capital Ratio": "232%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "17,847",
"Cost of Goods Sold": "0",
"Intangible Assets": "420",
"Liabilities, Current": "1,636",
"Liabilities, Non-Current": "0",
"Other Assets": "7,520",
"Other Compr. Net Income": "0",
"Other Expenses": "31,323",
"Other Liabilities": "381",
"Other Net Income": "-8,195",
"Other Revenues": "0",
"Property and Equipment": "59",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "25,847",
"Liabilities": "2,017",
"Expenses": "31,323",
"Revenues": "0",
"Stockholders Equity": "23,830",
"Net Income": "-39,519",
"Comprehensive Net Income": "-39,519",
"BaseVar": "33,691",
"ECR before LimitedLiability": "89%",
"Economic Capital Ratio": "222%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "26,441",
"Cost of Goods Sold": "0",
"Intangible Assets": "735",
"Liabilities, Current": "2,473",
"Liabilities, Non-Current": "0",
"Other Assets": "7,544",
"Other Compr. Net Income": "0",
"Other Expenses": "82",
"Other Liabilities": "331",
"Other Net Income": "-8,130",
"Other Revenues": "0",
"Property and Equipment": "1,299",
"Research and Development": "35,474",
"Selling, General and Administrative Expense": "19,841"
},
"output_variables": {
"Assets": "36,019",
"Liabilities": "2,804",
"Expenses": "55,397",
"Revenues": "0",
"Stockholders Equity": "33,215",
"Net Income": "-63,527",
"Comprehensive Net Income": "-63,527",
"BaseVar": "51,175",
"ECR before LimitedLiability": "46%",
"Economic Capital Ratio": "184%"
}
}
},
"top_rated": false,
"trend": -40.0,
"value": 1.8445806401826284,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001411906.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001411906.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001411906.svg"
},
{
"company_id": "0000885590",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000885590.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000885590.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000885590.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000885590_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000885590_main_keyfigs.svg",
"name": "Bausch Health Companies Inc",
"rank": 155,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000885590.svg",
"report_text": "The relative strengths and weaknesses of Bausch Health Companies Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Bausch Health Companies Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 83% points.The greatest weakness of Bausch Health Companies Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 164% points.
The company's Economic Capital Ratio, given in the ranking table, is 181%, being 62% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000885590_2014_Bausch_Health_Companies_Inc.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-10.9",
"Assets": "47.4",
"Liabilities": "-75.2",
"Stockholders Equity": "-0.525",
"ECR before LimitedLiability": "-31.0",
"Assets, Current": "-35.4",
"Property and Equipment": "-10.8",
"Intangible Assets": "126",
"Liabilities, Current": "20.2",
"Other Liabilities": "-16.8",
"Liabilities, Non-Current": "-80.4",
"Selling, General and Administrative Expense": "13.6",
"Expenses": "27.4",
"Revenues": "-21.1",
"Net Income": "4.87",
"Research and Development": "8.81",
"Cost of Goods Sold": "3.77",
"Other Expenses": "0.605",
"Other Revenues": "-21.1",
"Comprehensive Net Income": "4.88",
"Economic Capital Ratio": "-37.3"
},
"2011": {
"Other Assets": "-10.0",
"Assets": "61.3",
"Liabilities": "-106",
"Stockholders Equity": "-21.1",
"ECR before LimitedLiability": "55.4",
"Intangible Assets": "116",
"Property and Equipment": "-4.46",
"Assets, Current": "-52.9",
"Other Liabilities": "-7.26",
"Liabilities, Non-Current": "-138",
"Liabilities, Current": "29.2",
"Research and Development": "28.8",
"Expenses": "50.2",
"Revenues": "-6.82",
"Net Income": "44.7",
"Other Expenses": "-3.51",
"Cost of Goods Sold": "3.20",
"Selling, General and Administrative Expense": "20.1",
"Other Revenues": "-6.82",
"Comprehensive Net Income": "44.4",
"Economic Capital Ratio": "-20.2"
},
"2012": {
"Property and Equipment": "-6.52",
"Assets": "47.4",
"Liabilities": "-113",
"Stockholders Equity": "-38.9",
"ECR before LimitedLiability": "41.4",
"Assets, Current": "-58.2",
"Intangible Assets": "88.4",
"Other Assets": "-8.83",
"Liabilities, Current": "27.3",
"Other Liabilities": "2.22",
"Liabilities, Non-Current": "-156",
"Selling, General and Administrative Expense": "21.9",
"Expenses": "47.4",
"Revenues": "-5.00",
"Net Income": "47.3",
"Research and Development": "26.9",
"Cost of Goods Sold": "3.91",
"Other Revenues": "-5.00",
"Comprehensive Net Income": "47.3",
"Other Net Income": "1.97",
"Economic Capital Ratio": "-31.7"
},
"2013": {
"Other Assets": "-12.0",
"Assets": "21.8",
"Liabilities": "-110",
"Stockholders Equity": "-62.6",
"ECR before LimitedLiability": "-34.1",
"Intangible Assets": "83.4",
"Property and Equipment": "-1.85",
"Assets, Current": "-74.1",
"Liabilities, Non-Current": "-164",
"Liabilities, Current": "32.3",
"Other Liabilities": "4.90",
"Selling, General and Administrative Expense": "20.8",
"Expenses": "39.6",
"Revenues": "-1.54",
"Net Income": "39.6",
"Other Expenses": "-5.88",
"Research and Development": "25.2",
"Cost of Goods Sold": "2.85",
"Other Revenues": "-1.54",
"Comprehensive Net Income": "39.6",
"Economic Capital Ratio": "-62.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000885590_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,020,166",
"Cost of Goods Sold": "0",
"Intangible Assets": "9,374,156",
"Liabilities, Current": "692,456",
"Liabilities, Non-Current": "3,608,699",
"Other Assets": "119,043",
"Other Compr. Net Income": "0",
"Other Expenses": "919,231",
"Other Liabilities": "1,582,866",
"Other Net Income": "-36,097",
"Other Revenues": "1,181,237",
"Property and Equipment": "281,752",
"Research and Development": "157,556",
"Selling, General and Administrative Expense": "276,546"
},
"output_variables": {
"Assets": "10,795,117",
"Liabilities": "5,884,021",
"Expenses": "1,353,333",
"Revenues": "1,181,237",
"Stockholders Equity": "4,911,096",
"Net Income": "-208,193",
"Comprehensive Net Income": "-208,193",
"BaseVar": "9,624,902",
"ECR before LimitedLiability": "126%",
"Economic Capital Ratio": "250%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,357,506",
"Cost of Goods Sold": "0",
"Intangible Assets": "11,256,584",
"Liabilities, Current": "924,272",
"Liabilities, Non-Current": "6,616,439",
"Other Assets": "113,381",
"Other Compr. Net Income": "0",
"Other Expenses": "1,682,299",
"Other Liabilities": "1,593,986",
"Other Net Income": "16,567",
"Other Revenues": "2,463,450",
"Property and Equipment": "414,242",
"Research and Development": "65,687",
"Selling, General and Administrative Expense": "572,472"
},
"output_variables": {
"Assets": "13,141,713",
"Liabilities": "9,134,697",
"Expenses": "2,320,458",
"Revenues": "2,463,450",
"Stockholders Equity": "4,007,016",
"Net Income": "159,559",
"Comprehensive Net Income": "159,559",
"BaseVar": "13,538,442",
"ECR before LimitedLiability": "80%",
"Economic Capital Ratio": "214%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "2,777,451",
"Cost of Goods Sold": "0",
"Intangible Assets": "14,450,035",
"Liabilities, Current": "1,822,752",
"Liabilities, Non-Current": "10,669,609",
"Other Assets": "260,169",
"Other Compr. Net Income": "160,220",
"Other Expenses": "2,835,199",
"Other Liabilities": "1,740,620",
"Other Net Income": "7,683",
"Other Revenues": "3,546,626",
"Property and Equipment": "462,724",
"Research and Development": "79,052",
"Selling, General and Administrative Expense": "756,083"
},
"output_variables": {
"Assets": "17,950,379",
"Liabilities": "14,232,981",
"Expenses": "3,670,334",
"Revenues": "3,546,626",
"Stockholders Equity": "3,717,398",
"Net Income": "-116,025",
"Comprehensive Net Income": "-35,915",
"BaseVar": "19,784,112",
"ECR before LimitedLiability": "50%",
"Economic Capital Ratio": "188%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "3,885,889",
"Cost of Goods Sold": "0",
"Intangible Assets": "22,600,260",
"Liabilities, Current": "2,512,396",
"Liabilities, Non-Current": "17,323,439",
"Other Assets": "250,412",
"Other Compr. Net Income": "159,367",
"Other Expenses": "16,486,350",
"Other Liabilities": "2,901,640",
"Other Net Income": "-40,013",
"Other Revenues": "16,873,552",
"Property and Equipment": "1,234,236",
"Research and Development": "132,705",
"Selling, General and Administrative Expense": "4,043,912"
},
"output_variables": {
"Assets": "27,970,797",
"Liabilities": "22,737,475",
"Expenses": "20,662,968",
"Revenues": "16,873,552",
"Stockholders Equity": "5,233,322",
"Net Income": "-3,829,429",
"Comprehensive Net Income": "-3,749,746",
"BaseVar": "44,222,086",
"ECR before LimitedLiability": "30%",
"Economic Capital Ratio": "170%"
}
}
},
"top_rated": false,
"trend": -24.0,
"value": 1.8067134372887013,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000885590.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000885590.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000885590.svg"
},
{
"company_id": "0001017491",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001017491.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001017491.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001017491.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001017491_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001017491_main_keyfigs.svg",
"name": "Seelos Therapeutics INC",
"rank": 156,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001017491.svg",
"report_text": "The relative strengths and weaknesses of Seelos Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Seelos Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 38% points.The greatest weakness of Seelos Therapeutics INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 76% points.
The company's Economic Capital Ratio, given in the ranking table, is 178%, being 64% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001017491_2014_Seelos_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.32",
"Assets": "-3.09",
"Liabilities": "-3.18",
"Stockholders Equity": "-40.1",
"ECR before LimitedLiability": "-20.7",
"Intangible Assets": "3.40",
"Property and Equipment": "9.40",
"Assets, Current": "-26.7",
"Other Liabilities": "1.21",
"Liabilities, Non-Current": "1.74",
"Liabilities, Current": "-30.1",
"Research and Development": "1.72",
"Expenses": "-2.76",
"Revenues": "-1.90",
"Net Income": "-3.18",
"Other Expenses": "-1.78",
"Cost of Goods Sold": "0.761",
"Selling, General and Administrative Expense": "-2.82",
"Other Revenues": "-1.90",
"Comprehensive Net Income": "-3.19",
"Economic Capital Ratio": "-96.2"
},
"2012": {
"Property and Equipment": "-3.52",
"Assets": "-7.51",
"Liabilities": "-2.84",
"Stockholders Equity": "-26.7",
"ECR before LimitedLiability": "-13.5",
"Assets, Current": "-3.74",
"Intangible Assets": "-5.61",
"Liabilities, Current": "-2.63",
"Other Liabilities": "-2.79",
"Liabilities, Non-Current": "2.81",
"Selling, General and Administrative Expense": "-3.63",
"Expenses": "-3.41",
"Revenues": "-1.45",
"Net Income": "-6.81",
"Research and Development": "5.43",
"Other Expenses": "-4.77",
"Cost of Goods Sold": "1.44",
"Other Revenues": "-1.45",
"Comprehensive Net Income": "-6.70",
"Other Net Income": "-4.06",
"Economic Capital Ratio": "-86.6"
},
"2013": {
"Liabilities, Non-Current": "12.8",
"Liabilities": "-25.1",
"Stockholders Equity": "-21.4",
"ECR before LimitedLiability": "-36.3",
"Liabilities, Current": "-76.0",
"Other Liabilities": "32.2",
"Selling, General and Administrative Expense": "-34.7",
"Expenses": "-15.2",
"Net Income": "-26.9",
"Other Expenses": "10.4",
"Research and Development": "6.90",
"Cost of Goods Sold": "3.79",
"Other Revenues": "-16.2",
"Revenues": "-16.2",
"Intangible Assets": "-22.2",
"Property and Equipment": "-4.32",
"Other Assets": "-17.0",
"Assets, Current": "37.9",
"Comprehensive Net Income": "-27.3",
"Other Net Income": "4.16",
"Economic Capital Ratio": "-64.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001017491_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "8,191",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,760",
"Liabilities, Current": "10,021",
"Liabilities, Non-Current": "28",
"Other Assets": "280",
"Other Compr. Net Income": "0",
"Other Expenses": "4,997",
"Other Liabilities": "1,749",
"Other Net Income": "63",
"Other Revenues": "4,101",
"Property and Equipment": "4,384",
"Research and Development": "5,821",
"Selling, General and Administrative Expense": "11,463"
},
"output_variables": {
"Assets": "16,616",
"Liabilities": "11,797",
"Expenses": "22,281",
"Revenues": "4,101",
"Stockholders Equity": "4,818",
"Net Income": "-18,117",
"Comprehensive Net Income": "-18,117",
"BaseVar": "27,429",
"ECR before LimitedLiability": "-54%",
"Economic Capital Ratio": "138%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "20,895",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "10,766",
"Liabilities, Non-Current": "196",
"Other Assets": "2,383",
"Other Compr. Net Income": "641",
"Other Expenses": "13,074",
"Other Liabilities": "6,296",
"Other Net Income": "-6,361",
"Other Revenues": "8,416",
"Property and Equipment": "601",
"Research and Development": "5,375",
"Selling, General and Administrative Expense": "15,377"
},
"output_variables": {
"Assets": "23,879",
"Liabilities": "17,258",
"Expenses": "33,826",
"Revenues": "8,416",
"Stockholders Equity": "6,621",
"Net Income": "-31,771",
"Comprehensive Net Income": "-31,450",
"BaseVar": "45,190",
"ECR before LimitedLiability": "-83%",
"Economic Capital Ratio": "134%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "22,264",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "11,760",
"Liabilities, Non-Current": "91",
"Other Assets": "91",
"Other Compr. Net Income": "0",
"Other Expenses": "1,201",
"Other Liabilities": "487",
"Other Net Income": "429",
"Other Revenues": "2,511",
"Property and Equipment": "955",
"Research and Development": "5,123",
"Selling, General and Administrative Expense": "13,554"
},
"output_variables": {
"Assets": "23,310",
"Liabilities": "12,338",
"Expenses": "19,878",
"Revenues": "2,511",
"Stockholders Equity": "10,972",
"Net Income": "-16,938",
"Comprehensive Net Income": "-16,938",
"BaseVar": "29,233",
"ECR before LimitedLiability": "39%",
"Economic Capital Ratio": "178%"
}
}
},
"top_rated": false,
"trend": 6.0,
"value": 1.7849312945117932,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001017491.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001017491.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001017491.svg"
},
{
"company_id": "0001011835",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001011835.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001011835.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001011835_main_keyfigs.svg",
"name": "Medivation INC",
"rank": 157,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001011835.svg",
"report_text": "The relative strengths and weaknesses of Medivation INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Medivation INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 36% points.The greatest weakness of Medivation INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 99% points.
The company's Economic Capital Ratio, given in the ranking table, is 175%, being 68% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001011835_2014_Medivation_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-0.426",
"Assets": "-0.224",
"Liabilities": "-116",
"Stockholders Equity": "-92.0",
"ECR before LimitedLiability": "-17.9",
"Intangible Assets": "-7.61",
"Property and Equipment": "-0.464",
"Assets, Current": "7.31",
"Other Liabilities": "-62.3",
"Liabilities, Non-Current": "0.605",
"Liabilities, Current": "-36.6",
"Expenses": "3.09",
"Revenues": "-16.0",
"Net Income": "3.20",
"Other Expenses": "0.984",
"Cost of Goods Sold": "0.237",
"Selling, General and Administrative Expense": "1.13",
"Other Revenues": "-16.0",
"Comprehensive Net Income": "3.15",
"Other Net Income": "3.25",
"Economic Capital Ratio": "-93.5"
},
"2012": {
"Property and Equipment": "-8.28",
"Assets": "3.96",
"Liabilities": "-85.4",
"Stockholders Equity": "-62.9",
"ECR before LimitedLiability": "28.2",
"Assets, Current": "34.5",
"Intangible Assets": "-20.8",
"Other Assets": "-8.09",
"Liabilities, Current": "11.8",
"Other Liabilities": "-111",
"Liabilities, Non-Current": "9.05",
"Expenses": "34.2",
"Revenues": "-31.0",
"Net Income": "34.7",
"Research and Development": "8.51",
"Other Expenses": "20.4",
"Cost of Goods Sold": "5.14",
"Other Revenues": "-31.0",
"Comprehensive Net Income": "34.7",
"Other Net Income": "34.5",
"Economic Capital Ratio": "-44.9"
},
"2013": {
"Other Assets": "-9.44",
"Assets": "-45.7",
"Liabilities": "-60.9",
"Stockholders Equity": "-99.4",
"ECR before LimitedLiability": "-39.8",
"Intangible Assets": "-24.3",
"Property and Equipment": "-6.49",
"Assets, Current": "-12.0",
"Liabilities, Non-Current": "8.10",
"Liabilities, Current": "19.3",
"Other Liabilities": "-93.3",
"Selling, General and Administrative Expense": "-9.66",
"Expenses": "17.7",
"Revenues": "-30.8",
"Net Income": "34.5",
"Other Expenses": "18.3",
"Research and Development": "5.19",
"Other Revenues": "-30.8",
"Comprehensive Net Income": "34.5",
"Other Net Income": "35.6",
"Economic Capital Ratio": "-67.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001011835_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "168,189",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "89,634",
"Liabilities, Non-Current": "653",
"Other Assets": "6,208",
"Other Compr. Net Income": "0",
"Other Expenses": "-4,331",
"Other Liabilities": "83,509",
"Other Net Income": "60,147",
"Other Revenues": "0",
"Property and Equipment": "720",
"Research and Development": "73,432",
"Selling, General and Administrative Expense": "29,887"
},
"output_variables": {
"Assets": "175,117",
"Liabilities": "173,796",
"Expenses": "98,988",
"Revenues": "0",
"Stockholders Equity": "1,321",
"Net Income": "-38,841",
"Comprehensive Net Income": "-38,841",
"BaseVar": "254,024",
"ECR before LimitedLiability": "-21%",
"Economic Capital Ratio": "141%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "344,216",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "84,886",
"Liabilities, Non-Current": "8,863",
"Other Assets": "14,388",
"Other Compr. Net Income": "20",
"Other Expenses": "7.0",
"Other Liabilities": "204,472",
"Other Net Income": "166,660",
"Other Revenues": "0",
"Property and Equipment": "13,262",
"Research and Development": "95,628",
"Selling, General and Administrative Expense": "112,282"
},
"output_variables": {
"Assets": "371,866",
"Liabilities": "298,221",
"Expenses": "207,917",
"Revenues": "0",
"Stockholders Equity": "73,645",
"Net Income": "-41,257",
"Comprehensive Net Income": "-41,247",
"BaseVar": "522,342",
"ECR before LimitedLiability": "36%",
"Economic Capital Ratio": "175%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "353,979",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "95,689",
"Liabilities, Non-Current": "11,600",
"Other Assets": "21,636",
"Other Compr. Net Income": "-33",
"Other Expenses": "115",
"Other Liabilities": "208,414",
"Other Net Income": "252,685",
"Other Revenues": "0",
"Property and Equipment": "17,035",
"Research and Development": "118,952",
"Selling, General and Administrative Expense": "176,231"
},
"output_variables": {
"Assets": "392,650",
"Liabilities": "315,703",
"Expenses": "295,298",
"Revenues": "0",
"Stockholders Equity": "76,947",
"Net Income": "-42,613",
"Comprehensive Net Income": "-42,630",
"BaseVar": "628,184",
"ECR before LimitedLiability": "35%",
"Economic Capital Ratio": "175%"
}
}
},
"top_rated": false,
"trend": -21.0,
"value": 1.7497189554522121,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001011835.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001011835.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001011835.svg"
},
{
"company_id": "0001367083",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001367083.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001367083.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001367083.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001367083_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001367083_main_keyfigs.svg",
"name": "Sonoma Pharmaceuticals Inc",
"rank": 158,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001367083.svg",
"report_text": "The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 36% points.The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 138% points.
The company's Economic Capital Ratio, given in the ranking table, is 173%, being 70% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001367083_2014_Sonoma_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.02",
"Assets": "-86.7",
"Stockholders Equity": "-121",
"Other Liabilities": "3.43",
"Intangible Assets": "-3.45",
"Property and Equipment": "-1.33",
"Assets, Current": "-26.1",
"Research and Development": "8.76",
"Expenses": "-3.21",
"Revenues": "9.56",
"Net Income": "1.45",
"Other Expenses": "2.37",
"Cost of Goods Sold": "-2.92",
"Selling, General and Administrative Expense": "-31.4",
"Other Revenues": "9.56",
"ECR before LimitedLiability": "-20.7",
"Liabilities, Non-Current": "-2.01",
"Liabilities, Current": "-1.15",
"Comprehensive Net Income": "1.43",
"Other Net Income": "0.899",
"Economic Capital Ratio": "-96.2"
},
"2012": {
"Property and Equipment": "-3.94",
"Assets": "-94.4",
"Liabilities": "-1.05",
"Stockholders Equity": "-139",
"ECR before LimitedLiability": "-19.5",
"Assets, Current": "-41.6",
"Intangible Assets": "-10.3",
"Other Assets": "-7.96",
"Other Liabilities": "1.26",
"Liabilities, Non-Current": "-3.21",
"Selling, General and Administrative Expense": "-12.9",
"Expenses": "-9.20",
"Revenues": "24.5",
"Net Income": "11.8",
"Research and Development": "13.0",
"Other Expenses": "7.03",
"Cost of Goods Sold": "-7.44",
"Other Revenues": "24.5",
"Comprehensive Net Income": "11.6",
"Other Net Income": "2.07",
"Economic Capital Ratio": "-92.6"
},
"2013": {
"Other Assets": "-25.7",
"Assets": "-106",
"Liabilities": "32.0",
"Stockholders Equity": "-138",
"ECR before LimitedLiability": "-41.8",
"Intangible Assets": "-35.9",
"Property and Equipment": "-9.61",
"Assets, Current": "-72.4",
"Liabilities, Non-Current": "9.48",
"Liabilities, Current": "14.5",
"Other Liabilities": "9.88",
"Selling, General and Administrative Expense": "-45.9",
"Expenses": "-29.6",
"Revenues": "36.0",
"Net Income": "32.5",
"Other Expenses": "17.2",
"Research and Development": "32.0",
"Cost of Goods Sold": "-33.5",
"Other Revenues": "36.0",
"Comprehensive Net Income": "32.5",
"Economic Capital Ratio": "-69.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001367083_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "7,809",
"Cost of Goods Sold": "3,613",
"Intangible Assets": "0",
"Liabilities, Current": "4,415",
"Liabilities, Non-Current": "1,638",
"Other Assets": "53",
"Other Compr. Net Income": "87",
"Other Expenses": "581",
"Other Liabilities": "910",
"Other Net Income": "138",
"Other Revenues": "9,754",
"Property and Equipment": "802",
"Research and Development": "2,046",
"Selling, General and Administrative Expense": "11,600"
},
"output_variables": {
"Assets": "8,664",
"Liabilities": "6,963",
"Expenses": "17,840",
"Revenues": "9,754",
"Stockholders Equity": "1,701",
"Net Income": "-7,948",
"Comprehensive Net Income": "-7,904",
"BaseVar": "21,723",
"ECR before LimitedLiability": "-54%",
"Economic Capital Ratio": "138%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "6,960",
"Cost of Goods Sold": "4,030",
"Intangible Assets": "0",
"Liabilities, Current": "4,749",
"Liabilities, Non-Current": "1,824",
"Other Assets": "72",
"Other Compr. Net Income": "-152",
"Other Expenses": "1,148",
"Other Liabilities": "2,133",
"Other Net Income": "286",
"Other Revenues": "12,744",
"Property and Equipment": "806",
"Research and Development": "1,981",
"Selling, General and Administrative Expense": "13,200"
},
"output_variables": {
"Assets": "7,838",
"Liabilities": "8,706",
"Expenses": "20,359",
"Revenues": "12,744",
"Stockholders Equity": "-868",
"Net Income": "-7,329",
"Comprehensive Net Income": "-7,405",
"BaseVar": "25,042",
"ECR before LimitedLiability": "-112%",
"Economic Capital Ratio": "127%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "11,534",
"Cost of Goods Sold": "4,709",
"Intangible Assets": "0",
"Liabilities, Current": "5,127",
"Liabilities, Non-Current": "676",
"Other Assets": "231",
"Other Compr. Net Income": "62",
"Other Expenses": "1,232",
"Other Liabilities": "2,681",
"Other Net Income": "-825",
"Other Revenues": "15,452",
"Property and Equipment": "800",
"Research and Development": "2,223",
"Selling, General and Administrative Expense": "11,894"
},
"output_variables": {
"Assets": "12,565",
"Liabilities": "8,484",
"Expenses": "20,058",
"Revenues": "15,452",
"Stockholders Equity": "4,081",
"Net Income": "-5,431",
"Comprehensive Net Income": "-5,400",
"BaseVar": "28,723",
"ECR before LimitedLiability": "33%",
"Economic Capital Ratio": "173%"
}
}
},
"top_rated": false,
"trend": 11.0,
"value": 1.7303063315643687,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001367083.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001367083.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001367083.svg"
},
{
"company_id": "0001326190",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001326190.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001326190.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001326190.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001326190_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001326190_main_keyfigs.svg",
"name": "Altimmune Inc",
"rank": 159,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001326190.svg",
"report_text": "The relative strengths and weaknesses of Altimmune Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Altimmune Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 41% points.The greatest weakness of Altimmune Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 113% points.
The company's Economic Capital Ratio, given in the ranking table, is 172%, being 71% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001326190_2014_Altimmune_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-15.0",
"Assets": "-43.3",
"Liabilities": "105",
"Stockholders Equity": "-34.2",
"ECR before LimitedLiability": "148",
"Intangible Assets": "-9.75",
"Property and Equipment": "-9.46",
"Assets, Current": "-20.6",
"Other Liabilities": "28.7",
"Liabilities, Non-Current": "25.8",
"Liabilities, Current": "58.3",
"Research and Development": "-33.2",
"Expenses": "-21.0",
"Revenues": "56.6",
"Net Income": "78.2",
"Other Expenses": "17.8",
"Selling, General and Administrative Expense": "-12.1",
"Other Revenues": "56.6",
"Comprehensive Net Income": "76.9",
"Other Net Income": "41.3",
"Economic Capital Ratio": "72.3"
},
"2012": {
"Property and Equipment": "-13.4",
"Assets": "-48.9",
"Liabilities": "53.5",
"Stockholders Equity": "-45.4",
"ECR before LimitedLiability": "99.8",
"Assets, Current": "-22.2",
"Intangible Assets": "-8.67",
"Other Assets": "-16.0",
"Liabilities, Current": "20.0",
"Other Liabilities": "37.8",
"Selling, General and Administrative Expense": "-4.02",
"Expenses": "-7.76",
"Revenues": "-44.0",
"Net Income": "76.4",
"Research and Development": "-35.8",
"Other Expenses": "27.3",
"Cost of Goods Sold": "7.41",
"Other Revenues": "-44.0",
"Comprehensive Net Income": "76.8",
"Other Net Income": "108",
"Economic Capital Ratio": "26.7"
},
"2013": {
"Other Assets": "-28.2",
"Assets": "-100.0",
"Liabilities": "30.9",
"Stockholders Equity": "-113",
"ECR before LimitedLiability": "-43.2",
"Intangible Assets": "-8.75",
"Property and Equipment": "-17.4",
"Assets, Current": "-74.5",
"Liabilities, Current": "9.76",
"Other Liabilities": "30.6",
"Selling, General and Administrative Expense": "-34.5",
"Expenses": "-50.4",
"Revenues": "-46.4",
"Net Income": "18.3",
"Other Expenses": "26.7",
"Research and Development": "-46.9",
"Cost of Goods Sold": "6.37",
"Other Revenues": "-46.4",
"Comprehensive Net Income": "17.7",
"Other Net Income": "41.2",
"Economic Capital Ratio": "-71.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001326190_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "19,613",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,348",
"Liabilities, Current": "4,615",
"Liabilities, Non-Current": "0",
"Other Assets": "53",
"Other Compr. Net Income": "-240",
"Other Expenses": "461",
"Other Liabilities": "2,336",
"Other Net Income": "7,928",
"Other Revenues": "24,266",
"Property and Equipment": "789",
"Research and Development": "21,220",
"Selling, General and Administrative Expense": "14,311"
},
"output_variables": {
"Assets": "22,804",
"Liabilities": "6,952",
"Expenses": "35,992",
"Revenues": "24,266",
"Stockholders Equity": "15,852",
"Net Income": "-3,798",
"Comprehensive Net Income": "-3,918",
"BaseVar": "49,091",
"ECR before LimitedLiability": "206%",
"Economic Capital Ratio": "306%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "19,796",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,348",
"Liabilities, Current": "7,488",
"Liabilities, Non-Current": "2,284",
"Other Assets": "113",
"Other Compr. Net Income": "0",
"Other Expenses": "499",
"Other Liabilities": "1,296",
"Other Net Income": "26,718",
"Other Revenues": "0",
"Property and Equipment": "484",
"Research and Development": "19,510",
"Selling, General and Administrative Expense": "11,629"
},
"output_variables": {
"Assets": "22,741",
"Liabilities": "11,068",
"Expenses": "31,638",
"Revenues": "0",
"Stockholders Equity": "11,674",
"Net Income": "-4,920",
"Comprehensive Net Income": "-4,920",
"BaseVar": "46,082",
"ECR before LimitedLiability": "121%",
"Economic Capital Ratio": "247%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "14,339",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,348",
"Liabilities, Current": "6,796",
"Liabilities, Non-Current": "1,319",
"Other Assets": "66",
"Other Compr. Net Income": "0",
"Other Expenses": "244",
"Other Liabilities": "1,689",
"Other Net Income": "17,095",
"Other Revenues": "0",
"Property and Equipment": "386",
"Research and Development": "15,290",
"Selling, General and Administrative Expense": "13,279"
},
"output_variables": {
"Assets": "17,139",
"Liabilities": "9,804",
"Expenses": "28,814",
"Revenues": "0",
"Stockholders Equity": "7,336",
"Net Income": "-11,718",
"Comprehensive Net Income": "-11,718",
"BaseVar": "36,426",
"ECR before LimitedLiability": "32%",
"Economic Capital Ratio": "172%"
}
}
},
"top_rated": false,
"trend": -57.0,
"value": 1.7163911152822329,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001326190.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001326190.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001326190.svg"
},
{
"company_id": "0001436161",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001436161.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001436161.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001436161_main_keyfigs.svg",
"name": "United Cannabis Corp",
"rank": 160,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001436161.svg",
"report_text": "The relative strengths and weaknesses of United Cannabis Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of United Cannabis Corp compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 41% points.The greatest weakness of United Cannabis Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 186% points.
The company's Economic Capital Ratio, given in the ranking table, is 170%, being 73% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001436161_2014_United_Cannabis_Corp.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-17.4",
"Assets": "-52.0",
"Liabilities": "-59.0",
"Stockholders Equity": "-108",
"Assets, Current": "-17.9",
"Intangible Assets": "-26.1",
"Other Assets": "0.352",
"Liabilities, Current": "-133",
"Other Liabilities": "1.99",
"Liabilities, Non-Current": "0.564",
"Selling, General and Administrative Expense": "-57.4",
"Expenses": "0.440",
"Revenues": "1.98",
"Net Income": "4.13",
"Research and Development": "3.07",
"Other Expenses": "1.15",
"Cost of Goods Sold": "0.135",
"Other Revenues": "1.98",
"ECR before LimitedLiability": "-5.99",
"Comprehensive Net Income": "4.17",
"Economic Capital Ratio": "-79.1"
},
"2013": {
"Other Assets": "27.8",
"Assets": "-125",
"Liabilities": "27.6",
"Stockholders Equity": "-186",
"ECR before LimitedLiability": "-45.0",
"Intangible Assets": "-39.2",
"Property and Equipment": "-24.2",
"Assets, Current": "-111",
"Liabilities, Non-Current": "24.9",
"Liabilities, Current": "-73.3",
"Other Liabilities": "30.2",
"Selling, General and Administrative Expense": "-108",
"Expenses": "-25.9",
"Revenues": "40.9",
"Net Income": "36.0",
"Other Expenses": "28.8",
"Research and Development": "30.2",
"Cost of Goods Sold": "7.04",
"Other Revenues": "40.9",
"Comprehensive Net Income": "35.9",
"Economic Capital Ratio": "-72.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001436161_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "91",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "96",
"Liabilities, Non-Current": "0",
"Other Assets": "17",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "84",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "115"
},
"output_variables": {
"Assets": "108",
"Liabilities": "96",
"Expenses": "115",
"Revenues": "84",
"Stockholders Equity": "12",
"Net Income": "-31",
"Comprehensive Net Income": "-31",
"BaseVar": "202",
"ECR before LimitedLiability": "-5.0%",
"Economic Capital Ratio": "141%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "41",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "50",
"Liabilities, Non-Current": "0",
"Other Assets": "18",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "106",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "109"
},
"output_variables": {
"Assets": "59",
"Liabilities": "50",
"Expenses": "109",
"Revenues": "106",
"Stockholders Equity": "8.9",
"Net Income": "-3.2",
"Comprehensive Net Income": "-3.2",
"BaseVar": "162",
"ECR before LimitedLiability": "30%",
"Economic Capital Ratio": "170%"
}
}
},
"top_rated": false,
"trend": -11.0,
"value": 1.698397342869619,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001436161.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001436161.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001436161.svg"
},
{
"company_id": "0001400431",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001400431.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001400431.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001400431_main_keyfigs.svg",
"name": "Patheon INC",
"rank": 161,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001400431.svg",
"report_text": "The relative strengths and weaknesses of Patheon INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Patheon INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 30% points.The greatest weakness of Patheon INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 133% points.
The company's Economic Capital Ratio, given in the ranking table, is 164%, being 79% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001400431_2014_Patheon_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "36.5",
"Assets": "-63.3",
"Liabilities": "-38.9",
"Stockholders Equity": "-107",
"ECR before LimitedLiability": "17.5",
"Assets, Current": "-86.4",
"Intangible Assets": "-28.9",
"Other Assets": "-16.4",
"Liabilities, Current": "23.5",
"Other Liabilities": "-75.6",
"Liabilities, Non-Current": "5.53",
"Selling, General and Administrative Expense": "23.5",
"Expenses": "18.9",
"Revenues": "25.0",
"Net Income": "27.0",
"Research and Development": "24.4",
"Other Expenses": "-63.2",
"Cost of Goods Sold": "7.40",
"Other Revenues": "25.0",
"Comprehensive Net Income": "27.0",
"Economic Capital Ratio": "-55.6"
},
"2013": {
"Other Assets": "-15.4",
"Assets": "-76.1",
"Liabilities": "-50.8",
"Stockholders Equity": "-133",
"ECR before LimitedLiability": "-50.8",
"Intangible Assets": "-9.55",
"Property and Equipment": "29.6",
"Assets, Current": "-98.3",
"Liabilities, Non-Current": "8.46",
"Liabilities, Current": "23.2",
"Other Liabilities": "-103",
"Selling, General and Administrative Expense": "23.0",
"Expenses": "16.3",
"Revenues": "24.6",
"Net Income": "26.1",
"Other Expenses": "-53.3",
"Research and Development": "23.4",
"Cost of Goods Sold": "4.86",
"Other Revenues": "24.6",
"Comprehensive Net Income": "26.0",
"Economic Capital Ratio": "-78.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001400431_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "300,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,500",
"Liabilities, Current": "208,200",
"Liabilities, Non-Current": "47,800",
"Other Assets": "23,000",
"Other Compr. Net Income": "0",
"Other Expenses": "700,400",
"Other Liabilities": "362,600",
"Other Net Income": "-26,800",
"Other Revenues": "749,100",
"Property and Equipment": "416,400",
"Research and Development": "0",
"Selling, General and Administrative Expense": "128,600"
},
"output_variables": {
"Assets": "742,900",
"Liabilities": "618,600",
"Expenses": "829,000",
"Revenues": "749,100",
"Stockholders Equity": "124,300",
"Net Income": "-106,700",
"Comprehensive Net Income": "-106,700",
"BaseVar": "1,483,200",
"ECR before LimitedLiability": "24%",
"Economic Capital Ratio": "165%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "415,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "117,700",
"Liabilities, Current": "246,900",
"Liabilities, Non-Current": "41,800",
"Other Assets": "47,700",
"Other Compr. Net Income": "0",
"Other Expenses": "838,600",
"Other Liabilities": "662,700",
"Other Net Income": "-45,900",
"Other Revenues": "1,023,100",
"Property and Equipment": "496,700",
"Research and Development": "10,900",
"Selling, General and Administrative Expense": "163,600"
},
"output_variables": {
"Assets": "1,077,800",
"Liabilities": "951,400",
"Expenses": "1,013,100",
"Revenues": "1,023,100",
"Stockholders Equity": "126,400",
"Net Income": "-35,900",
"Comprehensive Net Income": "-35,900",
"BaseVar": "2,055,650",
"ECR before LimitedLiability": "24%",
"Economic Capital Ratio": "164%"
}
}
},
"top_rated": false,
"trend": -21.0,
"value": 1.6403959575261913,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001400431.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001400431.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001400431.svg"
},
{
"company_id": "0001389545",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001389545.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001389545.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001389545.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001389545_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001389545_main_keyfigs.svg",
"name": "Stablecoin Development Corp",
"rank": 162,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001389545.svg",
"report_text": "The relative strengths and weaknesses of Stablecoin Development Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Stablecoin Development Corp compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 21% points.The greatest weakness of Stablecoin Development Corp is the variable Research and Development, reducing the Economic Capital Ratio by 58% points.
The company's Economic Capital Ratio, given in the ranking table, is 163%, being 80% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001389545_2014_Stablecoin_Development_Corp.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-2.85",
"Assets": "19.0",
"Liabilities": "47.6",
"Stockholders Equity": "70.4",
"ECR before LimitedLiability": "151",
"Assets, Current": "58.1",
"Intangible Assets": "-11.7",
"Other Assets": "-8.22",
"Liabilities, Current": "26.3",
"Other Liabilities": "5.13",
"Liabilities, Non-Current": "17.9",
"Other Revenues": "8.62",
"Revenues": "8.62",
"Net Income": "19.9",
"Other Net Income": "9.52",
"Comprehensive Net Income": "20.2",
"Research and Development": "-19.1",
"Selling, General and Administrative Expense": "-2.22",
"Other Expenses": "18.7",
"Cost of Goods Sold": "4.74",
"Economic Capital Ratio": "77.9"
},
"2013": {
"Other Assets": "-21.0",
"Assets": "-35.7",
"Liabilities": "16.4",
"Stockholders Equity": "-26.8",
"ECR before LimitedLiability": "-52.2",
"Intangible Assets": "-28.7",
"Property and Equipment": "-6.05",
"Assets, Current": "21.4",
"Liabilities, Non-Current": "16.9",
"Liabilities, Current": "18.4",
"Other Liabilities": "-19.7",
"Selling, General and Administrative Expense": "-11.0",
"Expenses": "-45.1",
"Revenues": "-9.88",
"Net Income": "-55.3",
"Other Expenses": "21.2",
"Research and Development": "-57.6",
"Cost of Goods Sold": "4.79",
"Other Revenues": "-9.88",
"Comprehensive Net Income": "-55.7",
"Economic Capital Ratio": "-80.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001389545_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "18,281",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,173",
"Liabilities, Non-Current": "0",
"Other Assets": "63",
"Other Compr. Net Income": "31",
"Other Expenses": "2.0",
"Other Liabilities": "2,013",
"Other Net Income": "1,284",
"Other Revenues": "6,947",
"Property and Equipment": "891",
"Research and Development": "9,275",
"Selling, General and Administrative Expense": "5,981"
},
"output_variables": {
"Assets": "19,235",
"Liabilities": "5,186",
"Expenses": "15,258",
"Revenues": "6,947",
"Stockholders Equity": "14,049",
"Net Income": "-7,027",
"Comprehensive Net Income": "-7,012",
"BaseVar": "23,970",
"ECR before LimitedLiability": "193%",
"Economic Capital Ratio": "298%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "14,791",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,627",
"Liabilities, Non-Current": "0",
"Other Assets": "141",
"Other Compr. Net Income": "-2.0",
"Other Expenses": "2.0",
"Other Liabilities": "3,507",
"Other Net Income": "-493",
"Other Revenues": "3,254",
"Property and Equipment": "718",
"Research and Development": "12,461",
"Selling, General and Administrative Expense": "6,340"
},
"output_variables": {
"Assets": "15,650",
"Liabilities": "7,134",
"Expenses": "18,803",
"Revenues": "3,254",
"Stockholders Equity": "8,516",
"Net Income": "-16,042",
"Comprehensive Net Income": "-16,043",
"BaseVar": "22,668",
"ECR before LimitedLiability": "22%",
"Economic Capital Ratio": "163%"
}
}
},
"top_rated": false,
"trend": -93.0,
"value": 1.6263279473728696,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001389545.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001389545.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001389545.svg"
},
{
"company_id": "0001208261",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001208261.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001208261.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001208261_main_keyfigs.svg",
"name": "Immune Pharmaceuticals INC",
"rank": 163,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001208261.svg",
"report_text": "The relative strengths and weaknesses of Immune Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Immune Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 95% points.The greatest weakness of Immune Pharmaceuticals INC is the variable Liabilities, reducing the Economic Capital Ratio by 116% points.
The company's Economic Capital Ratio, given in the ranking table, is 162%, being 81% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001208261_2014_Immune_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-7.50",
"Assets": "-59.7",
"Liabilities": "-39.6",
"Stockholders Equity": "-117",
"ECR before LimitedLiability": "-99.0",
"Intangible Assets": "-16.2",
"Property and Equipment": "-9.41",
"Assets, Current": "-38.0",
"Other Liabilities": "-15.4",
"Liabilities, Current": "-10.8",
"Research and Development": "-1.66",
"Expenses": "1.80",
"Revenues": "-10.7",
"Net Income": "-11.0",
"Other Expenses": "2.95",
"Cost of Goods Sold": "1.53",
"Selling, General and Administrative Expense": "-1.06",
"Other Revenues": "-10.7",
"Comprehensive Net Income": "-10.9",
"Other Net Income": "-2.18",
"Economic Capital Ratio": "-175"
},
"2012": {
"Property and Equipment": "-12.1",
"Assets": "-94.2",
"Liabilities": "-18.7",
"Stockholders Equity": "-222",
"ECR before LimitedLiability": "-104",
"Assets, Current": "-81.4",
"Intangible Assets": "-18.4",
"Other Assets": "-12.2",
"Liabilities, Current": "-4.75",
"Other Liabilities": "-7.34",
"Selling, General and Administrative Expense": "-1.72",
"Expenses": "8.71",
"Revenues": "11.2",
"Net Income": "19.0",
"Research and Development": "2.58",
"Other Expenses": "6.13",
"Cost of Goods Sold": "1.95",
"Other Revenues": "11.2",
"Comprehensive Net Income": "16.6",
"Other Compr. Net Income": "-3.40",
"Economic Capital Ratio": "-177"
},
"2013": {
"Other Assets": "94.9",
"Assets": "21.1",
"Liabilities": "-116",
"Stockholders Equity": "-65.9",
"ECR before LimitedLiability": "-52.7",
"Intangible Assets": "5.12",
"Property and Equipment": "-10.6",
"Assets, Current": "-92.2",
"Liabilities, Non-Current": "10.4",
"Liabilities, Current": "-32.6",
"Other Liabilities": "-90.1",
"Selling, General and Administrative Expense": "7.53",
"Expenses": "21.3",
"Revenues": "-22.0",
"Net Income": "21.1",
"Other Expenses": "12.8",
"Research and Development": "13.9",
"Other Revenues": "-22.0",
"Comprehensive Net Income": "21.0",
"Other Net Income": "12.4",
"Economic Capital Ratio": "-80.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001208261_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,737",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "12,237",
"Liabilities, Non-Current": "365",
"Other Assets": "664",
"Other Compr. Net Income": "299",
"Other Expenses": "696",
"Other Liabilities": "12,065",
"Other Net Income": "-1,599",
"Other Revenues": "944",
"Property and Equipment": "120",
"Research and Development": "7,853",
"Selling, General and Administrative Expense": "6,452"
},
"output_variables": {
"Assets": "7,521",
"Liabilities": "24,667",
"Expenses": "15,001",
"Revenues": "944",
"Stockholders Equity": "-17,146",
"Net Income": "-15,656",
"Comprehensive Net Income": "-15,506",
"BaseVar": "25,016",
"ECR before LimitedLiability": "-329%",
"Economic Capital Ratio": "59%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,197",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,801",
"Liabilities, Non-Current": "0",
"Other Assets": "75",
"Other Compr. Net Income": "-2,146",
"Other Expenses": "403",
"Other Liabilities": "7,496",
"Other Net Income": "0",
"Other Revenues": "7,804",
"Property and Equipment": "56",
"Research and Development": "3,400",
"Selling, General and Administrative Expense": "4,607"
},
"output_variables": {
"Assets": "1,328",
"Liabilities": "15,297",
"Expenses": "8,410",
"Revenues": "7,804",
"Stockholders Equity": "-13,969",
"Net Income": "-606",
"Comprehensive Net Income": "-1,679",
"BaseVar": "17,492",
"ECR before LimitedLiability": "-387%",
"Economic Capital Ratio": "43%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "267",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,607",
"Liabilities, Current": "11,268",
"Liabilities, Non-Current": "0",
"Other Assets": "27,580",
"Other Compr. Net Income": "0",
"Other Expenses": "11",
"Other Liabilities": "14,750",
"Other Net Income": "3,251",
"Other Revenues": "19",
"Property and Equipment": "47",
"Research and Development": "3,571",
"Selling, General and Administrative Expense": "5,448"
},
"output_variables": {
"Assets": "31,501",
"Liabilities": "26,018",
"Expenses": "9,030",
"Revenues": "19",
"Stockholders Equity": "5,483",
"Net Income": "-5,760",
"Comprehensive Net Income": "-5,760",
"BaseVar": "34,910",
"ECR before LimitedLiability": "22%",
"Economic Capital Ratio": "162%"
}
}
},
"top_rated": false,
"trend": 34.0,
"value": 1.6205868840970792,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001208261.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001208261.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001208261.svg"
},
{
"company_id": "0001396814",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001396814.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001396814.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001396814.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001396814_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001396814_main_keyfigs.svg",
"name": "Pacira Biosciences Inc",
"rank": 164,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001396814.svg",
"report_text": "The relative strengths and weaknesses of Pacira Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Pacira Biosciences Inc compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 19% points.The greatest weakness of Pacira Biosciences Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 110% points.
The company's Economic Capital Ratio, given in the ranking table, is 158%, being 85% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001396814_2014_Pacira_Biosciences_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "65.9",
"Assets": "19.3",
"Liabilities": "6.96",
"Stockholders Equity": "30.5",
"ECR before LimitedLiability": "95.2",
"Assets, Current": "-17.3",
"Other Assets": "-11.2",
"Liabilities, Current": "37.1",
"Other Liabilities": "24.3",
"Liabilities, Non-Current": "-60.4",
"Selling, General and Administrative Expense": "-12.1",
"Expenses": "5.10",
"Revenues": "6.40",
"Net Income": "11.2",
"Research and Development": "25.0",
"Other Expenses": "19.9",
"Cost of Goods Sold": "-25.3",
"Other Revenues": "6.40",
"Comprehensive Net Income": "11.4",
"Other Net Income": "-0.432",
"Economic Capital Ratio": "22.1"
},
"2013": {
"Other Assets": "-17.4",
"Assets": "-47.2",
"Liabilities": "-52.9",
"Stockholders Equity": "-94.9",
"Intangible Assets": "-13.4",
"Property and Equipment": "18.8",
"Assets, Current": "-57.0",
"Liabilities, Non-Current": "10.7",
"Liabilities, Current": "-110",
"Other Liabilities": "17.5",
"Expenses": "9.97",
"Revenues": "17.1",
"Net Income": "17.2",
"Other Expenses": "17.1",
"Research and Development": "17.2",
"Cost of Goods Sold": "-29.8",
"Other Revenues": "17.1",
"ECR before LimitedLiability": "-56.7",
"Comprehensive Net Income": "17.2",
"Other Net Income": "-4.86",
"Economic Capital Ratio": "-84.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001396814_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "60,922",
"Cost of Goods Sold": "32,139",
"Intangible Assets": "11,505",
"Liabilities, Current": "14,156",
"Liabilities, Non-Current": "27,466",
"Other Assets": "511",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "4,577",
"Other Net Income": "-2,983",
"Other Revenues": "39,084",
"Property and Equipment": "39,116",
"Research and Development": "9,937",
"Selling, General and Administrative Expense": "46,306"
},
"output_variables": {
"Assets": "112,054",
"Liabilities": "46,199",
"Expenses": "88,382",
"Revenues": "39,084",
"Stockholders Equity": "65,855",
"Net Income": "-52,281",
"Comprehensive Net Income": "-52,281",
"BaseVar": "144,351",
"ECR before LimitedLiability": "115%",
"Economic Capital Ratio": "242%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "106,751",
"Cost of Goods Sold": "54,772",
"Intangible Assets": "11,485",
"Liabilities, Current": "121,943",
"Liabilities, Non-Current": "3,190",
"Other Assets": "3,402",
"Other Compr. Net Income": "-22",
"Other Expenses": "-442",
"Other Liabilities": "3,438",
"Other Net Income": "-11,062",
"Other Revenues": "85,551",
"Property and Equipment": "48,182",
"Research and Development": "21,560",
"Selling, General and Administrative Expense": "62,508"
},
"output_variables": {
"Assets": "169,820",
"Liabilities": "128,571",
"Expenses": "138,398",
"Revenues": "85,551",
"Stockholders Equity": "41,249",
"Net Income": "-63,909",
"Comprehensive Net Income": "-63,920",
"BaseVar": "266,712",
"ECR before LimitedLiability": "17%",
"Economic Capital Ratio": "158%"
}
}
},
"top_rated": false,
"trend": -58.0,
"value": 1.5813374565215006,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001396814.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001396814.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001396814.svg"
},
{
"company_id": "0001168220",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001168220.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001168220.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001168220_main_keyfigs.svg",
"name": "Altrazeal Life Sciences Inc",
"rank": 165,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001168220.svg",
"report_text": "The relative strengths and weaknesses of Altrazeal Life Sciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Altrazeal Life Sciences Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 44% points.The greatest weakness of Altrazeal Life Sciences Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 87% points.
The company's Economic Capital Ratio, given in the ranking table, is 155%, being 88% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001168220_2014_Altrazeal_Life_Sciences_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-12.3",
"Assets": "61.4",
"Liabilities": "-26.6",
"Stockholders Equity": "41.2",
"ECR before LimitedLiability": "69.5",
"Intangible Assets": "103",
"Property and Equipment": "19.2",
"Assets, Current": "-48.5",
"Other Liabilities": "28.0",
"Liabilities, Non-Current": "-27.0",
"Liabilities, Current": "-29.2",
"Research and Development": "19.0",
"Expenses": "3.82",
"Revenues": "-21.6",
"Net Income": "-15.7",
"Other Expenses": "-10.5",
"Cost of Goods Sold": "3.81",
"Selling, General and Administrative Expense": "-7.79",
"Other Revenues": "-21.6",
"Comprehensive Net Income": "-15.9",
"Economic Capital Ratio": "-6.10"
},
"2012": {
"Property and Equipment": "7.84",
"Assets": "9.73",
"Liabilities": "-96.2",
"Stockholders Equity": "-39.7",
"Economic Capital Ratio": "-71.2",
"Assets, Current": "-77.0",
"Intangible Assets": "31.3",
"Other Assets": "8.18",
"Liabilities, Current": "-80.8",
"Other Liabilities": "8.22",
"Liabilities, Non-Current": "-43.1",
"Selling, General and Administrative Expense": "3.24",
"Expenses": "8.15",
"Revenues": "-23.4",
"Net Income": "4.00",
"Research and Development": "7.96",
"Other Expenses": "-2.27",
"Cost of Goods Sold": "4.72",
"Other Revenues": "-23.4",
"Comprehensive Net Income": "4.20",
"Other Net Income": "3.28"
},
"2013": {
"Other Assets": "-13.4",
"Assets": "13.3",
"Liabilities": "-79.1",
"Stockholders Equity": "-53.8",
"Intangible Assets": "43.8",
"Property and Equipment": "13.0",
"Assets, Current": "-78.7",
"Liabilities, Non-Current": "-27.6",
"Liabilities, Current": "-86.9",
"Other Liabilities": "14.0",
"Selling, General and Administrative Expense": "5.05",
"Expenses": "10.1",
"Revenues": "-19.0",
"Net Income": "-6.19",
"Other Expenses": "-12.9",
"Research and Development": "13.6",
"Cost of Goods Sold": "3.41",
"Other Revenues": "-19.0",
"ECR before LimitedLiability": "-60.1",
"Comprehensive Net Income": "-6.48",
"Economic Capital Ratio": "-88.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001168220_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,349",
"Cost of Goods Sold": "0",
"Intangible Assets": "4,622",
"Liabilities, Current": "2,054",
"Liabilities, Non-Current": "907",
"Other Assets": "18",
"Other Compr. Net Income": "0",
"Other Expenses": "1,343",
"Other Liabilities": "0",
"Other Net Income": "11",
"Other Revenues": "485",
"Property and Equipment": "1,072",
"Research and Development": "947",
"Selling, General and Administrative Expense": "2,277"
},
"output_variables": {
"Assets": "7,062",
"Liabilities": "2,961",
"Expenses": "4,566",
"Revenues": "485",
"Stockholders Equity": "4,101",
"Net Income": "-4,070",
"Comprehensive Net Income": "-4,070",
"BaseVar": "7,543",
"ECR before LimitedLiability": "97%",
"Economic Capital Ratio": "228%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,116",
"Cost of Goods Sold": "0",
"Intangible Assets": "4,146",
"Liabilities, Current": "3,890",
"Liabilities, Non-Current": "1,587",
"Other Assets": "1,221",
"Other Compr. Net Income": "0",
"Other Expenses": "1,340",
"Other Liabilities": "0",
"Other Net Income": "62",
"Other Revenues": "371",
"Property and Equipment": "846",
"Research and Development": "833",
"Selling, General and Administrative Expense": "1,791"
},
"output_variables": {
"Assets": "7,328",
"Liabilities": "5,477",
"Expenses": "3,964",
"Revenues": "371",
"Stockholders Equity": "1,851",
"Net Income": "-3,531",
"Comprehensive Net Income": "-3,531",
"BaseVar": "8,600",
"ECR before LimitedLiability": "7.9%",
"Economic Capital Ratio": "149%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "1,487",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,671",
"Liabilities, Current": "3,270",
"Liabilities, Non-Current": "898",
"Other Assets": "105",
"Other Compr. Net Income": "0",
"Other Expenses": "1,449",
"Other Liabilities": "0",
"Other Net Income": "73",
"Other Revenues": "371",
"Property and Equipment": "639",
"Research and Development": "788",
"Selling, General and Administrative Expense": "1,288"
},
"output_variables": {
"Assets": "5,902",
"Liabilities": "4,168",
"Expenses": "3,525",
"Revenues": "371",
"Stockholders Equity": "1,733",
"Net Income": "-3,081",
"Comprehensive Net Income": "-3,081",
"BaseVar": "7,019",
"ECR before LimitedLiability": "14%",
"Economic Capital Ratio": "155%"
}
}
},
"top_rated": false,
"trend": -23.0,
"value": 1.546926705872383,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001168220.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001168220.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001168220.svg"
},
{
"company_id": "0001010086",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001010086.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001010086.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001010086.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001010086_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001010086_main_keyfigs.svg",
"name": "SIGA Technologies INC",
"rank": 166,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001010086.svg",
"report_text": "The relative strengths and weaknesses of SIGA Technologies INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of SIGA Technologies INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 15% points.The greatest weakness of SIGA Technologies INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 206% points.
The company's Economic Capital Ratio, given in the ranking table, is 152%, being 91% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001010086_2014_SIGA_Technologies_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-8.81",
"Assets": "50.7",
"Liabilities": "-106",
"Stockholders Equity": "-20.1",
"ECR before LimitedLiability": "44.1",
"Assets, Current": "50.6",
"Intangible Assets": "-13.3",
"Other Assets": "26.6",
"Liabilities, Current": "13.0",
"Other Liabilities": "-126",
"Selling, General and Administrative Expense": "13.4",
"Expenses": "47.5",
"Revenues": "-22.7",
"Net Income": "33.2",
"Research and Development": "7.61",
"Other Expenses": "20.9",
"Cost of Goods Sold": "3.72",
"Other Revenues": "-22.7",
"Comprehensive Net Income": "33.4",
"Other Net Income": "10.6",
"Economic Capital Ratio": "-29.0"
},
"2013": {
"Other Assets": "15.0",
"Assets": "11.8",
"Liabilities": "-144",
"Stockholders Equity": "-74.3",
"ECR before LimitedLiability": "-63.2",
"Intangible Assets": "-16.4",
"Property and Equipment": "-8.77",
"Assets, Current": "4.42",
"Liabilities, Non-Current": "6.92",
"Liabilities, Current": "11.1",
"Other Liabilities": "-206",
"Selling, General and Administrative Expense": "10.6",
"Expenses": "12.3",
"Revenues": "-20.1",
"Net Income": "11.1",
"Other Expenses": "10.6",
"Research and Development": "10.6",
"Other Revenues": "-20.1",
"Comprehensive Net Income": "11.1",
"Other Net Income": "4.29",
"Economic Capital Ratio": "-91.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001010086_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "84,946",
"Cost of Goods Sold": "0",
"Intangible Assets": "898",
"Liabilities, Current": "15,716",
"Liabilities, Non-Current": "3,955",
"Other Assets": "19,004",
"Other Compr. Net Income": "0",
"Other Expenses": "-6,124",
"Other Liabilities": "57,218",
"Other Net Income": "8,971",
"Other Revenues": "0",
"Property and Equipment": "988",
"Research and Development": "18,213",
"Selling, General and Administrative Expense": "11,410"
},
"output_variables": {
"Assets": "105,836",
"Liabilities": "76,889",
"Expenses": "23,500",
"Revenues": "0",
"Stockholders Equity": "28,947",
"Net Income": "-14,528",
"Comprehensive Net Income": "-14,528",
"BaseVar": "107,598",
"ECR before LimitedLiability": "53%",
"Economic Capital Ratio": "191%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "123,942",
"Cost of Goods Sold": "0",
"Intangible Assets": "898",
"Liabilities, Current": "12,189",
"Liabilities, Non-Current": "1,990",
"Other Assets": "67,602",
"Other Compr. Net Income": "0",
"Other Expenses": "-4,403",
"Other Liabilities": "162,670",
"Other Net Income": "5,521",
"Other Revenues": "0",
"Property and Equipment": "1,382",
"Research and Development": "13,856",
"Selling, General and Administrative Expense": "13,245"
},
"output_variables": {
"Assets": "193,824",
"Liabilities": "176,849",
"Expenses": "22,698",
"Revenues": "0",
"Stockholders Equity": "16,975",
"Net Income": "-17,177",
"Comprehensive Net Income": "-17,177",
"BaseVar": "199,446",
"ECR before LimitedLiability": "11%",
"Economic Capital Ratio": "152%"
}
}
},
"top_rated": false,
"trend": -37.0,
"value": 1.5161730950942238,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001010086.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001010086.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001010086.svg"
},
{
"company_id": "0001576263",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001576263.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001576263.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001576263.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001576263_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001576263_main_keyfigs.svg",
"name": "Mirati Therapeutics Inc",
"rank": 167,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001576263.svg",
"report_text": "The relative strengths and weaknesses of Mirati Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Mirati Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 14% points.The greatest weakness of Mirati Therapeutics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 107% points.
The company's Economic Capital Ratio, given in the ranking table, is 148%, being 95% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001576263_2014_Mirati_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-19.2",
"Assets": "6.87",
"Liabilities": "-49.4",
"Stockholders Equity": "-34.6",
"Intangible Assets": "-24.0",
"Property and Equipment": "-13.2",
"Assets, Current": "13.8",
"Liabilities, Non-Current": "6.89",
"Liabilities, Current": "-107",
"Other Liabilities": "7.68",
"Selling, General and Administrative Expense": "6.88",
"Expenses": "-12.7",
"Revenues": "-28.3",
"Net Income": "-40.3",
"Other Expenses": "-22.8",
"Research and Development": "-4.85",
"Cost of Goods Sold": "3.76",
"Other Revenues": "-28.3",
"ECR before LimitedLiability": "-66.9",
"Comprehensive Net Income": "-40.6",
"Economic Capital Ratio": "-94.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001576263_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "64,215",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "38,652",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-13",
"Other Expenses": "20,801",
"Other Liabilities": "0",
"Other Net Income": "-1,117",
"Other Revenues": "0",
"Property and Equipment": "322",
"Research and Development": "19,797",
"Selling, General and Administrative Expense": "11,144"
},
"output_variables": {
"Assets": "64,537",
"Liabilities": "38,652",
"Expenses": "51,742",
"Revenues": "0",
"Stockholders Equity": "25,885",
"Net Income": "-52,859",
"Comprehensive Net Income": "-52,866",
"BaseVar": "78,030",
"ECR before LimitedLiability": "6.9%",
"Economic Capital Ratio": "148%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.479008952921741,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001576263.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001576263.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001576263.svg"
},
{
"company_id": "0001316175",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001316175.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001316175.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001316175_main_keyfigs.svg",
"name": "Anthera Pharmaceuticals Inc",
"rank": 168,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001316175.svg",
"report_text": "The relative strengths and weaknesses of Anthera Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Anthera Pharmaceuticals Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 7.9% points.The greatest weakness of Anthera Pharmaceuticals Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 79% points.
The company's Economic Capital Ratio, given in the ranking table, is 145%, being 97% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001316175_2014_Anthera_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-7.99",
"Assets": "-39.7",
"Liabilities": "-14.9",
"Stockholders Equity": "-48.6",
"ECR before LimitedLiability": "-57.3",
"Assets, Current": "-15.6",
"Intangible Assets": "-16.8",
"Other Assets": "-12.0",
"Liabilities, Current": "-9.93",
"Other Liabilities": "-7.46",
"Liabilities, Non-Current": "2.93",
"Selling, General and Administrative Expense": "8.20",
"Expenses": "-21.4",
"Revenues": "-15.5",
"Net Income": "-36.5",
"Research and Development": "-37.6",
"Other Expenses": "9.72",
"Other Revenues": "-15.5",
"Comprehensive Net Income": "-36.4",
"Other Net Income": "-2.96",
"Economic Capital Ratio": "-130"
},
"2013": {
"Other Assets": "7.86",
"Assets": "4.40",
"Liabilities": "-50.5",
"Stockholders Equity": "-37.0",
"Intangible Assets": "-24.3",
"Property and Equipment": "-9.27",
"Assets, Current": "-7.42",
"Liabilities, Non-Current": "4.45",
"Liabilities, Current": "4.44",
"Other Liabilities": "-79.4",
"Selling, General and Administrative Expense": "4.43",
"Expenses": "-6.67",
"Revenues": "-28.5",
"Net Income": "-40.8",
"Other Expenses": "4.54",
"Research and Development": "-36.7",
"Other Revenues": "-28.5",
"ECR before LimitedLiability": "-69.4",
"Comprehensive Net Income": "-41.0",
"Other Net Income": "-6.62",
"Economic Capital Ratio": "-97.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001316175_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "25,179",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "18,750",
"Liabilities, Non-Current": "0",
"Other Assets": "116",
"Other Compr. Net Income": "12",
"Other Expenses": "0",
"Other Liabilities": "11,221",
"Other Net Income": "-3,465",
"Other Revenues": "0",
"Property and Equipment": "1,150",
"Research and Development": "49,219",
"Selling, General and Administrative Expense": "6,715"
},
"output_variables": {
"Assets": "26,445",
"Liabilities": "29,971",
"Expenses": "55,934",
"Revenues": "0",
"Stockholders Equity": "-3,526",
"Net Income": "-59,399",
"Comprehensive Net Income": "-59,393",
"BaseVar": "57,914",
"ECR before LimitedLiability": "-238%",
"Economic Capital Ratio": "90%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "26,304",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,561",
"Liabilities, Non-Current": "0",
"Other Assets": "10,301",
"Other Compr. Net Income": "17",
"Other Expenses": "0",
"Other Liabilities": "15,098",
"Other Net Income": "-2,614",
"Other Revenues": "0",
"Property and Equipment": "812",
"Research and Development": "21,684",
"Selling, General and Administrative Expense": "6,563"
},
"output_variables": {
"Assets": "37,417",
"Liabilities": "22,659",
"Expenses": "28,247",
"Revenues": "0",
"Stockholders Equity": "14,758",
"Net Income": "-30,861",
"Comprehensive Net Income": "-30,852",
"BaseVar": "45,477",
"ECR before LimitedLiability": "4.4%",
"Economic Capital Ratio": "145%"
}
}
},
"top_rated": false,
"trend": 9.0,
"value": 1.4541984333698201,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001316175.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001316175.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001316175.svg"
},
{
"company_id": "0000934473",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000934473.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000934473.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000934473_main_keyfigs.svg",
"name": "Genvec INC",
"rank": 169,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000934473.svg",
"report_text": "The relative strengths and weaknesses of Genvec INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Genvec INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 7.9% points.The greatest weakness of Genvec INC is the variable Assets, reducing the Economic Capital Ratio by 106% points.
The company's Economic Capital Ratio, given in the ranking table, is 142%, being 101% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000934473_2014_Genvec_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-6.14",
"Assets": "8.64",
"Liabilities": "102",
"Stockholders Equity": "101",
"ECR before LimitedLiability": "213",
"Intangible Assets": "-8.29",
"Property and Equipment": "-3.71",
"Assets, Current": "39.1",
"Other Liabilities": "45.8",
"Liabilities, Non-Current": "20.6",
"Liabilities, Current": "48.7",
"Research and Development": "-27.9",
"Expenses": "-3.87",
"Revenues": "32.8",
"Net Income": "32.1",
"Other Expenses": "13.7",
"Cost of Goods Sold": "4.87",
"Selling, General and Administrative Expense": "4.81",
"Other Revenues": "32.8",
"Comprehensive Net Income": "31.7",
"Economic Capital Ratio": "137"
},
"2012": {
"Property and Equipment": "-6.38",
"Assets": "-12.7",
"Liabilities": "97.8",
"Stockholders Equity": "64.7",
"ECR before LimitedLiability": "121",
"Assets, Current": "31.6",
"Intangible Assets": "-18.4",
"Other Assets": "-12.0",
"Liabilities, Current": "96.2",
"Other Liabilities": "-22.2",
"Liabilities, Non-Current": "23.0",
"Selling, General and Administrative Expense": "-18.7",
"Expenses": "-38.8",
"Revenues": "22.8",
"Net Income": "-14.4",
"Research and Development": "-50.6",
"Other Expenses": "26.2",
"Cost of Goods Sold": "6.57",
"Other Revenues": "22.8",
"Comprehensive Net Income": "-14.2",
"Economic Capital Ratio": "48.1"
},
"2013": {
"Other Assets": "-31.3",
"Assets": "-106",
"Liabilities": "7.86",
"Stockholders Equity": "-63.2",
"Intangible Assets": "-42.8",
"Property and Equipment": "-6.31",
"Assets, Current": "-60.1",
"Liabilities, Non-Current": "1.24",
"Liabilities, Current": "0.734",
"Other Liabilities": "4.41",
"Selling, General and Administrative Expense": "-96.3",
"Expenses": "-105",
"Revenues": "1.32",
"Net Income": "-82.6",
"Other Expenses": "1.69",
"Research and Development": "-46.1",
"Cost of Goods Sold": "0.719",
"Other Revenues": "1.32",
"ECR before LimitedLiability": "-73.1",
"Comprehensive Net Income": "-83.1",
"Economic Capital Ratio": "-101"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000934473_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "29,067",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,328",
"Liabilities, Non-Current": "0",
"Other Assets": "107",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "41",
"Other Revenues": "17,744",
"Property and Equipment": "692",
"Research and Development": "17,416",
"Selling, General and Administrative Expense": "7,810"
},
"output_variables": {
"Assets": "29,866",
"Liabilities": "3,328",
"Expenses": "25,226",
"Revenues": "17,744",
"Stockholders Equity": "26,538",
"Net Income": "-7,441",
"Comprehensive Net Income": "-7,441",
"BaseVar": "38,102",
"ECR before LimitedLiability": "304%",
"Economic Capital Ratio": "371%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "16,428",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "197",
"Other Compr. Net Income": "-19",
"Other Expenses": "0",
"Other Liabilities": "3,687",
"Other Net Income": "42",
"Other Revenues": "9,353",
"Property and Equipment": "805",
"Research and Development": "14,348",
"Selling, General and Administrative Expense": "9,102"
},
"output_variables": {
"Assets": "17,430",
"Liabilities": "3,687",
"Expenses": "23,450",
"Revenues": "9,353",
"Stockholders Equity": "13,743",
"Net Income": "-14,055",
"Comprehensive Net Income": "-14,064",
"BaseVar": "26,990",
"ECR before LimitedLiability": "151%",
"Economic Capital Ratio": "268%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "6,643",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,644",
"Liabilities, Non-Current": "0",
"Other Assets": "97",
"Other Compr. Net Income": "5.0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "3,957",
"Property and Equipment": "514",
"Research and Development": "5,492",
"Selling, General and Administrative Expense": "8,484"
},
"output_variables": {
"Assets": "7,254",
"Liabilities": "2,644",
"Expenses": "13,976",
"Revenues": "3,957",
"Stockholders Equity": "4,610",
"Net Income": "-10,019",
"Comprehensive Net Income": "-10,016",
"BaseVar": "13,918",
"ECR before LimitedLiability": "0.67%",
"Economic Capital Ratio": "142%"
}
}
},
"top_rated": false,
"trend": -83.0,
"value": 1.417197482246477,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000934473.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000934473.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000934473.svg"
},
{
"company_id": "0001135906",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001135906.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001135906.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001135906_main_keyfigs.svg",
"name": "Epirus Biopharmaceuticals Inc",
"rank": 170,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001135906.svg",
"report_text": "The relative strengths and weaknesses of Epirus Biopharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Epirus Biopharmaceuticals Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 3.5% points.The greatest weakness of Epirus Biopharmaceuticals Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 86% points.
The company's Economic Capital Ratio, given in the ranking table, is 141%, being 102% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001135906_2014_Epirus_Biopharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.15",
"Assets": "59.0",
"Liabilities": "36.0",
"Stockholders Equity": "117",
"ECR before LimitedLiability": "148",
"Intangible Assets": "28.6",
"Assets, Current": "25.0",
"Other Liabilities": "29.8",
"Liabilities, Non-Current": "12.9",
"Liabilities, Current": "-6.32",
"Research and Development": "-19.1",
"Expenses": "-1.80",
"Revenues": "-15.5",
"Net Income": "-15.0",
"Other Expenses": "3.08",
"Cost of Goods Sold": "3.43",
"Selling, General and Administrative Expense": "11.0",
"Other Revenues": "-15.5",
"Comprehensive Net Income": "-15.2",
"Other Net Income": "2.31",
"Economic Capital Ratio": "72.3"
},
"2012": {
"Property and Equipment": "-1.89",
"Assets": "30.7",
"Liabilities": "29.9",
"Stockholders Equity": "65.7",
"ECR before LimitedLiability": "95.1",
"Intangible Assets": "44.0",
"Other Assets": "-7.16",
"Liabilities, Current": "-25.1",
"Other Liabilities": "36.6",
"Liabilities, Non-Current": "17.0",
"Selling, General and Administrative Expense": "16.6",
"Expenses": "-15.2",
"Revenues": "-8.33",
"Net Income": "-20.4",
"Research and Development": "-41.6",
"Other Expenses": "7.13",
"Cost of Goods Sold": "5.11",
"Other Revenues": "-8.33",
"Comprehensive Net Income": "-20.1",
"Other Net Income": "2.98",
"Economic Capital Ratio": "22.0"
},
"2013": {
"Other Assets": "-12.4",
"Assets": "-85.3",
"Liabilities": "2.72",
"Stockholders Equity": "-66.6",
"Intangible Assets": "0.920",
"Assets, Current": "-86.1",
"Liabilities, Non-Current": "0.661",
"Liabilities, Current": "-25.9",
"Other Liabilities": "3.47",
"Selling, General and Administrative Expense": "0.780",
"Expenses": "-74.1",
"Revenues": "0.390",
"Net Income": "-59.0",
"Other Expenses": "-18.8",
"Research and Development": "-77.7",
"Cost of Goods Sold": "0.108",
"Other Revenues": "0.390",
"ECR before LimitedLiability": "-73.8",
"Comprehensive Net Income": "-59.4",
"Other Net Income": "0.0495",
"Economic Capital Ratio": "-102"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001135906_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "51,207",
"Cost of Goods Sold": "0",
"Intangible Assets": "21,546",
"Liabilities, Current": "15,544",
"Liabilities, Non-Current": "0",
"Other Assets": "1,872",
"Other Compr. Net Income": "0",
"Other Expenses": "4,689",
"Other Liabilities": "0",
"Other Net Income": "156",
"Other Revenues": "8,184",
"Property and Equipment": "5,258",
"Research and Development": "35,294",
"Selling, General and Administrative Expense": "10,400"
},
"output_variables": {
"Assets": "79,883",
"Liabilities": "15,544",
"Expenses": "50,383",
"Revenues": "8,184",
"Stockholders Equity": "64,339",
"Net Income": "-42,043",
"Comprehensive Net Income": "-42,043",
"BaseVar": "77,075",
"ECR before LimitedLiability": "206%",
"Economic Capital Ratio": "306%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "38,369",
"Cost of Goods Sold": "0",
"Intangible Assets": "17,654",
"Liabilities, Current": "19,631",
"Liabilities, Non-Current": "0",
"Other Assets": "1,817",
"Other Compr. Net Income": "18",
"Other Expenses": "6,718",
"Other Liabilities": "0",
"Other Net Income": "241",
"Other Revenues": "12,550",
"Property and Equipment": "3,535",
"Research and Development": "41,423",
"Selling, General and Administrative Expense": "8,977"
},
"output_variables": {
"Assets": "61,375",
"Liabilities": "19,631",
"Expenses": "57,118",
"Revenues": "12,550",
"Stockholders Equity": "41,744",
"Net Income": "-44,327",
"Comprehensive Net Income": "-44,318",
"BaseVar": "75,466",
"ECR before LimitedLiability": "115%",
"Economic Capital Ratio": "242%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "20,742",
"Cost of Goods Sold": "0",
"Intangible Assets": "7,200",
"Liabilities, Current": "14,892",
"Liabilities, Non-Current": "0",
"Other Assets": "1,801",
"Other Compr. Net Income": "-10",
"Other Expenses": "11,921",
"Other Liabilities": "0",
"Other Net Income": "60",
"Other Revenues": "14,731",
"Property and Equipment": "2,363",
"Research and Development": "33,964",
"Selling, General and Administrative Expense": "7,523"
},
"output_variables": {
"Assets": "32,106",
"Liabilities": "14,892",
"Expenses": "53,408",
"Revenues": "14,731",
"Stockholders Equity": "17,214",
"Net Income": "-38,617",
"Comprehensive Net Income": "-38,622",
"BaseVar": "57,604",
"ECR before LimitedLiability": "-4.7%",
"Economic Capital Ratio": "141%"
}
}
},
"top_rated": false,
"trend": -63.0,
"value": 1.4102287549259616,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001135906.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001135906.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001135906.svg"
},
{
"company_id": "0001070698",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001070698.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001070698.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001070698_main_keyfigs.svg",
"name": "Horizon Pharmaceutical LLC",
"rank": 171,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001070698.svg",
"report_text": "The relative strengths and weaknesses of Horizon Pharmaceutical LLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Horizon Pharmaceutical LLC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 0.82% points.The greatest weakness of Horizon Pharmaceutical LLC is the variable Other Liabilities, reducing the Economic Capital Ratio by 78% points.
The company's Economic Capital Ratio, given in the ranking table, is 141%, being 102% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001070698_2014_Horizon_Pharmaceutical_LLC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-11.9",
"Assets": "52.7",
"Liabilities": "-18.6",
"Stockholders Equity": "40.0",
"ECR before LimitedLiability": "46.7",
"Assets, Current": "54.6",
"Intangible Assets": "5.54",
"Other Assets": "-12.9",
"Liabilities, Current": "-70.4",
"Other Liabilities": "31.6",
"Liabilities, Non-Current": "14.7",
"Selling, General and Administrative Expense": "-4.81",
"Expenses": "-9.16",
"Revenues": "-29.8",
"Net Income": "-34.5",
"Research and Development": "-19.9",
"Other Expenses": "11.3",
"Cost of Goods Sold": "4.94",
"Other Revenues": "-29.8",
"Comprehensive Net Income": "-34.3",
"Economic Capital Ratio": "-26.4"
},
"2013": {
"Other Assets": "-4.42",
"Assets": "-9.65",
"Liabilities": "-63.3",
"Stockholders Equity": "-69.6",
"Intangible Assets": "-4.99",
"Property and Equipment": "-4.07",
"Assets, Current": "0.817",
"Liabilities, Non-Current": "0.406",
"Other Liabilities": "-78.0",
"Selling, General and Administrative Expense": "-0.0639",
"Expenses": "-0.0329",
"Revenues": "-4.88",
"Net Income": "-5.00",
"Other Expenses": "-0.0463",
"Research and Development": "0.0701",
"Cost of Goods Sold": "0.0849",
"Other Revenues": "-4.88",
"ECR before LimitedLiability": "-73.8",
"Comprehensive Net Income": "-5.50",
"Other Net Income": "0.0411",
"Economic Capital Ratio": "-102"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001070698_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "42,167",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,480",
"Liabilities, Current": "21,541",
"Liabilities, Non-Current": "0",
"Other Assets": "239",
"Other Compr. Net Income": "-50",
"Other Expenses": "3,176",
"Other Liabilities": "13",
"Other Net Income": "698",
"Other Revenues": "0",
"Property and Equipment": "403",
"Research and Development": "21,443",
"Selling, General and Administrative Expense": "14,723"
},
"output_variables": {
"Assets": "48,289",
"Liabilities": "21,554",
"Expenses": "39,342",
"Revenues": "0",
"Stockholders Equity": "26,735",
"Net Income": "-38,644",
"Comprehensive Net Income": "-38,669",
"BaseVar": "54,966",
"ECR before LimitedLiability": "56%",
"Economic Capital Ratio": "194%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "96,299",
"Cost of Goods Sold": "0",
"Intangible Assets": "6,488",
"Liabilities, Current": "30,115",
"Liabilities, Non-Current": "0",
"Other Assets": "4,129",
"Other Compr. Net Income": "-308",
"Other Expenses": "19,232",
"Other Liabilities": "50,041",
"Other Net Income": "68",
"Other Revenues": "16,872",
"Property and Equipment": "1,810",
"Research and Development": "29,177",
"Selling, General and Administrative Expense": "37,948"
},
"output_variables": {
"Assets": "108,726",
"Liabilities": "80,156",
"Expenses": "86,357",
"Revenues": "16,872",
"Stockholders Equity": "28,570",
"Net Income": "-69,417",
"Comprehensive Net Income": "-69,571",
"BaseVar": "146,244",
"ECR before LimitedLiability": "-7.7%",
"Economic Capital Ratio": "141%"
}
}
},
"top_rated": false,
"trend": -43.0,
"value": 1.4098020740252586,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001070698.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001070698.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001070698.svg"
},
{
"company_id": "0001053691",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001053691.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001053691.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001053691_main_keyfigs.svg",
"name": "Cervomed Inc",
"rank": 172,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001053691.svg",
"report_text": "The relative strengths and weaknesses of Cervomed Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cervomed Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 113% points.The greatest weakness of Cervomed Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 106% points.
The company's Economic Capital Ratio, given in the ranking table, is 141%, being 102% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001053691_2014_Cervomed_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "31.6",
"Assets": "-104",
"Stockholders Equity": "-91.6",
"Other Liabilities": "0.141",
"ECR before LimitedLiability": "-127",
"Intangible Assets": "-31.5",
"Property and Equipment": "-17.4",
"Assets, Current": "-107",
"Research and Development": "16.6",
"Expenses": "-72.4",
"Revenues": "-18.0",
"Net Income": "-87.0",
"Other Expenses": "-54.5",
"Cost of Goods Sold": "-12.5",
"Selling, General and Administrative Expense": "-26.3",
"Other Revenues": "-18.0",
"Liabilities, Current": "-0.252",
"Comprehensive Net Income": "-87.3",
"Other Net Income": "4.70",
"Other Compr. Net Income": "-0.185",
"Economic Capital Ratio": "-202"
},
"2012": {
"Property and Equipment": "-9.84",
"Assets": "-87.0",
"Liabilities": "-13.3",
"Stockholders Equity": "-174",
"ECR before LimitedLiability": "-109",
"Assets, Current": "-78.5",
"Intangible Assets": "-14.8",
"Other Assets": "6.79",
"Liabilities, Current": "-24.3",
"Other Liabilities": "0.628",
"Selling, General and Administrative Expense": "0.373",
"Expenses": "2.21",
"Revenues": "-9.61",
"Net Income": "4.38",
"Research and Development": "9.59",
"Other Expenses": "-10.4",
"Cost of Goods Sold": "1.03",
"Other Revenues": "-9.61",
"Comprehensive Net Income": "4.44",
"Other Net Income": "10.2",
"Economic Capital Ratio": "-182"
},
"2013": {
"Other Assets": "-6.12",
"Assets": "-9.34",
"Liabilities, Non-Current": "0.917",
"Stockholders Equity": "-8.63",
"Intangible Assets": "113",
"Property and Equipment": "-0.456",
"Assets, Current": "-106",
"Selling, General and Administrative Expense": "1.96",
"Expenses": "0.703",
"Revenues": "-16.1",
"Net Income": "-72.1",
"Other Expenses": "-38.8",
"Research and Development": "3.72",
"Cost of Goods Sold": "0.237",
"Other Revenues": "-16.1",
"ECR before LimitedLiability": "-74.2",
"Liabilities, Current": "-43.8",
"Other Liabilities": "3.40",
"Comprehensive Net Income": "-72.4",
"Other Net Income": "-51.5",
"Economic Capital Ratio": "-102"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001053691_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "186",
"Cost of Goods Sold": "2,309",
"Intangible Assets": "0",
"Liabilities, Current": "3,786",
"Liabilities, Non-Current": "0",
"Other Assets": "3,409",
"Other Compr. Net Income": "0",
"Other Expenses": "7,992",
"Other Liabilities": "0",
"Other Net Income": "592",
"Other Revenues": "570",
"Property and Equipment": "78",
"Research and Development": "0",
"Selling, General and Administrative Expense": "6,699"
},
"output_variables": {
"Assets": "3,674",
"Liabilities": "3,786",
"Expenses": "17,000",
"Revenues": "570",
"Stockholders Equity": "-113",
"Net Income": "-15,837",
"Comprehensive Net Income": "-15,837",
"BaseVar": "12,811",
"ECR before LimitedLiability": "-431%",
"Economic Capital Ratio": "32%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "462",
"Cost of Goods Sold": "236",
"Intangible Assets": "0",
"Liabilities, Current": "20,853",
"Liabilities, Non-Current": "0",
"Other Assets": "1,936",
"Other Compr. Net Income": "0",
"Other Expenses": "7,360",
"Other Liabilities": "0",
"Other Net Income": "4,942",
"Other Revenues": "375",
"Property and Equipment": "49",
"Research and Development": "0",
"Selling, General and Administrative Expense": "4,570"
},
"output_variables": {
"Assets": "2,446",
"Liabilities": "20,853",
"Expenses": "12,166",
"Revenues": "375",
"Stockholders Equity": "-18,406",
"Net Income": "-6,850",
"Comprehensive Net Income": "-6,850",
"BaseVar": "20,391",
"ECR before LimitedLiability": "-403%",
"Economic Capital Ratio": "38%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,998",
"Cost of Goods Sold": "0",
"Intangible Assets": "15,335",
"Liabilities, Current": "8,878",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "10,981",
"Other Liabilities": "0",
"Other Net Income": "-10,459",
"Other Revenues": "72",
"Property and Equipment": "11",
"Research and Development": "0",
"Selling, General and Administrative Expense": "2,008"
},
"output_variables": {
"Assets": "18,344",
"Liabilities": "8,878",
"Expenses": "12,989",
"Revenues": "72",
"Stockholders Equity": "9,466",
"Net Income": "-23,377",
"Comprehensive Net Income": "-23,377",
"BaseVar": "25,371",
"ECR before LimitedLiability": "-20%",
"Economic Capital Ratio": "141%"
}
}
},
"top_rated": false,
"trend": 30.0,
"value": 1.405904056246181,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001053691.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001053691.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001053691.svg"
},
{
"company_id": "0001356576",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001356576.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001356576.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001356576.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001356576_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001356576_main_keyfigs.svg",
"name": "Supernus Pharmaceuticals INC",
"rank": 173,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001356576.svg",
"report_text": "The relative strengths and weaknesses of Supernus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Supernus Pharmaceuticals INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 1.1% points.The greatest weakness of Supernus Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 59% points.
The company's Economic Capital Ratio, given in the ranking table, is 141%, being 102% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001356576_2014_Supernus_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-6.23",
"Assets": "84.0",
"Liabilities": "-19.9",
"Stockholders Equity": "70.1",
"ECR before LimitedLiability": "99.8",
"Assets, Current": "109",
"Intangible Assets": "-11.0",
"Other Assets": "-8.59",
"Liabilities, Current": "-17.1",
"Other Liabilities": "-10.7",
"Liabilities, Non-Current": "7.83",
"Expenses": "17.4",
"Revenues": "-21.2",
"Net Income": "-7.67",
"Research and Development": "-2.08",
"Other Expenses": "14.7",
"Cost of Goods Sold": "3.73",
"Other Revenues": "-21.2",
"Comprehensive Net Income": "-7.55",
"Other Net Income": "-2.93",
"Economic Capital Ratio": "26.7"
},
"2013": {
"Assets": "-3.81",
"Liabilities": "-38.0",
"Stockholders Equity": "-55.0",
"Intangible Assets": "-5.98",
"Property and Equipment": "-0.372",
"Assets, Current": "0.820",
"Liabilities, Non-Current": "0.396",
"Liabilities, Current": "0.565",
"Other Liabilities": "-59.4",
"Selling, General and Administrative Expense": "-3.28",
"Expenses": "0.921",
"Revenues": "-0.470",
"Net Income": "-14.2",
"Other Expenses": "1.06",
"Research and Development": "1.14",
"Cost of Goods Sold": "0.206",
"Other Revenues": "-0.470",
"ECR before LimitedLiability": "-74.2",
"Comprehensive Net Income": "-14.5",
"Other Net Income": "-10.0",
"Economic Capital Ratio": "-102"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001356576_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "91,741",
"Cost of Goods Sold": "0",
"Intangible Assets": "683",
"Liabilities, Current": "22,983",
"Liabilities, Non-Current": "1,509",
"Other Assets": "144",
"Other Compr. Net Income": "-58",
"Other Expenses": "0",
"Other Liabilities": "11,927",
"Other Net Income": "-4,115",
"Other Revenues": "1,480",
"Property and Equipment": "1,421",
"Research and Development": "23,517",
"Selling, General and Administrative Expense": "20,132"
},
"output_variables": {
"Assets": "93,989",
"Liabilities": "36,419",
"Expenses": "43,649",
"Revenues": "1,480",
"Stockholders Equity": "57,570",
"Net Income": "-46,284",
"Comprehensive Net Income": "-46,313",
"BaseVar": "89,855",
"ECR before LimitedLiability": "121%",
"Economic Capital Ratio": "247%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "97,161",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,158",
"Liabilities, Current": "26,400",
"Liabilities, Non-Current": "2,677",
"Other Assets": "10,122",
"Other Compr. Net Income": "57",
"Other Expenses": "1,104",
"Other Liabilities": "48,454",
"Other Net Income": "-30,353",
"Other Revenues": "12,019",
"Property and Equipment": "2,554",
"Research and Development": "17,245",
"Selling, General and Administrative Expense": "55,590"
},
"output_variables": {
"Assets": "110,995",
"Liabilities": "77,531",
"Expenses": "73,939",
"Revenues": "12,019",
"Stockholders Equity": "33,464",
"Net Income": "-92,273",
"Comprehensive Net Income": "-92,244",
"BaseVar": "152,447",
"ECR before LimitedLiability": "-20%",
"Economic Capital Ratio": "141%"
}
}
},
"top_rated": false,
"trend": -72.0,
"value": 1.4057550274865391,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001356576.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001356576.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001356576.svg"
},
{
"company_id": "0001069899",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001069899.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001069899.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001069899.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001069899_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001069899_main_keyfigs.svg",
"name": "Phibro Animal Health CORP",
"rank": 174,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001069899.svg",
"report_text": "The relative strengths and weaknesses of Phibro Animal Health CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Phibro Animal Health CORP compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 14% points.The greatest weakness of Phibro Animal Health CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 177% points.
The company's Economic Capital Ratio, given in the ranking table, is 140%, being 102% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001069899_2014_Phibro_Animal_Health_CORP.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-0.604",
"Assets": "-101",
"Liabilities": "-37.9",
"Stockholders Equity": "-177",
"Intangible Assets": "-1.27",
"Property and Equipment": "1.95",
"Assets, Current": "-93.2",
"Liabilities, Non-Current": "-0.328",
"Liabilities, Current": "4.40",
"Other Liabilities": "-90.8",
"Selling, General and Administrative Expense": "2.19",
"Expenses": "0.480",
"Revenues": "12.1",
"Net Income": "14.3",
"Other Expenses": "-47.2",
"Research and Development": "5.49",
"Cost of Goods Sold": "0.355",
"Other Revenues": "12.1",
"ECR before LimitedLiability": "-74.5",
"Comprehensive Net Income": "14.1",
"Economic Capital Ratio": "-102"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001069899_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "296,386",
"Cost of Goods Sold": "0",
"Intangible Assets": "35,155",
"Liabilities, Current": "115,404",
"Liabilities, Non-Current": "62,136",
"Other Assets": "38,179",
"Other Compr. Net Income": "-2,816",
"Other Expenses": "502,915",
"Other Liabilities": "365,540",
"Other Net Income": "-3,112",
"Other Revenues": "653,151",
"Property and Equipment": "104,422",
"Research and Development": "0",
"Selling, General and Administrative Expense": "122,233"
},
"output_variables": {
"Assets": "474,142",
"Liabilities": "543,080",
"Expenses": "625,148",
"Revenues": "653,151",
"Stockholders Equity": "-68,938",
"Net Income": "24,891",
"Comprehensive Net Income": "23,483",
"BaseVar": "1,150,724",
"ECR before LimitedLiability": "-25%",
"Economic Capital Ratio": "140%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.4034778691746963,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001069899.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001069899.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001069899.svg"
},
{
"company_id": "0001041024",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001041024.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001041024.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001041024.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001041024_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001041024_main_keyfigs.svg",
"name": "Rockwell Medical INC",
"rank": 175,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001041024.svg",
"report_text": "The relative strengths and weaknesses of Rockwell Medical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Rockwell Medical INC compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 22% points.The greatest weakness of Rockwell Medical INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 156% points.
The company's Economic Capital Ratio, given in the ranking table, is 140%, being 103% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001041024_2014_Rockwell_Medical_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-20.7",
"Assets": "-95.5",
"Liabilities": "74.1",
"Stockholders Equity": "-100",
"ECR before LimitedLiability": "55.8",
"Intangible Assets": "-30.9",
"Property and Equipment": "-14.1",
"Assets, Current": "-66.4",
"Other Liabilities": "65.4",
"Liabilities, Non-Current": "28.6",
"Liabilities, Current": "13.9",
"Research and Development": "20.0",
"Expenses": "-59.9",
"Revenues": "75.4",
"Net Income": "47.0",
"Other Expenses": "-113",
"Cost of Goods Sold": "9.63",
"Selling, General and Administrative Expense": "38.3",
"Other Revenues": "75.4",
"Comprehensive Net Income": "46.2",
"Economic Capital Ratio": "-19.8"
},
"2012": {
"Property and Equipment": "-19.0",
"Assets": "-159",
"Liabilities": "3.57",
"Stockholders Equity": "-183",
"ECR before LimitedLiability": "-92.1",
"Assets, Current": "-99.6",
"Intangible Assets": "-31.9",
"Other Assets": "-26.8",
"Liabilities, Current": "-5.71",
"Other Liabilities": "4.87",
"Selling, General and Administrative Expense": "13.3",
"Expenses": "-59.2",
"Revenues": "30.5",
"Net Income": "-14.8",
"Research and Development": "-36.4",
"Other Expenses": "-44.3",
"Cost of Goods Sold": "4.74",
"Other Revenues": "30.5",
"Comprehensive Net Income": "-14.4",
"Other Net Income": "2.69",
"Economic Capital Ratio": "-165"
},
"2013": {
"Other Assets": "-11.7",
"Assets": "-152",
"Liabilities": "18.2",
"Stockholders Equity": "-156",
"Intangible Assets": "-23.7",
"Property and Equipment": "-1.06",
"Assets, Current": "-119",
"Liabilities, Non-Current": "2.88",
"Liabilities, Current": "2.18",
"Other Liabilities": "10.1",
"Selling, General and Administrative Expense": "3.29",
"Expenses": "-102",
"Revenues": "21.9",
"Net Income": "-1.08",
"Other Expenses": "-86.8",
"Research and Development": "-29.7",
"Cost of Goods Sold": "0.772",
"Other Revenues": "21.9",
"ECR before LimitedLiability": "-74.8",
"Comprehensive Net Income": "-1.08",
"Economic Capital Ratio": "-103"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001041024_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "25,897",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,755",
"Liabilities, Current": "13,692",
"Liabilities, Non-Current": "0",
"Other Assets": "1,998",
"Other Compr. Net Income": "0",
"Other Expenses": "43,325",
"Other Liabilities": "0",
"Other Net Income": "242",
"Other Revenues": "48,966",
"Property and Equipment": "2,290",
"Research and Development": "17,805",
"Selling, General and Administrative Expense": "9,522"
},
"output_variables": {
"Assets": "31,940",
"Liabilities": "13,692",
"Expenses": "70,653",
"Revenues": "48,966",
"Stockholders Equity": "18,247",
"Net Income": "-21,445",
"Comprehensive Net Income": "-21,445",
"BaseVar": "82,747",
"ECR before LimitedLiability": "80%",
"Economic Capital Ratio": "214%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "13,149",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,587",
"Liabilities, Current": "26,987",
"Liabilities, Non-Current": "0",
"Other Assets": "430",
"Other Compr. Net Income": "281",
"Other Expenses": "43,149",
"Other Liabilities": "0",
"Other Net Income": "241",
"Other Revenues": "49,842",
"Property and Equipment": "1,858",
"Research and Development": "48,272",
"Selling, General and Administrative Expense": "12,684"
},
"output_variables": {
"Assets": "17,025",
"Liabilities": "26,987",
"Expenses": "104,104",
"Revenues": "49,842",
"Stockholders Equity": "-9,962",
"Net Income": "-54,022",
"Comprehensive Net Income": "-53,881",
"BaseVar": "99,240",
"ECR before LimitedLiability": "-344%",
"Economic Capital Ratio": "55%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "31,918",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,420",
"Liabilities, Current": "17,850",
"Liabilities, Non-Current": "0",
"Other Assets": "1,375",
"Other Compr. Net Income": "32",
"Other Expenses": "45,720",
"Other Liabilities": "0",
"Other Net Income": "-1,724",
"Other Revenues": "52,380",
"Property and Equipment": "1,649",
"Research and Development": "39,382",
"Selling, General and Administrative Expense": "14,336"
},
"output_variables": {
"Assets": "36,362",
"Liabilities": "17,850",
"Expenses": "99,439",
"Revenues": "52,380",
"Stockholders Equity": "18,512",
"Net Income": "-48,783",
"Comprehensive Net Income": "-48,767",
"BaseVar": "103,893",
"ECR before LimitedLiability": "-31%",
"Economic Capital Ratio": "140%"
}
}
},
"top_rated": false,
"trend": 14.0,
"value": 1.3996535510918995,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001041024.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001041024.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001041024.svg"
},
{
"company_id": "0000858803",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000858803.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000858803.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000858803_main_keyfigs.svg",
"name": "Avanir Pharmaceuticals INC",
"rank": 176,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000858803.svg",
"report_text": "The relative strengths and weaknesses of Avanir Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Avanir Pharmaceuticals INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 10% points.The greatest weakness of Avanir Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 128% points.
The company's Economic Capital Ratio, given in the ranking table, is 138%, being 105% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000858803_2014_Avanir_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-15.4",
"Assets": "-27.2",
"Liabilities": "-7.22",
"Stockholders Equity": "-37.6",
"ECR before LimitedLiability": "23.4",
"Assets, Current": "29.4",
"Intangible Assets": "-27.4",
"Other Assets": "-12.2",
"Liabilities, Current": "22.4",
"Other Liabilities": "-52.4",
"Liabilities, Non-Current": "19.2",
"Selling, General and Administrative Expense": "-54.1",
"Expenses": "-15.0",
"Revenues": "8.08",
"Comprehensive Net Income": "2.26",
"Research and Development": "14.7",
"Other Expenses": "22.3",
"Cost of Goods Sold": "6.87",
"Other Revenues": "8.08",
"Other Net Income": "9.33",
"Economic Capital Ratio": "-49.7"
},
"2013": {
"Other Assets": "-2.55",
"Assets": "-101",
"Liabilities": "2.18",
"Stockholders Equity": "-128",
"Intangible Assets": "-3.08",
"Property and Equipment": "-2.18",
"Assets, Current": "-52.2",
"Liabilities, Non-Current": "2.10",
"ECR before LimitedLiability": "-76.9",
"Liabilities, Current": "0.623",
"Other Liabilities": "-0.514",
"Selling, General and Administrative Expense": "1.93",
"Expenses": "-20.6",
"Revenues": "10.5",
"Net Income": "-0.777",
"Other Expenses": "-27.1",
"Research and Development": "-1.47",
"Cost of Goods Sold": "0.836",
"Other Revenues": "10.5",
"Comprehensive Net Income": "-0.837",
"Economic Capital Ratio": "-105"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000858803_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "80,915",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "20,318",
"Liabilities, Non-Current": "0",
"Other Assets": "3,289",
"Other Compr. Net Income": "0",
"Other Expenses": "3,509",
"Other Liabilities": "28,856",
"Other Net Income": "4,247",
"Other Revenues": "37,075",
"Property and Equipment": "1,809",
"Research and Development": "23,066",
"Selling, General and Administrative Expense": "74,491"
},
"output_variables": {
"Assets": "86,012",
"Liabilities": "49,175",
"Expenses": "101,066",
"Revenues": "37,075",
"Stockholders Equity": "36,837",
"Net Income": "-59,744",
"Comprehensive Net Income": "-59,744",
"BaseVar": "138,787",
"ECR before LimitedLiability": "30%",
"Economic Capital Ratio": "170%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "71,844",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "34,792",
"Liabilities, Non-Current": "1,393",
"Other Assets": "2,643",
"Other Compr. Net Income": "0",
"Other Expenses": "71,453",
"Other Liabilities": "21,422",
"Other Net Income": "52",
"Other Revenues": "75,366",
"Property and Equipment": "1,593",
"Research and Development": "49,506",
"Selling, General and Administrative Expense": "29,935"
},
"output_variables": {
"Assets": "76,079",
"Liabilities": "57,607",
"Expenses": "150,894",
"Revenues": "75,366",
"Stockholders Equity": "18,472",
"Net Income": "-75,476",
"Comprehensive Net Income": "-75,476",
"BaseVar": "179,999",
"ECR before LimitedLiability": "-53%",
"Economic Capital Ratio": "138%"
}
}
},
"top_rated": false,
"trend": -38.0,
"value": 1.3795133727677436,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000858803.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000858803.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000858803.svg"
},
{
"company_id": "0001061027",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001061027.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001061027.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001061027.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001061027_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001061027_main_keyfigs.svg",
"name": "Viracta Therapeutics Inc",
"rank": 177,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001061027.svg",
"report_text": "The relative strengths and weaknesses of Viracta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Viracta Therapeutics Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 4.9% points.The greatest weakness of Viracta Therapeutics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 91% points.
The company's Economic Capital Ratio, given in the ranking table, is 138%, being 105% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001061027_2014_Viracta_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-7.43",
"Assets": "40.1",
"Liabilities": "48.6",
"Stockholders Equity": "108",
"ECR before LimitedLiability": "162",
"Intangible Assets": "-10.0",
"Property and Equipment": "-6.33",
"Assets, Current": "102",
"Other Liabilities": "32.8",
"Liabilities, Non-Current": "14.3",
"Liabilities, Current": "3.38",
"Other Revenues": "-17.0",
"Revenues": "-17.0",
"Net Income": "-1.65",
"Research and Development": "-22.2",
"Comprehensive Net Income": "-1.89",
"Cost of Goods Sold": "3.70",
"Selling, General and Administrative Expense": "7.38",
"Other Expenses": "10.5",
"Other Net Income": "16.3",
"Economic Capital Ratio": "86.4"
},
"2012": {
"Property and Equipment": "-10.9",
"Assets": "66.2",
"Liabilities": "-22.1",
"Stockholders Equity": "47.5",
"ECR before LimitedLiability": "73.5",
"Assets, Current": "85.5",
"Intangible Assets": "-15.4",
"Other Assets": "-11.2",
"Liabilities, Current": "-71.3",
"Other Liabilities": "29.8",
"Liabilities, Non-Current": "13.8",
"Selling, General and Administrative Expense": "14.3",
"Expenses": "16.6",
"Revenues": "-20.9",
"Net Income": "-14.5",
"Research and Development": "-15.7",
"Other Expenses": "14.2",
"Cost of Goods Sold": "4.34",
"Other Revenues": "-20.9",
"Comprehensive Net Income": "-14.3",
"Other Net Income": "-9.38",
"Economic Capital Ratio": "0.409"
},
"2013": {
"Other Assets": "-2.35",
"Assets": "-3.33",
"Liabilities": "-20.6",
"Stockholders Equity": "-67.4",
"ECR before LimitedLiability": "-77.1",
"Intangible Assets": "-2.74",
"Property and Equipment": "-1.88",
"Assets, Current": "2.68",
"Liabilities, Non-Current": "1.64",
"Liabilities, Current": "-90.5",
"Other Liabilities": "4.95",
"Selling, General and Administrative Expense": "1.03",
"Expenses": "-1.79",
"Revenues": "-1.26",
"Net Income": "-2.46",
"Other Expenses": "1.39",
"Research and Development": "-3.10",
"Cost of Goods Sold": "0.528",
"Other Revenues": "-1.26",
"Comprehensive Net Income": "-2.48",
"Economic Capital Ratio": "-105"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001061027_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "45,665",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,383",
"Liabilities, Non-Current": "0",
"Other Assets": "130",
"Other Compr. Net Income": "34",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "5,725",
"Other Revenues": "5,000",
"Property and Equipment": "74",
"Research and Development": "22,563",
"Selling, General and Administrative Expense": "8,303"
},
"output_variables": {
"Assets": "45,869",
"Liabilities": "8,383",
"Expenses": "30,866",
"Revenues": "5,000",
"Stockholders Equity": "37,486",
"Net Income": "-20,141",
"Comprehensive Net Income": "-20,124",
"BaseVar": "47,938",
"ECR before LimitedLiability": "227%",
"Economic Capital Ratio": "320%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "72,932",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "31,741",
"Liabilities, Non-Current": "0",
"Other Assets": "42",
"Other Compr. Net Income": "19",
"Other Expenses": "1,855",
"Other Liabilities": "0",
"Other Net Income": "-7,490",
"Other Revenues": "3,754",
"Property and Equipment": "43",
"Research and Development": "29,185",
"Selling, General and Administrative Expense": "9,175"
},
"output_variables": {
"Assets": "73,017",
"Liabilities": "31,741",
"Expenses": "40,215",
"Revenues": "3,754",
"Stockholders Equity": "41,276",
"Net Income": "-43,951",
"Comprehensive Net Income": "-43,942",
"BaseVar": "78,118",
"ECR before LimitedLiability": "88%",
"Economic Capital Ratio": "220%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "40,492",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "33,972",
"Liabilities, Non-Current": "0",
"Other Assets": "10",
"Other Compr. Net Income": "-41",
"Other Expenses": "2,917",
"Other Liabilities": "0",
"Other Net Income": "92",
"Other Revenues": "7,956",
"Property and Equipment": "23",
"Research and Development": "28,891",
"Selling, General and Administrative Expense": "10,838"
},
"output_variables": {
"Assets": "40,525",
"Liabilities": "33,972",
"Expenses": "42,646",
"Revenues": "7,956",
"Stockholders Equity": "6,553",
"Net Income": "-34,598",
"Comprehensive Net Income": "-34,618",
"BaseVar": "62,616",
"ECR before LimitedLiability": "-55%",
"Economic Capital Ratio": "138%"
}
}
},
"top_rated": false,
"trend": -61.0,
"value": 1.3772483784178247,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001061027.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001061027.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001061027.svg"
},
{
"company_id": "0001063104",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001063104.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001063104.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001063104_main_keyfigs.svg",
"name": "Proteo INC",
"rank": 178,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001063104.svg",
"report_text": "The relative strengths and weaknesses of Proteo INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Proteo INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 7.5% points.The greatest weakness of Proteo INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 153% points.
The company's Economic Capital Ratio, given in the ranking table, is 136%, being 107% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001063104_2014_Proteo_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-14.5",
"Assets": "1.71",
"Liabilities": "-90.1",
"Stockholders Equity": "-47.3",
"Intangible Assets": "-20.4",
"Property and Equipment": "0.200",
"Assets, Current": "9.20",
"Other Liabilities": "1.10",
"Liabilities, Non-Current": "-132",
"Liabilities, Current": "0.0865",
"Research and Development": "2.31",
"Expenses": "0.330",
"Revenues": "-29.3",
"Net Income": "-11.6",
"Other Expenses": "-27.5",
"Cost of Goods Sold": "0.0811",
"Other Revenues": "-29.3",
"ECR before LimitedLiability": "-17.5",
"Comprehensive Net Income": "-9.76",
"Other Net Income": "0.121",
"Economic Capital Ratio": "-93.1"
},
"2012": {
"Assets": "-1.64",
"Liabilities": "-47.1",
"Stockholders Equity": "-47.1",
"ECR before LimitedLiability": "-11.4",
"Assets, Current": "7.52",
"Intangible Assets": "-3.49",
"Other Assets": "-2.72",
"Liabilities, Current": "5.87",
"Other Liabilities": "4.39",
"Liabilities, Non-Current": "-154",
"Expenses": "1.92",
"Net Income": "-1.93",
"Research and Development": "6.84",
"Other Expenses": "-3.52",
"Cost of Goods Sold": "0.848",
"Other Revenues": "-3.97",
"Revenues": "-3.97",
"Comprehensive Net Income": "-1.18",
"Other Compr. Net Income": "0.923",
"Other Net Income": "1.34",
"Economic Capital Ratio": "-84.4"
},
"2013": {
"Other Assets": "-2.62",
"Assets": "-2.71",
"Liabilities": "-72.0",
"Stockholders Equity": "-71.5",
"ECR before LimitedLiability": "-78.9",
"Intangible Assets": "-3.16",
"Property and Equipment": "-1.39",
"Assets, Current": "7.47",
"Liabilities, Non-Current": "-153",
"Liabilities, Current": "3.08",
"Other Liabilities": "4.35",
"Selling, General and Administrative Expense": "1.01",
"Expenses": "3.95",
"Revenues": "-3.16",
"Net Income": "-1.10",
"Other Expenses": "-2.13",
"Research and Development": "5.21",
"Other Revenues": "-3.16",
"Comprehensive Net Income": "-0.672",
"Other Net Income": "-0.689",
"Economic Capital Ratio": "-107"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001063104_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,067",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "248",
"Liabilities, Non-Current": "622",
"Other Assets": "0",
"Other Compr. Net Income": "46",
"Other Expenses": "482",
"Other Liabilities": "0",
"Other Net Income": "35",
"Other Revenues": "0",
"Property and Equipment": "123",
"Research and Development": "0",
"Selling, General and Administrative Expense": "332"
},
"output_variables": {
"Assets": "1,190",
"Liabilities": "870",
"Expenses": "814",
"Revenues": "0",
"Stockholders Equity": "320",
"Net Income": "-779",
"Comprehensive Net Income": "-756",
"BaseVar": "1,477",
"ECR before LimitedLiability": "-5.7%",
"Economic Capital Ratio": "141%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "785",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "92",
"Liabilities, Non-Current": "753",
"Other Assets": "0",
"Other Compr. Net Income": "97",
"Other Expenses": "428",
"Other Liabilities": "0",
"Other Net Income": "49",
"Other Revenues": "0",
"Property and Equipment": "83",
"Research and Development": "0",
"Selling, General and Administrative Expense": "315"
},
"output_variables": {
"Assets": "867",
"Liabilities": "846",
"Expenses": "743",
"Revenues": "0",
"Stockholders Equity": "22",
"Net Income": "-694",
"Comprehensive Net Income": "-646",
"BaseVar": "1,300",
"ECR before LimitedLiability": "-70%",
"Economic Capital Ratio": "136%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "870",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "151",
"Liabilities, Non-Current": "785",
"Other Assets": "0",
"Other Compr. Net Income": "64",
"Other Expenses": "282",
"Other Liabilities": "0",
"Other Net Income": "-60",
"Other Revenues": "0",
"Property and Equipment": "21",
"Research and Development": "0",
"Selling, General and Administrative Expense": "210"
},
"output_variables": {
"Assets": "890",
"Liabilities": "936",
"Expenses": "492",
"Revenues": "0",
"Stockholders Equity": "-46",
"Net Income": "-552",
"Comprehensive Net Income": "-520",
"BaseVar": "1,221",
"ECR before LimitedLiability": "-68%",
"Economic Capital Ratio": "136%"
}
}
},
"top_rated": false,
"trend": -18.0,
"value": 1.3594847533117955,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001063104.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001063104.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001063104.svg"
},
{
"company_id": "0001183765",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001183765.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001183765.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001183765_main_keyfigs.svg",
"name": "Molecular Templates Inc",
"rank": 179,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001183765.svg",
"report_text": "The relative strengths and weaknesses of Molecular Templates Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Molecular Templates Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 6.7% points.The greatest weakness of Molecular Templates Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 128% points.
The company's Economic Capital Ratio, given in the ranking table, is 136%, being 107% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001183765_2014_Molecular_Templates_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-0.298",
"Assets": "-138",
"Stockholders Equity": "-14.2",
"ECR before LimitedLiability": "-159",
"Intangible Assets": "-1.41",
"Property and Equipment": "-0.198",
"Assets, Current": "-99.2",
"Other Liabilities": "0",
"Liabilities": "-0.437",
"Liabilities, Non-Current": "0",
"Liabilities, Current": "-0.140",
"Research and Development": "-33.7",
"Expenses": "-45.8",
"Net Income": "-73.1",
"Other Expenses": "0",
"Selling, General and Administrative Expense": "-0.0195",
"Other Revenues": "-0.0350",
"Revenues": "-0.0350",
"Comprehensive Net Income": "-73.8",
"Other Net Income": "0",
"Economic Capital Ratio": "-234"
},
"2012": {
"Property and Equipment": "-3.54",
"Assets": "-1.56",
"Liabilities": "-49.9",
"Stockholders Equity": "-44.4",
"ECR before LimitedLiability": "-17.9",
"Assets, Current": "17.2",
"Intangible Assets": "-5.34",
"Other Assets": "-3.52",
"Liabilities, Current": "3.26",
"Other Liabilities": "-99.0",
"Liabilities, Non-Current": "2.18",
"Selling, General and Administrative Expense": "5.81",
"Expenses": "16.3",
"Revenues": "-5.84",
"Net Income": "-2.76",
"Research and Development": "3.11",
"Other Expenses": "4.41",
"Other Revenues": "-5.84",
"Comprehensive Net Income": "-2.72",
"Other Net Income": "-7.85",
"Economic Capital Ratio": "-91.0"
},
"2013": {
"Other Assets": "3.18",
"Assets": "-2.14",
"Liabilities": "-108",
"Stockholders Equity": "-88.4",
"ECR before LimitedLiability": "-79.0",
"Intangible Assets": "-2.99",
"Property and Equipment": "-1.73",
"Assets, Current": "0.505",
"Liabilities, Non-Current": "1.36",
"Liabilities, Current": "0.365",
"Other Liabilities": "-128",
"Selling, General and Administrative Expense": "3.16",
"Expenses": "6.70",
"Revenues": "-2.97",
"Net Income": "3.96",
"Other Expenses": "2.12",
"Cost of Goods Sold": "0.464",
"Other Revenues": "-2.97",
"Comprehensive Net Income": "3.91",
"Other Net Income": "1.67",
"Economic Capital Ratio": "-107"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001183765_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "20,544",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,591",
"Liabilities, Non-Current": "0",
"Other Assets": "1,349",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "9,362",
"Other Net Income": "15,557",
"Other Revenues": "5,089",
"Property and Equipment": "543",
"Research and Development": "203,035",
"Selling, General and Administrative Expense": "69,207"
},
"output_variables": {
"Assets": "22,436",
"Liabilities": "17,953",
"Expenses": "272,242",
"Revenues": "5,089",
"Stockholders Equity": "4,483",
"Net Income": "-251,596",
"Comprehensive Net Income": "-251,596",
"BaseVar": "166,638",
"ECR before LimitedLiability": "-1,197%",
"Economic Capital Ratio": "0.0015%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "87,650",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "17,451",
"Liabilities, Non-Current": "0",
"Other Assets": "1,059",
"Other Compr. Net Income": "12",
"Other Expenses": "0",
"Other Liabilities": "85,923",
"Other Net Income": "-45,269",
"Other Revenues": "0",
"Property and Equipment": "812",
"Research and Development": "18,786",
"Selling, General and Administrative Expense": "7,080"
},
"output_variables": {
"Assets": "89,521",
"Liabilities": "103,374",
"Expenses": "25,866",
"Revenues": "0",
"Stockholders Equity": "-13,853",
"Net Income": "-71,135",
"Comprehensive Net Income": "-71,129",
"BaseVar": "132,021",
"ECR before LimitedLiability": "-105%",
"Economic Capital Ratio": "129%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "86,009",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "27,016",
"Liabilities, Non-Current": "0",
"Other Assets": "17,423",
"Other Compr. Net Income": "17",
"Other Expenses": "202",
"Other Liabilities": "100,577",
"Other Net Income": "10,306",
"Other Revenues": "0",
"Property and Equipment": "686",
"Research and Development": "29,334",
"Selling, General and Administrative Expense": "9,185"
},
"output_variables": {
"Assets": "104,118",
"Liabilities": "127,593",
"Expenses": "38,721",
"Revenues": "0",
"Stockholders Equity": "-23,475",
"Net Income": "-28,415",
"Comprehensive Net Income": "-28,406",
"BaseVar": "140,378",
"ECR before LimitedLiability": "-69%",
"Economic Capital Ratio": "136%"
}
}
},
"top_rated": false,
"trend": -13.0,
"value": 1.3582246562045497,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001183765.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001183765.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001183765.svg"
},
{
"company_id": "0001100412",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001100412.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001100412.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001100412_main_keyfigs.svg",
"name": "Array Biopharma INC",
"rank": 180,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001100412.svg",
"report_text": "The relative strengths and weaknesses of Array Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Array Biopharma INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 5.8% points.The greatest weakness of Array Biopharma INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 111% points.
The company's Economic Capital Ratio, given in the ranking table, is 135%, being 108% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001100412_2014_Array_Biopharma_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-9.58",
"Assets": "-40.6",
"Liabilities": "-43.7",
"Stockholders Equity": "-139",
"ECR before LimitedLiability": "-63.6",
"Intangible Assets": "-14.8",
"Property and Equipment": "0.921",
"Assets, Current": "-30.6",
"Other Liabilities": "5.06",
"Liabilities, Non-Current": "-43.9",
"Liabilities, Current": "-5.60",
"Research and Development": "1.89",
"Expenses": "7.89",
"Revenues": "1.62",
"Net Income": "10.6",
"Cost of Goods Sold": "-4.50",
"Selling, General and Administrative Expense": "9.82",
"Other Revenues": "1.62",
"Comprehensive Net Income": "9.88",
"Other Net Income": "1.09",
"Economic Capital Ratio": "-139"
},
"2012": {
"Property and Equipment": "-0.822",
"Assets": "-18.8",
"Liabilities": "-49.7",
"Stockholders Equity": "-120",
"ECR before LimitedLiability": "-26.3",
"Assets, Current": "-12.7",
"Intangible Assets": "-8.55",
"Other Assets": "-5.22",
"Liabilities, Current": "-7.20",
"Other Liabilities": "6.15",
"Liabilities, Non-Current": "-43.0",
"Selling, General and Administrative Expense": "8.07",
"Expenses": "10.0",
"Revenues": "5.46",
"Net Income": "17.1",
"Other Expenses": "4.02",
"Cost of Goods Sold": "-2.68",
"Other Revenues": "5.46",
"Comprehensive Net Income": "17.1",
"Other Net Income": "0.783",
"Economic Capital Ratio": "-99.4"
},
"2013": {
"Other Assets": "-2.69",
"Assets": "-19.1",
"Liabilities": "-43.7",
"Stockholders Equity": "-111",
"ECR before LimitedLiability": "-79.9",
"Intangible Assets": "-4.22",
"Property and Equipment": "-0.466",
"Assets, Current": "-5.09",
"Liabilities, Non-Current": "-99.0",
"Other Liabilities": "5.83",
"Selling, General and Administrative Expense": "4.38",
"Expenses": "1.27",
"Revenues": "2.49",
"Net Income": "4.41",
"Other Expenses": "0.525",
"Research and Development": "-0.510",
"Cost of Goods Sold": "-2.35",
"Other Revenues": "2.49",
"Comprehensive Net Income": "4.34",
"Other Net Income": "0.357",
"Economic Capital Ratio": "-108"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001100412_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "70,562",
"Cost of Goods Sold": "28,916",
"Intangible Assets": "0",
"Liabilities, Current": "69,808",
"Liabilities, Non-Current": "150,424",
"Other Assets": "3,114",
"Other Compr. Net Income": "-5,525",
"Other Expenses": "19,550",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "71,901",
"Property and Equipment": "15,698",
"Research and Development": "63,498",
"Selling, General and Administrative Expense": "16,261"
},
"output_variables": {
"Assets": "89,374",
"Liabilities": "220,232",
"Expenses": "128,225",
"Revenues": "71,901",
"Stockholders Equity": "-130,858",
"Net Income": "-56,324",
"Comprehensive Net Income": "-59,086",
"BaseVar": "257,628",
"ECR before LimitedLiability": "-222%",
"Economic Capital Ratio": "95%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "93,107",
"Cost of Goods Sold": "24,261",
"Intangible Assets": "0",
"Liabilities, Current": "75,936",
"Liabilities, Non-Current": "117,943",
"Other Assets": "2,907",
"Other Compr. Net Income": "-4.0",
"Other Expenses": "12,534",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "85,135",
"Property and Equipment": "12,059",
"Research and Development": "56,719",
"Selling, General and Administrative Expense": "15,202"
},
"output_variables": {
"Assets": "108,073",
"Liabilities": "193,879",
"Expenses": "108,716",
"Revenues": "85,135",
"Stockholders Equity": "-85,806",
"Net Income": "-23,581",
"Comprehensive Net Income": "-23,583",
"BaseVar": "247,904",
"ECR before LimitedLiability": "-140%",
"Economic Capital Ratio": "121%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "121,309",
"Cost of Goods Sold": "30,078",
"Intangible Assets": "0",
"Liabilities, Current": "50,577",
"Liabilities, Non-Current": "107,320",
"Other Assets": "4,630",
"Other Compr. Net Income": "-1.0",
"Other Expenses": "22,400",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "69,580",
"Property and Equipment": "10,049",
"Research and Development": "59,420",
"Selling, General and Administrative Expense": "19,624"
},
"output_variables": {
"Assets": "135,988",
"Liabilities": "157,897",
"Expenses": "131,522",
"Revenues": "69,580",
"Stockholders Equity": "-21,909",
"Net Income": "-61,942",
"Comprehensive Net Income": "-61,942",
"BaseVar": "247,494",
"ECR before LimitedLiability": "-75%",
"Economic Capital Ratio": "135%"
}
}
},
"top_rated": false,
"trend": -8.0,
"value": 1.3489620235764337,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001100412.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001100412.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001100412.svg"
},
{
"company_id": "0000906709",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000906709.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000906709.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000906709.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000906709_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000906709_main_keyfigs.svg",
"name": "Nektar Therapeutics",
"rank": 181,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000906709.svg",
"report_text": "The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Nektar Therapeutics compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 5.4% points.The greatest weakness of Nektar Therapeutics is the variable Other Liabilities, reducing the Economic Capital Ratio by 106% points.
The company's Economic Capital Ratio, given in the ranking table, is 135%, being 108% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000906709_2014_Nektar_Therapeutics.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "52.3",
"Assets": "54.8",
"Liabilities": "-96.8",
"Stockholders Equity": "-20.8",
"ECR before LimitedLiability": "37.3",
"Intangible Assets": "6.32",
"Property and Equipment": "14.6",
"Assets, Current": "-13.0",
"Other Liabilities": "-29.6",
"Liabilities, Non-Current": "7.32",
"Liabilities, Current": "-71.3",
"Research and Development": "9.41",
"Expenses": "38.9",
"Revenues": "-15.2",
"Net Income": "22.7",
"Other Expenses": "6.02",
"Cost of Goods Sold": "3.53",
"Selling, General and Administrative Expense": "18.6",
"Other Revenues": "-15.2",
"Comprehensive Net Income": "22.4",
"Economic Capital Ratio": "-38.3"
},
"2012": {
"Property and Equipment": "0.969",
"Assets": "1.52",
"Liabilities": "-107",
"Stockholders Equity": "-64.8",
"Assets, Current": "-0.139",
"Intangible Assets": "0.593",
"Liabilities, Current": "1.14",
"Other Liabilities": "-150",
"Liabilities, Non-Current": "0.367",
"Selling, General and Administrative Expense": "1.32",
"Expenses": "3.17",
"Revenues": "-0.239",
"Net Income": "1.38",
"Research and Development": "0.0462",
"Other Expenses": "0.549",
"Cost of Goods Sold": "0.184",
"Other Revenues": "-0.239",
"ECR before LimitedLiability": "-6.20",
"Comprehensive Net Income": "1.40",
"Other Net Income": "-0.114",
"Economic Capital Ratio": "-79.3"
},
"2013": {
"Other Assets": "-1.02",
"Assets": "-5.94",
"Liabilities": "-70.5",
"Stockholders Equity": "-102",
"ECR before LimitedLiability": "-79.9",
"Intangible Assets": "1.68",
"Property and Equipment": "3.28",
"Assets, Current": "-8.05",
"Liabilities, Non-Current": "0.546",
"Liabilities, Current": "2.93",
"Other Liabilities": "-106",
"Selling, General and Administrative Expense": "4.46",
"Expenses": "5.40",
"Revenues": "0.324",
"Net Income": "4.48",
"Other Expenses": "1.30",
"Research and Development": "-1.07",
"Cost of Goods Sold": "0.614",
"Comprehensive Net Income": "4.41",
"Other Net Income": "-0.983",
"Economic Capital Ratio": "-108"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000906709_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "276,706",
"Cost of Goods Sold": "0",
"Intangible Assets": "76,501",
"Liabilities, Current": "275,532",
"Liabilities, Non-Current": "7,159",
"Other Assets": "174,767",
"Other Compr. Net Income": "0",
"Other Expenses": "22,909",
"Other Liabilities": "126,048",
"Other Net Income": "-9,023",
"Other Revenues": "71,480",
"Property and Equipment": "78,576",
"Research and Development": "126,766",
"Selling, General and Administrative Expense": "46,760"
},
"output_variables": {
"Assets": "606,550",
"Liabilities": "408,739",
"Expenses": "196,435",
"Revenues": "71,480",
"Stockholders Equity": "197,811",
"Net Income": "-133,978",
"Comprehensive Net Income": "-133,978",
"BaseVar": "646,114",
"ECR before LimitedLiability": "59%",
"Economic Capital Ratio": "196%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "314,631",
"Cost of Goods Sold": "0",
"Intangible Assets": "76,501",
"Liabilities, Current": "78,537",
"Liabilities, Non-Current": "8,407",
"Other Assets": "34,443",
"Other Compr. Net Income": "0",
"Other Expenses": "32,509",
"Other Liabilities": "363,828",
"Other Net Income": "-30,248",
"Other Revenues": "81,191",
"Property and Equipment": "72,215",
"Research and Development": "148,675",
"Selling, General and Administrative Expense": "41,614"
},
"output_variables": {
"Assets": "497,790",
"Liabilities": "450,772",
"Expenses": "222,798",
"Revenues": "81,191",
"Stockholders Equity": "47,018",
"Net Income": "-171,855",
"Comprehensive Net Income": "-171,855",
"BaseVar": "641,400",
"ECR before LimitedLiability": "-15%",
"Economic Capital Ratio": "141%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "257,882",
"Cost of Goods Sold": "0",
"Intangible Assets": "76,501",
"Liabilities, Current": "98,221",
"Liabilities, Non-Current": "19,256",
"Other Assets": "33,170",
"Other Compr. Net Income": "0",
"Other Expenses": "40,754",
"Other Liabilities": "406,953",
"Other Net Income": "-39,638",
"Other Revenues": "148,921",
"Property and Equipment": "66,974",
"Research and Development": "190,010",
"Selling, General and Administrative Expense": "40,532"
},
"output_variables": {
"Assets": "434,527",
"Liabilities": "524,430",
"Expenses": "271,296",
"Revenues": "148,921",
"Stockholders Equity": "-89,903",
"Net Income": "-162,013",
"Comprehensive Net Income": "-162,013",
"BaseVar": "709,406",
"ECR before LimitedLiability": "-75%",
"Economic Capital Ratio": "135%"
}
}
},
"top_rated": false,
"trend": -31.0,
"value": 1.3489508750552974,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000906709.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000906709.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000906709.svg"
},
{
"company_id": "0001390478",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001390478.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001390478.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001390478.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001390478_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001390478_main_keyfigs.svg",
"name": "Sellas Life Sciences Group Inc",
"rank": 182,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001390478.svg",
"report_text": "The relative strengths and weaknesses of Sellas Life Sciences Group Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Sellas Life Sciences Group Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 15% points.The greatest weakness of Sellas Life Sciences Group Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 56% points.
The company's Economic Capital Ratio, given in the ranking table, is 135%, being 108% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001390478_2014_Sellas_Life_Sciences_Group_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "42.3",
"Assets": "15.0",
"Liabilities": "-72.5",
"Stockholders Equity": "-43.6",
"ECR before LimitedLiability": "21.4",
"Intangible Assets": "16.7",
"Property and Equipment": "-12.5",
"Assets, Current": "-47.1",
"Other Liabilities": "-52.5",
"Liabilities, Non-Current": "12.8",
"Liabilities, Current": "-31.7",
"Expenses": "19.1",
"Revenues": "-34.3",
"Net Income": "18.5",
"Other Expenses": "13.0",
"Cost of Goods Sold": "4.58",
"Selling, General and Administrative Expense": "1.49",
"Other Revenues": "-34.3",
"Comprehensive Net Income": "18.1",
"Other Net Income": "37.1",
"Economic Capital Ratio": "-54.1"
},
"2012": {
"Property and Equipment": "-7.63",
"Assets": "-14.0",
"Liabilities": "5.28",
"Stockholders Equity": "-8.43",
"ECR before LimitedLiability": "-22.7",
"Assets, Current": "-14.2",
"Intangible Assets": "-2.88",
"Other Assets": "15.9",
"Liabilities, Current": "3.12",
"Other Liabilities": "-1.83",
"Liabilities, Non-Current": "4.00",
"Selling, General and Administrative Expense": "-11.6",
"Expenses": "-4.56",
"Revenues": "-11.0",
"Net Income": "-57.7",
"Other Expenses": "9.68",
"Cost of Goods Sold": "2.16",
"Other Revenues": "-11.0",
"Comprehensive Net Income": "-57.3",
"Other Net Income": "-15.8",
"Economic Capital Ratio": "-95.8"
},
"2013": {
"Other Assets": "15.0",
"Assets": "-4.35",
"Liabilities": "-32.9",
"Stockholders Equity": "-55.9",
"ECR before LimitedLiability": "-80.0",
"Intangible Assets": "-1.95",
"Property and Equipment": "-2.27",
"Assets, Current": "-5.94",
"Liabilities, Non-Current": "-0.925",
"Liabilities, Current": "-30.3",
"Other Liabilities": "0.685",
"Selling, General and Administrative Expense": "6.29",
"Expenses": "8.27",
"Revenues": "-3.54",
"Net Income": "-4.14",
"Research and Development": "1.34",
"Cost of Goods Sold": "0.514",
"Other Revenues": "-3.54",
"Comprehensive Net Income": "-4.18",
"Other Net Income": "-5.35",
"Economic Capital Ratio": "-108"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001390478_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "11,810",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,898",
"Liabilities, Current": "11,202",
"Liabilities, Non-Current": "0",
"Other Assets": "12,867",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "9,654",
"Other Net Income": "9,302",
"Other Revenues": "0",
"Property and Equipment": "393",
"Research and Development": "11,538",
"Selling, General and Administrative Expense": "9,249"
},
"output_variables": {
"Assets": "30,968",
"Liabilities": "20,856",
"Expenses": "20,787",
"Revenues": "0",
"Stockholders Equity": "10,112",
"Net Income": "-11,485",
"Comprehensive Net Income": "-11,485",
"BaseVar": "40,956",
"ECR before LimitedLiability": "41%",
"Economic Capital Ratio": "180%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "36,121",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,898",
"Liabilities, Current": "15,919",
"Liabilities, Non-Current": "0",
"Other Assets": "12,938",
"Other Compr. Net Income": "0",
"Other Expenses": "-1,052",
"Other Liabilities": "11,311",
"Other Net Income": "-41,209",
"Other Revenues": "0",
"Property and Equipment": "29",
"Research and Development": "25,791",
"Selling, General and Administrative Expense": "46,290"
},
"output_variables": {
"Assets": "54,986",
"Liabilities": "27,230",
"Expenses": "71,029",
"Revenues": "0",
"Stockholders Equity": "27,756",
"Net Income": "-112,238",
"Comprehensive Net Income": "-112,238",
"BaseVar": "97,227",
"ECR before LimitedLiability": "-126%",
"Economic Capital Ratio": "124%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "53,455",
"Cost of Goods Sold": "520",
"Intangible Assets": "5,898",
"Liabilities, Current": "62,447",
"Liabilities, Non-Current": "7,743",
"Other Assets": "27,958",
"Other Compr. Net Income": "0",
"Other Expenses": "15,783",
"Other Liabilities": "11,900",
"Other Net Income": "-41,786",
"Other Revenues": "2,487",
"Property and Equipment": "665",
"Research and Development": "21,076",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "87,976",
"Liabilities": "82,090",
"Expenses": "37,379",
"Revenues": "2,487",
"Stockholders Equity": "5,886",
"Net Income": "-76,678",
"Comprehensive Net Income": "-76,678",
"BaseVar": "125,859",
"ECR before LimitedLiability": "-75%",
"Economic Capital Ratio": "135%"
}
}
},
"top_rated": false,
"trend": -12.0,
"value": 1.3482729119408219,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001390478.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001390478.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001390478.svg"
},
{
"company_id": "0001029125",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001029125.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001029125.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001029125_main_keyfigs.svg",
"name": "Panbela Therapeutics Inc",
"rank": 183,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001029125.svg",
"report_text": "The relative strengths and weaknesses of Panbela Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Panbela Therapeutics Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 29% points.The greatest weakness of Panbela Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 194% points.
The company's Economic Capital Ratio, given in the ranking table, is 133%, being 110% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001029125_2014_Panbela_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-22.5",
"Assets": "-108",
"Liabilities": "-22.1",
"Stockholders Equity": "-174",
"ECR before LimitedLiability": "18.4",
"Assets, Current": "-102",
"Intangible Assets": "-36.3",
"Other Assets": "25.7",
"Liabilities, Current": "-115",
"Other Liabilities": "25.2",
"Liabilities, Non-Current": "24.4",
"Selling, General and Administrative Expense": "24.7",
"Expenses": "21.9",
"Revenues": "36.9",
"Net Income": "43.7",
"Research and Development": "26.3",
"Other Expenses": "14.0",
"Cost of Goods Sold": "-83.9",
"Other Revenues": "36.9",
"Comprehensive Net Income": "43.8",
"Economic Capital Ratio": "-54.7"
},
"2013": {
"Other Assets": "-2.10",
"Assets": "-117",
"Liabilities": "-3.47",
"Stockholders Equity": "-194",
"Intangible Assets": "-6.89",
"Property and Equipment": "-3.98",
"Assets, Current": "-86.1",
"Liabilities, Non-Current": "3.70",
"ECR before LimitedLiability": "-81.7",
"Liabilities, Current": "-47.0",
"Other Liabilities": "10.2",
"Selling, General and Administrative Expense": "6.14",
"Expenses": "-5.41",
"Revenues": "28.9",
"Net Income": "18.5",
"Research and Development": "3.12",
"Cost of Goods Sold": "-8.48",
"Other Revenues": "28.9",
"Comprehensive Net Income": "18.3",
"Other Net Income": "0.679",
"Economic Capital Ratio": "-110"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001029125_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "337",
"Cost of Goods Sold": "692",
"Intangible Assets": "0",
"Liabilities, Current": "644",
"Liabilities, Non-Current": "0",
"Other Assets": "258",
"Other Compr. Net Income": "0",
"Other Expenses": "149",
"Other Liabilities": "8.2",
"Other Net Income": "1.0",
"Other Revenues": "1,233",
"Property and Equipment": "16",
"Research and Development": "0",
"Selling, General and Administrative Expense": "145"
},
"output_variables": {
"Assets": "611",
"Liabilities": "652",
"Expenses": "986",
"Revenues": "1,233",
"Stockholders Equity": "-41",
"Net Income": "247",
"Comprehensive Net Income": "247",
"BaseVar": "1,741",
"ECR before LimitedLiability": "25%",
"Economic Capital Ratio": "165%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "433",
"Cost of Goods Sold": "558",
"Intangible Assets": "0",
"Liabilities, Current": "664",
"Liabilities, Non-Current": "0",
"Other Assets": "80",
"Other Compr. Net Income": "0",
"Other Expenses": "168",
"Other Liabilities": "6.5",
"Other Net Income": "0",
"Other Revenues": "992",
"Property and Equipment": "19",
"Research and Development": "280",
"Selling, General and Administrative Expense": "198"
},
"output_variables": {
"Assets": "532",
"Liabilities": "670",
"Expenses": "1,204",
"Revenues": "992",
"Stockholders Equity": "-138",
"Net Income": "-212",
"Comprehensive Net Income": "-212",
"BaseVar": "1,699",
"ECR before LimitedLiability": "-85%",
"Economic Capital Ratio": "133%"
}
}
},
"top_rated": false,
"trend": -44.0,
"value": 1.3307775191346929,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001029125.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001029125.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001029125.svg"
},
{
"company_id": "0000897448",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000897448.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000897448.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000897448.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000897448_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000897448_main_keyfigs.svg",
"name": "Amarin CORP PLC UK",
"rank": 184,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000897448.svg",
"report_text": "The relative strengths and weaknesses of Amarin CORP PLC UK are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Amarin CORP PLC UK compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 11% points.The greatest weakness of Amarin CORP PLC UK is the variable Other Liabilities, reducing the Economic Capital Ratio by 162% points.
The company's Economic Capital Ratio, given in the ranking table, is 132%, being 110% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000897448_2014_Amarin_CORP_PLC_UK.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-1.01",
"Assets": "3.41",
"Liabilities": "-99.2",
"Stockholders Equity": "-56.6",
"ECR before LimitedLiability": "-21.9",
"Intangible Assets": "-2.95",
"Property and Equipment": "-1.99",
"Assets, Current": "18.6",
"Other Liabilities": "-171",
"Liabilities, Non-Current": "1.29",
"Liabilities, Current": "4.81",
"Research and Development": "2.96",
"Expenses": "8.12",
"Revenues": "-3.34",
"Comprehensive Net Income": "-0.313",
"Other Expenses": "1.39",
"Cost of Goods Sold": "0.573",
"Selling, General and Administrative Expense": "1.89",
"Other Revenues": "-3.34",
"Other Net Income": "-1.84",
"Economic Capital Ratio": "-97.5"
},
"2012": {
"Property and Equipment": "-1.88",
"Assets": "3.89",
"Liabilities": "-85.4",
"Stockholders Equity": "-45.6",
"ECR before LimitedLiability": "-9.97",
"Assets, Current": "14.9",
"Intangible Assets": "-1.81",
"Other Assets": "-0.946",
"Liabilities, Current": "7.36",
"Other Liabilities": "-190",
"Liabilities, Non-Current": "1.47",
"Selling, General and Administrative Expense": "1.64",
"Expenses": "6.31",
"Revenues": "-2.93",
"Net Income": "-0.0753",
"Research and Development": "1.77",
"Other Expenses": "1.29",
"Cost of Goods Sold": "0.624",
"Other Revenues": "-2.93",
"Other Net Income": "-1.10",
"Economic Capital Ratio": "-83.0"
},
"2013": {
"Other Assets": "-1.000",
"Assets": "-8.37",
"Liabilities": "-35.8",
"Stockholders Equity": "-90.6",
"ECR before LimitedLiability": "-82.4",
"Intangible Assets": "-3.79",
"Property and Equipment": "-3.16",
"Assets, Current": "-5.25",
"Liabilities, Non-Current": "2.09",
"Liabilities, Current": "11.0",
"Other Liabilities": "-162",
"Selling, General and Administrative Expense": "-1.98",
"Expenses": "0.417",
"Revenues": "-3.58",
"Net Income": "0.0692",
"Other Expenses": "0.262",
"Research and Development": "1.55",
"Cost of Goods Sold": "0.765",
"Other Revenues": "-3.58",
"Other Net Income": "4.01",
"Economic Capital Ratio": "-110"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000897448_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "118,972",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,452",
"Liabilities, Non-Current": "0",
"Other Assets": "6,975",
"Other Compr. Net Income": "0",
"Other Expenses": "2,517",
"Other Liabilities": "123,889",
"Other Net Income": "-22,448",
"Other Revenues": "0",
"Property and Equipment": "432",
"Research and Development": "21,602",
"Selling, General and Administrative Expense": "22,559"
},
"output_variables": {
"Assets": "126,379",
"Liabilities": "132,341",
"Expenses": "46,678",
"Revenues": "0",
"Stockholders Equity": "-5,962",
"Net Income": "-69,126",
"Comprehensive Net Income": "-69,126",
"BaseVar": "163,923",
"ECR before LimitedLiability": "-63%",
"Economic Capital Ratio": "137%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "285,694",
"Cost of Goods Sold": "0",
"Intangible Assets": "11,355",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "12,995",
"Other Compr. Net Income": "0",
"Other Expenses": "27,207",
"Other Liabilities": "314,852",
"Other Net Income": "-35,227",
"Other Revenues": "0",
"Property and Equipment": "811",
"Research and Development": "58,956",
"Selling, General and Administrative Expense": "57,794"
},
"output_variables": {
"Assets": "310,855",
"Liabilities": "314,852",
"Expenses": "143,957",
"Revenues": "0",
"Stockholders Equity": "-3,997",
"Net Income": "-179,184",
"Comprehensive Net Income": "-179,184",
"BaseVar": "402,446",
"ECR before LimitedLiability": "-60%",
"Economic Capital Ratio": "137%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "219,402",
"Cost of Goods Sold": "0",
"Intangible Assets": "10,709",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "21,786",
"Other Compr. Net Income": "0",
"Other Expenses": "42,897",
"Other Liabilities": "286,332",
"Other Net Income": "46,864",
"Other Revenues": "26,351",
"Property and Equipment": "579",
"Research and Development": "72,750",
"Selling, General and Administrative Expense": "123,795"
},
"output_variables": {
"Assets": "252,476",
"Liabilities": "286,332",
"Expenses": "239,442",
"Revenues": "26,351",
"Stockholders Equity": "-33,856",
"Net Income": "-166,227",
"Comprehensive Net Income": "-166,227",
"BaseVar": "425,732",
"ECR before LimitedLiability": "-89%",
"Economic Capital Ratio": "132%"
}
}
},
"top_rated": false,
"trend": -27.0,
"value": 1.3236835555106445,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000897448.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000897448.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000897448.svg"
},
{
"company_id": "0001176309",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001176309.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001176309.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001176309.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001176309_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001176309_main_keyfigs.svg",
"name": "Oramed Pharmaceuticals INC",
"rank": 185,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001176309.svg",
"report_text": "The relative strengths and weaknesses of Oramed Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Oramed Pharmaceuticals INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 60% points.The greatest weakness of Oramed Pharmaceuticals INC is the variable Other Net Income, reducing the Economic Capital Ratio by 295% points.
The company's Economic Capital Ratio, given in the ranking table, is 132%, being 111% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001176309_2014_Oramed_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-7.51",
"Assets": "-70.3",
"Liabilities": "34.1",
"Stockholders Equity": "12.8",
"ECR before LimitedLiability": "-83.1",
"Intangible Assets": "-8.50",
"Property and Equipment": "-6.21",
"Assets, Current": "-6.88",
"Liabilities, Non-Current": "4.46",
"Liabilities, Current": "20.0",
"Other Liabilities": "13.1",
"Selling, General and Administrative Expense": "19.3",
"Expenses": "59.7",
"Revenues": "-8.62",
"Net Income": "-206",
"Other Expenses": "8.34",
"Research and Development": "19.3",
"Other Revenues": "-8.62",
"Comprehensive Net Income": "-205",
"Other Net Income": "-295",
"Economic Capital Ratio": "-111"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001176309_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "8,644",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "498",
"Liabilities, Non-Current": "31",
"Other Assets": "10",
"Other Compr. Net Income": "303",
"Other Expenses": "36",
"Other Liabilities": "0",
"Other Net Income": "-22,088",
"Other Revenues": "0",
"Property and Equipment": "5.8",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "8,660",
"Liabilities": "529",
"Expenses": "36",
"Revenues": "0",
"Stockholders Equity": "8,131",
"Net Income": "-22,124",
"Comprehensive Net Income": "-21,972",
"BaseVar": "15,808",
"ECR before LimitedLiability": "-92%",
"Economic Capital Ratio": "132%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.3173008587615769,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001176309.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001176309.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001176309.svg"
},
{
"company_id": "0000899460",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000899460.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000899460.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000899460.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000899460_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000899460_main_keyfigs.svg",
"name": "Mannkind CORP",
"rank": 186,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000899460.svg",
"report_text": "The relative strengths and weaknesses of Mannkind CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Mannkind CORP compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 66% points.The greatest weakness of Mannkind CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 67% points.
The company's Economic Capital Ratio, given in the ranking table, is 132%, being 111% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000899460_2014_Mannkind_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.86",
"Assets": "-121",
"Liabilities": "0.751",
"Stockholders Equity": "-95.9",
"ECR before LimitedLiability": "-157",
"Intangible Assets": "-9.14",
"Property and Equipment": "1.79",
"Assets, Current": "-110",
"Other Liabilities": "1.85",
"Liabilities, Non-Current": "-0.495",
"Liabilities, Current": "-2.31",
"Research and Development": "-24.3",
"Expenses": "-31.5",
"Revenues": "-3.44",
"Net Income": "-51.9",
"Other Expenses": "-0.771",
"Selling, General and Administrative Expense": "-0.392",
"Other Revenues": "-3.44",
"Comprehensive Net Income": "-52.2",
"Other Net Income": "0.352",
"Economic Capital Ratio": "-232"
},
"2012": {
"Property and Equipment": "66.0",
"Assets": "-4.88",
"Liabilities": "-63.2",
"Stockholders Equity": "-61.5",
"ECR before LimitedLiability": "-24.8",
"Assets, Current": "-17.6",
"Intangible Assets": "-6.61",
"Other Assets": "-4.81",
"Liabilities, Current": "-8.69",
"Other Liabilities": "-18.8",
"Liabilities, Non-Current": "2.20",
"Selling, General and Administrative Expense": "4.04",
"Expenses": "7.81",
"Revenues": "-6.91",
"Comprehensive Net Income": "0.318",
"Research and Development": "-0.587",
"Other Expenses": "2.89",
"Cost of Goods Sold": "1.20",
"Other Revenues": "-6.91",
"Other Net Income": "0.488",
"Economic Capital Ratio": "-97.9"
},
"2013": {
"Other Assets": "-3.05",
"Assets": "-5.47",
"Liabilities": "-53.3",
"Stockholders Equity": "-67.3",
"ECR before LimitedLiability": "-83.2",
"Intangible Assets": "-4.73",
"Property and Equipment": "65.9",
"Assets, Current": "-28.0",
"Liabilities, Current": "-5.84",
"Other Liabilities": "-9.33",
"Selling, General and Administrative Expense": "1.65",
"Expenses": "1.74",
"Revenues": "-4.38",
"Net Income": "-2.79",
"Other Expenses": "1.44",
"Research and Development": "-1.89",
"Cost of Goods Sold": "0.678",
"Other Revenues": "-4.38",
"Comprehensive Net Income": "-2.84",
"Other Net Income": "0.302",
"Economic Capital Ratio": "-111"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000899460_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "5,821",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "25,360",
"Liabilities, Non-Current": "0",
"Other Assets": "703",
"Other Compr. Net Income": "0",
"Other Expenses": "228,308",
"Other Liabilities": "487,845",
"Other Net Income": "35,913",
"Other Revenues": "3,131",
"Property and Equipment": "193,029",
"Research and Development": "1,366,051",
"Selling, General and Administrative Expense": "380,231"
},
"output_variables": {
"Assets": "199,553",
"Liabilities": "513,205",
"Expenses": "1,974,590",
"Revenues": "3,131",
"Stockholders Equity": "-313,652",
"Net Income": "-1,935,546",
"Comprehensive Net Income": "-1,935,546",
"BaseVar": "1,363,196",
"ECR before LimitedLiability": "-735%",
"Economic Capital Ratio": "1.9%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "66,810",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "144,775",
"Liabilities, Non-Current": "0",
"Other Assets": "543",
"Other Compr. Net Income": "-50",
"Other Expenses": "21,222",
"Other Liabilities": "217,218",
"Other Net Income": "-1,184",
"Other Revenues": "35",
"Property and Equipment": "183,961",
"Research and Development": "101,522",
"Selling, General and Administrative Expense": "45,473"
},
"output_variables": {
"Assets": "251,314",
"Liabilities": "361,993",
"Expenses": "168,217",
"Revenues": "35",
"Stockholders Equity": "-110,679",
"Net Income": "-169,366",
"Comprehensive Net Income": "-169,391",
"BaseVar": "391,396",
"ECR before LimitedLiability": "-134%",
"Economic Capital Ratio": "122%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "76,275",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "127,794",
"Liabilities, Non-Current": "13,605",
"Other Assets": "5,814",
"Other Compr. Net Income": "2.0",
"Other Expenses": "21,080",
"Other Liabilities": "147,960",
"Other Net Income": "-627",
"Other Revenues": "3,166",
"Property and Equipment": "176,557",
"Research and Development": "109,719",
"Selling, General and Administrative Expense": "59,682"
},
"output_variables": {
"Assets": "258,646",
"Liabilities": "289,359",
"Expenses": "190,481",
"Revenues": "3,166",
"Stockholders Equity": "-30,713",
"Net Income": "-187,942",
"Comprehensive Net Income": "-187,941",
"BaseVar": "371,140",
"ECR before LimitedLiability": "-93%",
"Economic Capital Ratio": "132%"
}
}
},
"top_rated": false,
"trend": -15.0,
"value": 1.3161280514315907,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000899460.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000899460.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000899460.svg"
},
{
"company_id": "0001317880",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001317880.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001317880.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001317880_main_keyfigs.svg",
"name": "Plandai Biotechnology Inc",
"rank": 187,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001317880.svg",
"report_text": "The relative strengths and weaknesses of Plandai Biotechnology Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Plandai Biotechnology Inc compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 86% points.The greatest weakness of Plandai Biotechnology Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 130% points.
The company's Economic Capital Ratio, given in the ranking table, is 131%, being 112% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001317880_2014_Plandai_Biotechnology_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-1.79",
"Assets": "0.807",
"Liabilities": "-72.8",
"Stockholders Equity": "-50.7",
"ECR before LimitedLiability": "-14.5",
"Assets, Current": "-49.1",
"Intangible Assets": "-4.19",
"Other Assets": "106",
"Liabilities, Current": "8.32",
"Other Liabilities": "-3.72",
"Liabilities, Non-Current": "-113",
"Selling, General and Administrative Expense": "5.27",
"Expenses": "5.30",
"Revenues": "-4.53",
"Net Income": "-0.232",
"Research and Development": "6.81",
"Other Expenses": "-5.50",
"Cost of Goods Sold": "0.893",
"Other Revenues": "-4.53",
"Other Net Income": "0.352",
"Economic Capital Ratio": "-87.5"
},
"2013": {
"Other Assets": "-2.06",
"Assets": "-5.67",
"Liabilities": "-101",
"Stockholders Equity": "-94.4",
"ECR before LimitedLiability": "-83.7",
"Intangible Assets": "-4.48",
"Property and Equipment": "85.7",
"Assets, Current": "-48.2",
"Liabilities, Non-Current": "-130",
"Liabilities, Current": "5.68",
"Other Liabilities": "-2.58",
"Selling, General and Administrative Expense": "5.18",
"Expenses": "9.79",
"Revenues": "-3.72",
"Net Income": "4.31",
"Other Expenses": "-2.23",
"Research and Development": "6.01",
"Other Revenues": "-3.72",
"Comprehensive Net Income": "5.30",
"Other Compr. Net Income": "0.856",
"Economic Capital Ratio": "-112"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001317880_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "5.1",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "100",
"Liabilities, Non-Current": "5,229",
"Other Assets": "5,836",
"Other Compr. Net Income": "65",
"Other Expenses": "3,536",
"Other Liabilities": "1,610",
"Other Net Income": "-29",
"Other Revenues": "74",
"Property and Equipment": "216",
"Research and Development": "0",
"Selling, General and Administrative Expense": "348"
},
"output_variables": {
"Assets": "6,057",
"Liabilities": "6,939",
"Expenses": "3,884",
"Revenues": "74",
"Stockholders Equity": "-882",
"Net Income": "-3,838",
"Comprehensive Net Income": "-3,806",
"BaseVar": "8,524",
"ECR before LimitedLiability": "-88%",
"Economic Capital Ratio": "133%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "519",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "904",
"Liabilities, Non-Current": "9,174",
"Other Assets": "392",
"Other Compr. Net Income": "945",
"Other Expenses": "2,658",
"Other Liabilities": "2,242",
"Other Net Income": "-310",
"Other Revenues": "359",
"Property and Equipment": "7,925",
"Research and Development": "0",
"Selling, General and Administrative Expense": "359"
},
"output_variables": {
"Assets": "8,835",
"Liabilities": "12,320",
"Expenses": "3,017",
"Revenues": "359",
"Stockholders Equity": "-3,484",
"Net Income": "-2,968",
"Comprehensive Net Income": "-2,496",
"BaseVar": "12,894",
"ECR before LimitedLiability": "-95%",
"Economic Capital Ratio": "131%"
}
}
},
"top_rated": false,
"trend": -24.0,
"value": 1.3114215496482051,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001317880.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001317880.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001317880.svg"
},
{
"company_id": "0000791908",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000791908.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000791908.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000791908.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000791908_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000791908_main_keyfigs.svg",
"name": "XOMA Royalty Corp",
"rank": 188,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000791908.svg",
"report_text": "The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of XOMA Royalty Corp compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 6.1% points.The greatest weakness of XOMA Royalty Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 79% points.
The company's Economic Capital Ratio, given in the ranking table, is 131%, being 112% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000791908_2014_XOMA_Royalty_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-21.1",
"Assets": "-64.7",
"Liabilities": "-54.6",
"Stockholders Equity": "-116",
"Intangible Assets": "-35.8",
"Property and Equipment": "0.221",
"Assets, Current": "-30.0",
"Other Liabilities": "0.341",
"Liabilities, Non-Current": "-98.5",
"Liabilities, Current": "0.395",
"Other Revenues": "0.994",
"Revenues": "0.994",
"Net Income": "1.73",
"ECR before LimitedLiability": "-17.5",
"Research and Development": "-35.9",
"Other Compr. Net Income": "-0.490",
"Comprehensive Net Income": "1.68",
"Selling, General and Administrative Expense": "0.282",
"Other Expenses": "0.265",
"Other Net Income": "0.0983",
"Economic Capital Ratio": "-93.0"
},
"2012": {
"Property and Equipment": "-0.118",
"Assets": "-0.682",
"Liabilities": "-45.9",
"Stockholders Equity": "-57.6",
"ECR before LimitedLiability": "-6.66",
"Assets, Current": "3.00",
"Intangible Assets": "-5.19",
"Other Assets": "-0.644",
"Liabilities, Current": "1.39",
"Other Liabilities": "-0.521",
"Liabilities, Non-Current": "-54.9",
"Selling, General and Administrative Expense": "1.83",
"Expenses": "0.875",
"Revenues": "-0.176",
"Comprehensive Net Income": "0.103",
"Research and Development": "-5.80",
"Other Expenses": "1.01",
"Cost of Goods Sold": "0.377",
"Other Revenues": "-0.176",
"Other Net Income": "-0.364",
"Economic Capital Ratio": "-79.7"
},
"2013": {
"Other Assets": "-4.60",
"Assets": "-10.1",
"Liabilities": "-10.1",
"Stockholders Equity": "-78.8",
"ECR before LimitedLiability": "-84.0",
"Intangible Assets": "-5.97",
"Property and Equipment": "-1.74",
"Assets, Current": "-4.63",
"Liabilities, Non-Current": "-6.01",
"Liabilities, Current": "4.62",
"Other Liabilities": "-9.56",
"Selling, General and Administrative Expense": "5.43",
"Expenses": "6.06",
"Revenues": "-1.52",
"Net Income": "-4.25",
"Other Expenses": "3.27",
"Research and Development": "-3.17",
"Other Revenues": "-1.52",
"Comprehensive Net Income": "-4.31",
"Other Net Income": "-6.93",
"Economic Capital Ratio": "-112"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000791908_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "62,695",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "21,010",
"Liabilities, Non-Current": "34,476",
"Other Assets": "2,632",
"Other Compr. Net Income": "0",
"Other Expenses": "2,477",
"Other Liabilities": "7,539",
"Other Net Income": "3,689",
"Other Revenues": "58,196",
"Property and Equipment": "12,709",
"Research and Development": "68,137",
"Selling, General and Administrative Expense": "24,014"
},
"output_variables": {
"Assets": "78,036",
"Liabilities": "63,025",
"Expenses": "94,628",
"Revenues": "58,196",
"Stockholders Equity": "15,011",
"Net Income": "-32,743",
"Comprehensive Net Income": "-32,743",
"BaseVar": "148,787",
"ECR before LimitedLiability": "-0.027%",
"Economic Capital Ratio": "141%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "95,837",
"Cost of Goods Sold": "143",
"Intangible Assets": "0",
"Liabilities, Current": "23,657",
"Liabilities, Non-Current": "39,060",
"Other Assets": "1,696",
"Other Compr. Net Income": "8.0",
"Other Expenses": "9,387",
"Other Liabilities": "21,316",
"Other Net Income": "-10,128",
"Other Revenues": "33,782",
"Property and Equipment": "8,143",
"Research and Development": "68,231",
"Selling, General and Administrative Expense": "16,782"
},
"output_variables": {
"Assets": "105,676",
"Liabilities": "84,033",
"Expenses": "94,543",
"Revenues": "33,782",
"Stockholders Equity": "21,643",
"Net Income": "-70,889",
"Comprehensive Net Income": "-70,885",
"BaseVar": "164,085",
"ECR before LimitedLiability": "-25%",
"Economic Capital Ratio": "140%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "127,060",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "29,645",
"Liabilities, Non-Current": "35,150",
"Other Assets": "1,266",
"Other Compr. Net Income": "0",
"Other Expenses": "4,945",
"Other Liabilities": "73,974",
"Other Net Income": "-61,236",
"Other Revenues": "35,451",
"Property and Equipment": "6,456",
"Research and Development": "74,851",
"Selling, General and Administrative Expense": "18,477"
},
"output_variables": {
"Assets": "134,782",
"Liabilities": "138,769",
"Expenses": "98,273",
"Revenues": "35,451",
"Stockholders Equity": "-3,987",
"Net Income": "-124,058",
"Comprehensive Net Income": "-124,058",
"BaseVar": "234,256",
"ECR before LimitedLiability": "-97%",
"Economic Capital Ratio": "131%"
}
}
},
"top_rated": false,
"trend": -36.0,
"value": 1.3080871885041008,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000791908.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000791908.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000791908.svg"
},
{
"company_id": "0001261734",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001261734.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001261734.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001261734_main_keyfigs.svg",
"name": "Aeolus Pharmaceuticals INC",
"rank": 189,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001261734.svg",
"report_text": "The relative strengths and weaknesses of Aeolus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Aeolus Pharmaceuticals INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 68% points.The greatest weakness of Aeolus Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 172% points.
The company's Economic Capital Ratio, given in the ranking table, is 129%, being 113% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001261734_2014_Aeolus_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-12.4",
"Assets": "-81.3",
"Liabilities": "-47.6",
"Stockholders Equity": "-214",
"ECR before LimitedLiability": "-109",
"Intangible Assets": "-16.7",
"Property and Equipment": "-10.5",
"Assets, Current": "-63.4",
"Other Liabilities": "-76.8",
"Liabilities, Current": "1.44",
"Research and Development": "2.69",
"Expenses": "11.2",
"Revenues": "-12.4",
"Net Income": "17.5",
"Other Expenses": "4.13",
"Cost of Goods Sold": "1.47",
"Selling, General and Administrative Expense": "3.46",
"Other Revenues": "-12.4",
"Comprehensive Net Income": "17.4",
"Other Net Income": "17.3",
"Economic Capital Ratio": "-185"
},
"2012": {
"Property and Equipment": "-12.0",
"Assets": "-90.1",
"Liabilities": "-32.2",
"Stockholders Equity": "-233",
"ECR before LimitedLiability": "-101",
"Assets, Current": "-77.3",
"Intangible Assets": "-17.1",
"Other Assets": "-12.0",
"Liabilities, Current": "1.43",
"Other Liabilities": "-62.0",
"Selling, General and Administrative Expense": "4.49",
"Expenses": "10.3",
"Revenues": "-12.8",
"Net Income": "22.7",
"Research and Development": "-2.87",
"Other Expenses": "7.02",
"Cost of Goods Sold": "1.87",
"Other Revenues": "-12.8",
"Comprehensive Net Income": "22.7",
"Other Net Income": "23.3",
"Economic Capital Ratio": "-174"
},
"2013": {
"Other Assets": "-9.38",
"Assets": "-152",
"Liabilities": "22.8",
"Stockholders Equity": "-172",
"ECR before LimitedLiability": "-85.4",
"Intangible Assets": "-10.9",
"Property and Equipment": "-8.16",
"Assets, Current": "-106",
"Liabilities, Non-Current": "5.89",
"Other Liabilities": "16.0",
"Selling, General and Administrative Expense": "-19.6",
"Expenses": "-76.3",
"Revenues": "-11.0",
"Net Income": "-6.73",
"Other Expenses": "11.2",
"Research and Development": "-25.2",
"Cost of Goods Sold": "2.31",
"Other Revenues": "-11.0",
"Comprehensive Net Income": "-6.86",
"Other Net Income": "67.5",
"Economic Capital Ratio": "-113"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001261734_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,258",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,144",
"Liabilities, Non-Current": "0",
"Other Assets": "32",
"Other Compr. Net Income": "0",
"Other Expenses": "-21",
"Other Liabilities": "23,405",
"Other Net Income": "9,043",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "5,055",
"Selling, General and Administrative Expense": "3,668"
},
"output_variables": {
"Assets": "2,290",
"Liabilities": "25,549",
"Expenses": "8,702",
"Revenues": "0",
"Stockholders Equity": "-23,259",
"Net Income": "341",
"Comprehensive Net Income": "341",
"BaseVar": "22,792",
"ECR before LimitedLiability": "-362%",
"Economic Capital Ratio": "49%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,224",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,272",
"Liabilities, Non-Current": "0",
"Other Assets": "32",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "19,319",
"Other Net Income": "11,362",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "6,468",
"Selling, General and Administrative Expense": "3,196"
},
"output_variables": {
"Assets": "1,256",
"Liabilities": "21,591",
"Expenses": "9,664",
"Revenues": "0",
"Stockholders Equity": "-20,335",
"Net Income": "1,698",
"Comprehensive Net Income": "1,698",
"BaseVar": "21,936",
"ECR before LimitedLiability": "-373%",
"Economic Capital Ratio": "46%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "1,935",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,261",
"Liabilities, Non-Current": "0",
"Other Assets": "31",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "3,418",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "3,360",
"Selling, General and Administrative Expense": "3,266"
},
"output_variables": {
"Assets": "1,966",
"Liabilities": "1,261",
"Expenses": "6,626",
"Revenues": "0",
"Stockholders Equity": "705",
"Net Income": "-3,208",
"Comprehensive Net Income": "-3,208",
"BaseVar": "6,636",
"ECR before LimitedLiability": "-104%",
"Economic Capital Ratio": "129%"
}
}
},
"top_rated": false,
"trend": 5.0,
"value": 1.2944838315520772,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001261734.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001261734.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001261734.svg"
},
{
"company_id": "0001274792",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001274792.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001274792.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001274792_main_keyfigs.svg",
"name": "Merrimack Pharmaceuticals INC",
"rank": 190,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001274792.svg",
"report_text": "The relative strengths and weaknesses of Merrimack Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Merrimack Pharmaceuticals INC compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 5.7% points.The greatest weakness of Merrimack Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 91% points.
The company's Economic Capital Ratio, given in the ranking table, is 129%, being 114% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001274792_2014_Merrimack_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-1.67",
"Assets": "-4.22",
"Liabilities": "-46.0",
"Stockholders Equity": "-68.3",
"ECR before LimitedLiability": "-11.3",
"Intangible Assets": "-2.82",
"Other Assets": "-1.27",
"Liabilities, Current": "2.03",
"Other Liabilities": "-87.9",
"Liabilities, Non-Current": "2.07",
"Selling, General and Administrative Expense": "4.90",
"Expenses": "2.05",
"Revenues": "-0.683",
"Net Income": "1.91",
"Research and Development": "-4.55",
"Other Expenses": "3.84",
"Cost of Goods Sold": "0.909",
"Other Revenues": "-0.683",
"Comprehensive Net Income": "1.97",
"Other Net Income": "0.600",
"Economic Capital Ratio": "-84.4"
},
"2013": {
"Other Assets": "-3.50",
"Assets": "-10.9",
"Liabilities": "-34.7",
"Stockholders Equity": "-90.6",
"ECR before LimitedLiability": "-85.7",
"Intangible Assets": "-5.03",
"Property and Equipment": "-0.598",
"Assets, Current": "-6.69",
"Liabilities, Non-Current": "-11.6",
"Liabilities, Current": "1.51",
"Other Liabilities": "-6.10",
"Selling, General and Administrative Expense": "5.66",
"Expenses": "1.01",
"Revenues": "-1.64",
"Comprehensive Net Income": "-0.272",
"Other Expenses": "2.65",
"Research and Development": "-6.47",
"Cost of Goods Sold": "0.850",
"Other Revenues": "-1.64",
"Other Net Income": "0.517",
"Economic Capital Ratio": "-114"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001274792_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "128,301",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,770",
"Liabilities, Current": "38,520",
"Liabilities, Non-Current": "0",
"Other Assets": "8,606",
"Other Compr. Net Income": "439",
"Other Expenses": "553",
"Other Liabilities": "116,874",
"Other Net Income": "1,541",
"Other Revenues": "48,921",
"Property and Equipment": "6,297",
"Research and Development": "125,858",
"Selling, General and Administrative Expense": "15,805"
},
"output_variables": {
"Assets": "148,974",
"Liabilities": "155,394",
"Expenses": "142,216",
"Revenues": "48,921",
"Stockholders Equity": "-6,420",
"Net Income": "-91,754",
"Comprehensive Net Income": "-91,534",
"BaseVar": "248,742",
"ECR before LimitedLiability": "-69%",
"Economic Capital Ratio": "136%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "166,644",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,450",
"Liabilities, Current": "57,734",
"Liabilities, Non-Current": "103,427",
"Other Assets": "6,959",
"Other Compr. Net Income": "-226",
"Other Expenses": "10,938",
"Other Liabilities": "74,384",
"Other Net Income": "793",
"Other Revenues": "47,786",
"Property and Equipment": "13,364",
"Research and Development": "147,139",
"Selling, General and Administrative Expense": "21,187"
},
"output_variables": {
"Assets": "192,417",
"Liabilities": "235,545",
"Expenses": "179,264",
"Revenues": "47,786",
"Stockholders Equity": "-43,128",
"Net Income": "-130,685",
"Comprehensive Net Income": "-130,798",
"BaseVar": "328,016",
"ECR before LimitedLiability": "-105%",
"Economic Capital Ratio": "129%"
}
}
},
"top_rated": false,
"trend": -31.0,
"value": 1.2912596348386394,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001274792.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001274792.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001274792.svg"
},
{
"company_id": "0001318641",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001318641.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001318641.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001318641.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001318641_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001318641_main_keyfigs.svg",
"name": "Statera Biopharma Inc",
"rank": 191,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001318641.svg",
"report_text": "The relative strengths and weaknesses of Statera Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Statera Biopharma Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 24% points.The greatest weakness of Statera Biopharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 118% points.
The company's Economic Capital Ratio, given in the ranking table, is 128%, being 115% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001318641_2014_Statera_Biopharma_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-8.61",
"Assets": "-2.60",
"Liabilities": "39.3",
"Stockholders Equity": "30.1",
"ECR before LimitedLiability": "93.2",
"Assets, Current": "40.5",
"Intangible Assets": "-18.9",
"Other Assets": "-5.63",
"Liabilities, Current": "-22.1",
"Other Liabilities": "40.9",
"Liabilities, Non-Current": "19.5",
"Expenses": "-12.0",
"Revenues": "-35.4",
"Net Income": "-6.73",
"Research and Development": "-37.9",
"Other Expenses": "23.5",
"Cost of Goods Sold": "5.90",
"Other Revenues": "-35.4",
"Other Net Income": "45.3",
"Economic Capital Ratio": "20.2",
"Other Compr. Net Income": "8.56"
},
"2013": {
"Other Assets": "3.43",
"Assets": "-83.7",
"Liabilities, Non-Current": "3.88",
"Stockholders Equity": "-118",
"ECR before LimitedLiability": "-86.9",
"Intangible Assets": "-9.52",
"Property and Equipment": "-4.96",
"Assets, Current": "-54.8",
"Selling, General and Administrative Expense": "-5.71",
"Expenses": "-11.7",
"Revenues": "-9.30",
"Net Income": "-7.79",
"Other Expenses": "7.19",
"Research and Development": "-12.2",
"Other Revenues": "-9.30",
"Liabilities, Current": "3.94",
"Other Liabilities": "-7.72",
"Comprehensive Net Income": "-6.37",
"Other Net Income": "24.3",
"Other Compr. Net Income": "2.07",
"Economic Capital Ratio": "-115"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001318641_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "29,406",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "11,427",
"Liabilities, Non-Current": "0",
"Other Assets": "1,618",
"Other Compr. Net Income": "4,642",
"Other Expenses": "0",
"Other Liabilities": "98",
"Other Net Income": "11,203",
"Other Revenues": "0",
"Property and Equipment": "987",
"Research and Development": "22,502",
"Selling, General and Administrative Expense": "11,116"
},
"output_variables": {
"Assets": "32,010",
"Liabilities": "11,524",
"Expenses": "33,617",
"Revenues": "0",
"Stockholders Equity": "20,486",
"Net Income": "-22,415",
"Comprehensive Net Income": "-20,093",
"BaseVar": "46,498",
"ECR before LimitedLiability": "113%",
"Economic Capital Ratio": "240%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "11,157",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "5,986",
"Liabilities, Non-Current": "0",
"Other Assets": "3,081",
"Other Compr. Net Income": "2,627",
"Other Expenses": "0",
"Other Liabilities": "7,129",
"Other Net Income": "11,435",
"Other Revenues": "0",
"Property and Equipment": "458",
"Research and Development": "19,526",
"Selling, General and Administrative Expense": "12,039"
},
"output_variables": {
"Assets": "14,696",
"Liabilities": "13,115",
"Expenses": "31,565",
"Revenues": "0",
"Stockholders Equity": "1,581",
"Net Income": "-20,129",
"Comprehensive Net Income": "-18,816",
"BaseVar": "36,719",
"ECR before LimitedLiability": "-111%",
"Economic Capital Ratio": "128%"
}
}
},
"top_rated": false,
"trend": -83.0,
"value": 1.2791475878862864,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001318641.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001318641.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001318641.svg"
},
{
"company_id": "0001053369",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001053369.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001053369.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001053369.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001053369_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001053369_main_keyfigs.svg",
"name": "Elite Pharmaceuticals INC NV",
"rank": 192,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001053369.svg",
"report_text": "The relative strengths and weaknesses of Elite Pharmaceuticals INC NV are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Elite Pharmaceuticals INC NV compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 17% points.The greatest weakness of Elite Pharmaceuticals INC NV is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 134% points.
The company's Economic Capital Ratio, given in the ranking table, is 127%, being 115% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001053369_2014_Elite_Pharmaceuticals_INC_NV.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "19.4",
"Assets": "-45.1",
"Liabilities": "-43.2",
"Stockholders Equity": "-97.9",
"ECR before LimitedLiability": "-67.6",
"Assets, Current": "-53.9",
"Intangible Assets": "-10.0",
"Other Assets": "16.3",
"Liabilities, Current": "1.48",
"Other Liabilities": "3.98",
"Liabilities, Non-Current": "-57.1",
"Selling, General and Administrative Expense": "9.54",
"Expenses": "25.6",
"Revenues": "-7.35",
"Net Income": "-5.42",
"Research and Development": "9.40",
"Other Expenses": "7.77",
"Other Revenues": "-7.35",
"Comprehensive Net Income": "-5.34",
"Other Net Income": "-24.8",
"Economic Capital Ratio": "-141"
},
"2013": {
"Other Assets": "12.9",
"Assets": "-12.6",
"Liabilities": "-107",
"Stockholders Equity": "-133",
"ECR before LimitedLiability": "-87.4",
"Intangible Assets": "-3.76",
"Property and Equipment": "16.3",
"Assets, Current": "-34.4",
"Liabilities, Non-Current": "-134",
"Liabilities, Current": "-2.68",
"Other Liabilities": "5.51",
"Selling, General and Administrative Expense": "4.89",
"Expenses": "12.6",
"Net Income": "17.1",
"Other Revenues": "-1.00",
"Other Expenses": "3.87",
"Research and Development": "5.81",
"Cost of Goods Sold": "-2.55",
"Comprehensive Net Income": "17.0",
"Other Net Income": "4.70",
"Economic Capital Ratio": "-115"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001053369_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "1,498",
"Cost of Goods Sold": "1,014",
"Intangible Assets": "643",
"Liabilities, Current": "4,549",
"Liabilities, Non-Current": "20,746",
"Other Assets": "3,886",
"Other Compr. Net Income": "0",
"Other Expenses": "-253",
"Other Liabilities": "0",
"Other Net Income": "-13,576",
"Other Revenues": "2,424",
"Property and Equipment": "4,285",
"Research and Development": "1,736",
"Selling, General and Administrative Expense": "1,410"
},
"output_variables": {
"Assets": "10,312",
"Liabilities": "25,295",
"Expenses": "3,906",
"Revenues": "2,424",
"Stockholders Equity": "-14,984",
"Net Income": "-15,058",
"Comprehensive Net Income": "-15,058",
"BaseVar": "27,757",
"ECR before LimitedLiability": "-268%",
"Economic Capital Ratio": "79%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,543",
"Cost of Goods Sold": "2,315",
"Intangible Assets": "694",
"Liabilities, Current": "5,357",
"Liabilities, Non-Current": "14,441",
"Other Assets": "3,858",
"Other Compr. Net Income": "0",
"Other Expenses": "-191",
"Other Liabilities": "0",
"Other Net Income": "2,697",
"Other Revenues": "3,404",
"Property and Equipment": "4,029",
"Research and Development": "975",
"Selling, General and Administrative Expense": "1,513"
},
"output_variables": {
"Assets": "11,125",
"Liabilities": "19,799",
"Expenses": "4,613",
"Revenues": "3,404",
"Stockholders Equity": "-8,673",
"Net Income": "1,488",
"Comprehensive Net Income": "1,488",
"BaseVar": "20,819",
"ECR before LimitedLiability": "-113%",
"Economic Capital Ratio": "127%"
}
}
},
"top_rated": false,
"trend": -11.0,
"value": 1.2742767197620275,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001053369.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001053369.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001053369.svg"
},
{
"company_id": "0001267602",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001267602.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001267602.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001267602.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001267602_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001267602_main_keyfigs.svg",
"name": "Alimera Sciences INC",
"rank": 193,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001267602.svg",
"report_text": "The relative strengths and weaknesses of Alimera Sciences INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Alimera Sciences INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 23% points.The greatest weakness of Alimera Sciences INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 135% points.
The company's Economic Capital Ratio, given in the ranking table, is 126%, being 117% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001267602_2014_Alimera_Sciences_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.36",
"Assets": "76.8",
"Liabilities": "31.8",
"Stockholders Equity": "128",
"ECR before LimitedLiability": "134",
"Intangible Assets": "-10.9",
"Property and Equipment": "-6.29",
"Assets, Current": "152",
"Other Liabilities": "28.3",
"Liabilities, Non-Current": "12.2",
"Liabilities, Current": "-8.76",
"Research and Development": "6.13",
"Expenses": "-7.07",
"Revenues": "-25.9",
"Net Income": "-30.8",
"Other Expenses": "-20.7",
"Cost of Goods Sold": "3.34",
"Selling, General and Administrative Expense": "4.47",
"Other Revenues": "-25.9",
"Comprehensive Net Income": "-31.0",
"Economic Capital Ratio": "58.8"
},
"2012": {
"Property and Equipment": "-5.40",
"Assets": "76.9",
"Liabilities": "18.7",
"Stockholders Equity": "120",
"ECR before LimitedLiability": "161",
"Assets, Current": "147",
"Intangible Assets": "-7.95",
"Other Assets": "-5.79",
"Liabilities, Current": "-24.0",
"Other Liabilities": "27.7",
"Liabilities, Non-Current": "12.9",
"Selling, General and Administrative Expense": "8.27",
"Expenses": "13.8",
"Revenues": "-20.9",
"Comprehensive Net Income": "0.734",
"Research and Development": "6.30",
"Other Expenses": "-4.16",
"Cost of Goods Sold": "3.33",
"Other Revenues": "-20.9",
"Other Net Income": "8.03",
"Economic Capital Ratio": "87.7"
},
"2013": {
"Other Assets": "-9.69",
"Assets": "-57.7",
"Liabilities": "23.2",
"Stockholders Equity": "-7.22",
"ECR before LimitedLiability": "-88.6",
"Intangible Assets": "-11.4",
"Property and Equipment": "-3.91",
"Assets, Current": "-12.9",
"Liabilities, Non-Current": "4.58",
"Liabilities, Current": "8.16",
"Other Liabilities": "12.4",
"Selling, General and Administrative Expense": "-2.49",
"Expenses": "-20.5",
"Revenues": "-8.94",
"Net Income": "-133",
"Other Expenses": "-16.2",
"Cost of Goods Sold": "1.88",
"Other Revenues": "-8.94",
"Comprehensive Net Income": "-135",
"Other Net Income": "-13.8",
"Economic Capital Ratio": "-117"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001267602_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "34,501",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,718",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "9,229",
"Other Liabilities": "0",
"Other Net Income": "16",
"Other Revenues": "0",
"Property and Equipment": "197",
"Research and Development": "7,100",
"Selling, General and Administrative Expense": "6,203"
},
"output_variables": {
"Assets": "34,698",
"Liabilities": "6,718",
"Expenses": "22,532",
"Revenues": "0",
"Stockholders Equity": "27,980",
"Net Income": "-22,516",
"Comprehensive Net Income": "-22,516",
"BaseVar": "31,982",
"ECR before LimitedLiability": "186%",
"Economic Capital Ratio": "293%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "52,407",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "12,465",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "8,324",
"Other Liabilities": "0",
"Other Net Income": "3,088",
"Other Revenues": "0",
"Property and Equipment": "114",
"Research and Development": "7,935",
"Selling, General and Administrative Expense": "6,575"
},
"output_variables": {
"Assets": "52,521",
"Liabilities": "12,465",
"Expenses": "22,834",
"Revenues": "0",
"Stockholders Equity": "40,056",
"Net Income": "-19,746",
"Comprehensive Net Income": "-19,746",
"BaseVar": "45,454",
"ECR before LimitedLiability": "208%",
"Economic Capital Ratio": "308%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "18,638",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,949",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "-488",
"Other Expenses": "18,767",
"Other Liabilities": "0",
"Other Net Income": "-11,292",
"Other Revenues": "1,872",
"Property and Equipment": "982",
"Research and Development": "8,429",
"Selling, General and Administrative Expense": "9,613"
},
"output_variables": {
"Assets": "19,620",
"Liabilities": "4,949",
"Expenses": "36,809",
"Revenues": "1,872",
"Stockholders Equity": "14,671",
"Net Income": "-46,229",
"Comprehensive Net Income": "-46,473",
"BaseVar": "37,515",
"ECR before LimitedLiability": "-118%",
"Economic Capital Ratio": "126%"
}
}
},
"top_rated": false,
"trend": -132.0,
"value": 1.261899529172691,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001267602.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001267602.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001267602.svg"
},
{
"company_id": "0001279704",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001279704.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001279704.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001279704_main_keyfigs.svg",
"name": "Cellectar Biosciences Inc",
"rank": 194,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001279704.svg",
"report_text": "The relative strengths and weaknesses of Cellectar Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cellectar Biosciences Inc compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 28% points.The greatest weakness of Cellectar Biosciences Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 59% points.
The company's Economic Capital Ratio, given in the ranking table, is 126%, being 117% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001279704_2014_Cellectar_Biosciences_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-19.1",
"Assets": "-33.9",
"Liabilities": "27.4",
"Stockholders Equity": "11.9",
"ECR before LimitedLiability": "-51.5",
"Intangible Assets": "-4.00",
"Property and Equipment": "39.1",
"Assets, Current": "-34.0",
"Other Liabilities": "11.8",
"Liabilities, Non-Current": "1.62",
"Liabilities, Current": "19.1",
"Research and Development": "-96.9",
"Expenses": "-135",
"Revenues": "-24.6",
"Net Income": "-198",
"Other Expenses": "6.27",
"Cost of Goods Sold": "3.78",
"Selling, General and Administrative Expense": "-21.6",
"Other Revenues": "-24.6",
"Comprehensive Net Income": "-199",
"Economic Capital Ratio": "-127"
},
"2012": {
"Property and Equipment": "29.6",
"Assets": "72.1",
"Liabilities": "70.7",
"Stockholders Equity": "167",
"ECR before LimitedLiability": "161",
"Assets, Current": "-4.02",
"Intangible Assets": "10.5",
"Other Assets": "19.1",
"Liabilities, Current": "44.1",
"Other Liabilities": "33.2",
"Liabilities, Non-Current": "-3.81",
"Selling, General and Administrative Expense": "-11.6",
"Expenses": "-18.1",
"Revenues": "-25.1",
"Net Income": "-41.7",
"Research and Development": "-26.0",
"Other Expenses": "15.8",
"Cost of Goods Sold": "4.02",
"Other Revenues": "-25.1",
"Comprehensive Net Income": "-41.5",
"Economic Capital Ratio": "88.1"
},
"2013": {
"Other Assets": "-7.49",
"Assets": "-22.6",
"Liabilities": "-3.37",
"Stockholders Equity": "-43.4",
"ECR before LimitedLiability": "-88.8",
"Intangible Assets": "7.76",
"Property and Equipment": "28.1",
"Assets, Current": "-58.8",
"Liabilities, Current": "-11.1",
"Other Liabilities": "8.95",
"Selling, General and Administrative Expense": "-5.76",
"Expenses": "-13.6",
"Revenues": "-8.67",
"Net Income": "-14.4",
"Other Expenses": "1.32",
"Research and Development": "-12.0",
"Cost of Goods Sold": "1.33",
"Other Revenues": "-8.67",
"Comprehensive Net Income": "-14.4",
"Other Net Income": "7.82",
"Economic Capital Ratio": "-117"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001279704_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "5,816",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,675",
"Liabilities, Current": "504",
"Liabilities, Non-Current": "578",
"Other Assets": "27",
"Other Compr. Net Income": "0",
"Other Expenses": "799",
"Other Liabilities": "0",
"Other Net Income": "-214",
"Other Revenues": "0",
"Property and Equipment": "3,045",
"Research and Development": "20,805",
"Selling, General and Administrative Expense": "9,663"
},
"output_variables": {
"Assets": "10,563",
"Liabilities": "1,082",
"Expenses": "31,267",
"Revenues": "0",
"Stockholders Equity": "9,481",
"Net Income": "-31,480",
"Comprehensive Net Income": "-31,480",
"BaseVar": "21,563",
"ECR before LimitedLiability": "-186%",
"Economic Capital Ratio": "107%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "5,130",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,675",
"Liabilities, Current": "733",
"Liabilities, Non-Current": "587",
"Other Assets": "2,027",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-42",
"Other Revenues": "0",
"Property and Equipment": "2,645",
"Research and Development": "5,123",
"Selling, General and Administrative Expense": "3,632"
},
"output_variables": {
"Assets": "11,478",
"Liabilities": "1,320",
"Expenses": "8,755",
"Revenues": "0",
"Stockholders Equity": "10,158",
"Net Income": "-8,797",
"Comprehensive Net Income": "-8,797",
"BaseVar": "10,797",
"ECR before LimitedLiability": "209%",
"Economic Capital Ratio": "308%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,768",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,675",
"Liabilities, Current": "4,523",
"Liabilities, Non-Current": "593",
"Other Assets": "12",
"Other Compr. Net Income": "0",
"Other Expenses": "1,097",
"Other Liabilities": "0",
"Other Net Income": "1,620",
"Other Revenues": "0",
"Property and Equipment": "2,361",
"Research and Development": "6,860",
"Selling, General and Administrative Expense": "4,445"
},
"output_variables": {
"Assets": "6,816",
"Liabilities": "5,116",
"Expenses": "12,402",
"Revenues": "0",
"Stockholders Equity": "1,700",
"Net Income": "-10,782",
"Comprehensive Net Income": "-10,782",
"BaseVar": "12,977",
"ECR before LimitedLiability": "-119%",
"Economic Capital Ratio": "126%"
}
}
},
"top_rated": false,
"trend": -134.0,
"value": 1.2603096457813605,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001279704.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001279704.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001279704.svg"
},
{
"company_id": "0001355790",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001355790.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001355790.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001355790.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001355790_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001355790_main_keyfigs.svg",
"name": "International Stem Cell CORP",
"rank": 195,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001355790.svg",
"report_text": "The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of International Stem Cell CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 10% points.The greatest weakness of International Stem Cell CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 108% points.
The company's Economic Capital Ratio, given in the ranking table, is 126%, being 117% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001355790_2014_International_Stem_Cell_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-1.40",
"Assets": "-149",
"Stockholders Equity": "-17.4",
"ECR before LimitedLiability": "-159",
"Intangible Assets": "-0.729",
"Property and Equipment": "-0.0336",
"Assets, Current": "-132",
"Other Liabilities": "-0.0190",
"Liabilities": "-1.51",
"Liabilities, Non-Current": "-0.0225",
"Liabilities, Current": "-0.722",
"Research and Development": "-0.0950",
"Expenses": "-65.7",
"Net Income": "-105",
"Cost of Goods Sold": "0",
"Selling, General and Administrative Expense": "-10.6",
"Other Revenues": "0",
"Revenues": "0",
"Comprehensive Net Income": "-105",
"Other Net Income": "0",
"Economic Capital Ratio": "-234"
},
"2012": {
"Property and Equipment": "0",
"Assets": "-167",
"Stockholders Equity": "-3.72",
"ECR before LimitedLiability": "-147",
"Assets, Current": "-137",
"Intangible Assets": "-0.0182",
"Other Assets": "-0.0674",
"Liabilities, Current": "-0.0774",
"Liabilities": "-0.810",
"Other Liabilities": "-0.0116",
"Liabilities, Non-Current": "0",
"Selling, General and Administrative Expense": "-1.89",
"Expenses": "-39.7",
"Net Income": "-47.1",
"Research and Development": "0",
"Cost of Goods Sold": "0",
"Other Revenues": "0",
"Revenues": "0",
"Comprehensive Net Income": "-46.6",
"Other Net Income": "0",
"Economic Capital Ratio": "-220"
},
"2013": {
"Other Assets": "-8.55",
"Assets": "-73.1",
"Liabilities": "-2.03",
"Stockholders Equity": "-108",
"ECR before LimitedLiability": "-89.3",
"Intangible Assets": "7.34",
"Assets, Current": "-65.0",
"Liabilities, Non-Current": "3.84",
"Liabilities, Current": "-14.3",
"Other Liabilities": "10.4",
"Selling, General and Administrative Expense": "-5.68",
"Expenses": "-8.19",
"Revenues": "8.87",
"Net Income": "-8.72",
"Other Expenses": "-1.30",
"Research and Development": "1.97",
"Cost of Goods Sold": "-3.65",
"Other Revenues": "8.87",
"Comprehensive Net Income": "-8.82",
"Other Net Income": "-7.73",
"Economic Capital Ratio": "-117"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001355790_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "3,019",
"Cost of Goods Sold": "3,334",
"Intangible Assets": "1,282",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "16",
"Other Compr. Net Income": "0",
"Other Expenses": "3,881",
"Other Liabilities": "2,114",
"Other Net Income": "-3,490",
"Other Revenues": "7,766",
"Property and Equipment": "1,420",
"Research and Development": "18,294",
"Selling, General and Administrative Expense": "31,684"
},
"output_variables": {
"Assets": "5,737",
"Liabilities": "2,114",
"Expenses": "57,193",
"Revenues": "7,766",
"Stockholders Equity": "3,623",
"Net Income": "-52,917",
"Comprehensive Net Income": "-52,917",
"BaseVar": "38,150",
"ECR before LimitedLiability": "-1,147%",
"Economic Capital Ratio": "0.0038%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "2,582",
"Cost of Goods Sold": "4,606",
"Intangible Assets": "1,634",
"Liabilities, Current": "2,187",
"Liabilities, Non-Current": "0",
"Other Assets": "20",
"Other Compr. Net Income": "0",
"Other Expenses": "5,946",
"Other Liabilities": "0",
"Other Net Income": "-3,510",
"Other Revenues": "12,333",
"Property and Equipment": "1,134",
"Research and Development": "21,893",
"Selling, General and Administrative Expense": "39,128"
},
"output_variables": {
"Assets": "5,370",
"Liabilities": "2,187",
"Expenses": "71,573",
"Revenues": "12,333",
"Stockholders Equity": "3,183",
"Net Income": "-62,750",
"Comprehensive Net Income": "-62,750",
"BaseVar": "47,486",
"ECR before LimitedLiability": "-1,477%",
"Economic Capital Ratio": "0.0000037%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "4,626",
"Cost of Goods Sold": "1,643",
"Intangible Assets": "2,250",
"Liabilities, Current": "7,021",
"Liabilities, Non-Current": "0",
"Other Assets": "33",
"Other Compr. Net Income": "0",
"Other Expenses": "2,457",
"Other Liabilities": "0",
"Other Net Income": "-2,933",
"Other Revenues": "6,147",
"Property and Equipment": "830",
"Research and Development": "3,560",
"Selling, General and Administrative Expense": "6,033"
},
"output_variables": {
"Assets": "7,739",
"Liabilities": "7,021",
"Expenses": "13,693",
"Revenues": "6,147",
"Stockholders Equity": "718",
"Net Income": "-10,479",
"Comprehensive Net Income": "-10,479",
"BaseVar": "18,766",
"ECR before LimitedLiability": "-121%",
"Economic Capital Ratio": "126%"
}
}
},
"top_rated": false,
"trend": 21.0,
"value": 1.2551036883389937,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001355790.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001355790.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001355790.svg"
},
{
"company_id": "0001502152",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001502152.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001502152.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001502152_main_keyfigs.svg",
"name": "Globestar Therapeutics Corp",
"rank": 196,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001502152.svg",
"report_text": "The relative strengths and weaknesses of Globestar Therapeutics Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Globestar Therapeutics Corp compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 104% points.The greatest weakness of Globestar Therapeutics Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 89% points.
The company's Economic Capital Ratio, given in the ranking table, is 125%, being 117% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001502152_2014_Globestar_Therapeutics_Corp.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-15.8",
"Assets": "-86.6",
"Liabilities": "-1.40",
"Stockholders Equity": "-85.8",
"ECR before LimitedLiability": "-108",
"Assets, Current": "-97.1",
"Intangible Assets": "-22.8",
"Other Assets": "38.9",
"Liabilities, Current": "-3.50",
"Other Liabilities": "0.690",
"Selling, General and Administrative Expense": "13.6",
"Expenses": "23.5",
"Revenues": "-16.7",
"Net Income": "-67.6",
"Research and Development": "14.1",
"Other Expenses": "-3.15",
"Cost of Goods Sold": "2.33",
"Other Revenues": "-16.7",
"Comprehensive Net Income": "-67.5",
"Other Net Income": "-85.7",
"Economic Capital Ratio": "-181"
},
"2013": {
"Other Assets": "104",
"Assets": "-35.1",
"Liabilities": "9.91",
"Stockholders Equity": "-14.5",
"ECR before LimitedLiability": "-89.4",
"Intangible Assets": "-10.5",
"Property and Equipment": "-6.92",
"Assets, Current": "-89.1",
"Liabilities, Non-Current": "3.87",
"Liabilities, Current": "6.23",
"Selling, General and Administrative Expense": "-15.4",
"Expenses": "-41.4",
"Revenues": "-7.20",
"Net Income": "-68.8",
"Other Expenses": "-15.3",
"Research and Development": "15.9",
"Cost of Goods Sold": "1.60",
"Other Revenues": "-7.20",
"Comprehensive Net Income": "-69.2",
"Other Net Income": "0.816",
"Economic Capital Ratio": "-117"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001502152_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "1.4",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "358",
"Liabilities, Non-Current": "0",
"Other Assets": "281",
"Other Compr. Net Income": "0",
"Other Expenses": "164",
"Other Liabilities": "31",
"Other Net Income": "-945",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "283",
"Liabilities": "389",
"Expenses": "164",
"Revenues": "0",
"Stockholders Equity": "-106",
"Net Income": "-1,109",
"Comprehensive Net Income": "-1,109",
"BaseVar": "890",
"ECR before LimitedLiability": "-399%",
"Economic Capital Ratio": "39%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "138",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "121",
"Liabilities, Non-Current": "0",
"Other Assets": "324",
"Other Compr. Net Income": "0",
"Other Expenses": "448",
"Other Liabilities": "96",
"Other Net Income": "0",
"Other Revenues": "57",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "555"
},
"output_variables": {
"Assets": "463",
"Liabilities": "217",
"Expenses": "1,003",
"Revenues": "57",
"Stockholders Equity": "245",
"Net Income": "-946",
"Comprehensive Net Income": "-946",
"BaseVar": "870",
"ECR before LimitedLiability": "-121%",
"Economic Capital Ratio": "125%"
}
}
},
"top_rated": false,
"trend": 3.0,
"value": 1.2545070718606457,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001502152.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001502152.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001502152.svg"
},
{
"company_id": "0001016504",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001016504.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001016504.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001016504.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001016504_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001016504_main_keyfigs.svg",
"name": "Integrated Biopharma INC",
"rank": 197,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001016504.svg",
"report_text": "The relative strengths and weaknesses of Integrated Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Integrated Biopharma INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 42% points.The greatest weakness of Integrated Biopharma INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 231% points.
The company's Economic Capital Ratio, given in the ranking table, is 124%, being 118% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001016504_2014_Integrated_Biopharma_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-9.53",
"Assets": "-128",
"Liabilities": "-5.77",
"Stockholders Equity": "-226",
"ECR before LimitedLiability": "-30.2",
"Intangible Assets": "-9.61",
"Property and Equipment": "-4.97",
"Assets, Current": "-86.3",
"Other Liabilities": "11.1",
"Liabilities, Non-Current": "4.73",
"Liabilities, Current": "-41.9",
"Research and Development": "27.1",
"Expenses": "-3.85",
"Revenues": "44.9",
"Net Income": "37.1",
"Other Expenses": "-46.6",
"Cost of Goods Sold": "2.49",
"Selling, General and Administrative Expense": "4.77",
"Other Revenues": "44.9",
"Comprehensive Net Income": "36.8",
"Economic Capital Ratio": "-106"
},
"2012": {
"Property and Equipment": "-6.85",
"Assets": "-118",
"Liabilities": "-8.86",
"Stockholders Equity": "-209",
"ECR before LimitedLiability": "-28.8",
"Assets, Current": "-80.7",
"Intangible Assets": "-12.3",
"Other Assets": "-10.2",
"Liabilities, Current": "-3.14",
"Liabilities, Non-Current": "-5.50",
"Selling, General and Administrative Expense": "8.15",
"Expenses": "-2.30",
"Revenues": "46.4",
"Net Income": "41.1",
"Research and Development": "24.6",
"Other Expenses": "-22.2",
"Cost of Goods Sold": "3.30",
"Other Revenues": "46.4",
"Comprehensive Net Income": "41.3",
"Other Net Income": "-2.01",
"Economic Capital Ratio": "-102"
},
"2013": {
"Other Assets": "-9.09",
"Assets": "-124",
"Liabilities": "-10.1",
"Stockholders Equity": "-231",
"ECR before LimitedLiability": "-90.5",
"Intangible Assets": "-9.86",
"Property and Equipment": "-4.34",
"Assets, Current": "-92.0",
"Liabilities, Non-Current": "-6.19",
"Liabilities, Current": "-4.32",
"Selling, General and Administrative Expense": "10.8",
"Expenses": "-3.93",
"Revenues": "41.6",
"Net Income": "35.3",
"Other Expenses": "-17.8",
"Research and Development": "18.5",
"Cost of Goods Sold": "1.86",
"Other Revenues": "41.6",
"Comprehensive Net Income": "35.0",
"Other Net Income": "-0.476",
"Economic Capital Ratio": "-118"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001016504_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "10,635",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,294",
"Liabilities, Current": "21,329",
"Liabilities, Non-Current": "0",
"Other Assets": "54",
"Other Compr. Net Income": "0",
"Other Expenses": "30,503",
"Other Liabilities": "16",
"Other Net Income": "-1,919",
"Other Revenues": "40,665",
"Property and Equipment": "1,667",
"Research and Development": "0",
"Selling, General and Administrative Expense": "10,524"
},
"output_variables": {
"Assets": "13,650",
"Liabilities": "21,345",
"Expenses": "41,027",
"Revenues": "40,665",
"Stockholders Equity": "-7,695",
"Net Income": "-2,281",
"Comprehensive Net Income": "-2,281",
"BaseVar": "59,303",
"ECR before LimitedLiability": "-109%",
"Economic Capital Ratio": "128%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "8,684",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,154",
"Liabilities, Current": "12,203",
"Liabilities, Non-Current": "4,698",
"Other Assets": "590",
"Other Compr. Net Income": "0",
"Other Expenses": "28,997",
"Other Liabilities": "5,359",
"Other Net Income": "-2,207",
"Other Revenues": "36,604",
"Property and Equipment": "1,449",
"Research and Development": "0",
"Selling, General and Administrative Expense": "8,113"
},
"output_variables": {
"Assets": "11,877",
"Liabilities": "22,260",
"Expenses": "37,110",
"Revenues": "36,604",
"Stockholders Equity": "-10,383",
"Net Income": "-2,713",
"Comprehensive Net Income": "-2,713",
"BaseVar": "55,029",
"ECR before LimitedLiability": "-149%",
"Economic Capital Ratio": "118%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "9,928",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,017",
"Liabilities, Current": "12,416",
"Liabilities, Non-Current": "4,888",
"Other Assets": "431",
"Other Compr. Net Income": "0",
"Other Expenses": "28,139",
"Other Liabilities": "5,597",
"Other Net Income": "-1,006",
"Other Revenues": "33,623",
"Property and Equipment": "1,235",
"Research and Development": "0",
"Selling, General and Administrative Expense": "4,385"
},
"output_variables": {
"Assets": "12,611",
"Liabilities": "22,901",
"Expenses": "32,524",
"Revenues": "33,623",
"Stockholders Equity": "-10,290",
"Net Income": "93",
"Comprehensive Net Income": "93",
"BaseVar": "51,332",
"ECR before LimitedLiability": "-126%",
"Economic Capital Ratio": "124%"
}
}
},
"top_rated": false,
"trend": -24.0,
"value": 1.2427122296160904,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001016504.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001016504.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001016504.svg"
},
{
"company_id": "0000737207",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000737207.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000737207.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000737207.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000737207_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000737207_main_keyfigs.svg",
"name": "Adhera Therapeutics Inc",
"rank": 198,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000737207.svg",
"report_text": "The relative strengths and weaknesses of Adhera Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Adhera Therapeutics Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 64% points.The greatest weakness of Adhera Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 110% points.
The company's Economic Capital Ratio, given in the ranking table, is 118%, being 125% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000737207_2014_Adhera_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-5.64",
"Assets": "-14.4",
"Liabilities": "-102",
"Stockholders Equity": "-110",
"ECR before LimitedLiability": "-97.1",
"Intangible Assets": "63.5",
"Property and Equipment": "-4.25",
"Assets, Current": "-23.1",
"Liabilities, Non-Current": "1.82",
"Liabilities, Current": "-13.3",
"Other Liabilities": "-23.0",
"Selling, General and Administrative Expense": "2.79",
"Expenses": "13.6",
"Revenues": "-6.06",
"Net Income": "9.34",
"Other Expenses": "3.75",
"Research and Development": "5.59",
"Other Revenues": "-6.06",
"Comprehensive Net Income": "9.26",
"Other Net Income": "2.66",
"Economic Capital Ratio": "-125"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000737207_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "1,042",
"Cost of Goods Sold": "0",
"Intangible Assets": "6,700",
"Liabilities, Current": "6,216",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-39",
"Other Liabilities": "8,590",
"Other Net Income": "870",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "715",
"Selling, General and Administrative Expense": "1,765"
},
"output_variables": {
"Assets": "7,742",
"Liabilities": "14,806",
"Expenses": "2,441",
"Revenues": "0",
"Stockholders Equity": "-7,064",
"Net Income": "-1,571",
"Comprehensive Net Income": "-1,571",
"BaseVar": "12,930",
"ECR before LimitedLiability": "-151%",
"Economic Capital Ratio": "118%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.1766324496489224,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000737207.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000737207.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000737207.svg"
},
{
"company_id": "0000812796",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000812796.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000812796.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000812796.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000812796_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000812796_main_keyfigs.svg",
"name": "Soligenix INC",
"rank": 199,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000812796.svg",
"report_text": "The relative strengths and weaknesses of Soligenix INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Soligenix INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 8.7% points.The greatest weakness of Soligenix INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 92% points.
The company's Economic Capital Ratio, given in the ranking table, is 117%, being 126% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000812796_2014_Soligenix_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-10.2",
"Assets": "-15.3",
"Liabilities": "110",
"Stockholders Equity": "41.5",
"ECR before LimitedLiability": "182",
"Property and Equipment": "-8.50",
"Assets, Current": "4.63",
"Other Liabilities": "52.3",
"Liabilities, Non-Current": "23.3",
"Liabilities, Current": "46.4",
"Research and Development": "52.9",
"Expenses": "-18.2",
"Revenues": "58.7",
"Net Income": "43.7",
"Other Expenses": "-96.2",
"Cost of Goods Sold": "-23.0",
"Selling, General and Administrative Expense": "44.5",
"Other Revenues": "58.7",
"Comprehensive Net Income": "43.2",
"Other Net Income": "3.71",
"Economic Capital Ratio": "106"
},
"2012": {
"Property and Equipment": "-16.1",
"Assets": "-33.0",
"Liabilities": "104",
"Stockholders Equity": "36.1",
"ECR before LimitedLiability": "100",
"Assets, Current": "-11.6",
"Intangible Assets": "8.94",
"Other Assets": "-17.0",
"Liabilities, Current": "32.2",
"Other Liabilities": "53.7",
"Liabilities, Non-Current": "25.2",
"Selling, General and Administrative Expense": "-18.5",
"Expenses": "-49.1",
"Revenues": "35.3",
"Net Income": "-14.3",
"Research and Development": "-16.1",
"Other Expenses": "45.3",
"Cost of Goods Sold": "-55.6",
"Other Revenues": "35.3",
"Comprehensive Net Income": "-14.0",
"Economic Capital Ratio": "27.2"
},
"2013": {
"Other Assets": "-8.93",
"Assets": "-23.6",
"Liabilities": "-17.5",
"Stockholders Equity": "-91.6",
"ECR before LimitedLiability": "-97.6",
"Intangible Assets": "-6.64",
"Property and Equipment": "-6.66",
"Assets, Current": "-18.0",
"Liabilities, Non-Current": "3.01",
"Liabilities, Current": "-28.0",
"Other Liabilities": "8.07",
"Selling, General and Administrative Expense": "3.43",
"Expenses": "1.25",
"Revenues": "-0.606",
"Net Income": "-9.23",
"Other Expenses": "8.73",
"Research and Development": "-3.71",
"Cost of Goods Sold": "-6.23",
"Other Revenues": "-0.606",
"Comprehensive Net Income": "-9.33",
"Other Net Income": "-9.75",
"Economic Capital Ratio": "-126"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000812796_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "7,129",
"Cost of Goods Sold": "2,108",
"Intangible Assets": "1,080",
"Liabilities, Current": "1,433",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "7,941",
"Other Liabilities": "0",
"Other Net Income": "7.4",
"Other Revenues": "7,663",
"Property and Equipment": "15",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "8,224",
"Liabilities": "1,433",
"Expenses": "10,049",
"Revenues": "7,663",
"Stockholders Equity": "6,791",
"Net Income": "-2,379",
"Comprehensive Net Income": "-2,379",
"BaseVar": "13,688",
"ECR before LimitedLiability": "257%",
"Economic Capital Ratio": "340%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "3,836",
"Cost of Goods Sold": "2,593",
"Intangible Assets": "856",
"Liabilities, Current": "1,154",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-521",
"Other Liabilities": "0",
"Other Net Income": "6.2",
"Other Revenues": "3,145",
"Property and Equipment": "13",
"Research and Development": "2,609",
"Selling, General and Administrative Expense": "2,633"
},
"output_variables": {
"Assets": "4,705",
"Liabilities": "1,154",
"Expenses": "7,314",
"Revenues": "3,145",
"Stockholders Equity": "3,551",
"Net Income": "-4,163",
"Comprehensive Net Income": "-4,163",
"BaseVar": "8,162",
"ECR before LimitedLiability": "122%",
"Economic Capital Ratio": "247%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "7,609",
"Cost of Goods Sold": "2,544",
"Intangible Assets": "633",
"Liabilities, Current": "10,035",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-750",
"Other Liabilities": "0",
"Other Net Income": "-3,653",
"Other Revenues": "3,224",
"Property and Equipment": "24",
"Research and Development": "5,071",
"Selling, General and Administrative Expense": "2,765"
},
"output_variables": {
"Assets": "8,265",
"Liabilities": "10,035",
"Expenses": "9,630",
"Revenues": "3,224",
"Stockholders Equity": "-1,770",
"Net Income": "-10,059",
"Comprehensive Net Income": "-10,059",
"BaseVar": "17,404",
"ECR before LimitedLiability": "-152%",
"Economic Capital Ratio": "117%"
}
}
},
"top_rated": false,
"trend": -100.0,
"value": 1.1721782973274717,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000812796.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000812796.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000812796.svg"
},
{
"company_id": "0001103021",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001103021.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001103021.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001103021.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001103021_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001103021_main_keyfigs.svg",
"name": "Biodelivery Sciences International INC",
"rank": 200,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001103021.svg",
"report_text": "The relative strengths and weaknesses of Biodelivery Sciences International INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Biodelivery Sciences International INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 6.7% points.The greatest weakness of Biodelivery Sciences International INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 70% points.
The company's Economic Capital Ratio, given in the ranking table, is 117%, being 126% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001103021_2014_Biodelivery_Sciences_International_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.00",
"Assets": "-4.58",
"Liabilities": "-10.0",
"Stockholders Equity": "-54.0",
"ECR before LimitedLiability": "-22.4",
"Intangible Assets": "14.7",
"Property and Equipment": "1.95",
"Assets, Current": "-22.9",
"Other Liabilities": "2.59",
"Liabilities, Non-Current": "1.98",
"Liabilities, Current": "-54.2",
"Research and Development": "-4.34",
"Expenses": "-2.64",
"Revenues": "-3.52",
"Net Income": "-3.60",
"Other Expenses": "2.61",
"Selling, General and Administrative Expense": "1.34",
"Other Revenues": "-3.52",
"Comprehensive Net Income": "-3.63",
"Other Net Income": "3.39",
"Economic Capital Ratio": "-97.9"
},
"2012": {
"Property and Equipment": "-4.08",
"Assets": "4.00",
"Liabilities": "37.6",
"Stockholders Equity": "35.3",
"ECR before LimitedLiability": "167",
"Assets, Current": "17.6",
"Other Assets": "-7.90",
"Liabilities, Current": "-11.1",
"Other Liabilities": "29.8",
"Liabilities, Non-Current": "18.9",
"Selling, General and Administrative Expense": "18.8",
"Expenses": "26.8",
"Revenues": "41.6",
"Net Income": "65.8",
"Research and Development": "-13.1",
"Other Expenses": "18.8",
"Cost of Goods Sold": "2.37",
"Other Revenues": "41.6",
"Comprehensive Net Income": "66.0",
"Other Net Income": "-4.49",
"Economic Capital Ratio": "93.5"
},
"2013": {
"Other Assets": "-3.65",
"Assets": "-24.2",
"Liabilities": "-12.2",
"Stockholders Equity": "-69.7",
"ECR before LimitedLiability": "-98.1",
"Intangible Assets": "3.34",
"Property and Equipment": "-7.06",
"Assets, Current": "-23.4",
"Liabilities, Non-Current": "2.51",
"Liabilities, Current": "-9.88",
"Other Liabilities": "-4.83",
"Selling, General and Administrative Expense": "3.85",
"Expenses": "-14.5",
"Revenues": "-2.97",
"Net Income": "-16.5",
"Other Expenses": "6.66",
"Research and Development": "-20.3",
"Other Revenues": "-2.97",
"Comprehensive Net Income": "-16.6",
"Other Compr. Net Income": "-0.130",
"Economic Capital Ratio": "-126"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001103021_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "11,081",
"Cost of Goods Sold": "1,757",
"Intangible Assets": "8,865",
"Liabilities, Current": "17,878",
"Liabilities, Non-Current": "0",
"Other Assets": "411",
"Other Compr. Net Income": "0",
"Other Expenses": "81",
"Other Liabilities": "1,647",
"Other Net Income": "3,663",
"Other Revenues": "3,263",
"Property and Equipment": "3,288",
"Research and Development": "20,805",
"Selling, General and Administrative Expense": "7,608"
},
"output_variables": {
"Assets": "23,645",
"Liabilities": "19,525",
"Expenses": "30,251",
"Revenues": "3,263",
"Stockholders Equity": "4,120",
"Net Income": "-23,325",
"Comprehensive Net Income": "-23,325",
"BaseVar": "40,173",
"ECR before LimitedLiability": "-66%",
"Economic Capital Ratio": "136%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "63,936",
"Cost of Goods Sold": "1,910",
"Intangible Assets": "8,894",
"Liabilities, Current": "23,243",
"Liabilities, Non-Current": "0",
"Other Assets": "72",
"Other Compr. Net Income": "0",
"Other Expenses": "220",
"Other Liabilities": "2,718",
"Other Net Income": "-5,280",
"Other Revenues": "54,542",
"Property and Equipment": "2,836",
"Research and Development": "35,366",
"Selling, General and Administrative Expense": "10,115"
},
"output_variables": {
"Assets": "75,739",
"Liabilities": "25,961",
"Expenses": "47,610",
"Revenues": "54,542",
"Stockholders Equity": "49,777",
"Net Income": "1,652",
"Comprehensive Net Income": "1,652",
"BaseVar": "104,566",
"ECR before LimitedLiability": "217%",
"Economic Capital Ratio": "314%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "26,601",
"Cost of Goods Sold": "2,082",
"Intangible Assets": "7,911",
"Liabilities, Current": "24,992",
"Liabilities, Non-Current": "700",
"Other Assets": "3,315",
"Other Compr. Net Income": "0",
"Other Expenses": "46",
"Other Liabilities": "13,126",
"Other Net Income": "-992",
"Other Revenues": "11,356",
"Property and Equipment": "178",
"Research and Development": "53,327",
"Selling, General and Administrative Expense": "12,302"
},
"output_variables": {
"Assets": "38,005",
"Liabilities": "38,818",
"Expenses": "67,758",
"Revenues": "11,356",
"Stockholders Equity": "-812",
"Net Income": "-57,394",
"Comprehensive Net Income": "-57,394",
"BaseVar": "78,464",
"ECR before LimitedLiability": "-154%",
"Economic Capital Ratio": "117%"
}
}
},
"top_rated": false,
"trend": -142.0,
"value": 1.1666417421667943,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001103021.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001103021.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001103021.svg"
},
{
"company_id": "0001260990",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001260990.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001260990.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001260990_main_keyfigs.svg",
"name": "Oncternal Therapeutics Inc",
"rank": 201,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001260990.svg",
"report_text": "The relative strengths and weaknesses of Oncternal Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Oncternal Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 22% points.The greatest weakness of Oncternal Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 131% points.
The company's Economic Capital Ratio, given in the ranking table, is 109%, being 134% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001260990_2014_Oncternal_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.29",
"Assets": "41.8",
"Liabilities": "81.5",
"Stockholders Equity": "157",
"ECR before LimitedLiability": "206",
"Intangible Assets": "-6.66",
"Property and Equipment": "-3.31",
"Assets, Current": "87.1",
"Other Liabilities": "35.3",
"Liabilities, Non-Current": "15.6",
"Liabilities, Current": "39.4",
"Other Revenues": "-5.98",
"Revenues": "-5.98",
"Net Income": "-5.21",
"Research and Development": "-18.0",
"Comprehensive Net Income": "-5.50",
"Cost of Goods Sold": "3.70",
"Selling, General and Administrative Expense": "3.20",
"Other Expenses": "8.75",
"Other Net Income": "2.89",
"Economic Capital Ratio": "131"
},
"2012": {
"Property and Equipment": "-5.47",
"Assets": "39.9",
"Liabilities": "65.3",
"Stockholders Equity": "125",
"ECR before LimitedLiability": "177",
"Assets, Current": "89.6",
"Intangible Assets": "-8.97",
"Other Assets": "-5.73",
"Liabilities, Current": "16.4",
"Other Liabilities": "36.0",
"Liabilities, Non-Current": "17.0",
"Selling, General and Administrative Expense": "6.59",
"Expenses": "-2.64",
"Revenues": "-26.9",
"Net Income": "-0.361",
"Research and Development": "-47.5",
"Other Expenses": "34.4",
"Cost of Goods Sold": "4.26",
"Other Revenues": "-26.9",
"Other Net Income": "29.6",
"Economic Capital Ratio": "104"
},
"2013": {
"Other Assets": "-14.3",
"Assets": "-60.8",
"Liabilities": "21.9",
"Stockholders Equity": "-19.9",
"ECR before LimitedLiability": "-106",
"Intangible Assets": "-19.6",
"Property and Equipment": "-11.9",
"Assets, Current": "-26.8",
"Liabilities, Non-Current": "4.94",
"Liabilities, Current": "7.69",
"Other Liabilities": "12.7",
"Selling, General and Administrative Expense": "-11.8",
"Expenses": "-93.8",
"Revenues": "-17.6",
"Net Income": "-130",
"Other Expenses": "11.5",
"Research and Development": "-96.5",
"Other Revenues": "-17.6",
"Comprehensive Net Income": "-131",
"Other Net Income": "6.06",
"Economic Capital Ratio": "-134"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001260990_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "76,848",
"Cost of Goods Sold": "0",
"Intangible Assets": "240",
"Liabilities, Current": "6,076",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,055",
"Other Liabilities": "0",
"Other Net Income": "398",
"Other Revenues": "14,739",
"Property and Equipment": "1,096",
"Research and Development": "31,938",
"Selling, General and Administrative Expense": "15,438"
},
"output_variables": {
"Assets": "78,184",
"Liabilities": "6,076",
"Expenses": "48,431",
"Revenues": "14,739",
"Stockholders Equity": "72,108",
"Net Income": "-33,294",
"Comprehensive Net Income": "-33,294",
"BaseVar": "73,914",
"ECR before LimitedLiability": "294%",
"Economic Capital Ratio": "365%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "56,815",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,495",
"Liabilities, Non-Current": "0",
"Other Assets": "452",
"Other Compr. Net Income": "0",
"Other Expenses": "-8,821",
"Other Liabilities": "0",
"Other Net Income": "13,836",
"Other Revenues": "0",
"Property and Equipment": "507",
"Research and Development": "38,887",
"Selling, General and Administrative Expense": "10,845"
},
"output_variables": {
"Assets": "57,774",
"Liabilities": "9,495",
"Expenses": "40,911",
"Revenues": "0",
"Stockholders Equity": "48,279",
"Net Income": "-27,075",
"Comprehensive Net Income": "-27,075",
"BaseVar": "61,008",
"ECR before LimitedLiability": "232%",
"Economic Capital Ratio": "324%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "15,171",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,567",
"Liabilities, Non-Current": "0",
"Other Assets": "322",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "1,488",
"Other Revenues": "0",
"Property and Equipment": "112",
"Research and Development": "32,318",
"Selling, General and Administrative Expense": "11,281"
},
"output_variables": {
"Assets": "15,605",
"Liabilities": "4,567",
"Expenses": "43,599",
"Revenues": "0",
"Stockholders Equity": "11,038",
"Net Income": "-42,111",
"Comprehensive Net Income": "-42,111",
"BaseVar": "32,630",
"ECR before LimitedLiability": "-179%",
"Economic Capital Ratio": "109%"
}
}
},
"top_rated": false,
"trend": -150.0,
"value": 1.0917281401029275,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001260990.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001260990.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001260990.svg"
},
{
"company_id": "0001411879",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001411879.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001411879.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001411879_main_keyfigs.svg",
"name": "Innovus Pharmaceuticals INC",
"rank": 202,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001411879.svg",
"report_text": "The relative strengths and weaknesses of Innovus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Innovus Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 58% points.The greatest weakness of Innovus Pharmaceuticals INC is the variable Assets, Current, reducing the Economic Capital Ratio by 44% points.
The company's Economic Capital Ratio, given in the ranking table, is 105%, being 137% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001411879_2014_Innovus_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-0.503",
"Assets": "-32.1",
"Liabilities": "-14.7",
"Stockholders Equity": "-36.9",
"ECR before LimitedLiability": "-109",
"Intangible Assets": "58.4",
"Property and Equipment": "-5.25",
"Assets, Current": "-44.3",
"Liabilities, Non-Current": "-19.4",
"Liabilities, Current": "-4.78",
"Other Liabilities": "7.74",
"Selling, General and Administrative Expense": "-32.1",
"Expenses": "-20.3",
"Revenues": "-11.5",
"Net Income": "-28.2",
"Other Expenses": "6.89",
"Research and Development": "12.7",
"Cost of Goods Sold": "1.57",
"Other Revenues": "-11.5",
"Comprehensive Net Income": "-28.3",
"Economic Capital Ratio": "-137"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001411879_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "484",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,295",
"Liabilities, Current": "1,088",
"Liabilities, Non-Current": "1,083",
"Other Assets": "255",
"Other Compr. Net Income": "0",
"Other Expenses": "1.8",
"Other Liabilities": "0",
"Other Net Income": "-67",
"Other Revenues": "6.6",
"Property and Equipment": "79",
"Research and Development": "93",
"Selling, General and Administrative Expense": "3,801"
},
"output_variables": {
"Assets": "2,113",
"Liabilities": "2,172",
"Expenses": "3,896",
"Revenues": "6.6",
"Stockholders Equity": "-58",
"Net Income": "-3,956",
"Comprehensive Net Income": "-3,956",
"BaseVar": "4,127",
"ECR before LimitedLiability": "-191%",
"Economic Capital Ratio": "105%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.0548610141937547,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001411879.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001411879.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001411879.svg"
},
{
"company_id": "0001100397",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001100397.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001100397.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001100397.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001100397_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001100397_main_keyfigs.svg",
"name": "Ayala Pharmaceuticals Inc",
"rank": 203,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001100397.svg",
"report_text": "The relative strengths and weaknesses of Ayala Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ayala Pharmaceuticals Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 37% points.The greatest weakness of Ayala Pharmaceuticals Inc is the variable Expenses, reducing the Economic Capital Ratio by 147% points.
The company's Economic Capital Ratio, given in the ranking table, is 104%, being 138% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001100397_2014_Ayala_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-14.6",
"Assets": "-88.9",
"Liabilities": "-7.98",
"Stockholders Equity": "-115",
"ECR before LimitedLiability": "-99.5",
"Assets, Current": "-87.6",
"Intangible Assets": "16.7",
"Other Assets": "-9.18",
"Liabilities, Current": "-15.6",
"Other Liabilities": "1.55",
"Selling, General and Administrative Expense": "-7.13",
"Expenses": "-24.3",
"Revenues": "-17.3",
"Net Income": "-20.0",
"Research and Development": "-10.7",
"Other Expenses": "-7.71",
"Cost of Goods Sold": "2.50",
"Other Revenues": "-17.3",
"Comprehensive Net Income": "-19.9",
"Other Net Income": "17.2",
"Economic Capital Ratio": "-173"
},
"2013": {
"Other Assets": "-22.0",
"Assets": "-140",
"Liabilities": "30.7",
"Stockholders Equity": "-35.7",
"ECR before LimitedLiability": "-110",
"Intangible Assets": "-16.8",
"Property and Equipment": "-17.6",
"Assets, Current": "-85.1",
"Liabilities, Non-Current": "6.53",
"Liabilities, Current": "18.1",
"Other Liabilities": "14.9",
"Selling, General and Administrative Expense": "-34.2",
"Expenses": "-147",
"Revenues": "-21.7",
"Net Income": "-120",
"Other Expenses": "-12.9",
"Research and Development": "-33.8",
"Other Revenues": "-21.7",
"Comprehensive Net Income": "-121",
"Other Net Income": "37.2",
"Economic Capital Ratio": "-138"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001100397_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "895",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,414",
"Liabilities, Current": "9,340",
"Liabilities, Non-Current": "0",
"Other Assets": "429",
"Other Compr. Net Income": "0",
"Other Expenses": "4,190",
"Other Liabilities": "439",
"Other Net Income": "4,443",
"Other Revenues": "12",
"Property and Equipment": "78",
"Research and Development": "6,646",
"Selling, General and Administrative Expense": "5,689"
},
"output_variables": {
"Assets": "3,816",
"Liabilities": "9,779",
"Expenses": "16,525",
"Revenues": "12",
"Stockholders Equity": "-5,963",
"Net Income": "-12,070",
"Comprehensive Net Income": "-12,070",
"BaseVar": "17,287",
"ECR before LimitedLiability": "-369%",
"Economic Capital Ratio": "48%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "20,810",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,529",
"Liabilities, Current": "4,937",
"Liabilities, Non-Current": "0",
"Other Assets": "167",
"Other Compr. Net Income": "0",
"Other Expenses": "13,321",
"Other Liabilities": "647",
"Other Net Income": "15,278",
"Other Revenues": "1,863",
"Property and Equipment": "80",
"Research and Development": "35,425",
"Selling, General and Administrative Expense": "35,940"
},
"output_variables": {
"Assets": "23,586",
"Liabilities": "5,584",
"Expenses": "84,686",
"Revenues": "1,863",
"Stockholders Equity": "18,002",
"Net Income": "-67,544",
"Comprehensive Net Income": "-67,544",
"BaseVar": "65,499",
"ECR before LimitedLiability": "-194%",
"Economic Capital Ratio": "104%"
}
}
},
"top_rated": false,
"trend": -10.0,
"value": 1.0436554879723556,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001100397.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001100397.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001100397.svg"
},
{
"company_id": "0001335105",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001335105.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001335105.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001335105_main_keyfigs.svg",
"name": "Lixte Biotechnology Holdings INC",
"rank": 204,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001335105.svg",
"report_text": "The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 9.9% points.The greatest weakness of Lixte Biotechnology Holdings INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 54% points.
The company's Economic Capital Ratio, given in the ranking table, is 104%, being 139% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001335105_2014_Lixte_Biotechnology_Holdings_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-2.05",
"Assets": "-10.9",
"Liabilities": "17.9",
"Stockholders Equity": "18.6",
"Assets, Current": "15.5",
"Intangible Assets": "-14.8",
"Other Assets": "-2.86",
"Liabilities, Current": "6.49",
"Other Liabilities": "5.87",
"Liabilities, Non-Current": "2.27",
"Selling, General and Administrative Expense": "-12.5",
"Expenses": "-123",
"Revenues": "-30.3",
"Net Income": "-163",
"Research and Development": "-2.08",
"Other Expenses": "-70.3",
"Cost of Goods Sold": "0.825",
"Other Revenues": "-30.3",
"ECR before LimitedLiability": "-7.14",
"Comprehensive Net Income": "-163",
"Economic Capital Ratio": "-80.2"
},
"2013": {
"Other Assets": "-14.7",
"Assets": "-36.7",
"Liabilities": "6.35",
"Stockholders Equity": "-32.4",
"ECR before LimitedLiability": "-111",
"Intangible Assets": "-18.0",
"Property and Equipment": "-11.2",
"Assets, Current": "-21.9",
"Liabilities, Non-Current": "3.82",
"Liabilities, Current": "-8.88",
"Other Liabilities": "9.90",
"Selling, General and Administrative Expense": "-16.8",
"Expenses": "-36.1",
"Revenues": "-15.3",
"Net Income": "-53.3",
"Other Expenses": "9.33",
"Research and Development": "-34.1",
"Cost of Goods Sold": "2.11",
"Other Revenues": "-15.3",
"Comprehensive Net Income": "-53.8",
"Economic Capital Ratio": "-139"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001335105_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "1,753",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "261",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,474",
"Other Liabilities": "0",
"Other Net Income": "0.0080",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "1,012",
"Selling, General and Administrative Expense": "1,094"
},
"output_variables": {
"Assets": "1,753",
"Liabilities": "261",
"Expenses": "3,579",
"Revenues": "0",
"Stockholders Equity": "1,492",
"Net Income": "-3,579",
"Comprehensive Net Income": "-3,579",
"BaseVar": "2,797",
"ECR before LimitedLiability": "-32%",
"Economic Capital Ratio": "140%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "558",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "322",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "0.0030",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "880",
"Selling, General and Administrative Expense": "495"
},
"output_variables": {
"Assets": "558",
"Liabilities": "322",
"Expenses": "1,375",
"Revenues": "0",
"Stockholders Equity": "236",
"Net Income": "-1,375",
"Comprehensive Net Income": "-1,375",
"BaseVar": "1,127",
"ECR before LimitedLiability": "-195%",
"Economic Capital Ratio": "104%"
}
}
},
"top_rated": false,
"trend": -51.0,
"value": 1.0390757562810884,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001335105.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001335105.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001335105.svg"
},
{
"company_id": "0000072170",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000072170.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000072170.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000072170_main_keyfigs.svg",
"name": "Inergetics INC",
"rank": 205,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000072170.svg",
"report_text": "The relative strengths and weaknesses of Inergetics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Inergetics INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 15% points.The greatest weakness of Inergetics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 114% points.
The company's Economic Capital Ratio, given in the ranking table, is 102%, being 141% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000072170_2014_Inergetics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-7.72",
"Assets": "-99.7",
"Liabilities": "9.48",
"Stockholders Equity": "-130",
"ECR before LimitedLiability": "-148",
"Intangible Assets": "-10.6",
"Property and Equipment": "-6.32",
"Assets, Current": "-69.3",
"Other Liabilities": "2.28",
"Liabilities, Current": "7.54",
"Research and Development": "4.35",
"Expenses": "-2.24",
"Revenues": "-5.21",
"Net Income": "-16.2",
"Other Expenses": "1.39",
"Cost of Goods Sold": "0.604",
"Selling, General and Administrative Expense": "-13.4",
"Other Revenues": "-5.21",
"Comprehensive Net Income": "-16.3",
"Other Net Income": "-5.24",
"Economic Capital Ratio": "-223"
},
"2012": {
"Property and Equipment": "-9.36",
"Assets": "-43.9",
"Liabilities": "-46.2",
"Stockholders Equity": "-93.9",
"ECR before LimitedLiability": "-72.5",
"Assets, Current": "-20.9",
"Intangible Assets": "-13.1",
"Other Assets": "-9.54",
"Liabilities, Current": "-61.0",
"Other Liabilities": "3.35",
"Selling, General and Administrative Expense": "-26.3",
"Expenses": "7.88",
"Revenues": "-10.4",
"Net Income": "-7.27",
"Research and Development": "11.2",
"Other Expenses": "20.0",
"Cost of Goods Sold": "1.72",
"Other Revenues": "-10.4",
"Comprehensive Net Income": "-7.20",
"Other Net Income": "-4.90",
"Economic Capital Ratio": "-146"
},
"2013": {
"Other Assets": "-4.09",
"Assets": "-29.6",
"Liabilities": "-39.3",
"Stockholders Equity": "-114",
"ECR before LimitedLiability": "-113",
"Intangible Assets": "-7.69",
"Property and Equipment": "-6.21",
"Assets, Current": "-19.5",
"Liabilities, Non-Current": "1.55",
"Liabilities, Current": "-43.1",
"Selling, General and Administrative Expense": "-12.3",
"Expenses": "12.0",
"Revenues": "-5.45",
"Net Income": "2.49",
"Other Expenses": "14.5",
"Research and Development": "9.54",
"Cost of Goods Sold": "1.09",
"Other Revenues": "-5.45",
"Comprehensive Net Income": "2.40",
"Other Net Income": "-3.70",
"Economic Capital Ratio": "-141"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000072170_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "394",
"Cost of Goods Sold": "0",
"Intangible Assets": "5.5",
"Liabilities, Current": "3,734",
"Liabilities, Non-Current": "30",
"Other Assets": "2.3",
"Other Compr. Net Income": "0",
"Other Expenses": "79",
"Other Liabilities": "1,426",
"Other Net Income": "-1,397",
"Other Revenues": "137",
"Property and Equipment": "0",
"Research and Development": "38",
"Selling, General and Administrative Expense": "4,094"
},
"output_variables": {
"Assets": "402",
"Liabilities": "5,189",
"Expenses": "4,211",
"Revenues": "137",
"Stockholders Equity": "-4,787",
"Net Income": "-5,471",
"Comprehensive Net Income": "-5,471",
"BaseVar": "5,668",
"ECR before LimitedLiability": "-569%",
"Economic Capital Ratio": "11%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "2,745",
"Cost of Goods Sold": "0",
"Intangible Assets": "4.9",
"Liabilities, Current": "7,264",
"Liabilities, Non-Current": "40",
"Other Assets": "2.3",
"Other Compr. Net Income": "0",
"Other Expenses": "-2,123",
"Other Liabilities": "0",
"Other Net Income": "-855",
"Other Revenues": "92",
"Property and Equipment": "0",
"Research and Development": "46",
"Selling, General and Administrative Expense": "5,591"
},
"output_variables": {
"Assets": "2,752",
"Liabilities": "7,303",
"Expenses": "3,513",
"Revenues": "92",
"Stockholders Equity": "-4,551",
"Net Income": "-4,276",
"Comprehensive Net Income": "-4,276",
"BaseVar": "7,258",
"ECR before LimitedLiability": "-282%",
"Economic Capital Ratio": "75%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "5,373",
"Cost of Goods Sold": "0",
"Intangible Assets": "284",
"Liabilities, Current": "11,496",
"Liabilities, Non-Current": "104",
"Other Assets": "421",
"Other Compr. Net Income": "0",
"Other Expenses": "-2,749",
"Other Liabilities": "1,426",
"Other Net Income": "-1,249",
"Other Revenues": "848",
"Property and Equipment": "0",
"Research and Development": "44",
"Selling, General and Administrative Expense": "6,492"
},
"output_variables": {
"Assets": "6,078",
"Liabilities": "13,026",
"Expenses": "3,787",
"Revenues": "848",
"Stockholders Equity": "-6,947",
"Net Income": "-4,188",
"Comprehensive Net Income": "-4,188",
"BaseVar": "12,494",
"ECR before LimitedLiability": "-202%",
"Economic Capital Ratio": "102%"
}
}
},
"top_rated": false,
"trend": -23.0,
"value": 1.0163460051362645,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000072170.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000072170.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000072170.svg"
},
{
"company_id": "0001285819",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001285819.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001285819.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001285819.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001285819_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001285819_main_keyfigs.svg",
"name": "Omeros CORP",
"rank": 206,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001285819.svg",
"report_text": "The relative strengths and weaknesses of Omeros CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Omeros CORP compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 33% points.The greatest weakness of Omeros CORP is the variable Assets, reducing the Economic Capital Ratio by 110% points.
The company's Economic Capital Ratio, given in the ranking table, is 100%, being 143% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001285819_2014_Omeros_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.03",
"Assets": "-2.24",
"Liabilities": "-9.44",
"Stockholders Equity": "-36.3",
"ECR before LimitedLiability": "-20.1",
"Intangible Assets": "-2.46",
"Property and Equipment": "-1.49",
"Assets, Current": "9.64",
"Other Liabilities": "4.11",
"Liabilities, Non-Current": "1.59",
"Liabilities, Current": "-72.4",
"Research and Development": "-5.65",
"Expenses": "-2.20",
"Revenues": "-2.08",
"Net Income": "-3.33",
"Other Expenses": "0.964",
"Selling, General and Administrative Expense": "0.919",
"Other Revenues": "-2.08",
"Comprehensive Net Income": "-3.78",
"Other Net Income": "0.781",
"Economic Capital Ratio": "-95.6"
},
"2012": {
"Property and Equipment": "-11.3",
"Assets": "-35.2",
"Liabilities": "4.05",
"Stockholders Equity": "0.655",
"Assets, Current": "1.80",
"Intangible Assets": "-32.6",
"Other Assets": "-14.2",
"Liabilities, Current": "-4.45",
"Other Liabilities": "2.72",
"Liabilities, Non-Current": "0.757",
"Selling, General and Administrative Expense": "-0.406",
"Expenses": "-79.1",
"Revenues": "-16.0",
"Net Income": "-91.6",
"Research and Development": "-101",
"Other Expenses": "0.884",
"Cost of Goods Sold": "0.172",
"Other Revenues": "-16.0",
"ECR before LimitedLiability": "-5.98",
"Comprehensive Net Income": "-91.4",
"Economic Capital Ratio": "-79.1"
},
"2013": {
"Other Assets": "-15.6",
"Assets": "-110",
"Liabilities": "12.2",
"Stockholders Equity": "-90.0",
"ECR before LimitedLiability": "-115",
"Intangible Assets": "-23.9",
"Property and Equipment": "-9.64",
"Assets, Current": "-51.1",
"Liabilities, Non-Current": "4.87",
"Liabilities, Current": "-5.50",
"Other Liabilities": "12.2",
"Selling, General and Administrative Expense": "-11.4",
"Expenses": "-40.9",
"Revenues": "-17.6",
"Net Income": "-37.0",
"Other Expenses": "7.05",
"Research and Development": "-40.5",
"Other Revenues": "-17.6",
"Comprehensive Net Income": "-37.1",
"Other Net Income": "32.6",
"Economic Capital Ratio": "-143"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001285819_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "25,948",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "18,985",
"Liabilities, Non-Current": "0",
"Other Assets": "295",
"Other Compr. Net Income": "0",
"Other Expenses": "1,884",
"Other Liabilities": "0",
"Other Net Income": "748",
"Other Revenues": "4,524",
"Property and Equipment": "739",
"Research and Development": "23,718",
"Selling, General and Administrative Expense": "8,216"
},
"output_variables": {
"Assets": "26,982",
"Liabilities": "18,985",
"Expenses": "33,818",
"Revenues": "4,524",
"Stockholders Equity": "7,997",
"Net Income": "-28,546",
"Comprehensive Net Income": "-28,546",
"BaseVar": "42,528",
"ECR before LimitedLiability": "-48%",
"Economic Capital Ratio": "138%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "24,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,318",
"Liabilities, Non-Current": "0",
"Other Assets": "838",
"Other Compr. Net Income": "0",
"Other Expenses": "1,729",
"Other Liabilities": "0",
"Other Net Income": "170",
"Other Revenues": "6,022",
"Property and Equipment": "1,037",
"Research and Development": "31,922",
"Selling, General and Administrative Expense": "10,985"
},
"output_variables": {
"Assets": "26,575",
"Liabilities": "9,318",
"Expenses": "44,636",
"Revenues": "6,022",
"Stockholders Equity": "17,257",
"Net Income": "-38,444",
"Comprehensive Net Income": "-38,444",
"BaseVar": "43,360",
"ECR before LimitedLiability": "-4.6%",
"Economic Capital Ratio": "141%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "14,817",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "11,873",
"Liabilities, Non-Current": "0",
"Other Assets": "779",
"Other Compr. Net Income": "0",
"Other Expenses": "2,366",
"Other Liabilities": "0",
"Other Net Income": "13,086",
"Other Revenues": "1,600",
"Property and Equipment": "939",
"Research and Development": "36,297",
"Selling, General and Administrative Expense": "15,819"
},
"output_variables": {
"Assets": "16,535",
"Liabilities": "11,873",
"Expenses": "54,482",
"Revenues": "1,600",
"Stockholders Equity": "4,662",
"Net Income": "-39,796",
"Comprehensive Net Income": "-39,796",
"BaseVar": "48,788",
"ECR before LimitedLiability": "-209%",
"Economic Capital Ratio": "100%"
}
}
},
"top_rated": false,
"trend": -59.0,
"value": 0.995745731678749,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001285819.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001285819.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001285819.svg"
},
{
"company_id": "0001522724",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001522724.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001522724.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001522724_main_keyfigs.svg",
"name": "Global Green INC",
"rank": 207,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001522724.svg",
"report_text": "The relative strengths and weaknesses of Global Green INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Global Green INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 9.7% points.The greatest weakness of Global Green INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 103% points.
The company's Economic Capital Ratio, given in the ranking table, is 98%, being 144% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001522724_2014_Global_Green_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Liabilities": "-10.1",
"Liabilities": "29.4",
"Stockholders Equity": "31.7",
"ECR before LimitedLiability": "6.96",
"Liabilities, Non-Current": "20.0",
"Liabilities, Current": "28.4",
"Research and Development": "26.6",
"Expenses": "-111",
"Net Income": "-149",
"Other Expenses": "-194",
"Cost of Goods Sold": "7.44",
"Selling, General and Administrative Expense": "25.0",
"Other Revenues": "-54.2",
"Revenues": "-54.2",
"Other Assets": "-28.6",
"Property and Equipment": "-24.3",
"Assets, Current": "31.7",
"Intangible Assets": "-21.5",
"Comprehensive Net Income": "-150",
"Other Net Income": "4.53",
"Economic Capital Ratio": "-68.6"
},
"2012": {
"Property and Equipment": "-3.83",
"Assets": "-117",
"Liabilities": "0.544",
"Stockholders Equity": "-82.5",
"ECR before LimitedLiability": "-145",
"Assets, Current": "-96.5",
"Other Assets": "-3.98",
"Liabilities, Current": "-2.54",
"Other Liabilities": "1.58",
"Liabilities, Non-Current": "-0.512",
"Selling, General and Administrative Expense": "-0.518",
"Expenses": "-27.6",
"Revenues": "-2.52",
"Net Income": "-46.6",
"Research and Development": "1.08",
"Other Expenses": "-47.2",
"Cost of Goods Sold": "0.235",
"Other Revenues": "-2.52",
"Comprehensive Net Income": "-46.5",
"Other Net Income": "0.120",
"Economic Capital Ratio": "-218"
},
"2013": {
"Other Assets": "-8.51",
"Assets": "-30.1",
"Liabilities": "-41.5",
"Stockholders Equity": "-103",
"ECR before LimitedLiability": "-116",
"Intangible Assets": "-7.87",
"Property and Equipment": "-6.38",
"Assets, Current": "-15.4",
"Liabilities, Non-Current": "1.89",
"Liabilities, Current": "4.53",
"Other Liabilities": "-85.6",
"Selling, General and Administrative Expense": "1.90",
"Expenses": "5.06",
"Revenues": "-8.35",
"Net Income": "-2.93",
"Other Expenses": "-7.42",
"Research and Development": "9.72",
"Cost of Goods Sold": "1.09",
"Other Revenues": "-8.35",
"Comprehensive Net Income": "-3.02",
"Economic Capital Ratio": "-144"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001522724_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "107",
"Cost of Goods Sold": "0",
"Intangible Assets": "6.5",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "185",
"Other Liabilities": "18",
"Other Net Income": "0",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "6.7"
},
"output_variables": {
"Assets": "113",
"Liabilities": "18",
"Expenses": "192",
"Revenues": "0",
"Stockholders Equity": "96",
"Net Income": "-192",
"Comprehensive Net Income": "-192",
"BaseVar": "161",
"ECR before LimitedLiability": "25%",
"Economic Capital Ratio": "165%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "5.2",
"Cost of Goods Sold": "0",
"Intangible Assets": "6.1",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "92",
"Other Liabilities": "31",
"Other Net Income": "0",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "23"
},
"output_variables": {
"Assets": "11",
"Liabilities": "31",
"Expenses": "115",
"Revenues": "0",
"Stockholders Equity": "-19",
"Net Income": "-115",
"Comprehensive Net Income": "-115",
"BaseVar": "78",
"ECR before LimitedLiability": "-749%",
"Economic Capital Ratio": "1.6%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "120",
"Cost of Goods Sold": "0",
"Intangible Assets": "5.8",
"Liabilities, Current": "26",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "71",
"Other Liabilities": "235",
"Other Net Income": "0",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "45"
},
"output_variables": {
"Assets": "126",
"Liabilities": "261",
"Expenses": "116",
"Revenues": "0",
"Stockholders Equity": "-135",
"Net Income": "-116",
"Comprehensive Net Income": "-116",
"BaseVar": "252",
"ECR before LimitedLiability": "-212%",
"Economic Capital Ratio": "98%"
}
}
},
"top_rated": false,
"trend": 5.0,
"value": 0.9840403951895863,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001522724.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001522724.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001522724.svg"
},
{
"company_id": "0001498382",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001498382.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001498382.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001498382_main_keyfigs.svg",
"name": "Tuhura Biosciences Inc NV",
"rank": 208,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001498382.svg",
"report_text": "The relative strengths and weaknesses of Tuhura Biosciences Inc NV are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tuhura Biosciences Inc NV compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 93% points.The greatest weakness of Tuhura Biosciences Inc NV is the variable Assets, Current, reducing the Economic Capital Ratio by 64% points.
The company's Economic Capital Ratio, given in the ranking table, is 98%, being 145% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001498382_2014_Tuhura_Biosciences_Inc_NV.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "92.8",
"Assets": "-38.0",
"Liabilities": "-18.8",
"Stockholders Equity": "-49.2",
"ECR before LimitedLiability": "-117",
"Intangible Assets": "-14.9",
"Property and Equipment": "-9.06",
"Assets, Current": "-63.9",
"Liabilities, Non-Current": "2.69",
"Liabilities, Current": "10.7",
"Other Liabilities": "-39.4",
"Selling, General and Administrative Expense": "-13.5",
"Expenses": "-8.15",
"Revenues": "-11.9",
"Net Income": "-29.6",
"Other Expenses": "6.95",
"Research and Development": "-2.67",
"Other Revenues": "-11.9",
"Comprehensive Net Income": "-29.6",
"Other Net Income": "-12.8",
"Economic Capital Ratio": "-145"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001498382_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "0",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "249",
"Liabilities, Non-Current": "0",
"Other Assets": "4,319",
"Other Compr. Net Income": "21",
"Other Expenses": "0",
"Other Liabilities": "4,887",
"Other Net Income": "-1,996",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "2,343",
"Selling, General and Administrative Expense": "3,952"
},
"output_variables": {
"Assets": "4,319",
"Liabilities": "5,137",
"Expenses": "6,295",
"Revenues": "0",
"Stockholders Equity": "-818",
"Net Income": "-8,291",
"Comprehensive Net Income": "-8,280",
"BaseVar": "8,884",
"ECR before LimitedLiability": "-213%",
"Economic Capital Ratio": "98%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.9816336768953987,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001498382.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001498382.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001498382.svg"
},
{
"company_id": "0001158223",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001158223.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001158223.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001158223_main_keyfigs.svg",
"name": "Affymax INC",
"rank": 209,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001158223.svg",
"report_text": "The relative strengths and weaknesses of Affymax INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Affymax INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 82% points.The greatest weakness of Affymax INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 114% points.
The company's Economic Capital Ratio, given in the ranking table, is 97%, being 145% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001158223_2014_Affymax_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.28",
"Assets": "9.34",
"Liabilities": "17.2",
"Stockholders Equity": "27.1",
"ECR before LimitedLiability": "93.8",
"Intangible Assets": "-18.1",
"Property and Equipment": "-7.99",
"Assets, Current": "53.1",
"Other Liabilities": "-19.5",
"Liabilities, Non-Current": "11.6",
"Liabilities, Current": "24.2",
"Research and Development": "-28.1",
"Expenses": "-6.95",
"Revenues": "7.23",
"Net Income": "3.17",
"Other Expenses": "13.2",
"Cost of Goods Sold": "4.68",
"Selling, General and Administrative Expense": "4.51",
"Other Revenues": "7.23",
"Other Net Income": "3.02",
"Economic Capital Ratio": "18.2"
},
"2012": {
"Property and Equipment": "-2.79",
"Assets": "-41.7",
"Liabilities": "-4.23",
"Stockholders Equity": "-89.0",
"Assets, Current": "-4.65",
"Intangible Assets": "-4.12",
"Liabilities, Current": "-37.5",
"ECR before LimitedLiability": "-10.8",
"Other Liabilities": "3.67",
"Liabilities, Non-Current": "2.59",
"Selling, General and Administrative Expense": "-3.09",
"Expenses": "-2.42",
"Revenues": "5.67",
"Net Income": "2.69",
"Research and Development": "1.33",
"Other Expenses": "-1.30",
"Cost of Goods Sold": "1.21",
"Other Revenues": "5.67",
"Comprehensive Net Income": "2.74",
"Other Net Income": "0.587",
"Economic Capital Ratio": "-83.9"
},
"2013": {
"Assets": "-41.6",
"Liabilities": "-15.6",
"Stockholders Equity": "-64.8",
"ECR before LimitedLiability": "-117",
"Intangible Assets": "-16.2",
"Property and Equipment": "-9.91",
"Assets, Current": "-34.2",
"Liabilities, Non-Current": "2.92",
"Liabilities, Current": "-32.0",
"Other Liabilities": "7.62",
"Selling, General and Administrative Expense": "-114",
"Expenses": "-23.3",
"Revenues": "-7.77",
"Net Income": "-28.5",
"Other Expenses": "82.1",
"Research and Development": "-29.4",
"Cost of Goods Sold": "1.74",
"Other Revenues": "-7.77",
"Comprehensive Net Income": "-28.6",
"Other Net Income": "1.02",
"Economic Capital Ratio": "-145"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001158223_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "107,620",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "19,766",
"Liabilities, Non-Current": "1,526",
"Other Assets": "8,362",
"Other Compr. Net Income": "0",
"Other Expenses": "145",
"Other Liabilities": "21,706",
"Other Net Income": "184",
"Other Revenues": "47,720",
"Property and Equipment": "3,013",
"Research and Development": "76,308",
"Selling, General and Administrative Expense": "32,818"
},
"output_variables": {
"Assets": "118,995",
"Liabilities": "42,998",
"Expenses": "109,271",
"Revenues": "47,720",
"Stockholders Equity": "75,997",
"Net Income": "-61,367",
"Comprehensive Net Income": "-61,367",
"BaseVar": "159,584",
"ECR before LimitedLiability": "129%",
"Economic Capital Ratio": "252%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "102,510",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "99,075",
"Liabilities, Non-Current": "799",
"Other Assets": "12,726",
"Other Compr. Net Income": "-20",
"Other Expenses": "46,373",
"Other Liabilities": "10,062",
"Other Net Income": "43",
"Other Revenues": "94,370",
"Property and Equipment": "2,981",
"Research and Development": "51,738",
"Selling, General and Administrative Expense": "89,714"
},
"output_variables": {
"Assets": "118,217",
"Liabilities": "109,936",
"Expenses": "187,825",
"Revenues": "94,370",
"Stockholders Equity": "8,281",
"Net Income": "-93,412",
"Comprehensive Net Income": "-93,422",
"BaseVar": "255,206",
"ECR before LimitedLiability": "-66%",
"Economic Capital Ratio": "136%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "6,322",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,871",
"Liabilities, Non-Current": "0",
"Other Assets": "1,121",
"Other Compr. Net Income": "2.0",
"Other Expenses": "-23,564",
"Other Liabilities": "0",
"Other Net Income": "29",
"Other Revenues": "1,369",
"Property and Equipment": "0",
"Research and Development": "11,857",
"Selling, General and Administrative Expense": "27,529"
},
"output_variables": {
"Assets": "7,443",
"Liabilities": "8,871",
"Expenses": "15,822",
"Revenues": "1,369",
"Stockholders Equity": "-1,428",
"Net Income": "-14,424",
"Comprehensive Net Income": "-14,423",
"BaseVar": "16,768",
"ECR before LimitedLiability": "-215%",
"Economic Capital Ratio": "97%"
}
}
},
"top_rated": false,
"trend": -51.0,
"value": 0.9745197109402753,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001158223.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001158223.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001158223.svg"
},
{
"company_id": "0001388320",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001388320.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001388320.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001388320.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001388320_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001388320_main_keyfigs.svg",
"name": "Actinium Pharmaceuticals Inc",
"rank": 210,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001388320.svg",
"report_text": "The relative strengths and weaknesses of Actinium Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Actinium Pharmaceuticals Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 12% points.The greatest weakness of Actinium Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 55% points.
The company's Economic Capital Ratio, given in the ranking table, is 97%, being 146% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001388320_2014_Actinium_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-4.49",
"Assets": "-6.16",
"Liabilities": "-8.24",
"Stockholders Equity": "-10.1",
"ECR before LimitedLiability": "-16.1",
"Assets, Current": "14.3",
"Intangible Assets": "-5.98",
"Other Assets": "-4.61",
"Liabilities, Current": "-36.3",
"Other Liabilities": "6.11",
"Liabilities, Non-Current": "2.76",
"Selling, General and Administrative Expense": "-7.11",
"Expenses": "-6.00",
"Revenues": "-6.65",
"Net Income": "-9.02",
"Research and Development": "-4.07",
"Other Expenses": "5.57",
"Other Revenues": "-6.65",
"Comprehensive Net Income": "-9.00",
"Other Net Income": "2.35",
"Economic Capital Ratio": "-89.2"
},
"2013": {
"Other Assets": "-11.8",
"Assets": "-38.4",
"Liabilities": "-21.4",
"Stockholders Equity": "-55.4",
"ECR before LimitedLiability": "-118",
"Intangible Assets": "-14.7",
"Property and Equipment": "-8.70",
"Assets, Current": "-20.2",
"Liabilities, Non-Current": "2.58",
"Liabilities, Current": "11.7",
"Other Liabilities": "-43.1",
"Selling, General and Administrative Expense": "-6.51",
"Expenses": "1.46",
"Revenues": "-11.7",
"Net Income": "-27.9",
"Other Expenses": "6.73",
"Cost of Goods Sold": "1.54",
"Other Revenues": "-11.7",
"Comprehensive Net Income": "-28.0",
"Other Net Income": "-19.5",
"Economic Capital Ratio": "-146"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001388320_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "5,786",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,643",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0.58",
"Other Liabilities": "0",
"Other Net Income": "414",
"Other Revenues": "0",
"Property and Equipment": "3.0",
"Research and Development": "3,440",
"Selling, General and Administrative Expense": "4,506"
},
"output_variables": {
"Assets": "5,789",
"Liabilities": "4,643",
"Expenses": "7,947",
"Revenues": "0",
"Stockholders Equity": "1,146",
"Net Income": "-7,533",
"Comprehensive Net Income": "-7,533",
"BaseVar": "9,397",
"ECR before LimitedLiability": "-97%",
"Economic Capital Ratio": "131%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "5,752",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "5.7",
"Other Liabilities": "7,325",
"Other Net Income": "-4,182",
"Other Revenues": "0",
"Property and Equipment": "14",
"Research and Development": "2,667",
"Selling, General and Administrative Expense": "3,919"
},
"output_variables": {
"Assets": "5,766",
"Liabilities": "7,325",
"Expenses": "6,592",
"Revenues": "0",
"Stockholders Equity": "-1,560",
"Net Income": "-10,774",
"Comprehensive Net Income": "-10,774",
"BaseVar": "11,932",
"ECR before LimitedLiability": "-217%",
"Economic Capital Ratio": "97%"
}
}
},
"top_rated": false,
"trend": -46.0,
"value": 0.9692861111720512,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001388320.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001388320.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001388320.svg"
},
{
"company_id": "0000802724",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000802724.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000802724.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000802724_main_keyfigs.svg",
"name": "Insite Vision INC",
"rank": 211,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000802724.svg",
"report_text": "The relative strengths and weaknesses of Insite Vision INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Insite Vision INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 31% points.The greatest weakness of Insite Vision INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 209% points.
The company's Economic Capital Ratio, given in the ranking table, is 95%, being 148% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000802724_2014_Insite_Vision_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.99",
"Assets": "-21.8",
"Liabilities": "-80.2",
"Stockholders Equity": "-124",
"ECR before LimitedLiability": "-45.2",
"Intangible Assets": "-10.1",
"Property and Equipment": "-6.14",
"Assets, Current": "-9.94",
"Other Liabilities": "-89.2",
"Liabilities, Non-Current": "2.18",
"Liabilities, Current": "-1.30",
"Research and Development": "7.91",
"Expenses": "13.0",
"Revenues": "-1.15",
"Net Income": "14.1",
"Other Expenses": "-3.39",
"Cost of Goods Sold": "1.37",
"Selling, General and Administrative Expense": "6.99",
"Other Revenues": "-1.15",
"Comprehensive Net Income": "14.0",
"Other Net Income": "2.19",
"Economic Capital Ratio": "-121"
},
"2012": {
"Property and Equipment": "-9.64",
"Assets": "-52.5",
"Liabilities": "-48.7",
"Stockholders Equity": "-157",
"ECR before LimitedLiability": "-63.9",
"Assets, Current": "-42.4",
"Intangible Assets": "-15.0",
"Other Assets": "-3.30",
"Liabilities, Current": "-4.23",
"Other Liabilities": "-45.2",
"Liabilities, Non-Current": "2.22",
"Selling, General and Administrative Expense": "8.49",
"Expenses": "9.85",
"Revenues": "5.89",
"Net Income": "18.2",
"Other Expenses": "-1.21",
"Cost of Goods Sold": "2.08",
"Other Revenues": "5.89",
"Comprehensive Net Income": "18.2",
"Other Net Income": "2.70",
"Economic Capital Ratio": "-137"
},
"2013": {
"Other Assets": "-12.5",
"Assets": "-52.2",
"Liabilities": "-43.0",
"Stockholders Equity": "-209",
"ECR before LimitedLiability": "-120",
"Intangible Assets": "-15.6",
"Property and Equipment": "-4.87",
"Assets, Current": "-44.1",
"Liabilities, Non-Current": "2.62",
"Liabilities, Current": "-101",
"Other Liabilities": "5.98",
"Selling, General and Administrative Expense": "8.09",
"Expenses": "9.78",
"Revenues": "20.4",
"Net Income": "31.2",
"Other Expenses": "-1.79",
"Research and Development": "1.85",
"Cost of Goods Sold": "1.62",
"Other Revenues": "20.4",
"Comprehensive Net Income": "31.1",
"Economic Capital Ratio": "-148"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000802724_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "28,971",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "14,668",
"Liabilities, Non-Current": "0",
"Other Assets": "3,085",
"Other Compr. Net Income": "0",
"Other Expenses": "12,084",
"Other Liabilities": "52,272",
"Other Net Income": "2,201",
"Other Revenues": "15,923",
"Property and Equipment": "345",
"Research and Development": "7,337",
"Selling, General and Administrative Expense": "5,645"
},
"output_variables": {
"Assets": "32,401",
"Liabilities": "66,940",
"Expenses": "25,066",
"Revenues": "15,923",
"Stockholders Equity": "-34,539",
"Net Income": "-6,942",
"Comprehensive Net Income": "-6,942",
"BaseVar": "71,266",
"ECR before LimitedLiability": "-166%",
"Economic Capital Ratio": "113%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "14,716",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "18,140",
"Liabilities, Non-Current": "0",
"Other Assets": "2,666",
"Other Compr. Net Income": "0",
"Other Expenses": "10,556",
"Other Liabilities": "41,488",
"Other Net Income": "1,898",
"Other Revenues": "21,641",
"Property and Equipment": "377",
"Research and Development": "15,479",
"Selling, General and Administrative Expense": "5,781"
},
"output_variables": {
"Assets": "17,759",
"Liabilities": "59,628",
"Expenses": "31,816",
"Revenues": "21,641",
"Stockholders Equity": "-41,869",
"Net Income": "-8,277",
"Comprehensive Net Income": "-8,277",
"BaseVar": "66,371",
"ECR before LimitedLiability": "-257%",
"Economic Capital Ratio": "83%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "12,734",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "48,397",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "8,281",
"Other Liabilities": "922",
"Other Net Income": "572",
"Other Revenues": "30,822",
"Property and Equipment": "1,431",
"Research and Development": "11,578",
"Selling, General and Administrative Expense": "5,754"
},
"output_variables": {
"Assets": "14,165",
"Liabilities": "49,319",
"Expenses": "25,613",
"Revenues": "30,822",
"Stockholders Equity": "-35,154",
"Net Income": "5,781",
"Comprehensive Net Income": "5,781",
"BaseVar": "60,246",
"ECR before LimitedLiability": "-223%",
"Economic Capital Ratio": "95%"
}
}
},
"top_rated": false,
"trend": -32.0,
"value": 0.9467747039219241,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000802724.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000802724.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000802724.svg"
},
{
"company_id": "0001175680",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001175680.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001175680.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001175680.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001175680_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001175680_main_keyfigs.svg",
"name": "Cytodyn Inc",
"rank": 212,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001175680.svg",
"report_text": "The relative strengths and weaknesses of Cytodyn Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cytodyn Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 74% points.The greatest weakness of Cytodyn Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 58% points.
The company's Economic Capital Ratio, given in the ranking table, is 90%, being 152% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001175680_2014_Cytodyn_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-10.8",
"Assets": "-54.5",
"Liabilities": "-46.6",
"Stockholders Equity": "-118",
"ECR before LimitedLiability": "-98.0",
"Intangible Assets": "-14.8",
"Property and Equipment": "-9.24",
"Assets, Current": "-29.2",
"Other Liabilities": "2.04",
"Liabilities, Non-Current": "0.907",
"Liabilities, Current": "-64.8",
"Research and Development": "8.79",
"Expenses": "2.30",
"Revenues": "-11.5",
"Net Income": "-8.16",
"Other Expenses": "-1.02",
"Cost of Goods Sold": "1.40",
"Selling, General and Administrative Expense": "-7.33",
"Other Revenues": "-11.5",
"Comprehensive Net Income": "-8.27",
"Economic Capital Ratio": "-174"
},
"2012": {
"Property and Equipment": "-8.50",
"Assets": "-97.9",
"Liabilities": "7.47",
"Stockholders Equity": "-120",
"ECR before LimitedLiability": "-132",
"Assets, Current": "-68.8",
"Intangible Assets": "-11.7",
"Other Assets": "-8.69",
"Liabilities, Current": "11.2",
"Other Liabilities": "-1.17",
"Liabilities, Non-Current": "-0.556",
"Selling, General and Administrative Expense": "-23.8",
"Expenses": "-17.5",
"Revenues": "-7.54",
"Net Income": "-28.9",
"Research and Development": "4.14",
"Other Expenses": "-2.44",
"Cost of Goods Sold": "0.988",
"Other Revenues": "-7.54",
"Comprehensive Net Income": "-28.8",
"Economic Capital Ratio": "-205"
},
"2013": {
"Other Assets": "-14.9",
"Assets": "-48.1",
"Liabilities": "-9.49",
"Stockholders Equity": "-50.4",
"ECR before LimitedLiability": "-124",
"Intangible Assets": "74.3",
"Property and Equipment": "-11.2",
"Assets, Current": "-57.7",
"Liabilities, Non-Current": "2.87",
"Liabilities, Current": "-12.2",
"Selling, General and Administrative Expense": "-30.4",
"Expenses": "-32.7",
"Revenues": "-14.5",
"Net Income": "-40.1",
"Other Expenses": "-16.2",
"Research and Development": "11.7",
"Cost of Goods Sold": "1.90",
"Other Revenues": "-14.5",
"Comprehensive Net Income": "-40.2",
"Other Net Income": "3.97",
"Economic Capital Ratio": "-152"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001175680_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,974",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,995",
"Liabilities, Non-Current": "0",
"Other Assets": "16",
"Other Compr. Net Income": "0",
"Other Expenses": "713",
"Other Liabilities": "6.9",
"Other Net Income": "0",
"Other Revenues": "0",
"Property and Equipment": "5.4",
"Research and Development": "481",
"Selling, General and Administrative Expense": "2,526"
},
"output_variables": {
"Assets": "1,995",
"Liabilities": "7,002",
"Expenses": "3,720",
"Revenues": "0",
"Stockholders Equity": "-5,008",
"Net Income": "-3,720",
"Comprehensive Net Income": "-3,720",
"BaseVar": "6,358",
"ECR before LimitedLiability": "-325%",
"Economic Capital Ratio": "60%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,028",
"Cost of Goods Sold": "0",
"Intangible Assets": "39",
"Liabilities, Current": "5,044",
"Liabilities, Non-Current": "0",
"Other Assets": "3.1",
"Other Compr. Net Income": "0",
"Other Expenses": "1,490",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "0",
"Property and Equipment": "0.80",
"Research and Development": "530",
"Selling, General and Administrative Expense": "5,454"
},
"output_variables": {
"Assets": "1,071",
"Liabilities": "5,044",
"Expenses": "7,474",
"Revenues": "0",
"Stockholders Equity": "-3,973",
"Net Income": "-7,474",
"Comprehensive Net Income": "-7,474",
"BaseVar": "6,795",
"ECR before LimitedLiability": "-528%",
"Economic Capital Ratio": "15%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "840",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,317",
"Liabilities, Current": "3,229",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "3,118",
"Other Liabilities": "1,153",
"Other Net Income": "374",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "620",
"Selling, General and Administrative Expense": "6,205"
},
"output_variables": {
"Assets": "4,158",
"Liabilities": "4,382",
"Expenses": "9,942",
"Revenues": "0",
"Stockholders Equity": "-224",
"Net Income": "-9,568",
"Comprehensive Net Income": "-9,568",
"BaseVar": "9,428",
"ECR before LimitedLiability": "-236%",
"Economic Capital Ratio": "90%"
}
}
},
"top_rated": false,
"trend": -4.0,
"value": 0.9049465605199115,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001175680.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001175680.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001175680.svg"
},
{
"company_id": "0001335103",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001335103.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001335103.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001335103_main_keyfigs.svg",
"name": "Protea Biosciences Group Inc",
"rank": 213,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001335103.svg",
"report_text": "The relative strengths and weaknesses of Protea Biosciences Group Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Protea Biosciences Group Inc compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 41% points.The greatest weakness of Protea Biosciences Group Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 87% points.
The company's Economic Capital Ratio, given in the ranking table, is 82%, being 160% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001335103_2014_Protea_Biosciences_Group_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-15.7",
"Assets": "-54.7",
"Liabilities": "-19.9",
"Stockholders Equity": "-65.2",
"ECR before LimitedLiability": "-82.8",
"Intangible Assets": "-20.7",
"Property and Equipment": "53.8",
"Assets, Current": "-59.0",
"Other Liabilities": "4.53",
"Liabilities, Current": "-35.7",
"Research and Development": "-16.0",
"Expenses": "-20.6",
"Revenues": "-13.8",
"Net Income": "-36.3",
"Other Expenses": "6.24",
"Cost of Goods Sold": "2.23",
"Selling, General and Administrative Expense": "-13.3",
"Other Revenues": "-13.8",
"Comprehensive Net Income": "-36.4",
"Other Net Income": "-2.76",
"Economic Capital Ratio": "-158"
},
"2012": {
"Property and Equipment": "34.9",
"Assets": "-59.2",
"Liabilities": "-28.1",
"Stockholders Equity": "-82.7",
"ECR before LimitedLiability": "-82.3",
"Assets, Current": "-62.0",
"Intangible Assets": "-16.5",
"Other Assets": "-11.6",
"Liabilities, Current": "-46.0",
"Other Liabilities": "3.14",
"Liabilities, Non-Current": "1.51",
"Selling, General and Administrative Expense": "-10.5",
"Expenses": "-7.19",
"Revenues": "-9.44",
"Net Income": "-18.4",
"Research and Development": "-7.01",
"Other Expenses": "7.80",
"Cost of Goods Sold": "2.04",
"Other Revenues": "-9.44",
"Comprehensive Net Income": "-18.4",
"Economic Capital Ratio": "-155"
},
"2013": {
"Other Assets": "-14.0",
"Assets": "-54.9",
"Liabilities": "-20.4",
"Stockholders Equity": "-86.6",
"ECR before LimitedLiability": "-133",
"Intangible Assets": "-18.0",
"Property and Equipment": "41.3",
"Assets, Current": "-55.6",
"Liabilities, Non-Current": "-8.18",
"Liabilities, Current": "-19.5",
"Other Liabilities": "5.97",
"Selling, General and Administrative Expense": "-27.5",
"Expenses": "-17.4",
"Revenues": "-7.42",
"Net Income": "-28.6",
"Other Expenses": "7.45",
"Cost of Goods Sold": "1.72",
"Other Revenues": "-7.42",
"Comprehensive Net Income": "-28.7",
"Other Net Income": "-4.51",
"Economic Capital Ratio": "-160"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001335103_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,432",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,083",
"Liabilities, Non-Current": "0",
"Other Assets": "18",
"Other Compr. Net Income": "19",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-722",
"Other Revenues": "713",
"Property and Equipment": "3,319",
"Research and Development": "6,243",
"Selling, General and Administrative Expense": "5,246"
},
"output_variables": {
"Assets": "4,769",
"Liabilities": "7,083",
"Expenses": "11,489",
"Revenues": "713",
"Stockholders Equity": "-2,314",
"Net Income": "-11,497",
"Comprehensive Net Income": "-11,488",
"BaseVar": "12,397",
"ECR before LimitedLiability": "-279%",
"Economic Capital Ratio": "76%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,399",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "10,033",
"Liabilities, Non-Current": "0",
"Other Assets": "23",
"Other Compr. Net Income": "-21",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-551",
"Other Revenues": "834",
"Property and Equipment": "2,790",
"Research and Development": "4,596",
"Selling, General and Administrative Expense": "5,219"
},
"output_variables": {
"Assets": "4,212",
"Liabilities": "10,033",
"Expenses": "9,815",
"Revenues": "834",
"Stockholders Equity": "-5,821",
"Net Income": "-9,531",
"Comprehensive Net Income": "-9,542",
"BaseVar": "12,733",
"ECR before LimitedLiability": "-312%",
"Economic Capital Ratio": "65%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,509",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,225",
"Liabilities, Non-Current": "2,204",
"Other Assets": "23",
"Other Compr. Net Income": "30",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-1,093",
"Other Revenues": "1,223",
"Property and Equipment": "2,886",
"Research and Development": "2,773",
"Selling, General and Administrative Expense": "8,775"
},
"output_variables": {
"Assets": "5,418",
"Liabilities": "8,429",
"Expenses": "11,548",
"Revenues": "1,223",
"Stockholders Equity": "-3,011",
"Net Income": "-11,418",
"Comprehensive Net Income": "-11,403",
"BaseVar": "13,871",
"ECR before LimitedLiability": "-260%",
"Economic Capital Ratio": "82%"
}
}
},
"top_rated": false,
"trend": -27.0,
"value": 0.8229729933269679,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001335103.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001335103.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001335103.svg"
},
{
"company_id": "0001355250",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001355250.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001355250.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001355250.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001355250_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001355250_main_keyfigs.svg",
"name": "Innovation Pharmaceuticals Inc",
"rank": 214,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001355250.svg",
"report_text": "The relative strengths and weaknesses of Innovation Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Innovation Pharmaceuticals Inc compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 7.2% points.The greatest weakness of Innovation Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 121% points.
The company's Economic Capital Ratio, given in the ranking table, is 82%, being 161% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001355250_2014_Innovation_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-9.51",
"Assets": "-43.1",
"Liabilities": "-51.8",
"Stockholders Equity": "-121",
"ECR before LimitedLiability": "-133",
"Intangible Assets": "-11.8",
"Property and Equipment": "-7.08",
"Assets, Current": "-25.4",
"Liabilities, Non-Current": "1.49",
"Liabilities, Current": "-62.5",
"Other Liabilities": "3.96",
"Selling, General and Administrative Expense": "7.23",
"Expenses": "7.01",
"Revenues": "-8.67",
"Net Income": "-2.52",
"Other Expenses": "-1.78",
"Cost of Goods Sold": "1.11",
"Other Revenues": "-8.67",
"Comprehensive Net Income": "-2.62",
"Other Net Income": "-0.910",
"Economic Capital Ratio": "-161"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001355250_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "2,960",
"Cost of Goods Sold": "0",
"Intangible Assets": "10",
"Liabilities, Current": "8,140",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,074",
"Other Liabilities": "0",
"Other Net Income": "-241",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "1,510",
"Selling, General and Administrative Expense": "399"
},
"output_variables": {
"Assets": "2,970",
"Liabilities": "8,140",
"Expenses": "2,983",
"Revenues": "0",
"Stockholders Equity": "-5,170",
"Net Income": "-3,224",
"Comprehensive Net Income": "-3,224",
"BaseVar": "7,167",
"ECR before LimitedLiability": "-261%",
"Economic Capital Ratio": "82%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.8181207736687861,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001355250.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001355250.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001355250.svg"
},
{
"company_id": "0001420030",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001420030.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001420030.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001420030_main_keyfigs.svg",
"name": "Targeted Medical Pharma Inc",
"rank": 215,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001420030.svg",
"report_text": "The relative strengths and weaknesses of Targeted Medical Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Targeted Medical Pharma Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 19% points.The greatest weakness of Targeted Medical Pharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 196% points.
The company's Economic Capital Ratio, given in the ranking table, is 72%, being 171% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001420030_2014_Targeted_Medical_Pharma_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "8.22",
"Assets": "-62.4",
"Liabilities": "-24.0",
"Stockholders Equity": "-126",
"Intangible Assets": "2.12",
"Property and Equipment": "-1.37",
"Assets, Current": "-84.5",
"Other Liabilities": "1.89",
"Liabilities, Non-Current": "1.81",
"Liabilities, Current": "-70.5",
"Other Revenues": "6.38",
"Revenues": "6.38",
"Net Income": "6.10",
"ECR before LimitedLiability": "-19.5",
"Research and Development": "9.65",
"Comprehensive Net Income": "5.99",
"Cost of Goods Sold": "-1.68",
"Selling, General and Administrative Expense": "-38.8",
"Other Expenses": "7.06",
"Other Net Income": "-0.502",
"Economic Capital Ratio": "-95.1"
},
"2012": {
"Property and Equipment": "-4.35",
"Assets": "-12.7",
"Liabilities": "-12.3",
"Stockholders Equity": "-83.9",
"ECR before LimitedLiability": "-18.8",
"Assets, Current": "-55.0",
"Other Assets": "41.1",
"Liabilities, Current": "-36.1",
"Other Liabilities": "2.69",
"Liabilities, Non-Current": "3.15",
"Selling, General and Administrative Expense": "-6.56",
"Expenses": "11.9",
"Revenues": "3.11",
"Net Income": "2.50",
"Research and Development": "11.9",
"Other Expenses": "13.6",
"Cost of Goods Sold": "-3.78",
"Other Revenues": "3.11",
"Comprehensive Net Income": "2.57",
"Other Net Income": "-8.73",
"Economic Capital Ratio": "-91.9"
},
"2013": {
"Other Assets": "-19.7",
"Assets": "-96.0",
"Liabilities": "-14.9",
"Stockholders Equity": "-196",
"ECR before LimitedLiability": "-143",
"Intangible Assets": "3.55",
"Property and Equipment": "-11.7",
"Assets, Current": "-68.9",
"Liabilities, Non-Current": "2.47",
"Liabilities, Current": "-31.4",
"Other Liabilities": "4.56",
"Selling, General and Administrative Expense": "-20.5",
"Expenses": "-23.4",
"Revenues": "18.9",
"Comprehensive Net Income": "-1.55",
"Other Expenses": "-12.6",
"Research and Development": "18.1",
"Cost of Goods Sold": "-9.60",
"Other Revenues": "18.9",
"Other Net Income": "1.83",
"Economic Capital Ratio": "-171"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001420030_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,900",
"Cost of Goods Sold": "2,757",
"Intangible Assets": "2,388",
"Liabilities, Current": "7,585",
"Liabilities, Non-Current": "0",
"Other Assets": "3,089",
"Other Compr. Net Income": "-3.2",
"Other Expenses": "-2,472",
"Other Liabilities": "989",
"Other Net Income": "-868",
"Other Revenues": "8,810",
"Property and Equipment": "412",
"Research and Development": "163",
"Selling, General and Administrative Expense": "11,670"
},
"output_variables": {
"Assets": "8,788",
"Liabilities": "8,574",
"Expenses": "12,119",
"Revenues": "8,810",
"Stockholders Equity": "214",
"Net Income": "-4,177",
"Comprehensive Net Income": "-4,179",
"BaseVar": "19,581",
"ECR before LimitedLiability": "-43%",
"Economic Capital Ratio": "139%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "2,599",
"Cost of Goods Sold": "3,201",
"Intangible Assets": "2,319",
"Liabilities, Current": "12,315",
"Liabilities, Non-Current": "0",
"Other Assets": "6,518",
"Other Compr. Net Income": "0",
"Other Expenses": "-3,186",
"Other Liabilities": "1,463",
"Other Net Income": "-6,632",
"Other Revenues": "7,296",
"Property and Equipment": "340",
"Research and Development": "134",
"Selling, General and Administrative Expense": "10,101"
},
"output_variables": {
"Assets": "11,775",
"Liabilities": "13,777",
"Expenses": "10,250",
"Revenues": "7,296",
"Stockholders Equity": "-2,002",
"Net Income": "-9,586",
"Comprehensive Net Income": "-9,586",
"BaseVar": "24,866",
"ECR before LimitedLiability": "-109%",
"Economic Capital Ratio": "128%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,630",
"Cost of Goods Sold": "2,989",
"Intangible Assets": "2,133",
"Liabilities, Current": "11,261",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "5,667",
"Other Liabilities": "755",
"Other Net Income": "170",
"Other Revenues": "9,556",
"Property and Equipment": "236",
"Research and Development": "229",
"Selling, General and Administrative Expense": "10,179"
},
"output_variables": {
"Assets": "4,998",
"Liabilities": "12,015",
"Expenses": "19,063",
"Revenues": "9,556",
"Stockholders Equity": "-7,018",
"Net Income": "-9,338",
"Comprehensive Net Income": "-9,338",
"BaseVar": "22,901",
"ECR before LimitedLiability": "-290%",
"Economic Capital Ratio": "72%"
}
}
},
"top_rated": false,
"trend": -47.0,
"value": 0.7210272597686835,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001420030.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001420030.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001420030.svg"
},
{
"company_id": "0000890821",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000890821.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000890821.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000890821.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000890821_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000890821_main_keyfigs.svg",
"name": "Enveric Biosciences Inc",
"rank": 216,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000890821.svg",
"report_text": "The relative strengths and weaknesses of Enveric Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Enveric Biosciences Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 17% points.The greatest weakness of Enveric Biosciences Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 166% points.
The company's Economic Capital Ratio, given in the ranking table, is 68%, being 175% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000890821_2014_Enveric_Biosciences_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-6.66",
"Assets": "-8.86",
"Liabilities": "-11.0",
"Stockholders Equity": "-14.4",
"ECR before LimitedLiability": "-31.9",
"Intangible Assets": "-8.30",
"Property and Equipment": "-5.72",
"Assets, Current": "18.1",
"Other Liabilities": "6.16",
"Liabilities, Non-Current": "2.61",
"Liabilities, Current": "-19.9",
"Research and Development": "13.9",
"Expenses": "31.8",
"Revenues": "-8.95",
"Net Income": "-13.8",
"Other Expenses": "1.56",
"Selling, General and Administrative Expense": "11.5",
"Other Revenues": "-8.95",
"Comprehensive Net Income": "-13.8",
"Other Net Income": "-48.9",
"Economic Capital Ratio": "-107"
},
"2012": {
"Property and Equipment": "-9.62",
"Assets": "-81.9",
"Liabilities": "0.301",
"Stockholders Equity": "-110",
"ECR before LimitedLiability": "-116",
"Assets, Current": "-55.3",
"Intangible Assets": "-14.0",
"Other Assets": "-9.88",
"Liabilities, Current": "0.504",
"Selling, General and Administrative Expense": "8.03",
"Expenses": "17.0",
"Revenues": "-9.42",
"Net Income": "-19.9",
"Research and Development": "8.30",
"Other Expenses": "2.57",
"Cost of Goods Sold": "1.34",
"Other Revenues": "-9.42",
"Comprehensive Net Income": "-19.8",
"Other Net Income": "-39.7",
"Other Compr. Net Income": "0.0570",
"Economic Capital Ratio": "-190"
},
"2013": {
"Other Assets": "-8.39",
"Assets": "-52.9",
"Liabilities": "-70.3",
"Stockholders Equity": "-166",
"ECR before LimitedLiability": "-147",
"Intangible Assets": "-10.7",
"Property and Equipment": "-6.22",
"Assets, Current": "-37.3",
"Liabilities, Non-Current": "0.921",
"Liabilities, Current": "-134",
"Other Liabilities": "2.45",
"Selling, General and Administrative Expense": "7.75",
"Expenses": "16.5",
"Revenues": "-7.15",
"Net Income": "13.2",
"Research and Development": "7.75",
"Cost of Goods Sold": "0.900",
"Other Revenues": "-7.15",
"Comprehensive Net Income": "13.1",
"Other Net Income": "3.33",
"Economic Capital Ratio": "-175"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000890821_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "22",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "18",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "2.0",
"Other Liabilities": "0",
"Other Net Income": "-31",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "22",
"Liabilities": "18",
"Expenses": "2.0",
"Revenues": "0",
"Stockholders Equity": "4.6",
"Net Income": "-33",
"Comprehensive Net Income": "-33",
"BaseVar": "37",
"ECR before LimitedLiability": "-116%",
"Economic Capital Ratio": "127%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "5.6",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "26",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1.9",
"Other Liabilities": "0",
"Other Net Income": "-23",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "5.6",
"Liabilities": "26",
"Expenses": "1.9",
"Revenues": "0",
"Stockholders Equity": "-20",
"Net Income": "-25",
"Comprehensive Net Income": "-25",
"BaseVar": "28",
"ECR before LimitedLiability": "-437%",
"Economic Capital Ratio": "31%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "4.5",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "25",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1.4",
"Other Liabilities": "0",
"Other Net Income": "1.3",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "4.5",
"Liabilities": "25",
"Expenses": "1.4",
"Revenues": "0",
"Stockholders Equity": "-20",
"Net Income": "-0.16",
"Comprehensive Net Income": "-0.16",
"BaseVar": "16",
"ECR before LimitedLiability": "-304%",
"Economic Capital Ratio": "68%"
}
}
},
"top_rated": false,
"trend": -11.0,
"value": 0.675024856952162,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000890821.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000890821.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000890821.svg"
},
{
"company_id": "0000034956",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000034956.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000034956.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000034956_main_keyfigs.svg",
"name": "Tenax Therapeutics INC",
"rank": 217,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000034956.svg",
"report_text": "The relative strengths and weaknesses of Tenax Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tenax Therapeutics INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 3.0% points.The greatest weakness of Tenax Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 86% points.
The company's Economic Capital Ratio, given in the ranking table, is 60%, being 183% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000034956_2014_Tenax_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-10.3",
"Assets": "-86.9",
"Liabilities": "-0.433",
"Stockholders Equity": "-77.6",
"ECR before LimitedLiability": "-103",
"Assets, Current": "-78.0",
"Intangible Assets": "-3.02",
"Other Assets": "-9.42",
"Liabilities, Current": "-1.19",
"Liabilities, Non-Current": "0.872",
"Selling, General and Administrative Expense": "-22.0",
"Expenses": "-58.7",
"Revenues": "-16.7",
"Net Income": "-75.1",
"Research and Development": "3.45",
"Other Expenses": "-41.8",
"Cost of Goods Sold": "2.73",
"Other Revenues": "-16.7",
"Comprehensive Net Income": "-75.0",
"Other Net Income": "0.867",
"Economic Capital Ratio": "-176"
},
"2013": {
"Other Assets": "-12.6",
"Assets": "-78.7",
"Liabilities": "-7.51",
"Stockholders Equity": "-86.4",
"ECR before LimitedLiability": "-155",
"Intangible Assets": "3.04",
"Property and Equipment": "-7.83",
"Assets, Current": "-75.8",
"Liabilities, Non-Current": "1.38",
"Other Liabilities": "-10.8",
"Selling, General and Administrative Expense": "-11.8",
"Expenses": "-40.0",
"Revenues": "-6.05",
"Net Income": "-45.1",
"Other Expenses": "-27.8",
"Research and Development": "-1.95",
"Cost of Goods Sold": "1.92",
"Other Revenues": "-6.05",
"Comprehensive Net Income": "-45.3",
"Other Net Income": "1.09",
"Economic Capital Ratio": "-183"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000034956_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "2,631",
"Cost of Goods Sold": "0",
"Intangible Assets": "873",
"Liabilities, Current": "3,127",
"Liabilities, Non-Current": "0",
"Other Assets": "344",
"Other Compr. Net Income": "0",
"Other Expenses": "7,442",
"Other Liabilities": "1,361",
"Other Net Income": "-80",
"Other Revenues": "364",
"Property and Equipment": "294",
"Research and Development": "2,463",
"Selling, General and Administrative Expense": "6,092"
},
"output_variables": {
"Assets": "4,142",
"Liabilities": "4,488",
"Expenses": "15,996",
"Revenues": "364",
"Stockholders Equity": "-346",
"Net Income": "-15,712",
"Comprehensive Net Income": "-15,712",
"BaseVar": "12,535",
"ECR before LimitedLiability": "-382%",
"Economic Capital Ratio": "44%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "1,842",
"Cost of Goods Sold": "0",
"Intangible Assets": "925",
"Liabilities, Current": "1,910",
"Liabilities, Non-Current": "55",
"Other Assets": "208",
"Other Compr. Net Income": "0",
"Other Expenses": "4,486",
"Other Liabilities": "2,994",
"Other Net Income": "12",
"Other Revenues": "1,191",
"Property and Equipment": "205",
"Research and Development": "2,456",
"Selling, General and Administrative Expense": "3,676"
},
"output_variables": {
"Assets": "3,181",
"Liabilities": "4,959",
"Expenses": "10,618",
"Revenues": "1,191",
"Stockholders Equity": "-1,778",
"Net Income": "-9,416",
"Comprehensive Net Income": "-9,416",
"BaseVar": "9,980",
"ECR before LimitedLiability": "-327%",
"Economic Capital Ratio": "60%"
}
}
},
"top_rated": false,
"trend": -21.0,
"value": 0.6008158608279658,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000034956.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000034956.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000034956.svg"
},
{
"company_id": "0001228627",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001228627.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001228627.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001228627.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001228627_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001228627_main_keyfigs.svg",
"name": "Opus Genetics Inc",
"rank": 218,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001228627.svg",
"report_text": "The relative strengths and weaknesses of Opus Genetics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Opus Genetics Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 9.6% points.The greatest weakness of Opus Genetics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 133% points.
The company's Economic Capital Ratio, given in the ranking table, is 55%, being 187% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001228627_2014_Opus_Genetics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "5.42",
"Liabilities": "67.5",
"Stockholders Equity": "68.2",
"ECR before LimitedLiability": "105",
"Intangible Assets": "-18.9",
"Property and Equipment": "-11.3",
"Assets, Current": "46.9",
"Other Liabilities": "-34.0",
"Liabilities, Non-Current": "17.6",
"Liabilities, Current": "80.1",
"Research and Development": "-55.4",
"Expenses": "-34.8",
"Revenues": "-39.2",
"Net Income": "-31.2",
"Other Expenses": "9.56",
"Cost of Goods Sold": "5.20",
"Selling, General and Administrative Expense": "7.83",
"Other Revenues": "-39.2",
"Comprehensive Net Income": "-31.6",
"Other Net Income": "47.6",
"Economic Capital Ratio": "29.3"
},
"2012": {
"Property and Equipment": "-26.3",
"Assets": "-106",
"Liabilities": "1.34",
"Stockholders Equity": "-47.5",
"ECR before LimitedLiability": "-112",
"Assets, Current": "-87.3",
"Intangible Assets": "-38.5",
"Other Assets": "-16.1",
"Liabilities, Current": "1.23",
"Liabilities, Non-Current": "0.366",
"Selling, General and Administrative Expense": "-57.5",
"Expenses": "-104",
"Revenues": "-29.3",
"Net Income": "-107",
"Research and Development": "-73.1",
"Other Expenses": "7.02",
"Cost of Goods Sold": "3.69",
"Other Revenues": "-29.3",
"Comprehensive Net Income": "-106",
"Other Net Income": "12.1",
"Economic Capital Ratio": "-185"
},
"2013": {
"Other Assets": "-27.8",
"Assets": "-104",
"Liabilities": "8.49",
"Stockholders Equity": "-59.4",
"ECR before LimitedLiability": "-159",
"Intangible Assets": "-36.6",
"Property and Equipment": "-21.5",
"Assets, Current": "-77.2",
"Liabilities, Non-Current": "2.09",
"Liabilities, Current": "7.97",
"Selling, General and Administrative Expense": "-56.1",
"Expenses": "-89.4",
"Revenues": "-25.8",
"Net Income": "-132",
"Other Expenses": "4.84",
"Research and Development": "-65.2",
"Cost of Goods Sold": "3.03",
"Other Revenues": "-25.8",
"Comprehensive Net Income": "-133",
"Other Net Income": "9.64",
"Economic Capital Ratio": "-187"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001228627_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "12,163",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "1,432",
"Other Compr. Net Income": "0",
"Other Expenses": "591",
"Other Liabilities": "2,984",
"Other Net Income": "4,786",
"Other Revenues": "0",
"Property and Equipment": "95",
"Research and Development": "11,992",
"Selling, General and Administrative Expense": "3,548"
},
"output_variables": {
"Assets": "13,690",
"Liabilities": "2,984",
"Expenses": "16,131",
"Revenues": "0",
"Stockholders Equity": "10,706",
"Net Income": "-11,345",
"Comprehensive Net Income": "-11,345",
"BaseVar": "18,795",
"ECR before LimitedLiability": "144%",
"Economic Capital Ratio": "263%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "13,775",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "1,092",
"Other Compr. Net Income": "0",
"Other Expenses": "3,215",
"Other Liabilities": "5,385",
"Other Net Income": "5,242",
"Other Revenues": "0",
"Property and Equipment": "52",
"Research and Development": "35,278",
"Selling, General and Administrative Expense": "30,060"
},
"output_variables": {
"Assets": "14,919",
"Liabilities": "5,385",
"Expenses": "68,554",
"Revenues": "0",
"Stockholders Equity": "9,534",
"Net Income": "-63,311",
"Comprehensive Net Income": "-63,311",
"BaseVar": "47,050",
"ECR before LimitedLiability": "-419%",
"Economic Capital Ratio": "35%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "19,295",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "196",
"Other Compr. Net Income": "0",
"Other Expenses": "3,680",
"Other Liabilities": "6,931",
"Other Net Income": "3,722",
"Other Revenues": "0",
"Property and Equipment": "65",
"Research and Development": "38,532",
"Selling, General and Administrative Expense": "34,321"
},
"output_variables": {
"Assets": "19,556",
"Liabilities": "6,931",
"Expenses": "76,533",
"Revenues": "0",
"Stockholders Equity": "12,625",
"Net Income": "-72,811",
"Comprehensive Net Income": "-72,811",
"BaseVar": "53,371",
"ECR before LimitedLiability": "-342%",
"Economic Capital Ratio": "55%"
}
}
},
"top_rated": false,
"trend": -15.0,
"value": 0.5534865367036264,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001228627.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001228627.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001228627.svg"
},
{
"company_id": "0001072379",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001072379.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001072379.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001072379_main_keyfigs.svg",
"name": "Northwest Biotherapeutics INC",
"rank": 219,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001072379.svg",
"report_text": "The relative strengths and weaknesses of Northwest Biotherapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Northwest Biotherapeutics INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 3.3% points.The greatest weakness of Northwest Biotherapeutics INC is the variable Assets, reducing the Economic Capital Ratio by 86% points.
The company's Economic Capital Ratio, given in the ranking table, is 52%, being 190% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001072379_2014_Northwest_Biotherapeutics_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-3.79",
"Assets": "-125",
"Liabilities": "-0.696",
"Stockholders Equity": "-62.4",
"ECR before LimitedLiability": "-146",
"Assets, Current": "-84.2",
"Intangible Assets": "-7.25",
"Other Assets": "-4.16",
"Liabilities, Current": "0.396",
"Other Liabilities": "-1.20",
"Selling, General and Administrative Expense": "-0.971",
"Expenses": "-41.8",
"Revenues": "-2.24",
"Net Income": "-65.5",
"Research and Development": "-6.96",
"Other Expenses": "-6.85",
"Cost of Goods Sold": "0.207",
"Other Revenues": "-2.24",
"Comprehensive Net Income": "-65.3",
"Other Net Income": "0.182",
"Economic Capital Ratio": "-219"
},
"2013": {
"Other Assets": "-20.5",
"Assets": "-86.3",
"Liabilities, Non-Current": "1.30",
"Stockholders Equity": "-83.3",
"ECR before LimitedLiability": "-163",
"Intangible Assets": "-26.3",
"Property and Equipment": "-14.9",
"Assets, Current": "-67.5",
"Selling, General and Administrative Expense": "-0.655",
"Expenses": "-62.0",
"Revenues": "-16.0",
"Net Income": "-73.3",
"Other Expenses": "-8.84",
"Research and Development": "-54.6",
"Cost of Goods Sold": "2.06",
"Other Revenues": "-16.0",
"Liabilities, Current": "-7.43",
"Other Liabilities": "3.26",
"Comprehensive Net Income": "-73.4",
"Other Net Income": "2.81",
"Economic Capital Ratio": "-190"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001072379_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "7,458",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "10,744",
"Liabilities, Non-Current": "1,882",
"Other Assets": "17",
"Other Compr. Net Income": "0",
"Other Expenses": "24,110",
"Other Liabilities": "0",
"Other Net Income": "601",
"Other Revenues": "772",
"Property and Equipment": "95",
"Research and Development": "28,908",
"Selling, General and Administrative Expense": "15,675"
},
"output_variables": {
"Assets": "7,570",
"Liabilities": "12,626",
"Expenses": "68,693",
"Revenues": "772",
"Stockholders Equity": "-5,056",
"Net Income": "-67,320",
"Comprehensive Net Income": "-67,320",
"BaseVar": "45,131",
"ECR before LimitedLiability": "-776%",
"Economic Capital Ratio": "1.1%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "18,646",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "19,689",
"Liabilities, Non-Current": "0",
"Other Assets": "55",
"Other Compr. Net Income": "0",
"Other Expenses": "11,484",
"Other Liabilities": "0",
"Other Net Income": "1,156",
"Other Revenues": "809",
"Property and Equipment": "83",
"Research and Development": "43,906",
"Selling, General and Administrative Expense": "12,364"
},
"output_variables": {
"Assets": "18,784",
"Liabilities": "19,689",
"Expenses": "67,754",
"Revenues": "809",
"Stockholders Equity": "-905",
"Net Income": "-65,789",
"Comprehensive Net Income": "-65,789",
"BaseVar": "54,096",
"ECR before LimitedLiability": "-352%",
"Economic Capital Ratio": "52%"
}
}
},
"top_rated": false,
"trend": -6.0,
"value": 0.522696838453518,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001072379.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001072379.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001072379.svg"
},
{
"company_id": "0001410098",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001410098.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001410098.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001410098.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001410098_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001410098_main_keyfigs.svg",
"name": "Cormedix Inc",
"rank": 220,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001410098.svg",
"report_text": "The relative strengths and weaknesses of Cormedix Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cormedix Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 5.0% points.The greatest weakness of Cormedix Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 93% points.
The company's Economic Capital Ratio, given in the ranking table, is 50%, being 193% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001410098_2014_Cormedix_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "0",
"Assets": "-131",
"Stockholders Equity": "0",
"ECR before LimitedLiability": "-159",
"Intangible Assets": "0",
"Property and Equipment": "0",
"Assets, Current": "-67.7",
"Other Liabilities": "0",
"Liabilities": "-0.0147",
"Liabilities, Non-Current": "0",
"Liabilities, Current": "0",
"Research and Development": "0",
"Expenses": "-6.49",
"Net Income": "-49.2",
"Other Expenses": "0",
"Cost of Goods Sold": "0",
"Selling, General and Administrative Expense": "0",
"Other Revenues": "0",
"Revenues": "0",
"Comprehensive Net Income": "-50.1",
"Economic Capital Ratio": "-234"
},
"2012": {
"Property and Equipment": "-14.1",
"Assets": "-64.2",
"Liabilities": "-9.86",
"Stockholders Equity": "-73.6",
"ECR before LimitedLiability": "-85.1",
"Assets, Current": "-34.8",
"Intangible Assets": "-20.4",
"Other Assets": "-13.7",
"Liabilities, Current": "-21.6",
"Other Liabilities": "3.39",
"Liabilities, Non-Current": "1.70",
"Selling, General and Administrative Expense": "-27.3",
"Expenses": "-34.1",
"Revenues": "-16.6",
"Net Income": "-49.1",
"Research and Development": "-10.3",
"Cost of Goods Sold": "2.50",
"Other Revenues": "-16.6",
"Comprehensive Net Income": "-49.0",
"Other Net Income": "1.29",
"Economic Capital Ratio": "-158"
},
"2013": {
"Other Assets": "-13.8",
"Assets": "-78.6",
"Liabilities": "-13.3",
"Stockholders Equity": "-92.6",
"ECR before LimitedLiability": "-165",
"Intangible Assets": "-18.1",
"Property and Equipment": "-9.64",
"Assets, Current": "-57.6",
"Liabilities, Non-Current": "0.805",
"Other Liabilities": "-17.8",
"Selling, General and Administrative Expense": "-8.32",
"Expenses": "-9.72",
"Revenues": "-11.5",
"Net Income": "-34.9",
"Other Expenses": "-8.09",
"Research and Development": "4.97",
"Cost of Goods Sold": "1.38",
"Other Revenues": "-11.5",
"Comprehensive Net Income": "-35.1",
"Other Net Income": "-11.6",
"Economic Capital Ratio": "-193"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001410098_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,531",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,305",
"Liabilities, Non-Current": "0",
"Other Assets": "13",
"Other Compr. Net Income": "0",
"Other Expenses": "10,418",
"Other Liabilities": "14",
"Other Net Income": "124",
"Other Revenues": "421",
"Property and Equipment": "12",
"Research and Development": "22,156",
"Selling, General and Administrative Expense": "10,919"
},
"output_variables": {
"Assets": "2,556",
"Liabilities": "1,319",
"Expenses": "43,493",
"Revenues": "421",
"Stockholders Equity": "1,237",
"Net Income": "-42,948",
"Comprehensive Net Income": "-42,948",
"BaseVar": "23,957",
"ECR before LimitedLiability": "-2,077%",
"Economic Capital Ratio": "0.00000000000014%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,135",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,616",
"Liabilities, Non-Current": "0",
"Other Assets": "13",
"Other Compr. Net Income": "0",
"Other Expenses": "383",
"Other Liabilities": "12",
"Other Net Income": "2.0",
"Other Revenues": "0",
"Property and Equipment": "4.7",
"Research and Development": "1,188",
"Selling, General and Administrative Expense": "1,857"
},
"output_variables": {
"Assets": "1,153",
"Liabilities": "1,629",
"Expenses": "3,428",
"Revenues": "0",
"Stockholders Equity": "-475",
"Net Income": "-3,426",
"Comprehensive Net Income": "-3,426",
"BaseVar": "3,106",
"ECR before LimitedLiability": "-321%",
"Economic Capital Ratio": "62%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,916",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,674",
"Liabilities, Non-Current": "0",
"Other Assets": "16",
"Other Compr. Net Income": "0",
"Other Expenses": "2,390",
"Other Liabilities": "5,316",
"Other Net Income": "-2,023",
"Other Revenues": "-4.5",
"Property and Equipment": "36",
"Research and Development": "1,227",
"Selling, General and Administrative Expense": "3,489"
},
"output_variables": {
"Assets": "2,968",
"Liabilities": "6,990",
"Expenses": "7,106",
"Revenues": "-4.5",
"Stockholders Equity": "-4,022",
"Net Income": "-9,133",
"Comprehensive Net Income": "-9,133",
"BaseVar": "9,546",
"ECR before LimitedLiability": "-360%",
"Economic Capital Ratio": "50%"
}
}
},
"top_rated": false,
"trend": -33.0,
"value": 0.5014387256677053,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001410098.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001410098.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001410098.svg"
},
{
"company_id": "0001438533",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001438533.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001438533.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001438533.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001438533_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001438533_main_keyfigs.svg",
"name": "Travere Therapeutics Inc",
"rank": 221,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001438533.svg",
"report_text": "The relative strengths and weaknesses of Travere Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Travere Therapeutics Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 30% points.The greatest weakness of Travere Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 91% points.
The company's Economic Capital Ratio, given in the ranking table, is 49%, being 194% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001438533_2014_Travere_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "30.4",
"Assets": "-82.2",
"Liabilities": "-8.32",
"Stockholders Equity": "-91.3",
"ECR before LimitedLiability": "-166",
"Intangible Assets": "-20.1",
"Property and Equipment": "-11.2",
"Assets, Current": "-82.9",
"Liabilities, Current": "-13.4",
"Other Liabilities": "1.13",
"Selling, General and Administrative Expense": "-2.81",
"Expenses": "2.63",
"Revenues": "-12.7",
"Net Income": "-46.9",
"Other Expenses": "-2.84",
"Research and Development": "6.45",
"Cost of Goods Sold": "1.53",
"Other Revenues": "-12.7",
"Comprehensive Net Income": "-47.1",
"Other Net Income": "-35.7",
"Economic Capital Ratio": "-194"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001438533_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "7,501",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "35,210",
"Liabilities, Non-Current": "0",
"Other Assets": "12,870",
"Other Compr. Net Income": "-110",
"Other Expenses": "9,851",
"Other Liabilities": "3,601",
"Other Net Income": "-33,748",
"Other Revenues": "0",
"Property and Equipment": "127",
"Research and Development": "7,084",
"Selling, General and Administrative Expense": "16,888"
},
"output_variables": {
"Assets": "20,499",
"Liabilities": "38,811",
"Expenses": "33,824",
"Revenues": "0",
"Stockholders Equity": "-18,312",
"Net Income": "-67,571",
"Comprehensive Net Income": "-67,626",
"BaseVar": "63,495",
"ECR before LimitedLiability": "-363%",
"Economic Capital Ratio": "49%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.49250437999615193,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001438533.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001438533.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001438533.svg"
},
{
"company_id": "0001124524",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001124524.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001124524.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001124524.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001124524_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001124524_main_keyfigs.svg",
"name": "Cryoport Inc",
"rank": 222,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001124524.svg",
"report_text": "The relative strengths and weaknesses of Cryoport Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cryoport Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 9.8% points.The greatest weakness of Cryoport Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 116% points.
The company's Economic Capital Ratio, given in the ranking table, is 42%, being 201% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001124524_2014_Cryoport_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-12.9",
"Assets": "67.2",
"Liabilities": "-40.3",
"Stockholders Equity": "31.6",
"ECR before LimitedLiability": "59.3",
"Intangible Assets": "-11.5",
"Assets, Current": "78.7",
"Other Liabilities": "-21.6",
"Liabilities, Non-Current": "11.5",
"Liabilities, Current": "-30.1",
"Research and Development": "29.7",
"Expenses": "13.7",
"Revenues": "-23.9",
"Net Income": "-14.3",
"Other Expenses": "10.7",
"Cost of Goods Sold": "-9.39",
"Selling, General and Administrative Expense": "-15.7",
"Other Revenues": "-23.9",
"Comprehensive Net Income": "-14.6",
"Other Net Income": "-3.33",
"Economic Capital Ratio": "-16.3"
},
"2012": {
"Property and Equipment": "6.80",
"Assets": "2.62",
"Liabilities": "7.12",
"Stockholders Equity": "7.28",
"Assets, Current": "7.68",
"Intangible Assets": "-14.7",
"Other Assets": "-21.5",
"Liabilities, Current": "7.40",
"Economic Capital Ratio": "-72.2",
"Other Liabilities": "-27.1",
"Liabilities, Non-Current": "6.95",
"Selling, General and Administrative Expense": "-82.4",
"Expenses": "-48.4",
"Revenues": "-31.2",
"Net Income": "-80.4",
"Research and Development": "7.86",
"Other Expenses": "7.29",
"Cost of Goods Sold": "-23.7",
"Other Revenues": "-31.2",
"Comprehensive Net Income": "-80.2",
"Other Net Income": "-5.44"
},
"2013": {
"Other Assets": "-17.3",
"Assets": "-96.5",
"Liabilities": "-3.76",
"Stockholders Equity": "-116",
"ECR before LimitedLiability": "-173",
"Intangible Assets": "-12.3",
"Property and Equipment": "6.38",
"Assets, Current": "-91.9",
"Liabilities, Current": "-2.83",
"Other Liabilities": "-1.29",
"Selling, General and Administrative Expense": "-43.1",
"Expenses": "-37.7",
"Revenues": "-2.80",
"Net Income": "-40.0",
"Other Expenses": "6.25",
"Research and Development": "9.84",
"Cost of Goods Sold": "-14.3",
"Other Revenues": "-2.80",
"Comprehensive Net Income": "-40.2",
"Other Net Income": "1.01",
"Economic Capital Ratio": "-201"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001124524_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "9,998",
"Cost of Goods Sold": "1,303",
"Intangible Assets": "355",
"Liabilities, Current": "3,238",
"Liabilities, Non-Current": "0",
"Other Assets": "9.4",
"Other Compr. Net Income": "0",
"Other Expenses": "1.6",
"Other Liabilities": "1,845",
"Other Net Income": "-554",
"Other Revenues": "476",
"Property and Equipment": "670",
"Research and Development": "449",
"Selling, General and Administrative Expense": "4,320"
},
"output_variables": {
"Assets": "11,031",
"Liabilities": "5,083",
"Expenses": "6,074",
"Revenues": "476",
"Stockholders Equity": "5,948",
"Net Income": "-6,152",
"Comprehensive Net Income": "-6,152",
"BaseVar": "11,609",
"ECR before LimitedLiability": "85%",
"Economic Capital Ratio": "218%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "5,133",
"Cost of Goods Sold": "1,392",
"Intangible Assets": "379",
"Liabilities, Current": "1,109",
"Liabilities, Non-Current": "0",
"Other Assets": "20",
"Other Compr. Net Income": "0",
"Other Expenses": "1.6",
"Other Liabilities": "1,375",
"Other Net Income": "-397",
"Other Revenues": "556",
"Property and Equipment": "682",
"Research and Development": "492",
"Selling, General and Administrative Expense": "6,106"
},
"output_variables": {
"Assets": "6,214",
"Liabilities": "2,484",
"Expenses": "7,992",
"Revenues": "556",
"Stockholders Equity": "3,730",
"Net Income": "-7,833",
"Comprehensive Net Income": "-7,833",
"BaseVar": "8,821",
"ECR before LimitedLiability": "6.8%",
"Economic Capital Ratio": "148%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "958",
"Cost of Goods Sold": "1,588",
"Intangible Assets": "272",
"Liabilities, Current": "2,497",
"Liabilities, Non-Current": "0",
"Other Assets": "20",
"Other Compr. Net Income": "0",
"Other Expenses": "74",
"Other Liabilities": "1,322",
"Other Net Income": "16",
"Other Revenues": "1,101",
"Property and Equipment": "505",
"Research and Development": "425",
"Selling, General and Administrative Expense": "5,412"
},
"output_variables": {
"Assets": "1,756",
"Liabilities": "3,819",
"Expenses": "7,499",
"Revenues": "1,101",
"Stockholders Equity": "-2,063",
"Net Income": "-6,382",
"Comprehensive Net Income": "-6,382",
"BaseVar": "7,096",
"ECR before LimitedLiability": "-390%",
"Economic Capital Ratio": "42%"
}
}
},
"top_rated": false,
"trend": -79.0,
"value": 0.416872657723287,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001124524.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001124524.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001124524.svg"
},
{
"company_id": "0001422143",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001422143.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001422143.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001422143_main_keyfigs.svg",
"name": "Kura Oncology Inc",
"rank": 223,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001422143.svg",
"report_text": "The relative strengths and weaknesses of Kura Oncology Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Kura Oncology Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 12% points.The greatest weakness of Kura Oncology Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 176% points.
The company's Economic Capital Ratio, given in the ranking table, is 34%, being 209% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001422143_2014_Kura_Oncology_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "4.84",
"Assets": "-77.8",
"Liabilities": "-10.1",
"Stockholders Equity": "-176",
"ECR before LimitedLiability": "-181",
"Intangible Assets": "-10.1",
"Property and Equipment": "-5.76",
"Assets, Current": "-70.4",
"Liabilities, Current": "0.378",
"Other Liabilities": "-28.0",
"Selling, General and Administrative Expense": "5.76",
"Expenses": "12.2",
"Revenues": "-5.72",
"Net Income": "1.57",
"Other Expenses": "1.11",
"Research and Development": "5.76",
"Cost of Goods Sold": "0.692",
"Other Revenues": "-5.72",
"Comprehensive Net Income": "1.51",
"Other Net Income": "-7.48",
"Economic Capital Ratio": "-209"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001422143_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "0",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "0.35",
"Liabilities, Non-Current": "0",
"Other Assets": "9.1",
"Other Compr. Net Income": "0",
"Other Expenses": "5.9",
"Other Liabilities": "133",
"Other Net Income": "-23",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "9.1",
"Liabilities": "133",
"Expenses": "5.9",
"Revenues": "0",
"Stockholders Equity": "-124",
"Net Income": "-29",
"Comprehensive Net Income": "-29",
"BaseVar": "85",
"ECR before LimitedLiability": "-421%",
"Economic Capital Ratio": "34%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.34250890314061294,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001422143.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001422143.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001422143.svg"
},
{
"company_id": "0001422142",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001422142.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001422142.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001422142.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001422142_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001422142_main_keyfigs.svg",
"name": "Whitehawk Therapeutics Inc",
"rank": 224,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001422142.svg",
"report_text": "The relative strengths and weaknesses of Whitehawk Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Whitehawk Therapeutics Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 12% points.The greatest weakness of Whitehawk Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 177% points.
The company's Economic Capital Ratio, given in the ranking table, is 34%, being 209% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001422142_2014_Whitehawk_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "4.45",
"Assets": "-78.1",
"Liabilities": "-8.82",
"Stockholders Equity": "-177",
"ECR before LimitedLiability": "-181",
"Intangible Assets": "-10.1",
"Property and Equipment": "-5.73",
"Assets, Current": "-70.4",
"Liabilities, Current": "-15.5",
"Other Liabilities": "0.192",
"Selling, General and Administrative Expense": "5.71",
"Expenses": "12.1",
"Revenues": "-5.68",
"Net Income": "1.52",
"Other Expenses": "1.10",
"Research and Development": "5.72",
"Cost of Goods Sold": "0.687",
"Other Revenues": "-5.68",
"Comprehensive Net Income": "1.46",
"Other Net Income": "-7.47",
"Economic Capital Ratio": "-209"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001422142_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "0",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "133",
"Liabilities, Non-Current": "0",
"Other Assets": "8.8",
"Other Compr. Net Income": "0",
"Other Expenses": "5.9",
"Other Liabilities": "0",
"Other Net Income": "-23",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "8.8",
"Liabilities": "133",
"Expenses": "5.9",
"Revenues": "0",
"Stockholders Equity": "-124",
"Net Income": "-29",
"Comprehensive Net Income": "-29",
"BaseVar": "85",
"ECR before LimitedLiability": "-422%",
"Economic Capital Ratio": "34%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.3382650466759745,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001422142.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001422142.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001422142.svg"
},
{
"company_id": "0001409565",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001409565.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001409565.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001409565_main_keyfigs.svg",
"name": "Puramed Bioscience Inc",
"rank": 225,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001409565.svg",
"report_text": "The relative strengths and weaknesses of Puramed Bioscience Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Puramed Bioscience Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 6.2% points.The greatest weakness of Puramed Bioscience Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 149% points.
The company's Economic Capital Ratio, given in the ranking table, is 32%, being 211% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001409565_2014_Puramed_Bioscience_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.46",
"Assets": "-80.2",
"Liabilities": "-6.71",
"Stockholders Equity": "-100",
"ECR before LimitedLiability": "-119",
"Property and Equipment": "-11.0",
"Assets, Current": "-71.5",
"Other Liabilities": "-0.402",
"Liabilities, Non-Current": "0.350",
"Liabilities, Current": "-6.65",
"Research and Development": "11.1",
"Expenses": "-5.55",
"Revenues": "-13.7",
"Net Income": "-37.0",
"Other Expenses": "-34.1",
"Cost of Goods Sold": "1.61",
"Selling, General and Administrative Expense": "8.69",
"Other Revenues": "-13.7",
"Comprehensive Net Income": "-37.2",
"Other Net Income": "-14.2",
"Economic Capital Ratio": "-195"
},
"2012": {
"Property and Equipment": "-13.9",
"Assets": "-104",
"Liabilities": "-0.290",
"Stockholders Equity": "-134",
"ECR before LimitedLiability": "-116",
"Assets, Current": "-94.3",
"Intangible Assets": "-11.8",
"Other Assets": "-4.41",
"Liabilities, Current": "-0.632",
"Selling, General and Administrative Expense": "8.38",
"Expenses": "-11.0",
"Revenues": "2.99",
"Net Income": "-16.8",
"Research and Development": "11.7",
"Other Expenses": "-46.4",
"Cost of Goods Sold": "2.02",
"Other Revenues": "2.99",
"Comprehensive Net Income": "-16.7",
"Other Net Income": "-8.29",
"Other Compr. Net Income": "0.0865",
"Economic Capital Ratio": "-189"
},
"2013": {
"Other Assets": "-4.11",
"Assets": "-87.7",
"Liabilities": "-1.25",
"Stockholders Equity": "-149",
"ECR before LimitedLiability": "-183",
"Intangible Assets": "-10.8",
"Property and Equipment": "-7.07",
"Assets, Current": "-73.6",
"Liabilities, Current": "-2.13",
"Selling, General and Administrative Expense": "4.97",
"Expenses": "-4.98",
"Revenues": "-6.66",
"Net Income": "-11.7",
"Other Expenses": "-20.7",
"Research and Development": "6.24",
"Cost of Goods Sold": "0.859",
"Other Revenues": "-6.66",
"Comprehensive Net Income": "-11.8",
"Other Net Income": "0.445",
"Other Compr. Net Income": "-0.0765",
"Economic Capital Ratio": "-211"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001409565_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "192",
"Cost of Goods Sold": "0",
"Intangible Assets": "134",
"Liabilities, Current": "856",
"Liabilities, Non-Current": "0",
"Other Assets": "69",
"Other Compr. Net Income": "0",
"Other Expenses": "957",
"Other Liabilities": "192",
"Other Net Income": "-402",
"Other Revenues": "8.6",
"Property and Equipment": "8.8",
"Research and Development": "59",
"Selling, General and Administrative Expense": "80"
},
"output_variables": {
"Assets": "404",
"Liabilities": "1,048",
"Expenses": "1,096",
"Revenues": "8.6",
"Stockholders Equity": "-644",
"Net Income": "-1,489",
"Comprehensive Net Income": "-1,489",
"BaseVar": "1,479",
"ECR before LimitedLiability": "-399%",
"Economic Capital Ratio": "40%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "209",
"Cost of Goods Sold": "0",
"Intangible Assets": "86",
"Liabilities, Current": "1,467",
"Liabilities, Non-Current": "0",
"Other Assets": "98",
"Other Compr. Net Income": "0",
"Other Expenses": "1,843",
"Other Liabilities": "0",
"Other Net Income": "-373",
"Other Revenues": "693",
"Property and Equipment": "7.2",
"Research and Development": "18",
"Selling, General and Administrative Expense": "181"
},
"output_variables": {
"Assets": "400",
"Liabilities": "1,467",
"Expenses": "2,042",
"Revenues": "693",
"Stockholders Equity": "-1,066",
"Net Income": "-1,721",
"Comprehensive Net Income": "-1,721",
"BaseVar": "2,487",
"ECR before LimitedLiability": "-433%",
"Economic Capital Ratio": "31%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "326",
"Cost of Goods Sold": "0",
"Intangible Assets": "38",
"Liabilities, Current": "3,171",
"Liabilities, Non-Current": "0",
"Other Assets": "108",
"Other Compr. Net Income": "0",
"Other Expenses": "1,778",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "43",
"Property and Equipment": "4.9",
"Research and Development": "75",
"Selling, General and Administrative Expense": "195"
},
"output_variables": {
"Assets": "476",
"Liabilities": "3,171",
"Expenses": "2,048",
"Revenues": "43",
"Stockholders Equity": "-2,695",
"Net Income": "-2,006",
"Comprehensive Net Income": "-2,006",
"BaseVar": "2,869",
"ECR before LimitedLiability": "-432%",
"Economic Capital Ratio": "32%"
}
}
},
"top_rated": false,
"trend": -21.0,
"value": 0.31672861449009426,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001409565.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001409565.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001409565.svg"
},
{
"company_id": "0000805326",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000805326.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000805326.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000805326_main_keyfigs.svg",
"name": "Emisphere Technologies INC",
"rank": 226,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000805326.svg",
"report_text": "The relative strengths and weaknesses of Emisphere Technologies INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Emisphere Technologies INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 10% points.The greatest weakness of Emisphere Technologies INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 178% points.
The company's Economic Capital Ratio, given in the ranking table, is 31%, being 212% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000805326_2014_Emisphere_Technologies_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-7.58",
"Assets": "-80.3",
"Liabilities": "-0.959",
"Stockholders Equity": "-178",
"ECR before LimitedLiability": "-184",
"Intangible Assets": "-9.85",
"Property and Equipment": "-5.51",
"Assets, Current": "-62.7",
"Other Liabilities": "-1.56",
"Selling, General and Administrative Expense": "2.71",
"Expenses": "10.3",
"Revenues": "-5.46",
"Net Income": "0.964",
"Other Expenses": "2.78",
"Research and Development": "5.13",
"Cost of Goods Sold": "0.658",
"Other Revenues": "-5.46",
"Comprehensive Net Income": "0.906",
"Other Net Income": "-5.95",
"Other Compr. Net Income": "-0.0585",
"Economic Capital Ratio": "-212"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000805326_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "4,905",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,303",
"Liabilities, Non-Current": "0",
"Other Assets": "34",
"Other Compr. Net Income": "0",
"Other Expenses": "47",
"Other Liabilities": "85,477",
"Other Net Income": "-13,307",
"Other Revenues": "0",
"Property and Equipment": "40",
"Research and Development": "836",
"Selling, General and Administrative Expense": "6,749"
},
"output_variables": {
"Assets": "4,979",
"Liabilities": "91,780",
"Expenses": "7,632",
"Revenues": "0",
"Stockholders Equity": "-86,801",
"Net Income": "-20,939",
"Comprehensive Net Income": "-20,939",
"BaseVar": "58,849",
"ECR before LimitedLiability": "-434%",
"Economic Capital Ratio": "31%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.3116833105289955,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000805326.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000805326.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000805326.svg"
},
{
"company_id": "0001509261",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001509261.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001509261.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001509261_main_keyfigs.svg",
"name": "Rezolute Inc",
"rank": 227,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001509261.svg",
"report_text": "The relative strengths and weaknesses of Rezolute Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Rezolute Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 11% points.The greatest weakness of Rezolute Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 121% points.
The company's Economic Capital Ratio, given in the ranking table, is 20%, being 223% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001509261_2014_Rezolute_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-10.3",
"Assets": "-103",
"Liabilities": "6.93",
"Stockholders Equity": "-121",
"ECR before LimitedLiability": "-195",
"Intangible Assets": "-13.9",
"Property and Equipment": "-0.815",
"Assets, Current": "-86.2",
"Liabilities, Current": "11.2",
"Other Liabilities": "-0.973",
"Selling, General and Administrative Expense": "6.07",
"Expenses": "-14.0",
"Revenues": "-7.09",
"Net Income": "-28.7",
"Other Expenses": "-40.0",
"Research and Development": "6.17",
"Cost of Goods Sold": "0.796",
"Other Revenues": "-7.09",
"Comprehensive Net Income": "-28.8",
"Other Net Income": "-2.76",
"Economic Capital Ratio": "-223"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001509261_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "816",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "5,266",
"Liabilities, Non-Current": "0",
"Other Assets": "13",
"Other Compr. Net Income": "0",
"Other Expenses": "6,075",
"Other Liabilities": "0",
"Other Net Income": "-621",
"Other Revenues": "0",
"Property and Equipment": "276",
"Research and Development": "3.5",
"Selling, General and Administrative Expense": "29"
},
"output_variables": {
"Assets": "1,104",
"Liabilities": "5,266",
"Expenses": "6,107",
"Revenues": "0",
"Stockholders Equity": "-4,162",
"Net Income": "-6,727",
"Comprehensive Net Income": "-6,727",
"BaseVar": "6,549",
"ECR before LimitedLiability": "-496%",
"Economic Capital Ratio": "20%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.19691679476544552,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001509261.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001509261.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001509261.svg"
},
{
"company_id": "0000811779",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000811779.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000811779.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000811779_main_keyfigs.svg",
"name": "Multicell Technologies Inc",
"rank": 228,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000811779.svg",
"report_text": "The relative strengths and weaknesses of Multicell Technologies Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Multicell Technologies Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 11% points.The greatest weakness of Multicell Technologies Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 149% points.
The company's Economic Capital Ratio, given in the ranking table, is 20%, being 223% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000811779_2014_Multicell_Technologies_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-14.3",
"Assets": "-76.1",
"Liabilities": "-21.8",
"Stockholders Equity": "-128",
"ECR before LimitedLiability": "-109",
"Intangible Assets": "-19.0",
"Property and Equipment": "-12.0",
"Assets, Current": "-49.8",
"Liabilities, Non-Current": "-5.67",
"Liabilities, Current": "-12.9",
"Research and Development": "13.7",
"Expenses": "-8.62",
"Revenues": "-13.3",
"Net Income": "-14.2",
"Other Expenses": "-6.59",
"Cost of Goods Sold": "1.68",
"Selling, General and Administrative Expense": "-20.2",
"Other Revenues": "-13.3",
"Comprehensive Net Income": "-14.3",
"Other Net Income": "7.19",
"Economic Capital Ratio": "-184"
},
"2012": {
"Property and Equipment": "-9.01",
"Assets": "-96.1",
"Liabilities": "8.36",
"Stockholders Equity": "-136",
"ECR before LimitedLiability": "-124",
"Assets, Current": "-71.8",
"Intangible Assets": "-13.2",
"Other Assets": "-9.24",
"Liabilities, Current": "5.00",
"Liabilities, Non-Current": "2.24",
"Selling, General and Administrative Expense": "-7.77",
"Expenses": "-6.49",
"Revenues": "-7.38",
"Net Income": "-9.47",
"Research and Development": "7.02",
"Other Expenses": "-9.25",
"Cost of Goods Sold": "1.16",
"Other Revenues": "-7.38",
"Comprehensive Net Income": "-9.41",
"Other Net Income": "3.95",
"Economic Capital Ratio": "-198"
},
"2013": {
"Other Assets": "-8.97",
"Assets": "-99.9",
"Liabilities": "10.6",
"Stockholders Equity": "-149",
"ECR before LimitedLiability": "-195",
"Intangible Assets": "-11.7",
"Property and Equipment": "-6.49",
"Assets, Current": "-78.5",
"Liabilities, Non-Current": "2.37",
"Liabilities, Current": "7.50",
"Other Liabilities": "-0.854",
"Selling, General and Administrative Expense": "-9.46",
"Expenses": "-8.09",
"Revenues": "-4.99",
"Net Income": "-13.9",
"Other Expenses": "-0.619",
"Research and Development": "0.960",
"Cost of Goods Sold": "0.680",
"Other Revenues": "-4.99",
"Comprehensive Net Income": "-14.0",
"Economic Capital Ratio": "-223"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000811779_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "719",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,706",
"Liabilities, Non-Current": "769",
"Other Assets": "1.7",
"Other Compr. Net Income": "0",
"Other Expenses": "622",
"Other Liabilities": "0",
"Other Net Income": "360",
"Other Revenues": "49",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "1,739"
},
"output_variables": {
"Assets": "721",
"Liabilities": "2,474",
"Expenses": "2,361",
"Revenues": "49",
"Stockholders Equity": "-1,754",
"Net Income": "-1,952",
"Comprehensive Net Income": "-1,952",
"BaseVar": "2,983",
"ECR before LimitedLiability": "-361%",
"Economic Capital Ratio": "50%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "211",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,255",
"Liabilities, Non-Current": "574",
"Other Assets": "0.28",
"Other Compr. Net Income": "0",
"Other Expenses": "754",
"Other Liabilities": "0",
"Other Net Income": "216",
"Other Revenues": "49",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "870"
},
"output_variables": {
"Assets": "211",
"Liabilities": "1,830",
"Expenses": "1,624",
"Revenues": "49",
"Stockholders Equity": "-1,618",
"Net Income": "-1,359",
"Comprehensive Net Income": "-1,359",
"BaseVar": "1,965",
"ECR before LimitedLiability": "-479%",
"Economic Capital Ratio": "23%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "179",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,279",
"Liabilities, Non-Current": "468",
"Other Assets": "0.28",
"Other Compr. Net Income": "0",
"Other Expenses": "224",
"Other Liabilities": "0",
"Other Net Income": "-1.4",
"Other Revenues": "49",
"Property and Equipment": "0",
"Research and Development": "314",
"Selling, General and Administrative Expense": "879"
},
"output_variables": {
"Assets": "179",
"Liabilities": "1,747",
"Expenses": "1,417",
"Revenues": "49",
"Stockholders Equity": "-1,567",
"Net Income": "-1,369",
"Comprehensive Net Income": "-1,369",
"BaseVar": "1,697",
"ECR before LimitedLiability": "-497%",
"Economic Capital Ratio": "20%"
}
}
},
"top_rated": false,
"trend": -21.0,
"value": 0.1952970781814731,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000811779.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000811779.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000811779.svg"
},
{
"company_id": "0001140098",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001140098.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001140098.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001140098_main_keyfigs.svg",
"name": "Ocata Therapeutics Inc",
"rank": 229,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001140098.svg",
"report_text": "The relative strengths and weaknesses of Ocata Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ocata Therapeutics Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 9.8% points.The greatest weakness of Ocata Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 126% points.
The company's Economic Capital Ratio, given in the ranking table, is 15%, being 228% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001140098_2014_Ocata_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.30",
"Assets": "-88.4",
"Liabilities": "3.17",
"Stockholders Equity": "-113",
"ECR before LimitedLiability": "-131",
"Intangible Assets": "-16.9",
"Property and Equipment": "-9.93",
"Assets, Current": "-61.0",
"Other Liabilities": "7.53",
"Liabilities, Current": "-0.537",
"Research and Development": "5.28",
"Expenses": "11.3",
"Revenues": "-10.7",
"Net Income": "-28.7",
"Other Expenses": "3.23",
"Cost of Goods Sold": "1.04",
"Selling, General and Administrative Expense": "3.30",
"Other Revenues": "-10.7",
"Comprehensive Net Income": "-28.8",
"Other Net Income": "-35.1",
"Economic Capital Ratio": "-207"
},
"2012": {
"Property and Equipment": "-9.63",
"Assets": "-73.5",
"Liabilities": "-11.5",
"Stockholders Equity": "-99.1",
"ECR before LimitedLiability": "-105",
"Assets, Current": "-51.5",
"Intangible Assets": "-15.3",
"Other Assets": "-6.40",
"Liabilities, Current": "-9.18",
"Other Liabilities": "-1.20",
"Liabilities, Non-Current": "0.444",
"Other Revenues": "-11.1",
"Revenues": "-11.1",
"Net Income": "-22.1",
"Other Net Income": "-9.59",
"Comprehensive Net Income": "-22.0",
"Research and Development": "-4.44",
"Selling, General and Administrative Expense": "-4.02",
"Other Expenses": "6.08",
"Cost of Goods Sold": "1.62",
"Economic Capital Ratio": "-178"
},
"2013": {
"Other Assets": "-7.88",
"Assets": "-106",
"Liabilities": "8.99",
"Stockholders Equity": "-126",
"ECR before LimitedLiability": "-200",
"Intangible Assets": "-12.0",
"Property and Equipment": "-3.00",
"Assets, Current": "-86.8",
"Liabilities, Non-Current": "-0.460",
"Liabilities, Current": "9.85",
"Selling, General and Administrative Expense": "-4.99",
"Expenses": "-13.2",
"Revenues": "-5.78",
"Net Income": "-23.3",
"Other Expenses": "-2.57",
"Research and Development": "-4.47",
"Cost of Goods Sold": "0.640",
"Other Revenues": "-5.78",
"Comprehensive Net Income": "-23.4",
"Other Net Income": "-0.663",
"Economic Capital Ratio": "-228"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001140098_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "13,407",
"Cost of Goods Sold": "344",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "1,624",
"Other Compr. Net Income": "0",
"Other Expenses": "226",
"Other Liabilities": "59,880",
"Other Net Income": "-51,685",
"Other Revenues": "506",
"Property and Equipment": "155",
"Research and Development": "10,022",
"Selling, General and Administrative Expense": "11,025"
},
"output_variables": {
"Assets": "15,185",
"Liabilities": "59,880",
"Expenses": "21,617",
"Revenues": "506",
"Stockholders Equity": "-44,695",
"Net Income": "-72,795",
"Comprehensive Net Income": "-72,795",
"BaseVar": "74,437",
"ECR before LimitedLiability": "-454%",
"Economic Capital Ratio": "27%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "7,553",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "22,205",
"Liabilities, Non-Current": "0",
"Other Assets": "769",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "6,552",
"Other Net Income": "-7,039",
"Other Revenues": "0",
"Property and Equipment": "175",
"Research and Development": "11,035",
"Selling, General and Administrative Expense": "10,452"
},
"output_variables": {
"Assets": "8,497",
"Liabilities": "28,757",
"Expenses": "21,487",
"Revenues": "0",
"Stockholders Equity": "-20,260",
"Net Income": "-28,526",
"Comprehensive Net Income": "-28,526",
"BaseVar": "32,890",
"ECR before LimitedLiability": "-390%",
"Economic Capital Ratio": "42%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "2,912",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "22,917",
"Liabilities, Non-Current": "0",
"Other Assets": "242",
"Other Compr. Net Income": "0",
"Other Expenses": "6,229",
"Other Liabilities": "3,525",
"Other Net Income": "-1,172",
"Other Revenues": "0",
"Property and Equipment": "754",
"Research and Development": "11,565",
"Selling, General and Administrative Expense": "12,057"
},
"output_variables": {
"Assets": "3,908",
"Liabilities": "26,442",
"Expenses": "29,850",
"Revenues": "0",
"Stockholders Equity": "-22,534",
"Net Income": "-31,022",
"Comprehensive Net Income": "-31,022",
"BaseVar": "30,686",
"ECR before LimitedLiability": "-528%",
"Economic Capital Ratio": "15%"
}
}
},
"top_rated": false,
"trend": -31.0,
"value": 0.1514309623222601,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001140098.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001140098.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001140098.svg"
},
{
"company_id": "0001366541",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001366541.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001366541.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001366541_main_keyfigs.svg",
"name": "Q Therapeutics Inc",
"rank": 230,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001366541.svg",
"report_text": "The relative strengths and weaknesses of Q Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Q Therapeutics Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 11% points.The greatest weakness of Q Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 130% points.
The company's Economic Capital Ratio, given in the ranking table, is 11%, being 232% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001366541_2014_Q_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-9.91",
"Assets": "50.1",
"Liabilities": "80.1",
"Stockholders Equity": "152",
"ECR before LimitedLiability": "136",
"Intangible Assets": "-13.3",
"Property and Equipment": "-7.10",
"Assets, Current": "140",
"Other Liabilities": "35.3",
"Liabilities, Non-Current": "15.3",
"Liabilities, Current": "34.2",
"Other Revenues": "-25.1",
"Revenues": "-25.1",
"Net Income": "-57.9",
"Research and Development": "17.9",
"Comprehensive Net Income": "-58.2",
"Cost of Goods Sold": "4.20",
"Selling, General and Administrative Expense": "-36.2",
"Other Expenses": "11.9",
"Other Net Income": "-30.0",
"Economic Capital Ratio": "60.2"
},
"2012": {
"Property and Equipment": "-13.5",
"Assets": "-47.6",
"Liabilities": "-5.00",
"Stockholders Equity": "-48.6",
"ECR before LimitedLiability": "-55.9",
"Assets, Current": "-28.4",
"Intangible Assets": "-20.1",
"Other Assets": "-14.5",
"Liabilities, Current": "-21.6",
"Other Liabilities": "7.56",
"Liabilities, Non-Current": "3.66",
"Selling, General and Administrative Expense": "-17.4",
"Expenses": "-32.9",
"Revenues": "-6.83",
"Net Income": "-36.6",
"Research and Development": "-30.8",
"Other Expenses": "12.1",
"Cost of Goods Sold": "3.10",
"Other Revenues": "-6.83",
"Comprehensive Net Income": "-36.5",
"Economic Capital Ratio": "-129"
},
"2013": {
"Other Assets": "-7.10",
"Assets": "-107",
"Liabilities": "9.35",
"Stockholders Equity": "-130",
"ECR before LimitedLiability": "-204",
"Intangible Assets": "-9.76",
"Property and Equipment": "-4.28",
"Assets, Current": "-85.5",
"Liabilities, Non-Current": "-0.489",
"Liabilities, Current": "10.9",
"Other Liabilities": "-1.31",
"Selling, General and Administrative Expense": "-3.91",
"Expenses": "-8.59",
"Revenues": "-4.26",
"Net Income": "-16.7",
"Other Expenses": "2.00",
"Research and Development": "-7.33",
"Other Revenues": "-4.26",
"Comprehensive Net Income": "-16.8",
"Other Net Income": "-0.888",
"Economic Capital Ratio": "-232"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001366541_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,795",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "294",
"Liabilities, Non-Current": "0",
"Other Assets": "7.5",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-762",
"Other Revenues": "175",
"Property and Equipment": "32",
"Research and Development": "445",
"Selling, General and Administrative Expense": "1,567"
},
"output_variables": {
"Assets": "2,835",
"Liabilities": "294",
"Expenses": "2,012",
"Revenues": "175",
"Stockholders Equity": "2,541",
"Net Income": "-2,599",
"Comprehensive Net Income": "-2,599",
"BaseVar": "3,039",
"ECR before LimitedLiability": "188%",
"Economic Capital Ratio": "294%"
}
},
"2012": {
"input_variables": {
"Assets, Current": "1,282",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,301",
"Liabilities, Non-Current": "0",
"Other Assets": "7.5",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "4.5",
"Other Revenues": "485",
"Property and Equipment": "16",
"Research and Development": "2,089",
"Selling, General and Administrative Expense": "1,458"
},
"output_variables": {
"Assets": "1,306",
"Liabilities": "1,301",
"Expenses": "3,547",
"Revenues": "485",
"Stockholders Equity": "5.0",
"Net Income": "-3,058",
"Comprehensive Net Income": "-3,058",
"BaseVar": "3,322",
"ECR before LimitedLiability": "-234%",
"Economic Capital Ratio": "91%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "222",
"Cost of Goods Sold": "4.8",
"Intangible Assets": "0",
"Liabilities, Current": "3,299",
"Liabilities, Non-Current": "0",
"Other Assets": "7.5",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-198",
"Other Revenues": "26",
"Property and Equipment": "28",
"Research and Development": "1,828",
"Selling, General and Administrative Expense": "1,385"
},
"output_variables": {
"Assets": "257",
"Liabilities": "3,299",
"Expenses": "3,217",
"Revenues": "26",
"Stockholders Equity": "-3,042",
"Net Income": "-3,389",
"Comprehensive Net Income": "-3,389",
"BaseVar": "3,499",
"ECR before LimitedLiability": "-564%",
"Economic Capital Ratio": "11%"
}
}
},
"top_rated": false,
"trend": -54.0,
"value": 0.11113454460859992,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001366541.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001366541.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001366541.svg"
},
{
"company_id": "0001024626",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001024626.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001024626.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001024626_main_keyfigs.svg",
"name": "Cannabis Science INC",
"rank": 231,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001024626.svg",
"report_text": "The relative strengths and weaknesses of Cannabis Science INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cannabis Science INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 9.3% points.The greatest weakness of Cannabis Science INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 131% points.
The company's Economic Capital Ratio, given in the ranking table, is 9.4%, being 233% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001024626_2014_Cannabis_Science_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "-0.269",
"Assets": "-119",
"Liabilities": "-0.0421",
"Stockholders Equity": "-30.5",
"ECR before LimitedLiability": "-147",
"Assets, Current": "-83.8",
"Intangible Assets": "-0.340",
"Other Assets": "-0.168",
"Liabilities, Current": "0.0150",
"Other Liabilities": "-0.105",
"Liabilities, Non-Current": "-0.0304",
"Selling, General and Administrative Expense": "-0.0743",
"Expenses": "-4.85",
"Revenues": "-0.0872",
"Net Income": "-28.2",
"Research and Development": "0.0139",
"Other Expenses": "-7.11",
"Other Revenues": "-0.0872",
"Comprehensive Net Income": "-28.1",
"Other Net Income": "-0.0453",
"Economic Capital Ratio": "-220"
},
"2013": {
"Other Assets": "-7.98",
"Assets": "-113",
"Liabilities": "6.91",
"Stockholders Equity": "-131",
"ECR before LimitedLiability": "-205",
"Intangible Assets": "-3.58",
"Property and Equipment": "-5.58",
"Assets, Current": "-96.6",
"Liabilities, Non-Current": "-0.572",
"Liabilities, Current": "-2.32",
"Other Liabilities": "9.26",
"Selling, General and Administrative Expense": "-10.4",
"Expenses": "-1.36",
"Revenues": "-4.26",
"Net Income": "-25.3",
"Other Expenses": "1.25",
"Research and Development": "3.66",
"Other Revenues": "-4.26",
"Comprehensive Net Income": "-25.4",
"Other Net Income": "-13.8",
"Economic Capital Ratio": "-233"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001024626_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "713",
"Cost of Goods Sold": "0",
"Intangible Assets": "231",
"Liabilities, Current": "3,276",
"Liabilities, Non-Current": "0",
"Other Assets": "147",
"Other Compr. Net Income": "0",
"Other Expenses": "11,611",
"Other Liabilities": "0",
"Other Net Income": "-2,029",
"Other Revenues": "37",
"Property and Equipment": "16",
"Research and Development": "0",
"Selling, General and Administrative Expense": "5,068"
},
"output_variables": {
"Assets": "1,107",
"Liabilities": "3,276",
"Expenses": "16,679",
"Revenues": "37",
"Stockholders Equity": "-2,169",
"Net Income": "-18,672",
"Comprehensive Net Income": "-18,672",
"BaseVar": "11,564",
"ECR before LimitedLiability": "-1,068%",
"Economic Capital Ratio": "0.015%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "303",
"Cost of Goods Sold": "0",
"Intangible Assets": "273",
"Liabilities, Current": "166",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "235",
"Other Liabilities": "3,930",
"Other Net Income": "-2,568",
"Other Revenues": "83",
"Property and Equipment": "1.5",
"Research and Development": "0",
"Selling, General and Administrative Expense": "3,213"
},
"output_variables": {
"Assets": "577",
"Liabilities": "4,096",
"Expenses": "3,449",
"Revenues": "83",
"Stockholders Equity": "-3,519",
"Net Income": "-5,934",
"Comprehensive Net Income": "-5,934",
"BaseVar": "5,387",
"ECR before LimitedLiability": "-582%",
"Economic Capital Ratio": "9.4%"
}
}
},
"top_rated": false,
"trend": -17.0,
"value": 0.09368926795176775,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001024626.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001024626.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001024626.svg"
},
{
"company_id": "0000822370",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0000822370.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0000822370.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000822370.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000822370_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000822370_main_keyfigs.svg",
"name": "Emmaus Life Sciences Inc",
"rank": 232,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0000822370.svg",
"report_text": "The relative strengths and weaknesses of Emmaus Life Sciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Emmaus Life Sciences Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 4.4% points.The greatest weakness of Emmaus Life Sciences Inc is the variable Assets, reducing the Economic Capital Ratio by 124% points.
The company's Economic Capital Ratio, given in the ranking table, is 5.9%, being 237% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0000822370_2014_Emmaus_Life_Sciences_Inc.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-8.53",
"Assets": "-124",
"Liabilities": "1.80",
"Stockholders Equity": "-117",
"ECR before LimitedLiability": "-209",
"Intangible Assets": "-12.4",
"Property and Equipment": "-5.83",
"Assets, Current": "-98.0",
"Liabilities, Non-Current": "-0.711",
"Liabilities, Current": "4.44",
"Other Liabilities": "-1.96",
"Selling, General and Administrative Expense": "-2.22",
"Expenses": "0.557",
"Revenues": "-4.90",
"Net Income": "-57.7",
"Other Expenses": "-2.56",
"Research and Development": "3.14",
"Other Revenues": "-4.90",
"Comprehensive Net Income": "-58.0",
"Other Net Income": "-41.7",
"Economic Capital Ratio": "-237"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0000822370_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "1,364",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,556",
"Liabilities, Non-Current": "6.0",
"Other Assets": "22",
"Other Compr. Net Income": "0",
"Other Expenses": "1,778",
"Other Liabilities": "0",
"Other Net Income": "-6,575",
"Other Revenues": "0",
"Property and Equipment": "17",
"Research and Development": "0",
"Selling, General and Administrative Expense": "2,554"
},
"output_variables": {
"Assets": "1,402",
"Liabilities": "3,562",
"Expenses": "4,332",
"Revenues": "0",
"Stockholders Equity": "-2,160",
"Net Income": "-10,907",
"Comprehensive Net Income": "-10,907",
"BaseVar": "7,936",
"ECR before LimitedLiability": "-629%",
"Economic Capital Ratio": "5.9%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.059458043668578334,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0000822370.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0000822370.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0000822370.svg"
},
{
"company_id": "0001445815",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001445815.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001445815.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001445815_main_keyfigs.svg",
"name": "Bioxytran INC",
"rank": 233,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001445815.svg",
"report_text": "The relative strengths and weaknesses of Bioxytran INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Bioxytran INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 1.9% points.The greatest weakness of Bioxytran INC is the variable Other Expenses, reducing the Economic Capital Ratio by 344% points.
The company's Economic Capital Ratio, given in the ranking table, is 2.0%, being 241% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001445815_2014_Bioxytran_INC.pdf",
"shrinked_graph_json": {
"2012": {
"Property and Equipment": "4.13",
"Assets": "-156",
"Liabilities": "-8.62",
"Stockholders Equity": "-37.5",
"ECR before LimitedLiability": "-139",
"Assets, Current": "-130",
"Intangible Assets": "-35.7",
"Other Assets": "-23.1",
"Liabilities, Current": "-6.50",
"Other Liabilities": "-2.09",
"Liabilities, Non-Current": "-1.75",
"Selling, General and Administrative Expense": "6.20",
"Expenses": "-133",
"Revenues": "-2.37",
"Net Income": "-141",
"Research and Development": "6.30",
"Other Expenses": "-386",
"Cost of Goods Sold": "1.60",
"Other Revenues": "-2.37",
"Comprehensive Net Income": "-140",
"Economic Capital Ratio": "-213"
},
"2013": {
"Other Assets": "-17.6",
"Assets": "-232",
"Liabilities": "-7.05",
"Stockholders Equity": "-136",
"ECR before LimitedLiability": "-213",
"Intangible Assets": "-26.4",
"Property and Equipment": "1.91",
"Assets, Current": "-198",
"Liabilities, Non-Current": "-1.11",
"Liabilities, Current": "-2.84",
"Other Liabilities": "-3.23",
"Selling, General and Administrative Expense": "1.75",
"Expenses": "-129",
"Revenues": "0.683",
"Net Income": "-89.8",
"Other Expenses": "-344",
"Research and Development": "1.75",
"Other Revenues": "0.683",
"Comprehensive Net Income": "-90.4",
"Other Net Income": "1.38",
"Economic Capital Ratio": "-241"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001445815_strength_weakness.svg",
"table_records": {
"2012": {
"input_variables": {
"Assets, Current": "299",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "2,603",
"Other Liabilities": "74",
"Other Net Income": "-3.5",
"Other Revenues": "313",
"Property and Equipment": "129",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "428",
"Liabilities": "74",
"Expenses": "2,603",
"Revenues": "313",
"Stockholders Equity": "354",
"Net Income": "-2,293",
"Comprehensive Net Income": "-2,293",
"BaseVar": "1,711",
"ECR before LimitedLiability": "-605%",
"Economic Capital Ratio": "7.5%"
}
},
"2013": {
"input_variables": {
"Assets, Current": "93",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "183",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "2,390",
"Other Liabilities": "0",
"Other Net Income": "194",
"Other Revenues": "417",
"Property and Equipment": "165",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "258",
"Liabilities": "183",
"Expenses": "2,390",
"Revenues": "417",
"Stockholders Equity": "75",
"Net Income": "-1,779",
"Comprehensive Net Income": "-1,779",
"BaseVar": "1,721",
"ECR before LimitedLiability": "-731%",
"Economic Capital Ratio": "2.0%"
}
}
},
"top_rated": false,
"trend": -24.0,
"value": 0.019557562797218927,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001445815.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001445815.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001445815.svg"
},
{
"company_id": "0001385508",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution_0001385508.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2013/graphs/IME_0001385508.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001385508.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001385508_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001385508_main_keyfigs.svg",
"name": "Opiant Pharmaceuticals INC",
"rank": 234,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_0001385508.svg",
"report_text": "The relative strengths and weaknesses of Opiant Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Opiant Pharmaceuticals INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 0.071% points.The greatest weakness of Opiant Pharmaceuticals INC is the variable Assets, reducing the Economic Capital Ratio by 132% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.097%, being 243% points below the market average of 243%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2013/report/0001385508_2014_Opiant_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2013": {
"Other Assets": "-1.18",
"Assets": "-132",
"Liabilities": "-0.143",
"Stockholders Equity": "-69.0",
"ECR before LimitedLiability": "-215",
"Intangible Assets": "-1.81",
"Property and Equipment": "-0.634",
"Assets, Current": "-102",
"Liabilities, Non-Current": "-0.0937",
"Liabilities, Current": "-0.102",
"Other Liabilities": "0.0412",
"Selling, General and Administrative Expense": "-2.44",
"Expenses": "-19.0",
"Revenues": "-0.287",
"Net Income": "-44.6",
"Other Expenses": "-4.63",
"Research and Development": "0.0709",
"Other Revenues": "-0.287",
"Comprehensive Net Income": "-44.9",
"Other Net Income": "-0.0474",
"Economic Capital Ratio": "-243"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2013/plot_over_time/0001385508_strength_weakness.svg",
"table_records": {
"2013": {
"input_variables": {
"Assets, Current": "620",
"Cost of Goods Sold": "0",
"Intangible Assets": "23",
"Liabilities, Current": "883",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "4,041",
"Other Liabilities": "750",
"Other Net Income": "-371",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "283",
"Selling, General and Administrative Expense": "4,002"
},
"output_variables": {
"Assets": "643",
"Liabilities": "1,633",
"Expenses": "8,325",
"Revenues": "0",
"Stockholders Equity": "-990",
"Net Income": "-8,696",
"Comprehensive Net Income": "-8,696",
"BaseVar": "5,486",
"ECR before LimitedLiability": "-954%",
"Economic Capital Ratio": "0.097%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.0009743794154677052,
"company_index": "https://www.realrate-archive.com/us_pharma/2013/industry_indexes/0001385508.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2013/analytics/equity/0001385508.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2013/analytics/profit_loss/0001385508.svg"
}
],
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2013/feature_distribution/feature_distribution.svg",
"final_var_label": "Economic Capital Ratio",
"industry_box": [
[
"Revenues",
"299 B"
],
[
"Assets",
"682 B"
],
[
"Expenses",
"257 B"
],
[
"Stockholders Equity",
"391 B"
]
],
"industry_id": "us_pharma",
"industry_label": "Pharmaceutical",
"num_companies": 234,
"num_top_companies": 58,
"ecr_records": {
"2009": {
"0000850693": {
"rank": 1,
"ecr": "414"
},
"0000310158": {
"rank": 2,
"ecr": "402"
},
"0000038074": {
"rank": 3,
"ecr": "397"
},
"0001274057": {
"rank": 4,
"ecr": "388"
},
"0000001800": {
"rank": 5,
"ecr": "355"
},
"0000936402": {
"rank": 6,
"ecr": "252"
},
"0000078003": {
"rank": 7,
"ecr": "248"
},
"0000059478": {
"rank": 8,
"ecr": "239"
}
},
"2010": {
"0000899866": {
"rank": 1,
"ecr": "395"
},
"0000038074": {
"rank": 2,
"ecr": "394"
},
"0001274057": {
"rank": 3,
"ecr": "389"
},
"0000310158": {
"rank": 4,
"ecr": "386"
},
"0001100962": {
"rank": 5,
"ecr": "376"
},
"0000850693": {
"rank": 6,
"ecr": "369"
},
"0001113481": {
"rank": 7,
"ecr": "368"
},
"0000859368": {
"rank": 8,
"ecr": "352"
},
"0000001800": {
"rank": 9,
"ecr": "337"
},
"0000881464": {
"rank": 10,
"ecr": "328"
},
"0001130591": {
"rank": 11,
"ecr": "326"
},
"0001107332": {
"rank": 12,
"ecr": "326"
},
"0001182129": {
"rank": 13,
"ecr": "316"
},
"0000792977": {
"rank": 14,
"ecr": "311"
},
"0001082554": {
"rank": 15,
"ecr": "308"
},
"0001048477": {
"rank": 16,
"ecr": "300"
},
"0000200406": {
"rank": 17,
"ecr": "287"
},
"0000884629": {
"rank": 18,
"ecr": "286"
},
"0000912183": {
"rank": 19,
"ecr": "262"
},
"0000936402": {
"rank": 20,
"ecr": "262"
},
"0000078003": {
"rank": 21,
"ecr": "255"
},
"0000059478": {
"rank": 22,
"ecr": "253"
},
"0000872589": {
"rank": 23,
"ecr": "251"
},
"0000885590": {
"rank": 24,
"ecr": "250"
},
"0000874015": {
"rank": 25,
"ecr": "238"
},
"0000820096": {
"rank": 26,
"ecr": "232"
},
"0001178670": {
"rank": 27,
"ecr": "227"
},
"0000069499": {
"rank": 28,
"ecr": "218"
},
"0000875320": {
"rank": 29,
"ecr": "164"
},
"0001323854": {
"rank": 30,
"ecr": "141"
},
"0001415684": {
"rank": 31,
"ecr": "4.8"
}
},
"2011": {
"0000786947": {
"rank": 1,
"ecr": "501"
},
"0000875622": {
"rank": 2,
"ecr": "483"
},
"0000847464": {
"rank": 3,
"ecr": "472"
},
"0000926844": {
"rank": 4,
"ecr": "445"
},
"0001052284": {
"rank": 5,
"ecr": "441"
},
"0001059790": {
"rank": 6,
"ecr": "436"
},
"0001362718": {
"rank": 7,
"ecr": "434"
},
"0000887497": {
"rank": 8,
"ecr": "429"
},
"0001178711": {
"rank": 9,
"ecr": "428"
},
"0001401667": {
"rank": 10,
"ecr": "427"
},
"0001173784": {
"rank": 11,
"ecr": "427"
},
"0000863894": {
"rank": 12,
"ecr": "424"
},
"0000835887": {
"rank": 13,
"ecr": "423"
},
"0000850693": {
"rank": 14,
"ecr": "416"
},
"0001232524": {
"rank": 15,
"ecr": "415"
},
"0001325879": {
"rank": 16,
"ecr": "412"
},
"0001092662": {
"rank": 17,
"ecr": "411"
},
"0001443242": {
"rank": 18,
"ecr": "406"
},
"0001459450": {
"rank": 19,
"ecr": "403"
},
"0001087294": {
"rank": 20,
"ecr": "399"
},
"0001520512": {
"rank": 21,
"ecr": "396"
},
"0000891288": {
"rank": 22,
"ecr": "394"
},
"0001005201": {
"rank": 23,
"ecr": "393"
},
"0001034842": {
"rank": 24,
"ecr": "392"
},
"0000310158": {
"rank": 25,
"ecr": "389"
},
"0001416083": {
"rank": 26,
"ecr": "388"
},
"0001100962": {
"rank": 27,
"ecr": "386"
},
"0001354071": {
"rank": 28,
"ecr": "384"
},
"0001274057": {
"rank": 29,
"ecr": "384"
},
"0000881524": {
"rank": 30,
"ecr": "383"
},
"0001087432": {
"rank": 31,
"ecr": "380"
},
"0001520262": {
"rank": 32,
"ecr": "379"
},
"0000038074": {
"rank": 33,
"ecr": "377"
},
"0001107332": {
"rank": 34,
"ecr": "376"
},
"0000934473": {
"rank": 35,
"ecr": "371"
},
"0001322505": {
"rank": 36,
"ecr": "371"
},
"0001375247": {
"rank": 37,
"ecr": "370"
},
"0000944809": {
"rank": 38,
"ecr": "365"
},
"0001260990": {
"rank": 39,
"ecr": "365"
},
"0000919722": {
"rank": 40,
"ecr": "362"
},
"0001096294": {
"rank": 41,
"ecr": "360"
},
"0000949699": {
"rank": 42,
"ecr": "358"
},
"0001003642": {
"rank": 43,
"ecr": "355"
},
"0001130591": {
"rank": 44,
"ecr": "355"
},
"0001379006": {
"rank": 45,
"ecr": "353"
},
"0001235007": {
"rank": 46,
"ecr": "352"
},
"0001367644": {
"rank": 47,
"ecr": "351"
},
"0000001800": {
"rank": 48,
"ecr": "348"
},
"0000881464": {
"rank": 49,
"ecr": "347"
},
"0001145404": {
"rank": 50,
"ecr": "344"
},
"0000812796": {
"rank": 51,
"ecr": "340"
},
"0000886744": {
"rank": 52,
"ecr": "340"
},
"0000831547": {
"rank": 53,
"ecr": "332"
},
"0000057725": {
"rank": 54,
"ecr": "331"
},
"0000352998": {
"rank": 55,
"ecr": "330"
},
"0001080709": {
"rank": 56,
"ecr": "326"
},
"0001070336": {
"rank": 57,
"ecr": "325"
},
"0001098880": {
"rank": 58,
"ecr": "324"
},
"0001428522": {
"rank": 59,
"ecr": "323"
},
"0001159019": {
"rank": 60,
"ecr": "321"
},
"0001029142": {
"rank": 61,
"ecr": "321"
},
"0001061027": {
"rank": 62,
"ecr": "320"
},
"0001130166": {
"rank": 63,
"ecr": "318"
},
"0001082554": {
"rank": 64,
"ecr": "317"
},
"0001413754": {
"rank": 65,
"ecr": "316"
},
"0001124105": {
"rank": 66,
"ecr": "314"
},
"0001182129": {
"rank": 67,
"ecr": "314"
},
"0001356857": {
"rank": 68,
"ecr": "309"
},
"0001326190": {
"rank": 69,
"ecr": "306"
},
"0001135906": {
"rank": 70,
"ecr": "306"
},
"0000859368": {
"rank": 71,
"ecr": "303"
},
"0001484478": {
"rank": 72,
"ecr": "299"
},
"0000768710": {
"rank": 73,
"ecr": "298"
},
"0001062822": {
"rank": 74,
"ecr": "295"
},
"0001366541": {
"rank": 75,
"ecr": "294"
},
"0001267602": {
"rank": 76,
"ecr": "293"
},
"0000816284": {
"rank": 77,
"ecr": "292"
},
"0000200406": {
"rank": 78,
"ecr": "291"
},
"0001001316": {
"rank": 79,
"ecr": "290"
},
"0000792977": {
"rank": 80,
"ecr": "288"
},
"0001048477": {
"rank": 81,
"ecr": "287"
},
"0001369786": {
"rank": 82,
"ecr": "287"
},
"0001348362": {
"rank": 83,
"ecr": "285"
},
"0000749647": {
"rank": 84,
"ecr": "284"
},
"0000003116": {
"rank": 85,
"ecr": "283"
},
"0001095858": {
"rank": 86,
"ecr": "282"
},
"0000855654": {
"rank": 87,
"ecr": "280"
},
"0000936402": {
"rank": 88,
"ecr": "277"
},
"0000884629": {
"rank": 89,
"ecr": "277"
},
"0001333248": {
"rank": 90,
"ecr": "275"
},
"0000275053": {
"rank": 91,
"ecr": "273"
},
"0000820096": {
"rank": 92,
"ecr": "269"
},
"0001178879": {
"rank": 93,
"ecr": "266"
},
"0001228627": {
"rank": 94,
"ecr": "263"
},
"0000908259": {
"rank": 95,
"ecr": "263"
},
"0001114220": {
"rank": 96,
"ecr": "262"
},
"0001070494": {
"rank": 97,
"ecr": "259"
},
"0000078003": {
"rank": 98,
"ecr": "253"
},
"0001158223": {
"rank": 99,
"ecr": "252"
},
"0000715446": {
"rank": 100,
"ecr": "252"
},
"0000875320": {
"rank": 101,
"ecr": "249"
},
"0000059478": {
"rank": 102,
"ecr": "248"
},
"0000748592": {
"rank": 103,
"ecr": "248"
},
"0001069530": {
"rank": 104,
"ecr": "248"
},
"0000912183": {
"rank": 105,
"ecr": "245"
},
"0000896747": {
"rank": 106,
"ecr": "237"
},
"0001513856": {
"rank": 107,
"ecr": "233"
},
"0001411906": {
"rank": 108,
"ecr": "232"
},
"0001168220": {
"rank": 109,
"ecr": "228"
},
"0001274644": {
"rank": 110,
"ecr": "227"
},
"0001036968": {
"rank": 111,
"ecr": "222"
},
"0001178670": {
"rank": 112,
"ecr": "222"
},
"0001124524": {
"rank": 113,
"ecr": "218"
},
"0000069499": {
"rank": 114,
"ecr": "217"
},
"0000820081": {
"rank": 115,
"ecr": "214"
},
"0001041024": {
"rank": 116,
"ecr": "214"
},
"0000885590": {
"rank": 117,
"ecr": "214"
},
"0000070793": {
"rank": 118,
"ecr": "212"
},
"0000872589": {
"rank": 119,
"ecr": "212"
},
"0001411158": {
"rank": 120,
"ecr": "208"
},
"0000874015": {
"rank": 121,
"ecr": "208"
},
"0001023024": {
"rank": 122,
"ecr": "206"
},
"0000906709": {
"rank": 123,
"ecr": "196"
},
"0001019695": {
"rank": 124,
"ecr": "191"
},
"0001365216": {
"rank": 125,
"ecr": "187"
},
"0000886163": {
"rank": 126,
"ecr": "181"
},
"0001390478": {
"rank": 127,
"ecr": "180"
},
"0001347178": {
"rank": 128,
"ecr": "178"
},
"0001368148": {
"rank": 129,
"ecr": "177"
},
"0001522724": {
"rank": 130,
"ecr": "165"
},
"0001338042": {
"rank": 131,
"ecr": "154"
},
"0000704562": {
"rank": 132,
"ecr": "153"
},
"0001473579": {
"rank": 133,
"ecr": "151"
},
"0001323854": {
"rank": 134,
"ecr": "147"
},
"0000791908": {
"rank": 135,
"ecr": "141"
},
"0001113148": {
"rank": 136,
"ecr": "141"
},
"0001063104": {
"rank": 137,
"ecr": "141"
},
"0001011835": {
"rank": 138,
"ecr": "141"
},
"0001133416": {
"rank": 139,
"ecr": "140"
},
"0001420030": {
"rank": 140,
"ecr": "139"
},
"0001107421": {
"rank": 141,
"ecr": "139"
},
"0001285819": {
"rank": 142,
"ecr": "138"
},
"0000849636": {
"rank": 143,
"ecr": "138"
},
"0001017491": {
"rank": 144,
"ecr": "138"
},
"0001367083": {
"rank": 145,
"ecr": "138"
},
"0000832489": {
"rank": 146,
"ecr": "137"
},
"0000897448": {
"rank": 147,
"ecr": "137"
},
"0001103021": {
"rank": 148,
"ecr": "136"
},
"0001262104": {
"rank": 149,
"ecr": "133"
},
"0001429260": {
"rank": 150,
"ecr": "129"
},
"0001016504": {
"rank": 151,
"ecr": "128"
},
"0000890821": {
"rank": 152,
"ecr": "127"
},
"0001160308": {
"rank": 153,
"ecr": "120"
},
"0001427925": {
"rank": 154,
"ecr": "116"
},
"0000802724": {
"rank": 155,
"ecr": "113"
},
"0001133818": {
"rank": 156,
"ecr": "109"
},
"0001279704": {
"rank": 157,
"ecr": "107"
},
"0001347613": {
"rank": 158,
"ecr": "104"
},
"0001100412": {
"rank": 159,
"ecr": "95"
},
"0001377053": {
"rank": 160,
"ecr": "84"
},
"0001335103": {
"rank": 161,
"ecr": "76"
},
"0001375200": {
"rank": 162,
"ecr": "75"
},
"0001421204": {
"rank": 163,
"ecr": "61"
},
"0000318306": {
"rank": 164,
"ecr": "61"
},
"0001175680": {
"rank": 165,
"ecr": "60"
},
"0001208261": {
"rank": 166,
"ecr": "59"
},
"0000822411": {
"rank": 167,
"ecr": "58"
},
"0000811779": {
"rank": 168,
"ecr": "50"
},
"0001261734": {
"rank": 169,
"ecr": "49"
},
"0000704384": {
"rank": 170,
"ecr": "40"
},
"0001409565": {
"rank": 171,
"ecr": "40"
},
"0000025743": {
"rank": 172,
"ecr": "39"
},
"0000887247": {
"rank": 173,
"ecr": "36"
},
"0000849146": {
"rank": 174,
"ecr": "34"
},
"0001053691": {
"rank": 175,
"ecr": "32"
},
"0001226616": {
"rank": 176,
"ecr": "29"
},
"0001415684": {
"rank": 177,
"ecr": "29"
},
"0001140098": {
"rank": 178,
"ecr": "27"
},
"0001360214": {
"rank": 179,
"ecr": "26"
},
"0001174940": {
"rank": 180,
"ecr": "23"
},
"0001195116": {
"rank": 181,
"ecr": "17"
},
"0001094038": {
"rank": 182,
"ecr": "16"
},
"0001385818": {
"rank": 183,
"ecr": "15"
},
"0000072170": {
"rank": 184,
"ecr": "11"
},
"0001346973": {
"rank": 185,
"ecr": "9.2"
},
"0001088856": {
"rank": 186,
"ecr": "8.6"
},
"0001369568": {
"rank": 187,
"ecr": "3.3"
},
"0000899460": {
"rank": 188,
"ecr": "1.9"
},
"0000315545": {
"rank": 189,
"ecr": "0.043"
},
"0001061983": {
"rank": 190,
"ecr": "0.018"
},
"0000879407": {
"rank": 191,
"ecr": "0.012"
},
"0001355790": {
"rank": 192,
"ecr": "0.0038"
},
"0000707511": {
"rank": 193,
"ecr": "0.0029"
},
"0001183765": {
"rank": 194,
"ecr": "0.0015"
},
"0001069308": {
"rank": 195,
"ecr": "0.00000000042"
},
"0001410098": {
"rank": 196,
"ecr": "0.00000000000014"
}
},
"2012": {
"0000875622": {
"rank": 1,
"ecr": "465"
},
"0001052284": {
"rank": 2,
"ecr": "437"
},
"0001178711": {
"rank": 3,
"ecr": "431"
},
"0001082038": {
"rank": 4,
"ecr": "427"
},
"0000821995": {
"rank": 5,
"ecr": "424"
},
"0001124105": {
"rank": 6,
"ecr": "418"
},
"0001106644": {
"rank": 7,
"ecr": "418"
},
"0000850693": {
"rank": 8,
"ecr": "413"
},
"0001096294": {
"rank": 9,
"ecr": "406"
},
"0001070494": {
"rank": 10,
"ecr": "406"
},
"0000887497": {
"rank": 11,
"ecr": "403"
},
"0001459450": {
"rank": 12,
"ecr": "402"
},
"0001113148": {
"rank": 13,
"ecr": "399"
},
"0001087294": {
"rank": 14,
"ecr": "399"
},
"0001362718": {
"rank": 15,
"ecr": "396"
},
"0000919722": {
"rank": 16,
"ecr": "393"
},
"0001059790": {
"rank": 17,
"ecr": "391"
},
"0000786947": {
"rank": 18,
"ecr": "390"
},
"0001130591": {
"rank": 19,
"ecr": "390"
},
"0001416083": {
"rank": 20,
"ecr": "386"
},
"0000891288": {
"rank": 21,
"ecr": "383"
},
"0000310158": {
"rank": 22,
"ecr": "380"
},
"0001274057": {
"rank": 23,
"ecr": "375"
},
"0001544227": {
"rank": 24,
"ecr": "373"
},
"0000001800": {
"rank": 25,
"ecr": "374"
},
"0001003642": {
"rank": 26,
"ecr": "370"
},
"0001092662": {
"rank": 27,
"ecr": "369"
},
"0001340652": {
"rank": 28,
"ecr": "368"
},
"0001088856": {
"rank": 29,
"ecr": "367"
},
"0001375247": {
"rank": 30,
"ecr": "366"
},
"0001080709": {
"rank": 31,
"ecr": "361"
},
"0001360214": {
"rank": 32,
"ecr": "360"
},
"0000038074": {
"rank": 33,
"ecr": "360"
},
"0001367644": {
"rank": 34,
"ecr": "360"
},
"0001178879": {
"rank": 35,
"ecr": "360"
},
"0000057725": {
"rank": 36,
"ecr": "358"
},
"0000357097": {
"rank": 37,
"ecr": "356"
},
"0000899866": {
"rank": 38,
"ecr": "355"
},
"0001379006": {
"rank": 39,
"ecr": "352"
},
"0000949699": {
"rank": 40,
"ecr": "343"
},
"0001354071": {
"rank": 41,
"ecr": "341"
},
"0000835887": {
"rank": 42,
"ecr": "339"
},
"0001369786": {
"rank": 43,
"ecr": "339"
},
"0001082554": {
"rank": 44,
"ecr": "335"
},
"0001087432": {
"rank": 45,
"ecr": "333"
},
"0000849146": {
"rank": 46,
"ecr": "332"
},
"0001070336": {
"rank": 47,
"ecr": "330"
},
"0000872589": {
"rank": 48,
"ecr": "327"
},
"0001100962": {
"rank": 49,
"ecr": "327"
},
"0001401667": {
"rank": 50,
"ecr": "327"
},
"0001260990": {
"rank": 51,
"ecr": "324"
},
"0001107332": {
"rank": 52,
"ecr": "323"
},
"0000881524": {
"rank": 53,
"ecr": "320"
},
"0001005201": {
"rank": 54,
"ecr": "318"
},
"0001368148": {
"rank": 55,
"ecr": "317"
},
"0000944809": {
"rank": 56,
"ecr": "316"
},
"0001029142": {
"rank": 57,
"ecr": "315"
},
"0001103021": {
"rank": 58,
"ecr": "314"
},
"0000792977": {
"rank": 59,
"ecr": "309"
},
"0001279704": {
"rank": 60,
"ecr": "308"
},
"0001267602": {
"rank": 61,
"ecr": "308"
},
"0001095858": {
"rank": 62,
"ecr": "308"
},
"0000886744": {
"rank": 63,
"ecr": "307"
},
"0001325879": {
"rank": 64,
"ecr": "306"
},
"0000275053": {
"rank": 65,
"ecr": "305"
},
"0000768710": {
"rank": 66,
"ecr": "304"
},
"0001062822": {
"rank": 67,
"ecr": "301"
},
"0001443242": {
"rank": 68,
"ecr": "299"
},
"0001389545": {
"rank": 69,
"ecr": "298"
},
"0000847464": {
"rank": 70,
"ecr": "297"
},
"0001048477": {
"rank": 71,
"ecr": "297"
},
"0000748592": {
"rank": 72,
"ecr": "293"
},
"0001436304": {
"rank": 73,
"ecr": "291"
},
"0001322505": {
"rank": 74,
"ecr": "289"
},
"0001106838": {
"rank": 75,
"ecr": "287"
},
"0001019695": {
"rank": 76,
"ecr": "287"
},
"0000003116": {
"rank": 77,
"ecr": "285"
},
"0001520262": {
"rank": 78,
"ecr": "284"
},
"0000200406": {
"rank": 79,
"ecr": "283"
},
"0000936402": {
"rank": 80,
"ecr": "280"
},
"0001375850": {
"rank": 81,
"ecr": "279"
},
"0001505512": {
"rank": 82,
"ecr": "277"
},
"0001173784": {
"rank": 83,
"ecr": "276"
},
"0000912183": {
"rank": 84,
"ecr": "276"
},
"0000816284": {
"rank": 85,
"ecr": "272"
},
"0000934473": {
"rank": 86,
"ecr": "268"
},
"0001356857": {
"rank": 87,
"ecr": "267"
},
"0001159019": {
"rank": 88,
"ecr": "264"
},
"0000820096": {
"rank": 89,
"ecr": "262"
},
"0001444307": {
"rank": 90,
"ecr": "260"
},
"0001023024": {
"rank": 91,
"ecr": "258"
},
"0001133416": {
"rank": 92,
"ecr": "257"
},
"0000059478": {
"rank": 93,
"ecr": "255"
},
"0000820081": {
"rank": 94,
"ecr": "256"
},
"0000078003": {
"rank": 95,
"ecr": "255"
},
"0000919745": {
"rank": 96,
"ecr": "255"
},
"0001338042": {
"rank": 97,
"ecr": "251"
},
"0001145404": {
"rank": 98,
"ecr": "248"
},
"0000812796": {
"rank": 99,
"ecr": "247"
},
"0000875320": {
"rank": 100,
"ecr": "247"
},
"0001356576": {
"rank": 101,
"ecr": "247"
},
"0001326190": {
"rank": 102,
"ecr": "247"
},
"0001377053": {
"rank": 103,
"ecr": "246"
},
"0001174940": {
"rank": 104,
"ecr": "246"
},
"0001420720": {
"rank": 105,
"ecr": "243"
},
"0001396814": {
"rank": 106,
"ecr": "242"
},
"0001135906": {
"rank": 107,
"ecr": "242"
},
"0001318641": {
"rank": 108,
"ecr": "240"
},
"0000715446": {
"rank": 109,
"ecr": "238"
},
"0000822411": {
"rank": 110,
"ecr": "238"
},
"0001036968": {
"rank": 111,
"ecr": "232"
},
"0000070793": {
"rank": 112,
"ecr": "224"
},
"0001365216": {
"rank": 113,
"ecr": "224"
},
"0001411906": {
"rank": 114,
"ecr": "222"
},
"0001178670": {
"rank": 115,
"ecr": "221"
},
"0001061027": {
"rank": 116,
"ecr": "220"
},
"0001098880": {
"rank": 117,
"ecr": "216"
},
"0001274644": {
"rank": 118,
"ecr": "214"
},
"0000855654": {
"rank": 119,
"ecr": "213"
},
"0000069499": {
"rank": 120,
"ecr": "212"
},
"0000874015": {
"rank": 121,
"ecr": "209"
},
"0000884629": {
"rank": 122,
"ecr": "206"
},
"0001344413": {
"rank": 123,
"ecr": "202"
},
"0000886163": {
"rank": 124,
"ecr": "200"
},
"0001262104": {
"rank": 125,
"ecr": "198"
},
"0001130166": {
"rank": 126,
"ecr": "197"
},
"0000908259": {
"rank": 127,
"ecr": "195"
},
"0001070698": {
"rank": 128,
"ecr": "194"
},
"0001010086": {
"rank": 129,
"ecr": "191"
},
"0001484478": {
"rank": 130,
"ecr": "190"
},
"0000885590": {
"rank": 131,
"ecr": "188"
},
"0001069530": {
"rank": 132,
"ecr": "188"
},
"0001461993": {
"rank": 133,
"ecr": "188"
},
"0000896747": {
"rank": 134,
"ecr": "184"
},
"0000832489": {
"rank": 135,
"ecr": "181"
},
"0001011835": {
"rank": 136,
"ecr": "175"
},
"0001333248": {
"rank": 137,
"ecr": "171"
},
"0000858803": {
"rank": 138,
"ecr": "170"
},
"0001029125": {
"rank": 139,
"ecr": "165"
},
"0001400431": {
"rank": 140,
"ecr": "165"
},
"0001537917": {
"rank": 141,
"ecr": "151"
},
"0001168220": {
"rank": 142,
"ecr": "149"
},
"0001124524": {
"rank": 143,
"ecr": "148"
},
"0001226616": {
"rank": 144,
"ecr": "145"
},
"0001411158": {
"rank": 145,
"ecr": "145"
},
"0001473579": {
"rank": 146,
"ecr": "144"
},
"0001285819": {
"rank": 147,
"ecr": "141"
},
"0001347178": {
"rank": 148,
"ecr": "141"
},
"0001436161": {
"rank": 149,
"ecr": "141"
},
"0000906709": {
"rank": 150,
"ecr": "141"
},
"0001323854": {
"rank": 151,
"ecr": "141"
},
"0000791908": {
"rank": 152,
"ecr": "140"
},
"0001335105": {
"rank": 153,
"ecr": "140"
},
"0001293310": {
"rank": 154,
"ecr": "139"
},
"0001347613": {
"rank": 155,
"ecr": "138"
},
"0001375200": {
"rank": 156,
"ecr": "137"
},
"0000897448": {
"rank": 157,
"ecr": "137"
},
"0001158223": {
"rank": 158,
"ecr": "136"
},
"0001274792": {
"rank": 159,
"ecr": "136"
},
"0001063104": {
"rank": 160,
"ecr": "136"
},
"0000704562": {
"rank": 161,
"ecr": "134"
},
"0001017491": {
"rank": 162,
"ecr": "134"
},
"0001317880": {
"rank": 163,
"ecr": "133"
},
"0001388320": {
"rank": 164,
"ecr": "131"
},
"0001427925": {
"rank": 165,
"ecr": "130"
},
"0001183765": {
"rank": 166,
"ecr": "129"
},
"0001369568": {
"rank": 167,
"ecr": "128"
},
"0001420030": {
"rank": 168,
"ecr": "128"
},
"0001367083": {
"rank": 169,
"ecr": "127"
},
"0001390478": {
"rank": 170,
"ecr": "124"
},
"0000899460": {
"rank": 171,
"ecr": "122"
},
"0001100412": {
"rank": 172,
"ecr": "121"
},
"0001016504": {
"rank": 173,
"ecr": "118"
},
"0001386858": {
"rank": 174,
"ecr": "106"
},
"0001195116": {
"rank": 175,
"ecr": "97"
},
"0001366541": {
"rank": 176,
"ecr": "91"
},
"0001316175": {
"rank": 177,
"ecr": "90"
},
"0001428522": {
"rank": 178,
"ecr": "88"
},
"0000802724": {
"rank": 179,
"ecr": "83"
},
"0001313938": {
"rank": 180,
"ecr": "82"
},
"0001053369": {
"rank": 181,
"ecr": "79"
},
"0000072170": {
"rank": 182,
"ecr": "75"
},
"0000025743": {
"rank": 183,
"ecr": "70"
},
"0000911216": {
"rank": 184,
"ecr": "70"
},
"0001107421": {
"rank": 185,
"ecr": "68"
},
"0001335103": {
"rank": 186,
"ecr": "65"
},
"0001410098": {
"rank": 187,
"ecr": "62"
},
"0001538495": {
"rank": 188,
"ecr": "60"
},
"0001041024": {
"rank": 189,
"ecr": "55"
},
"0001415684": {
"rank": 190,
"ecr": "54"
},
"0000707511": {
"rank": 191,
"ecr": "52"
},
"0001160308": {
"rank": 192,
"ecr": "48"
},
"0001100397": {
"rank": 193,
"ecr": "48"
},
"0001261734": {
"rank": 194,
"ecr": "46"
},
"0001391135": {
"rank": 195,
"ecr": "44"
},
"0000034956": {
"rank": 196,
"ecr": "44"
},
"0001208261": {
"rank": 197,
"ecr": "43"
},
"0001140098": {
"rank": 198,
"ecr": "42"
},
"0001502152": {
"rank": 199,
"ecr": "39"
},
"0000704384": {
"rank": 200,
"ecr": "39"
},
"0001530746": {
"rank": 201,
"ecr": "39"
},
"0001053691": {
"rank": 202,
"ecr": "38"
},
"0001228627": {
"rank": 203,
"ecr": "35"
},
"0001409565": {
"rank": 204,
"ecr": "31"
},
"0000890821": {
"rank": 205,
"ecr": "31"
},
"0000318306": {
"rank": 206,
"ecr": "25"
},
"0000811779": {
"rank": 207,
"ecr": "23"
},
"0001175680": {
"rank": 208,
"ecr": "15"
},
"0001445815": {
"rank": 209,
"ecr": "7.5"
},
"0001520512": {
"rank": 210,
"ecr": "4.6"
},
"0001061983": {
"rank": 211,
"ecr": "2.9"
},
"0001522724": {
"rank": 212,
"ecr": "1.6"
},
"0001072379": {
"rank": 213,
"ecr": "1.1"
},
"0001024626": {
"rank": 214,
"ecr": "0.015"
},
"0000879407": {
"rank": 215,
"ecr": "0.0075"
},
"0001355790": {
"rank": 216,
"ecr": "0.0000037"
},
"0001533040": {
"rank": 217,
"ecr": "0.0000000000000019"
},
"0000315545": {
"rank": 218,
"ecr": "0.0000000000000000000000036"
}
},
"2013": {
"0001069530": {
"rank": 1,
"ecr": "543"
},
"0000847464": {
"rank": 2,
"ecr": "494"
},
"0001178879": {
"rank": 3,
"ecr": "486"
},
"0000875622": {
"rank": 4,
"ecr": "479"
},
"0001177648": {
"rank": 5,
"ecr": "443"
},
"0001580149": {
"rank": 6,
"ecr": "442"
},
"0001354071": {
"rank": 7,
"ecr": "432"
},
"0001232524": {
"rank": 8,
"ecr": "425"
},
"0001503802": {
"rank": 9,
"ecr": "422"
},
"0001023024": {
"rank": 10,
"ecr": "419"
},
"0001535955": {
"rank": 11,
"ecr": "416"
},
"0001070494": {
"rank": 12,
"ecr": "414"
},
"0001362718": {
"rank": 13,
"ecr": "413"
},
"0000850693": {
"rank": 14,
"ecr": "406"
},
"0001087294": {
"rank": 15,
"ecr": "407"
},
"0001559053": {
"rank": 16,
"ecr": "404"
},
"0001516479": {
"rank": 17,
"ecr": "404"
},
"0001340652": {
"rank": 18,
"ecr": "402"
},
"0001309057": {
"rank": 19,
"ecr": "401"
},
"0001178711": {
"rank": 20,
"ecr": "397"
},
"0001262104": {
"rank": 21,
"ecr": "395"
},
"0000822411": {
"rank": 22,
"ecr": "394"
},
"0001386858": {
"rank": 23,
"ecr": "393"
},
"0001434868": {
"rank": 24,
"ecr": "388"
},
"0001596783": {
"rank": 25,
"ecr": "386"
},
"0001070336": {
"rank": 26,
"ecr": "382"
},
"0000310158": {
"rank": 27,
"ecr": "377"
},
"0001476963": {
"rank": 28,
"ecr": "380"
},
"0001513856": {
"rank": 29,
"ecr": "380"
},
"0000949699": {
"rank": 30,
"ecr": "379"
},
"0001003642": {
"rank": 31,
"ecr": "379"
},
"0001124105": {
"rank": 32,
"ecr": "378"
},
"0000887151": {
"rank": 33,
"ecr": "378"
},
"0001092662": {
"rank": 34,
"ecr": "375"
},
"0001226616": {
"rank": 35,
"ecr": "372"
},
"0001029142": {
"rank": 36,
"ecr": "372"
},
"0000821995": {
"rank": 37,
"ecr": "371"
},
"0001274057": {
"rank": 38,
"ecr": "367"
},
"0001551152": {
"rank": 39,
"ecr": "365"
},
"0000001800": {
"rank": 40,
"ecr": "365"
},
"0001367644": {
"rank": 41,
"ecr": "360"
},
"0000057725": {
"rank": 42,
"ecr": "358"
},
"0001369786": {
"rank": 43,
"ecr": "357"
},
"0001436304": {
"rank": 44,
"ecr": "355"
},
"0001117480": {
"rank": 45,
"ecr": "354"
},
"0001274644": {
"rank": 46,
"ecr": "353"
},
"0001080709": {
"rank": 47,
"ecr": "353"
},
"0001466301": {
"rank": 48,
"ecr": "349"
},
"0001447028": {
"rank": 49,
"ecr": "348"
},
"0001439222": {
"rank": 50,
"ecr": "347"
},
"0000038074": {
"rank": 51,
"ecr": "344"
},
"0000025743": {
"rank": 52,
"ecr": "343"
},
"0000899866": {
"rank": 53,
"ecr": "339"
},
"0001098880": {
"rank": 54,
"ecr": "334"
},
"0001087432": {
"rank": 55,
"ecr": "334"
},
"0000886744": {
"rank": 56,
"ecr": "332"
},
"0001104506": {
"rank": 57,
"ecr": "332"
},
"0001005201": {
"rank": 58,
"ecr": "331"
},
"0001505512": {
"rank": 59,
"ecr": "331"
},
"0001563855": {
"rank": 60,
"ecr": "330"
},
"0001410939": {
"rank": 61,
"ecr": "330"
},
"0001113148": {
"rank": 62,
"ecr": "329"
},
"0001369568": {
"rank": 63,
"ecr": "328"
},
"0001557421": {
"rank": 64,
"ecr": "327"
},
"0000872589": {
"rank": 65,
"ecr": "363"
},
"0001130166": {
"rank": 66,
"ecr": "327"
},
"0001544227": {
"rank": 67,
"ecr": "324"
},
"0001160308": {
"rank": 68,
"ecr": "323"
},
"0001385228": {
"rank": 69,
"ecr": "322"
},
"0000818033": {
"rank": 70,
"ecr": "322"
},
"0001095858": {
"rank": 71,
"ecr": "321"
},
"0000936402": {
"rank": 72,
"ecr": "271"
},
"0000891288": {
"rank": 73,
"ecr": "313"
},
"0001082038": {
"rank": 74,
"ecr": "313"
},
"0001338042": {
"rank": 75,
"ecr": "311"
},
"0000849146": {
"rank": 76,
"ecr": "310"
},
"0001082554": {
"rank": 77,
"ecr": "316"
},
"0001069308": {
"rank": 78,
"ecr": "308"
},
"0001174940": {
"rank": 79,
"ecr": "307"
},
"0001322505": {
"rank": 80,
"ecr": "306"
},
"0000832489": {
"rank": 81,
"ecr": "306"
},
"0000003116": {
"rank": 82,
"ecr": "305"
},
"0000792977": {
"rank": 83,
"ecr": "307"
},
"0001125345": {
"rank": 84,
"ecr": "302"
},
"0001488039": {
"rank": 85,
"ecr": "296"
},
"0000944809": {
"rank": 86,
"ecr": "294"
},
"0001293310": {
"rank": 87,
"ecr": "293"
},
"0001567514": {
"rank": 88,
"ecr": "293"
},
"0001427925": {
"rank": 89,
"ecr": "292"
},
"0000200406": {
"rank": 90,
"ecr": "297"
},
"0000768710": {
"rank": 91,
"ecr": "292"
},
"0001368148": {
"rank": 92,
"ecr": "287"
},
"0001178670": {
"rank": 93,
"ecr": "273"
},
"0001130598": {
"rank": 94,
"ecr": "286"
},
"0000748592": {
"rank": 95,
"ecr": "285"
},
"0001048477": {
"rank": 96,
"ecr": "282"
},
"0000357097": {
"rank": 97,
"ecr": "284"
},
"0001516551": {
"rank": 98,
"ecr": "283"
},
"0001088856": {
"rank": 99,
"ecr": "281"
},
"0001461993": {
"rank": 100,
"ecr": "280"
},
"0000275053": {
"rank": 101,
"ecr": "280"
},
"0000059478": {
"rank": 102,
"ecr": "281"
},
"0001325879": {
"rank": 103,
"ecr": "276"
},
"0001375850": {
"rank": 104,
"ecr": "274"
},
"0001019695": {
"rank": 105,
"ecr": "274"
},
"0001107332": {
"rank": 106,
"ecr": "295"
},
"0001510964": {
"rank": 107,
"ecr": "273"
},
"0000831547": {
"rank": 108,
"ecr": "271"
},
"0001061983": {
"rank": 109,
"ecr": "269"
},
"0001235007": {
"rank": 110,
"ecr": "266"
},
"0001383701": {
"rank": 111,
"ecr": "265"
},
"0000875320": {
"rank": 112,
"ecr": "231"
},
"0001534525": {
"rank": 113,
"ecr": "263"
},
"0001130591": {
"rank": 114,
"ecr": "283"
},
"0001311596": {
"rank": 115,
"ecr": "263"
},
"0000078003": {
"rank": 116,
"ecr": "287"
},
"0001062822": {
"rank": 117,
"ecr": "261"
},
"0001373707": {
"rank": 118,
"ecr": "259"
},
"0001024126": {
"rank": 119,
"ecr": "259"
},
"0001114220": {
"rank": 120,
"ecr": "259"
},
"0001106838": {
"rank": 121,
"ecr": "256"
},
"0000919745": {
"rank": 122,
"ecr": "255"
},
"0001585364": {
"rank": 123,
"ecr": "255"
},
"0001042074": {
"rank": 124,
"ecr": "254"
},
"0000816284": {
"rank": 125,
"ecr": "253"
},
"0000786947": {
"rank": 126,
"ecr": "252"
},
"0000855654": {
"rank": 127,
"ecr": "250"
},
"0000912183": {
"rank": 128,
"ecr": "233"
},
"0000891293": {
"rank": 129,
"ecr": "246"
},
"0000874015": {
"rank": 130,
"ecr": "267"
},
"0000908259": {
"rank": 131,
"ecr": "242"
},
"0001578845": {
"rank": 132,
"ecr": "239"
},
"0001444307": {
"rank": 133,
"ecr": "238"
},
"0000879407": {
"rank": 134,
"ecr": "230"
},
"0001344413": {
"rank": 135,
"ecr": "229"
},
"0001473579": {
"rank": 136,
"ecr": "225"
},
"0001133416": {
"rank": 137,
"ecr": "221"
},
"0001302573": {
"rank": 138,
"ecr": "218"
},
"0001533040": {
"rank": 139,
"ecr": "217"
},
"0001059790": {
"rank": 140,
"ecr": "217"
},
"0001295947": {
"rank": 141,
"ecr": "209"
},
"0000704562": {
"rank": 142,
"ecr": "207"
},
"0001036968": {
"rank": 143,
"ecr": "207"
},
"0001420720": {
"rank": 144,
"ecr": "207"
},
"0001159019": {
"rank": 145,
"ecr": "206"
},
"0001333248": {
"rank": 146,
"ecr": "206"
},
"0001401667": {
"rank": 147,
"ecr": "206"
},
"0001379006": {
"rank": 148,
"ecr": "205"
},
"0001347178": {
"rank": 149,
"ecr": "199"
},
"0001430306": {
"rank": 150,
"ecr": "197"
},
"0001415684": {
"rank": 151,
"ecr": "405"
},
"0000069499": {
"rank": 152,
"ecr": "187"
},
"0000896747": {
"rank": 153,
"ecr": "188"
},
"0001411906": {
"rank": 154,
"ecr": "184"
},
"0000885590": {
"rank": 155,
"ecr": "170"
},
"0001017491": {
"rank": 156,
"ecr": "178"
},
"0001011835": {
"rank": 157,
"ecr": "175"
},
"0001367083": {
"rank": 158,
"ecr": "173"
},
"0001326190": {
"rank": 159,
"ecr": "172"
},
"0001436161": {
"rank": 160,
"ecr": "170"
},
"0001400431": {
"rank": 161,
"ecr": "164"
},
"0001389545": {
"rank": 162,
"ecr": "163"
},
"0001208261": {
"rank": 163,
"ecr": "162"
},
"0001396814": {
"rank": 164,
"ecr": "158"
},
"0001168220": {
"rank": 165,
"ecr": "155"
},
"0001010086": {
"rank": 166,
"ecr": "152"
},
"0001576263": {
"rank": 167,
"ecr": "148"
},
"0001316175": {
"rank": 168,
"ecr": "145"
},
"0000934473": {
"rank": 169,
"ecr": "142"
},
"0001135906": {
"rank": 170,
"ecr": "141"
},
"0001070698": {
"rank": 171,
"ecr": "141"
},
"0001053691": {
"rank": 172,
"ecr": "141"
},
"0001356576": {
"rank": 173,
"ecr": "141"
},
"0001069899": {
"rank": 174,
"ecr": "140"
},
"0001041024": {
"rank": 175,
"ecr": "140"
},
"0000858803": {
"rank": 176,
"ecr": "138"
},
"0001061027": {
"rank": 177,
"ecr": "138"
},
"0001063104": {
"rank": 178,
"ecr": "136"
},
"0001183765": {
"rank": 179,
"ecr": "136"
},
"0001100412": {
"rank": 180,
"ecr": "135"
},
"0000906709": {
"rank": 181,
"ecr": "135"
},
"0001390478": {
"rank": 182,
"ecr": "135"
},
"0001029125": {
"rank": 183,
"ecr": "133"
},
"0000897448": {
"rank": 184,
"ecr": "132"
},
"0001176309": {
"rank": 185,
"ecr": "132"
},
"0000899460": {
"rank": 186,
"ecr": "132"
},
"0001317880": {
"rank": 187,
"ecr": "131"
},
"0000791908": {
"rank": 188,
"ecr": "131"
},
"0001261734": {
"rank": 189,
"ecr": "129"
},
"0001274792": {
"rank": 190,
"ecr": "129"
},
"0001318641": {
"rank": 191,
"ecr": "128"
},
"0001053369": {
"rank": 192,
"ecr": "127"
},
"0001267602": {
"rank": 193,
"ecr": "126"
},
"0001279704": {
"rank": 194,
"ecr": "126"
},
"0001355790": {
"rank": 195,
"ecr": "126"
},
"0001502152": {
"rank": 196,
"ecr": "125"
},
"0001016504": {
"rank": 197,
"ecr": "124"
},
"0000737207": {
"rank": 198,
"ecr": "118"
},
"0000812796": {
"rank": 199,
"ecr": "117"
},
"0001103021": {
"rank": 200,
"ecr": "117"
},
"0001260990": {
"rank": 201,
"ecr": "109"
},
"0001411879": {
"rank": 202,
"ecr": "105"
},
"0001100397": {
"rank": 203,
"ecr": "104"
},
"0001335105": {
"rank": 204,
"ecr": "104"
},
"0000072170": {
"rank": 205,
"ecr": "102"
},
"0001285819": {
"rank": 206,
"ecr": "100"
},
"0001522724": {
"rank": 207,
"ecr": "98"
},
"0001498382": {
"rank": 208,
"ecr": "98"
},
"0001158223": {
"rank": 209,
"ecr": "97"
},
"0001388320": {
"rank": 210,
"ecr": "97"
},
"0000802724": {
"rank": 211,
"ecr": "95"
},
"0001175680": {
"rank": 212,
"ecr": "90"
},
"0001335103": {
"rank": 213,
"ecr": "82"
},
"0001355250": {
"rank": 214,
"ecr": "82"
},
"0001420030": {
"rank": 215,
"ecr": "72"
},
"0000890821": {
"rank": 216,
"ecr": "68"
},
"0000034956": {
"rank": 217,
"ecr": "60"
},
"0001228627": {
"rank": 218,
"ecr": "55"
},
"0001072379": {
"rank": 219,
"ecr": "52"
},
"0001410098": {
"rank": 220,
"ecr": "50"
},
"0001438533": {
"rank": 221,
"ecr": "49"
},
"0001124524": {
"rank": 222,
"ecr": "42"
},
"0001422143": {
"rank": 223,
"ecr": "34"
},
"0001422142": {
"rank": 224,
"ecr": "34"
},
"0001409565": {
"rank": 225,
"ecr": "32"
},
"0000805326": {
"rank": 226,
"ecr": "31"
},
"0001509261": {
"rank": 227,
"ecr": "20"
},
"0000811779": {
"rank": 228,
"ecr": "20"
},
"0001140098": {
"rank": 229,
"ecr": "15"
},
"0001366541": {
"rank": 230,
"ecr": "11"
},
"0001024626": {
"rank": 231,
"ecr": "9.4"
},
"0000822370": {
"rank": 232,
"ecr": "5.9"
},
"0001445815": {
"rank": 233,
"ecr": "2.0"
},
"0001385508": {
"rank": 234,
"ecr": "0.097"
}
}
},
"rating_box": [
[
"Top rated",
"58 of 234"
],
[
"Best, worst rating",
"543 %, 0.0974 %"
],
[
"New companies",
"60"
]
],
"regression_plot": "https://www.realrate-archive.com/us_pharma/2013/backtesting_correlation/regression_2013.svg",
"scentences": [
"Hyperion Therapeutics INC climbed 151 positions from 174 to 23 due to its excellent Stockholders Equity.",
"Oncternal Therapeutics Inc lost 150 positions from 51 to 201 due to its bad Comprehensive Net Income.",
"Enanta Pharmaceuticals INC entered the 2014 ranking at rank 5, making it the best newcomer."
],
"url_segment": "2014-us-pharma",
"year": 2014,
"feature_importance": "https://www.realrate-archive.com/us_pharma/2013/feature_importance/feature_importance.svg",
"obs_ecr": {
"0000001800": {
"2011": {
"obs_EconomicCapitalRatio": 1.713107979288017
},
"2012": {
"obs_EconomicCapitalRatio": 1.9818897856107043
},
"2013": {
"obs_EconomicCapitalRatio": 1.769123933983911
},
"2014": {
"obs_EconomicCapitalRatio": 2.1310058713021722
},
"2015": {
"obs_EconomicCapitalRatio": 2.183359905306885
},
"2016": {
"obs_EconomicCapitalRatio": 1.5961090407785672
},
"2017": {
"obs_EconomicCapitalRatio": 2.000468071061702
},
"2018": {
"obs_EconomicCapitalRatio": 2.810827504766453
},
"2019": {
"obs_EconomicCapitalRatio": 3.481865615110975
},
"2020": {
"obs_EconomicCapitalRatio": 4.107812733572192
},
"2021": {
"obs_EconomicCapitalRatio": 5.136856213515629
},
"2022": {
"obs_EconomicCapitalRatio": 3.9093024416771485
},
"2023": {
"obs_EconomicCapitalRatio": 4.126727193145108
},
"2024": {
"obs_EconomicCapitalRatio": 4.006765354897495
},
"2025": {
"obs_EconomicCapitalRatio": 4.169990837258094
}
},
"0000059478": {
"2011": {
"obs_EconomicCapitalRatio": 1.3011542204549682
},
"2012": {
"obs_EconomicCapitalRatio": 1.6073698634051163
},
"2013": {
"obs_EconomicCapitalRatio": 1.7086734027999013
},
"2014": {
"obs_EconomicCapitalRatio": 2.168132783245762
},
"2015": {
"obs_EconomicCapitalRatio": 2.828430576978719
},
"2016": {
"obs_EconomicCapitalRatio": 2.1987283790775205
},
"2017": {
"obs_EconomicCapitalRatio": 2.123950765224203
},
"2018": {
"obs_EconomicCapitalRatio": 2.731455167628783
},
"2019": {
"obs_EconomicCapitalRatio": 3.077422071844895
},
"2020": {
"obs_EconomicCapitalRatio": 3.4529271354729705
},
"2021": {
"obs_EconomicCapitalRatio": 5.70344420672454
},
"2022": {
"obs_EconomicCapitalRatio": 7.6589144018063715
},
"2023": {
"obs_EconomicCapitalRatio": 9.17322017661815
},
"2024": {
"obs_EconomicCapitalRatio": 10.183951826657761
},
"2025": {
"obs_EconomicCapitalRatio": 10.21482121245407
}
},
"0000078003": {
"2011": {
"obs_EconomicCapitalRatio": 0.6204658798489293
},
"2012": {
"obs_EconomicCapitalRatio": 0.7275629998959219
},
"2013": {
"obs_EconomicCapitalRatio": 0.8708003565331511
},
"2014": {
"obs_EconomicCapitalRatio": 0.9027716576964234
},
"2015": {
"obs_EconomicCapitalRatio": 0.9342018064245718
},
"2016": {
"obs_EconomicCapitalRatio": 0.907660993640416
},
"2019": {
"obs_EconomicCapitalRatio": 1.1640232368871106
},
"2020": {
"obs_EconomicCapitalRatio": 1.2783936545298629
},
"2021": {
"obs_EconomicCapitalRatio": 1.8276579049294321
},
"2022": {
"obs_EconomicCapitalRatio": 1.570764514575865
},
"2023": {
"obs_EconomicCapitalRatio": 0.7485848149955884
},
"2024": {
"obs_EconomicCapitalRatio": 0.8004626854205364
},
"2025": {
"obs_EconomicCapitalRatio": 0.8358387669038688
}
},
"0000310158": {
"2011": {
"obs_EconomicCapitalRatio": 1.1838108948285708
},
"2012": {
"obs_EconomicCapitalRatio": 1.3266057959183948
},
"2013": {
"obs_EconomicCapitalRatio": 1.5875598350732738
},
"2014": {
"obs_EconomicCapitalRatio": 1.9668047289520008
},
"2015": {
"obs_EconomicCapitalRatio": 1.765264109808397
},
"2016": {
"obs_EconomicCapitalRatio": 2.179324674206441
},
"2017": {
"obs_EconomicCapitalRatio": 2.2179160781193725
},
"2018": {
"obs_EconomicCapitalRatio": 2.918914539340223
},
"2019": {
"obs_EconomicCapitalRatio": 3.5493653686617934
},
"2020": {
"obs_EconomicCapitalRatio": 2.861832807217268
},
"2021": {
"obs_EconomicCapitalRatio": 2.598974464066237
},
"2022": {
"obs_EconomicCapitalRatio": 3.7956011713029745
},
"2024": {
"obs_EconomicCapitalRatio": 3.2845310383661435
},
"2025": {
"obs_EconomicCapitalRatio": 3.1141288688122706
}
},
"0000200406": {
"2011": {
"obs_EconomicCapitalRatio": 1.585118624542793
},
"2012": {
"obs_EconomicCapitalRatio": 1.504690567647153
},
"2013": {
"obs_EconomicCapitalRatio": 1.9242798191550312
},
"2014": {
"obs_EconomicCapitalRatio": 2.2278890509924185
},
"2016": {
"obs_EconomicCapitalRatio": 2.4777357391297277
},
"2017": {
"obs_EconomicCapitalRatio": 2.3520652022077133
},
"2018": {
"obs_EconomicCapitalRatio": 2.2634671786176646
},
"2019": {
"obs_EconomicCapitalRatio": 2.5042625665138107
},
"2021": {
"obs_EconomicCapitalRatio": 2.7314212375357267
},
"2022": {
"obs_EconomicCapitalRatio": 2.878621220487235
},
"2023": {
"obs_EconomicCapitalRatio": 2.6197519723699583
},
"2024": {
"obs_EconomicCapitalRatio": 2.3191305413843795
},
"2025": {
"obs_EconomicCapitalRatio": 3.119823423001993
}
},
"0000872589": {
"2011": {
"obs_EconomicCapitalRatio": 4.582076910345481
},
"2012": {
"obs_EconomicCapitalRatio": 0.24585036111793895
},
"2013": {
"obs_EconomicCapitalRatio": 0.2815811600194353
},
"2014": {
"obs_EconomicCapitalRatio": 0.3100470608736094
},
"2015": {
"obs_EconomicCapitalRatio": 0.27182465887451096
},
"2016": {
"obs_EconomicCapitalRatio": 0.14892623314075953
},
"2017": {
"obs_EconomicCapitalRatio": 0.12780427752058388
},
"2018": {
"obs_EconomicCapitalRatio": 0.09353815222614291
},
"2019": {
"obs_EconomicCapitalRatio": 0.07405318854905384
},
"2020": {
"obs_EconomicCapitalRatio": 0.07704699466107758
},
"2021": {
"obs_EconomicCapitalRatio": 0.0708054489047348
},
"2022": {
"obs_EconomicCapitalRatio": 0.0728389877336521
},
"2023": {
"obs_EconomicCapitalRatio": 0.0762989818667771
},
"2024": {
"obs_EconomicCapitalRatio": 0.05570410882668733
},
"2025": {
"obs_EconomicCapitalRatio": 0.056457061472648826
}
},
"0000874015": {
"2011": {
"obs_EconomicCapitalRatio": 1.7488613998301505
},
"2012": {
"obs_EconomicCapitalRatio": 2.270155255658294
},
"2013": {
"obs_EconomicCapitalRatio": 7.062785583504883
},
"2014": {
"obs_EconomicCapitalRatio": 8.820019473688006
},
"2015": {
"obs_EconomicCapitalRatio": 8.300195128294876
},
"2016": {
"obs_EconomicCapitalRatio": 7.244631215797163
},
"2017": {
"obs_EconomicCapitalRatio": 5.7055360292456125
},
"2018": {
"obs_EconomicCapitalRatio": 3.4034656712267033
},
"2019": {
"obs_EconomicCapitalRatio": 3.6247798271585627
},
"2020": {
"obs_EconomicCapitalRatio": 4.057757935086542
},
"2021": {
"obs_EconomicCapitalRatio": 2.0111035177647114
},
"2022": {
"obs_EconomicCapitalRatio": 2.405605379604031
},
"2023": {
"obs_EconomicCapitalRatio": 2.5857751168273673
},
"2025": {
"obs_EconomicCapitalRatio": 3.8706342956245274
}
},
"0000875320": {
"2011": {
"obs_EconomicCapitalRatio": 4.011950728873362
},
"2012": {
"obs_EconomicCapitalRatio": 4.271057005011649
},
"2013": {
"obs_EconomicCapitalRatio": 10.465959059153883
},
"2014": {
"obs_EconomicCapitalRatio": 15.896010008565815
},
"2015": {
"obs_EconomicCapitalRatio": 15.592867642583915
},
"2016": {
"obs_EconomicCapitalRatio": 8.296574202463598
},
"2017": {
"obs_EconomicCapitalRatio": 14.958650129119075
},
"2018": {
"obs_EconomicCapitalRatio": 10.253923586592718
},
"2019": {
"obs_EconomicCapitalRatio": 10.706680332118959
},
"2020": {
"obs_EconomicCapitalRatio": 8.238943652191004
},
"2021": {
"obs_EconomicCapitalRatio": 6.737638276287789
},
"2022": {
"obs_EconomicCapitalRatio": 6.652462385791637
},
"2023": {
"obs_EconomicCapitalRatio": 7.506270617948925
},
"2024": {
"obs_EconomicCapitalRatio": 7.310208963840968
},
"2025": {
"obs_EconomicCapitalRatio": 7.120028571708822
}
},
"0000885590": {
"2011": {
"obs_EconomicCapitalRatio": 1.2666859338583747
},
"2012": {
"obs_EconomicCapitalRatio": 1.133546210262225
},
"2013": {
"obs_EconomicCapitalRatio": 1.4857321204621172
},
"2014": {
"obs_EconomicCapitalRatio": 2.022848068353309
},
"2015": {
"obs_EconomicCapitalRatio": 0.8112057344714052
},
"2017": {
"obs_EconomicCapitalRatio": 0.2138501706421959
},
"2018": {
"obs_EconomicCapitalRatio": 0.21104827651258354
},
"2019": {
"obs_EconomicCapitalRatio": 0.31527749153545165
},
"2020": {
"obs_EconomicCapitalRatio": 0.23248358716778134
},
"2021": {
"obs_EconomicCapitalRatio": 0.339482039945958
},
"2022": {
"obs_EconomicCapitalRatio": 0.09104758594800844
},
"2023": {
"obs_EconomicCapitalRatio": 0.09992833157007878
},
"2024": {
"obs_EconomicCapitalRatio": 0.10434237028585064
},
"2025": {
"obs_EconomicCapitalRatio": 0.09893661457111663
}
},
"0001048477": {
"2011": {
"obs_EconomicCapitalRatio": 4.191088034178572
},
"2012": {
"obs_EconomicCapitalRatio": 5.537160403950625
},
"2013": {
"obs_EconomicCapitalRatio": 6.234147377653601
},
"2014": {
"obs_EconomicCapitalRatio": 7.769566635963881
},
"2015": {
"obs_EconomicCapitalRatio": 6.696971026740999
},
"2016": {
"obs_EconomicCapitalRatio": 5.5154730752925385
},
"2017": {
"obs_EconomicCapitalRatio": 4.9407181151439135
},
"2018": {
"obs_EconomicCapitalRatio": 5.116817632896571
},
"2019": {
"obs_EconomicCapitalRatio": 4.872335389121422
},
"2020": {
"obs_EconomicCapitalRatio": 4.209123471121257
},
"2021": {
"obs_EconomicCapitalRatio": 4.250038133443851
},
"2022": {
"obs_EconomicCapitalRatio": 4.766788663625819
},
"2023": {
"obs_EconomicCapitalRatio": 4.161003152678966
},
"2024": {
"obs_EconomicCapitalRatio": 3.023712826972472
},
"2025": {
"obs_EconomicCapitalRatio": 2.5199974939053984
}
},
"0001082554": {
"2011": {
"obs_EconomicCapitalRatio": 2.5911979399197222
},
"2012": {
"obs_EconomicCapitalRatio": 2.465978801573956
},
"2013": {
"obs_EconomicCapitalRatio": 3.924599868968605
},
"2014": {
"obs_EconomicCapitalRatio": 4.970769469753602
},
"2015": {
"obs_EconomicCapitalRatio": 5.218004291411121
},
"2016": {
"obs_EconomicCapitalRatio": 4.35971495180887
},
"2017": {
"obs_EconomicCapitalRatio": 3.262507002920337
},
"2018": {
"obs_EconomicCapitalRatio": 2.2953600704628623
},
"2019": {
"obs_EconomicCapitalRatio": 1.5558122744235194
},
"2020": {
"obs_EconomicCapitalRatio": 2.270010361107863
},
"2021": {
"obs_EconomicCapitalRatio": 3.0205299234286707
},
"2022": {
"obs_EconomicCapitalRatio": 3.437755821443613
},
"2023": {
"obs_EconomicCapitalRatio": 2.471650006778008
},
"2024": {
"obs_EconomicCapitalRatio": 3.880904249672765
},
"2025": {
"obs_EconomicCapitalRatio": 5.057179921650618
}
},
"0001178670": {
"2011": {
"obs_EconomicCapitalRatio": 1.5487006572365678
},
"2012": {
"obs_EconomicCapitalRatio": 4.348978489565005
},
"2013": {
"obs_EconomicCapitalRatio": 14.4117591901869
},
"2014": {
"obs_EconomicCapitalRatio": 12.210984605617043
},
"2015": {
"obs_EconomicCapitalRatio": 10.225771894885957
},
"2016": {
"obs_EconomicCapitalRatio": 4.357512767955176
},
"2017": {
"obs_EconomicCapitalRatio": 10.37169962203894
},
"2018": {
"obs_EconomicCapitalRatio": 7.48962729612636
},
"2019": {
"obs_EconomicCapitalRatio": 7.779988241681978
},
"2020": {
"obs_EconomicCapitalRatio": 5.528023267295534
},
"2021": {
"obs_EconomicCapitalRatio": 6.399472454496644
},
"2022": {
"obs_EconomicCapitalRatio": 8.062817835829533
},
"2023": {
"obs_EconomicCapitalRatio": 6.027810663540046
},
"2024": {
"obs_EconomicCapitalRatio": 7.376380265814746
},
"2025": {
"obs_EconomicCapitalRatio": 11.523330894989943
}
},
"0000025743": {
"2011": {
"obs_EconomicCapitalRatio": 60.20949105963872
},
"2012": {
"obs_EconomicCapitalRatio": 44.69064821898129
},
"2013": {
"obs_EconomicCapitalRatio": 21.201251272186344
},
"2014": {
"obs_EconomicCapitalRatio": 19.322141949843708
},
"2015": {
"obs_EconomicCapitalRatio": 44.10663573129477
},
"2016": {
"obs_EconomicCapitalRatio": 14.66973471892876
},
"2017": {
"obs_EconomicCapitalRatio": 16.58982671505257
},
"2018": {
"obs_EconomicCapitalRatio": 5.458000746358346
},
"2019": {
"obs_EconomicCapitalRatio": 2.484721409784232
},
"2020": {
"obs_EconomicCapitalRatio": 1.3438452828795873
},
"2021": {
"obs_EconomicCapitalRatio": 0.7957005830337637
},
"2022": {
"obs_EconomicCapitalRatio": 0.7475072146889215
},
"2023": {
"obs_EconomicCapitalRatio": 0.8688035841356281
}
},
"0000275053": {
"2011": {
"obs_EconomicCapitalRatio": 1.2531988908057246
},
"2012": {
"obs_EconomicCapitalRatio": 1.1558901920083584
},
"2013": {
"obs_EconomicCapitalRatio": 1.4698845321423835
},
"2014": {
"obs_EconomicCapitalRatio": 1.8506510041043027
},
"2015": {
"obs_EconomicCapitalRatio": 1.3828122477889726
},
"2016": {
"obs_EconomicCapitalRatio": 1.8800614803325786
},
"2017": {
"obs_EconomicCapitalRatio": 1.5906624242068597
},
"2018": {
"obs_EconomicCapitalRatio": 1.0639683885140225
},
"2019": {
"obs_EconomicCapitalRatio": 1.1261240844321403
},
"2020": {
"obs_EconomicCapitalRatio": 1.614631166398386
},
"2021": {
"obs_EconomicCapitalRatio": 2.041252601886645
},
"2022": {
"obs_EconomicCapitalRatio": 1.0248487934144268
},
"2023": {
"obs_EconomicCapitalRatio": 1.9759150347492755
},
"2024": {
"obs_EconomicCapitalRatio": 1.733962234691023
},
"2025": {
"obs_EconomicCapitalRatio": 2.1266911651471774
}
},
"0000315545": {
"2011": {
"obs_EconomicCapitalRatio": 9.728230006085877
},
"2012": {
"obs_EconomicCapitalRatio": 15.887423730276764
},
"2016": {
"obs_EconomicCapitalRatio": 1.0066834133413627
},
"2021": {
"obs_EconomicCapitalRatio": 3.8900064558665526
},
"2022": {
"obs_EconomicCapitalRatio": 8.87714792904606
},
"2023": {
"obs_EconomicCapitalRatio": 7.797781413794207
},
"2024": {
"obs_EconomicCapitalRatio": 12.847856868898074
},
"2025": {
"obs_EconomicCapitalRatio": 6.551754447968051
}
},
"0000318306": {
"2011": {
"obs_EconomicCapitalRatio": 3.1752133102955193
},
"2015": {
"obs_EconomicCapitalRatio": 2.5013091166697334
},
"2016": {
"obs_EconomicCapitalRatio": 3.069615158757255
},
"2017": {
"obs_EconomicCapitalRatio": 7.910921427809256
},
"2018": {
"obs_EconomicCapitalRatio": 3.0094651589500496
},
"2019": {
"obs_EconomicCapitalRatio": 1.3725865674867888
},
"2020": {
"obs_EconomicCapitalRatio": 1.5776662593509971
},
"2021": {
"obs_EconomicCapitalRatio": 0.605095364063935
},
"2022": {
"obs_EconomicCapitalRatio": 0.878496970737568
},
"2023": {
"obs_EconomicCapitalRatio": 2.1538587998309753
},
"2024": {
"obs_EconomicCapitalRatio": 2.8283640249010116
},
"2025": {
"obs_EconomicCapitalRatio": 2.046279329648632
}
},
"0000715446": {
"2012": {
"obs_EconomicCapitalRatio": 8.892991148763185
},
"2014": {
"obs_EconomicCapitalRatio": 3.6906327637788694
},
"2015": {
"obs_EconomicCapitalRatio": 3.876288621898964
},
"2017": {
"obs_EconomicCapitalRatio": 7.917082397538187
},
"2018": {
"obs_EconomicCapitalRatio": 18.202537277953734
},
"2019": {
"obs_EconomicCapitalRatio": 15.15218182490549
},
"2020": {
"obs_EconomicCapitalRatio": 12.697740921912375
},
"2021": {
"obs_EconomicCapitalRatio": 4.776368566800651
},
"2022": {
"obs_EconomicCapitalRatio": 7.387227293212897
},
"2023": {
"obs_EconomicCapitalRatio": 8.690130111527727
},
"2024": {
"obs_EconomicCapitalRatio": 6.821617650312289
},
"2025": {
"obs_EconomicCapitalRatio": 11.76766152312355
}
},
"0000748592": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.6925555190903209
},
"2023": {
"obs_EconomicCapitalRatio": 0.22247029122106401
},
"2024": {
"obs_EconomicCapitalRatio": 3.3355484422032364
},
"2025": {
"obs_EconomicCapitalRatio": 2.100490419769073
}
},
"0000749647": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 1.2119887459957592
},
"2018": {
"obs_EconomicCapitalRatio": 0.7571314740855524
},
"2019": {
"obs_EconomicCapitalRatio": 1.1777291102712146
},
"2020": {
"obs_EconomicCapitalRatio": 0.9468259412544934
},
"2022": {
"obs_EconomicCapitalRatio": 0.3413380313211731
},
"2023": {
"obs_EconomicCapitalRatio": 0.46505525070218745
},
"2024": {
"obs_EconomicCapitalRatio": 1.5915148096808187
},
"2025": {
"obs_EconomicCapitalRatio": 1.2902447483616575
}
},
"0000791908": {
"2011": {
"obs_EconomicCapitalRatio": 0.5583856749916702
},
"2012": {
"obs_EconomicCapitalRatio": 2.1709958491689902
},
"2013": {
"obs_EconomicCapitalRatio": 4.620702296336393
},
"2014": {
"obs_EconomicCapitalRatio": 4.499100115951777
},
"2015": {
"obs_EconomicCapitalRatio": 2.1564470760800925
},
"2016": {
"obs_EconomicCapitalRatio": 0.6280492703738663
},
"2017": {
"obs_EconomicCapitalRatio": 6.4554819522962195
},
"2018": {
"obs_EconomicCapitalRatio": 1.9052029000318187
},
"2019": {
"obs_EconomicCapitalRatio": 3.265630189155313
},
"2020": {
"obs_EconomicCapitalRatio": 5.954049697671537
},
"2021": {
"obs_EconomicCapitalRatio": 2.601758183620559
},
"2022": {
"obs_EconomicCapitalRatio": 2.5787179787158876
},
"2023": {
"obs_EconomicCapitalRatio": 1.1152712280926076
}
},
"0000812796": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 1.3457726017492695
},
"2017": {
"obs_EconomicCapitalRatio": 2.662725746021708
},
"2018": {
"obs_EconomicCapitalRatio": 1.0112986820465009
},
"2019": {
"obs_EconomicCapitalRatio": 3.9109096857646555
},
"2020": {
"obs_EconomicCapitalRatio": 2.1465813648935557
},
"2021": {
"obs_EconomicCapitalRatio": 1.4351857012915932
},
"2022": {
"obs_EconomicCapitalRatio": 1.6716849128061206
},
"2023": {
"obs_EconomicCapitalRatio": 0.7417373755183468
},
"2024": {
"obs_EconomicCapitalRatio": 1.0535798266037453
}
},
"0000832489": {
"2020": {
"obs_EconomicCapitalRatio": 2.533577843676224
},
"2022": {
"obs_EconomicCapitalRatio": 0.9397960609714056
},
"2023": {
"obs_EconomicCapitalRatio": 1.6326053628418118
},
"2024": {
"obs_EconomicCapitalRatio": 3.8621601278642066
},
"2025": {
"obs_EconomicCapitalRatio": 1.1837070965076288
}
},
"0000849146": {
"2011": {
"obs_EconomicCapitalRatio": 5.133799114691684
},
"2012": {
"obs_EconomicCapitalRatio": 7.0759325639561705
},
"2013": {
"obs_EconomicCapitalRatio": 3.8064085468765803
},
"2014": {
"obs_EconomicCapitalRatio": 2.169949711761878
},
"2015": {
"obs_EconomicCapitalRatio": 2.73458678948633
},
"2016": {
"obs_EconomicCapitalRatio": 2.270039911669275
},
"2017": {
"obs_EconomicCapitalRatio": 1.5925782016539693
},
"2018": {
"obs_EconomicCapitalRatio": 3.884682222330364
},
"2019": {
"obs_EconomicCapitalRatio": 4.525643174601984
},
"2020": {
"obs_EconomicCapitalRatio": 2.824684450107507
},
"2021": {
"obs_EconomicCapitalRatio": 1.2348824711451079
},
"2022": {
"obs_EconomicCapitalRatio": 0.7537315251607775
},
"2023": {
"obs_EconomicCapitalRatio": 1.5398212604493489
},
"2024": {
"obs_EconomicCapitalRatio": 4.544921489881177
}
},
"0000863894": {
"2011": {
"obs_EconomicCapitalRatio": 10.700068515838652
},
"2015": {
"obs_EconomicCapitalRatio": 2.006174387707465
},
"2016": {
"obs_EconomicCapitalRatio": 1.4325559018195881
},
"2017": {
"obs_EconomicCapitalRatio": 2.1228772969992913
},
"2018": {
"obs_EconomicCapitalRatio": 2.4982538018636133
},
"2019": {
"obs_EconomicCapitalRatio": 5.21705955273325
},
"2020": {
"obs_EconomicCapitalRatio": 16.967671288010344
},
"2021": {
"obs_EconomicCapitalRatio": 4.876334264454306
},
"2022": {
"obs_EconomicCapitalRatio": 4.237261674743829
},
"2023": {
"obs_EconomicCapitalRatio": 1.6059750284116059
},
"2024": {
"obs_EconomicCapitalRatio": 2.149766238076027
},
"2025": {
"obs_EconomicCapitalRatio": 1.7665972830796772
}
},
"0000879407": {
"2011": {
"obs_EconomicCapitalRatio": 4.558164646367193
},
"2012": {
"obs_EconomicCapitalRatio": 2.7337420538024295
},
"2013": {
"obs_EconomicCapitalRatio": 16.935793379415518
},
"2014": {
"obs_EconomicCapitalRatio": 3.5359828982433434
},
"2015": {
"obs_EconomicCapitalRatio": 4.70934763569825
},
"2016": {
"obs_EconomicCapitalRatio": 1.3333215592276315
},
"2017": {
"obs_EconomicCapitalRatio": 4.183361895725003
},
"2018": {
"obs_EconomicCapitalRatio": 17.57601912062697
},
"2019": {
"obs_EconomicCapitalRatio": 27.19874135672785
},
"2020": {
"obs_EconomicCapitalRatio": 28.20740718699276
},
"2021": {
"obs_EconomicCapitalRatio": 14.158611567248395
},
"2022": {
"obs_EconomicCapitalRatio": 8.308844151619333
},
"2023": {
"obs_EconomicCapitalRatio": 5.212086989973918
},
"2024": {
"obs_EconomicCapitalRatio": 2.325391915553657
},
"2025": {
"obs_EconomicCapitalRatio": 8.216237250704822
}
},
"0000886163": {
"2011": {
"obs_EconomicCapitalRatio": 2.0528169474592
},
"2012": {
"obs_EconomicCapitalRatio": 4.688551600471962
},
"2016": {
"obs_EconomicCapitalRatio": 5.191668762826494
},
"2017": {
"obs_EconomicCapitalRatio": 6.247336815338922
},
"2018": {
"obs_EconomicCapitalRatio": 2.9187542937303745
},
"2019": {
"obs_EconomicCapitalRatio": 1.6909103782381305
},
"2020": {
"obs_EconomicCapitalRatio": 1.6235498567426718
},
"2021": {
"obs_EconomicCapitalRatio": 2.9450386595365905
},
"2022": {
"obs_EconomicCapitalRatio": 2.3986179476784764
},
"2025": {
"obs_EconomicCapitalRatio": 3.675901913739014
}
},
"0000886744": {
"2011": {
"obs_EconomicCapitalRatio": 2.1521859391249407
},
"2012": {
"obs_EconomicCapitalRatio": 3.557226129775963
},
"2013": {
"obs_EconomicCapitalRatio": 16.540241022155513
},
"2014": {
"obs_EconomicCapitalRatio": 4.731529553667248
},
"2015": {
"obs_EconomicCapitalRatio": 9.876524947988056
},
"2016": {
"obs_EconomicCapitalRatio": 4.793318515735717
},
"2017": {
"obs_EconomicCapitalRatio": 5.111053783735203
},
"2018": {
"obs_EconomicCapitalRatio": 1.9713747376326156
},
"2019": {
"obs_EconomicCapitalRatio": 2.9500565017262677
},
"2020": {
"obs_EconomicCapitalRatio": 3.0435783432248256
},
"2021": {
"obs_EconomicCapitalRatio": 2.6099809060401853
},
"2022": {
"obs_EconomicCapitalRatio": 5.278895972838991
},
"2025": {
"obs_EconomicCapitalRatio": 1.876268265003127
}
},
"0000890821": {
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0000897448": {
"2011": {
"obs_EconomicCapitalRatio": 7.060017923283657
}
},
"0000899460": {
"2011": {
"obs_EconomicCapitalRatio": 0.987680321189219
},
"2012": {
"obs_EconomicCapitalRatio": 1.7592520406979646
},
"2013": {
"obs_EconomicCapitalRatio": 6.741934446075487
},
"2014": {
"obs_EconomicCapitalRatio": 5.074493209423393
},
"2015": {
"obs_EconomicCapitalRatio": 2.0503086064890024
},
"2016": {
"obs_EconomicCapitalRatio": 1.6718936044598256
},
"2017": {
"obs_EconomicCapitalRatio": 1.4830988576198576
},
"2018": {
"obs_EconomicCapitalRatio": 0.9114209531413758
},
"2019": {
"obs_EconomicCapitalRatio": 1.4635164586620224
},
"2020": {
"obs_EconomicCapitalRatio": 3.966029438015374
},
"2021": {
"obs_EconomicCapitalRatio": 2.5902381462411137
},
"2022": {
"obs_EconomicCapitalRatio": 3.198017637267306
}
},
"0000906709": {
"2011": {
"obs_EconomicCapitalRatio": 1.2198840615029938
},
"2012": {
"obs_EconomicCapitalRatio": 1.7021961631875409
},
"2013": {
"obs_EconomicCapitalRatio": 2.7465545409505356
},
"2014": {
"obs_EconomicCapitalRatio": 4.680730778508984
},
"2015": {
"obs_EconomicCapitalRatio": 4.5531019930727235
},
"2016": {
"obs_EconomicCapitalRatio": 3.6584647178446996
},
"2017": {
"obs_EconomicCapitalRatio": 19.71925223631124
},
"2018": {
"obs_EconomicCapitalRatio": 4.447823678924978
},
"2019": {
"obs_EconomicCapitalRatio": 2.9932544199314077
},
"2020": {
"obs_EconomicCapitalRatio": 3.349493049250769
},
"2021": {
"obs_EconomicCapitalRatio": 3.5440957945153957
},
"2022": {
"obs_EconomicCapitalRatio": 0.8167920134851411
}
},
"0000908259": {
"2011": {
"obs_EconomicCapitalRatio": 2.2928948216517826
},
"2012": {
"obs_EconomicCapitalRatio": 29.962434305066648
},
"2013": {
"obs_EconomicCapitalRatio": 1.8595490030165929
},
"2014": {
"obs_EconomicCapitalRatio": 2.0938306536143934
},
"2018": {
"obs_EconomicCapitalRatio": 3.38121902646468
},
"2019": {
"obs_EconomicCapitalRatio": 0.9813033712527973
},
"2021": {
"obs_EconomicCapitalRatio": 3.0536485439404255
},
"2022": {
"obs_EconomicCapitalRatio": 0.7373792125771812
},
"2023": {
"obs_EconomicCapitalRatio": 0.6595581698615146
},
"2024": {
"obs_EconomicCapitalRatio": 0.5326676859160112
},
"2025": {
"obs_EconomicCapitalRatio": 0.15128398062521595
}
},
"0000944809": {
"2011": {
"obs_EconomicCapitalRatio": 10.212715569467793
},
"2012": {
"obs_EconomicCapitalRatio": 7.462920051834949
},
"2013": {
"obs_EconomicCapitalRatio": 3.7615161019547734
},
"2014": {
"obs_EconomicCapitalRatio": 4.924906406362779
},
"2015": {
"obs_EconomicCapitalRatio": 3.049230320818117
},
"2016": {
"obs_EconomicCapitalRatio": 3.790950737489276
},
"2017": {
"obs_EconomicCapitalRatio": 1.6797136409187279
},
"2018": {
"obs_EconomicCapitalRatio": 1.000574746336909
},
"2019": {
"obs_EconomicCapitalRatio": 0.6714096811879043
},
"2020": {
"obs_EconomicCapitalRatio": 1.7371110357496995
},
"2021": {
"obs_EconomicCapitalRatio": 2.095893547803228
},
"2022": {
"obs_EconomicCapitalRatio": 0.6548492146984649
},
"2023": {
"obs_EconomicCapitalRatio": 0.9273707539895665
},
"2024": {
"obs_EconomicCapitalRatio": 0.6813640563694751
}
},
"0001001316": {
"2011": {
"obs_EconomicCapitalRatio": 0.02094069371323602
},
"2014": {
"obs_EconomicCapitalRatio": 15.082869869678678
},
"2016": {
"obs_EconomicCapitalRatio": 7.018209109082157
},
"2017": {
"obs_EconomicCapitalRatio": 9.289800999999851
},
"2018": {
"obs_EconomicCapitalRatio": 4.428644142234769
},
"2019": {
"obs_EconomicCapitalRatio": 7.527390932886038
},
"2020": {
"obs_EconomicCapitalRatio": 19.08396570545782
},
"2021": {
"obs_EconomicCapitalRatio": 10.30790574467113
}
},
"0001016504": {
"2011": {
"obs_EconomicCapitalRatio": 0.035945261091117155
},
"2012": {
"obs_EconomicCapitalRatio": 0.18525507371166935
},
"2013": {
"obs_EconomicCapitalRatio": 0.22557068088200882
},
"2014": {
"obs_EconomicCapitalRatio": 0.11401012787599316
},
"2015": {
"obs_EconomicCapitalRatio": 0.1231491667258505
},
"2016": {
"obs_EconomicCapitalRatio": 0.2446976706070115
},
"2017": {
"obs_EconomicCapitalRatio": 0.20948385072936013
},
"2018": {
"obs_EconomicCapitalRatio": 0.2563069722468672
},
"2019": {
"obs_EconomicCapitalRatio": 0.37656625156663687
},
"2020": {
"obs_EconomicCapitalRatio": 1.1464993618718018
},
"2021": {
"obs_EconomicCapitalRatio": 1.697303158889242
},
"2022": {
"obs_EconomicCapitalRatio": 0.7974054290207178
},
"2023": {
"obs_EconomicCapitalRatio": 0.47029170963407396
},
"2024": {
"obs_EconomicCapitalRatio": 0.580653182102171
}
},
"0001023024": {
"2025": {
"obs_EconomicCapitalRatio": 1.5697482097453828
}
},
"0001034842": {
"2011": {
"obs_EconomicCapitalRatio": 4.184973940587285
},
"2018": {
"obs_EconomicCapitalRatio": 4.53448892985124
},
"2019": {
"obs_EconomicCapitalRatio": 3.4290834421731513
},
"2020": {
"obs_EconomicCapitalRatio": 8.246867354558892
},
"2021": {
"obs_EconomicCapitalRatio": 4.014400705411107
},
"2022": {
"obs_EconomicCapitalRatio": 1.531292181419975
},
"2023": {
"obs_EconomicCapitalRatio": 1.782837907433584
},
"2024": {
"obs_EconomicCapitalRatio": 1.8533923185575185
}
},
"0001041024": {
"2011": {
"obs_EconomicCapitalRatio": 6.864401419926169
},
"2012": {
"obs_EconomicCapitalRatio": 7.665477298235786
},
"2013": {
"obs_EconomicCapitalRatio": 16.200961448783545
},
"2014": {
"obs_EconomicCapitalRatio": 6.823227479640062
},
"2015": {
"obs_EconomicCapitalRatio": 10.781551495937341
},
"2016": {
"obs_EconomicCapitalRatio": 7.080561630250149
},
"2017": {
"obs_EconomicCapitalRatio": 9.204121624289595
},
"2018": {
"obs_EconomicCapitalRatio": 3.7248376391274483
},
"2019": {
"obs_EconomicCapitalRatio": 4.411810117408765
},
"2020": {
"obs_EconomicCapitalRatio": 1.534718360025618
},
"2021": {
"obs_EconomicCapitalRatio": 0.7865871894137169
},
"2022": {
"obs_EconomicCapitalRatio": 0.2909490633684185
},
"2023": {
"obs_EconomicCapitalRatio": 1.2794707220084427
},
"2024": {
"obs_EconomicCapitalRatio": 1.5814864872422232
}
},
"0001061983": {
"2011": {
"obs_EconomicCapitalRatio": 2.499653747304144
},
"2012": {
"obs_EconomicCapitalRatio": 2.265925122836351
},
"2013": {
"obs_EconomicCapitalRatio": 3.4818397980547005
},
"2014": {
"obs_EconomicCapitalRatio": 2.398166528838458
},
"2015": {
"obs_EconomicCapitalRatio": 5.132953958619455
},
"2016": {
"obs_EconomicCapitalRatio": 4.003531368306603
},
"2017": {
"obs_EconomicCapitalRatio": 1.886835990998462
},
"2018": {
"obs_EconomicCapitalRatio": 1.7279073639824796
},
"2019": {
"obs_EconomicCapitalRatio": 2.0578846433493947
},
"2020": {
"obs_EconomicCapitalRatio": 3.0945606278198854
},
"2021": {
"obs_EconomicCapitalRatio": 5.258808656390064
},
"2022": {
"obs_EconomicCapitalRatio": 4.01908917413911
}
},
"0001062822": {
"2011": {
"obs_EconomicCapitalRatio": 1.3677650735673388
},
"2012": {
"obs_EconomicCapitalRatio": 4.183731183292958
},
"2013": {
"obs_EconomicCapitalRatio": 4.9070900906027735
},
"2014": {
"obs_EconomicCapitalRatio": 1.4003761344938945
},
"2015": {
"obs_EconomicCapitalRatio": 2.704397422234801
},
"2017": {
"obs_EconomicCapitalRatio": 2.617264752541097
},
"2018": {
"obs_EconomicCapitalRatio": 2.3298433436614046
},
"2019": {
"obs_EconomicCapitalRatio": 1.2634354219312478
},
"2020": {
"obs_EconomicCapitalRatio": 3.9708097565733844
},
"2021": {
"obs_EconomicCapitalRatio": 7.685335401596773
},
"2022": {
"obs_EconomicCapitalRatio": 2.688334739503511
},
"2023": {
"obs_EconomicCapitalRatio": 1.727707860094187
},
"2024": {
"obs_EconomicCapitalRatio": 1.1785439552715242
},
"2025": {
"obs_EconomicCapitalRatio": 3.254076663809848
}
},
"0001069530": {
"2011": {
"obs_EconomicCapitalRatio": 1.6920367721878569
},
"2012": {
"obs_EconomicCapitalRatio": 2.353113921576425
},
"2013": {
"obs_EconomicCapitalRatio": 8.035629301696703
},
"2014": {
"obs_EconomicCapitalRatio": 4.453386467914091
},
"2015": {
"obs_EconomicCapitalRatio": 4.863351449111631
},
"2016": {
"obs_EconomicCapitalRatio": 2.8915258260504832
},
"2017": {
"obs_EconomicCapitalRatio": 4.636648807456758
},
"2018": {
"obs_EconomicCapitalRatio": 1.4092308454695395
},
"2019": {
"obs_EconomicCapitalRatio": 5.275240949415371
},
"2020": {
"obs_EconomicCapitalRatio": 3.988044196645427
},
"2021": {
"obs_EconomicCapitalRatio": 12.502340699582172
},
"2022": {
"obs_EconomicCapitalRatio": 10.744987341161343
},
"2023": {
"obs_EconomicCapitalRatio": 12.416401043316418
},
"2024": {
"obs_EconomicCapitalRatio": 1.3663714024841915
},
"2025": {
"obs_EconomicCapitalRatio": 1.3036319444534121
}
},
"0001070494": {
"2011": {
"obs_EconomicCapitalRatio": 2.932953680881476
},
"2012": {
"obs_EconomicCapitalRatio": 4.5529405778863055
},
"2013": {
"obs_EconomicCapitalRatio": 23.302183453643206
},
"2014": {
"obs_EconomicCapitalRatio": 18.54984696092805
},
"2015": {
"obs_EconomicCapitalRatio": 28.934092219944826
},
"2016": {
"obs_EconomicCapitalRatio": 11.449655133128285
},
"2017": {
"obs_EconomicCapitalRatio": 16.67808614739591
},
"2018": {
"obs_EconomicCapitalRatio": 6.5373853496850005
},
"2019": {
"obs_EconomicCapitalRatio": 15.725238773169458
},
"2020": {
"obs_EconomicCapitalRatio": 18.655998772273424
},
"2021": {
"obs_EconomicCapitalRatio": 9.02784999201308
},
"2022": {
"obs_EconomicCapitalRatio": 6.442054975572726
}
},
"0001087294": {
"2011": {
"obs_EconomicCapitalRatio": 2.133325711370675
},
"2012": {
"obs_EconomicCapitalRatio": 1.4741118648312574
},
"2013": {
"obs_EconomicCapitalRatio": 1.9420121698610198
},
"2014": {
"obs_EconomicCapitalRatio": 1.8405724060005366
},
"2016": {
"obs_EconomicCapitalRatio": 1.5541808322415878
},
"2017": {
"obs_EconomicCapitalRatio": 1.889112943592727
},
"2018": {
"obs_EconomicCapitalRatio": 1.1292501763391123
},
"2019": {
"obs_EconomicCapitalRatio": 0.9859121896587316
},
"2021": {
"obs_EconomicCapitalRatio": 1.0973775649988797
},
"2022": {
"obs_EconomicCapitalRatio": 0.4333168488598409
},
"2023": {
"obs_EconomicCapitalRatio": 0.3715399695981037
},
"2024": {
"obs_EconomicCapitalRatio": 0.5087599565594081
},
"2025": {
"obs_EconomicCapitalRatio": 0.963869140200575
}
},
"0001088856": {
"2011": {
"obs_EconomicCapitalRatio": 12.880945590095282
},
"2012": {
"obs_EconomicCapitalRatio": 2.840563583246527
},
"2013": {
"obs_EconomicCapitalRatio": 7.846638973918242
},
"2014": {
"obs_EconomicCapitalRatio": 12.810210834279417
},
"2015": {
"obs_EconomicCapitalRatio": 14.759813082944229
},
"2016": {
"obs_EconomicCapitalRatio": 18.296036223725203
},
"2017": {
"obs_EconomicCapitalRatio": 16.029930900609163
},
"2018": {
"obs_EconomicCapitalRatio": 8.65608179405391
},
"2019": {
"obs_EconomicCapitalRatio": 6.358701486657653
},
"2020": {
"obs_EconomicCapitalRatio": 9.972013421558033
},
"2021": {
"obs_EconomicCapitalRatio": 9.64819974668179
},
"2022": {
"obs_EconomicCapitalRatio": 6.602885091667568
},
"2023": {
"obs_EconomicCapitalRatio": 8.970790437540055
},
"2024": {
"obs_EconomicCapitalRatio": 10.835124023970803
},
"2025": {
"obs_EconomicCapitalRatio": 16.849652464590477
}
},
"0001094038": {
"2017": {
"obs_EconomicCapitalRatio": 12.248591009591806
},
"2022": {
"obs_EconomicCapitalRatio": 0.9337214180332358
},
"2023": {
"obs_EconomicCapitalRatio": 3.7356145408172226
}
},
"0001107421": {
"2011": {
"obs_EconomicCapitalRatio": 4.3489446663070765
},
"2012": {
"obs_EconomicCapitalRatio": 5.827030060175055
},
"2018": {
"obs_EconomicCapitalRatio": 5.6631567818400965
},
"2020": {
"obs_EconomicCapitalRatio": 7.575407591507219
},
"2021": {
"obs_EconomicCapitalRatio": 4.171108524583441
},
"2022": {
"obs_EconomicCapitalRatio": 2.883405722314086
}
},
"0001124105": {
"2011": {
"obs_EconomicCapitalRatio": 0.20196174709409623
},
"2012": {
"obs_EconomicCapitalRatio": 0.2876341525006027
},
"2013": {
"obs_EconomicCapitalRatio": 0.33472830653949776
},
"2015": {
"obs_EconomicCapitalRatio": 0.07621137264136414
},
"2016": {
"obs_EconomicCapitalRatio": 0.039853488863282854
},
"2017": {
"obs_EconomicCapitalRatio": 0.3820750886265207
},
"2018": {
"obs_EconomicCapitalRatio": 0.2297698596314896
},
"2019": {
"obs_EconomicCapitalRatio": 0.2159376702997681
},
"2020": {
"obs_EconomicCapitalRatio": 0.41223677548471455
},
"2021": {
"obs_EconomicCapitalRatio": 0.143358984955954
},
"2022": {
"obs_EconomicCapitalRatio": 0.43278504174366134
}
},
"0001124524": {
"2011": {
"obs_EconomicCapitalRatio": 2.4648333091878083
},
"2012": {
"obs_EconomicCapitalRatio": 1.8593608580180503
},
"2013": {
"obs_EconomicCapitalRatio": 7.3656864720939925
},
"2014": {
"obs_EconomicCapitalRatio": 8.359677065323194
},
"2015": {
"obs_EconomicCapitalRatio": 5.583052291948538
},
"2017": {
"obs_EconomicCapitalRatio": 19.729762301247288
},
"2018": {
"obs_EconomicCapitalRatio": 7.676546478299643
},
"2020": {
"obs_EconomicCapitalRatio": 5.19008689022509
},
"2021": {
"obs_EconomicCapitalRatio": 3.4190316765012354
},
"2022": {
"obs_EconomicCapitalRatio": 1.09260354339657
},
"2023": {
"obs_EconomicCapitalRatio": 1.0997798689853466
}
},
"0001130166": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001133416": {
"2011": {
"obs_EconomicCapitalRatio": 16.88270157281871
},
"2012": {
"obs_EconomicCapitalRatio": 5.842248119350461
},
"2013": {
"obs_EconomicCapitalRatio": 22.267375550627374
},
"2018": {
"obs_EconomicCapitalRatio": 27.945147556095687
},
"2019": {
"obs_EconomicCapitalRatio": 6.382354795772914
},
"2020": {
"obs_EconomicCapitalRatio": 7.956581110405078
},
"2021": {
"obs_EconomicCapitalRatio": 3.287870628790478
},
"2022": {
"obs_EconomicCapitalRatio": 1.8599439115005227
},
"2023": {
"obs_EconomicCapitalRatio": 1.7657258004588605
},
"2025": {
"obs_EconomicCapitalRatio": 3.119665476127909
}
},
"0001133818": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 1.8441117010428738
},
"2019": {
"obs_EconomicCapitalRatio": 1.9003845840591052
},
"2020": {
"obs_EconomicCapitalRatio": 1.8771993245543837
},
"2021": {
"obs_EconomicCapitalRatio": 2.175547460076075
},
"2022": {
"obs_EconomicCapitalRatio": 1.254415758667267
},
"2023": {
"obs_EconomicCapitalRatio": 1.9355732103322663
}
},
"0001160308": {
"2017": {
"obs_EconomicCapitalRatio": 4.745640338481788
},
"2018": {
"obs_EconomicCapitalRatio": 2.608425955539138
},
"2019": {
"obs_EconomicCapitalRatio": 0.8425161535078196
},
"2020": {
"obs_EconomicCapitalRatio": 1.0736826396507102
},
"2021": {
"obs_EconomicCapitalRatio": 1.3531258013583032
},
"2022": {
"obs_EconomicCapitalRatio": 1.9983725428604209
}
},
"0001174940": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 6.639869177624493
},
"2022": {
"obs_EconomicCapitalRatio": 3.4580165138523955
},
"2023": {
"obs_EconomicCapitalRatio": 4.027329150416326
},
"2024": {
"obs_EconomicCapitalRatio": 2.8724066451160235
},
"2025": {
"obs_EconomicCapitalRatio": 0.5801836078992786
}
},
"0001175680": {
"2012": {
"obs_EconomicCapitalRatio": 11.990129245785083
},
"2013": {
"obs_EconomicCapitalRatio": 12.895495155433496
},
"2018": {
"obs_EconomicCapitalRatio": 12.37742571335845
},
"2019": {
"obs_EconomicCapitalRatio": 10.798161833204716
},
"2020": {
"obs_EconomicCapitalRatio": 60.212585469417306
},
"2021": {
"obs_EconomicCapitalRatio": 4.985942038812679
},
"2022": {
"obs_EconomicCapitalRatio": 2.6172100457911642
},
"2023": {
"obs_EconomicCapitalRatio": 3.114671171984183
}
},
"0001226616": {
"2011": {
"obs_EconomicCapitalRatio": 1.537941564786132
},
"2012": {
"obs_EconomicCapitalRatio": 2.3546405810486153
},
"2013": {
"obs_EconomicCapitalRatio": 2.8607221186039924
},
"2014": {
"obs_EconomicCapitalRatio": 4.577912758120495
},
"2015": {
"obs_EconomicCapitalRatio": 4.904665514441517
},
"2016": {
"obs_EconomicCapitalRatio": 10.416358307263954
},
"2017": {
"obs_EconomicCapitalRatio": 10.052119682955091
},
"2018": {
"obs_EconomicCapitalRatio": 8.212750684667608
},
"2019": {
"obs_EconomicCapitalRatio": 7.170880167965075
},
"2020": {
"obs_EconomicCapitalRatio": 6.36238702776273
},
"2021": {
"obs_EconomicCapitalRatio": 2.9543530255773915
},
"2022": {
"obs_EconomicCapitalRatio": 2.575833676860721
}
},
"0001228627": {
"2011": {
"obs_EconomicCapitalRatio": 4.8858943708985025
},
"2012": {
"obs_EconomicCapitalRatio": 2.6145991303811
},
"2013": {
"obs_EconomicCapitalRatio": 5.051688102935165
},
"2014": {
"obs_EconomicCapitalRatio": 6.044271975481872
},
"2015": {
"obs_EconomicCapitalRatio": 4.276801962477386
},
"2016": {
"obs_EconomicCapitalRatio": 2.731363504841381
},
"2017": {
"obs_EconomicCapitalRatio": 3.285683833578194
},
"2018": {
"obs_EconomicCapitalRatio": 3.49693809277238
},
"2019": {
"obs_EconomicCapitalRatio": 0.9733713874489118
},
"2021": {
"obs_EconomicCapitalRatio": 4.329166205231533
},
"2022": {
"obs_EconomicCapitalRatio": 2.1231238489802973
},
"2023": {
"obs_EconomicCapitalRatio": 2.1080021065509533
}
},
"0001232524": {
"2011": {
"obs_EconomicCapitalRatio": 10.532355239038857
},
"2013": {
"obs_EconomicCapitalRatio": 5.889833169313314
},
"2014": {
"obs_EconomicCapitalRatio": 5.64349843494089
},
"2015": {
"obs_EconomicCapitalRatio": 4.871215974868773
},
"2016": {
"obs_EconomicCapitalRatio": 2.5562075124184336
},
"2017": {
"obs_EconomicCapitalRatio": 2.9738332853576335
},
"2018": {
"obs_EconomicCapitalRatio": 2.6756193268421327
},
"2019": {
"obs_EconomicCapitalRatio": 2.9055945060951887
},
"2020": {
"obs_EconomicCapitalRatio": 2.4278244366726334
},
"2021": {
"obs_EconomicCapitalRatio": 1.1999951953961885
},
"2022": {
"obs_EconomicCapitalRatio": 1.6900419826766677
},
"2023": {
"obs_EconomicCapitalRatio": 1.1819590371878657
},
"2024": {
"obs_EconomicCapitalRatio": 1.1400872089425345
},
"2025": {
"obs_EconomicCapitalRatio": 1.4846995550060347
}
},
"0001262104": {
"2011": {
"obs_EconomicCapitalRatio": 2.976131474060693
},
"2012": {
"obs_EconomicCapitalRatio": 29.84004095620544
},
"2013": {
"obs_EconomicCapitalRatio": 7.194268741361899
},
"2016": {
"obs_EconomicCapitalRatio": 1.5454523453078879
},
"2017": {
"obs_EconomicCapitalRatio": 1.9367829777284602
},
"2018": {
"obs_EconomicCapitalRatio": 1.450311890880624
},
"2019": {
"obs_EconomicCapitalRatio": 1.9689337997298595
},
"2020": {
"obs_EconomicCapitalRatio": 1.4548882386917967
},
"2021": {
"obs_EconomicCapitalRatio": 1.4860588196065856
},
"2022": {
"obs_EconomicCapitalRatio": 0.17066667598512655
}
},
"0001279704": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.7802934836126804
},
"2019": {
"obs_EconomicCapitalRatio": 2.409518801482663
},
"2020": {
"obs_EconomicCapitalRatio": 1.6673740926374905
},
"2021": {
"obs_EconomicCapitalRatio": 1.8215826030676574
},
"2022": {
"obs_EconomicCapitalRatio": 1.0140222570705515
}
},
"0001285819": {
"2011": {
"obs_EconomicCapitalRatio": 3.9008953991679225
},
"2012": {
"obs_EconomicCapitalRatio": 8.856529930836997
},
"2013": {
"obs_EconomicCapitalRatio": 23.416633068756767
},
"2014": {
"obs_EconomicCapitalRatio": 52.38187959476351
},
"2015": {
"obs_EconomicCapitalRatio": 17.417008725890156
},
"2016": {
"obs_EconomicCapitalRatio": 10.493546623850774
},
"2017": {
"obs_EconomicCapitalRatio": 13.17928717267996
},
"2018": {
"obs_EconomicCapitalRatio": 8.556002006090099
},
"2019": {
"obs_EconomicCapitalRatio": 7.515377707617327
},
"2020": {
"obs_EconomicCapitalRatio": 8.340041355471396
},
"2021": {
"obs_EconomicCapitalRatio": 1.9397706515990498
},
"2022": {
"obs_EconomicCapitalRatio": 0.383787450562039
},
"2023": {
"obs_EconomicCapitalRatio": 0.9380626426710665
},
"2024": {
"obs_EconomicCapitalRatio": 3.267956572971576
},
"2025": {
"obs_EconomicCapitalRatio": 4.383705131472446
}
},
"0001326190": {
"2017": {
"obs_EconomicCapitalRatio": 0.6508211474874072
},
"2018": {
"obs_EconomicCapitalRatio": 0.5494527370680612
},
"2019": {
"obs_EconomicCapitalRatio": 0.8698678361974307
},
"2020": {
"obs_EconomicCapitalRatio": 2.992421119800507
},
"2021": {
"obs_EconomicCapitalRatio": 3.0562409786664384
},
"2022": {
"obs_EconomicCapitalRatio": 6.357729243605622
},
"2023": {
"obs_EconomicCapitalRatio": 4.155348811357878
}
},
"0001347178": {
"2011": {
"obs_EconomicCapitalRatio": 0.7547629174581635
},
"2012": {
"obs_EconomicCapitalRatio": 0.8349347296948693
},
"2013": {
"obs_EconomicCapitalRatio": 3.200328803096651
},
"2014": {
"obs_EconomicCapitalRatio": 5.1801032398517055
},
"2015": {
"obs_EconomicCapitalRatio": 2.784492138224985
},
"2016": {
"obs_EconomicCapitalRatio": 4.859040274237193
},
"2017": {
"obs_EconomicCapitalRatio": 4.847027555030574
},
"2018": {
"obs_EconomicCapitalRatio": 6.838860800683274
},
"2019": {
"obs_EconomicCapitalRatio": 3.2008903413809926
},
"2020": {
"obs_EconomicCapitalRatio": 2.368962168982374
},
"2021": {
"obs_EconomicCapitalRatio": 2.7331520944826213
},
"2022": {
"obs_EconomicCapitalRatio": 1.0969963189923904
},
"2023": {
"obs_EconomicCapitalRatio": 0.6082415452655552
},
"2024": {
"obs_EconomicCapitalRatio": 0.7203169054780709
},
"2025": {
"obs_EconomicCapitalRatio": 1.2660125487260627
}
},
"0001348362": {
"2021": {
"obs_EconomicCapitalRatio": 3.688977745827279
},
"2022": {
"obs_EconomicCapitalRatio": 3.6289445963532447
},
"2023": {
"obs_EconomicCapitalRatio": 7.572181575460779
},
"2024": {
"obs_EconomicCapitalRatio": 7.638141696833459
},
"2025": {
"obs_EconomicCapitalRatio": 4.640465465175871
}
},
"0001355790": {
"2011": {
"obs_EconomicCapitalRatio": 9.179995649598776
},
"2012": {
"obs_EconomicCapitalRatio": 4.978283029972212
},
"2013": {
"obs_EconomicCapitalRatio": 4.670844633739837
},
"2014": {
"obs_EconomicCapitalRatio": 2.3489847354135502
},
"2015": {
"obs_EconomicCapitalRatio": 1.3378663555234789
},
"2016": {
"obs_EconomicCapitalRatio": 0.7698728160811572
},
"2017": {
"obs_EconomicCapitalRatio": 1.1388606479717176
},
"2018": {
"obs_EconomicCapitalRatio": 1.5664269146568608
},
"2019": {
"obs_EconomicCapitalRatio": 0.630516760385617
},
"2020": {
"obs_EconomicCapitalRatio": 0.6396888771805517
},
"2021": {
"obs_EconomicCapitalRatio": 0.6840686118043124
},
"2022": {
"obs_EconomicCapitalRatio": 0.267067323314091
}
},
"0001360214": {
"2012": {
"obs_EconomicCapitalRatio": 11.271163127854932
},
"2014": {
"obs_EconomicCapitalRatio": 11.638297387028627
},
"2015": {
"obs_EconomicCapitalRatio": 4.6241476669712975
},
"2016": {
"obs_EconomicCapitalRatio": 1.3484853410256559
},
"2017": {
"obs_EconomicCapitalRatio": 1.4895887864053496
},
"2018": {
"obs_EconomicCapitalRatio": 3.139266496743132
},
"2019": {
"obs_EconomicCapitalRatio": 4.022032566775388
},
"2021": {
"obs_EconomicCapitalRatio": 2.5406885482118433
},
"2022": {
"obs_EconomicCapitalRatio": 2.6086812218171045
},
"2023": {
"obs_EconomicCapitalRatio": 1.3459592890349485
},
"2024": {
"obs_EconomicCapitalRatio": 3.4220324055830136
},
"2025": {
"obs_EconomicCapitalRatio": 4.8861055897922885
}
},
"0001367083": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 1.994470946458264
},
"2014": {
"obs_EconomicCapitalRatio": 0.7868720336054744
},
"2015": {
"obs_EconomicCapitalRatio": 1.891607107582308
},
"2016": {
"obs_EconomicCapitalRatio": 2.6568269721745104
},
"2017": {
"obs_EconomicCapitalRatio": 1.5709904421686274
},
"2018": {
"obs_EconomicCapitalRatio": 0.42252706083525265
},
"2019": {
"obs_EconomicCapitalRatio": 0.6068179714239148
},
"2020": {
"obs_EconomicCapitalRatio": 1.4163627569047794
},
"2021": {
"obs_EconomicCapitalRatio": 1.2007561835223088
},
"2022": {
"obs_EconomicCapitalRatio": 0.24080595316110787
},
"2023": {
"obs_EconomicCapitalRatio": 0.17877829794683045
},
"2024": {
"obs_EconomicCapitalRatio": 0.30807278696085183
},
"2025": {
"obs_EconomicCapitalRatio": 0.5338305819074114
}
},
"0001367644": {
"2011": {
"obs_EconomicCapitalRatio": 1.7976370649598783
},
"2012": {
"obs_EconomicCapitalRatio": 1.6553627727050257
},
"2013": {
"obs_EconomicCapitalRatio": 2.2274553933987518
},
"2014": {
"obs_EconomicCapitalRatio": 1.5230589567105508
},
"2015": {
"obs_EconomicCapitalRatio": 2.1371256774520164
},
"2016": {
"obs_EconomicCapitalRatio": 2.0215611137578677
},
"2017": {
"obs_EconomicCapitalRatio": 3.1513393230994735
},
"2019": {
"obs_EconomicCapitalRatio": 1.5667597014802146
},
"2020": {
"obs_EconomicCapitalRatio": 2.302469812906637
},
"2021": {
"obs_EconomicCapitalRatio": 1.1285330392970574
},
"2022": {
"obs_EconomicCapitalRatio": 0.22635234499274465
},
"2023": {
"obs_EconomicCapitalRatio": 0.08309536561881938
},
"2024": {
"obs_EconomicCapitalRatio": 0.39093964867994657
},
"2025": {
"obs_EconomicCapitalRatio": 0.6154566792280605
}
},
"0001369568": {
"2011": {
"obs_EconomicCapitalRatio": 6.3889201791876715
},
"2012": {
"obs_EconomicCapitalRatio": 1.6500315683457198
},
"2013": {
"obs_EconomicCapitalRatio": 7.24899447590868
},
"2014": {
"obs_EconomicCapitalRatio": 7.717318407302692
},
"2015": {
"obs_EconomicCapitalRatio": 6.397961577879862
},
"2016": {
"obs_EconomicCapitalRatio": 4.096110143541204
},
"2017": {
"obs_EconomicCapitalRatio": 7.592382758094557
},
"2018": {
"obs_EconomicCapitalRatio": 5.934355974386351
},
"2019": {
"obs_EconomicCapitalRatio": 5.80155007335537
},
"2020": {
"obs_EconomicCapitalRatio": 3.295770377836332
},
"2021": {
"obs_EconomicCapitalRatio": 5.317984424463229
},
"2022": {
"obs_EconomicCapitalRatio": 8.584912933619535
},
"2023": {
"obs_EconomicCapitalRatio": 6.301951486531034
}
},
"0001379006": {
"2012": {
"obs_EconomicCapitalRatio": 8.82692233269271
},
"2014": {
"obs_EconomicCapitalRatio": 5.005091122551198
},
"2015": {
"obs_EconomicCapitalRatio": 2.279453044698694
},
"2016": {
"obs_EconomicCapitalRatio": 2.6540924954040306
},
"2017": {
"obs_EconomicCapitalRatio": 3.610151360278
},
"2018": {
"obs_EconomicCapitalRatio": 1.999905258053884
},
"2019": {
"obs_EconomicCapitalRatio": 1.2415729695877673
},
"2020": {
"obs_EconomicCapitalRatio": 2.8594669245643027
},
"2021": {
"obs_EconomicCapitalRatio": 2.974100414432412
},
"2022": {
"obs_EconomicCapitalRatio": 1.1703385171652987
}
},
"0001385818": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.47539841134977767
},
"2019": {
"obs_EconomicCapitalRatio": 0.6184507895794792
},
"2020": {
"obs_EconomicCapitalRatio": 7.419178312245873
},
"2021": {
"obs_EconomicCapitalRatio": 0.21444895471445116
},
"2022": {
"obs_EconomicCapitalRatio": 0.10542865791319143
},
"2023": {
"obs_EconomicCapitalRatio": 0.13920572699943723
},
"2024": {
"obs_EconomicCapitalRatio": 0.08701631303291904
}
},
"0001390478": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 13.057185525906862
},
"2017": {
"obs_EconomicCapitalRatio": 0.5909151161860207
},
"2018": {
"obs_EconomicCapitalRatio": 1.957224034983383
},
"2019": {
"obs_EconomicCapitalRatio": 1.4332895378611077
},
"2021": {
"obs_EconomicCapitalRatio": 5.6975438796109055
},
"2022": {
"obs_EconomicCapitalRatio": 2.5238461075906766
},
"2023": {
"obs_EconomicCapitalRatio": 3.471029264381213
},
"2024": {
"obs_EconomicCapitalRatio": 4.405008459786115
}
},
"0001401667": {
"2012": {
"obs_EconomicCapitalRatio": 6.208129575901305
},
"2013": {
"obs_EconomicCapitalRatio": 47.28546182478878
},
"2016": {
"obs_EconomicCapitalRatio": 8.166416840300958
},
"2017": {
"obs_EconomicCapitalRatio": 26.524215277890093
},
"2018": {
"obs_EconomicCapitalRatio": 3.3687600343432424
},
"2019": {
"obs_EconomicCapitalRatio": 1.515901568624176
},
"2020": {
"obs_EconomicCapitalRatio": 1.793524192155767
},
"2022": {
"obs_EconomicCapitalRatio": 0.9862356814586613
},
"2023": {
"obs_EconomicCapitalRatio": 0.9476593306311685
},
"2024": {
"obs_EconomicCapitalRatio": 0.8715847856281287
},
"2025": {
"obs_EconomicCapitalRatio": 1.9772070498623269
}
},
"0001410098": {
"2011": {
"obs_EconomicCapitalRatio": 1.707348625435781
},
"2012": {
"obs_EconomicCapitalRatio": 5.495184693083727
},
"2013": {
"obs_EconomicCapitalRatio": 3.5549801222373585
},
"2014": {
"obs_EconomicCapitalRatio": 10.54156882709548
},
"2015": {
"obs_EconomicCapitalRatio": 3.5823663057939346
},
"2016": {
"obs_EconomicCapitalRatio": 5.255700805598911
},
"2017": {
"obs_EconomicCapitalRatio": 3.8414521129507024
},
"2018": {
"obs_EconomicCapitalRatio": 8.20786823667722
},
"2022": {
"obs_EconomicCapitalRatio": 4.731337422878887
}
},
"0001427925": {
"2011": {
"obs_EconomicCapitalRatio": 1.3034921695309352
},
"2012": {
"obs_EconomicCapitalRatio": 1.8794397350645533
},
"2013": {
"obs_EconomicCapitalRatio": 6.190613990895643
},
"2014": {
"obs_EconomicCapitalRatio": 4.632558275150405
},
"2015": {
"obs_EconomicCapitalRatio": 1.6283040693257576
},
"2020": {
"obs_EconomicCapitalRatio": 1.2009877482213018
},
"2021": {
"obs_EconomicCapitalRatio": 0.6909657662137705
},
"2022": {
"obs_EconomicCapitalRatio": 0.43682041596359344
},
"2023": {
"obs_EconomicCapitalRatio": 0.98467364218298
},
"2024": {
"obs_EconomicCapitalRatio": 0.7297125653194421
},
"2025": {
"obs_EconomicCapitalRatio": 2.4292445713278736
}
},
"0001429260": {
"2011": {
"obs_EconomicCapitalRatio": 3.253092521290889
},
"2015": {
"obs_EconomicCapitalRatio": 1.6662457324617772
},
"2016": {
"obs_EconomicCapitalRatio": 0.8588979539480799
},
"2018": {
"obs_EconomicCapitalRatio": 0.35840342417624116
},
"2019": {
"obs_EconomicCapitalRatio": 0.9183721904509325
}
},
"0001520262": {
"2011": {
"obs_EconomicCapitalRatio": 8.732023309477322
},
"2012": {
"obs_EconomicCapitalRatio": 2.517461855559167
},
"2021": {
"obs_EconomicCapitalRatio": 2.592124046221965
},
"2022": {
"obs_EconomicCapitalRatio": 2.9128639481286616
}
},
"0000034956": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.3540114054548826
},
"2019": {
"obs_EconomicCapitalRatio": 2.8899991460190257
},
"2020": {
"obs_EconomicCapitalRatio": 4.897165306601755
},
"2022": {
"obs_EconomicCapitalRatio": 3.2820129462831895
}
},
"0001010086": {
"2012": {
"obs_EconomicCapitalRatio": 0.9648025582518476
},
"2013": {
"obs_EconomicCapitalRatio": 0.6122333166847467
},
"2014": {
"obs_EconomicCapitalRatio": 0.17171419351669243
},
"2015": {
"obs_EconomicCapitalRatio": 0.0432894554129469
},
"2016": {
"obs_EconomicCapitalRatio": 0.3312190917217559
},
"2017": {
"obs_EconomicCapitalRatio": 0.8228692095294068
},
"2018": {
"obs_EconomicCapitalRatio": 2.367189708200457
},
"2019": {
"obs_EconomicCapitalRatio": 1.6709424646890423
},
"2020": {
"obs_EconomicCapitalRatio": 4.320985928424905
},
"2021": {
"obs_EconomicCapitalRatio": 2.8752768361840704
},
"2022": {
"obs_EconomicCapitalRatio": 3.4587745773706
},
"2023": {
"obs_EconomicCapitalRatio": 1.9068535975232734
},
"2024": {
"obs_EconomicCapitalRatio": 2.5027926004205803
},
"2025": {
"obs_EconomicCapitalRatio": 3.3031185345796064
}
},
"0001053369": {
"2012": {
"obs_EconomicCapitalRatio": 1.6726245064737015
},
"2013": {
"obs_EconomicCapitalRatio": 3.942127979494112
},
"2014": {
"obs_EconomicCapitalRatio": 2.3327765420151856
},
"2015": {
"obs_EconomicCapitalRatio": 10.622213853856026
},
"2019": {
"obs_EconomicCapitalRatio": 4.007498141213826
},
"2021": {
"obs_EconomicCapitalRatio": 1.6749061695400072
},
"2022": {
"obs_EconomicCapitalRatio": 1.3496143238340297
},
"2023": {
"obs_EconomicCapitalRatio": 5.373588498873877
},
"2024": {
"obs_EconomicCapitalRatio": 10.709577886668663
},
"2025": {
"obs_EconomicCapitalRatio": 7.561446798527235
}
},
"0001072379": {
"2012": {
"obs_EconomicCapitalRatio": 4.228018601326807
},
"2013": {
"obs_EconomicCapitalRatio": 7.2865613000880245
},
"2014": {
"obs_EconomicCapitalRatio": 4.52993998077677
},
"2015": {
"obs_EconomicCapitalRatio": 4.527295199401648
},
"2016": {
"obs_EconomicCapitalRatio": 0.6543832260773149
},
"2017": {
"obs_EconomicCapitalRatio": 1.0230629448163566
},
"2018": {
"obs_EconomicCapitalRatio": 2.3408783084374467
},
"2019": {
"obs_EconomicCapitalRatio": 4.249206486316114
},
"2020": {
"obs_EconomicCapitalRatio": 5.050165155650398
},
"2022": {
"obs_EconomicCapitalRatio": 10.296921656988848
},
"2023": {
"obs_EconomicCapitalRatio": 16.389711808491185
}
},
"0001106644": {
"2012": {
"obs_EconomicCapitalRatio": 0.10529819253310034
},
"2017": {
"obs_EconomicCapitalRatio": 0.20418745392206505
},
"2018": {
"obs_EconomicCapitalRatio": 0.30945320350833017
},
"2019": {
"obs_EconomicCapitalRatio": 0.5937127287741156
},
"2020": {
"obs_EconomicCapitalRatio": 1.145776768270793
},
"2021": {
"obs_EconomicCapitalRatio": 1.0364130811908552
},
"2022": {
"obs_EconomicCapitalRatio": 0.39625593318918223
},
"2023": {
"obs_EconomicCapitalRatio": 0.29740034984607266
}
},
"0001335105": {
"2012": {
"obs_EconomicCapitalRatio": 49.54886091585484
},
"2013": {
"obs_EconomicCapitalRatio": 73.73107600728025
},
"2014": {
"obs_EconomicCapitalRatio": 184.6777060447673
},
"2015": {
"obs_EconomicCapitalRatio": 227.5628680751955
},
"2016": {
"obs_EconomicCapitalRatio": 123.34925799596552
},
"2017": {
"obs_EconomicCapitalRatio": 59.98915919863948
},
"2018": {
"obs_EconomicCapitalRatio": 143.21102280858813
},
"2019": {
"obs_EconomicCapitalRatio": 193.5388975202505
},
"2020": {
"obs_EconomicCapitalRatio": 85.08478882834855
},
"2021": {
"obs_EconomicCapitalRatio": 6.317707417866715
},
"2022": {
"obs_EconomicCapitalRatio": 2.82344689908857
},
"2023": {
"obs_EconomicCapitalRatio": 2.1556305622560687
},
"2024": {
"obs_EconomicCapitalRatio": 6.146495357589595
},
"2025": {
"obs_EconomicCapitalRatio": 3.1498425897523785
}
},
"0001356576": {
"2012": {
"obs_EconomicCapitalRatio": 2.695540367680527
},
"2013": {
"obs_EconomicCapitalRatio": 2.6819507906417344
},
"2014": {
"obs_EconomicCapitalRatio": 3.6192991362911293
},
"2015": {
"obs_EconomicCapitalRatio": 5.316418467284552
},
"2016": {
"obs_EconomicCapitalRatio": 5.88475069658678
},
"2017": {
"obs_EconomicCapitalRatio": 6.845847663884459
},
"2018": {
"obs_EconomicCapitalRatio": 2.2751603686509516
},
"2019": {
"obs_EconomicCapitalRatio": 1.4335697423386706
},
"2020": {
"obs_EconomicCapitalRatio": 1.166670190388528
},
"2021": {
"obs_EconomicCapitalRatio": 1.2466838685294064
},
"2022": {
"obs_EconomicCapitalRatio": 1.5813024649466632
},
"2024": {
"obs_EconomicCapitalRatio": 2.335857420368807
},
"2025": {
"obs_EconomicCapitalRatio": 3.1951230806398243
}
},
"0001388320": {
"2012": {
"obs_EconomicCapitalRatio": 3.1758383030536113
},
"2013": {
"obs_EconomicCapitalRatio": 20.019256940326006
},
"2014": {
"obs_EconomicCapitalRatio": 21.102887995768853
},
"2015": {
"obs_EconomicCapitalRatio": 6.972635870887473
},
"2016": {
"obs_EconomicCapitalRatio": 3.96230988267313
},
"2017": {
"obs_EconomicCapitalRatio": 4.591006599702462
},
"2018": {
"obs_EconomicCapitalRatio": 4.370547084943421
},
"2019": {
"obs_EconomicCapitalRatio": 3.906735389662115
},
"2020": {
"obs_EconomicCapitalRatio": 4.214246383862464
},
"2021": {
"obs_EconomicCapitalRatio": 3.2352607848056922
},
"2022": {
"obs_EconomicCapitalRatio": 3.2565770272742274
},
"2023": {
"obs_EconomicCapitalRatio": 2.1343787594410806
}
},
"0001389545": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 5.799501346685527
},
"2023": {
"obs_EconomicCapitalRatio": 0.14129171741239246
},
"2024": {
"obs_EconomicCapitalRatio": 0.5000556342652639
},
"2025": {
"obs_EconomicCapitalRatio": 29.918924920830538
}
},
"0001396814": {
"2012": {
"obs_EconomicCapitalRatio": 6.812999715393255
},
"2013": {
"obs_EconomicCapitalRatio": 12.636013346815789
},
"2018": {
"obs_EconomicCapitalRatio": 3.3327445733519814
},
"2019": {
"obs_EconomicCapitalRatio": 2.9220177647014838
},
"2020": {
"obs_EconomicCapitalRatio": 2.6584057140847492
},
"2021": {
"obs_EconomicCapitalRatio": 1.5788473346705905
}
},
"0001420720": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.34077731721950805
},
"2019": {
"obs_EconomicCapitalRatio": 0.26100959550370434
},
"2020": {
"obs_EconomicCapitalRatio": 3.164789801549658
},
"2021": {
"obs_EconomicCapitalRatio": 1.4815209121315438
},
"2022": {
"obs_EconomicCapitalRatio": 0.057123507229856735
}
},
"0001445815": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.08307183763266385
},
"2018": {
"obs_EconomicCapitalRatio": 311.14325814608617
},
"2019": {
"obs_EconomicCapitalRatio": 39.30893470756033
},
"2020": {
"obs_EconomicCapitalRatio": 17.983410572796405
},
"2022": {
"obs_EconomicCapitalRatio": 24.0879966140076
},
"2024": {
"obs_EconomicCapitalRatio": 7.4472678808704975
},
"2025": {
"obs_EconomicCapitalRatio": 3.879519452350511
}
},
"0001530746": {
"2012": {
"obs_EconomicCapitalRatio": 48.743731158522266
},
"2015": {
"obs_EconomicCapitalRatio": 2.874689942555272
},
"2020": {
"obs_EconomicCapitalRatio": 5.888234447141673
},
"2021": {
"obs_EconomicCapitalRatio": 0.22244353315329501
}
},
"0001533040": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.6486316593055985
},
"2023": {
"obs_EconomicCapitalRatio": 0.3373636555128727
},
"2024": {
"obs_EconomicCapitalRatio": 0.6281623329011384
},
"2025": {
"obs_EconomicCapitalRatio": 0.9997190225657764
}
},
"0001538495": {
"2014": {
"obs_EconomicCapitalRatio": 90.5824484998404
},
"2018": {
"obs_EconomicCapitalRatio": 97.152601082712
},
"2019": {
"obs_EconomicCapitalRatio": 8.080338857180678
},
"2023": {
"obs_EconomicCapitalRatio": 8.712763067559049
},
"2024": {
"obs_EconomicCapitalRatio": 13.4928062961499
},
"2025": {
"obs_EconomicCapitalRatio": 7.536035522691852
}
},
"0001544227": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 5.756485829560471
}
},
"0000818033": {
"2013": {
"obs_EconomicCapitalRatio": 3.2901186557493314
},
"2014": {
"obs_EconomicCapitalRatio": 6.2947477925451345
},
"2016": {
"obs_EconomicCapitalRatio": 6.69787657841924
},
"2017": {
"obs_EconomicCapitalRatio": 5.773831569020795
},
"2018": {
"obs_EconomicCapitalRatio": 6.710899739303245
},
"2019": {
"obs_EconomicCapitalRatio": 7.210154006316952
},
"2020": {
"obs_EconomicCapitalRatio": 7.984729054440954
},
"2021": {
"obs_EconomicCapitalRatio": 3.7120049615170845
},
"2022": {
"obs_EconomicCapitalRatio": 1.227031168154277
}
},
"0000822370": {
"2013": {
"obs_EconomicCapitalRatio": 16.953206263457304
},
"2014": {
"obs_EconomicCapitalRatio": 12.503291998490209
},
"2015": {
"obs_EconomicCapitalRatio": 0.9501448579961315
},
"2016": {
"obs_EconomicCapitalRatio": 13.956093492017365
},
"2017": {
"obs_EconomicCapitalRatio": 3.983601278513772
},
"2018": {
"obs_EconomicCapitalRatio": 1.715303466761049
},
"2021": {
"obs_EconomicCapitalRatio": 1.1111050021413131
},
"2022": {
"obs_EconomicCapitalRatio": 0.25056198404886904
}
},
"0000887151": {
"2016": {
"obs_EconomicCapitalRatio": 3.851922974427995
},
"2017": {
"obs_EconomicCapitalRatio": 3.076097907239819
}
},
"0001069899": {
"2014": {
"obs_EconomicCapitalRatio": 0.8935879204520644
},
"2015": {
"obs_EconomicCapitalRatio": 0.9508600960375623
},
"2016": {
"obs_EconomicCapitalRatio": 0.793610361831243
},
"2017": {
"obs_EconomicCapitalRatio": 1.016798789211543
},
"2018": {
"obs_EconomicCapitalRatio": 0.9354751915827592
},
"2019": {
"obs_EconomicCapitalRatio": 0.6931133060887299
},
"2020": {
"obs_EconomicCapitalRatio": 0.49350298466545506
},
"2021": {
"obs_EconomicCapitalRatio": 0.5200930672010649
},
"2022": {
"obs_EconomicCapitalRatio": 0.313936991934562
}
},
"0001104506": {
"2013": {
"obs_EconomicCapitalRatio": 6.239386499572907
},
"2014": {
"obs_EconomicCapitalRatio": 5.559776850126781
}
},
"0001125345": {
"2013": {
"obs_EconomicCapitalRatio": 7.803881980904605
},
"2014": {
"obs_EconomicCapitalRatio": 8.424909912013891
},
"2015": {
"obs_EconomicCapitalRatio": 5.284021545136552
},
"2016": {
"obs_EconomicCapitalRatio": 3.9013252707834996
},
"2017": {
"obs_EconomicCapitalRatio": 3.1599055119679273
},
"2018": {
"obs_EconomicCapitalRatio": 2.527222996513196
},
"2019": {
"obs_EconomicCapitalRatio": 2.6990521646869077
},
"2020": {
"obs_EconomicCapitalRatio": 5.983826636156595
},
"2021": {
"obs_EconomicCapitalRatio": 4.738597933159698
},
"2022": {
"obs_EconomicCapitalRatio": 1.7374711486845418
},
"2023": {
"obs_EconomicCapitalRatio": 2.7508258106149883
},
"2024": {
"obs_EconomicCapitalRatio": 0.9955773842653965
},
"2025": {
"obs_EconomicCapitalRatio": 0.44188357025285224
}
},
"0001130598": {
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.8760307150595883
}
},
"0001176309": {
"2013": {
"obs_EconomicCapitalRatio": 18.96374780999439
},
"2015": {
"obs_EconomicCapitalRatio": 6.853734582183693
},
"2016": {
"obs_EconomicCapitalRatio": 2.526336074927299
},
"2017": {
"obs_EconomicCapitalRatio": 4.125791873249401
},
"2018": {
"obs_EconomicCapitalRatio": 1.7197718408127676
},
"2019": {
"obs_EconomicCapitalRatio": 3.430129084485662
},
"2020": {
"obs_EconomicCapitalRatio": 3.471973647944272
},
"2021": {
"obs_EconomicCapitalRatio": 7.578119224307776
},
"2023": {
"obs_EconomicCapitalRatio": 0.6042175137645596
},
"2024": {
"obs_EconomicCapitalRatio": 1.0805057222764693
}
},
"0001177648": {
"2013": {
"obs_EconomicCapitalRatio": 8.112576671408831
},
"2014": {
"obs_EconomicCapitalRatio": 11.458921414358276
},
"2015": {
"obs_EconomicCapitalRatio": 4.739370496323121
},
"2016": {
"obs_EconomicCapitalRatio": 4.347583184663215
},
"2017": {
"obs_EconomicCapitalRatio": 6.320430181270734
},
"2018": {
"obs_EconomicCapitalRatio": 6.28232019258115
},
"2019": {
"obs_EconomicCapitalRatio": 4.868766833283514
},
"2020": {
"obs_EconomicCapitalRatio": 3.31097125848491
},
"2021": {
"obs_EconomicCapitalRatio": 6.40068695232658
},
"2022": {
"obs_EconomicCapitalRatio": 4.51700389556921
},
"2023": {
"obs_EconomicCapitalRatio": 0.5518999495160052
}
},
"0001295947": {
"2013": {
"obs_EconomicCapitalRatio": 1.234083101191435
},
"2017": {
"obs_EconomicCapitalRatio": 0.6751705902222275
},
"2018": {
"obs_EconomicCapitalRatio": 0.5002811341605694
},
"2019": {
"obs_EconomicCapitalRatio": 0.702931364694115
},
"2020": {
"obs_EconomicCapitalRatio": 0.5977205081707389
},
"2021": {
"obs_EconomicCapitalRatio": 1.12929687903751
},
"2022": {
"obs_EconomicCapitalRatio": 1.0708172655863475
},
"2023": {
"obs_EconomicCapitalRatio": 1.1593510793678938
},
"2024": {
"obs_EconomicCapitalRatio": 1.5607829762146974
}
},
"0001422142": {
"2018": {
"obs_EconomicCapitalRatio": 2.0166717971745087
},
"2019": {
"obs_EconomicCapitalRatio": 1.0673470561314449
},
"2020": {
"obs_EconomicCapitalRatio": 2.074347492998886
},
"2021": {
"obs_EconomicCapitalRatio": 5.79141032727474
},
"2022": {
"obs_EconomicCapitalRatio": 2.893564453874418
},
"2023": {
"obs_EconomicCapitalRatio": 0.6359938686600423
},
"2024": {
"obs_EconomicCapitalRatio": 1.6662710669263088
}
},
"0001422143": {
"2015": {
"obs_EconomicCapitalRatio": 3.369248096829516
},
"2016": {
"obs_EconomicCapitalRatio": 3.1625897198124835
},
"2017": {
"obs_EconomicCapitalRatio": 8.25384480595116
},
"2018": {
"obs_EconomicCapitalRatio": 4.985778240350756
},
"2019": {
"obs_EconomicCapitalRatio": 4.867052264367894
},
"2020": {
"obs_EconomicCapitalRatio": 5.976791842622965
},
"2021": {
"obs_EconomicCapitalRatio": 3.5394127480171993
},
"2022": {
"obs_EconomicCapitalRatio": 3.261053122473768
}
},
"0001430306": {
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 0.7326351572316913
},
"2025": {
"obs_EconomicCapitalRatio": 1.2786182495279823
}
},
"0001434868": {
"2013": {
"obs_EconomicCapitalRatio": 4.990914676628872
},
"2014": {
"obs_EconomicCapitalRatio": 9.726111733017273
},
"2015": {
"obs_EconomicCapitalRatio": 3.3754092489620873
},
"2016": {
"obs_EconomicCapitalRatio": 2.2034935943965324
},
"2017": {
"obs_EconomicCapitalRatio": 10.321430770156113
},
"2018": {
"obs_EconomicCapitalRatio": 11.344584986079722
},
"2019": {
"obs_EconomicCapitalRatio": 7.5531542464423955
},
"2020": {
"obs_EconomicCapitalRatio": 1.9574243547929262
},
"2021": {
"obs_EconomicCapitalRatio": 0.30890702629983063
},
"2022": {
"obs_EconomicCapitalRatio": 1.0976268299515959
},
"2023": {
"obs_EconomicCapitalRatio": 0.6167576764568707
},
"2024": {
"obs_EconomicCapitalRatio": 0.8127698162651695
},
"2025": {
"obs_EconomicCapitalRatio": 1.505606914542882
}
},
"0001438533": {
"2013": {
"obs_EconomicCapitalRatio": 4.338907006980449
},
"2014": {
"obs_EconomicCapitalRatio": 2.2438108045252743
},
"2015": {
"obs_EconomicCapitalRatio": 1.9909044593386087
},
"2016": {
"obs_EconomicCapitalRatio": 1.9465652604480188
},
"2017": {
"obs_EconomicCapitalRatio": 2.3240419148596247
},
"2018": {
"obs_EconomicCapitalRatio": 1.6932986955759188
},
"2019": {
"obs_EconomicCapitalRatio": 1.2469359762444685
},
"2020": {
"obs_EconomicCapitalRatio": 2.7955623418513964
},
"2021": {
"obs_EconomicCapitalRatio": 2.987538852042171
},
"2022": {
"obs_EconomicCapitalRatio": 1.990765953595929
},
"2023": {
"obs_EconomicCapitalRatio": 0.966461297382591
},
"2024": {
"obs_EconomicCapitalRatio": 2.3819207475662103
},
"2025": {
"obs_EconomicCapitalRatio": 6.058174443400131
}
},
"0001439222": {
"2013": {
"obs_EconomicCapitalRatio": 6.010792545649196
},
"2014": {
"obs_EconomicCapitalRatio": 14.427215733512456
},
"2015": {
"obs_EconomicCapitalRatio": 10.152840121937325
},
"2016": {
"obs_EconomicCapitalRatio": 5.1377806433858195
},
"2017": {
"obs_EconomicCapitalRatio": 6.359322116960603
},
"2018": {
"obs_EconomicCapitalRatio": 5.099084201225455
},
"2019": {
"obs_EconomicCapitalRatio": 4.9771337691935384
},
"2020": {
"obs_EconomicCapitalRatio": 4.619781227945105
},
"2021": {
"obs_EconomicCapitalRatio": 2.3379954495073885
},
"2022": {
"obs_EconomicCapitalRatio": 2.240306141532274
},
"2023": {
"obs_EconomicCapitalRatio": 2.421286069721265
},
"2024": {
"obs_EconomicCapitalRatio": 2.226980796611712
},
"2025": {
"obs_EconomicCapitalRatio": 2.1892605948265986
}
},
"0001447028": {
"2014": {
"obs_EconomicCapitalRatio": 4.137390561672009
},
"2015": {
"obs_EconomicCapitalRatio": 0.5718949329772033
},
"2016": {
"obs_EconomicCapitalRatio": 0.7939316007515166
},
"2017": {
"obs_EconomicCapitalRatio": 1.8297281847793387
},
"2018": {
"obs_EconomicCapitalRatio": 1.6735901287268171
},
"2021": {
"obs_EconomicCapitalRatio": 4.5460396854681004
},
"2022": {
"obs_EconomicCapitalRatio": 2.950860947004616
},
"2023": {
"obs_EconomicCapitalRatio": 4.256969558004361
},
"2024": {
"obs_EconomicCapitalRatio": 7.315003596033688
}
},
"0001488039": {
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 1.464336515563814
},
"2019": {
"obs_EconomicCapitalRatio": 1.8789726658392594
},
"2020": {
"obs_EconomicCapitalRatio": 0.31720077467551944
},
"2021": {
"obs_EconomicCapitalRatio": 3.084746010229382
},
"2022": {
"obs_EconomicCapitalRatio": 1.1138704020398191
}
},
"0001498382": {
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 3.577001255121189
},
"2021": {
"obs_EconomicCapitalRatio": 6.072430958497425
},
"2022": {
"obs_EconomicCapitalRatio": 68.63174459169403
}
},
"0001503802": {
"2014": {
"obs_EconomicCapitalRatio": 10.568267673318969
},
"2015": {
"obs_EconomicCapitalRatio": 4.234783843903932
},
"2017": {
"obs_EconomicCapitalRatio": 3.9041353963426646
},
"2018": {
"obs_EconomicCapitalRatio": 2.2353114096595594
},
"2019": {
"obs_EconomicCapitalRatio": 4.452252617312478
},
"2020": {
"obs_EconomicCapitalRatio": 4.039306074089596
},
"2021": {
"obs_EconomicCapitalRatio": 1.4804850726715195
},
"2022": {
"obs_EconomicCapitalRatio": 0.6665063990066935
}
},
"0001509261": {
"2013": {
"obs_EconomicCapitalRatio": 5.086219265656686
},
"2014": {
"obs_EconomicCapitalRatio": 6.0707381417572925
},
"2015": {
"obs_EconomicCapitalRatio": 4.985934370337063
},
"2016": {
"obs_EconomicCapitalRatio": 6.283976228503316
},
"2017": {
"obs_EconomicCapitalRatio": 6.795295310951352
},
"2018": {
"obs_EconomicCapitalRatio": 1.3518936383405822
},
"2019": {
"obs_EconomicCapitalRatio": 3.0683180651136253
},
"2020": {
"obs_EconomicCapitalRatio": 16.80130407778926
},
"2021": {
"obs_EconomicCapitalRatio": 2.4576320665776623
},
"2022": {
"obs_EconomicCapitalRatio": 0.9410206800819028
}
},
"0001510964": {
"2013": {
"obs_EconomicCapitalRatio": 14.68082349336576
},
"2014": {
"obs_EconomicCapitalRatio": 7.935457650084689
},
"2015": {
"obs_EconomicCapitalRatio": 0.40491650603475937
},
"2016": {
"obs_EconomicCapitalRatio": 1.4697979619780515
},
"2017": {
"obs_EconomicCapitalRatio": 2.555887871177016
},
"2018": {
"obs_EconomicCapitalRatio": 18.640806572937688
},
"2019": {
"obs_EconomicCapitalRatio": 2.5922748033763816
},
"2020": {
"obs_EconomicCapitalRatio": 1.9188970641079883
},
"2021": {
"obs_EconomicCapitalRatio": 0.7811896639092076
},
"2022": {
"obs_EconomicCapitalRatio": 0.34310972374923965
}
},
"0001516551": {
"2015": {
"obs_EconomicCapitalRatio": 4.119831509212193
},
"2016": {
"obs_EconomicCapitalRatio": 7.634612941564023
},
"2017": {
"obs_EconomicCapitalRatio": 4.691264869308869
},
"2018": {
"obs_EconomicCapitalRatio": 5.017589306013457
},
"2019": {
"obs_EconomicCapitalRatio": 14.945189639139171
},
"2020": {
"obs_EconomicCapitalRatio": 4.395640268516184
},
"2021": {
"obs_EconomicCapitalRatio": 3.8168424336686164
},
"2022": {
"obs_EconomicCapitalRatio": 1.1601060857746122
},
"2023": {
"obs_EconomicCapitalRatio": 2.7796492108229773
},
"2024": {
"obs_EconomicCapitalRatio": 2.1016027261151256
},
"2025": {
"obs_EconomicCapitalRatio": 1.4748690162029767
}
},
"0001534525": {
"2017": {
"obs_EconomicCapitalRatio": 1.4490394659367776
},
"2018": {
"obs_EconomicCapitalRatio": 1.7484343180061497
},
"2019": {
"obs_EconomicCapitalRatio": 0.6382098530180732
},
"2020": {
"obs_EconomicCapitalRatio": 1.7628676846384046
},
"2021": {
"obs_EconomicCapitalRatio": 1.7651874702486943
},
"2022": {
"obs_EconomicCapitalRatio": 0.543535154049098
},
"2023": {
"obs_EconomicCapitalRatio": 0.9367081985114467
},
"2024": {
"obs_EconomicCapitalRatio": 1.6132142321110672
},
"2025": {
"obs_EconomicCapitalRatio": 1.0385019129814923
}
},
"0001535955": {
"2013": {
"obs_EconomicCapitalRatio": 3.80951395842458
},
"2014": {
"obs_EconomicCapitalRatio": 4.484665187952989
},
"2015": {
"obs_EconomicCapitalRatio": 9.666698677538678
},
"2016": {
"obs_EconomicCapitalRatio": 4.874530917876101
},
"2017": {
"obs_EconomicCapitalRatio": 4.6990766813576395
},
"2018": {
"obs_EconomicCapitalRatio": 1.7078513542217602
},
"2019": {
"obs_EconomicCapitalRatio": 0.5361184010136972
},
"2020": {
"obs_EconomicCapitalRatio": 5.216460021131948
},
"2021": {
"obs_EconomicCapitalRatio": 3.08629287481249
},
"2022": {
"obs_EconomicCapitalRatio": 1.8362438163077024
},
"2023": {
"obs_EconomicCapitalRatio": 1.214237420839552
},
"2024": {
"obs_EconomicCapitalRatio": 2.1281845992346944
},
"2025": {
"obs_EconomicCapitalRatio": 2.6318924774286794
}
},
"0001551152": {
"2013": {
"obs_EconomicCapitalRatio": 2.830790180578059
},
"2014": {
"obs_EconomicCapitalRatio": 3.433454015057143
},
"2015": {
"obs_EconomicCapitalRatio": 1.9423485332421722
},
"2016": {
"obs_EconomicCapitalRatio": 1.7976357034299837
},
"2017": {
"obs_EconomicCapitalRatio": 2.4973235713716044
},
"2018": {
"obs_EconomicCapitalRatio": 2.4285136647028804
},
"2019": {
"obs_EconomicCapitalRatio": 1.9353808052892818
},
"2020": {
"obs_EconomicCapitalRatio": 1.6600659528716244
},
"2021": {
"obs_EconomicCapitalRatio": 2.207745471098879
},
"2022": {
"obs_EconomicCapitalRatio": 3.004369768582203
},
"2023": {
"obs_EconomicCapitalRatio": 2.896346731964981
},
"2024": {
"obs_EconomicCapitalRatio": 3.4184774378859855
},
"2025": {
"obs_EconomicCapitalRatio": 4.486019242804715
}
},
"0001559053": {
"2013": {
"obs_EconomicCapitalRatio": 6.274475527995295
},
"2014": {
"obs_EconomicCapitalRatio": 3.555240237199364
},
"2015": {
"obs_EconomicCapitalRatio": 10.781347415563726
},
"2016": {
"obs_EconomicCapitalRatio": 6.262097250121002
},
"2017": {
"obs_EconomicCapitalRatio": 4.853544935160512
},
"2018": {
"obs_EconomicCapitalRatio": 1.203722221822252
},
"2019": {
"obs_EconomicCapitalRatio": 2.234599621041635
},
"2020": {
"obs_EconomicCapitalRatio": 2.1603142399661874
},
"2024": {
"obs_EconomicCapitalRatio": 2.690037933050509
},
"2025": {
"obs_EconomicCapitalRatio": 2.7366970621221456
}
},
"0001580149": {
"2020": {
"obs_EconomicCapitalRatio": 16.645305521172176
},
"2022": {
"obs_EconomicCapitalRatio": 11.007711429755684
},
"2023": {
"obs_EconomicCapitalRatio": 1.7609395614375387
},
"2024": {
"obs_EconomicCapitalRatio": 2.1427383390745054
}
},
"0001585364": {
"2014": {
"obs_EconomicCapitalRatio": 1.797467911617485
},
"2016": {
"obs_EconomicCapitalRatio": 0.8588285460560211
},
"2017": {
"obs_EconomicCapitalRatio": 1.1182437890174832
},
"2018": {
"obs_EconomicCapitalRatio": 0.5289068467907572
},
"2019": {
"obs_EconomicCapitalRatio": 0.6971525678852332
},
"2020": {
"obs_EconomicCapitalRatio": 0.5723944883354882
},
"2021": {
"obs_EconomicCapitalRatio": 0.5576594937896573
},
"2022": {
"obs_EconomicCapitalRatio": 0.4367027339465495
},
"2023": {
"obs_EconomicCapitalRatio": 0.4500543240745834
},
"2024": {
"obs_EconomicCapitalRatio": 0.43153707026666605
},
"2025": {
"obs_EconomicCapitalRatio": 0.25459107099964257
}
},
"0000894158": {
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.45840814733792534
},
"2019": {
"obs_EconomicCapitalRatio": 0.7458799373449941
},
"2020": {
"obs_EconomicCapitalRatio": 1.2450476388168137
},
"2021": {
"obs_EconomicCapitalRatio": 1.104415694485011
},
"2022": {
"obs_EconomicCapitalRatio": 0.158159831871509
},
"2023": {
"obs_EconomicCapitalRatio": 0.2288718953647814
}
},
"0001005286": {
"2014": {
"obs_EconomicCapitalRatio": 1.7964608968568716
},
"2015": {
"obs_EconomicCapitalRatio": 1.3881882041224352
},
"2016": {
"obs_EconomicCapitalRatio": 1.6000760916448888
},
"2017": {
"obs_EconomicCapitalRatio": 1.3934041904536012
},
"2018": {
"obs_EconomicCapitalRatio": 1.274525956308206
},
"2019": {
"obs_EconomicCapitalRatio": 0.8782635756660979
},
"2020": {
"obs_EconomicCapitalRatio": 0.7241950199416594
},
"2021": {
"obs_EconomicCapitalRatio": 0.8085732734578128
},
"2023": {
"obs_EconomicCapitalRatio": 0.7946687239882525
}
},
"0001081938": {
"2014": {
"obs_EconomicCapitalRatio": 24.798158649712516
},
"2018": {
"obs_EconomicCapitalRatio": 3.0340184485227577
},
"2019": {
"obs_EconomicCapitalRatio": 4.094288661085645
},
"2020": {
"obs_EconomicCapitalRatio": 1.400630499064566
},
"2022": {
"obs_EconomicCapitalRatio": 0.22856186348027485
},
"2023": {
"obs_EconomicCapitalRatio": 0.02085915706496507
},
"2024": {
"obs_EconomicCapitalRatio": 0.274704453126574
},
"2025": {
"obs_EconomicCapitalRatio": 0.15591606480719788
}
},
"0001157601": {
"2014": {
"obs_EconomicCapitalRatio": 4.341188952805879
},
"2018": {
"obs_EconomicCapitalRatio": 6.488683448986104
},
"2019": {
"obs_EconomicCapitalRatio": 6.067750596961241
},
"2020": {
"obs_EconomicCapitalRatio": 10.865689025506962
},
"2021": {
"obs_EconomicCapitalRatio": 8.130161003271429
},
"2022": {
"obs_EconomicCapitalRatio": 17.64314754873853
},
"2023": {
"obs_EconomicCapitalRatio": 10.491030513883619
},
"2024": {
"obs_EconomicCapitalRatio": 10.157226400900424
},
"2025": {
"obs_EconomicCapitalRatio": 13.989437963906283
}
},
"0001178253": {
"2014": {
"obs_EconomicCapitalRatio": 3.6521598876967274
},
"2015": {
"obs_EconomicCapitalRatio": 2.8445582088352213
},
"2017": {
"obs_EconomicCapitalRatio": 1.8020299925753376
},
"2018": {
"obs_EconomicCapitalRatio": 0.5211327320508553
},
"2019": {
"obs_EconomicCapitalRatio": 0.8852073910277948
},
"2020": {
"obs_EconomicCapitalRatio": 0.8514995515209948
},
"2021": {
"obs_EconomicCapitalRatio": 1.6132436985084486
},
"2022": {
"obs_EconomicCapitalRatio": 0.5986303702132718
}
},
"0001253689": {
"2022": {
"obs_EconomicCapitalRatio": 3.563091100578236
},
"2023": {
"obs_EconomicCapitalRatio": 5.536842666003607
}
},
"0001297184": {
"2014": {
"obs_EconomicCapitalRatio": 2.1269462487249093
},
"2015": {
"obs_EconomicCapitalRatio": 2.65513432698816
},
"2016": {
"obs_EconomicCapitalRatio": 3.5203039587929785
},
"2017": {
"obs_EconomicCapitalRatio": 3.1242555268336623
},
"2018": {
"obs_EconomicCapitalRatio": 2.7752269134021916
},
"2019": {
"obs_EconomicCapitalRatio": 2.4411844945872296
},
"2020": {
"obs_EconomicCapitalRatio": 2.217148801257373
},
"2021": {
"obs_EconomicCapitalRatio": 2.4283466270366865
},
"2022": {
"obs_EconomicCapitalRatio": 2.8741219144747516
},
"2023": {
"obs_EconomicCapitalRatio": 2.4367223036504586
}
},
"0001343009": {
"2014": {
"obs_EconomicCapitalRatio": 11.135576808625036
},
"2015": {
"obs_EconomicCapitalRatio": 29.204850072482998
},
"2017": {
"obs_EconomicCapitalRatio": 57.14357766254051
},
"2018": {
"obs_EconomicCapitalRatio": 21.073064451886307
},
"2019": {
"obs_EconomicCapitalRatio": 1.6521169122003325
},
"2020": {
"obs_EconomicCapitalRatio": 25.04805838183159
},
"2021": {
"obs_EconomicCapitalRatio": 5.575010777304091
},
"2022": {
"obs_EconomicCapitalRatio": 2.222389581523738
},
"2023": {
"obs_EconomicCapitalRatio": 0.25153193883875463
}
},
"0001393434": {
"2014": {
"obs_EconomicCapitalRatio": 9.723762656180517
},
"2015": {
"obs_EconomicCapitalRatio": 3.6396014649500734
},
"2016": {
"obs_EconomicCapitalRatio": 4.245367407321326
},
"2017": {
"obs_EconomicCapitalRatio": 3.1586602946560784
},
"2018": {
"obs_EconomicCapitalRatio": 3.098624810304815
},
"2019": {
"obs_EconomicCapitalRatio": 2.3784652282637255
},
"2020": {
"obs_EconomicCapitalRatio": 6.806910043019627
},
"2021": {
"obs_EconomicCapitalRatio": 3.3165392530152924
},
"2022": {
"obs_EconomicCapitalRatio": 1.6004878747764422
},
"2023": {
"obs_EconomicCapitalRatio": 1.5903378431512945
}
},
"0001401914": {
"2014": {
"obs_EconomicCapitalRatio": 3.9749108988053177
},
"2015": {
"obs_EconomicCapitalRatio": 1.7793294237143362
},
"2016": {
"obs_EconomicCapitalRatio": 0.647193872144733
},
"2021": {
"obs_EconomicCapitalRatio": 4.188590883783982
},
"2022": {
"obs_EconomicCapitalRatio": 1.899653309523115
},
"2023": {
"obs_EconomicCapitalRatio": 1.3773038942544311
},
"2024": {
"obs_EconomicCapitalRatio": 1.1054306529956048
}
},
"0001404281": {
"2014": {
"obs_EconomicCapitalRatio": 5.641429299848193
},
"2021": {
"obs_EconomicCapitalRatio": 0.7230097507704459
},
"2022": {
"obs_EconomicCapitalRatio": 0.6498330155428738
}
},
"0001404644": {
"2014": {
"obs_EconomicCapitalRatio": 3.112438741240614
},
"2015": {
"obs_EconomicCapitalRatio": 3.66314659749228
},
"2016": {
"obs_EconomicCapitalRatio": 4.666188054215424
},
"2017": {
"obs_EconomicCapitalRatio": 4.472501841321298
},
"2018": {
"obs_EconomicCapitalRatio": 1.2201436186914152
},
"2022": {
"obs_EconomicCapitalRatio": 0.2718573870509964
},
"2023": {
"obs_EconomicCapitalRatio": 1.1061815689134848
},
"2024": {
"obs_EconomicCapitalRatio": 1.861957314482675
}
},
"0001437402": {
"2014": {
"obs_EconomicCapitalRatio": 4.926661749470438
},
"2015": {
"obs_EconomicCapitalRatio": 7.937166009598443
},
"2016": {
"obs_EconomicCapitalRatio": 5.864265172195904
},
"2017": {
"obs_EconomicCapitalRatio": 3.5416783481777787
},
"2018": {
"obs_EconomicCapitalRatio": 0.8694093294722323
},
"2019": {
"obs_EconomicCapitalRatio": 2.97619547684202
},
"2020": {
"obs_EconomicCapitalRatio": 4.502454051781784
},
"2021": {
"obs_EconomicCapitalRatio": 1.167873651644269
},
"2022": {
"obs_EconomicCapitalRatio": 3.1398158634339004
},
"2023": {
"obs_EconomicCapitalRatio": 6.850181889159298
},
"2024": {
"obs_EconomicCapitalRatio": 3.222650149881341
},
"2025": {
"obs_EconomicCapitalRatio": 3.367464199027977
}
},
"0001485003": {
"2023": {
"obs_EconomicCapitalRatio": 1.5632126082991586
},
"2024": {
"obs_EconomicCapitalRatio": 0.4148454443859101
}
},
"0001517022": {
"2014": {
"obs_EconomicCapitalRatio": 4.010819223234276
},
"2015": {
"obs_EconomicCapitalRatio": 4.8237243575533135
},
"2016": {
"obs_EconomicCapitalRatio": 1.4730434380249977
},
"2017": {
"obs_EconomicCapitalRatio": 2.3876562009982942
},
"2018": {
"obs_EconomicCapitalRatio": 0.48055421021598477
},
"2019": {
"obs_EconomicCapitalRatio": 1.3494051436213654
},
"2020": {
"obs_EconomicCapitalRatio": 0.8291826353614926
},
"2021": {
"obs_EconomicCapitalRatio": 0.870633819197869
},
"2022": {
"obs_EconomicCapitalRatio": 0.2233559190516168
},
"2023": {
"obs_EconomicCapitalRatio": 0.875991209192467
},
"2024": {
"obs_EconomicCapitalRatio": 1.6501753585300492
},
"2025": {
"obs_EconomicCapitalRatio": 1.219065982409421
}
},
"0001517681": {
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001527728": {
"2018": {
"obs_EconomicCapitalRatio": 2.302516553080004
},
"2019": {
"obs_EconomicCapitalRatio": 2.3775735808175726
},
"2023": {
"obs_EconomicCapitalRatio": 6.055969830162965
},
"2024": {
"obs_EconomicCapitalRatio": 1.6861727041832997
}
},
"0001540159": {
"2015": {
"obs_EconomicCapitalRatio": 8.276585544563552
},
"2016": {
"obs_EconomicCapitalRatio": 2.6501242318372156
},
"2017": {
"obs_EconomicCapitalRatio": 1.9270691516342444
},
"2018": {
"obs_EconomicCapitalRatio": 0.7880523009856242
},
"2020": {
"obs_EconomicCapitalRatio": 8.152620731319265
},
"2022": {
"obs_EconomicCapitalRatio": 5.054299772437978
},
"2023": {
"obs_EconomicCapitalRatio": 2.854481801541483
},
"2024": {
"obs_EconomicCapitalRatio": 2.1800251672491813
},
"2025": {
"obs_EconomicCapitalRatio": 1.6714362166326928
}
},
"0001574235": {
"2014": {
"obs_EconomicCapitalRatio": 2.0469770380681473
},
"2015": {
"obs_EconomicCapitalRatio": 2.207632602380119
},
"2016": {
"obs_EconomicCapitalRatio": 0.7181712517809893
},
"2017": {
"obs_EconomicCapitalRatio": 2.8167511874971356
},
"2018": {
"obs_EconomicCapitalRatio": 1.626270015339166
},
"2019": {
"obs_EconomicCapitalRatio": 0.5494034407077054
},
"2020": {
"obs_EconomicCapitalRatio": 1.5457787375224854
},
"2021": {
"obs_EconomicCapitalRatio": 0.6892383766578533
},
"2022": {
"obs_EconomicCapitalRatio": 0.49146228292780314
},
"2023": {
"obs_EconomicCapitalRatio": 0.28093937465011043
},
"2024": {
"obs_EconomicCapitalRatio": 4.120047303893817
},
"2025": {
"obs_EconomicCapitalRatio": 3.8419290070237064
}
},
"0001582313": {
"2014": {
"obs_EconomicCapitalRatio": 4.392368429265987
},
"2015": {
"obs_EconomicCapitalRatio": 3.476660776453972
},
"2016": {
"obs_EconomicCapitalRatio": 4.103680140318783
},
"2017": {
"obs_EconomicCapitalRatio": 1.614193722770627
},
"2018": {
"obs_EconomicCapitalRatio": 2.093243843844552
},
"2019": {
"obs_EconomicCapitalRatio": 3.3904067163153058
},
"2020": {
"obs_EconomicCapitalRatio": 4.973343390727814
},
"2021": {
"obs_EconomicCapitalRatio": 5.3605927874064205
},
"2022": {
"obs_EconomicCapitalRatio": 6.135998550200953
}
},
"0001582554": {
"2014": {
"obs_EconomicCapitalRatio": 6.583806821973907
},
"2015": {
"obs_EconomicCapitalRatio": 8.203102613253769
},
"2016": {
"obs_EconomicCapitalRatio": 12.462807120338587
},
"2017": {
"obs_EconomicCapitalRatio": 14.12256248864945
},
"2018": {
"obs_EconomicCapitalRatio": 5.7222806221190705
},
"2019": {
"obs_EconomicCapitalRatio": 12.112346070508153
},
"2020": {
"obs_EconomicCapitalRatio": 5.299472496229888
},
"2021": {
"obs_EconomicCapitalRatio": 6.349425394200524
},
"2022": {
"obs_EconomicCapitalRatio": 4.169448789703781
},
"2023": {
"obs_EconomicCapitalRatio": 3.1366592849168913
},
"2024": {
"obs_EconomicCapitalRatio": 0.3033443877558794
},
"2025": {
"obs_EconomicCapitalRatio": 0.9102057238354853
}
},
"0001583107": {
"2014": {
"obs_EconomicCapitalRatio": 2.524510289086943
},
"2015": {
"obs_EconomicCapitalRatio": 3.5502715758954673
},
"2016": {
"obs_EconomicCapitalRatio": 4.769352639402022
},
"2017": {
"obs_EconomicCapitalRatio": 5.97018939026352
},
"2018": {
"obs_EconomicCapitalRatio": 4.009561421194865
},
"2019": {
"obs_EconomicCapitalRatio": 5.525429130789294
},
"2020": {
"obs_EconomicCapitalRatio": 3.9967540930032373
},
"2021": {
"obs_EconomicCapitalRatio": 3.6474585228242065
},
"2022": {
"obs_EconomicCapitalRatio": 2.371147972942393
},
"2023": {
"obs_EconomicCapitalRatio": 2.7435188030991986
}
},
"0001583648": {
"2015": {
"obs_EconomicCapitalRatio": 4.7747987863209085
},
"2016": {
"obs_EconomicCapitalRatio": 2.596238426600483
},
"2017": {
"obs_EconomicCapitalRatio": 2.7677828179053505
},
"2018": {
"obs_EconomicCapitalRatio": 1.141407671889934
},
"2019": {
"obs_EconomicCapitalRatio": 1.5409437503001444
},
"2020": {
"obs_EconomicCapitalRatio": 1.6540422363874783
},
"2021": {
"obs_EconomicCapitalRatio": 1.8727478616863706
},
"2022": {
"obs_EconomicCapitalRatio": 0.8323592340556023
},
"2023": {
"obs_EconomicCapitalRatio": 0.6057469211723506
}
},
"0000014272": {
"2015": {
"obs_EconomicCapitalRatio": 3.2475450415220855
},
"2016": {
"obs_EconomicCapitalRatio": 2.7259590116089485
},
"2017": {
"obs_EconomicCapitalRatio": 2.650646716670952
},
"2018": {
"obs_EconomicCapitalRatio": 2.199930130401309
},
"2020": {
"obs_EconomicCapitalRatio": 1.114835636149512
},
"2021": {
"obs_EconomicCapitalRatio": 1.2419398460280224
},
"2022": {
"obs_EconomicCapitalRatio": 1.612627956472529
},
"2023": {
"obs_EconomicCapitalRatio": 1.138243408987469
},
"2024": {
"obs_EconomicCapitalRatio": 1.2721676304709277
},
"2025": {
"obs_EconomicCapitalRatio": 1.321169806314478
}
},
"0000873303": {
"2015": {
"obs_EconomicCapitalRatio": 9.668485604102845
},
"2016": {
"obs_EconomicCapitalRatio": 6.233662004332542
},
"2017": {
"obs_EconomicCapitalRatio": 3.924175866378392
},
"2018": {
"obs_EconomicCapitalRatio": 6.339103672060055
},
"2019": {
"obs_EconomicCapitalRatio": 6.823271045904484
},
"2020": {
"obs_EconomicCapitalRatio": 5.29119921898451
},
"2021": {
"obs_EconomicCapitalRatio": 2.9435836473847226
},
"2022": {
"obs_EconomicCapitalRatio": 3.8077405647956177
}
},
"0001128189": {
"2016": {
"obs_EconomicCapitalRatio": 42.5561641662153
},
"2017": {
"obs_EconomicCapitalRatio": 44.12701545013146
},
"2018": {
"obs_EconomicCapitalRatio": 100.30969158981598
},
"2019": {
"obs_EconomicCapitalRatio": 88.26242021178395
},
"2020": {
"obs_EconomicCapitalRatio": 104.06358738597007
},
"2021": {
"obs_EconomicCapitalRatio": 89.94199206829096
},
"2022": {
"obs_EconomicCapitalRatio": 41.60826773992075
},
"2023": {
"obs_EconomicCapitalRatio": 22.90371520612683
},
"2024": {
"obs_EconomicCapitalRatio": 12.311765432860431
}
},
"0001267565": {
"2015": {
"obs_EconomicCapitalRatio": 9.545499460498341
},
"2016": {
"obs_EconomicCapitalRatio": 4.83483609366986
},
"2017": {
"obs_EconomicCapitalRatio": 7.157401045644926
},
"2018": {
"obs_EconomicCapitalRatio": 2.1923205454261003
},
"2019": {
"obs_EconomicCapitalRatio": 2.5638217711610176
},
"2020": {
"obs_EconomicCapitalRatio": 1.1945982442476681
},
"2021": {
"obs_EconomicCapitalRatio": 1.1275846582888194
},
"2022": {
"obs_EconomicCapitalRatio": 0.7166745350456436
},
"2023": {
"obs_EconomicCapitalRatio": 0.9397213313234996
},
"2025": {
"obs_EconomicCapitalRatio": 1.0262046808470957
}
},
"0001281895": {
"2015": {
"obs_EconomicCapitalRatio": 5.0364370997148225
},
"2016": {
"obs_EconomicCapitalRatio": 1.9822646801810113
},
"2017": {
"obs_EconomicCapitalRatio": 0.8946573077218604
},
"2018": {
"obs_EconomicCapitalRatio": 3.5163891482923164
},
"2019": {
"obs_EconomicCapitalRatio": 5.289572624031411
},
"2020": {
"obs_EconomicCapitalRatio": 9.152568054550002
},
"2021": {
"obs_EconomicCapitalRatio": 5.464254934454973
},
"2022": {
"obs_EconomicCapitalRatio": 4.816510052502813
}
},
"0001326732": {
"2015": {
"obs_EconomicCapitalRatio": 4.7370337142113
},
"2016": {
"obs_EconomicCapitalRatio": 3.9967030445270955
},
"2017": {
"obs_EconomicCapitalRatio": 4.202511162476909
},
"2018": {
"obs_EconomicCapitalRatio": 6.073969875839424
},
"2019": {
"obs_EconomicCapitalRatio": 5.83986745888784
},
"2020": {
"obs_EconomicCapitalRatio": 6.222607779114316
},
"2021": {
"obs_EconomicCapitalRatio": 4.9964835227058515
},
"2022": {
"obs_EconomicCapitalRatio": 3.2034867036915506
},
"2023": {
"obs_EconomicCapitalRatio": 2.070616845257262
},
"2024": {
"obs_EconomicCapitalRatio": 2.7552069968217667
},
"2025": {
"obs_EconomicCapitalRatio": 1.9795640740863942
}
},
"0001348911": {
"2015": {
"obs_EconomicCapitalRatio": 0.20211091249350502
},
"2016": {
"obs_EconomicCapitalRatio": 12.845502948864823
},
"2017": {
"obs_EconomicCapitalRatio": 5.386046168520068
},
"2019": {
"obs_EconomicCapitalRatio": 4.363753356040546
},
"2020": {
"obs_EconomicCapitalRatio": 6.251934538262092
},
"2021": {
"obs_EconomicCapitalRatio": 2.3451793339305693
},
"2022": {
"obs_EconomicCapitalRatio": 1.2250090948446972
}
},
"0001372514": {
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 4.8687372773255175
},
"2020": {
"obs_EconomicCapitalRatio": 2.1345849403381534
},
"2021": {
"obs_EconomicCapitalRatio": 0.8948813852784885
},
"2022": {
"obs_EconomicCapitalRatio": 0.24485864375810124
},
"2023": {
"obs_EconomicCapitalRatio": 0.3888692783137503
},
"2024": {
"obs_EconomicCapitalRatio": 0.4182487345061539
}
},
"0001374690": {
"2015": {
"obs_EconomicCapitalRatio": 20.943435399614355
},
"2016": {
"obs_EconomicCapitalRatio": 15.15781782827369
},
"2017": {
"obs_EconomicCapitalRatio": 20.69114475239754
},
"2018": {
"obs_EconomicCapitalRatio": 29.417509168744573
},
"2019": {
"obs_EconomicCapitalRatio": 8.48372085170697
},
"2020": {
"obs_EconomicCapitalRatio": 5.486558924421429
},
"2021": {
"obs_EconomicCapitalRatio": 4.021593630675525
},
"2022": {
"obs_EconomicCapitalRatio": 2.6954254166627156
}
},
"0001434647": {
"2015": {
"obs_EconomicCapitalRatio": 4.4921423898171
},
"2016": {
"obs_EconomicCapitalRatio": 0.5165262290733772
},
"2017": {
"obs_EconomicCapitalRatio": 0.6848099016426473
},
"2018": {
"obs_EconomicCapitalRatio": 0.865624026468524
},
"2019": {
"obs_EconomicCapitalRatio": 0.24683179633840263
},
"2020": {
"obs_EconomicCapitalRatio": 24.491947700213355
},
"2023": {
"obs_EconomicCapitalRatio": 1.2615329818804297
},
"2024": {
"obs_EconomicCapitalRatio": 2.8610987447081255
},
"2025": {
"obs_EconomicCapitalRatio": 2.3330351772908413
}
},
"0001460702": {
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 2.2107914692835418
},
"2022": {
"obs_EconomicCapitalRatio": 3.7082246599908757
},
"2023": {
"obs_EconomicCapitalRatio": 0.9723846982305767
},
"2024": {
"obs_EconomicCapitalRatio": 0.8966105358545655
},
"2025": {
"obs_EconomicCapitalRatio": 0.7992021507471163
}
},
"0001501989": {
"2015": {
"obs_EconomicCapitalRatio": 5.593684092339584
},
"2016": {
"obs_EconomicCapitalRatio": 2.619381599651744
},
"2017": {
"obs_EconomicCapitalRatio": 2.3376888954500075
},
"2018": {
"obs_EconomicCapitalRatio": 1.6725413392645991
},
"2019": {
"obs_EconomicCapitalRatio": 1.2386537359077794
},
"2020": {
"obs_EconomicCapitalRatio": 1.036637404678561
},
"2021": {
"obs_EconomicCapitalRatio": 0.9597362946003473
},
"2022": {
"obs_EconomicCapitalRatio": 0.3339390654966768
}
},
"0001506251": {
"2015": {
"obs_EconomicCapitalRatio": 68.18891485061765
},
"2016": {
"obs_EconomicCapitalRatio": 2.7992844910974117
},
"2017": {
"obs_EconomicCapitalRatio": 2.685011457384177
},
"2018": {
"obs_EconomicCapitalRatio": 1.0813813832971078
},
"2020": {
"obs_EconomicCapitalRatio": 2.2591166917938206
},
"2023": {
"obs_EconomicCapitalRatio": 2.159536016547452
},
"2024": {
"obs_EconomicCapitalRatio": 6.035944830417154
}
},
"0001526119": {
"2015": {
"obs_EconomicCapitalRatio": 1.10776532837638
},
"2017": {
"obs_EconomicCapitalRatio": 2.0776084538190913
},
"2018": {
"obs_EconomicCapitalRatio": 1.1626992843450203
},
"2019": {
"obs_EconomicCapitalRatio": 0.7040930043916058
},
"2020": {
"obs_EconomicCapitalRatio": 3.968963717126026
},
"2021": {
"obs_EconomicCapitalRatio": 6.306571084828538
},
"2022": {
"obs_EconomicCapitalRatio": 1.0850427238616216
},
"2023": {
"obs_EconomicCapitalRatio": 1.839270489546306
}
},
"0001527599": {
"2015": {
"obs_EconomicCapitalRatio": 42.38419100270754
},
"2016": {
"obs_EconomicCapitalRatio": 15.55508778937919
},
"2017": {
"obs_EconomicCapitalRatio": 42.78514884794768
},
"2018": {
"obs_EconomicCapitalRatio": 34.08047468923924
},
"2019": {
"obs_EconomicCapitalRatio": 10.248352718914434
},
"2020": {
"obs_EconomicCapitalRatio": 13.415002946338147
},
"2021": {
"obs_EconomicCapitalRatio": 24.718119187681346
},
"2022": {
"obs_EconomicCapitalRatio": 10.796971933946313
}
},
"0001541157": {
"2015": {
"obs_EconomicCapitalRatio": 333.2338112169181
},
"2025": {
"obs_EconomicCapitalRatio": 557.3736464203313
}
},
"0001553643": {
"2015": {
"obs_EconomicCapitalRatio": 1.7338821891929213
},
"2016": {
"obs_EconomicCapitalRatio": 1.1816013242874706
},
"2017": {
"obs_EconomicCapitalRatio": 4.599958387137025
},
"2018": {
"obs_EconomicCapitalRatio": 5.631594568993065
},
"2020": {
"obs_EconomicCapitalRatio": 8.070490617556281
},
"2021": {
"obs_EconomicCapitalRatio": 3.189405967515967
},
"2023": {
"obs_EconomicCapitalRatio": 1.648304465498439
}
},
"0001557746": {
"2016": {
"obs_EconomicCapitalRatio": 6.604216738408072
},
"2017": {
"obs_EconomicCapitalRatio": 5.6131375883934025
},
"2018": {
"obs_EconomicCapitalRatio": 1.7019790590737285
},
"2019": {
"obs_EconomicCapitalRatio": 1.212098674624993
},
"2020": {
"obs_EconomicCapitalRatio": 5.435226457505301
},
"2021": {
"obs_EconomicCapitalRatio": 5.8301042520779305
},
"2022": {
"obs_EconomicCapitalRatio": 6.499861999475928
},
"2023": {
"obs_EconomicCapitalRatio": 0.6170529806766536
}
},
"0001569340": {
"2015": {
"obs_EconomicCapitalRatio": 9.116142223062687
},
"2020": {
"obs_EconomicCapitalRatio": 11.37309540355387
}
},
"0001585608": {
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001595097": {
"2015": {
"obs_EconomicCapitalRatio": 7.150216686101165
},
"2016": {
"obs_EconomicCapitalRatio": 28.092542245692012
},
"2017": {
"obs_EconomicCapitalRatio": 10.055725124496933
},
"2018": {
"obs_EconomicCapitalRatio": 9.993523112769557
},
"2019": {
"obs_EconomicCapitalRatio": 7.498768621961081
},
"2020": {
"obs_EconomicCapitalRatio": 1.4308728416796583
},
"2021": {
"obs_EconomicCapitalRatio": 1.104648603895476
},
"2022": {
"obs_EconomicCapitalRatio": 0.27635414874298914
}
},
"0001598646": {
"2015": {
"obs_EconomicCapitalRatio": 2.634548670759021
},
"2016": {
"obs_EconomicCapitalRatio": 5.485442013339983
},
"2017": {
"obs_EconomicCapitalRatio": 1.9859162487009006
},
"2018": {
"obs_EconomicCapitalRatio": 2.747774885570393
},
"2019": {
"obs_EconomicCapitalRatio": 4.208753853253404
},
"2020": {
"obs_EconomicCapitalRatio": 3.3886058732353694
},
"2021": {
"obs_EconomicCapitalRatio": 0.5251543288767053
},
"2022": {
"obs_EconomicCapitalRatio": 0.2067192346550029
}
},
"0001607678": {
"2015": {
"obs_EconomicCapitalRatio": 1.9834389723963093
},
"2016": {
"obs_EconomicCapitalRatio": 2.0814310306844765
},
"2017": {
"obs_EconomicCapitalRatio": 7.592782060667528
},
"2018": {
"obs_EconomicCapitalRatio": 3.5884317978740667
},
"2019": {
"obs_EconomicCapitalRatio": 4.005092177058184
},
"2020": {
"obs_EconomicCapitalRatio": 3.3915361928929455
},
"2021": {
"obs_EconomicCapitalRatio": 3.468945823287514
},
"2022": {
"obs_EconomicCapitalRatio": 6.479499566971428
}
},
"0001609809": {
"2015": {
"obs_EconomicCapitalRatio": 12.371324494321517
},
"2016": {
"obs_EconomicCapitalRatio": 1.9421880149134538
},
"2017": {
"obs_EconomicCapitalRatio": 2.5908631473715626
},
"2018": {
"obs_EconomicCapitalRatio": 1.384064290835004
},
"2019": {
"obs_EconomicCapitalRatio": 1.8615650337156782
},
"2020": {
"obs_EconomicCapitalRatio": 8.781524800983108
},
"2021": {
"obs_EconomicCapitalRatio": 2.7321700147524
},
"2022": {
"obs_EconomicCapitalRatio": 1.9955432209497879
}
},
"0001618835": {
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 27.260771879425697
},
"2021": {
"obs_EconomicCapitalRatio": 1.304128340362082
},
"2022": {
"obs_EconomicCapitalRatio": 0.14293480962284852
},
"2023": {
"obs_EconomicCapitalRatio": 0.01667205175592019
},
"2024": {
"obs_EconomicCapitalRatio": 0.015834009366340877
},
"2025": {
"obs_EconomicCapitalRatio": 0.023036945432258746
}
},
"0001621221": {
"2019": {
"obs_EconomicCapitalRatio": 2.4753873505624306
},
"2020": {
"obs_EconomicCapitalRatio": 4.264908581177564
},
"2021": {
"obs_EconomicCapitalRatio": 4.02697447143019
},
"2023": {
"obs_EconomicCapitalRatio": 0.6054883871847317
},
"2024": {
"obs_EconomicCapitalRatio": 0.9901373189844184
},
"2025": {
"obs_EconomicCapitalRatio": 0.9241621649519836
}
},
"0001631574": {
"2015": {
"obs_EconomicCapitalRatio": 4.069113217531914
},
"2016": {
"obs_EconomicCapitalRatio": 7.185150465314827
},
"2017": {
"obs_EconomicCapitalRatio": 9.051139386919285
},
"2018": {
"obs_EconomicCapitalRatio": 4.859865684220317
},
"2019": {
"obs_EconomicCapitalRatio": 2.1475345165686233
},
"2020": {
"obs_EconomicCapitalRatio": 1.769382687303525
},
"2021": {
"obs_EconomicCapitalRatio": 1.0659833362894395
},
"2022": {
"obs_EconomicCapitalRatio": 3.2970693329247367
}
},
"0001641489": {
"2015": {
"obs_EconomicCapitalRatio": 1.2552103799603973
},
"2016": {
"obs_EconomicCapitalRatio": 1.3459374903125807
},
"2017": {
"obs_EconomicCapitalRatio": 1.1345479524457975
},
"2018": {
"obs_EconomicCapitalRatio": 1.2383672431029904
},
"2019": {
"obs_EconomicCapitalRatio": 4.491518150513322
},
"2020": {
"obs_EconomicCapitalRatio": 7.976879057591623
},
"2021": {
"obs_EconomicCapitalRatio": 3.9162067227323436
},
"2022": {
"obs_EconomicCapitalRatio": 1.826215242233967
},
"2023": {
"obs_EconomicCapitalRatio": 35.7174631241012
},
"2024": {
"obs_EconomicCapitalRatio": 1.1686335633140843
},
"2025": {
"obs_EconomicCapitalRatio": 2.5435087644018997
}
},
"0000812306": {
"2017": {
"obs_EconomicCapitalRatio": 0.7679844265560579
},
"2018": {
"obs_EconomicCapitalRatio": 1.3238043750261224
},
"2019": {
"obs_EconomicCapitalRatio": 1.553680659218853
},
"2020": {
"obs_EconomicCapitalRatio": 3.951228396195592
},
"2021": {
"obs_EconomicCapitalRatio": 1.0293958339533176
},
"2022": {
"obs_EconomicCapitalRatio": 0.9173385873482564
},
"2023": {
"obs_EconomicCapitalRatio": 0.6230011525278941
}
},
"0001014763": {
"2021": {
"obs_EconomicCapitalRatio": 3.2970328242500426
},
"2022": {
"obs_EconomicCapitalRatio": 0.6373987318483224
},
"2023": {
"obs_EconomicCapitalRatio": 2.2353109180655855
},
"2024": {
"obs_EconomicCapitalRatio": 0.2989579783403101
},
"2025": {
"obs_EconomicCapitalRatio": 0.5564579677349022
}
},
"0001395937": {
"2016": {
"obs_EconomicCapitalRatio": 2.0274181405815592
},
"2017": {
"obs_EconomicCapitalRatio": 2.3708227426577966
},
"2018": {
"obs_EconomicCapitalRatio": 1.7735484369185335
},
"2019": {
"obs_EconomicCapitalRatio": 5.012956899172152
},
"2020": {
"obs_EconomicCapitalRatio": 5.657839182322721
},
"2021": {
"obs_EconomicCapitalRatio": 4.338131466604313
},
"2022": {
"obs_EconomicCapitalRatio": 5.533006676662477
}
},
"0001539029": {
"2016": {
"obs_EconomicCapitalRatio": 3.8001069543615715
},
"2017": {
"obs_EconomicCapitalRatio": 5.511027749062352
},
"2018": {
"obs_EconomicCapitalRatio": 1.0708192486420613
},
"2019": {
"obs_EconomicCapitalRatio": 5.457817849157306
},
"2020": {
"obs_EconomicCapitalRatio": 6.830495344600248
}
},
"0001555280": {
"2016": {
"obs_EconomicCapitalRatio": 3.5294023070229286
},
"2017": {
"obs_EconomicCapitalRatio": 4.26721278609896
},
"2019": {
"obs_EconomicCapitalRatio": 5.830222610803596
},
"2020": {
"obs_EconomicCapitalRatio": 6.2465194766286976
},
"2021": {
"obs_EconomicCapitalRatio": 9.433935491487597
},
"2022": {
"obs_EconomicCapitalRatio": 5.098553510112966
},
"2023": {
"obs_EconomicCapitalRatio": 7.413320323582953
},
"2024": {
"obs_EconomicCapitalRatio": 6.132488673752045
},
"2025": {
"obs_EconomicCapitalRatio": 3.9456146954632536
}
},
"0001579428": {
"2016": {
"obs_EconomicCapitalRatio": 4.731285154323032
},
"2017": {
"obs_EconomicCapitalRatio": 4.395347931767885
},
"2018": {
"obs_EconomicCapitalRatio": 4.458882968102999
},
"2019": {
"obs_EconomicCapitalRatio": 26.65313506898581
},
"2022": {
"obs_EconomicCapitalRatio": 11.82261524078376
}
},
"0001583771": {
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 1.4764049161692996
},
"2020": {
"obs_EconomicCapitalRatio": 0.6820121179955333
},
"2021": {
"obs_EconomicCapitalRatio": 1.6165558445799055
},
"2022": {
"obs_EconomicCapitalRatio": 0.6594129903533573
},
"2023": {
"obs_EconomicCapitalRatio": 0.9993418815360613
},
"2024": {
"obs_EconomicCapitalRatio": 1.36001469804817
},
"2025": {
"obs_EconomicCapitalRatio": 0.43504776570784937
}
},
"0001590560": {
"2017": {
"obs_EconomicCapitalRatio": 3.443816673125471
},
"2018": {
"obs_EconomicCapitalRatio": 5.436808380747137
},
"2019": {
"obs_EconomicCapitalRatio": 10.904943748745998
},
"2020": {
"obs_EconomicCapitalRatio": 7.792438910067191
},
"2021": {
"obs_EconomicCapitalRatio": 1.9302182695305188
},
"2022": {
"obs_EconomicCapitalRatio": 2.290830914690775
},
"2023": {
"obs_EconomicCapitalRatio": 0.4456950008088053
}
},
"0001626878": {
"2016": {
"obs_EconomicCapitalRatio": 7.28422372646887
},
"2017": {
"obs_EconomicCapitalRatio": 3.755245458715203
},
"2019": {
"obs_EconomicCapitalRatio": 1.5759474094123005
},
"2020": {
"obs_EconomicCapitalRatio": 2.345949117862805
},
"2021": {
"obs_EconomicCapitalRatio": 2.433294962975098
},
"2022": {
"obs_EconomicCapitalRatio": 0.7500901950035245
},
"2023": {
"obs_EconomicCapitalRatio": 1.0375765523682057
},
"2025": {
"obs_EconomicCapitalRatio": 0.9328657551171378
}
},
"0001626971": {
"2016": {
"obs_EconomicCapitalRatio": 4.277405407531264
},
"2017": {
"obs_EconomicCapitalRatio": 4.149375012876857
},
"2019": {
"obs_EconomicCapitalRatio": 2.6843077546283682
},
"2020": {
"obs_EconomicCapitalRatio": 2.241320520434651
},
"2021": {
"obs_EconomicCapitalRatio": 1.9728459381286443
},
"2022": {
"obs_EconomicCapitalRatio": 0.9395855641792878
},
"2023": {
"obs_EconomicCapitalRatio": 3.1431390679772337
}
},
"0001636282": {
"2016": {
"obs_EconomicCapitalRatio": 1.911949666807195
},
"2017": {
"obs_EconomicCapitalRatio": 2.7490583145413074
},
"2018": {
"obs_EconomicCapitalRatio": 4.003210640999432
},
"2019": {
"obs_EconomicCapitalRatio": 4.235264567342523
},
"2020": {
"obs_EconomicCapitalRatio": 4.34926970229657
},
"2021": {
"obs_EconomicCapitalRatio": 3.0591140227060354
},
"2022": {
"obs_EconomicCapitalRatio": 0.480811302312216
},
"2023": {
"obs_EconomicCapitalRatio": 0.3451585198947146
},
"2024": {
"obs_EconomicCapitalRatio": 3.4522188932719113
},
"2025": {
"obs_EconomicCapitalRatio": 6.1043163744290645
}
},
"0001638287": {
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 9.290038100241892
}
},
"0001651308": {
"2016": {
"obs_EconomicCapitalRatio": 55.07257988517769
},
"2017": {
"obs_EconomicCapitalRatio": 80.78994328623331
},
"2018": {
"obs_EconomicCapitalRatio": 75.19069906966709
},
"2019": {
"obs_EconomicCapitalRatio": 117.56902263238351
},
"2020": {
"obs_EconomicCapitalRatio": 83.7077839131438
},
"2021": {
"obs_EconomicCapitalRatio": 60.09190503077995
},
"2022": {
"obs_EconomicCapitalRatio": 70.79176203538113
},
"2023": {
"obs_EconomicCapitalRatio": 60.354771279349215
},
"2024": {
"obs_EconomicCapitalRatio": 58.74717564636796
},
"2025": {
"obs_EconomicCapitalRatio": 74.46961209797139
}
},
"0001659617": {
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 1.402227694170675
},
"2022": {
"obs_EconomicCapitalRatio": 1.2594041493424097
},
"2023": {
"obs_EconomicCapitalRatio": 0.909656247498064
},
"2025": {
"obs_EconomicCapitalRatio": 13.456130084491564
}
},
"0001680048": {
"2017": {
"obs_EconomicCapitalRatio": 0.2596643535753641
},
"2018": {
"obs_EconomicCapitalRatio": 0.07895219091057175
},
"2019": {
"obs_EconomicCapitalRatio": 0.0501303238990739
},
"2020": {
"obs_EconomicCapitalRatio": 0.03952130469039673
},
"2021": {
"obs_EconomicCapitalRatio": 0.016593300619834713
},
"2022": {
"obs_EconomicCapitalRatio": 0.003244066029327926
},
"2023": {
"obs_EconomicCapitalRatio": 0.06359334012047171
}
},
"0000109657": {
"2020": {
"obs_EconomicCapitalRatio": 1.6846332758244982
},
"2022": {
"obs_EconomicCapitalRatio": 3.276889997621411
},
"2023": {
"obs_EconomicCapitalRatio": 1.0101946437098341
},
"2024": {
"obs_EconomicCapitalRatio": 1.2853889944280936
},
"2025": {
"obs_EconomicCapitalRatio": 1.622201918946696
}
},
"0001173313": {
"2017": {
"obs_EconomicCapitalRatio": 133.7703825988571
},
"2019": {
"obs_EconomicCapitalRatio": 14.62906593991791
},
"2020": {
"obs_EconomicCapitalRatio": 10.431590816230356
},
"2021": {
"obs_EconomicCapitalRatio": 11.24254806221214
},
"2022": {
"obs_EconomicCapitalRatio": 2.569020672124645
},
"2023": {
"obs_EconomicCapitalRatio": 0.8218812740633279
}
},
"0001370053": {
"2017": {
"obs_EconomicCapitalRatio": 13.167988751469355
},
"2018": {
"obs_EconomicCapitalRatio": 6.2142651603584
},
"2019": {
"obs_EconomicCapitalRatio": 1.921164157298367
},
"2020": {
"obs_EconomicCapitalRatio": 2.81203464508538
},
"2021": {
"obs_EconomicCapitalRatio": 2.991710648767185
},
"2022": {
"obs_EconomicCapitalRatio": 2.6017630895148307
},
"2023": {
"obs_EconomicCapitalRatio": 2.2108411190227493
},
"2024": {
"obs_EconomicCapitalRatio": 1.6017455543069687
}
},
"0001377121": {
"2017": {
"obs_EconomicCapitalRatio": 3.914023929056892
},
"2018": {
"obs_EconomicCapitalRatio": 1.9371601789637214
},
"2019": {
"obs_EconomicCapitalRatio": 1.6918961236380876
},
"2020": {
"obs_EconomicCapitalRatio": 4.6012149122973
},
"2021": {
"obs_EconomicCapitalRatio": 8.232979661392296
},
"2022": {
"obs_EconomicCapitalRatio": 3.4935072045172726
},
"2023": {
"obs_EconomicCapitalRatio": 6.698251527915118
}
},
"0001411685": {
"2017": {
"obs_EconomicCapitalRatio": 3.827433625855536
},
"2018": {
"obs_EconomicCapitalRatio": 5.7207627820698495
},
"2019": {
"obs_EconomicCapitalRatio": 3.0027583042272052
},
"2020": {
"obs_EconomicCapitalRatio": 11.917054122105522
},
"2021": {
"obs_EconomicCapitalRatio": 6.12552075504253
},
"2022": {
"obs_EconomicCapitalRatio": 0.4842481960234831
},
"2023": {
"obs_EconomicCapitalRatio": 9.274635539846695
},
"2024": {
"obs_EconomicCapitalRatio": 1.0717075833225695
}
},
"0001412486": {
"2017": {
"obs_EconomicCapitalRatio": 2.460451307469997
},
"2018": {
"obs_EconomicCapitalRatio": 2.5120455856560415
}
},
"0001420565": {
"2017": {
"obs_EconomicCapitalRatio": 5.1023289307496595
},
"2018": {
"obs_EconomicCapitalRatio": 0.5726969681607266
},
"2019": {
"obs_EconomicCapitalRatio": 0.8727951563208037
},
"2020": {
"obs_EconomicCapitalRatio": 4.163633669590643
},
"2021": {
"obs_EconomicCapitalRatio": 1.850461391873863
},
"2022": {
"obs_EconomicCapitalRatio": 16.418427885256513
}
},
"0001509745": {
"2017": {
"obs_EconomicCapitalRatio": 2.4505707185375876
},
"2018": {
"obs_EconomicCapitalRatio": 2.369922122381597
},
"2019": {
"obs_EconomicCapitalRatio": 2.8635571965108215
},
"2020": {
"obs_EconomicCapitalRatio": 4.25639470917342
},
"2021": {
"obs_EconomicCapitalRatio": 4.100610570922096
},
"2022": {
"obs_EconomicCapitalRatio": 1.0865248758170611
},
"2023": {
"obs_EconomicCapitalRatio": 1.9134670273083285
}
},
"0001514946": {
"2017": {
"obs_EconomicCapitalRatio": 73.39159388942399
},
"2018": {
"obs_EconomicCapitalRatio": 7.96001803039942
},
"2022": {
"obs_EconomicCapitalRatio": 0.7094745888114613
},
"2023": {
"obs_EconomicCapitalRatio": 0.5978697836515268
}
},
"0001528172": {
"2017": {
"obs_EconomicCapitalRatio": 0.019099386123103267
},
"2018": {
"obs_EconomicCapitalRatio": 0.8283695524372952
},
"2019": {
"obs_EconomicCapitalRatio": 142.77801500563763
},
"2020": {
"obs_EconomicCapitalRatio": 0.05812407823255177
},
"2021": {
"obs_EconomicCapitalRatio": 0.11790771971716654
}
},
"0001534120": {
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 1.1778632103795506
},
"2023": {
"obs_EconomicCapitalRatio": 131.79765640599854
},
"2024": {
"obs_EconomicCapitalRatio": 1.1101645179123487
}
},
"0001566044": {
"2018": {
"obs_EconomicCapitalRatio": 1.317547784011202
},
"2019": {
"obs_EconomicCapitalRatio": 2.6616596600295654
},
"2020": {
"obs_EconomicCapitalRatio": 3.9600248195471717
},
"2021": {
"obs_EconomicCapitalRatio": 1.3698621993549591
},
"2022": {
"obs_EconomicCapitalRatio": 0.32575957408979317
},
"2023": {
"obs_EconomicCapitalRatio": 0.6649149421403918
},
"2024": {
"obs_EconomicCapitalRatio": 1.012622254166815
},
"2025": {
"obs_EconomicCapitalRatio": 0.909971665771834
}
},
"0001589150": {
"2017": {
"obs_EconomicCapitalRatio": 1.5939039321287882
},
"2021": {
"obs_EconomicCapitalRatio": 5.815418147348666
},
"2022": {
"obs_EconomicCapitalRatio": 3.3803374988335997
},
"2023": {
"obs_EconomicCapitalRatio": 0.9680986000563736
}
},
"0001595248": {
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 2.2975715784653983
},
"2025": {
"obs_EconomicCapitalRatio": 0.6890334170541527
}
},
"0001615219": {
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.4266213271995585
},
"2023": {
"obs_EconomicCapitalRatio": 0.8817239426328813
},
"2024": {
"obs_EconomicCapitalRatio": 1.0538230226625522
}
},
"0001645469": {
"2019": {
"obs_EconomicCapitalRatio": 25.93457561963354
},
"2020": {
"obs_EconomicCapitalRatio": 7.94561875748812
},
"2021": {
"obs_EconomicCapitalRatio": 3.8337806849507885
},
"2022": {
"obs_EconomicCapitalRatio": 3.7394488995043447
},
"2023": {
"obs_EconomicCapitalRatio": 1.237974920283715
},
"2024": {
"obs_EconomicCapitalRatio": 3.90769690668125
},
"2025": {
"obs_EconomicCapitalRatio": 6.343918823471869
}
},
"0001671584": {
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001682639": {
"2018": {
"obs_EconomicCapitalRatio": 2.2837564752113586
},
"2019": {
"obs_EconomicCapitalRatio": 7.0391953952305535
},
"2020": {
"obs_EconomicCapitalRatio": 5.154502189305028
},
"2021": {
"obs_EconomicCapitalRatio": 5.026111355492541
},
"2022": {
"obs_EconomicCapitalRatio": 2.5051335831758266
},
"2023": {
"obs_EconomicCapitalRatio": 3.079128218817466
}
},
"0001698530": {
"2018": {
"obs_EconomicCapitalRatio": 8.357163676148797
},
"2019": {
"obs_EconomicCapitalRatio": 2.9887187823059307
},
"2020": {
"obs_EconomicCapitalRatio": 2.483895035470864
},
"2021": {
"obs_EconomicCapitalRatio": 0.3380830254064559
},
"2022": {
"obs_EconomicCapitalRatio": 0.36138827407151963
},
"2023": {
"obs_EconomicCapitalRatio": 0.5142840533526112
},
"2024": {
"obs_EconomicCapitalRatio": 3.239869857320238
}
},
"0001701108": {
"2017": {
"obs_EconomicCapitalRatio": 3.249938964861851
},
"2018": {
"obs_EconomicCapitalRatio": 1.533993943015218
},
"2019": {
"obs_EconomicCapitalRatio": 2.918587726691467
},
"2020": {
"obs_EconomicCapitalRatio": 6.327245808454878
},
"2021": {
"obs_EconomicCapitalRatio": 3.5665420006235404
},
"2022": {
"obs_EconomicCapitalRatio": 0.9629564817040931
}
},
"0000818686": {
"2018": {
"obs_EconomicCapitalRatio": 0.32514906136361227
},
"2019": {
"obs_EconomicCapitalRatio": 0.2178319843684473
},
"2020": {
"obs_EconomicCapitalRatio": 0.23675779404262848
},
"2021": {
"obs_EconomicCapitalRatio": 0.21886047552551496
},
"2022": {
"obs_EconomicCapitalRatio": 0.25601351138535516
},
"2023": {
"obs_EconomicCapitalRatio": 0.2979363623480095
},
"2024": {
"obs_EconomicCapitalRatio": 0.6887107587567836
}
},
"0001205922": {
"2018": {
"obs_EconomicCapitalRatio": 3.558545253032523
},
"2019": {
"obs_EconomicCapitalRatio": 14.107889173710923
},
"2020": {
"obs_EconomicCapitalRatio": 3.848820391735063
},
"2021": {
"obs_EconomicCapitalRatio": 6.534633254036944
},
"2022": {
"obs_EconomicCapitalRatio": 5.585500529255729
}
},
"0001398733": {
"2018": {
"obs_EconomicCapitalRatio": 2.0335208694788927
},
"2019": {
"obs_EconomicCapitalRatio": 1.6769019425473788
},
"2020": {
"obs_EconomicCapitalRatio": 2.480994835552515
},
"2021": {
"obs_EconomicCapitalRatio": 1.556911477192337
},
"2022": {
"obs_EconomicCapitalRatio": 0.41985375789917745
},
"2023": {
"obs_EconomicCapitalRatio": 1.2066939811949051
},
"2024": {
"obs_EconomicCapitalRatio": 2.4787610336985555
},
"2025": {
"obs_EconomicCapitalRatio": 4.105635682704048
}
},
"0001401040": {
"2019": {
"obs_EconomicCapitalRatio": 9.581231195149424
},
"2020": {
"obs_EconomicCapitalRatio": 11.44489460295306
},
"2021": {
"obs_EconomicCapitalRatio": 3.9817759093568927
},
"2023": {
"obs_EconomicCapitalRatio": 3.74479963887114
},
"2024": {
"obs_EconomicCapitalRatio": 8.787097452657084
},
"2025": {
"obs_EconomicCapitalRatio": 12.966407842541559
}
},
"0001426800": {
"2018": {
"obs_EconomicCapitalRatio": 3.2715032567189795
},
"2019": {
"obs_EconomicCapitalRatio": 2.656833630410397
},
"2020": {
"obs_EconomicCapitalRatio": 1.2260807054391023
},
"2021": {
"obs_EconomicCapitalRatio": 1.012923367531431
},
"2022": {
"obs_EconomicCapitalRatio": 1.0245394097639269
}
},
"0001513525": {
"2018": {
"obs_EconomicCapitalRatio": 15.29204527391044
},
"2019": {
"obs_EconomicCapitalRatio": 7.422992112609702
},
"2020": {
"obs_EconomicCapitalRatio": 9.195160674374737
},
"2023": {
"obs_EconomicCapitalRatio": 0.8112821129859077
}
},
"0001570562": {
"2018": {
"obs_EconomicCapitalRatio": 2.4644934958280946
},
"2019": {
"obs_EconomicCapitalRatio": 1.6526450097941916
},
"2020": {
"obs_EconomicCapitalRatio": 0.504423451769479
},
"2021": {
"obs_EconomicCapitalRatio": 1.6900619644881842
},
"2022": {
"obs_EconomicCapitalRatio": 2.3100849590901413
},
"2023": {
"obs_EconomicCapitalRatio": 2.8583602912038395
},
"2024": {
"obs_EconomicCapitalRatio": 3.0213055263832986
},
"2025": {
"obs_EconomicCapitalRatio": 1.8769865134086707
}
},
"0001604191": {
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.6221840865782279
},
"2023": {
"obs_EconomicCapitalRatio": 10.104779725932428
}
},
"0001622229": {
"2019": {
"obs_EconomicCapitalRatio": 0.653173704312413
},
"2020": {
"obs_EconomicCapitalRatio": 1.041837424690067
},
"2021": {
"obs_EconomicCapitalRatio": 2.68914694631765
},
"2022": {
"obs_EconomicCapitalRatio": 4.443547993300266
}
},
"0001655759": {
"2018": {
"obs_EconomicCapitalRatio": 3.2808490818527978
},
"2019": {
"obs_EconomicCapitalRatio": 7.486499358429144
},
"2020": {
"obs_EconomicCapitalRatio": 8.251738168682177
},
"2021": {
"obs_EconomicCapitalRatio": 3.5375048165770537
},
"2022": {
"obs_EconomicCapitalRatio": 1.833701160049044
},
"2023": {
"obs_EconomicCapitalRatio": 2.188090869424132
},
"2024": {
"obs_EconomicCapitalRatio": 1.599250605197483
},
"2025": {
"obs_EconomicCapitalRatio": 1.5230753357527844
}
},
"0001659323": {
"2018": {
"obs_EconomicCapitalRatio": 1.2956470910456483
},
"2019": {
"obs_EconomicCapitalRatio": 0.9991685577319022
},
"2020": {
"obs_EconomicCapitalRatio": 0.7321175401737595
},
"2021": {
"obs_EconomicCapitalRatio": 1.2505648158055298
},
"2022": {
"obs_EconomicCapitalRatio": 0.19588772714124267
}
},
"0001661181": {
"2019": {
"obs_EconomicCapitalRatio": 2.4337172392910094
},
"2020": {
"obs_EconomicCapitalRatio": 3.178293633366289
},
"2021": {
"obs_EconomicCapitalRatio": 3.7505662449012793
},
"2022": {
"obs_EconomicCapitalRatio": 1.067092580296219
}
},
"0001661998": {
"2018": {
"obs_EconomicCapitalRatio": 5.061694686560405
},
"2019": {
"obs_EconomicCapitalRatio": 5.264587553460372
},
"2020": {
"obs_EconomicCapitalRatio": 3.3929572131000203
},
"2021": {
"obs_EconomicCapitalRatio": 1.8249824165964792
},
"2022": {
"obs_EconomicCapitalRatio": 0.5213274307293991
}
},
"0001668243": {
"2019": {
"obs_EconomicCapitalRatio": 6.351614519380273
},
"2020": {
"obs_EconomicCapitalRatio": 5.627440820998476
},
"2021": {
"obs_EconomicCapitalRatio": 1.8434655464148624
},
"2022": {
"obs_EconomicCapitalRatio": 1.0245192387938165
},
"2023": {
"obs_EconomicCapitalRatio": 2.1951516473304666
},
"2024": {
"obs_EconomicCapitalRatio": 1.5615001591597384
},
"2025": {
"obs_EconomicCapitalRatio": 4.298345678378464
}
},
"0001708599": {
"2020": {
"obs_EconomicCapitalRatio": 9.389529401288595
},
"2022": {
"obs_EconomicCapitalRatio": 1.7540810203784016
},
"2023": {
"obs_EconomicCapitalRatio": 1.5714257944094645
},
"2024": {
"obs_EconomicCapitalRatio": 7.338972673386068
}
},
"0001711786": {
"2019": {
"obs_EconomicCapitalRatio": 31.04911251583365
},
"2021": {
"obs_EconomicCapitalRatio": 2.852022738805497
},
"2022": {
"obs_EconomicCapitalRatio": 1.0174342861200536
},
"2023": {
"obs_EconomicCapitalRatio": 1.083925115542916
}
},
"0001720893": {
"2018": {
"obs_EconomicCapitalRatio": 2.031438132927808
},
"2019": {
"obs_EconomicCapitalRatio": 7.684337873792798
},
"2020": {
"obs_EconomicCapitalRatio": 10.558813026558067
},
"2021": {
"obs_EconomicCapitalRatio": 4.729842390339243
},
"2022": {
"obs_EconomicCapitalRatio": 3.5299603687448617
},
"2023": {
"obs_EconomicCapitalRatio": 0.8587140121727126
}
},
"0001723128": {
"2018": {
"obs_EconomicCapitalRatio": 0.415203533677114
},
"2019": {
"obs_EconomicCapitalRatio": 0.18065044713560116
},
"2020": {
"obs_EconomicCapitalRatio": 0.1718239942463209
},
"2021": {
"obs_EconomicCapitalRatio": 0.19469925420081194
},
"2022": {
"obs_EconomicCapitalRatio": 0.08732183232289117
},
"2023": {
"obs_EconomicCapitalRatio": 0.5032006156988483
},
"2024": {
"obs_EconomicCapitalRatio": 0.6880617097541213
},
"2025": {
"obs_EconomicCapitalRatio": 1.0974009973927321
}
},
"0001724521": {
"2018": {
"obs_EconomicCapitalRatio": 3.008208356388294
},
"2019": {
"obs_EconomicCapitalRatio": 3.7292180755241033
},
"2020": {
"obs_EconomicCapitalRatio": 3.8563550492511514
},
"2021": {
"obs_EconomicCapitalRatio": 2.512052521732088
},
"2022": {
"obs_EconomicCapitalRatio": 1.9429558255953299
},
"2023": {
"obs_EconomicCapitalRatio": 2.1356368645167483
},
"2024": {
"obs_EconomicCapitalRatio": 2.0590112050369846
},
"2025": {
"obs_EconomicCapitalRatio": 3.641939566168213
}
},
"0001730430": {
"2018": {
"obs_EconomicCapitalRatio": 1.8816380603461278
},
"2019": {
"obs_EconomicCapitalRatio": 1.660159439750396
},
"2020": {
"obs_EconomicCapitalRatio": 3.045260196566863
},
"2021": {
"obs_EconomicCapitalRatio": 3.055856469183665
},
"2022": {
"obs_EconomicCapitalRatio": 2.032152591371752
},
"2023": {
"obs_EconomicCapitalRatio": 2.091221132933098
}
},
"0001739104": {
"2018": {
"obs_EconomicCapitalRatio": 1.7973732754806913
},
"2019": {
"obs_EconomicCapitalRatio": 1.7481325752317818
},
"2020": {
"obs_EconomicCapitalRatio": 1.0662567361290218
},
"2021": {
"obs_EconomicCapitalRatio": 1.0621834473295215
},
"2022": {
"obs_EconomicCapitalRatio": 0.4773477266025837
},
"2023": {
"obs_EconomicCapitalRatio": 0.6392950171837957
},
"2024": {
"obs_EconomicCapitalRatio": 0.613419169390112
},
"2025": {
"obs_EconomicCapitalRatio": 1.100692110544838
}
},
"0001746466": {
"2018": {
"obs_EconomicCapitalRatio": 4.161873700106537
},
"2019": {
"obs_EconomicCapitalRatio": 2.1735982867865347
},
"2020": {
"obs_EconomicCapitalRatio": 2.357638972989078
},
"2021": {
"obs_EconomicCapitalRatio": 2.3162186799119553
},
"2022": {
"obs_EconomicCapitalRatio": 0.5143186328567134
}
},
"0001534248": {
"2020": {
"obs_EconomicCapitalRatio": 19.16575959466217
},
"2021": {
"obs_EconomicCapitalRatio": 2.3500071338810997
},
"2022": {
"obs_EconomicCapitalRatio": 20.54831421144658
}
},
"0001622244": {
"2019": {
"obs_EconomicCapitalRatio": 59.08664512486836
},
"2020": {
"obs_EconomicCapitalRatio": 3.315685453794312
},
"2021": {
"obs_EconomicCapitalRatio": 2.3576372934404723
},
"2022": {
"obs_EconomicCapitalRatio": 1.4501694306847879
}
},
"0001623526": {
"2019": {
"obs_EconomicCapitalRatio": 7.74739908520579
},
"2020": {
"obs_EconomicCapitalRatio": 12.964685852432778
},
"2021": {
"obs_EconomicCapitalRatio": 6.1805890569330995
},
"2022": {
"obs_EconomicCapitalRatio": 2.0107832271209825
}
},
"0001649904": {
"2019": {
"obs_EconomicCapitalRatio": 6.079937722420159
},
"2021": {
"obs_EconomicCapitalRatio": 3.0156025697181783
},
"2022": {
"obs_EconomicCapitalRatio": 6.556528414134431
},
"2025": {
"obs_EconomicCapitalRatio": 21.653552672060908
}
},
"0001661059": {
"2019": {
"obs_EconomicCapitalRatio": 6.661137772072324
},
"2020": {
"obs_EconomicCapitalRatio": 1.8583391549245685
},
"2021": {
"obs_EconomicCapitalRatio": 1.3036217049364485
},
"2022": {
"obs_EconomicCapitalRatio": 0.3444290342244711
},
"2023": {
"obs_EconomicCapitalRatio": 0.44731514854614707
}
},
"0001680581": {
"2019": {
"obs_EconomicCapitalRatio": 5.7808098137940505
},
"2020": {
"obs_EconomicCapitalRatio": 4.260748062645979
},
"2021": {
"obs_EconomicCapitalRatio": 5.545902455372892
},
"2022": {
"obs_EconomicCapitalRatio": 2.5634132861588323
}
},
"0001690585": {
"2019": {
"obs_EconomicCapitalRatio": 102.2366531448102
},
"2020": {
"obs_EconomicCapitalRatio": 67.62029350291377
},
"2021": {
"obs_EconomicCapitalRatio": 43.073906165303356
},
"2022": {
"obs_EconomicCapitalRatio": 3.8790288898853373
}
},
"0001703647": {
"2019": {
"obs_EconomicCapitalRatio": 3.9689334067178352
},
"2020": {
"obs_EconomicCapitalRatio": 6.751884175181702
},
"2021": {
"obs_EconomicCapitalRatio": 1.5606886586463908
},
"2022": {
"obs_EconomicCapitalRatio": 0.964573573675129
}
},
"0001710340": {
"2019": {
"obs_EconomicCapitalRatio": 10.551165338630362
},
"2020": {
"obs_EconomicCapitalRatio": 11.152305168792797
},
"2021": {
"obs_EconomicCapitalRatio": 5.580918001036222
},
"2022": {
"obs_EconomicCapitalRatio": 4.076857430236477
},
"2023": {
"obs_EconomicCapitalRatio": 4.8694454718614555
},
"2024": {
"obs_EconomicCapitalRatio": 5.113958645322763
},
"2025": {
"obs_EconomicCapitalRatio": 5.65958338479525
}
},
"0001743881": {
"2019": {
"obs_EconomicCapitalRatio": 11.817891342219891
},
"2020": {
"obs_EconomicCapitalRatio": 12.923862718869536
},
"2021": {
"obs_EconomicCapitalRatio": 2.80267550168653
},
"2022": {
"obs_EconomicCapitalRatio": 0.9685514686017004
},
"2025": {
"obs_EconomicCapitalRatio": 7.423081982971124
}
},
"0001755237": {
"2019": {
"obs_EconomicCapitalRatio": 0.6467154509978333
},
"2020": {
"obs_EconomicCapitalRatio": 1.6091658350418265
},
"2021": {
"obs_EconomicCapitalRatio": 2.1222352909850035
},
"2022": {
"obs_EconomicCapitalRatio": 1.8967159585278592
}
},
"0001759425": {
"2019": {
"obs_EconomicCapitalRatio": 6.740158002097331
},
"2020": {
"obs_EconomicCapitalRatio": 3.0273910929081205
},
"2021": {
"obs_EconomicCapitalRatio": 2.050862904586447
},
"2022": {
"obs_EconomicCapitalRatio": 2.387721311230474
},
"2024": {
"obs_EconomicCapitalRatio": 3.573666967858353
},
"2025": {
"obs_EconomicCapitalRatio": 5.932467369373917
}
},
"0001761612": {
"2019": {
"obs_EconomicCapitalRatio": 2.487174279392095
},
"2020": {
"obs_EconomicCapitalRatio": 3.602705733294328
},
"2021": {
"obs_EconomicCapitalRatio": 5.652923697425659
},
"2022": {
"obs_EconomicCapitalRatio": 3.2433037923492805
}
},
"0001768224": {
"2019": {
"obs_EconomicCapitalRatio": 2.494416324374605
},
"2020": {
"obs_EconomicCapitalRatio": 8.691195070865797
},
"2021": {
"obs_EconomicCapitalRatio": 3.784184735102964
},
"2022": {
"obs_EconomicCapitalRatio": 1.4539389804718246
}
},
"0001781983": {
"2019": {
"obs_EconomicCapitalRatio": 11.417820453559177
},
"2020": {
"obs_EconomicCapitalRatio": 9.845984775457229
},
"2021": {
"obs_EconomicCapitalRatio": 2.165256182243437
},
"2022": {
"obs_EconomicCapitalRatio": 1.0867464139946783
},
"2023": {
"obs_EconomicCapitalRatio": 1.0559407672736314
}
},
"0001783183": {
"2019": {
"obs_EconomicCapitalRatio": 4.508790694494323
},
"2020": {
"obs_EconomicCapitalRatio": 5.193042395538745
},
"2021": {
"obs_EconomicCapitalRatio": 3.9761973177993113
},
"2022": {
"obs_EconomicCapitalRatio": 2.265079167617603
}
},
"0001808898": {
"2020": {
"obs_EconomicCapitalRatio": 2.1143833140342334
},
"2021": {
"obs_EconomicCapitalRatio": 1.9672621564562023
},
"2022": {
"obs_EconomicCapitalRatio": 1.0124988074946555
},
"2023": {
"obs_EconomicCapitalRatio": 1.9162068530827412
}
},
"0000921299": {
"2020": {
"obs_EconomicCapitalRatio": 6.037695737495577
},
"2021": {
"obs_EconomicCapitalRatio": 2.0679100904341126
},
"2022": {
"obs_EconomicCapitalRatio": 2.3772951556496356
}
},
"0001444192": {
"2020": {
"obs_EconomicCapitalRatio": 1.8212668931042104
},
"2021": {
"obs_EconomicCapitalRatio": 1.601910280914289
}
},
"0001453687": {
"2020": {
"obs_EconomicCapitalRatio": 1.885318991628831
},
"2021": {
"obs_EconomicCapitalRatio": 2.583586463141516
},
"2022": {
"obs_EconomicCapitalRatio": 1.37528869806314
},
"2023": {
"obs_EconomicCapitalRatio": 0.2969628497898465
},
"2024": {
"obs_EconomicCapitalRatio": 1.0950299982334744
},
"2025": {
"obs_EconomicCapitalRatio": 0.4954362901108546
}
},
"0001468639": {
"2020": {
"obs_EconomicCapitalRatio": 41.71486278196386
},
"2021": {
"obs_EconomicCapitalRatio": 91.93342781717148
},
"2022": {
"obs_EconomicCapitalRatio": 58.302482661739276
}
},
"0001472012": {
"2020": {
"obs_EconomicCapitalRatio": 4.454862991960487
},
"2021": {
"obs_EconomicCapitalRatio": 5.523992589733809
},
"2022": {
"obs_EconomicCapitalRatio": 2.422759521127661
},
"2023": {
"obs_EconomicCapitalRatio": 4.280267182756013
},
"2024": {
"obs_EconomicCapitalRatio": 4.585594760034545
}
},
"0001477845": {
"2020": {
"obs_EconomicCapitalRatio": 10.403516812427029
},
"2021": {
"obs_EconomicCapitalRatio": 6.81015427205511
},
"2022": {
"obs_EconomicCapitalRatio": 4.367600605808978
},
"2023": {
"obs_EconomicCapitalRatio": 9.447126381813128
}
},
"0001549595": {
"2020": {
"obs_EconomicCapitalRatio": 6.056262987617507
},
"2021": {
"obs_EconomicCapitalRatio": 4.328866026019691
},
"2022": {
"obs_EconomicCapitalRatio": 1.9390477295987234
},
"2023": {
"obs_EconomicCapitalRatio": 1.8453547894611453
},
"2024": {
"obs_EconomicCapitalRatio": 3.4698470832360737
},
"2025": {
"obs_EconomicCapitalRatio": 3.516804360887202
}
},
"0001571934": {
"2020": {
"obs_EconomicCapitalRatio": 1.9367055523471661
},
"2021": {
"obs_EconomicCapitalRatio": 3.0562030121239125
},
"2022": {
"obs_EconomicCapitalRatio": 0.3571391225015261
},
"2023": {
"obs_EconomicCapitalRatio": 0.3055024340497261
}
},
"0001593899": {
"2020": {
"obs_EconomicCapitalRatio": 4.982388173173559
},
"2021": {
"obs_EconomicCapitalRatio": 1.7889261352116168
},
"2022": {
"obs_EconomicCapitalRatio": 1.1023371148257655
}
},
"0001599298": {
"2020": {
"obs_EconomicCapitalRatio": 7.253437136286895
},
"2021": {
"obs_EconomicCapitalRatio": 3.630304594545802
},
"2022": {
"obs_EconomicCapitalRatio": 1.3285352790419083
},
"2023": {
"obs_EconomicCapitalRatio": 11.018534843177335
},
"2024": {
"obs_EconomicCapitalRatio": 55.96920150546034
},
"2025": {
"obs_EconomicCapitalRatio": 31.41912147041661
}
},
"0001600620": {
"2021": {
"obs_EconomicCapitalRatio": 9.703248034518616
},
"2022": {
"obs_EconomicCapitalRatio": 2.374302612487517
},
"2023": {
"obs_EconomicCapitalRatio": 3.7093327061713572
},
"2024": {
"obs_EconomicCapitalRatio": 3.588324024493516
},
"2025": {
"obs_EconomicCapitalRatio": 4.595182884458584
}
},
"0001636651": {
"2020": {
"obs_EconomicCapitalRatio": 3.065681924492594
},
"2021": {
"obs_EconomicCapitalRatio": 2.117481637967616
},
"2022": {
"obs_EconomicCapitalRatio": 1.3598528063187154
},
"2023": {
"obs_EconomicCapitalRatio": 2.4106470615597217
},
"2024": {
"obs_EconomicCapitalRatio": 1.2035985474563016
}
},
"0001664710": {
"2020": {
"obs_EconomicCapitalRatio": 11.15743911511553
},
"2021": {
"obs_EconomicCapitalRatio": 9.823255567688177
},
"2022": {
"obs_EconomicCapitalRatio": 7.868704196501648
},
"2023": {
"obs_EconomicCapitalRatio": 5.476382983993136
},
"2024": {
"obs_EconomicCapitalRatio": 2.0694873777143337
},
"2025": {
"obs_EconomicCapitalRatio": 3.3872065454063467
}
},
"0001672619": {
"2020": {
"obs_EconomicCapitalRatio": 32.27703889816523
},
"2021": {
"obs_EconomicCapitalRatio": 4.815995993435351
}
},
"0001676725": {
"2020": {
"obs_EconomicCapitalRatio": 1.910906464785605
},
"2021": {
"obs_EconomicCapitalRatio": 3.888299033936247
},
"2022": {
"obs_EconomicCapitalRatio": 3.8187736139631454
}
},
"0001677077": {
"2021": {
"obs_EconomicCapitalRatio": 134.03651058526592
},
"2022": {
"obs_EconomicCapitalRatio": 10.957841768849988
},
"2023": {
"obs_EconomicCapitalRatio": 1.445083947343951
},
"2024": {
"obs_EconomicCapitalRatio": 3.3768356960216277
}
},
"0001678660": {
"2020": {
"obs_EconomicCapitalRatio": 29.852580691842824
},
"2021": {
"obs_EconomicCapitalRatio": 3.7897608225132036
},
"2022": {
"obs_EconomicCapitalRatio": 1.9743198737884817
}
},
"0001680367": {
"2020": {
"obs_EconomicCapitalRatio": 11.337515983150187
},
"2021": {
"obs_EconomicCapitalRatio": 2.2396700444705333
},
"2022": {
"obs_EconomicCapitalRatio": 0.8695375359442132
},
"2023": {
"obs_EconomicCapitalRatio": 3.2164383492063244
},
"2025": {
"obs_EconomicCapitalRatio": 4.095392329748731
}
},
"0001695473": {
"2020": {
"obs_EconomicCapitalRatio": 4.669797408223305
},
"2021": {
"obs_EconomicCapitalRatio": 4.255756953222455
},
"2022": {
"obs_EconomicCapitalRatio": 0.9977644045203846
},
"2023": {
"obs_EconomicCapitalRatio": 1.937291648646682
},
"2024": {
"obs_EconomicCapitalRatio": 1.1364421533009899
}
},
"0001699382": {
"2020": {
"obs_EconomicCapitalRatio": 12.848011118817782
},
"2021": {
"obs_EconomicCapitalRatio": 5.929521083876715
},
"2022": {
"obs_EconomicCapitalRatio": 2.715854942883037
}
},
"0001720580": {
"2020": {
"obs_EconomicCapitalRatio": 2.81568620431054
},
"2021": {
"obs_EconomicCapitalRatio": 2.6874207501034557
},
"2022": {
"obs_EconomicCapitalRatio": 1.8902049958954465
}
},
"0001725160": {
"2020": {
"obs_EconomicCapitalRatio": 10.979229591790343
},
"2021": {
"obs_EconomicCapitalRatio": 13.702353859771764
},
"2022": {
"obs_EconomicCapitalRatio": 3.3174172620290943
},
"2023": {
"obs_EconomicCapitalRatio": 3.089962409485199
},
"2024": {
"obs_EconomicCapitalRatio": 0.8290663394065225
}
},
"0001726711": {
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001728328": {
"2020": {
"obs_EconomicCapitalRatio": 4.577471381356152
},
"2021": {
"obs_EconomicCapitalRatio": 3.271531063244177
},
"2022": {
"obs_EconomicCapitalRatio": 0.17978140318971794
},
"2023": {
"obs_EconomicCapitalRatio": 0.23825555809900759
},
"2024": {
"obs_EconomicCapitalRatio": 3.88013069052814
}
},
"0001742927": {
"2020": {
"obs_EconomicCapitalRatio": 7.287951365168326
},
"2022": {
"obs_EconomicCapitalRatio": 5.5409080631952605
},
"2023": {
"obs_EconomicCapitalRatio": 4.613513866544896
},
"2024": {
"obs_EconomicCapitalRatio": 3.7878517832107255
},
"2025": {
"obs_EconomicCapitalRatio": 3.1156774432362093
}
},
"0001746473": {
"2020": {
"obs_EconomicCapitalRatio": 5.857802788342808
},
"2021": {
"obs_EconomicCapitalRatio": 4.3773197207660886
},
"2022": {
"obs_EconomicCapitalRatio": 4.726552714214153
},
"2023": {
"obs_EconomicCapitalRatio": 3.7010006534345026
},
"2024": {
"obs_EconomicCapitalRatio": 3.333291209670626
},
"2025": {
"obs_EconomicCapitalRatio": 0.5568651663918129
}
},
"0001763950": {
"2020": {
"obs_EconomicCapitalRatio": 11.355252435808278
},
"2021": {
"obs_EconomicCapitalRatio": 2.1722035078289954
},
"2022": {
"obs_EconomicCapitalRatio": 1.9693754788301854
},
"2023": {
"obs_EconomicCapitalRatio": 1.9424356466155677
},
"2024": {
"obs_EconomicCapitalRatio": 2.3113357750235837
},
"2025": {
"obs_EconomicCapitalRatio": 4.7509364652543695
}
},
"0001787306": {
"2020": {
"obs_EconomicCapitalRatio": 7.791943253314391
},
"2021": {
"obs_EconomicCapitalRatio": 3.910142729960259
},
"2022": {
"obs_EconomicCapitalRatio": 2.524778961577347
},
"2023": {
"obs_EconomicCapitalRatio": 0.8833479379113233
},
"2024": {
"obs_EconomicCapitalRatio": 6.317635141059226
},
"2025": {
"obs_EconomicCapitalRatio": 10.417323618496392
}
},
"0001787400": {
"2020": {
"obs_EconomicCapitalRatio": 12.296919314685818
},
"2021": {
"obs_EconomicCapitalRatio": 3.3411289373909545
},
"2022": {
"obs_EconomicCapitalRatio": 0.9793904296250519
}
},
"0001792044": {
"2020": {
"obs_EconomicCapitalRatio": 2.8519194602188337e-08
},
"2021": {
"obs_EconomicCapitalRatio": 0.3023160057060142
},
"2022": {
"obs_EconomicCapitalRatio": 0.2882186828643058
},
"2023": {
"obs_EconomicCapitalRatio": 0.3069370365291023
},
"2024": {
"obs_EconomicCapitalRatio": 0.4330347985069521
},
"2025": {
"obs_EconomicCapitalRatio": 0.46088319499372177
}
},
"0001799788": {
"2020": {
"obs_EconomicCapitalRatio": 30.42976875216127
},
"2021": {
"obs_EconomicCapitalRatio": 24.51891800687105
},
"2022": {
"obs_EconomicCapitalRatio": 26.799867229313154
},
"2023": {
"obs_EconomicCapitalRatio": 37.84356462519523
},
"2024": {
"obs_EconomicCapitalRatio": 56.6613741545884
},
"2025": {
"obs_EconomicCapitalRatio": 36.68280029973951
}
},
"0001802665": {
"2020": {
"obs_EconomicCapitalRatio": 5.468950647202746
},
"2021": {
"obs_EconomicCapitalRatio": 7.357291711352325
},
"2022": {
"obs_EconomicCapitalRatio": 6.968809248214065
},
"2023": {
"obs_EconomicCapitalRatio": 3.318508034292695
}
},
"0001802768": {
"2020": {
"obs_EconomicCapitalRatio": 1.5083605602075743
},
"2021": {
"obs_EconomicCapitalRatio": 1.2404006192636492
},
"2022": {
"obs_EconomicCapitalRatio": 1.3215216000222363
},
"2023": {
"obs_EconomicCapitalRatio": 1.0095920224940342
},
"2024": {
"obs_EconomicCapitalRatio": 0.8300691833941843
},
"2025": {
"obs_EconomicCapitalRatio": 1.1156824324208434
}
},
"0001810182": {
"2020": {
"obs_EconomicCapitalRatio": 14.62861782260423
},
"2021": {
"obs_EconomicCapitalRatio": 4.550269504823056
},
"2022": {
"obs_EconomicCapitalRatio": 2.487207345201067
}
},
"0001818794": {
"2020": {
"obs_EconomicCapitalRatio": 5.4526504778285885
},
"2021": {
"obs_EconomicCapitalRatio": 2.641862011132604
},
"2022": {
"obs_EconomicCapitalRatio": 3.6937309216583993
}
},
"0001819576": {
"2021": {
"obs_EconomicCapitalRatio": 3.8709267163294454
},
"2022": {
"obs_EconomicCapitalRatio": 4.761078308530657
},
"2023": {
"obs_EconomicCapitalRatio": 7.8453765509689095
}
},
"0001822462": {
"2020": {
"obs_EconomicCapitalRatio": 4.751909233181428
},
"2021": {
"obs_EconomicCapitalRatio": 1.6675293224063918
},
"2022": {
"obs_EconomicCapitalRatio": 0.6272968813672785
},
"2023": {
"obs_EconomicCapitalRatio": 0.8280520764862019
},
"2024": {
"obs_EconomicCapitalRatio": 0.8980197292338962
}
},
"0001280776": {
"2021": {
"obs_EconomicCapitalRatio": 3.3340617426522416
},
"2022": {
"obs_EconomicCapitalRatio": 0.7059338103397217
},
"2023": {
"obs_EconomicCapitalRatio": 1.666027643790281
},
"2024": {
"obs_EconomicCapitalRatio": 2.945386156378902
},
"2025": {
"obs_EconomicCapitalRatio": 2.5033241416493146
}
},
"0001419041": {
"2021": {
"obs_EconomicCapitalRatio": 1.4209741119297001
},
"2022": {
"obs_EconomicCapitalRatio": 0.9297002390649902
}
},
"0001452804": {
"2022": {
"obs_EconomicCapitalRatio": 3168.512429183764
}
},
"0001490978": {
"2025": {
"obs_EconomicCapitalRatio": 2.117089071809597
}
},
"0001574094": {
"2021": {
"obs_EconomicCapitalRatio": 5.150953517551173
},
"2022": {
"obs_EconomicCapitalRatio": 4.409128500339078
},
"2023": {
"obs_EconomicCapitalRatio": 3.3439971517133937
},
"2024": {
"obs_EconomicCapitalRatio": 5.205257127532486
}
},
"0001601485": {
"2021": {
"obs_EconomicCapitalRatio": 1.415639197764491
},
"2022": {
"obs_EconomicCapitalRatio": 0.8165700887487293
},
"2023": {
"obs_EconomicCapitalRatio": 2.5601919164746474
},
"2024": {
"obs_EconomicCapitalRatio": 1.6178696291329993
},
"2025": {
"obs_EconomicCapitalRatio": 5.583320492672247
}
},
"0001637715": {
"2021": {
"obs_EconomicCapitalRatio": 2.6119057182116054
},
"2022": {
"obs_EconomicCapitalRatio": 0.9188554177683708
}
},
"0001641281": {
"2021": {
"obs_EconomicCapitalRatio": 0.9512093355759328
},
"2022": {
"obs_EconomicCapitalRatio": 0.3446517584862095
}
},
"0001645460": {
"2021": {
"obs_EconomicCapitalRatio": 7.119845614894133
},
"2022": {
"obs_EconomicCapitalRatio": 1.6334346042316759
}
},
"0001660334": {
"2021": {
"obs_EconomicCapitalRatio": 3.9992043021661643
},
"2022": {
"obs_EconomicCapitalRatio": 4.416390192021974
},
"2025": {
"obs_EconomicCapitalRatio": 2.233302684760354
}
},
"0001671858": {
"2021": {
"obs_EconomicCapitalRatio": 1.3161514949634543
},
"2022": {
"obs_EconomicCapitalRatio": 2.0094306464423357
}
},
"0001683553": {
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001684144": {
"2021": {
"obs_EconomicCapitalRatio": 2.325411279249918
},
"2022": {
"obs_EconomicCapitalRatio": 1.1047721659202565
},
"2023": {
"obs_EconomicCapitalRatio": 1.5634931168213562
}
},
"0001689375": {
"2021": {
"obs_EconomicCapitalRatio": 3.4050607267756394
},
"2022": {
"obs_EconomicCapitalRatio": 3.277871231738275
},
"2023": {
"obs_EconomicCapitalRatio": 1.4420649053685184
},
"2024": {
"obs_EconomicCapitalRatio": 2.091201556950649
},
"2025": {
"obs_EconomicCapitalRatio": 1.8060770649526663
}
},
"0001689548": {
"2021": {
"obs_EconomicCapitalRatio": 5.257153136894679
},
"2022": {
"obs_EconomicCapitalRatio": 1.4008110546579007
},
"2023": {
"obs_EconomicCapitalRatio": 48.6720633206395
},
"2024": {
"obs_EconomicCapitalRatio": 5.492877727846892
},
"2025": {
"obs_EconomicCapitalRatio": 13.798237590422602
}
},
"0001703057": {
"2021": {
"obs_EconomicCapitalRatio": 5.128698575879268
},
"2022": {
"obs_EconomicCapitalRatio": 3.148047741990266
},
"2023": {
"obs_EconomicCapitalRatio": 1.8105113718561898
},
"2024": {
"obs_EconomicCapitalRatio": 1.023568114995679
},
"2025": {
"obs_EconomicCapitalRatio": 1.218246727455875
}
},
"0001710072": {
"2021": {
"obs_EconomicCapitalRatio": 5.066391448451008
},
"2022": {
"obs_EconomicCapitalRatio": 2.735818420050592
},
"2023": {
"obs_EconomicCapitalRatio": 3.2535404403961716
},
"2024": {
"obs_EconomicCapitalRatio": 10.977887819024053
}
},
"0001716947": {
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.28645113019466883
},
"2023": {
"obs_EconomicCapitalRatio": 1.1047546706759725
},
"2024": {
"obs_EconomicCapitalRatio": 41.079123913525216
},
"2025": {
"obs_EconomicCapitalRatio": 0.656978176046888
}
},
"0001736243": {
"2021": {
"obs_EconomicCapitalRatio": 6.565093390600356
},
"2022": {
"obs_EconomicCapitalRatio": 7.884893700132662
},
"2023": {
"obs_EconomicCapitalRatio": 9.335254148753522
}
},
"0001750284": {
"2021": {
"obs_EconomicCapitalRatio": 2.511734257269554
},
"2022": {
"obs_EconomicCapitalRatio": 0.8463406216798857
}
},
"0001752828": {
"2021": {
"obs_EconomicCapitalRatio": 1.6228382618914432
},
"2022": {
"obs_EconomicCapitalRatio": 0.5793503252191476
},
"2024": {
"obs_EconomicCapitalRatio": 0.3913511061415067
},
"2025": {
"obs_EconomicCapitalRatio": 0.2903284139304872
}
},
"0001761918": {
"2021": {
"obs_EconomicCapitalRatio": 6.429819762928459
},
"2022": {
"obs_EconomicCapitalRatio": 1.6612816937900394
}
},
"0001768446": {
"2021": {
"obs_EconomicCapitalRatio": 3.163784830589746
},
"2022": {
"obs_EconomicCapitalRatio": 1.0700868561112922
}
},
"0001782223": {
"2021": {
"obs_EconomicCapitalRatio": 2.111294265873082
},
"2022": {
"obs_EconomicCapitalRatio": 0.3323020132912376
}
},
"0001785530": {
"2021": {
"obs_EconomicCapitalRatio": 3.1720410978971088
},
"2022": {
"obs_EconomicCapitalRatio": 0.5601135472074897
},
"2023": {
"obs_EconomicCapitalRatio": 0.9462244042196647
},
"2024": {
"obs_EconomicCapitalRatio": 0.7704248818211188
}
},
"0001790340": {
"2021": {
"obs_EconomicCapitalRatio": 5.672639281594998
},
"2022": {
"obs_EconomicCapitalRatio": 1.708970518177094
},
"2023": {
"obs_EconomicCapitalRatio": 3.80062421348927
},
"2024": {
"obs_EconomicCapitalRatio": 2.1236015682286755
},
"2025": {
"obs_EconomicCapitalRatio": 3.4114869322297863
}
},
"0001798749": {
"2021": {
"obs_EconomicCapitalRatio": 2.7499402452773416
},
"2022": {
"obs_EconomicCapitalRatio": 9.087261432076014
},
"2023": {
"obs_EconomicCapitalRatio": 7.725094101880131
}
},
"0001806952": {
"2021": {
"obs_EconomicCapitalRatio": 2.7658237776442247
},
"2022": {
"obs_EconomicCapitalRatio": 1.4549797893575631
},
"2023": {
"obs_EconomicCapitalRatio": 1.2100115484779883
},
"2024": {
"obs_EconomicCapitalRatio": 0.5879123817937689
},
"2025": {
"obs_EconomicCapitalRatio": 3.361295963504125
}
},
"0001807120": {
"2021": {
"obs_EconomicCapitalRatio": 5.110273773093571
},
"2022": {
"obs_EconomicCapitalRatio": 2.9091935322443994
}
},
"0001810560": {
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001811063": {
"2021": {
"obs_EconomicCapitalRatio": 4.4594460489134535
},
"2022": {
"obs_EconomicCapitalRatio": 1.156596156073967
}
},
"0001815903": {
"2021": {
"obs_EconomicCapitalRatio": 0.9315853262360096
},
"2022": {
"obs_EconomicCapitalRatio": 1.8389462883029757
},
"2023": {
"obs_EconomicCapitalRatio": 0.11262634902034269
}
},
"0001815974": {
"2021": {
"obs_EconomicCapitalRatio": 13.860591563674177
},
"2022": {
"obs_EconomicCapitalRatio": 8.012390333548375
},
"2023": {
"obs_EconomicCapitalRatio": 9.79937517371494
},
"2024": {
"obs_EconomicCapitalRatio": 17.533372649206587
}
},
"0001816590": {
"2022": {
"obs_EconomicCapitalRatio": 3.469069793877861
},
"2023": {
"obs_EconomicCapitalRatio": 3.181819330791114
},
"2024": {
"obs_EconomicCapitalRatio": 1.9976368353893532
}
},
"0001816736": {
"2021": {
"obs_EconomicCapitalRatio": 1.5673969847038716
},
"2022": {
"obs_EconomicCapitalRatio": 17.946181285719497
}
},
"0001817713": {
"2021": {
"obs_EconomicCapitalRatio": 4.222290083037995
},
"2022": {
"obs_EconomicCapitalRatio": 2.4602137482729134
}
},
"0001818844": {
"2021": {
"obs_EconomicCapitalRatio": 5.108939352094039
},
"2022": {
"obs_EconomicCapitalRatio": 0.9600408848841279
},
"2023": {
"obs_EconomicCapitalRatio": 5.086933153035263
}
},
"0001819133": {
"2021": {
"obs_EconomicCapitalRatio": 2.9059148447166874
},
"2022": {
"obs_EconomicCapitalRatio": 2.1709711795560804
}
},
"0001819411": {
"2021": {
"obs_EconomicCapitalRatio": 3.076434388579569
},
"2022": {
"obs_EconomicCapitalRatio": 2.4217228765908048
},
"2023": {
"obs_EconomicCapitalRatio": 2.6616627665067916
}
},
"0001821825": {
"2021": {
"obs_EconomicCapitalRatio": 0.9514939785370281
},
"2022": {
"obs_EconomicCapitalRatio": 0.9005471267937213
},
"2023": {
"obs_EconomicCapitalRatio": 0.2657689617152537
},
"2024": {
"obs_EconomicCapitalRatio": 0.2860582314552151
},
"2025": {
"obs_EconomicCapitalRatio": 0.14698366747611746
}
},
"0001823239": {
"2021": {
"obs_EconomicCapitalRatio": 3.324821543814707
},
"2022": {
"obs_EconomicCapitalRatio": 1.0187043552243467
},
"2023": {
"obs_EconomicCapitalRatio": 0.7979658106136953
},
"2024": {
"obs_EconomicCapitalRatio": 1.079141954197552
},
"2025": {
"obs_EconomicCapitalRatio": 0.82289065119173
}
},
"0001824293": {
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 1.766930002257645
},
"2025": {
"obs_EconomicCapitalRatio": 0.18999951389172234
}
},
"0001828673": {
"2021": {
"obs_EconomicCapitalRatio": 3.034524794547648
},
"2022": {
"obs_EconomicCapitalRatio": 2.4330632068491176
}
},
"0001829635": {
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 7.880452829308091
}
},
"0001829802": {
"2021": {
"obs_EconomicCapitalRatio": 2.1770565929437673
},
"2022": {
"obs_EconomicCapitalRatio": 0.6635101635348523
}
},
"0001840233": {
"2021": {
"obs_EconomicCapitalRatio": 3.411233264533946
},
"2022": {
"obs_EconomicCapitalRatio": 0.7416409577746491
},
"2023": {
"obs_EconomicCapitalRatio": 0.36062284533159966
}
},
"0001840904": {
"2021": {
"obs_EconomicCapitalRatio": 5.634686356849057
},
"2022": {
"obs_EconomicCapitalRatio": 2.701176549058382
}
},
"0001857044": {
"2021": {
"obs_EconomicCapitalRatio": 2.126214716188324
},
"2022": {
"obs_EconomicCapitalRatio": 0.8140410650242103
},
"2023": {
"obs_EconomicCapitalRatio": 1.748806858580108
},
"2024": {
"obs_EconomicCapitalRatio": 1.7037172495363144
},
"2025": {
"obs_EconomicCapitalRatio": 0.5309387175287837
}
},
"0001858685": {
"2021": {
"obs_EconomicCapitalRatio": 2.0565299498420657
},
"2022": {
"obs_EconomicCapitalRatio": 0.6194003825807052
},
"2023": {
"obs_EconomicCapitalRatio": 0.17770193395364212
},
"2024": {
"obs_EconomicCapitalRatio": 0.395556793187993
},
"2025": {
"obs_EconomicCapitalRatio": 0.3598275158539455
}
},
"0001861560": {
"2021": {
"obs_EconomicCapitalRatio": 5.488287614155773
},
"2022": {
"obs_EconomicCapitalRatio": 5.949742697006308
}
},
"0001861657": {
"2022": {
"obs_EconomicCapitalRatio": 1.1921959530489235
},
"2023": {
"obs_EconomicCapitalRatio": 1.4108271541154638
},
"2024": {
"obs_EconomicCapitalRatio": 1.0148133307016274
}
},
"0001863127": {
"2021": {
"obs_EconomicCapitalRatio": 3.6689204765827528
},
"2022": {
"obs_EconomicCapitalRatio": 2.3778352646735605
}
},
"0001865494": {
"2021": {
"obs_EconomicCapitalRatio": 1.984167670127024
},
"2022": {
"obs_EconomicCapitalRatio": 0.912960344779015
}
},
"0001867096": {
"2021": {
"obs_EconomicCapitalRatio": 1.1827520422190887
},
"2022": {
"obs_EconomicCapitalRatio": 0.5343457845599805
},
"2023": {
"obs_EconomicCapitalRatio": 0.8876602074616373
},
"2024": {
"obs_EconomicCapitalRatio": 1.5068427753479947
},
"2025": {
"obs_EconomicCapitalRatio": 3.213363246006965
}
},
"0001873835": {
"2022": {
"obs_EconomicCapitalRatio": 3.612121626948463
},
"2023": {
"obs_EconomicCapitalRatio": 9.546066891374704
},
"2024": {
"obs_EconomicCapitalRatio": 3.6907687937165123
},
"2025": {
"obs_EconomicCapitalRatio": 3.2771052417139117
}
},
"0001231457": {
"2023": {
"obs_EconomicCapitalRatio": 20.58658297936221
},
"2024": {
"obs_EconomicCapitalRatio": 3.8012970654339866
},
"2025": {
"obs_EconomicCapitalRatio": 12.487756265058431
}
},
"0001575142": {
"2023": {
"obs_EconomicCapitalRatio": 0.46157616565160214
},
"2024": {
"obs_EconomicCapitalRatio": 137.2589511115023
},
"2025": {
"obs_EconomicCapitalRatio": 0.20558168607917748
}
},
"0001690080": {
"2023": {
"obs_EconomicCapitalRatio": 0.24947006630043778
}
},
"0001704292": {
"2025": {
"obs_EconomicCapitalRatio": 23.99537244484833
}
},
"0001719406": {
"2023": {
"obs_EconomicCapitalRatio": 2.8107941259243874
},
"2024": {
"obs_EconomicCapitalRatio": 1.2123808991964091
},
"2025": {
"obs_EconomicCapitalRatio": 3.256314248115792
}
},
"0001728117": {
"2023": {
"obs_EconomicCapitalRatio": 0.7082923364427968
},
"2024": {
"obs_EconomicCapitalRatio": 0.6442715394449453
}
},
"0001729427": {
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 1.3765743708780394
},
"2025": {
"obs_EconomicCapitalRatio": 0.6059397013669012
}
},
"0001771910": {
"2024": {
"obs_EconomicCapitalRatio": 0.4591204113571571
},
"2025": {
"obs_EconomicCapitalRatio": 1.0509994743294888
}
},
"0001834105": {
"2024": {
"obs_EconomicCapitalRatio": 1.0074543225769161
},
"2025": {
"obs_EconomicCapitalRatio": 5.449758180736699
}
},
"0001847903": {
"2023": {
"obs_EconomicCapitalRatio": 3.1551998397667322
},
"2024": {
"obs_EconomicCapitalRatio": 5.9799791062469065
}
},
"0001860657": {
"2023": {
"obs_EconomicCapitalRatio": 0.22728545269121814
},
"2024": {
"obs_EconomicCapitalRatio": 0.2806654262934393
},
"2025": {
"obs_EconomicCapitalRatio": 1.2323411898099832
}
},
"0001873875": {
"2023": {
"obs_EconomicCapitalRatio": 456.5184457750075
},
"2024": {
"obs_EconomicCapitalRatio": 2.550487370004812
}
},
"0001904286": {
"2023": {
"obs_EconomicCapitalRatio": 5.895620284301549
},
"2024": {
"obs_EconomicCapitalRatio": 9.85535789993241
},
"2025": {
"obs_EconomicCapitalRatio": 10.827874200411674
}
},
"0001610820": {
"2024": {
"obs_EconomicCapitalRatio": 3.431083357476488
},
"2025": {
"obs_EconomicCapitalRatio": 1.1485388588887744
}
},
"0001625297": {
"2025": {
"obs_EconomicCapitalRatio": 3.599845897191032
}
},
"0001677940": {
"2025": {
"obs_EconomicCapitalRatio": 1.9832255110904602
}
},
"0001679628": {
"2024": {
"obs_EconomicCapitalRatio": 88.34065319613647
},
"2025": {
"obs_EconomicCapitalRatio": 5.844019823713041
}
}
}
}